Naloxone	B-CHEMICAL
reverses	O
the	O
antihypertensive	O
effect	O
of	O
clonidine	B-CHEMICAL
.	O
In	O
unanesthetized	O
,	O
spontaneously	O
hypertensive	B-DISEASE
rats	O
the	O
decrease	O
in	O
blood	O
pressure	O
and	O
heart	O
rate	O
produced	O
by	O
intravenous	O
clonidine	B-CHEMICAL
,	O
5	O
to	O
20	O
micrograms	O
/	O
kg	O
,	O
was	O
inhibited	O
or	O
reversed	O
by	O
nalozone	O
,	O
0.2	O
to	O
2	O
mg	O
/	O
kg	O
.	O
The	O
hypotensive	B-DISEASE
effect	O
of	O
100	O
mg	O
/	O
kg	O
alpha	O
-	O
methyldopa	B-CHEMICAL
was	O
also	O
partially	O
reversed	O
by	O
naloxone	B-CHEMICAL
.	O
Naloxone	B-CHEMICAL
alone	O
did	O
not	O
affect	O
either	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O
In	O
brain	O
membranes	O
from	O
spontaneously	O
hypertensive	B-DISEASE
rats	O
clonidine	B-CHEMICAL
,	O
10(-8	O
)	O
to	O
10(-5	O
)	O
M	O
,	O
did	O
not	O
influence	O
stereoselective	O
binding	O
of	O
[	O
3H]-naloxone	O
(	O
8	O
nM	O
)	O
,	O
and	O
naloxone	B-CHEMICAL
,	O
10(-8	O
)	O
to	O
10(-4	O
)	O
M	O
,	O
did	O
not	O
influence	O
clonidine	B-CHEMICAL
-	O
suppressible	O
binding	O
of	O
[	O
3H]-dihydroergocryptine	O
(	O
1	O
nM	O
)	O
.	O
These	O
findings	O
indicate	O
that	O
in	O
spontaneously	O
hypertensive	B-DISEASE
rats	O
the	O
effects	O
of	O
central	O
alpha	O
-	O
adrenoceptor	O
stimulation	O
involve	O
activation	O
of	O
opiate	B-CHEMICAL
receptors	O
.	O
As	O
naloxone	B-CHEMICAL
and	O
clonidine	B-CHEMICAL
do	O
not	O
appear	O
to	O
interact	O
with	O
the	O
same	O
receptor	O
site	O
,	O
the	O
observed	O
functional	O
antagonism	O
suggests	O
the	O
release	O
of	O
an	O
endogenous	O
opiate	B-CHEMICAL
by	O
clonidine	B-CHEMICAL
or	O
alpha	O
-	O
methyldopa	B-CHEMICAL
and	O
the	O
possible	O
role	O
of	O
the	O
opiate	B-CHEMICAL
in	O
the	O
central	O
control	O
of	O
sympathetic	O
tone	O
.	O

Lidocaine	B-CHEMICAL
-	O
induced	O
cardiac	B-DISEASE
asystole	I-DISEASE
.	O
Intravenous	O
administration	O
of	O
a	O
single	O
50	O
-	O
mg	O
bolus	O
of	O
lidocaine	B-CHEMICAL
in	O
a	O
67	O
-	O
year	O
-	O
old	O
man	O
resulted	O
in	O
profound	O
depression	B-DISEASE
of	O
the	O
activity	O
of	O
the	O
sinoatrial	O
and	O
atrioventricular	O
nodal	O
pacemakers	O
.	O
The	O
patient	O
had	O
no	O
apparent	O
associated	O
conditions	O
which	O
might	O
have	O
predisposed	O
him	O
to	O
the	O
development	O
of	O
bradyarrhythmias	B-DISEASE
;	O
and	O
,	O
thus	O
,	O
this	O
probably	O
represented	O
a	O
true	O
idiosyncrasy	O
to	O
lidocaine	B-CHEMICAL
.	O

Suxamethonium	B-CHEMICAL
infusion	O
rate	O
and	O
observed	O
fasciculations	B-DISEASE
.	O
A	O
dose	O
-	O
response	O
study	O
.	O
Suxamethonium	B-CHEMICAL
chloride	O
(	O
Sch	O
)	O
was	O
administered	O
i.v	O
.	O
to	O
36	O
adult	O
males	O
at	O
six	O
rates	O
:	O
0.25	O
mg	O
s-1	O
to	O
20	O
mg	O
s-1	O
.	O
The	O
infusion	O
was	O
discontinued	O
either	O
when	O
there	O
was	O
no	O
muscular	O
response	O
to	O
tetanic	O
stimulation	O
of	O
the	O
ulnar	O
nerve	O
or	O
when	O
Sch	O
120	O
mg	O
was	O
exceeded	O
.	O
Six	O
additional	O
patients	O
received	O
a	O
30	O
-	O
mg	O
i.v	O
.	O
bolus	O
dose	O
.	O
Fasciculations	B-DISEASE
in	O
six	O
areas	O
of	O
the	O
body	O
were	O
scored	O
from	O
0	O
to	O
3	O
and	O
summated	O
as	O
a	O
total	O
fasciculation	B-DISEASE
score	O
.	O
The	O
times	O
to	O
first	O
fasciculation	B-DISEASE
,	O
twitch	O
suppression	O
and	O
tetanus	B-DISEASE
suppression	O
were	O
inversely	O
related	O
to	O
the	O
infusion	O
rates	O
.	O
Fasciculations	B-DISEASE
in	O
the	O
six	O
areas	O
and	O
the	O
total	O
fasciculation	B-DISEASE
score	O
were	O
related	O
directly	O
to	O
the	O
rate	O
of	O
infusion	O
.	O
Total	O
fasciculation	B-DISEASE
scores	O
in	O
the	O
30	O
-	O
mg	O
bolus	O
group	O
and	O
the	O
5	O
-	O
mg	O
s-1	O
and	O
20	O
-	O
mg	O
s-1	O
infusion	O
groups	O
were	O
not	O
significantly	O
different	O
.	O

Galanthamine	O
hydrobromide	O
,	O
a	O
longer	O
acting	O
anticholinesterase	O
drug	O
,	O
in	O
the	O
treatment	O
of	O
the	O
central	O
effects	O
of	O
scopolamine	B-CHEMICAL
(	O
Hyoscine	O
)	O
.	O
Galanthamine	O
hydrobromide	O
,	O
an	O
anticholinesterase	O
drug	O
capable	O
of	O
penetrating	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
was	O
used	O
in	O
a	O
patient	O
demonstrating	O
central	O
effects	O
of	O
scopolamine	B-CHEMICAL
(	O
hyoscine	O
)	O
overdosage	O
.	O
It	O
is	O
longer	O
acting	O
than	O
physostigmine	O
and	O
is	O
used	O
in	O
anaesthesia	O
to	O
reverse	O
the	O
non	O
-	O
depolarizing	O
neuromuscular	O
block	O
.	O
However	O
,	O
studies	O
into	O
the	O
dose	O
necessary	O
to	O
combating	O
scopolamine	B-CHEMICAL
intoxication	O
are	O
indicated	O
.	O

Effects	O
of	O
uninephrectomy	O
and	O
high	O
protein	O
feeding	O
on	O
lithium	B-CHEMICAL
-	O
induced	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
in	O
rats	O
.	O
Rats	O
with	O
lithium	B-CHEMICAL
-	O
induced	O
nephropathy	B-DISEASE
were	O
subjected	O
to	O
high	O
protein	O
(	O
HP	O
)	O
feeding	O
,	O
uninephrectomy	O
(	O
NX	O
)	O
or	O
a	O
combination	O
of	O
these	O
,	O
in	O
an	O
attempt	O
to	O
induce	O
glomerular	O
hyperfiltration	O
and	O
further	O
progression	O
of	O
renal	B-DISEASE
failure	I-DISEASE
.	O
Newborn	O
female	O
Wistar	O
rats	O
were	O
fed	O
a	O
lithium	B-CHEMICAL
-	O
containing	O
diet	O
(	O
50	O
mmol	O
/	O
kg	O
)	O
for	O
8	O
weeks	O
and	O
then	O
randomized	O
to	O
normal	O
diet	O
,	O
HP	O
diet	O
(	O
40	O
vs.	O
19	O
%	O
)	O
,	O
NX	O
or	O
HP+NX	O
for	O
another	O
8	O
weeks	O
.	O
Corresponding	O
non	O
-	O
lithium	B-CHEMICAL
pretreated	O
groups	O
were	O
generated	O
.	O
When	O
comparing	O
all	O
lithium	B-CHEMICAL
treated	O
versus	O
non	O
-	O
lithium	B-CHEMICAL
-	O
treated	O
groups	O
,	O
lithium	B-CHEMICAL
caused	O
a	O
reduction	O
in	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
without	O
significant	O
changes	O
in	O
effective	O
renal	O
plasma	O
flow	O
(	O
as	O
determined	O
by	O
a	O
marker	O
secreted	O
into	O
the	O
proximal	O
tubules	O
)	O
or	O
lithium	B-CHEMICAL
clearance	O
.	O
Consequently	O
,	O
lithium	B-CHEMICAL
pretreatment	O
caused	O
a	O
fall	O
in	O
filtration	O
fraction	O
and	O
an	O
increase	O
in	O
fractional	O
Li	O
excretion	O
.	O
Lithium	B-CHEMICAL
also	O
caused	O
proteinuria	B-DISEASE
and	O
systolic	O
hypertension	B-DISEASE
in	O
absence	O
of	O
glomerulosclerosis	O
.	O
HP	O
failed	O
to	O
accentuante	O
progression	O
of	O
renal	B-DISEASE
failure	I-DISEASE
and	O
in	O
fact	O
tended	O
to	O
increase	O
GFR	O
and	O
decrease	O
plasma	O
creatinine	B-CHEMICAL
levels	O
in	O
lithium	B-CHEMICAL
pretreated	O
rats	O
.	O
NX	O
caused	O
an	O
additive	O
deterioration	O
in	O
GFR	O
which	O
,	O
however	O
,	O
was	O
ameliorated	O
by	O
HP	O
.	O
NX+HP	O
caused	O
a	O
further	O
rise	O
in	O
blood	O
pressure	O
in	O
Li	O
-	O
pretreated	O
rats	O
.	O
The	O
results	O
indicate	O
that	O
Li	O
-	O
induced	O
nephropathy	B-DISEASE
,	O
even	O
when	O
the	O
GFR	O
is	O
only	O
modestly	O
reduced	O
,	O
is	O
associated	O
with	O
proteinuria	B-DISEASE
and	O
arterial	O
systolic	O
hypertension	B-DISEASE
.	O
In	O
this	O
model	O
of	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
the	O
decline	O
in	O
GFR	O
is	O
not	O
accompanied	O
by	O
a	O
corresponding	O
fall	O
in	O
effective	O
renal	O
plasma	O
flow	O
,	O
which	O
may	O
be	O
the	O
functional	O
expression	O
of	O
the	O
formation	O
of	O
nonfiltrating	O
atubular	O
glomeruli	O
.	O
The	O
fractional	O
reabsorption	O
of	O
tubular	O
fluid	O
by	O
the	O
proximal	O
tubules	O
is	O
reduced	O
,	O
leaving	O
the	O
distal	O
delivery	O
unchanged.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Treatment	O
of	O
Crohn	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
with	O
fusidic	O
acid	O
:	O
an	O
antibiotic	O
with	O
immunosuppressive	O
properties	O
similar	O
to	O
cyclosporin	O
.	O
Fusidic	O
acid	O
is	O
an	O
antibiotic	O
with	O
T	O
-	O
cell	O
specific	O
immunosuppressive	O
effects	O
similar	O
to	O
those	O
of	O
cyclosporin	O
.	O
Because	O
of	O
the	O
need	O
for	O
the	O
development	O
of	O
new	O
treatments	O
for	O
Crohn	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
,	O
a	O
pilot	O
study	O
was	O
undertaken	O
to	O
estimate	O
the	O
pharmacodynamics	O
and	O
tolerability	O
of	O
fusidic	O
acid	O
treatment	O
in	O
chronic	O
active	O
,	O
therapy	O
-	O
resistant	O
patients	O
.	O
Eight	O
Crohn	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
patients	O
were	O
included	O
.	O
Fusidic	O
acid	O
was	O
administered	O
orally	O
in	O
a	O
dose	O
of	O
500	O
mg	O
t.d.s	O
.	O
and	O
the	O
treatment	O
was	O
planned	O
to	O
last	O
8	O
weeks	O
.	O
The	O
disease	B-DISEASE
activity	O
was	O
primarily	O
measured	O
by	O
a	O
modified	O
individual	O
grading	O
score	O
.	O
Five	O
of	O
8	O
patients	O
(	O
63	O
%	O
)	O
improved	O
during	O
fusidic	O
acid	O
treatment	O
:	O
3	O
at	O
two	O
weeks	O
and	O
2	O
after	O
four	O
weeks	O
.	O
There	O
were	O
no	O
serious	O
clinical	O
side	O
effects	O
,	O
but	O
dose	O
reduction	O
was	O
required	O
in	O
two	O
patients	O
because	O
of	O
nausea	B-DISEASE
.	O
Biochemically	O
,	O
an	O
increase	O
in	O
alkaline	O
phosphatases	O
was	O
noted	O
in	O
5	O
of	O
8	O
cases	O
(	O
63	O
%	O
)	O
,	O
and	O
the	O
greatest	O
increases	O
were	O
seen	O
in	O
those	O
who	O
had	O
elevated	O
levels	O
prior	O
to	O
treatment	O
.	O
All	O
reversed	O
to	O
pre	O
-	O
treatment	O
levels	O
after	O
cessation	O
of	O
treatment	O
.	O
The	O
results	O
of	O
this	O
pilot	O
study	O
suggest	O
that	O
fusidic	O
acid	O
may	O
be	O
of	O
benefit	O
in	O
selected	O
chronic	O
active	O
Crohn	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
patients	O
in	O
whom	O
conventional	O
treatment	O
is	O
ineffective	O
.	O
Because	O
there	O
seems	O
to	O
exist	O
a	O
scientific	O
rationale	O
for	O
the	O
use	O
of	O
fusidic	O
acid	O
at	O
the	O
cytokine	O
level	O
in	O
inflammatory	O
bowel	O
disease	B-DISEASE
,	O
we	O
suggest	O
that	O
the	O
role	O
of	O
this	O
treatment	O
should	O
be	O
further	O
investigated	O
.	O

Electrocardiographic	O
evidence	O
of	O
myocardial	B-DISEASE
injury	I-DISEASE
in	O
psychiatrically	O
hospitalized	O
cocaine	B-CHEMICAL
abusers	O
.	O
The	O
electrocardiograms	O
(	O
ECG	O
)	O
of	O
99	O
cocaine	B-CHEMICAL
-	O
abusing	O
patients	O
were	O
compared	O
with	O
the	O
ECGs	O
of	O
50	O
schizophrenic	B-DISEASE
controls	O
.	O
Eleven	O
of	O
the	O
cocaine	B-CHEMICAL
abusers	O
and	O
none	O
of	O
the	O
controls	O
had	O
ECG	O
evidence	O
of	O
significant	O
myocardial	B-DISEASE
injury	I-DISEASE
defined	O
as	O
myocardial	B-DISEASE
infarction	I-DISEASE
,	O
ischemia	B-DISEASE
,	O
and	O
bundle	B-DISEASE
branch	I-DISEASE
block	I-DISEASE
.	O

Sulpiride	B-CHEMICAL
-	O
induced	O
tardive	B-DISEASE
dystonia	I-DISEASE
.	O
Sulpiride	B-CHEMICAL
is	O
a	O
selective	O
D2	O
-	O
receptor	O
antagonist	O
with	O
antipsychotic	O
and	O
antidepressant	O
properties	O
.	O
Although	O
initially	O
thought	O
to	O
be	O
free	O
of	O
extrapyramidal	O
side	O
effects	O
,	O
sulpiride	B-CHEMICAL
-	O
induced	O
tardive	B-DISEASE
dyskinesia	I-DISEASE
and	O
parkinsonism	B-DISEASE
have	O
been	O
reported	O
occasionally	O
.	O
We	O
studied	O
a	O
37	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
persistent	O
segmental	O
dystonia	B-DISEASE
within	O
2	O
months	O
after	O
starting	O
sulpiride	B-CHEMICAL
therapy	O
.	O
We	O
could	O
not	O
find	O
any	O
previous	O
reports	O
of	O
sulpiride	B-CHEMICAL
-	O
induced	O
tardive	B-DISEASE
dystonia	I-DISEASE
.	O

Ocular	O
and	O
auditory	O
toxicity	B-DISEASE
in	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	B-CHEMICAL
.	O
During	O
an	O
18	O
-	O
month	O
period	O
of	O
study	O
41	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	B-CHEMICAL
(	O
10	O
-	O
40	O
mg	O
/	O
kg	O
BW/3	O
times	O
weekly	O
)	O
for	O
the	O
first	O
time	O
were	O
monitored	O
for	O
detection	O
of	O
audiovisual	B-DISEASE
toxicity	I-DISEASE
.	O
6	O
patients	O
presented	O
clinical	O
symptoms	O
of	O
visual	O
or	O
auditory	O
toxicity	B-DISEASE
.	O
Moreover	O
,	O
detailed	O
ophthalmologic	O
and	O
audiologic	O
studies	O
disclosed	O
abnormalities	O
in	O
7	O
more	O
asymptomatic	O
patients	O
.	O
Visual	B-DISEASE
toxicity	I-DISEASE
was	O
of	O
retinal	O
origin	O
and	O
was	O
characterized	O
by	O
a	O
tritan	O
-	O
type	O
dyschromatopsy	B-DISEASE
,	O
sometimes	O
associated	O
with	O
a	B-DISEASE
loss	I-DISEASE
of	I-DISEASE
visual	I-DISEASE
acuity	I-DISEASE
and	O
pigmentary	O
retinal	O
deposits	O
.	O
Auditory	O
toxicity	B-DISEASE
was	O
characterized	O
by	O
a	O
mid-	O
to	O
high	O
-	O
frequency	O
neurosensorial	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
the	O
lesion	O
was	O
of	O
the	O
cochlear	O
type	O
.	O
Desferrioxamine	B-CHEMICAL
withdrawal	O
resulted	O
in	O
a	O
complete	O
recovery	O
of	O
visual	O
function	O
in	O
1	O
patient	O
and	O
partial	O
recovery	O
in	O
3	O
,	O
and	O
a	O
complete	O
reversal	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
3	O
patients	O
and	O
partial	O
recovery	O
in	O
3	O
.	O
This	O
toxicity	B-DISEASE
appeared	O
in	O
patients	O
receiving	O
the	O
higher	O
doses	O
of	O
desferrioxamine	B-CHEMICAL
or	O
coincided	O
with	O
the	O
normalization	O
of	O
ferritin	O
or	O
aluminium	O
serum	O
levels	O
.	O
The	O
data	O
indicate	O
that	O
audiovisual	B-DISEASE
toxicity	I-DISEASE
is	O
not	O
an	O
infrequent	O
complication	O
in	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	B-CHEMICAL
.	O
Periodical	O
audiovisual	O
monitoring	O
should	O
be	O
performed	O
on	O
hemodialyzed	O
patients	O
receiving	O
the	O
drug	O
in	O
order	O
to	O
detect	O
adverse	O
effects	O
as	O
early	O
as	O
possible	O
.	O

Myasthenia	B-DISEASE
gravis	I-DISEASE
presenting	O
as	O
weakness	B-DISEASE
after	O
magnesium	B-CHEMICAL
administration	O
.	O
We	O
studied	O
a	O
patient	O
with	O
no	O
prior	O
history	O
of	O
neuromuscular	O
disease	B-DISEASE
who	O
became	O
virtually	O
quadriplegic	O
after	O
parenteral	O
magnesium	B-CHEMICAL
administration	O
for	O
preeclampsia	O
.	O
The	O
serum	O
magnesium	B-CHEMICAL
concentration	O
was	O
3.0	O
mEq	O
/	O
L	O
,	O
which	O
is	O
usually	O
well	O
tolerated	O
.	O
The	O
magnesium	B-CHEMICAL
was	O
stopped	O
and	O
she	O
recovered	O
over	O
a	O
few	O
days	O
.	O
While	O
she	O
was	O
weak	O
,	O
2	O
-	O
Hz	O
repetitive	O
stimulation	O
revealed	O
a	O
decrement	O
without	O
significant	O
facilitation	O
at	O
rapid	O
rates	O
or	O
after	O
exercise	O
,	O
suggesting	O
postsynaptic	O
neuromuscular	O
blockade	O
.	O
After	O
her	O
strength	O
returned	O
,	O
repetitive	O
stimulation	O
was	O
normal	O
,	O
but	O
single	O
fiber	O
EMG	O
revealed	O
increased	O
jitter	O
and	O
blocking	O
.	O
Her	O
acetylcholine	O
receptor	O
antibody	O
level	O
was	O
markedly	O
elevated	O
.	O
Although	O
paralysis	B-DISEASE
after	O
magnesium	B-CHEMICAL
administration	O
has	O
been	O
described	O
in	O
patients	O
with	O
known	O
myasthenia	B-DISEASE
gravis	I-DISEASE
,	O
it	O
has	O
not	O
previously	O
been	O
reported	O
to	O
be	O
the	O
initial	O
or	O
only	O
manifestation	O
of	O
the	O
disease	B-DISEASE
.	O
Patients	O
who	O
are	O
unusually	O
sensitive	O
to	O
the	O
neuromuscular	O
effects	O
of	O
magnesium	B-CHEMICAL
should	O
be	O
suspected	O
of	O
having	O
an	O
underlying	O
disorder	B-DISEASE
of	I-DISEASE
neuromuscular	I-DISEASE
transmission	I-DISEASE
.	O

Chloroacetaldehyde	O
and	O
its	O
contribution	O
to	O
urotoxicity	O
during	O
treatment	O
with	O
cyclophosphamide	B-CHEMICAL
or	O
ifosfamide	B-CHEMICAL
.	O
An	O
experimental	O
study	O
/	O
short	O
communication	O
.	O
Based	O
on	O
clinical	O
data	O
,	O
indicating	O
that	O
chloroacetaldehyde	O
(	O
CAA	O
)	O
is	O
an	O
important	O
metabolite	O
of	O
oxazaphosphorine	O
cytostatics	O
,	O
an	O
experimental	O
study	O
was	O
carried	O
out	O
in	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
CAA	O
in	O
the	O
development	O
of	O
hemorrhagic	O
cystitis	B-DISEASE
.	O
The	O
data	O
demonstrate	O
that	O
CAA	O
after	O
i.v	O
.	O
administration	O
does	O
not	O
contribute	O
to	O
bladder	B-DISEASE
damage	I-DISEASE
.	O
When	O
instilled	O
directly	O
into	O
the	O
bladder	O
,	O
CAA	O
exerts	O
urotoxic	O
effects	O
,	O
it	O
is	O
,	O
however	O
,	O
susceptible	O
to	O
detoxification	O
with	O
mesna	B-CHEMICAL
.	O

Source	O
of	O
pain	B-DISEASE
and	O
primitive	O
dysfunction	O
in	O
migraine	B-DISEASE
:	O
an	O
identical	O
site	O
?	O
Twenty	O
common	O
migraine	B-DISEASE
patients	O
received	O
a	O
one	O
sided	O
frontotemporal	O
application	O
of	O
nitroglycerin	B-CHEMICAL
(	O
10	O
patients	O
)	O
or	O
placebo	O
ointment	O
(	O
10	O
patients	O
)	O
in	O
a	O
double	O
blind	B-DISEASE
study	O
.	O
Early	O
onset	O
migraine	B-DISEASE
attacks	O
were	O
induced	O
by	O
nitroglycerin	B-CHEMICAL
in	O
seven	O
out	O
of	O
10	O
patients	O
versus	O
no	O
patient	O
in	O
the	O
placebo	O
group	O
.	O
Subsequently	O
20	O
migraine	B-DISEASE
patients	O
,	O
who	O
developed	O
an	O
early	O
onset	O
attack	O
with	O
frontotemporal	O
nitroglycerin	B-CHEMICAL
,	O
received	O
the	O
drug	O
in	O
a	O
second	O
induction	O
test	O
at	O
other	O
body	O
areas	O
.	O
No	O
early	O
onset	O
migraine	B-DISEASE
was	O
observed	O
.	O
Thus	O
the	O
migraine	B-DISEASE
-	O
inducing	O
effect	O
of	O
nitroglycerin	B-CHEMICAL
seems	O
to	O
depend	O
on	O
direct	O
stimulation	O
of	O
the	O
habitual	O
site	O
of	O
pain	B-DISEASE
,	O
suggesting	O
that	O
the	O
frontotemporal	O
region	O
is	O
of	O
crucial	O
importance	O
in	O
the	O
development	O
of	O
a	O
migraine	B-DISEASE
crisis	O
.	O
This	O
is	O
not	O
consistent	O
with	O
a	O
CNS	O
origin	O
of	O
migraine	B-DISEASE
attack	O
.	O

Clotiazepam	B-CHEMICAL
-	O
induced	O
acute	B-DISEASE
hepatitis	I-DISEASE
.	O
We	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
acute	B-DISEASE
hepatitis	I-DISEASE
with	O
extensive	B-DISEASE
hepatocellular	I-DISEASE
necrosis	I-DISEASE
,	O
7	O
months	O
after	O
the	O
onset	O
of	O
administration	O
of	O
clotiazepam	B-CHEMICAL
,	O
a	O
thienodiazepine	O
derivative	O
.	O
Clotiazepam	B-CHEMICAL
withdrawal	O
was	O
followed	O
by	O
prompt	O
recovery	O
.	O
The	O
administration	O
of	O
several	O
benzodiazepines	O
,	O
chemically	O
related	O
to	O
clotiazepam	B-CHEMICAL
,	O
did	O
not	O
interfere	O
with	O
recovery	O
and	O
did	O
not	O
induce	O
any	O
relapse	O
of	O
hepatitis	B-DISEASE
.	O
This	O
observation	O
shows	O
that	O
clotiazepam	B-CHEMICAL
can	O
induce	O
acute	B-DISEASE
hepatitis	I-DISEASE
and	O
suggests	O
that	O
there	O
is	O
no	O
cross	O
hepatotoxicity	O
between	O
clotiazepam	B-CHEMICAL
and	O
several	O
benzodiazepines	O
.	O

Arterial	O
hypertension	B-DISEASE
as	O
a	O
complication	O
of	O
prolonged	O
ketoconazole	B-CHEMICAL
treatment	O
.	O
Two	O
of	O
14	O
patients	O
with	O
Cushing	O
's	O
syndrome	B-DISEASE
treated	O
on	O
a	O
long	O
-	O
term	O
basis	O
with	O
ketoconazole	B-CHEMICAL
developed	O
sustained	O
hypertension	B-DISEASE
.	O
In	O
both	O
cases	O
normal	O
plasma	O
and	O
urinary	O
free	O
cortisol	B-CHEMICAL
levels	O
had	O
been	O
achieved	O
following	O
ketoconazole	B-CHEMICAL
therapy	O
,	O
yet	O
continuous	O
blood	O
pressure	O
monitoring	O
demonstrated	O
hypertension	B-DISEASE
31	O
(	O
patient	O
1	O
)	O
and	O
52	O
weeks	O
(	O
patient	O
2	O
)	O
after	O
treatment	O
.	O
In	O
patient	O
1	O
,	O
plasma	O
levels	O
of	O
deoxycorticosterone	O
and	O
11	B-CHEMICAL
-	I-CHEMICAL
deoxycortisol	I-CHEMICAL
were	O
elevated	O
.	O
In	O
patient	O
2	O
,	O
in	O
addition	O
to	O
an	O
increase	O
in	O
both	O
deoxycorticosterone	O
and	O
11	B-CHEMICAL
-	I-CHEMICAL
deoxycortisol	I-CHEMICAL
levels	O
,	O
plasma	O
aldosterone	O
values	O
were	O
raised	O
,	O
with	O
a	O
concomitant	O
suppression	O
of	O
renin	O
levels	O
.	O
Our	O
findings	O
show	O
that	O
long	O
-	O
term	O
treatment	O
with	O
high	O
doses	O
of	O
ketoconazole	B-CHEMICAL
may	O
induce	O
enzyme	O
blockade	O
leading	O
to	O
mineralocorticoid	O
-	O
related	O
hypertension	B-DISEASE
.	O

Effects	O
of	O
an	O
inhibitor	O
of	O
angiotensin	O
converting	O
enzyme	O
(	O
Captopril	B-CHEMICAL
)	O
on	O
pulmonary	O
and	O
renal	B-DISEASE
insufficiency	I-DISEASE
due	O
to	O
intravascular	O
coagulation	O
in	O
the	O
rat	O
.	O
Induction	O
of	O
intravascular	O
coagulation	O
and	O
inhibition	O
of	O
fibrinolysis	O
by	O
injection	O
of	O
thrombin	O
and	O
tranexamic	O
acid	O
(	O
AMCA	O
)	O
in	O
the	O
rat	O
gives	O
rise	O
to	O
pulmonary	O
and	O
renal	B-DISEASE
insufficiency	I-DISEASE
resembling	O
that	O
occurring	O
after	O
trauma	O
or	O
sepsis	B-DISEASE
in	O
man	O
.	O
Injection	O
of	O
Captopril	B-CHEMICAL
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
an	O
inhibitor	O
of	O
angiotensin	O
converting	O
enzyme	O
(	O
ACE	O
)	O
,	O
reduced	O
both	O
pulmonary	O
and	O
renal	B-DISEASE
insufficiency	I-DISEASE
in	O
this	O
rat	O
model	O
.	O
The	O
lung	O
weights	O
were	O
lower	O
and	O
PaO2	O
was	O
improved	O
in	O
rats	O
given	O
this	O
enzyme	O
-	O
blocking	O
agent	O
.	O
The	O
contents	O
of	O
albumin	O
in	O
the	O
lungs	O
were	O
not	O
changed	O
,	O
indicating	O
that	O
Captopril	B-CHEMICAL
did	O
not	O
influence	O
the	O
extravasation	O
of	O
protein	O
.	O
Renal	B-DISEASE
damage	I-DISEASE
as	O
reflected	O
by	O
an	O
increase	O
in	O
serum	O
urea	B-CHEMICAL
and	O
in	O
kidney	O
weight	O
was	O
prevented	O
by	O
Captopril	B-CHEMICAL
.	O
The	O
amount	O
of	O
fibrin	O
in	O
the	O
kidneys	O
was	O
also	O
considerably	O
lower	O
than	O
in	O
animals	O
which	O
received	O
thrombin	O
and	O
AMCA	O
alone	O
.	O
It	O
is	O
suggested	O
that	O
the	O
effects	O
of	O
Captopril	B-CHEMICAL
on	O
the	O
lungs	O
may	O
be	O
attributable	O
to	O
a	O
vasodilatory	O
effect	O
due	O
to	O
a	O
reduction	O
in	O
the	O
circulating	O
level	O
of	O
Angiotension	O
II	O
and	O
an	O
increase	O
in	O
prostacyclin	O
(	O
secondary	O
to	O
an	O
increase	O
in	O
bradykinin	B-CHEMICAL
)	O
.	O
Captopril	B-CHEMICAL
may	O
,	O
by	O
the	O
same	O
mechanism	O
,	O
reduce	O
the	O
increase	O
in	O
glomerular	O
filtration	O
that	O
is	O
known	O
to	O
occur	O
after	O
an	O
injection	O
of	O
thrombin	O
,	O
thereby	O
diminishing	O
the	O
aggregation	O
of	O
fibrin	O
monomers	O
in	O
the	O
glomeruli	O
,	O
with	O
the	O
result	O
that	O
less	O
fibrin	O
will	O
be	O
deposited	O
and	O
thus	O
less	O
kidney	O
damage	O
will	O
be	O
produced	O
.	O

A	O
randomized	O
comparison	O
of	O
labetalol	B-CHEMICAL
and	O
nitroprusside	B-CHEMICAL
for	O
induced	O
hypotension	B-DISEASE
.	O
In	O
a	O
randomized	O
study	O
,	O
labetalol	B-CHEMICAL
-	O
induced	O
hypotension	B-DISEASE
and	O
nitroprusside	B-CHEMICAL
-	O
induced	O
hypotension	B-DISEASE
were	O
compared	O
in	O
20	O
patients	O
(	O
10	O
in	O
each	O
group	O
)	O
scheduled	O
for	O
major	O
orthopedic	O
procedures	O
.	O
Each	O
patient	O
was	O
subjected	O
to	O
an	O
identical	O
anesthetic	O
protocol	O
and	O
similar	O
drug	O
-	O
induced	O
reductions	O
in	O
mean	O
arterial	O
blood	O
pressure	O
(	O
BP	O
)	O
(	O
50	O
to	O
55	O
mmHg	O
)	O
.	O
Nitroprusside	B-CHEMICAL
infusion	O
was	O
associated	O
with	O
a	O
significant	O
(	O
p	O
less	O
than	O
0.05	O
)	O
increase	O
in	O
heart	O
rate	O
and	O
cardiac	O
output	O
;	O
rebound	O
hypertension	B-DISEASE
was	O
observed	O
in	O
three	O
patients	O
after	O
discontinuation	O
of	O
nitroprusside	B-CHEMICAL
.	O
Labetalol	B-CHEMICAL
administration	O
was	O
not	O
associated	O
with	O
any	O
of	O
these	O
findings	O
.	O
Arterial	O
PO2	O
decreased	O
in	O
both	O
groups	O
.	O
It	O
was	O
concluded	O
that	O
labetalol	B-CHEMICAL
offers	O
advantages	O
over	O
nitroprusside	B-CHEMICAL
.	O

Chronic	O
carbamazepine	B-CHEMICAL
treatment	O
in	O
the	O
rat	O
:	O
efficacy	O
,	O
toxicity	B-DISEASE
,	O
and	O
effect	O
on	O
plasma	O
and	O
tissue	O
folate	O
concentrations	O
.	O
Folate	O
depletion	O
has	O
often	O
been	O
a	O
problem	O
in	O
chronic	O
antiepileptic	O
drug	O
(	O
AED	O
)	O
therapy	O
.	O
Carbamazepine	B-CHEMICAL
(	O
CBZ	B-CHEMICAL
)	O
,	O
a	O
commonly	O
used	O
AED	O
,	O
has	O
been	O
implicated	O
in	O
some	O
clinical	O
studies	O
.	O
A	O
rat	O
model	O
was	O
developed	O
to	O
examine	O
the	O
effects	O
of	O
chronic	O
CBZ	B-CHEMICAL
treatment	O
on	O
folate	O
concentrations	O
in	O
the	O
rat	O
.	O
In	O
the	O
course	O
of	O
developing	O
this	O
model	O
,	O
a	O
common	O
vehicle	O
,	O
propylene	B-CHEMICAL
glycol	I-CHEMICAL
,	O
by	O
itself	O
in	O
high	O
doses	O
,	O
was	O
found	O
to	O
exhibit	O
protective	O
properties	O
against	O
induced	O
seizures	B-DISEASE
and	O
inhibited	O
weight	B-DISEASE
gain	I-DISEASE
.	O
Seizures	B-DISEASE
induced	O
by	O
hexafluorodiethyl	O
ether	O
(	O
HFDE	O
)	O
were	O
also	O
found	O
to	O
be	O
a	O
more	O
sensitive	O
measure	O
of	O
protection	O
by	O
CBZ	B-CHEMICAL
than	O
seizures	B-DISEASE
induced	O
by	O
maximal	O
electroshock	O
(	O
MES	O
)	O
.	O
Oral	O
administration	O
of	O
CBZ	B-CHEMICAL
as	O
an	O
aqueous	O
suspension	O
every	O
8	O
h	O
at	O
a	O
dose	O
of	O
250	O
mg	O
/	O
kg	O
was	O
continuously	O
protective	O
against	O
HFDE	O
-	O
induced	O
seizures	B-DISEASE
and	O
was	O
minimally	O
toxic	O
as	O
measured	O
by	O
weight	B-DISEASE
gain	I-DISEASE
over	O
8	O
weeks	O
of	O
treatment	O
.	O
The	O
CBZ	B-CHEMICAL
levels	O
measured	O
in	O
plasma	O
and	O
brain	O
of	O
these	O
animals	O
,	O
however	O
,	O
were	O
below	O
those	O
normally	O
considered	O
protective	O
.	O
This	O
treatment	O
with	O
CBZ	B-CHEMICAL
had	O
no	O
apparent	O
adverse	O
effect	O
on	O
folate	O
concentrations	O
in	O
the	O
rat	O
,	O
and	O
,	O
indeed	O
,	O
the	O
folate	O
concentration	O
increased	O
in	O
liver	O
after	O
6	O
weeks	O
of	O
treatment	O
and	O
in	O
plasma	O
at	O
8	O
weeks	O
of	O
treatment	O
.	O

Inhibition	O
of	O
sympathoadrenal	O
activity	O
by	O
atrial	B-CHEMICAL
natriuretic	I-CHEMICAL
factor	I-CHEMICAL
in	O
dogs	O
.	O
In	O
six	O
conscious	O
,	O
trained	O
dogs	O
,	O
maintained	O
on	O
a	O
normal	O
sodium	B-CHEMICAL
intake	O
of	O
2	O
to	O
4	O
mEq	O
/	O
kg	O
/	O
day	O
,	O
sympathetic	O
activity	O
was	O
assessed	O
as	O
the	O
release	O
rate	O
of	O
norepinephrine	B-CHEMICAL
and	O
epinephrine	B-CHEMICAL
during	O
15	O
-	O
minute	O
i.v	O
.	O
infusions	O
of	O
human	O
alpha	O
-	O
atrial	B-CHEMICAL
natriuretic	I-CHEMICAL
factor	I-CHEMICAL
.	O
Mean	O
arterial	O
pressure	O
(	O
as	O
a	O
percentage	O
of	O
control	O
+	O
/-	O
SEM	O
)	O
during	O
randomized	O
infusions	O
of	O
0.03	O
,	O
0.1	O
,	O
0.3	O
,	O
or	O
1.0	O
microgram	O
/	O
kg	O
/	O
min	O
was	O
99	O
+	O
/-	O
1	O
,	O
95	O
+	O
/-	O
1	O
(	O
p	O
less	O
than	O
0.05	O
)	O
,	O
93	O
+	O
/-	O
1	O
(	O
p	O
less	O
than	O
0.01	O
)	O
,	O
or	O
79	O
+	O
/-	O
6	O
%	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
respectively	O
,	O
but	O
no	O
tachycardia	B-DISEASE
and	O
no	O
augmentation	O
of	O
the	O
norepinephrine	B-CHEMICAL
release	O
rate	O
(	O
up	O
to	O
0.3	O
microgram	O
/	O
kg	O
/	O
min	O
)	O
were	O
observed	O
,	O
which	O
is	O
in	O
contrast	O
to	O
comparable	O
hypotension	B-DISEASE
induced	O
by	O
hydralazine	O
or	O
nitroglycerin	B-CHEMICAL
.	O
The	O
release	O
rate	O
of	O
epinephrine	B-CHEMICAL
(	O
control	O
,	O
6.7	O
+	O
/-	O
0.6	O
ng	O
/	O
kg	O
/	O
min	O
)	O
declined	O
immediately	O
during	O
infusions	O
of	O
atrial	B-CHEMICAL
natriuretic	I-CHEMICAL
factor	I-CHEMICAL
to	O
a	O
minimum	O
of	O
49	O
+	O
/-	O
5	O
%	O
of	O
control	O
(	O
p	O
less	O
than	O
0.001	O
)	O
during	O
0.1	O
microgram	O
/	O
kg	O
/	O
min	O
and	O
to	O
63	O
+	O
/-	O
5	O
%	O
(	O
0.1	O
greater	O
than	O
p	O
greater	O
than	O
0.05	O
)	O
or	O
95	O
+	O
/-	O
13	O
%	O
(	O
not	O
significant	O
)	O
during	O
0.3	O
or	O
1.0	O
microgram	O
/	O
kg	O
/	O
min	O
.	O
Steady	O
state	O
arterial	O
plasma	O
concentrations	O
of	O
atrial	B-CHEMICAL
natriuretic	I-CHEMICAL
factor	I-CHEMICAL
were	O
39	O
+	O
/-	O
10	O
pg	O
/	O
ml	O
(	O
n	O
=	O
6	O
)	O
during	O
infusions	O
of	O
saline	O
and	O
284	O
+	O
/-	O
24	O
pg	O
/	O
ml	O
(	O
n	O
=	O
6	O
)	O
and	O
1520	O
+	O
/-	O
300	O
pg	O
/	O
ml	O
(	O
n	O
=	O
9	O
)	O
during	O
0.03	O
and	O
0.1	O
microgram	O
/	O
kg	O
/	O
min	O
infusions	O
of	O
the	O
factor.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Death	B-DISEASE
from	O
chemotherapy	O
in	O
gestational	B-DISEASE
trophoblastic	I-DISEASE
disease	I-DISEASE
.	O
Multiple	O
cytotoxic	O
drug	O
administration	O
is	O
the	O
generally	O
accepted	O
treatment	O
of	O
patients	O
with	O
a	O
high	O
-	O
risk	O
stage	O
of	O
choriocarcinoma	B-DISEASE
.	O
Based	O
on	O
this	O
principle	O
a	O
27	O
-	O
year	O
old	O
woman	O
,	O
classified	O
as	O
being	O
in	O
the	O
high	O
-	O
risk	O
group	O
(	O
Goldstein	O
and	O
Berkowitz	O
score	O
:	O
11	O
)	O
,	O
was	O
treated	O
with	O
multiple	O
cytotoxic	O
drugs	O
.	O
The	O
multiple	O
drug	O
schema	O
consisted	O
of	O
:	O
Etoposide	B-CHEMICAL
16.213	O
,	O
Methotrexate	B-CHEMICAL
,	O
Cyclophosphamide	B-CHEMICAL
,	O
Actomycin	O
-	O
D	O
,	O
and	O
Cisplatin	B-CHEMICAL
.	O
On	O
the	O
first	O
day	O
of	O
the	O
schedule	O
,	O
moderate	O
high	O
doses	O
of	O
Methotrexate	B-CHEMICAL
,	O
Etoposide	B-CHEMICAL
and	O
Cyclophosphamide	B-CHEMICAL
were	O
administered	O
.	O
Within	O
8	O
hours	O
after	O
initiation	O
of	O
therapy	O
the	O
patient	O
died	O
with	O
a	O
clinical	O
picture	O
resembling	O
massive	O
pulmonary	O
obstruction	O
due	O
to	O
choriocarcinomic	O
tissue	O
plugs	O
,	O
probably	O
originating	O
from	O
the	O
uterus	O
.	O
Formation	O
of	O
these	O
plugs	O
was	O
probably	O
due	O
to	O
extensive	O
tumor	B-DISEASE
necrosis	B-DISEASE
at	O
the	O
level	O
of	O
the	O
walls	O
of	O
the	O
major	O
uterine	O
veins	O
,	O
which	O
resulted	O
in	O
an	O
open	O
exchange	O
of	O
tumor	B-DISEASE
plugs	O
to	O
the	O
vascular	O
spaces	O
;	O
decrease	O
in	O
tumor	B-DISEASE
tissue	O
coherence	O
secondary	O
to	O
chemotherapy	O
may	O
have	O
further	O
contributed	O
to	O
the	O
formation	O
of	O
tumor	B-DISEASE
emboli	O
.	O
In	O
view	O
of	O
the	O
close	O
time	O
association	O
between	O
the	O
start	O
of	O
chemotherapy	O
and	O
the	O
acute	O
onset	O
of	O
massive	O
embolism	B-DISEASE
other	O
explanations	O
,	O
such	O
as	O
spontaneous	O
necrosis	B-DISEASE
,	O
must	O
be	O
considered	O
less	O
likely	O
.	O
Patients	O
with	O
large	O
pelvic	O
tumor	B-DISEASE
loads	O
are	O
,	O
according	O
to	O
existing	O
classifications	O
,	O
at	O
high	O
risk	O
to	O
die	O
and	O
to	O
develop	O
drug	O
resistance	O
.	O
Notwithstanding	O
these	O
facts	O
our	O
findings	O
suggest	O
that	O
these	O
patients	O
might	O
benefit	O
from	O
relatively	O
mild	O
initial	O
treatment	O
,	O
especially	O
true	O
for	O
patients	O
not	O
previously	O
exposed	O
to	O
this	O
drug	O
.	O
Close	O
observation	O
of	O
the	O
response	O
status	O
both	O
clinically	O
and	O
with	O
beta	O
-	O
hCG	O
values	O
may	O
indicate	O
whether	O
and	O
when	O
more	O
agressive	O
combination	O
chemotherapy	O
should	O
be	O
started.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Sexual	B-DISEASE
dysfunction	I-DISEASE
among	O
patients	O
with	O
arthritis	B-DISEASE
.	O
The	O
relationship	O
of	O
arthritis	B-DISEASE
and	O
sexual	B-DISEASE
dysfunction	I-DISEASE
was	O
investigated	O
among	O
169	O
patients	O
with	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
,	O
osteoarthritis	B-DISEASE
and	O
spondyloarthropathy	O
,	O
130	O
of	O
whom	O
were	O
pair	O
-	O
matched	O
to	O
controls	O
.	O
Assessments	O
of	O
marital	O
happiness	O
and	O
depressed	B-DISEASE
mood	I-DISEASE
were	O
also	O
made	O
using	O
the	O
CES	O
-	O
D	O
and	O
the	O
Azrin	O
Marital	O
Happiness	O
Scale	O
(	O
AMHS	O
)	O
.	O
Sexual	B-DISEASE
dysfunctions	I-DISEASE
were	O
found	O
to	O
be	O
common	O
among	O
patients	O
and	O
controls	O
,	O
the	O
majority	O
in	O
both	O
groups	O
reporting	O
one	O
or	O
more	O
dysfunctions	O
.	O
Impotence	B-DISEASE
was	O
more	O
common	O
among	O
male	O
patients	O
than	O
controls	O
and	O
was	O
found	O
to	O
be	O
associated	O
with	O
co	B-CHEMICAL
-	O
morbidity	O
and	O
the	O
taking	O
of	O
methotrexate	B-CHEMICAL
.	O
Depressed	B-DISEASE
mood	I-DISEASE
was	O
more	O
common	O
among	O
patients	O
and	O
was	O
associated	O
with	O
certain	O
sexual	O
difficulties	O
,	O
but	O
not	O
with	O
impotence	B-DISEASE
.	O
Marital	O
unhappiness	O
,	O
as	O
indicated	O
by	O
AMHS	O
scores	O
,	O
was	O
not	O
associated	O
with	O
arthritis	B-DISEASE
but	O
was	O
associated	O
with	O
sexual	B-DISEASE
dysfunction	I-DISEASE
,	O
sexual	O
dissatisfaction	O
and	O
being	O
female	O
.	O

Does	O
paracetamol	B-CHEMICAL
cause	O
urothelial	O
cancer	B-DISEASE
or	O
renal	B-DISEASE
papillary	I-DISEASE
necrosis	I-DISEASE
?	O
The	O
risk	O
of	O
developing	O
renal	B-DISEASE
papillary	I-DISEASE
necrosis	I-DISEASE
or	O
cancer	B-DISEASE
of	O
the	O
renal	O
pelvis	O
,	O
ureter	O
or	O
bladder	O
associated	O
with	O
consumption	O
of	O
either	O
phenacetin	B-CHEMICAL
or	O
paracetamol	B-CHEMICAL
was	O
calculated	O
from	O
data	O
acquired	O
by	O
questionnaire	O
from	O
381	O
cases	O
and	O
808	O
controls	O
.	O
The	O
risk	O
of	O
renal	B-DISEASE
papillary	I-DISEASE
necrosis	I-DISEASE
was	O
increased	O
nearly	O
20	O
-	O
fold	O
by	O
consumption	O
of	O
phenacetin	B-CHEMICAL
,	O
which	O
also	O
increased	O
the	O
risk	O
for	O
cancer	B-DISEASE
of	O
the	O
renal	O
pelvis	O
and	O
bladder	O
but	O
not	O
for	O
ureteric	O
cancer	B-DISEASE
.	O
By	O
contrast	O
,	O
we	O
were	O
unable	O
to	O
substantiate	O
an	O
increased	O
risk	O
from	O
paracetamol	B-CHEMICAL
consumption	O
for	O
renal	B-DISEASE
papillary	I-DISEASE
necrosis	I-DISEASE
or	O
any	O
of	O
these	O
cancers	B-DISEASE
although	O
there	O
was	O
a	O
suggestion	O
of	O
an	O
association	O
with	O
cancer	B-DISEASE
of	I-DISEASE
the	I-DISEASE
ureter	I-DISEASE
.	O

Dapsone	B-CHEMICAL
-	O
associated	O
Heinz	O
body	O
hemolytic	O
anemia	B-DISEASE
in	O
a	O
Cambodian	O
woman	O
with	O
hemoglobin	O
E	O
trait	O
.	O
A	O
Cambodian	O
woman	O
with	O
hemoglobin	O
E	O
trait	O
(	O
AE	O
)	O
and	O
leprosy	B-DISEASE
developed	O
a	O
Heinz	O
body	O
hemolytic	O
anemia	B-DISEASE
while	O
taking	O
a	O
dose	O
of	O
dapsone	B-CHEMICAL
(	O
50	O
mg	O
/	O
day	O
)	O
not	O
usually	O
associated	O
with	O
clinical	O
hemolysis	B-DISEASE
.	O
Her	O
red	O
blood	O
cells	O
(	O
RBCs	O
)	O
had	O
increased	O
incubated	O
Heinz	O
body	O
formation	O
,	O
decreased	O
reduced	O
glutathione	B-CHEMICAL
(	O
GSH	O
)	O
,	O
and	O
decreased	O
GSH	O
stability	O
.	O
The	O
pentose	O
phosphate	B-CHEMICAL
shunt	O
activity	O
of	O
the	O
dapsone	B-CHEMICAL
-	O
exposed	O
AE	O
RBCs	O
was	O
increased	O
compared	O
to	O
normal	O
RBCs	O
.	O
Although	O
the	O
AE	O
RBCs	O
from	O
an	O
individual	O
not	O
taking	O
dapsone	B-CHEMICAL
had	O
increased	O
incubated	O
Heinz	O
body	O
formation	O
,	O
the	O
GSH	O
content	O
and	O
GSH	O
stability	O
were	O
normal	O
.	O
The	O
pentose	O
phosphate	B-CHEMICAL
shunt	O
activity	O
of	O
the	O
non	O
-	O
dapsone	B-CHEMICAL
-	O
exposed	O
AE	O
RBCs	O
was	O
decreased	O
compared	O
to	O
normal	O
RBCs	O
.	O
Thus	O
,	O
AE	O
RBCs	O
appear	O
to	O
have	O
an	O
increased	O
sensitivity	O
to	O
oxidant	O
stress	B-DISEASE
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
since	O
dapsone	B-CHEMICAL
does	O
not	O
cause	O
hemolytic	O
anemia	B-DISEASE
at	O
this	O
dose	O
in	O
hematologically	O
normal	O
individuals	O
.	O
Given	O
the	O
influx	O
of	O
Southeast	O
Asians	O
into	O
the	O
United	O
States	O
,	O
oxidant	O
medications	O
should	O
be	O
used	O
with	O
caution	O
,	O
especially	O
if	O
an	O
infection	B-DISEASE
is	O
present	O
,	O
in	O
individuals	O
of	O
ethnic	O
backgrounds	O
that	O
have	O
an	O
increased	O
prevalence	O
of	O
hemoglobin	O
E.	O

Severe	O
complications	B-DISEASE
of	O
antianginal	O
drug	O
therapy	O
in	O
a	O
patient	O
identified	O
as	O
a	O
poor	O
metabolizer	O
of	O
metoprolol	B-CHEMICAL
,	O
propafenone	O
,	O
diltiazem	B-CHEMICAL
,	O
and	O
sparteine	B-CHEMICAL
.	O
A	O
47	O
-	O
year	O
-	O
old	O
patient	O
suffering	O
from	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
was	O
admitted	O
to	O
the	O
CCU	O
in	O
shock	B-DISEASE
with	O
III	O
.	O
AV	B-DISEASE
block	I-DISEASE
,	O
severe	O
hypotension	B-DISEASE
,	O
and	O
impairment	O
of	O
ventricular	O
function	O
.	O
One	O
week	O
prior	O
to	O
admission	O
a	O
therapy	O
with	O
standard	O
doses	O
of	O
metoprolol	B-CHEMICAL
(	O
100	O
mg	O
t.i.d	O
.	O
and	O
then	O
100	O
mg	O
b.i.d	O
.	O
)	O
had	O
been	O
initiated	O
.	O
Two	O
days	O
before	O
admission	O
diltiazem	B-CHEMICAL
(	O
60	O
mg	O
b.i.d	O
.	O
)	O
was	O
prescribed	O
in	O
addition	O
.	O
Analyses	O
of	O
a	O
blood	O
sample	O
revealed	O
unusually	O
high	O
plasma	O
concentrations	O
of	O
metoprolol	B-CHEMICAL
(	O
greater	O
than	O
3000	O
ng	O
/	O
ml	O
)	O
and	O
diltiazem	B-CHEMICAL
(	O
526	O
ng	O
/	O
ml	O
)	O
.	O
The	O
patient	O
recovered	O
within	O
1	O
week	O
following	O
discontinuation	O
of	O
antianginal	O
therapy	O
.	O
Three	O
months	O
later	O
the	O
patient	O
was	O
exposed	O
to	O
a	O
single	O
dose	O
of	O
metoprolol	B-CHEMICAL
,	O
diltiazem	B-CHEMICAL
,	O
propafenone	O
(	O
since	O
he	O
had	O
received	O
this	O
drug	O
in	O
the	O
past	O
)	O
,	O
and	O
sparteine	B-CHEMICAL
(	O
as	O
a	O
probe	O
for	O
the	O
debrisoquine	O
/	O
sparteine	B-CHEMICAL
type	O
polymorphism	O
of	O
oxidative	O
drug	O
metabolism	O
)	O
.	O
It	O
was	O
found	O
that	O
he	O
was	O
a	O
poor	O
metabolizer	O
of	O
all	O
four	O
drugs	O
,	O
indicating	O
that	O
their	O
metabolism	O
is	O
under	O
the	O
same	O
genetic	O
control	O
.	O
Therefore	O
,	O
patients	O
belonging	O
to	O
the	O
poor	O
-	O
metabolizer	O
phenotype	O
of	O
sparteine	B-CHEMICAL
/	O
debrisoquine	O
polymorphism	O
in	O
drug	O
metabolism	O
,	O
which	O
constitutes	O
6.4	O
%	O
of	O
the	O
German	O
population	O
,	O
may	O
experience	O
adverse	B-DISEASE
drug	I-DISEASE
reactions	I-DISEASE
when	O
treated	O
with	O
standard	O
doses	O
of	O
one	O
of	O
these	O
drugs	O
alone	O
.	O
Moreover	O
,	O
the	O
coadministration	O
of	O
these	O
frequently	O
used	O
drugs	O
is	O
expected	O
to	O
be	O
especially	O
harmful	O
in	O
this	O
subgroup	O
of	O
patients	O
.	O

Triazolam	O
-	O
induced	O
brief	O
episodes	O
of	O
secondary	O
mania	B-DISEASE
in	O
a	O
depressed	B-DISEASE
patient	O
.	O
Large	O
doses	O
of	O
triazolam	O
repeatedly	O
induced	O
brief	O
episodes	O
of	O
mania	B-DISEASE
in	O
a	O
depressed	B-DISEASE
elderly	O
woman	O
.	O
Features	O
of	O
organic	O
mental	O
disorder	O
(	O
delirium	B-DISEASE
)	O
were	O
not	O
present	O
.	O
Manic	B-DISEASE
excitement	O
was	O
coincident	O
with	O
the	O
duration	O
of	O
action	O
of	O
triazolam	O
.	O
The	O
possible	O
contribution	O
of	O
the	O
triazolo	O
group	O
to	O
changes	O
in	O
affective	O
status	O
is	O
discussed	O
.	O

On	O
the	O
mechanisms	O
of	O
the	O
development	O
of	O
tolerance	O
to	O
the	O
muscular	O
rigidity	B-DISEASE
produced	O
by	O
morphine	B-CHEMICAL
in	O
rats	O
.	O
The	O
development	O
of	O
tolerance	O
to	O
the	O
muscular	O
rigidity	B-DISEASE
produced	O
by	O
morphine	B-CHEMICAL
was	O
studied	O
in	O
rats	O
.	O
Saline	O
-	O
pretreated	O
controls	O
given	O
a	O
test	O
dose	O
of	O
morphine	B-CHEMICAL
(	O
20	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
showed	O
a	O
pronounced	O
rigidity	B-DISEASE
recorded	O
as	O
tonic	O
activity	O
in	O
the	O
electromyogram	O
.	O
Rats	O
treated	O
for	O
11	O
days	O
with	O
morphine	B-CHEMICAL
and	O
withdrawn	O
for	O
36	O
-	O
40	O
h	O
showed	O
differences	O
in	O
the	O
development	O
of	O
tolerance	O
:	O
about	O
half	O
of	O
the	O
animals	O
showed	O
a	O
rigidity	B-DISEASE
after	O
the	O
test	O
dose	O
of	O
morphine	B-CHEMICAL
that	O
was	O
not	O
significantly	O
less	O
than	O
in	O
the	O
controls	O
and	O
were	O
akinetic	B-DISEASE
(	O
A	O
group	O
)	O
.	O
The	O
other	O
rats	O
showed	O
a	O
strong	O
decrease	O
in	O
the	O
rigidity	B-DISEASE
and	O
the	O
occurrence	O
of	O
stereotyped	O
(	O
S	O
)	O
licking	O
and/or	O
gnawing	O
in	O
presence	O
of	O
akinetic	B-DISEASE
or	O
hyperkinetic	O
(	O
K	O
)	O
behaviour	O
(	O
AS	O
/	O
KS	O
group	O
)	O
,	O
suggesting	O
signs	O
of	O
dopaminergic	O
activation	O
.	O
The	O
rigidity	B-DISEASE
was	O
considerably	O
decreased	O
in	O
both	O
groups	O
after	O
20	O
days	O
'	O
treatment	O
.	O
In	O
a	O
further	O
series	O
of	O
experiments	O
,	O
haloperidol	B-CHEMICAL
(	O
0.2	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
was	O
used	O
in	O
order	O
to	O
block	O
the	O
dopaminergic	O
activation	O
and	O
to	O
estimate	O
the	O
real	O
degree	O
of	O
the	O
tolerance	O
to	O
the	O
rigidity	B-DISEASE
without	O
any	O
dopaminergic	O
interference	O
.	O
Haloperidol	B-CHEMICAL
enhanced	O
the	O
rigidity	B-DISEASE
in	O
the	O
A	O
group	O
.	O
However	O
,	O
the	O
level	O
in	O
the	O
AS	O
/	O
KS	O
group	O
remained	O
considerably	O
lower	O
than	O
in	O
the	O
A	O
group	O
.	O
The	O
results	O
suggest	O
that	O
rigidity	B-DISEASE
,	O
which	O
is	O
assumed	O
to	O
be	O
due	O
to	O
an	O
action	O
of	O
morphine	B-CHEMICAL
in	O
the	O
striatum	O
,	O
can	O
be	O
antagonized	O
by	O
another	O
process	O
leading	O
to	O
dopaminergic	O
activation	O
in	O
the	O
striatum	O
.	O
Nevertheless	O
,	O
there	O
occurs	O
some	O
real	O
tolerance	O
to	O
this	O
effect	O
.	O
The	O
rapid	O
alternations	O
of	O
rigidity	B-DISEASE
and	O
the	O
signs	O
of	O
dopaminergic	O
activation	O
observed	O
in	O
the	O
animals	O
of	O
the	O
AS	O
/	O
KS	O
group	O
might	O
be	O
due	O
to	O
rapid	O
shifts	O
in	O
the	O
predominance	O
of	O
various	O
DA	O
-	O
innervated	O
structures	O
.	O

Compression	B-DISEASE
neuropathy	I-DISEASE
of	O
the	O
radial	O
nerve	O
due	O
to	O
pentazocine	B-CHEMICAL
-	O
induced	O
fibrous	B-DISEASE
myopathy	I-DISEASE
.	O
Fibrous	B-DISEASE
myopathy	I-DISEASE
is	O
a	O
common	O
,	O
well	O
-	O
known	O
side	O
effect	O
of	O
repeated	O
pentazocine	B-CHEMICAL
injection	O
.	O
However	O
,	O
compression	B-DISEASE
neuropathy	I-DISEASE
due	O
to	O
fibrotic	O
muscle	O
affected	O
by	O
pentazocine	B-CHEMICAL
-	O
induced	O
myopathy	B-DISEASE
has	O
not	O
previously	O
been	O
reported	O
.	O
In	O
a	O
37	O
-	O
year	O
-	O
old	O
woman	O
with	O
documented	O
pentazocine	B-CHEMICAL
-	O
induced	O
fibrous	B-DISEASE
myopathy	I-DISEASE
of	O
triceps	O
and	O
deltoid	O
muscles	O
bilaterally	O
and	O
a	O
three	O
-	O
week	O
history	O
of	O
right	O
wrist	O
drop	O
,	O
electrodiagnostic	O
examination	O
showed	O
a	O
severe	O
but	O
partial	O
lesion	O
of	O
the	O
right	O
radial	O
nerve	O
distal	O
to	O
the	O
branches	O
to	O
the	O
triceps	O
,	O
in	O
addition	O
to	O
the	O
fibrous	B-DISEASE
myopathy	I-DISEASE
.	O
Surgery	O
revealed	O
the	O
right	O
radial	O
nerve	O
to	O
be	O
severely	O
compressed	O
by	O
the	O
densely	O
fibrotic	O
lateral	O
head	O
of	O
the	O
triceps	O
.	O
Decompression	O
and	O
neurolysis	O
were	O
performed	O
with	O
good	O
subsequent	O
recovery	O
of	O
function	O
.	O

Recurrent	O
reversible	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
from	O
amphotericin	B-CHEMICAL
.	O
A	O
patient	O
with	O
cryptogenic	O
cirrhosis	B-DISEASE
and	O
disseminated	O
sporotrichosis	B-DISEASE
developed	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
immediately	O
following	O
the	O
administration	O
of	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
on	O
four	O
separate	O
occasions	O
.	O
The	O
abruptness	O
of	O
the	O
renal	B-DISEASE
failure	I-DISEASE
and	O
its	O
reversibility	O
within	O
days	O
suggests	O
that	O
there	O
was	O
a	O
functional	O
component	O
to	O
the	O
renal	B-DISEASE
dysfunction	I-DISEASE
.	O
We	O
propose	O
that	O
amphotericin	B-CHEMICAL
,	O
in	O
the	O
setting	O
of	O
reduced	O
effective	O
arterial	O
volume	O
,	O
may	O
activate	O
tubuloglomerular	O
feedback	O
,	O
thereby	O
contributing	O
to	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
.	O

Pneumonitis	B-DISEASE
with	O
pleural	O
and	O
pericardial	B-DISEASE
effusion	I-DISEASE
and	O
neuropathy	B-DISEASE
during	O
amiodarone	B-CHEMICAL
therapy	O
.	O
A	O
patient	O
with	O
sinuatrial	O
disease	B-DISEASE
and	O
implanted	O
pacemaker	O
was	O
treated	O
with	O
amiodarone	B-CHEMICAL
(	O
maximum	O
dose	O
1000	O
mg	O
,	O
maintenance	O
dose	O
800	O
mg	O
daily	O
)	O
for	O
10	O
months	O
,	O
for	O
control	O
of	O
supraventricular	O
tachyarrhythmias	O
.	O
He	O
developed	O
pneumonitis	B-DISEASE
,	O
pleural	O
and	O
pericardial	O
effusions	O
,	O
and	O
a	O
predominantly	O
proximal	O
motor	O
neuropathy	B-DISEASE
.	O
Immediate	O
but	O
gradual	O
improvement	O
followed	O
withdrawal	O
of	O
amiodarone	B-CHEMICAL
and	O
treatment	O
with	O
prednisolone	B-CHEMICAL
.	O
Review	O
of	O
this	O
and	O
previously	O
reported	O
cases	O
indicates	O
the	O
need	O
for	O
early	O
diagnosis	O
of	O
amiodarone	B-CHEMICAL
pneumonitis	B-DISEASE
,	O
immediate	O
withdrawal	O
of	O
amiodarone	B-CHEMICAL
,	O
and	O
prompt	O
but	O
continued	O
steroid	B-CHEMICAL
therapy	O
to	O
ensure	O
full	O
recovery	O
.	O

Indomethacin	B-CHEMICAL
-	O
induced	O
renal	B-DISEASE
insufficiency	I-DISEASE
:	O
recurrence	B-DISEASE
on	O
rechallenge	O
.	O
We	O
have	O
reported	O
a	O
case	O
of	O
acute	O
oliguric	O
renal	B-DISEASE
failure	I-DISEASE
with	O
hyperkalemia	B-DISEASE
in	O
a	O
patient	O
with	O
cirrhosis	B-DISEASE
,	O
ascites	B-DISEASE
,	O
and	O
cor	B-DISEASE
pulmonale	I-DISEASE
after	O
indomethacin	B-CHEMICAL
therapy	O
.	O
Prompt	O
restoration	O
of	O
renal	O
function	O
followed	O
drug	O
withdrawal	O
,	O
while	O
re	O
-	O
exposure	O
to	O
a	O
single	O
dose	O
of	O
indomethacin	B-CHEMICAL
caused	O
recurrence	B-DISEASE
of	O
acute	O
reversible	O
oliguria	B-DISEASE
.	O
Our	O
case	O
supports	O
the	O
hypothesis	O
that	O
endogenous	O
renal	O
prostaglandins	B-CHEMICAL
play	O
a	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
blood	O
flow	O
when	O
circulating	O
plasma	O
volume	O
is	O
diminished	O
.	O
Since	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
agents	O
interfere	O
with	O
this	O
compensatory	O
mechanism	O
and	O
may	O
cause	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
in	O
such	O
patients	O
.	O

Comparison	O
of	O
the	O
subjective	O
effects	O
and	O
plasma	O
concentrations	O
following	O
oral	O
and	O
i.m	O
.	O
administration	O
of	O
flunitrazepam	O
in	O
volunteers	O
.	O
Flunitrazepam	O
0.5	O
,	O
1.0	O
or	O
2.0	O
mg	O
was	O
given	O
by	O
the	O
oral	O
or	O
i.m	O
.	O
routes	O
to	O
groups	O
of	O
volunteers	O
and	O
its	O
effects	O
compared	O
.	O
Plasma	O
concentrations	O
of	O
the	O
drug	O
were	O
estimated	O
by	O
gas	O
-	O
liquid	O
chromatography	O
,	O
in	O
a	O
smaller	O
number	O
of	O
the	O
subjects	O
.	O
The	O
most	O
striking	O
effect	O
was	O
sedation	O
which	O
increased	O
with	O
the	O
dose	O
,	O
2	O
mg	O
producing	O
deep	O
sleep	O
although	O
the	O
subjects	O
could	O
still	O
be	O
aroused	O
.	O
The	O
effects	O
of	O
i.m	O
.	O
administration	O
were	O
apparent	O
earlier	O
and	O
sometimes	O
lasted	O
longer	O
than	O
those	O
following	O
oral	O
administration	O
.	O
Dizziness	B-DISEASE
was	O
less	O
marked	O
than	O
sedation	O
,	O
but	O
increased	O
with	O
the	O
dose	O
.	O
There	O
was	O
pain	B-DISEASE
on	O
i.m	O
.	O
injection	O
of	O
flunitrazepam	O
significantly	O
more	O
often	O
than	O
with	O
isotonic	O
saline	O
.	O
Plasma	O
concentrations	O
varied	O
with	O
dose	O
and	O
route	O
and	O
corresponded	O
qualitatively	O
with	O
the	O
subjective	O
effects	O
.	O
The	O
drug	O
was	O
still	O
present	O
in	O
measurable	O
quantities	O
after	O
24	O
h	O
even	O
with	O
the	O
smallest	O
dose	O
.	O

Changes	O
in	O
heart	O
size	O
during	O
long	O
-	O
term	O
timolol	B-CHEMICAL
treatment	O
after	O
myocardial	B-DISEASE
infarction	I-DISEASE
.	O
The	O
effect	O
of	O
long	O
-	O
term	O
timolol	B-CHEMICAL
treatment	O
on	O
heart	O
size	O
after	O
myocardial	B-DISEASE
infarction	I-DISEASE
was	O
evaluated	O
by	O
X	O
-	O
ray	O
in	O
a	O
double	O
-	O
blind	B-DISEASE
study	O
including	O
241	O
patients	O
(	O
placebo	O
126	O
,	O
timolol	B-CHEMICAL
115	O
)	O
.	O
The	O
follow	O
-	O
up	O
period	O
was	O
12	O
months	O
.	O
The	O
timolol	B-CHEMICAL
-	O
treated	O
patients	O
showed	O
a	O
small	O
but	O
significant	O
increase	O
in	O
heart	O
size	O
from	O
baseline	O
in	O
contrast	O
to	O
a	O
decrease	O
in	O
the	O
placebo	O
group	O
.	O
These	O
differences	O
may	O
be	O
caused	O
by	O
timolol	B-CHEMICAL
-	O
induced	O
bradycardia	B-DISEASE
and	O
a	O
compensatory	O
increase	O
in	O
end	O
-	O
diastolic	O
volume	O
.	O
The	O
timolol	B-CHEMICAL
-	O
related	O
increase	O
in	O
heart	O
size	O
was	O
observed	O
only	O
in	O
patients	O
with	O
normal	O
and	O
borderline	O
heart	O
size	O
.	O
In	O
patients	O
with	O
cardiomegaly	B-DISEASE
,	O
the	O
increase	O
in	O
heart	O
size	O
was	O
similar	O
in	O
both	O
groups	O
.	O
After	O
re	O
-	O
infarction	B-DISEASE
,	O
heart	O
size	O
increased	O
in	O
the	O
placebo	O
group	O
and	O
remained	O
unchanged	O
in	O
the	O
timolol	B-CHEMICAL
group	O
.	O

Vitamin	B-CHEMICAL
D3	I-CHEMICAL
toxicity	B-DISEASE
in	O
dairy	O
cows	O
.	O
Large	O
parenteral	O
doses	O
of	O
vitamin	B-CHEMICAL
D3	I-CHEMICAL
(	O
15	O
to	O
17.5	O
x	O
10(6	O
)	O
IU	O
vitamin	B-CHEMICAL
D3	I-CHEMICAL
)	O
were	O
associated	O
with	O
prolonged	O
hypercalcemia	B-DISEASE
,	O
hyperphosphatemia	B-DISEASE
,	O
and	O
large	O
increases	O
of	O
vitamin	B-CHEMICAL
D3	I-CHEMICAL
and	O
its	O
metabolites	O
in	O
the	O
blood	O
plasma	O
of	O
nonlactating	O
nonpregnant	O
and	O
pregnant	O
Jersey	O
cows	O
.	O
Calcium	B-CHEMICAL
concentrations	O
1	O
day	O
postpartum	O
were	O
higher	O
in	O
cows	O
treated	O
with	O
vitamin	B-CHEMICAL
D3	I-CHEMICAL
about	O
32	O
days	O
prepartum	O
(	O
8.8	O
mg/100	O
ml	O
)	O
than	O
in	O
control	O
cows	O
(	O
5.5	O
mg/100	O
ml	O
)	O
.	O
None	O
of	O
the	O
cows	O
treated	O
with	O
vitamin	B-CHEMICAL
D3	I-CHEMICAL
showed	O
signs	O
of	O
milk	B-DISEASE
fever	I-DISEASE
during	O
the	O
peripartal	O
period	O
;	O
however	O
,	O
22	O
%	O
of	O
the	O
control	O
cows	O
developed	O
clinical	O
signs	O
of	O
milk	B-DISEASE
fever	I-DISEASE
during	O
this	O
period	O
.	O
Signs	O
of	O
vitamin	B-CHEMICAL
D3	I-CHEMICAL
toxicity	B-DISEASE
were	O
not	O
observed	O
in	O
nonlactating	O
nonpregnant	O
cows	O
;	O
however	O
,	O
pregnant	O
cows	O
commonly	O
developed	O
severe	O
signs	O
of	O
vitamin	B-CHEMICAL
D3	I-CHEMICAL
toxicity	B-DISEASE
and	O
10	O
of	O
17	O
cows	O
died	O
.	O
There	O
was	O
widespread	O
metastatic	O
calcification	B-DISEASE
in	O
the	O
cows	O
that	O
died	O
.	O
Because	O
of	O
the	O
extreme	O
toxicity	B-DISEASE
of	O
vitamin	B-CHEMICAL
D3	I-CHEMICAL
in	O
pregnant	O
Jersey	O
cows	O
and	O
the	O
low	O
margin	O
of	O
safety	O
between	O
doses	O
of	O
vitamin	B-CHEMICAL
D3	I-CHEMICAL
that	O
prevent	O
milk	B-DISEASE
fever	I-DISEASE
and	O
doses	O
that	O
induce	O
milk	B-DISEASE
fever	I-DISEASE
,	O
we	O
concluded	O
that	O
vitamin	B-CHEMICAL
D3	I-CHEMICAL
can	O
not	O
be	O
used	O
practically	O
to	O
prevent	O
milk	B-DISEASE
fever	I-DISEASE
when	O
injected	O
several	O
weeks	O
prepartum	O
.	O

Diseases	B-DISEASE
of	O
peripheral	O
nerves	O
as	O
seen	O
in	O
the	O
Nigerian	O
African	O
.	O
The	O
anatomical	O
and	O
aetiological	O
diagnoses	O
of	O
peripheral	O
nerve	O
disease	B-DISEASE
excluding	O
its	O
primary	O
benign	O
and	O
malignant	O
disorders	O
,	O
as	O
seen	O
in	O
358	O
Nigerians	O
are	O
presented	O
.	O
There	O
is	O
a	O
male	O
preponderance	O
and	O
the	O
peak	O
incidence	O
is	O
in	O
the	O
fourth	O
decade	O
.	O
Sensori	B-DISEASE
-	I-DISEASE
motor	I-DISEASE
neuropathy	I-DISEASE
was	O
the	O
commonest	O
presentation	O
(	O
50	O
%	O
)	O
.	O
Guillain	O
-	O
Barr	O
  	O
syndrome	B-DISEASE
was	O
the	O
commonest	O
identifiable	O
cause	O
(	O
15.6	O
%	O
)	O
,	O
accounting	O
for	O
half	O
of	O
the	O
cases	O
with	O
motor	O
neuropathy	B-DISEASE
.	O
Peripheral	B-DISEASE
neuropathy	I-DISEASE
due	O
to	O
nutritional	O
deficiency	O
of	O
thiamine	O
and	O
riboflavin	O
was	O
common	O
(	O
10.1	O
%	O
)	O
and	O
presented	O
mainly	O
as	O
sensory	O
and	O
sensori	B-DISEASE
-	I-DISEASE
motor	I-DISEASE
neuropathy	I-DISEASE
.	O
Diabetes	B-DISEASE
mellitus	I-DISEASE
was	O
the	O
major	O
cause	O
of	O
autonomic	B-DISEASE
neuropathy	I-DISEASE
.	O
Isoniazid	B-CHEMICAL
was	O
the	O
most	O
frequent	O
agent	O
in	O
drug	O
-	O
induced	O
neuropathy	B-DISEASE
.	O
Migraine	B-DISEASE
(	O
20	O
%	O
)	O
was	O
not	O
an	O
uncommon	O
cause	O
of	O
cranial	B-DISEASE
neuropathy	I-DISEASE
although	O
malignancies	B-DISEASE
arising	O
from	O
the	O
reticuloendothelial	O
system	O
or	O
related	O
structures	O
of	O
the	O
head	O
and	O
neck	O
were	O
more	O
frequent	O
(	O
26	O
%	O
)	O
.	O
In	O
26.5	O
%	O
of	O
all	O
the	O
cases	O
,	O
the	O
aetiology	O
of	O
the	O
neuropathy	B-DISEASE
was	O
undetermined	O
.	O
Heredofamilial	O
and	O
connective	B-DISEASE
tissue	I-DISEASE
disorders	I-DISEASE
were	O
rare	O
.	O
Some	O
of	O
the	O
factors	O
related	O
to	O
the	O
clinical	O
presentation	O
and	O
pathogenesis	O
of	O
the	O
neuropathies	O
are	O
briefly	O
discussed	O
.	O

A	O
double	O
-	O
blind	B-DISEASE
study	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
dothiepin	B-CHEMICAL
hydrochloride	I-CHEMICAL
in	O
the	O
treatment	O
of	O
major	O
depressive	B-DISEASE
disorder	I-DISEASE
.	O
In	O
a	O
6	O
-	O
week	O
double	O
-	O
blind	B-DISEASE
parallel	O
treatment	O
study	O
,	O
dothiepin	B-CHEMICAL
and	O
amitriptyline	O
were	O
compared	O
to	O
placebo	O
in	O
the	O
treatment	O
of	O
33	O
depressed	B-DISEASE
outpatients	O
.	O
Dothiepin	B-CHEMICAL
and	O
amitriptyline	O
were	O
equally	O
effective	O
in	O
alleviating	O
the	O
symptoms	O
of	O
depressive	B-DISEASE
illness	I-DISEASE
,	O
and	O
both	O
were	O
significantly	O
superior	O
to	O
placebo	O
.	O
The	O
overall	O
incidence	O
of	O
side	O
effects	O
and	O
the	O
frequency	O
and	O
severity	O
of	O
blurred	B-DISEASE
vision	I-DISEASE
,	O
dry	B-DISEASE
mouth	I-DISEASE
,	O
and	O
drowsiness	B-DISEASE
were	O
significantly	O
less	O
with	O
dothiepin	B-CHEMICAL
than	O
with	O
amitriptyline	O
.	O
Dothiepin	B-CHEMICAL
also	O
produced	O
fewer	O
CNS	O
and	O
cardiovascular	O
effects	O
.	O
There	O
were	O
no	O
clinically	O
important	O
changes	O
in	O
laboratory	O
parameters	O
.	O
Dothiepin	B-CHEMICAL
thus	O
was	O
found	O
to	O
be	O
an	O
effective	O
antidepressant	O
drug	O
associated	O
with	O
fewer	O
side	O
effects	O
than	O
amitriptyline	O
in	O
the	O
treatment	O
of	O
depressed	B-DISEASE
outpatients	O
.	O

Behavioral	O
effects	O
of	O
diazepam	B-CHEMICAL
and	O
propranolol	B-CHEMICAL
in	O
patients	O
with	O
panic	B-DISEASE
disorder	I-DISEASE
and	O
agoraphobia	B-DISEASE
.	O
The	O
effects	O
of	O
oral	O
doses	O
of	O
diazepam	B-CHEMICAL
(	O
single	O
dose	O
of	O
10	O
mg	O
and	O
a	O
median	O
dose	O
of	O
30	O
mg	O
/	O
day	O
for	O
2	O
weeks	O
)	O
and	O
propranolol	B-CHEMICAL
(	O
single	O
dose	O
of	O
80	O
mg	O
and	O
a	O
median	O
dose	O
of	O
240	O
mg	O
/	O
day	O
for	O
2	O
weeks	O
)	O
on	O
psychological	O
performance	O
of	O
patients	O
with	O
panic	O
disorders	O
and	O
agoraphobia	B-DISEASE
were	O
investigated	O
in	O
a	O
double	O
-	O
blind	B-DISEASE
,	O
randomized	O
and	O
crossover	O
design	O
.	O
Both	O
drugs	O
impaired	O
immediate	O
free	O
recall	O
but	O
the	O
decrease	O
was	O
greater	O
for	O
diazepam	B-CHEMICAL
than	O
propranolol	B-CHEMICAL
.	O
Delayed	O
free	O
recall	O
was	O
also	O
impaired	O
but	O
the	O
two	O
drugs	O
did	O
not	O
differ	O
.	O
Patients	O
tapped	O
faster	O
after	O
propranolol	B-CHEMICAL
than	O
diazepam	B-CHEMICAL
and	O
they	O
were	O
more	O
sedated	O
after	O
diazepam	B-CHEMICAL
than	O
propranolol	B-CHEMICAL
.	O
After	O
2	O
weeks	O
of	O
treatment	O
,	O
patients	O
tested	O
5	O
-	O
8	O
h	O
after	O
the	O
last	O
dose	O
of	O
medication	O
did	O
not	O
show	O
any	O
decrement	O
of	O
performance	O
.	O
These	O
results	O
are	O
similar	O
to	O
those	O
previously	O
found	O
in	O
healthy	O
subjects	O
.	O
Accumulation	O
of	O
drugs	O
was	O
not	O
reflected	O
in	O
prolonged	O
behavioral	B-DISEASE
impairment	I-DISEASE
.	O

Effect	O
of	O
aspirin	O
on	O
N-[4-(5	O
-	O
nitro-2	O
-	O
furyl)-2	O
-	O
thiazolyl]-formamide	O
-	O
induced	O
epithelial	O
proliferation	O
in	O
the	O
urinary	O
bladder	O
and	O
forestomach	O
of	O
the	O
rat	O
.	O
The	O
co	B-CHEMICAL
-	O
administration	O
of	O
aspirin	O
with	O
N-[4-(5	O
-	O
nitro-2	O
-	O
furyl)-2	O
-	O
thiazolyl]-formamide	O
(	O
FANFT	O
)	O
to	O
rats	O
resulted	O
in	O
a	O
reduced	O
incidence	O
of	O
FANFT	O
-	O
induced	O
bladder	B-DISEASE
carcinomas	I-DISEASE
but	O
a	O
concomitant	O
induction	O
of	O
forestomach	O
tumors	B-DISEASE
.	O
An	O
autoradiographic	O
study	O
was	O
performed	O
on	O
male	O
F-344	O
rats	O
fed	O
diet	O
containing	O
FANFT	O
at	O
a	O
level	O
of	O
0.2	O
%	O
and/or	O
aspirin	O
at	O
a	O
level	O
of	O
0.5	O
%	O
to	O
evaluate	O
the	O
effect	O
of	O
aspirin	O
on	O
the	O
increased	O
cell	O
proliferation	O
induced	O
by	O
FANFT	O
in	O
the	O
forestomach	O
and	O
bladder	O
.	O
FANFT	O
-	O
induced	O
cell	O
proliferation	O
in	O
the	O
bladder	O
was	O
significantly	O
suppressed	O
by	O
aspirin	O
co	B-CHEMICAL
-	O
administration	O
after	O
4	O
weeks	O
but	O
not	O
after	O
12	O
weeks	O
.	O
In	O
the	O
forestomach	O
,	O
and	O
also	O
in	O
the	O
liver	O
,	O
aspirin	O
did	O
not	O
affect	O
the	O
FANFT	O
-	O
induced	O
increase	O
in	O
labeling	O
index	O
.	O
The	O
present	O
results	O
are	O
consistent	O
with	O
the	O
carcinogenicity	O
experiment	O
suggesting	O
that	O
different	O
mechanisms	O
are	O
involved	O
in	O
FANFT	O
carcinogenesis	B-DISEASE
in	O
the	O
bladder	O
and	O
forestomach	O
,	O
and	O
that	O
aspirin	O
's	O
effect	O
on	O
FANFT	O
in	O
the	O
forestomach	O
is	O
not	O
due	O
to	O
an	O
irritant	O
effect	O
associated	O
with	O
increased	O
cell	O
proliferation	O
.	O
Also	O
,	O
there	O
appears	O
to	O
be	O
an	O
adaptation	O
by	O
the	O
rats	O
to	O
the	O
chronic	O
ingestion	O
of	O
aspirin	O
.	O

Provocation	O
of	O
postural	O
hypotension	B-DISEASE
by	O
nitroglycerin	B-CHEMICAL
in	O
diabetic	B-DISEASE
autonomic	I-DISEASE
neuropathy	I-DISEASE
?	O
The	O
effect	O
of	O
nitroglycerin	B-CHEMICAL
on	O
heart	O
rate	O
and	O
systolic	O
blood	O
pressure	O
was	O
compared	O
in	O
5	O
normal	O
subjects	O
,	O
12	O
diabetic	B-DISEASE
subjects	O
without	O
autonomic	B-DISEASE
neuropathy	I-DISEASE
,	O
and	O
5	O
diabetic	B-DISEASE
subjects	O
with	O
autonomic	B-DISEASE
neuropathy	I-DISEASE
.	O
The	O
magnitude	O
and	O
time	O
course	O
of	O
the	O
increase	O
in	O
heart	O
rate	O
and	O
the	O
decrease	O
in	O
systolic	O
blood	O
pressure	O
after	O
nitroglycerin	B-CHEMICAL
were	O
similar	O
in	O
the	O
normal	O
and	O
diabetic	B-DISEASE
subjects	O
without	O
autonomic	B-DISEASE
neuropathy	I-DISEASE
,	O
whereas	O
a	O
lesser	O
increase	O
in	O
heart	O
rate	O
and	O
a	O
greater	O
decrease	O
in	O
systolic	O
blood	O
pressure	O
occurred	O
in	O
the	O
diabetic	B-DISEASE
subjects	O
with	O
autonomic	B-DISEASE
neuropathy	I-DISEASE
.	O
It	O
is	O
therefore	O
suggested	O
that	O
caution	O
should	O
be	O
exercised	O
when	O
prescribing	O
vasodilator	O
drugs	O
in	O
diabetic	B-DISEASE
patients	O
,	O
particularly	O
those	O
with	O
autonomic	B-DISEASE
neuropathy	I-DISEASE
.	O

Characterization	O
of	O
estrogen	B-CHEMICAL
-	O
induced	O
adenohypophyseal	B-DISEASE
tumors	I-DISEASE
in	O
the	O
Fischer	O
344	O
rat	O
.	O
Pituitary	B-DISEASE
tumors	I-DISEASE
were	O
induced	O
in	O
F344	O
female	O
rats	O
by	O
chronic	O
treatment	O
with	O
diethylstilbestrol	B-CHEMICAL
(	O
DES	O
,	O
8	O
-	O
10	O
mg	O
)	O
implanted	O
subcutaneously	O
in	O
silastic	O
capsules	O
.	O
Over	O
a	O
range	O
of	O
1	O
-	O
150	O
days	O
of	O
DES	O
treatment	O
,	O
pairs	O
of	O
control	O
and	O
DES	O
-	O
treated	O
rats	O
were	O
sacrificed	O
,	O
and	O
their	O
pituitaries	O
dissociated	O
enzymatically	O
into	O
single	O
-	O
cell	O
preparations	O
.	O
The	O
cell	O
populations	O
were	O
examined	O
regarding	O
total	O
cell	O
recovery	O
correlated	O
with	O
gland	O
weight	O
,	O
intracellular	O
prolactin	O
(	O
PRL	O
)	O
content	O
and	O
subsequent	O
release	O
in	O
primary	O
culture	O
,	O
immunocytochemical	O
PRL	O
staining	O
,	O
density	O
and/or	O
size	O
alterations	O
via	O
separation	O
on	O
Ficoll	O
-	O
Hypaque	O
and	O
by	O
unit	O
gravity	O
sedimentation	O
,	O
and	O
cell	O
cycle	O
analysis	O
,	O
after	O
acriflavine	O
DNA	O
staining	O
,	O
by	O
laser	O
flow	O
cytometry	O
.	O
Total	O
cell	O
yields	O
from	O
DES	O
-	O
treated	O
pituitaries	O
increased	O
from	O
1.3	O
times	O
control	O
yields	O
at	O
8	O
days	O
of	O
treatment	O
to	O
58.9	O
times	O
control	O
values	O
by	O
day	O
150	O
.	O
Intracellular	O
PRL	O
content	O
ranged	O
from	O
1.9	O
to	O
9.4	O
times	O
control	O
levels	O
,	O
and	O
PRL	O
release	O
in	O
vitro	O
was	O
significantly	O
and	O
consistently	O
higher	O
than	O
controls	O
,	O
after	O
at	O
least	O
8	O
days	O
of	O
DES	O
exposure	O
.	O
Beyond	O
8	O
days	O
of	O
DES	O
exposure	O
,	O
the	O
immunochemically	O
PRL	O
-	O
positive	O
proportion	O
of	O
cells	O
increased	O
to	O
over	O
50	O
%	O
of	O
the	O
total	O
population	O
.	O
Increased	O
density	O
and/or	O
size	O
and	O
PRL	O
content	O
were	O
indicated	O
for	O
the	O
majority	O
of	O
the	O
PRL	O
cell	O
population	O
in	O
both	O
types	O
of	O
separation	O
protocols	O
.	O
All	O
these	O
effects	O
of	O
DES	O
were	O
more	O
pronounced	O
among	O
previously	O
ovariectomized	O
animals	O
.	O
The	O
data	O
extend	O
the	O
findings	O
of	O
other	O
investigators	O
,	O
further	O
establishing	O
the	O
DES	O
-	O
induced	O
tumor	B-DISEASE
as	O
a	O
model	O
for	O
study	O
of	O
PRL	O
cellular	O
control	O
mechanisms	O
.	O

Triamterene	O
nephrolithiasis	B-DISEASE
complicating	O
dyazide	B-CHEMICAL
therapy	O
.	O
A	O
case	O
of	O
triamterene	O
nephrolithiasis	B-DISEASE
is	O
reported	O
in	O
a	O
man	O
after	O
4	O
years	O
of	O
hydrochlorothiazide	O
-	O
triamterene	O
therapy	O
for	O
hypertension	B-DISEASE
.	O
The	O
stone	O
passed	O
spontaneously	O
and	O
was	O
found	O
to	O
contain	O
a	O
triamterene	O
metabolite	O
admixed	O
with	O
uric	O
acid	O
salts	O
.	O
Factors	O
affecting	O
triamterene	O
nephrolithiasis	B-DISEASE
are	O
discussed	O
and	O
2	O
previously	O
reported	O
cases	O
are	O
reviewed	O
.	O

Metabolic	O
involvement	O
in	O
adriamycin	B-CHEMICAL
cardiotoxicity	B-DISEASE
.	O
The	O
cardiotoxic	B-DISEASE
effects	O
of	O
adriamycin	B-CHEMICAL
were	O
studied	O
in	O
mammalian	O
myocardial	O
cells	O
in	O
culture	O
as	O
a	O
model	O
system	O
.	O
Adriamycin	B-CHEMICAL
inhibited	O
cell	O
growth	O
and	O
the	O
rhythmic	O
contractions	O
characteristic	O
of	O
myocardial	O
cells	O
in	O
culture	O
.	O
A	O
possible	O
involvement	O
of	O
energy	O
metabolism	O
was	O
suggested	O
previously	O
,	O
and	O
in	O
this	O
study	O
the	O
adenylate	O
energy	O
charge	O
and	O
phosphorylcreatine	O
mole	O
fraction	O
were	O
determined	O
in	O
the	O
adriamycin	B-CHEMICAL
-	O
treated	O
cells	O
.	O
The	O
adenylate	O
energy	O
charge	O
was	O
found	O
to	O
be	O
significantly	O
decreased	O
,	O
while	O
the	O
phophorylcreatine	O
mole	O
fraction	O
was	O
unchanged	O
.	O
Such	O
disparity	O
suggests	O
an	O
inhibition	O
of	O
creatine	B-CHEMICAL
phosphokinase	O
.	O
The	O
addition	O
of	O
1	O
mM	O
adenosine	O
to	O
the	O
myocardial	O
cell	O
cultures	O
markedly	O
increases	O
the	O
ATP	B-CHEMICAL
concentration	O
through	O
a	O
pathway	O
reportedly	O
leading	O
to	O
a	O
compartmentalized	O
ATP	B-CHEMICAL
pool	O
.	O
In	O
the	O
adriamycin	B-CHEMICAL
-	O
treated	O
cells	O
,	O
the	O
addition	O
of	O
adenosine	O
increased	O
the	O
adenylate	O
charge	O
and	O
,	O
concomitant	O
with	O
this	O
inrcease	O
,	O
the	O
cells	O
'	O
functional	O
integrity	O
,	O
in	O
terms	O
of	O
percentage	O
of	O
beating	O
cells	O
and	O
rate	O
of	O
contractions	O
,	O
was	O
maintained	O
.	O

Age	O
-	O
dependent	O
sensitivity	O
of	O
the	O
rat	O
to	O
neurotoxic	B-DISEASE
effects	O
of	O
streptomycin	B-CHEMICAL
.	O
Streptomycin	B-CHEMICAL
sulfate	O
(	O
300	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
was	O
injected	O
for	O
various	O
periods	O
into	O
preweanling	O
rats	O
and	O
for	O
3	O
weeks	O
into	O
weanling	O
rats	O
.	O
Beginning	O
at	O
8	O
days	O
of	O
age	O
,	O
body	O
movement	O
and	O
hearing	O
were	O
examined	O
for	O
6	O
and	O
up	O
to	O
17	O
weeks	O
,	O
respectively	O
.	O
Abnormal	B-DISEASE
movements	I-DISEASE
and	O
deafness	B-DISEASE
occurred	O
only	O
in	O
rats	O
treated	O
during	O
the	O
preweaning	O
period	O
;	O
within	O
this	O
period	O
the	O
greatest	O
sensitivities	O
for	O
these	O
abnormalities	O
occurred	O
from	O
2	O
to	O
11	O
-	O
17	O
and	O
5	O
to	O
11	O
days	O
of	O
age	O
,	O
respectively	O
,	O
indicating	O
that	O
the	O
cochlea	O
is	O
more	O
sensitive	O
to	O
streptomycin	B-CHEMICAL
than	O
the	O
site	O
(	O
vestibular	O
or	O
central	O
)	O
responsible	O
for	O
the	O
dyskinesias	B-DISEASE
.	O

Crescentic	O
fibrillary	O
glomerulonephritis	B-DISEASE
associated	O
with	O
intermittent	O
rifampin	B-CHEMICAL
therapy	O
for	O
pulmonary	O
tuberculosis	B-DISEASE
.	O
This	O
case	O
study	O
reveals	O
an	O
unusual	O
finding	O
of	O
rapidly	O
proliferative	O
crescentic	O
glomerulonephritis	B-DISEASE
in	O
a	O
patient	O
treated	O
with	O
rifampin	B-CHEMICAL
who	O
had	O
no	O
other	O
identifiable	O
causes	O
for	O
developing	O
this	O
disease	B-DISEASE
.	O
This	O
patient	O
underwent	O
a	O
10	O
-	O
month	O
regimen	O
of	O
rifampin	B-CHEMICAL
and	O
isoniazid	B-CHEMICAL
for	O
pulmonary	O
tuberculosis	B-DISEASE
and	O
was	O
discovered	O
to	O
have	O
developed	O
signs	O
of	O
severe	O
renal	B-DISEASE
failure	I-DISEASE
five	O
weeks	O
after	O
completion	O
of	O
therapy	O
.	O
Renal	O
biopsy	O
revealed	O
severe	O
glomerulonephritis	B-DISEASE
with	O
crescents	O
,	O
electron	O
dense	O
fibrillar	O
deposits	O
and	O
moderate	O
lymphocytic	O
interstitial	O
infiltrate	O
.	O
Other	O
possible	O
causes	O
of	O
rapidly	O
progressive	O
glomerulonephritis	B-DISEASE
were	O
investigated	O
and	O
ruled	O
out	O
.	O
This	O
report	O
documents	O
the	O
unusual	O
occurrence	O
of	O
rapidly	O
progressive	O
glomerulonephritis	B-DISEASE
with	O
crescents	O
and	O
fibrillar	O
glomerulonephritis	B-DISEASE
in	O
a	O
patient	O
treated	O
with	O
rifampin	B-CHEMICAL
.	O

Time	O
course	O
of	O
lipid	O
peroxidation	O
in	O
puromycin	O
aminonucleoside	O
-	O
induced	O
nephropathy	B-DISEASE
.	O
Reactive	O
oxygen	B-CHEMICAL
species	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
acute	O
puromycin	O
aminonucleoside	O
(	O
PAN)-induced	O
nephropathy	B-DISEASE
,	O
with	O
antioxidants	B-CHEMICAL
significantly	O
reducing	O
the	O
proteinuria	B-DISEASE
.	O
The	O
temporal	O
relationship	O
between	O
lipid	O
peroxidation	O
in	O
the	O
kidney	O
and	O
proteinuria	B-DISEASE
was	O
examined	O
in	O
this	O
study	O
.	O
Rats	O
were	O
treated	O
with	O
a	O
single	O
IV	O
injection	O
of	O
puromycin	O
aminonucleoside	O
,	O
(	O
PAN	O
,	O
7.5	O
mg	O
/	O
kg	O
)	O
and	O
24	O
hour	O
urine	O
samples	O
were	O
obtained	O
prior	O
to	O
sacrifice	O
on	O
days	O
3,5,7,10,17,27,41	O
(	O
N	O
=	O
5	O
-	O
10	O
per	O
group	O
)	O
.	O
The	O
kidneys	O
were	O
removed	O
,	O
flushed	O
with	O
ice	B-CHEMICAL
cold	O
TRIS	B-CHEMICAL
buffer	I-CHEMICAL
.	O
Kidney	O
cortices	O
from	O
each	O
animal	O
were	O
used	O
to	O
prepare	O
homogenates	O
.	O
Tissue	O
lipid	O
peroxidation	O
was	O
measured	O
in	O
whole	O
homogenates	O
as	O
well	O
as	O
in	O
lipid	O
extracts	O
from	O
homogenates	O
as	O
thiobarbituric	B-CHEMICAL
acid	I-CHEMICAL
reactive	O
substances	O
.	O
Proteinuria	B-DISEASE
was	O
evident	O
at	O
day	O
5	O
,	O
peaked	O
at	O
day	O
7	O
and	O
persisted	O
to	O
day	O
27	O
.	O
Lipid	O
peroxidation	O
in	O
homogenates	O
was	O
maximal	O
at	O
day	O
3	O
and	O
declined	O
rapidly	O
to	O
control	O
levels	O
by	O
day	O
17	O
.	O
This	O
study	O
supports	O
the	O
role	O
of	O
lipid	O
peroxidation	O
in	O
mediating	O
the	O
proteinuric	O
injury	O
in	O
PAN	O
nephropathy	B-DISEASE
.	O

Clomipramine	B-CHEMICAL
-	O
induced	O
sleep	O
disturbance	O
does	O
not	O
impair	O
its	O
prolactin	O
-	O
releasing	O
action	O
.	O
The	O
present	O
study	O
was	O
undertaken	O
to	O
examine	O
the	O
role	O
of	O
sleep	O
disturbance	O
,	O
induced	O
by	O
clomipramine	B-CHEMICAL
administration	O
,	O
on	O
the	O
secretory	O
rate	O
of	O
prolactin	O
(	O
PRL	O
)	O
in	O
addition	O
to	O
the	O
direct	O
drug	O
effect	O
.	O
Two	O
groups	O
of	O
supine	O
subjects	O
were	O
studied	O
under	O
placebo	O
-	O
controlled	O
conditions	O
,	O
one	O
during	O
the	O
night	O
,	O
when	O
sleeping	O
(	O
n	O
=	O
7	O
)	O
and	O
the	O
other	O
at	O
daytime	O
,	O
when	O
awake	O
(	O
n	O
=	O
6	O
)	O
.	O
Each	O
subject	O
received	O
a	O
single	O
50	O
mg	O
dose	O
of	O
clomipramine	B-CHEMICAL
given	O
orally	O
2	O
hours	O
before	O
blood	O
collection	O
.	O
Plasma	O
PRL	O
concentrations	O
were	O
analysed	O
at	O
10	O
min	O
intervals	O
and	O
underlying	O
secretory	O
rates	O
calculated	O
by	O
a	O
deconvolution	O
procedure	O
.	O
For	O
both	O
experiments	O
the	O
drug	O
intake	O
led	O
to	O
significant	O
increases	O
in	O
PRL	O
secretion	O
,	O
acting	O
preferentially	O
on	O
tonic	O
secretion	O
as	O
pulse	O
amplitude	O
and	O
frequency	O
did	O
not	O
differ	O
significantly	O
from	O
corresponding	O
control	O
values	O
.	O
During	O
the	O
night	O
clomipramine	B-CHEMICAL
ingestion	O
altered	O
the	O
complete	O
sleep	O
architecture	O
in	O
that	O
it	O
suppressed	O
REM	O
sleep	O
and	O
the	O
sleep	O
cycles	O
and	O
induced	O
increased	O
wakefulness	O
.	O
As	O
the	O
relative	O
increase	O
in	O
PRL	O
secretion	O
expressed	O
as	O
a	O
percentage	O
of	O
the	O
mean	O
did	O
not	O
significantly	O
differ	O
between	O
the	O
night	O
and	O
day	O
time	O
studies	O
(	O
46	O
+	O
/-	O
19	O
%	O
vs	O
34	O
+	O
/-	O
10	O
%	O
)	O
,	O
it	O
can	O
be	O
concluded	O
that	O
the	O
observed	O
sleep	O
disturbance	O
did	O
not	O
interfere	O
with	O
the	O
drug	O
action	O
per	O
se	B-DISEASE
.	O
The	O
presence	O
of	O
REM	O
sleep	O
was	O
shown	O
not	O
to	O
be	O
a	O
determining	O
factor	O
either	O
for	O
secretory	O
pulse	O
amplitude	O
and	O
frequency	O
,	O
as	O
,	O
for	O
both	O
,	O
mean	O
nocturnal	O
values	O
were	O
similar	O
with	O
and	O
without	O
prior	O
clomipramine	B-CHEMICAL
ingestion	O
.	O

Angioedema	B-DISEASE
following	O
the	O
intravenous	O
administration	O
of	O
metoprolol	B-CHEMICAL
.	O
A	O
72	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
the	O
hospital	O
with	O
"	O
flash	O
"	O
pulmonary	B-DISEASE
edema	I-DISEASE
,	O
preceded	O
by	O
chest	B-DISEASE
pain	I-DISEASE
,	O
requiring	O
intubation	O
.	O
Her	O
medical	O
history	O
included	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
with	O
previous	O
myocardial	O
infarctions	O
,	O
hypertension	B-DISEASE
,	O
and	O
diabetes	B-DISEASE
mellitus	I-DISEASE
.	O
A	O
history	O
of	O
angioedema	B-DISEASE
secondary	O
to	O
lisinopril	O
therapy	O
was	O
elicited	O
.	O
Current	O
medications	O
did	O
not	O
include	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitors	O
or	O
beta	O
-	O
blockers	O
.	O
She	O
had	O
no	O
previous	O
beta	O
-	O
blocking	O
drug	O
exposure	O
.	O
During	O
the	O
first	O
day	O
of	O
hospitalization	O
(	O
while	O
intubated	O
)	O
,	O
intravenous	O
metoprolol	B-CHEMICAL
was	O
given	O
,	O
resulting	O
in	O
severe	O
angioedema	B-DISEASE
.	O
The	O
angioedema	B-DISEASE
resolved	O
after	O
therapy	O
with	O
intravenous	O
steroids	B-CHEMICAL
and	O
diphenhydramine	B-CHEMICAL
hydrochloride	O
.	O

Effect	O
of	O
coniine	B-CHEMICAL
on	O
the	O
developing	O
chick	O
embryo	O
.	O
Coniine	B-CHEMICAL
,	O
an	O
alkaloid	O
from	O
Conium	O
maculatum	O
(	O
poison	O
hemlock	O
)	O
,	O
has	O
been	O
shown	O
to	O
be	O
teratogenic	O
in	O
livestock	O
.	O
The	O
major	O
teratogenic	O
outcome	O
is	O
arthrogryposis	B-DISEASE
,	O
presumably	O
due	O
to	O
nicotinic	O
receptor	O
blockade	O
.	O
However	O
,	O
coniine	B-CHEMICAL
has	O
failed	O
to	O
produce	O
arthrogryposis	B-DISEASE
in	O
rats	O
or	O
mice	O
and	O
is	O
only	O
weakly	O
teratogenic	O
in	O
rabbits	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
and	O
compare	O
the	O
effects	O
of	O
coniine	B-CHEMICAL
and	O
nicotine	B-CHEMICAL
in	O
the	O
developing	O
chick	O
.	O
Concentrations	O
of	O
coniine	B-CHEMICAL
and	O
nicotine	B-CHEMICAL
sulfate	O
were	O
0.015	O
%	O
,	O
0.03	O
%	O
,	O
0.075	O
%	O
,	O
0.15	O
%	O
,	O
0.75	O
%	O
,	O
1.5	O
%	O
,	O
3	O
%	O
,	O
and	O
6	O
%	O
and	O
1	O
%	O
,	O
5	O
%	O
,	O
and	O
10	O
%	O
,	O
respectively	O
.	O
Both	O
compounds	O
caused	O
deformations	B-DISEASE
and	O
lethality	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
All	O
concentrations	O
of	O
nicotine	B-CHEMICAL
sulfate	O
caused	O
some	O
lethality	O
but	O
a	O
no	O
effect	O
level	O
for	O
coniine	B-CHEMICAL
lethality	O
was	O
0.75	O
%	O
.	O
The	O
deformations	B-DISEASE
caused	O
by	O
both	O
coniine	B-CHEMICAL
and	O
nicotine	B-CHEMICAL
sulfate	O
were	O
excessive	B-DISEASE
flexion	I-DISEASE
or	I-DISEASE
extension	I-DISEASE
of	I-DISEASE
one	I-DISEASE
or	I-DISEASE
more	I-DISEASE
toes	I-DISEASE
.	O
No	O
histopathological	O
alterations	O
or	O
differences	O
in	O
bone	O
formation	O
were	O
seen	O
in	O
the	O
limbs	O
or	O
toes	O
of	O
any	O
chicks	O
from	O
any	O
group	O
;	O
however	O
,	O
extensive	O
cranial	B-DISEASE
hemorrhage	I-DISEASE
occurred	O
in	O
all	O
nicotine	B-CHEMICAL
sulfate	O
-	O
treated	O
chicks	O
.	O
There	O
was	O
a	O
statistically	O
significant	O
(	O
P	O
<	O
or	O
=	O
0.01	O
)	O
decrease	O
in	O
movement	O
in	O
coniine	B-CHEMICAL
and	O
nicotine	B-CHEMICAL
sulfate	O
treated	O
chicks	O
as	O
determined	O
by	O
ultrasound	O
.	O
Control	O
chicks	O
were	O
in	O
motion	O
an	O
average	O
of	O
33.67	O
%	O
of	O
the	O
time	O
,	O
while	O
coniine	B-CHEMICAL
-	O
treated	O
chicks	O
were	O
only	O
moving	O
8.95	O
%	O
of	O
a	O
5	O
-	O
min	O
interval	O
,	O
and	O
no	O
movement	O
was	O
observed	O
for	O
nicotine	B-CHEMICAL
sulfate	O
treated	O
chicks	O
.	O
In	O
summary	O
,	O
the	O
chick	O
embryo	O
provides	O
a	O
reliable	O
and	O
simple	O
experimental	O
animal	O
model	O
of	O
coniine	B-CHEMICAL
-	O
induced	O
arthrogryposis	B-DISEASE
.	O
Data	O
from	O
this	O
model	O
support	O
a	O
mechanism	O
involving	O
nicotinic	O
receptor	O
blockade	O
with	O
subsequent	O
decreased	O
fetal	O
movement	O
.	O

Epidural	O
blood	O
flow	O
during	O
prostaglandin	B-CHEMICAL
E1	I-CHEMICAL
or	O
trimethaphan	O
induced	O
hypotension	B-DISEASE
.	O
To	O
evaluate	O
the	O
effect	O
of	O
prostaglandin	B-CHEMICAL
E1	I-CHEMICAL
(	O
PGE1	O
)	O
or	O
trimethaphan	O
(	O
TMP	O
)	O
induced	O
hypotension	B-DISEASE
on	O
epidural	O
blood	O
flow	O
(	O
EBF	O
)	O
during	O
spinal	O
surgery	O
,	O
EBF	O
was	O
measured	O
using	O
the	O
heat	O
clearance	O
method	O
in	O
30	O
patients	O
who	O
underwent	O
postero	O
-	O
lateral	O
interbody	O
fusion	O
under	O
isoflurane	B-CHEMICAL
anaesthesia	O
.	O
An	O
initial	O
dose	O
of	O
0.1	O
microgram.kg-1.min-1	O
of	O
PGE1	O
(	O
15	O
patients	O
)	O
,	O
or	O
10	O
micrograms.kg-1.min-1	O
of	O
TMP	O
(	O
15	O
patients	O
)	O
was	O
administered	O
intravenously	O
after	O
the	O
dural	O
opening	O
and	O
the	O
dose	O
was	O
adjusted	O
to	O
maintain	O
the	O
mean	O
arterial	O
blood	O
pressure	O
(	O
MAP	O
)	O
at	O
about	O
60	O
mmHg	O
.	O
The	O
hypotensive	B-DISEASE
drug	O
was	O
discontinued	O
at	O
the	O
completion	O
of	O
the	O
operative	O
procedure	O
.	O
After	O
starting	O
PGE1	O
or	O
TMP	O
,	O
MAP	O
and	O
rate	O
pressure	O
product	O
(	O
RPP	O
)	O
decreased	O
significantly	O
compared	O
with	O
preinfusion	O
values	O
(	O
P	O
<	O
0.01	O
)	O
,	O
and	O
the	O
degree	O
of	O
hypotension	B-DISEASE
due	O
to	O
PGE1	O
remained	O
constant	O
until	O
60	O
min	O
after	O
its	O
discontinuation	O
.	O
Heart	O
rate	O
(	O
HR	O
)	O
did	O
not	O
change	O
in	O
either	O
group	O
.	O
EBFF	O
did	O
not	O
change	O
during	O
PGE1	O
infusion	O
whereas	O
in	O
the	O
TMP	O
group	O
,	O
EBF	O
decreased	O
significantly	O
at	O
30	O
and	O
60	O
min	O
after	O
the	O
start	O
of	O
TMP	O
(	O
preinfusion	O
:	O
45.9	O
+	O
/-	O
13.9	O
ml/100g	O
/	O
min	O
.	O
30	O
min	O
:	O
32.3	O
+	O
/-	O
9.9	O
ml/100	O
g	O
/	O
min	O
(	O
P	O
<	O
0.05	O
)	O
.	O
60	O
min	O
:	O
30	O
+	O
/-	O
7.5	O
ml/100	O
g	O
/	O
min	O
(	O
P	O
<	O
0.05	O
)	O
)	O
.	O
These	O
results	O
suggest	O
that	O
PGE1	O
may	O
be	O
preferable	O
to	O
TMP	O
for	O
hypotensive	B-DISEASE
anaesthesia	O
in	O
spinal	O
surgery	O
because	O
TMP	O
decreased	O
EBF	O
.	O

Immunohistochemical	O
studies	O
with	O
antibodies	O
to	O
neurofilament	O
proteins	O
on	O
axonal	B-DISEASE
damage	I-DISEASE
in	O
experimental	O
focal	O
lesions	O
in	O
rat	O
.	O
Immunohistochemistry	O
with	O
monoclonal	O
antibodies	O
against	O
neurofilament	O
(	O
NF	O
)	O
proteins	O
of	O
middle	O
and	O
high	O
molecular	O
weight	O
class	O
,	O
NF	O
-	O
M	O
and	O
NF	O
-	O
H	O
,	O
was	O
used	O
to	O
study	O
axonal	B-DISEASE
injury	I-DISEASE
in	O
the	O
borderzone	O
of	O
focal	O
lesions	O
in	O
rats	O
.	O
Focal	O
injury	O
in	O
the	O
cortex	O
was	O
produced	O
by	O
infusion	O
of	O
lactate	O
at	O
acid	O
pH	O
or	O
by	O
stab	O
caused	O
by	O
needle	O
insertion	O
.	O
Infarcts	O
in	O
substantia	O
nigra	O
pars	O
reticulata	O
were	O
evoked	O
by	O
prolonged	O
pilocarpine	B-CHEMICAL
-	O
induced	O
status	B-DISEASE
epilepticus	I-DISEASE
.	O
Immunohistochemical	O
staining	O
for	O
NFs	O
showed	O
characteristic	O
terminal	O
clubs	O
of	O
axons	O
in	O
the	O
borderzone	O
of	O
lesions	O
.	O
Differences	O
in	O
the	O
labelling	O
pattern	O
occurred	O
with	O
different	O
antibodies	O
which	O
apparently	O
depended	O
on	O
molecular	O
weight	O
class	O
of	O
NFs	O
and	O
phosphorylation	O
state	O
.	O
These	O
immunohistochemical	O
changes	O
of	O
NFs	O
can	O
serve	O
as	O
a	O
marker	O
for	O
axonal	B-DISEASE
damage	I-DISEASE
in	O
various	O
experimental	O
traumatic	O
or	O
ischemic	B-DISEASE
lesions	O
.	O

Increase	O
of	O
Parkinson	O
disability	O
after	O
fluoxetine	B-CHEMICAL
medication	O
.	O
Depression	B-DISEASE
is	O
a	O
major	O
clinical	O
feature	O
of	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
.	O
We	O
report	O
the	O
increased	O
amount	O
of	O
motor	B-DISEASE
disability	I-DISEASE
in	O
four	O
patients	O
with	O
idiopathic	B-DISEASE
Parkinson	I-DISEASE
's	I-DISEASE
disease	I-DISEASE
after	O
exposure	O
to	O
the	O
antidepressant	O
fluoxetine	B-CHEMICAL
.	O
The	O
possibility	O
of	O
a	O
clinically	O
relevant	O
dopamine	B-CHEMICAL
-	O
antagonistic	O
capacity	O
of	O
fluoxetine	B-CHEMICAL
in	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
patients	O
must	O
be	O
considered	O
.	O

Acetaminophen	B-CHEMICAL
-	O
induced	O
hypotension	B-DISEASE
.	O
Through	O
30	O
years	O
of	O
widespread	O
use	O
,	O
acetaminophen	B-CHEMICAL
has	O
been	O
shown	O
to	O
be	O
a	O
remarkably	O
safe	O
medication	O
in	O
therapeutic	O
dosages	O
.	O
The	O
potential	O
for	O
acetaminophen	B-CHEMICAL
to	O
produce	O
cardiovascular	B-DISEASE
toxicities	I-DISEASE
is	O
very	O
low	O
.	O
However	O
,	O
acetaminophen	B-CHEMICAL
has	O
been	O
demonstrated	O
to	O
produce	O
symptoms	O
of	O
anaphylaxis	B-DISEASE
,	O
including	O
hypotension	B-DISEASE
,	O
in	O
sensitive	O
individuals	O
.	O
This	O
article	O
describes	O
two	O
critically	B-DISEASE
ill	I-DISEASE
patients	O
in	O
whom	O
transient	O
episodes	O
of	O
hypotension	B-DISEASE
reproducibly	O
developed	O
after	O
administration	O
of	O
acetaminophen	B-CHEMICAL
.	O
Other	O
symptoms	O
of	O
allergic	B-DISEASE
reactions	I-DISEASE
were	O
not	O
clinically	O
detectable	O
.	O
The	O
hypotensive	B-DISEASE
episodes	O
were	O
severe	O
enough	O
to	O
require	O
vasopressor	O
administration	O
.	O
The	O
reports	O
illustrate	O
the	O
need	O
for	O
clinicians	O
to	O
consider	O
acetaminophen	B-CHEMICAL
in	O
patients	O
with	O
hypotension	B-DISEASE
of	O
unknown	O
origin	O
.	O

Acute	O
hepatitis	B-DISEASE
,	I-DISEASE
autoimmune	I-DISEASE
hemolytic	O
anemia	B-DISEASE
,	O
and	O
erythroblastocytopenia	B-DISEASE
induced	O
by	O
ceftriaxone	B-CHEMICAL
.	O
An	O
80	O
-	O
yr	O
-	O
old	O
man	O
developed	O
acute	B-DISEASE
hepatitis	I-DISEASE
shortly	O
after	O
ingesting	O
oral	O
ceftriaxone	B-CHEMICAL
.	O
Although	O
the	O
transaminases	O
gradually	O
returned	O
to	O
baseline	O
after	O
withholding	O
the	O
beta	O
lactam	O
antibiotic	O
,	O
there	O
was	O
a	O
gradual	O
increase	O
in	O
serum	O
bilirubin	O
and	O
a	O
decrease	O
in	O
hemoglobin	O
concentration	O
caused	O
by	O
an	O
autoimmune	B-DISEASE
hemolytic	I-DISEASE
anemia	I-DISEASE
and	O
erythroblastocytopenia	B-DISEASE
.	O
These	O
responded	O
to	O
systemic	O
steroids	B-CHEMICAL
and	O
immunoglobulins	O
.	O
Despite	O
the	O
widespread	O
use	O
of	O
these	O
agents	O
this	O
triad	O
of	O
side	O
effects	O
has	O
not	O
previously	O
been	O
reported	O
in	O
connection	O
with	O
beta	O
lactam	O
antibiotics	O
.	O

Adverse	O
effects	O
of	O
the	O
atypical	O
antipsychotics	B-CHEMICAL
.	O
Collaborative	O
Working	O
Group	O
on	O
Clinical	O
Trial	O
Evaluations	O
.	O
Adverse	O
effects	O
of	O
antipsychotics	B-CHEMICAL
often	O
lead	O
to	O
noncompliance	O
.	O
Thus	O
,	O
clinicians	O
should	O
address	O
patients	O
'	O
concerns	O
about	O
adverse	O
effects	O
and	O
attempt	O
to	O
choose	O
medications	O
that	O
will	O
improve	O
their	O
patients	O
'	O
quality	O
of	O
life	O
as	O
well	O
as	O
overall	O
health	O
.	O
The	O
side	O
effect	O
profiles	O
of	O
the	O
atypical	O
antipsychotics	B-CHEMICAL
are	O
more	O
advantageous	O
than	O
those	O
of	O
the	O
conventional	O
neuroleptics	B-CHEMICAL
.	O
Conventional	O
agents	O
are	O
associated	O
with	O
unwanted	O
central	O
nervous	O
system	O
effects	O
,	O
including	O
extrapyramidal	B-DISEASE
symptoms	I-DISEASE
(	O
EPS	O
)	O
,	O
tardive	B-DISEASE
dyskinesia	I-DISEASE
,	O
sedation	O
,	O
and	O
possible	O
impairment	O
of	O
some	O
cognitive	O
measures	O
,	O
as	O
well	O
as	O
cardiac	O
effects	O
,	O
orthostatic	B-DISEASE
hypotension	I-DISEASE
,	O
hepatic	O
changes	O
,	O
anticholinergic	O
side	O
effects	O
,	O
sexual	B-DISEASE
dysfunction	I-DISEASE
,	O
and	O
weight	B-DISEASE
gain	I-DISEASE
.	O
The	O
newer	O
atypical	O
agents	O
have	O
a	O
lower	O
risk	O
of	O
EPS	O
,	O
but	O
are	O
associated	O
in	O
varying	O
degrees	O
with	O
sedation	O
,	O
cardiovascular	O
effects	O
,	O
anticholinergic	O
effects	O
,	O
weight	B-DISEASE
gain	I-DISEASE
,	O
sexual	B-DISEASE
dysfunction	I-DISEASE
,	O
hepatic	O
effects	O
,	O
lowered	O
seizure	B-DISEASE
threshold	O
(	O
primarily	O
clozapine	B-CHEMICAL
)	O
,	O
and	O
agranulocytosis	B-DISEASE
(	O
clozapine	B-CHEMICAL
only	O
)	O
.	O
Since	O
the	O
incidence	O
and	O
severity	O
of	O
specific	O
adverse	O
effects	O
differ	O
among	O
the	O
various	O
atypicals	O
,	O
the	O
clinician	O
should	O
carefully	O
consider	O
which	O
side	O
effects	O
are	O
most	O
likely	O
to	O
lead	O
to	O
the	O
individual	O
's	O
dissatisfaction	O
and	O
noncompliance	O
before	O
choosing	O
an	O
antipsychotic	O
for	O
a	O
particular	O
patient	O
.	O

Effects	O
of	O
tetrandrine	O
and	O
fangchinoline	B-CHEMICAL
on	O
experimental	O
thrombosis	B-DISEASE
in	O
mice	O
and	O
human	O
platelet	B-DISEASE
aggregation	I-DISEASE
.	O
Tetrandrine	O
(	O
TET	O
)	O
and	O
fangchinoline	B-CHEMICAL
(	O
FAN	O
)	O
are	O
two	O
naturally	O
occurring	O
analogues	O
with	O
a	O
bisbenzylisoquinoline	O
structure	O
.	O
The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	O
and	O
FAN	O
on	O
the	O
experimental	O
thrombosis	B-DISEASE
induced	O
by	O
collagen	O
plus	O
epinephrine	B-CHEMICAL
(	O
EP	O
)	O
in	O
mice	O
,	O
and	O
platelet	B-DISEASE
aggregation	I-DISEASE
and	O
blood	B-DISEASE
coagulation	I-DISEASE
in	O
vitro	O
.	O
In	O
the	O
in	O
vivo	O
study	O
,	O
the	O
administration	O
(	O
50	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
of	O
TET	O
and	O
FAN	O
in	O
mice	O
showed	O
the	O
inhibition	O
of	O
thrombosis	B-DISEASE
by	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	O
acid	O
(	O
ASA	B-CHEMICAL
,	O
50	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
,	O
a	O
positive	O
control	O
,	O
showed	O
only	O
30	O
%	O
inhibition	O
.	O
In	O
the	O
vitro	O
human	O
platelet	O
aggregations	O
induced	O
by	O
the	O
agonists	O
used	O
in	O
tests	O
,	O
TET	O
and	O
FAN	O
showed	O
the	O
inhibitions	O
dose	O
dependently	O
.	O
In	O
addition	O
,	O
neither	O
TET	O
nor	O
FAN	O
showed	O
any	O
anticoagulation	O
activities	O
in	O
the	O
measurement	O
of	O
the	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
)	O
,	O
prothrombin	O
time	O
(	O
PT	O
)	O
and	O
thrombin	O
time	O
(	O
TT	O
)	O
using	O
human	O
-	O
citrated	O
plasma	O
.	O
These	O
results	O
suggest	O
that	O
antithrombosis	O
of	O
TET	O
and	O
FAN	O
in	O
mice	O
may	O
be	O
mainly	O
related	O
to	O
the	O
antiplatelet	O
aggregation	O
activities	O
.	O

Gemcitabine	B-CHEMICAL
plus	O
vinorelbine	B-CHEMICAL
in	O
nonsmall	O
cell	O
lung	O
carcinoma	B-DISEASE
patients	O
age	O
70	O
years	O
or	O
older	O
or	O
patients	O
who	O
can	O
not	O
receive	O
cisplatin	B-CHEMICAL
.	O
Oncopaz	O
Cooperative	O
Group	O
.	O
BACKGROUND	O
:	O
Although	O
the	O
prevalence	O
of	O
nonsmall	O
cell	O
lung	O
carcinoma	B-DISEASE
(	O
NSCLC	O
)	O
is	O
high	O
among	O
elderly	O
patients	O
,	O
few	O
data	O
are	O
available	O
regarding	O
the	O
efficacy	O
and	O
toxicity	B-DISEASE
of	O
chemotherapy	O
in	O
this	O
group	O
of	O
patients	O
.	O
Recent	O
reports	O
indicate	O
that	O
single	O
agent	O
therapy	O
with	O
vinorelbine	B-CHEMICAL
(	O
VNB	O
)	O
or	O
gemcitabine	B-CHEMICAL
(	O
GEM	O
)	O
may	O
obtain	O
a	O
response	O
rate	O
of	O
20	O
-	O
30	O
%	O
in	O
elderly	O
patients	O
,	O
with	O
acceptable	O
toxicity	B-DISEASE
and	O
improvement	O
in	O
symptoms	O
and	O
quality	O
of	O
life	O
.	O
In	O
the	O
current	O
study	O
the	O
efficacy	O
and	O
toxicity	B-DISEASE
of	O
the	O
combination	O
of	O
GEM	O
and	O
VNB	O
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	O
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	B-CHEMICAL
were	O
assessed	O
.	O
METHODS	O
:	O
Forty	O
-	O
nine	O
patients	O
with	O
advanced	O
NSCLC	O
were	O
included	O
,	O
38	O
of	O
whom	O
were	O
age	O
>	O
/=	O
70	O
years	O
and	O
11	O
were	O
age	O
<	O
70	O
years	O
but	O
who	O
had	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	B-CHEMICAL
.	O
All	O
patients	O
were	O
evaluable	O
for	O
response	O
and	O
toxicity	B-DISEASE
.	O
Treatment	O
was	O
comprised	O
of	O
VNB	O
,	O
25	O
mg	O
/	O
m(2	O
)	O
,	O
plus	O
GEM	O
,	O
1000	O
mg	O
/	O
m(2	O
)	O
,	O
both	O
on	O
Days	O
1	O
,	O
8	O
,	O
and	O
15	O
every	O
28	O
days	O
.	O
Patients	O
received	O
a	O
minimum	O
of	O
three	O
courses	O
unless	O
progressive	O
disease	B-DISEASE
was	O
detected	O
.	O
RESULTS	O
:	O
One	O
hundred	O
sixty	O
-	O
five	O
courses	O
were	O
administered	O
,	O
with	O
a	O
median	O
of	O
3	O
.	O
6	O
courses	O
per	O
patient	O
.	O
The	O
overall	O
response	O
rate	O
was	O
26	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
15	O
-	O
41	O
%	O
)	O
.	O
Two	O
patients	O
attained	O
a	O
complete	O
response	O
(	O
4	O
%	O
)	O
and	O
11	O
patients	O
(	O
22	O
%	O
)	O
achieved	O
a	O
partial	O
response	O
.	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
improved	O
in	O
35	O
%	O
of	O
those	O
patients	O
with	O
an	O
initial	O
value	O
>	O
0	O
,	O
whereas	O
relief	O
of	O
at	O
least	O
1	O
symptom	O
without	O
worsening	O
of	O
other	O
symptoms	O
was	O
noted	O
in	O
27	O
patients	O
(	O
55	O
%	O
)	O
.	O
The	O
median	O
time	O
to	O
progression	O
was	O
16	O
weeks	O
and	O
the	O
1	O
-	O
year	O
survival	O
rate	O
was	O
33	O
%	O
.	O
Toxicity	B-DISEASE
was	O
mild	O
.	O
Six	O
patients	O
(	O
12	O
%	O
)	O
had	O
World	O
Health	O
Organization	O
Grade	O
3	O
-	O
4	O
neutropenia	B-DISEASE
,	O
2	O
patients	O
(	O
4	O
%	O
)	O
had	O
Grade	O
3	O
-	O
4	O
thrombocytopenia	B-DISEASE
,	O
and	O
2	O
patients	O
(	O
4	O
%	O
)	O
had	O
Grade	O
3	O
neurotoxicity	B-DISEASE
.	O
Three	O
patients	O
with	O
severe	O
neutropenia	B-DISEASE
(	O
6	O
%	O
)	O
died	O
of	O
sepsis	B-DISEASE
.	O
The	O
median	O
age	O
of	O
those	O
patients	O
developing	O
Grade	O
3	O
-	O
4	O
neutropenia	B-DISEASE
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
remaining	O
patients	O
(	O
75	O
years	O
vs.	O
72	O
years	O
;	O
P	O
=	O
0.047	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
combination	O
of	O
GEM	O
and	O
VNB	O
is	O
moderately	O
active	O
and	O
well	O
tolerated	O
except	O
in	O
patients	O
age	O
>	O
/=	O
75	O
years	O
.	O
This	O
age	O
group	O
had	O
an	O
increased	O
risk	O
of	O
myelosuppression	B-DISEASE
.	O
Therefore	O
the	O
prophylactic	O
use	O
of	O
granulocyte	O
-	O
colony	O
stimulating	O
factor	O
should	O
be	O
considered	O
with	O
this	O
treatment	O
.	O
New	O
chemotherapy	O
combinations	O
with	O
higher	O
activity	O
and	O
lower	O
toxicity	B-DISEASE
are	O
needed	O
for	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	O
.	O

Warfarin	B-CHEMICAL
-	O
induced	O
artery	B-DISEASE
calcification	I-DISEASE
is	O
accelerated	O
by	O
growth	O
and	O
vitamin	O
D.	O
The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
treatment	O
enhance	O
the	O
extent	O
of	O
artery	B-DISEASE
calcification	I-DISEASE
in	O
rats	O
given	O
sufficient	O
doses	O
of	O
Warfarin	B-CHEMICAL
to	O
inhibit	O
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	B-DISEASE
inhibitor	O
known	O
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O
The	O
first	O
series	O
of	O
experiments	O
examined	O
the	O
influence	O
of	O
age	O
and	O
growth	O
status	O
on	O
artery	B-DISEASE
calcification	I-DISEASE
in	O
Warfarin	B-CHEMICAL
-	O
treated	O
rats	O
.	O
Treatment	O
for	O
2	O
weeks	O
with	O
Warfarin	B-CHEMICAL
caused	O
massive	O
focal	O
calcification	B-DISEASE
of	I-DISEASE
the	I-DISEASE
artery	I-DISEASE
media	O
in	O
20	O
-	O
day	O
-	O
old	O
rats	O
and	O
less	O
extensive	O
focal	O
calcification	B-DISEASE
in	O
42	O
-	O
day	O
-	O
old	O
rats	O
.	O
In	O
contrast	O
,	O
no	O
artery	B-DISEASE
calcification	I-DISEASE
could	O
be	O
detected	O
in	O
10	O
-	O
month	O
-	O
old	O
adult	O
rats	O
even	O
after	O
4	O
weeks	O
of	O
Warfarin	B-CHEMICAL
treatment	O
.	O
To	O
directly	O
examine	O
the	O
importance	O
of	O
growth	O
to	O
Warfarin	B-CHEMICAL
-	O
induced	O
artery	B-DISEASE
calcification	I-DISEASE
in	O
animals	O
of	O
the	O
same	O
age	O
,	O
20	O
-	O
day	O
-	O
old	O
rats	O
were	O
fed	O
for	O
2	O
weeks	O
either	O
an	O
ad	O
libitum	O
diet	O
or	O
a	O
6	O
-	O
g	O
/	O
d	O
restricted	O
diet	O
that	O
maintains	O
weight	O
but	O
prevents	O
growth	O
.	O
Concurrent	O
treatment	O
of	O
both	O
dietary	O
groups	O
with	O
Warfarin	B-CHEMICAL
produced	O
massive	O
focal	O
calcification	B-DISEASE
of	I-DISEASE
the	I-DISEASE
artery	I-DISEASE
media	O
in	O
the	O
ad	O
libitum	O
-	O
fed	O
rats	O
but	O
no	O
detectable	O
artery	B-DISEASE
calcification	I-DISEASE
in	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
group	O
.	O
Although	O
the	O
explanation	O
for	O
the	O
association	O
between	O
artery	B-DISEASE
calcification	I-DISEASE
and	O
growth	O
status	O
can	O
not	O
be	O
determined	O
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	O
between	O
higher	O
serum	O
phosphate	B-CHEMICAL
and	O
susceptibility	O
to	O
artery	B-DISEASE
calcification	I-DISEASE
,	O
with	O
30	O
%	O
higher	O
levels	O
of	O
serum	O
phosphate	B-CHEMICAL
in	O
young	O
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	O
to	O
Warfarin	B-CHEMICAL
-	O
induced	O
artery	B-DISEASE
calcification	I-DISEASE
,	O
ie	O
,	O
the	O
10	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
young	O
rats	O
.	O
This	O
observation	O
suggests	O
that	O
increased	O
susceptibility	O
to	O
Warfarin	B-CHEMICAL
-	O
induced	O
artery	B-DISEASE
calcification	I-DISEASE
could	O
be	O
related	O
to	O
higher	O
serum	O
phosphate	B-CHEMICAL
levels	O
.	O
The	O
second	O
set	O
of	O
experiments	O
examined	O
the	O
possible	O
synergy	O
between	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
and	O
Warfarin	B-CHEMICAL
in	O
artery	B-DISEASE
calcification	I-DISEASE
.	O
High	O
doses	O
of	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
are	O
known	O
to	O
cause	O
calcification	B-DISEASE
of	I-DISEASE
the	I-DISEASE
artery	I-DISEASE
media	O
in	O
as	O
little	O
as	O
3	O
to	O
4	O
days	O
.	O
High	O
doses	O
of	O
the	O
vitamin	O
K	O
antagonist	O
Warfarin	B-CHEMICAL
are	O
also	O
known	O
to	O
cause	O
calcification	B-DISEASE
of	I-DISEASE
the	I-DISEASE
artery	I-DISEASE
media	O
,	O
but	O
at	O
treatment	O
times	O
of	O
2	O
weeks	O
or	O
longer	O
yet	O
not	O
at	O
1	O
week	O
.	O
In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
synergy	O
between	O
these	O
2	O
treatments	O
and	O
found	O
that	O
concurrent	O
Warfarin	B-CHEMICAL
administration	O
dramatically	O
increased	O
the	O
extent	O
of	O
calcification	B-DISEASE
in	O
the	O
media	O
of	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
-	O
treated	O
rats	O
at	O
3	O
and	O
4	O
days	O
.	O
There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
dose	O
on	O
artery	B-DISEASE
calcification	I-DISEASE
and	O
the	O
effect	O
of	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	B-CHEMICAL
,	O
which	O
suggests	O
that	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
may	O
induce	O
artery	B-DISEASE
calcification	I-DISEASE
through	O
its	O
effect	O
on	O
serum	O
calcium	B-CHEMICAL
.	O
Because	O
Warfarin	B-CHEMICAL
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	B-CHEMICAL
produced	O
by	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
,	O
the	O
synergy	O
between	O
Warfarin	B-CHEMICAL
and	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	B-CHEMICAL
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	B-DISEASE
inhibitor	O
.	O
High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	O
of	O
artery	B-DISEASE
calcification	I-DISEASE
in	O
rats	O
treated	O
with	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
plus	O
Warfarin	B-CHEMICAL
,	O
and	O
chemical	O
analysis	O
showed	O
that	O
the	O
protein	O
that	O
accumulated	O
was	O
indeed	O
not	O
gamma	O
-	O
carboxylated	O
.	O
These	O
observations	O
indicate	O
that	O
although	O
the	O
gamma	O
-	O
carboxyglutamate	O
residues	O
of	O
matrix	O
Gla	O
protein	O
are	O
apparently	O
required	O
for	O
its	O
function	O
as	O
a	O
calcification	B-DISEASE
inhibitor	O
,	O
they	O
are	O
not	O
required	O
for	O
its	O
accumulation	O
at	O
calcification	B-DISEASE
sites	O
.	O

Antidepressant	O
-	O
induced	O
mania	B-DISEASE
in	O
bipolar	B-DISEASE
patients	O
:	O
identification	O
of	O
risk	O
factors	O
.	O
BACKGROUND	O
:	O
Concerns	O
about	O
possible	O
risks	O
of	O
switching	O
to	O
mania	B-DISEASE
associated	O
with	O
antidepressants	O
continue	O
to	O
interfere	O
with	O
the	O
establishment	O
of	O
an	O
optimal	O
treatment	O
paradigm	O
for	O
bipolar	B-DISEASE
depression	I-DISEASE
.	O
METHOD	O
:	O
The	O
response	O
of	O
44	O
patients	O
meeting	O
DSM	O
-	O
IV	O
criteria	O
for	O
bipolar	B-DISEASE
disorder	I-DISEASE
to	O
naturalistic	O
treatment	O
was	O
assessed	O
for	O
at	O
least	O
6	O
weeks	O
using	O
the	O
Montgomery	O
-	O
Asberg	O
Depression	B-DISEASE
Rating	O
Scale	O
and	O
the	O
Bech	O
-	O
Rafaelson	O
Mania	B-DISEASE
Rating	O
Scale	O
.	O
Patients	O
who	O
experienced	O
a	O
manic	B-DISEASE
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	B-DISEASE
I	I-DISEASE
vs.	O
bipolar	B-DISEASE
II	I-DISEASE
)	O
,	O
number	O
of	O
previous	O
manic	B-DISEASE
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	B-CHEMICAL
vs.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O
RESULTS	O
:	O
Switches	O
to	O
hypomania	O
or	O
mania	B-DISEASE
occurred	O
in	O
27	O
%	O
of	O
all	O
patients	O
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24	O
%	O
of	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
SSRIs	O
[	O
8/33	O
]	O
)	O
;	O
16	O
%	O
(	O
N	O
=	O
7	O
)	O
experienced	O
manic	B-DISEASE
episodes	O
,	O
and	O
11	O
%	O
(	O
N	O
=	O
5	O
)	O
experienced	O
hypomanic	O
episodes	O
.	O
Sex	O
,	O
age	O
,	O
diagnosis	O
(	O
bipolar	B-DISEASE
I	I-DISEASE
vs.	O
bipolar	B-DISEASE
II	I-DISEASE
)	O
,	O
and	O
additional	O
treatment	O
did	O
not	O
affect	O
the	O
risk	O
of	O
switching	O
.	O
The	O
incidence	O
of	O
mood	O
switches	O
seemed	O
not	O
to	O
differ	O
between	O
patients	O
receiving	O
an	O
anticonvulsant	O
and	O
those	O
receiving	O
no	O
mood	O
stabilizer	O
.	O
In	O
contrast	O
,	O
mood	O
switches	O
were	O
less	O
frequent	O
in	O
patients	O
receiving	O
lithium	B-CHEMICAL
(	O
15	O
%	O
,	O
4/26	O
)	O
than	O
in	O
patients	O
not	O
treated	O
with	O
lithium	B-CHEMICAL
(	O
44	O
%	O
,	O
8/18	O
;	O
p	O
=	O
.04	O
)	O
.	O
The	O
number	O
of	O
previous	O
manic	B-DISEASE
episodes	O
did	O
not	O
affect	O
the	O
probability	O
of	O
switching	O
,	O
whereas	O
a	O
high	O
score	O
on	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semistructured	O
Affective	O
Temperament	O
Interview	O
was	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
switching	O
(	O
p	O
=	O
.008	O
)	O
.	O
CONCLUSION	O
:	O
The	O
frequency	O
of	O
mood	O
switching	O
associated	O
with	O
acute	O
antidepressant	O
therapy	O
may	O
be	O
reduced	O
by	O
lithium	B-CHEMICAL
treatment	O
.	O
Particular	O
attention	O
should	O
be	O
paid	O
to	O
patients	O
with	O
a	O
hyperthymic	O
temperament	O
,	O
who	O
have	O
a	O
greater	O
risk	O
of	O
mood	O
switches	O
.	O

Caffeine	B-CHEMICAL
-	O
induced	O
cardiac	B-DISEASE
arrhythmia	I-DISEASE
:	O
an	O
unrecognised	O
danger	O
of	O
healthfood	O
products	O
.	O
We	O
describe	O
a	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	O
pre	O
-	O
existing	O
mitral	B-DISEASE
valve	I-DISEASE
prolapse	I-DISEASE
who	O
developed	O
intractable	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
after	O
consuming	O
a	O
"	O
natural	O
energy	O
"	O
guarana	O
health	O
drink	O
containing	O
a	O
high	O
concentration	O
of	O
caffeine	B-CHEMICAL
.	O
This	O
case	O
highlights	O
the	O
need	O
for	O
adequate	O
labelling	O
and	O
regulation	O
of	O
such	O
products	O
.	O

Bladder	O
retention	O
of	O
urine	O
as	O
a	O
result	O
of	O
continuous	O
intravenous	O
infusion	O
of	O
fentanyl	B-CHEMICAL
:	O
2	O
case	O
reports	O
.	O
Sedation	O
has	O
been	O
commonly	O
used	O
in	O
the	O
neonate	O
to	O
decrease	O
the	O
stress	B-DISEASE
and	O
pain	B-DISEASE
from	O
the	O
noxious	O
stimuli	O
and	O
invasive	O
procedures	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
,	O
as	O
well	O
as	O
to	O
facilitate	O
synchrony	O
between	O
ventilator	O
and	O
spontaneous	O
breaths	O
.	O
Fentanyl	B-CHEMICAL
,	O
an	O
opioid	O
analgesic	O
,	O
is	O
frequently	O
used	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
setting	O
for	O
these	O
very	O
purposes	O
.	O
Various	O
reported	O
side	O
effects	O
of	O
fentanyl	B-CHEMICAL
administration	O
include	O
chest	B-DISEASE
wall	I-DISEASE
rigidity	I-DISEASE
,	O
hypotension	B-DISEASE
,	O
respiratory	B-DISEASE
depression	I-DISEASE
,	O
and	O
bradycardia	B-DISEASE
.	O
Here	O
,	O
2	O
cases	O
of	O
urinary	O
bladder	O
retention	O
leading	O
to	O
renal	O
pelvocalyceal	O
dilatation	O
mimicking	O
hydronephrosis	B-DISEASE
as	O
a	O
result	O
of	O
continuous	O
infusion	O
of	O
fentanyl	B-CHEMICAL
are	O
reported	O
.	O

Combined	O
antiretroviral	O
therapy	O
causes	O
cardiomyopathy	B-DISEASE
and	O
elevates	O
plasma	O
lactate	O
in	O
transgenic	O
AIDS	B-DISEASE
mice	O
.	O
Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cardiomyopathy	B-DISEASE
(	O
CM	B-DISEASE
)	O
and	O
in	O
elevated	O
plasma	O
lactate	O
(	O
LA	O
)	O
in	O
AIDS	B-DISEASE
through	O
mechanisms	O
of	O
mitochondrial	B-DISEASE
dysfunction	I-DISEASE
.	O
To	O
determine	O
mitochondrial	O
events	O
from	O
HAART	O
in	O
vivo	O
,	O
8	O
-	O
week	O
-	O
old	O
hemizygous	O
transgenic	O
AIDS	B-DISEASE
mice	O
(	O
NL4	O
-	O
3Delta	O
gag	O
/	O
pol	O
;	O
TG	O
)	O
and	O
wild	O
-	O
type	O
FVB	O
/	O
n	O
littermates	O
were	O
treated	O
with	O
the	O
HAART	O
combination	O
of	O
zidovudine	B-CHEMICAL
,	O
lamivudine	B-CHEMICAL
,	O
and	O
indinavir	B-CHEMICAL
or	O
vehicle	O
control	O
for	O
10	O
days	O
or	O
35	O
days	O
.	O
At	O
termination	O
of	O
the	O
experiments	O
,	O
mice	O
underwent	O
echocardiography	O
,	O
quantitation	O
of	O
abundance	O
of	O
molecular	O
markers	O
of	O
CM	B-DISEASE
(	O
ventricular	O
mRNA	O
encoding	O
atrial	B-CHEMICAL
natriuretic	I-CHEMICAL
factor	I-CHEMICAL
[	O
ANF	B-CHEMICAL
]	O
and	O
sarcoplasmic	O
calcium	B-CHEMICAL
ATPase	O
[	O
SERCA2	O
]	O
)	O
,	O
and	O
determination	O
of	O
plasma	O
LA	O
.	O
Myocardial	O
histologic	O
features	O
were	O
analyzed	O
semiquantitatively	O
and	O
results	O
were	O
confirmed	O
by	O
transmission	O
electron	O
microscopy	O
.	O
After	O
35	O
days	O
in	O
the	O
TG	O
+	O
HAART	O
cohort	O
,	O
left	O
ventricular	O
mass	O
increased	O
160	O
%	O
by	O
echocardiography	O
.	O
Molecularly	O
,	O
ANF	B-CHEMICAL
mRNA	O
increased	O
250	O
%	O
and	O
SERCA2	O
mRNA	O
decreased	O
57	O
%	O
.	O
Biochemically	O
,	O
LA	O
was	O
elevated	O
(	O
8.5	O
+	O
/-	O
2.0	O
mM	O
)	O
.	O
Pathologically	O
,	O
granular	O
cytoplasmic	O
changes	O
were	O
found	O
in	O
cardiac	O
myocytes	O
,	O
indicating	O
enlarged	O
,	O
damaged	O
mitochondria	O
.	O
Findings	O
were	O
confirmed	O
ultrastructurally	O
.	O
No	O
changes	O
were	O
found	O
in	O
other	O
cohorts	O
.	O
After	O
10	O
days	O
,	O
only	O
ANF	B-CHEMICAL
was	O
elevated	O
,	O
and	O
only	O
in	O
the	O
TG	O
+	O
HAART	O
cohort	O
.	O
Results	O
show	O
that	O
cumulative	O
HAART	O
caused	O
mitochondrial	O
CM	B-DISEASE
with	O
elevated	O
LA	O
in	O
AIDS	B-DISEASE
transgenic	O
mice	O
.	O

Oral	B-CHEMICAL
contraceptives	I-CHEMICAL
and	O
the	O
risk	O
of	O
myocardial	B-DISEASE
infarction	I-DISEASE
.	O
BACKGROUND	O
:	O
An	O
association	O
between	O
the	O
use	O
of	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
and	O
the	O
risk	O
of	O
myocardial	B-DISEASE
infarction	I-DISEASE
has	O
been	O
found	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
studies	O
.	O
We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i.e.	O
,	O
desogestrel	B-CHEMICAL
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i.e.	O
,	O
levonorgestrel	O
)	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
,	O
the	O
dose	O
of	O
estrogen	B-CHEMICAL
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	B-DISEASE
infarction	I-DISEASE
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	B-DISEASE
infarction	I-DISEASE
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O
Subjects	O
supplied	O
information	O
on	O
oral	O
-	O
contraceptive	O
use	O
and	O
major	O
cardiovascular	O
risk	O
factors	O
.	O
An	O
analysis	O
for	O
factor	B-CHEMICAL
V	I-CHEMICAL
Leiden	I-CHEMICAL
and	O
the	O
G20210A	O
mutation	O
in	O
the	O
prothrombin	O
gene	O
was	O
conducted	O
in	O
217	O
patients	O
and	O
763	O
controls	O
RESULTS	O
:	O
The	O
odds	O
ratio	O
for	O
myocardial	B-DISEASE
infarction	I-DISEASE
among	O
women	O
who	O
used	O
any	O
type	O
of	O
combined	O
oral	B-CHEMICAL
contraceptive	I-CHEMICAL
,	O
as	O
compared	O
with	O
nonusers	O
,	O
was	O
2.0	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1.5	O
to	O
2.8	O
)	O
.	O
The	O
adjusted	O
odds	O
ratio	O
was	O
2.5	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1.5	O
to	O
4.1	O
)	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
and	O
1.3	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0.7	O
to	O
2.5	O
)	O
among	O
those	O
who	O
used	O
third	O
-	O
generation	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
.	O
Among	O
women	O
who	O
used	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
,	O
the	O
odds	O
ratio	O
was	O
2.1	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1.5	O
to	O
3.0	O
)	O
for	O
those	O
without	O
a	O
prothrombotic	O
mutation	O
and	O
1.9	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0.6	O
to	O
5.5	O
)	O
for	O
those	O
with	O
a	O
mutation	O
CONCLUSIONS	O
:	O
The	O
risk	O
of	O
myocardial	B-DISEASE
infarction	I-DISEASE
was	O
increased	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
.	O
The	O
results	O
with	O
respect	O
to	O
the	O
use	O
of	O
third	O
-	O
generation	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
were	O
inconclusive	O
but	O
suggested	O
that	O
the	O
risk	O
was	O
lower	O
than	O
the	O
risk	O
associated	O
with	O
second	O
-	O
generation	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
.	O
The	O
risk	O
of	O
myocardial	B-DISEASE
infarction	I-DISEASE
was	O
similar	O
among	O
women	O
who	O
used	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
whether	O
or	O
not	O
they	O
had	O
a	O
prothrombotic	O
mutation	O
.	O

Effects	O
of	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbal	O
shell	O
or	O
core	O
on	O
the	O
cocaine	B-CHEMICAL
-	O
induced	O
locomotor	B-DISEASE
hyperactivity	I-DISEASE
in	O
rats	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
effect	O
of	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
subregions	O
of	O
the	O
nucleus	O
accumbens	O
(	O
the	O
shell	O
and	O
the	O
core	O
)	O
on	O
the	O
locomotor	B-DISEASE
hyperactivity	I-DISEASE
induced	O
by	O
cocaine	B-CHEMICAL
in	O
rats	O
.	O
Male	O
Wistar	O
rats	O
were	O
implanted	O
bilaterally	O
with	O
cannulae	O
into	O
the	O
accumbens	O
shell	O
or	O
core	O
,	O
and	O
then	O
were	O
locally	O
injected	O
with	O
GR	O
55562	O
(	O
an	O
antagonist	O
of	O
5	O
-	O
HT1B	O
receptors	O
)	O
or	O
CP	B-DISEASE
93129	O
(	O
an	O
agonist	O
of	O
5	O
-	O
HT1B	O
receptors	O
)	O
.	O
Given	O
alone	O
to	O
any	O
accumbal	O
subregion	O
,	O
GR	O
55562	O
(	O
0.1	O
-	O
10	O
microg	O
/	O
side	O
)	O
or	O
CP	B-DISEASE
93129	O
(	O
0.1	O
-	O
10	O
microg	O
/	O
side	O
)	O
did	O
not	O
change	O
basal	O
locomotor	O
activity	O
.	O
Systemic	O
cocaine	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
)	O
significantly	O
increased	O
the	O
locomotor	O
activity	O
of	O
rats	O
.	O
GR	O
55562	O
(	O
0.1	O
-	O
10	O
microg	O
/	O
side	O
)	O
,	O
administered	O
intra	O
-	O
accumbens	O
shell	O
prior	O
to	O
cocaine	B-CHEMICAL
,	O
dose	O
-	O
dependently	O
attenuated	O
the	O
psychostimulant	O
-	O
induced	O
locomotor	B-DISEASE
hyperactivity	I-DISEASE
.	O
Such	O
attenuation	O
was	O
not	O
found	O
in	O
animals	O
which	O
had	O
been	O
injected	O
with	O
GR	O
55562	O
into	O
the	O
accumbens	O
core	O
.	O
When	O
injected	O
into	O
the	O
accumbens	O
shell	O
(	O
but	O
not	O
the	O
core	O
)	O
before	O
cocaine	B-CHEMICAL
,	O
CP	B-DISEASE
93129	O
(	O
0.1	O
-	O
10	O
microg	O
/	O
side	O
)	O
enhanced	O
the	O
locomotor	O
response	O
to	O
cocaine	B-CHEMICAL
;	O
the	O
maximum	O
effect	O
being	O
observed	O
after	O
10	O
microg	O
/	O
side	O
of	O
the	O
agonist	O
.	O
The	O
later	O
enhancement	O
was	O
attenuated	O
after	O
intra	O
-	O
accumbens	O
shell	O
treatment	O
with	O
GR	O
55562	O
(	O
1	O
microg	O
/	O
side	O
)	O
.	O
Our	O
findings	O
indicate	O
that	O
cocaine	B-CHEMICAL
induced	O
hyperlocomotion	O
is	O
modified	O
by	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbens	O
shell	O
,	O
but	O
not	O
core	O
,	O
this	O
modification	O
consisting	O
in	O
inhibitory	O
and	O
facilitatory	O
effects	O
of	O
the	O
5	O
-	O
HT1B	O
receptor	O
antagonist	O
(	O
GR	O
55562	O
)	O
and	O
agonist	O
(	O
CP	B-DISEASE
93129	O
)	O
,	O
respectively	O
.	O
In	O
other	O
words	O
,	O
the	O
present	O
results	O
suggest	O
that	O
the	O
accumbal	O
shell	O
5	O
-	O
HT1B	O
receptors	O
play	O
a	O
permissive	O
role	O
in	O
the	O
behavioural	O
response	O
to	O
the	O
psychostimulant	O
.	O

Ticlopidine	B-CHEMICAL
-	O
induced	O
cholestatic	B-DISEASE
hepatitis	B-DISEASE
.	O
OBJECTIVE	O
:	O
To	O
report	O
2	O
cases	O
of	O
ticlopidine	B-CHEMICAL
-	O
induced	O
cholestatic	B-DISEASE
hepatitis	B-DISEASE
,	O
investigate	O
its	O
mechanism	O
,	O
and	O
compare	O
the	O
observed	O
main	O
characteristics	O
with	O
those	O
of	O
the	O
published	O
cases	O
.	O
CASE	O
SUMMARIES	O
:	O
Two	O
patients	O
developed	O
prolonged	O
cholestatic	B-DISEASE
hepatitis	B-DISEASE
after	O
receiving	O
ticlopidine	B-CHEMICAL
following	O
percutaneous	O
coronary	O
angioplasty	O
,	O
with	O
complete	O
remission	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O
T	O
-	O
cell	O
stimulation	O
by	O
therapeutic	O
concentration	O
of	O
ticlopidine	B-CHEMICAL
was	O
demonstrated	O
in	O
vitro	O
in	O
the	O
patients	O
,	O
but	O
not	O
in	O
healthy	O
controls	O
.	O
DISCUSSION	O
:	O
Cholestatic	B-DISEASE
hepatitis	B-DISEASE
is	O
a	O
rare	O
complication	O
of	O
the	O
antiplatelet	O
agent	O
ticlopidine	B-CHEMICAL
;	O
several	O
cases	O
have	O
been	O
reported	O
but	O
few	O
in	O
the	O
English	O
literature	O
.	O
Our	O
patients	O
developed	O
jaundice	B-DISEASE
following	O
treatment	O
with	O
ticlopidine	B-CHEMICAL
and	O
showed	O
the	O
clinical	O
and	O
laboratory	O
characteristics	O
of	O
cholestatic	B-DISEASE
hepatitis	B-DISEASE
,	O
which	O
resolved	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O
Hepatitis	B-DISEASE
may	O
develop	O
weeks	O
after	O
discontinuation	O
of	O
the	O
drug	O
and	O
may	O
run	O
a	O
prolonged	O
course	O
,	O
but	O
complete	O
remission	O
was	O
observed	O
in	O
all	O
reported	O
cases	O
.	O
An	O
objective	O
causality	O
assessment	O
revealed	O
that	O
the	O
adverse	O
drug	O
event	O
was	O
probably	O
related	O
to	O
the	O
use	O
of	O
ticlopidine	B-CHEMICAL
.	O
The	O
mechanisms	O
of	O
this	O
ticlopidine	B-CHEMICAL
-	O
induced	O
cholestasis	B-DISEASE
are	O
unclear	O
.	O
Immune	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
drug	O
's	O
hepatotoxicity	O
,	O
as	O
suggested	O
by	O
the	O
T	O
-	O
cell	O
stimulation	O
study	O
reported	O
here	O
.	O
CONCLUSIONS	O
:	O
Cholestatic	B-DISEASE
hepatitis	B-DISEASE
is	O
a	O
rare	O
adverse	O
effect	O
of	O
ticlopidine	B-CHEMICAL
that	O
may	O
be	O
immune	O
mediated	O
.	O
Patients	O
receiving	O
the	O
drug	O
should	O
be	O
monitored	O
with	O
liver	O
function	O
tests	O
along	O
with	O
complete	O
blood	O
cell	O
counts	O
.	O
This	O
complication	O
will	O
be	O
observed	O
even	O
less	O
often	O
in	O
the	O
future	O
as	O
ticlopidine	B-CHEMICAL
is	O
being	O
replaced	O
by	O
the	O
newer	O
antiplatelet	O
agent	O
clopidogrel	B-CHEMICAL
.	O

Epithelial	O
sodium	B-CHEMICAL
channel	O
(	O
ENaC	O
)	O
subunit	O
mRNA	O
and	O
protein	O
expression	O
in	O
rats	O
with	O
puromycin	O
aminonucleoside	O
-	O
induced	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
.	O
In	O
experimental	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
,	O
urinary	O
sodium	B-CHEMICAL
excretion	O
is	O
decreased	O
during	O
the	O
early	O
phase	O
of	O
the	O
disease	B-DISEASE
.	O
The	O
molecular	O
mechanism(s	O
)	O
leading	O
to	O
salt	B-CHEMICAL
retention	O
has	O
not	O
been	O
completely	O
elucidated	O
.	O
The	O
rate	O
-	O
limiting	O
constituent	O
of	O
collecting	O
duct	O
sodium	B-CHEMICAL
transport	O
is	O
the	O
epithelial	O
sodium	B-CHEMICAL
channel	O
(	O
ENaC	O
)	O
.	O
We	O
examined	O
the	O
abundance	O
of	O
ENaC	O
subunit	O
mRNAs	O
and	O
proteins	O
in	O
puromycin	O
aminonucleoside	O
(	O
PAN)-induced	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
.	O
The	O
time	O
courses	O
of	O
urinary	O
sodium	B-CHEMICAL
excretion	O
,	O
plasma	O
aldosterone	O
concentration	O
and	O
proteinuria	B-DISEASE
were	O
studied	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
a	O
single	O
dose	O
of	O
either	O
PAN	O
or	O
vehicle	O
.	O
The	O
relative	O
amounts	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
mRNAs	O
were	O
determined	O
in	O
kidneys	O
from	O
these	O
rats	O
by	O
real	O
-	O
time	O
quantitative	O
TaqMan	O
PCR	O
,	O
and	O
the	O
amounts	O
of	O
proteins	O
by	O
Western	O
blot	O
.	O
The	O
kinetics	O
of	O
urinary	O
sodium	B-CHEMICAL
excretion	O
and	O
the	O
appearance	O
of	O
proteinuria	B-DISEASE
were	O
comparable	O
with	O
those	O
reported	O
previously	O
.	O
Sodium	B-CHEMICAL
retention	O
occurred	O
on	O
days	O
2	O
,	O
3	O
and	O
6	O
after	O
PAN	O
injection	O
.	O
A	O
significant	O
up	O
-	O
regulation	O
of	O
alphaENaC	O
and	O
betaENaC	O
mRNA	O
abundance	O
on	O
days	O
1	O
and	O
2	O
preceded	O
sodium	B-CHEMICAL
retention	O
on	O
days	O
2	O
and	O
3	O
.	O
Conversely	O
,	O
down	O
-	O
regulation	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
mRNA	O
expression	O
on	O
day	O
3	O
occurred	O
in	O
the	O
presence	O
of	O
high	O
aldosterone	O
concentrations	O
,	O
and	O
was	O
followed	O
by	O
a	O
return	O
of	O
sodium	B-CHEMICAL
excretion	O
to	O
control	O
values	O
.	O
The	O
amounts	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
proteins	O
were	O
not	O
increased	O
during	O
PAN	O
-	O
induced	O
sodium	B-CHEMICAL
retention	O
.	O
In	O
conclusion	O
,	O
ENaC	O
mRNA	O
expression	O
,	O
especially	O
alphaENaC	O
,	O
is	O
increased	O
in	O
the	O
very	O
early	O
phase	O
of	O
the	O
experimental	O
model	O
of	O
PAN	O
-	O
induced	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
in	O
rats	O
,	O
but	O
appears	O
to	O
escape	O
from	O
the	O
regulation	O
by	O
aldosterone	O
after	O
day	O
3	O
.	O

NO	O
-	O
induced	O
migraine	B-DISEASE
attack	O
:	O
strong	O
increase	O
in	O
plasma	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	B-CHEMICAL
)	O
concentration	O
and	O
negative	O
correlation	O
with	O
platelet	O
serotonin	B-CHEMICAL
release	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
changes	O
in	O
the	O
plasma	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	B-CHEMICAL
)	O
concentration	O
and	O
platelet	O
serotonin	B-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytriptamine	I-CHEMICAL
,	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
content	O
during	O
the	O
immediate	O
headache	B-DISEASE
and	O
the	O
delayed	O
genuine	O
migraine	B-DISEASE
attack	O
provoked	O
by	O
nitroglycerin	B-CHEMICAL
.	O
Fifteen	O
female	O
migraineurs	O
(	O
without	O
aura	O
)	O
and	O
eight	O
controls	O
participated	O
in	O
the	O
study	O
.	O
Sublingual	O
nitroglycerin	B-CHEMICAL
(	O
0.5	O
mg	O
)	O
was	O
administered	O
.	O
Blood	O
was	O
collected	O
from	O
the	O
antecubital	O
vein	O
four	O
times	O
:	O
60	O
min	O
before	O
and	O
after	O
the	O
nitroglycerin	B-CHEMICAL
application	O
,	O
and	O
60	O
and	O
120	O
min	O
after	O
the	O
beginning	O
of	O
the	O
migraine	B-DISEASE
attack	O
(	O
mean	O
344	O
and	O
404	O
min	O
;	O
12	O
subjects	O
)	O
.	O
In	O
those	O
subjects	O
who	O
had	O
no	O
migraine	B-DISEASE
attack	O
(	O
11	O
subjects	O
)	O
a	O
similar	O
time	O
schedule	O
was	O
used	O
.	O
Plasma	O
CGRP	B-CHEMICAL
concentration	O
increased	O
significantly	O
(	O
P<0.01	O
)	O
during	O
the	O
migraine	B-DISEASE
attack	O
and	O
returned	O
to	O
baseline	O
after	O
the	O
cessation	O
of	O
the	O
migraine	B-DISEASE
.	O
In	O
addition	O
,	O
both	O
change	O
and	O
peak	O
,	O
showed	O
significant	O
positive	O
correlations	O
with	O
migraine	B-DISEASE
headache	B-DISEASE
intensity	O
(	O
P<0.001	O
)	O
.	O
However	O
,	O
plasma	O
CGRP	B-CHEMICAL
concentrations	O
failed	O
to	O
change	O
during	O
immediate	O
headache	B-DISEASE
and	O
in	O
the	O
subjects	O
with	O
no	O
migraine	B-DISEASE
attack	O
.	O
Basal	O
CGRP	B-CHEMICAL
concentration	O
was	O
significantly	O
higher	O
and	O
platelet	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
content	O
tended	O
to	O
be	O
lower	O
in	O
subjects	O
who	O
experienced	O
a	O
migraine	B-DISEASE
attack	O
.	O
Platelet	O
serotonin	B-CHEMICAL
content	O
decreased	O
significantly	O
(	O
P<0.01	O
)	O
after	O
nitroglycerin	B-CHEMICAL
in	O
subjects	O
with	O
no	O
migraine	B-DISEASE
attack	O
but	O
no	O
consistent	O
change	O
was	O
observed	O
in	O
patients	O
with	O
migraine	B-DISEASE
attack	O
.	O
In	O
conclusion	O
,	O
the	O
fact	O
that	O
plasma	O
CGRP	B-CHEMICAL
concentration	O
correlates	O
with	O
the	O
timing	O
and	O
severity	O
of	O
a	O
migraine	B-DISEASE
headache	B-DISEASE
suggests	O
a	O
direct	O
relationship	O
between	O
CGRP	B-CHEMICAL
and	O
migraine	B-DISEASE
.	O
In	O
contrast	O
,	O
serotonin	B-CHEMICAL
release	O
from	O
platelets	O
does	O
not	O
provoke	O
migraine	B-DISEASE
,	O
it	O
may	O
even	O
counteract	O
the	O
headache	B-DISEASE
and	O
the	O
concomitant	O
CGRP	B-CHEMICAL
release	O
in	O
this	O
model	O
.	O

Coronary	B-DISEASE
aneurysm	I-DISEASE
after	O
implantation	O
of	O
a	O
paclitaxel	B-CHEMICAL
-	O
eluting	O
stent	O
.	O
Formation	O
of	O
coronary	B-DISEASE
aneurysm	I-DISEASE
is	O
a	O
rare	O
complication	O
of	O
stenting	O
with	O
bare	O
metal	O
stents	O
,	O
but	O
based	O
on	O
experimental	O
studies	O
drug	O
-	O
eluting	O
stents	O
may	O
induce	O
toxic	O
effects	O
on	O
the	O
vessel	O
wall	O
with	O
incomplete	O
stent	O
apposition	O
,	O
aneurysm	B-DISEASE
formation	O
and	O
with	O
the	O
potential	O
of	O
stent	O
thrombosis	B-DISEASE
or	O
vessel	O
rupture	B-DISEASE
.	O
We	O
present	O
a	O
43	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
a	O
coronary	B-DISEASE
aneurysm	I-DISEASE
in	O
the	O
right	O
coronary	O
artery	O
6	O
months	O
after	O
receiving	O
a	O
paclitaxel	B-CHEMICAL
-	O
eluting	O
stent	O
.	O
The	O
patient	O
was	O
asymptomatic	O
and	O
the	O
aneurysm	B-DISEASE
was	O
detected	O
in	O
a	O
routine	O
control	O
.	O
Angiography	O
and	O
intracoronary	O
ultrasound	O
demonstrated	O
lack	O
of	O
contact	O
between	O
stent	O
and	O
vessel	O
wall	O
in	O
a	O
15	O
-	O
mm	O
long	O
segment	O
with	O
maximal	O
aneurysm	B-DISEASE
diameter	O
of	O
6.0	O
mm	O
.	O
The	O
patient	O
was	O
successfully	O
treated	O
with	O
a	O
graft	O
stent	O
.	O

Behavioral	O
effects	O
of	O
urotensin	O
-	O
II	O
centrally	O
administered	O
in	O
mice	O
.	O
Urotensin	O
-	O
II	O
(	O
U	O
-	O
II	O
)	O
receptors	O
are	O
widely	O
distributed	O
in	O
the	O
central	O
nervous	O
system	O
.	O
Intracerebroventricular	O
(	O
i.c.v	O
.	O
)	O
injection	O
of	O
U	O
-	O
II	O
causes	O
hypertension	B-DISEASE
and	O
bradycardia	B-DISEASE
and	O
stimulates	O
prolactin	O
and	O
thyrotropin	B-CHEMICAL
secretion	O
.	O
However	O
,	O
the	O
behavioral	O
effects	O
of	O
centrally	O
administered	O
U	O
-	O
II	O
have	O
received	O
little	O
attention	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
tested	O
the	O
effects	O
of	O
i.c.v	O
.	O
injections	O
of	O
U	O
-	O
II	O
on	O
behavioral	O
,	O
metabolic	O
,	O
and	O
endocrine	O
responses	O
in	O
mice	O
.	O
Administration	O
of	O
graded	O
doses	O
of	O
U	O
-	O
II	O
(	O
1	O
-	O
10,000	O
ng	O
/	O
mouse	O
)	O
provoked	O
:	O
(	O
1	O
)	O
a	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
number	O
of	O
head	O
dips	O
in	O
the	O
hole	O
-	O
board	O
test	O
;	O
(	O
2	O
)	O
a	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
white	O
chamber	O
in	O
the	O
black	O
-	O
and	O
-	O
white	O
compartment	O
test	O
,	O
and	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
central	O
platform	O
and	O
open	O
arms	O
in	O
the	O
plus	O
-	O
maze	O
test	O
;	O
and	O
(	O
3	O
)	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
duration	O
of	O
immobility	O
in	O
the	O
forced	O
-	O
swimming	O
test	O
and	O
tail	O
suspension	O
test	O
.	O
Intracerebroventricular	O
injection	O
of	O
U	O
-	O
II	O
also	O
caused	O
an	O
increase	O
in	O
:	O
food	O
intake	O
at	O
doses	O
of	O
100	O
and	O
1,000	O
ng	O
/	O
mouse	O
,	O
water	O
intake	O
at	O
doses	O
of	O
100	O
-	O
10,000	O
ng	O
/	O
mouse	O
,	O
and	O
horizontal	O
locomotion	O
activity	O
at	O
a	O
dose	O
of	O
10,000	O
ng	O
/	O
mouse	O
.	O
Whatever	O
was	O
the	O
dose	O
,	O
the	O
central	O
administration	O
of	O
U	O
-	O
II	O
had	O
no	O
effect	O
on	O
body	O
temperature	O
,	O
nociception	O
,	O
apomorphine	O
-	O
induced	O
penile	O
erection	O
and	O
climbing	O
behavior	O
,	O
and	O
stress	B-DISEASE
-	O
induced	O
plasma	O
corticosterone	B-CHEMICAL
level	O
.	O
Taken	O
together	O
,	O
the	O
present	O
study	O
demonstrates	O
that	O
the	O
central	O
injection	O
of	O
U	O
-	O
II	O
at	O
doses	O
of	O
1	O
-	O
10,000	O
ng	O
/	O
mouse	O
induces	O
anxiogenic-	O
and	O
depressant	O
-	O
like	O
effects	O
in	O
mouse	O
.	O
These	O
data	O
suggest	O
that	O
U	O
-	O
II	O
may	O
be	O
involved	O
in	O
some	O
aspects	O
of	O
psychiatric	B-DISEASE
disorders	O
.	O

Recurrent	O
dysphonia	B-DISEASE
and	O
acitretin	O
.	O
We	O
report	O
the	O
case	O
of	O
a	O
woman	O
complaining	O
of	O
dysphonia	B-DISEASE
while	O
she	O
was	O
treated	O
by	O
acitretin	O
.	O
Her	O
symptoms	O
totally	O
regressed	O
after	O
drug	O
withdrawal	O
and	O
reappeared	O
when	O
acitretin	O
was	O
reintroduced	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
acitretin	O
-	O
induced	O
dysphonia	B-DISEASE
.	O
This	O
effect	O
may	O
be	O
related	O
to	O
the	O
pharmacological	O
effect	O
of	O
this	O
drug	O
on	O
mucous	O
membranes	O
.	O

Pharmacological	O
modulation	O
of	O
pain	B-DISEASE
-	O
related	O
brain	O
activity	O
during	O
normal	O
and	O
central	O
sensitization	O
states	O
in	O
humans	O
.	O
Abnormal	O
processing	O
of	O
somatosensory	O
inputs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
central	O
sensitization	O
)	O
is	O
the	O
mechanism	O
accounting	O
for	O
the	O
enhanced	O
pain	B-DISEASE
sensitivity	O
in	O
the	O
skin	O
surrounding	O
tissue	O
injury	O
(	O
secondary	B-DISEASE
hyperalgesia	I-DISEASE
)	O
.	O
Secondary	B-DISEASE
hyperalgesia	I-DISEASE
shares	O
clinical	O
characteristics	O
with	O
neurogenic	O
hyperalgesia	B-DISEASE
in	O
patients	O
with	O
neuropathic	B-DISEASE
pain	I-DISEASE
.	O
Abnormal	O
brain	O
responses	O
to	O
somatosensory	O
stimuli	O
have	O
been	O
found	O
in	O
patients	O
with	O
hyperalgesia	B-DISEASE
as	O
well	O
as	O
in	O
normal	O
subjects	O
during	O
experimental	O
central	O
sensitization	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
gabapentin	B-CHEMICAL
,	O
a	O
drug	O
effective	O
in	O
neuropathic	B-DISEASE
pain	I-DISEASE
patients	O
,	O
on	O
brain	O
processing	O
of	O
nociceptive	O
information	O
in	O
normal	O
and	O
central	O
sensitization	O
states	O
.	O
Using	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
in	O
normal	O
volunteers	O
,	O
we	O
studied	O
the	O
gabapentin	B-CHEMICAL
-	O
induced	O
modulation	O
of	O
brain	O
activity	O
in	O
response	O
to	O
nociceptive	O
mechanical	O
stimulation	O
of	O
normal	O
skin	O
and	O
capsaicin	B-CHEMICAL
-	O
induced	O
secondary	B-DISEASE
hyperalgesia	I-DISEASE
.	O
The	O
dose	O
of	O
gabapentin	B-CHEMICAL
was	O
1,800	O
mg	O
per	O
os	O
,	O
in	O
a	O
single	O
administration	O
.	O
We	O
found	O
that	O
(	O
i	O
)	O
gabapentin	B-CHEMICAL
reduced	O
the	O
activations	O
in	O
the	O
bilateral	O
operculoinsular	O
cortex	O
,	O
independently	O
of	O
the	O
presence	O
of	O
central	O
sensitization	O
;	O
(	O
ii	O
)	O
gabapentin	B-CHEMICAL
reduced	O
the	O
activation	O
in	O
the	O
brainstem	O
,	O
only	O
during	O
central	O
sensitization	O
;	O
(	O
iii	O
)	O
gabapentin	B-CHEMICAL
suppressed	O
stimulus	O
-	O
induced	O
deactivations	O
,	O
only	O
during	O
central	O
sensitization	O
;	O
this	O
effect	O
was	O
more	O
robust	O
than	O
the	O
effect	O
on	O
brain	O
activation	O
.	O
The	O
observed	O
drug	O
-	O
induced	O
effects	O
were	O
not	O
due	O
to	O
changes	O
in	O
the	O
baseline	O
fMRI	O
signal	O
.	O
These	O
findings	O
indicate	O
that	O
gabapentin	B-CHEMICAL
has	O
a	O
measurable	O
antinociceptive	O
effect	O
and	O
a	O
stronger	O
antihyperalgesic	O
effect	O
most	O
evident	O
in	O
the	O
brain	O
areas	O
undergoing	O
deactivation	O
,	O
thus	O
supporting	O
the	O
concept	O
that	O
gabapentin	B-CHEMICAL
is	O
more	O
effective	O
in	O
modulating	O
nociceptive	O
transmission	O
when	O
central	O
sensitization	O
is	O
present	O
.	O

MDMA	O
polydrug	O
users	O
show	O
process	O
-	O
specific	O
central	O
executive	O
impairments	O
coupled	O
with	O
impaired	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O
In	O
recent	O
years	O
working	O
memory	O
deficits	O
have	O
been	O
reported	O
in	O
users	O
of	O
MDMA	O
(	O
3,4	B-CHEMICAL
-	I-CHEMICAL
methylenedioxymethamphetamine	I-CHEMICAL
,	O
ecstasy	B-CHEMICAL
)	O
.	O
The	O
current	O
study	O
aimed	O
to	O
assess	O
the	O
impact	O
of	O
MDMA	O
use	O
on	O
three	O
separate	O
central	O
executive	O
processes	O
(	O
set	O
shifting	O
,	O
inhibition	O
and	O
memory	O
updating	O
)	O
and	O
also	O
on	O
"	O
prefrontal	O
"	O
mediated	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O
Fifteen	O
polydrug	O
ecstasy	B-CHEMICAL
users	O
and	O
15	O
polydrug	O
non	O
-	O
ecstasy	B-CHEMICAL
user	O
controls	O
completed	O
a	O
general	O
drug	O
use	O
questionnaire	O
,	O
the	O
Brixton	O
Spatial	O
Anticipation	O
task	O
(	O
set	O
shifting	O
)	O
,	O
Backward	O
Digit	O
Span	O
procedure	O
(	O
memory	O
updating	O
)	O
,	O
Inhibition	O
of	O
Return	O
(	O
inhibition	O
)	O
,	O
an	O
emotional	O
intelligence	O
scale	O
,	O
the	O
Tromso	O
Social	O
Intelligence	O
Scale	O
and	O
the	O
Dysexecutive	O
Questionnaire	O
(	O
DEX	B-CHEMICAL
)	O
.	O
Compared	O
with	O
MDMA	O
-	O
free	O
polydrug	O
controls	O
,	O
MDMA	O
polydrug	O
users	O
showed	O
impairments	O
in	O
set	O
shifting	O
and	O
memory	O
updating	O
,	O
and	O
also	O
in	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O
The	O
latter	O
two	O
deficits	O
remained	O
significant	O
after	O
controlling	O
for	O
other	O
drug	O
use	O
.	O
These	O
data	O
lend	O
further	O
support	O
to	O
the	O
proposal	O
that	O
cognitive	O
processes	O
mediated	O
by	O
the	O
prefrontal	O
cortex	O
may	O
be	O
impaired	O
by	O
recreational	O
ecstasy	B-CHEMICAL
use	O
.	O

Severe	O
citrate	O
toxicity	B-DISEASE
complicating	O
volunteer	O
apheresis	O
platelet	O
donation	O
.	O
We	O
report	O
a	O
case	O
of	O
severe	O
citrate	O
toxicity	B-DISEASE
during	O
volunteer	O
donor	O
apheresis	O
platelet	O
collection	O
.	O
The	O
donor	O
was	O
a	O
40	O
-	O
year	O
-	O
old	O
female	O
,	O
first	O
-	O
time	O
apheresis	O
platelet	O
donor	O
.	O
Past	O
medical	O
history	O
was	O
remarkable	O
for	O
hypertension	B-DISEASE
,	O
hyperlipidemia	O
,	O
and	O
depression	B-DISEASE
.	O
Reported	O
medications	O
included	O
bumetanide	O
,	O
pravastatin	B-CHEMICAL
,	O
and	O
paroxetine	B-CHEMICAL
.	O
Thirty	O
minutes	O
from	O
the	O
start	O
of	O
the	O
procedure	O
,	O
the	O
donor	O
noted	O
tingling	O
around	O
the	O
mouth	O
,	O
hands	O
,	O
and	O
feet	O
.	O
She	O
then	O
very	O
rapidly	O
developed	O
acute	O
onset	O
of	O
severe	O
facial	O
and	O
extremity	O
tetany	B-DISEASE
.	O
Empirical	O
treatment	O
with	O
intravenous	O
calcium	B-CHEMICAL
gluconate	I-CHEMICAL
was	O
initiated	O
,	O
and	O
muscle	O
contractions	O
slowly	O
subsided	O
over	O
approximately	O
10	O
to	O
15	O
minutes	O
.	O
The	O
events	O
are	O
consistent	O
with	O
a	O
severe	O
reaction	O
to	O
calcium	B-CHEMICAL
chelation	O
by	O
sodium	B-CHEMICAL
citrate	I-CHEMICAL
anticoagulant	O
resulting	O
in	O
symptomatic	O
systemic	O
hypocalcemia	B-DISEASE
.	O
Upon	O
additional	O
retrospective	O
analysis	O
,	O
it	O
was	O
noted	O
that	O
bumetanide	O
is	O
a	O
loop	O
diuretic	B-CHEMICAL
that	O
may	O
cause	O
significant	O
hypocalcemia	B-DISEASE
.	O
We	O
conclude	O
that	O
careful	O
screening	O
for	O
medications	O
and	O
underlying	O
conditions	O
predisposing	O
to	O
hypocalcemia	B-DISEASE
is	O
recommended	O
to	O
help	O
prevent	O
severe	O
reactions	O
due	O
to	O
citrate	O
toxicity	B-DISEASE
.	O
Laboratory	O
measurement	O
of	O
pre	O
-	O
procedure	O
serum	O
calcium	B-CHEMICAL
levels	O
in	O
selected	O
donors	O
may	O
identify	O
cases	O
requiring	O
heightened	O
vigilance	O
.	O
The	O
case	O
also	O
illustrates	O
the	O
importance	O
of	O
maintaining	O
preparedness	O
for	O
managing	O
rare	O
but	O
serious	O
reactions	O
in	O
volunteer	O
apheresis	O
blood	O
donors	O
.	O

Proteinuria	B-DISEASE
after	O
conversion	O
to	O
sirolimus	B-CHEMICAL
in	O
renal	O
transplant	O
recipients	O
.	O
Sirolimus	B-CHEMICAL
(	O
SRL	O
)	O
is	O
a	O
new	O
,	O
potent	O
immunosuppressive	O
agent	O
.	O
More	O
recently	O
,	O
proteinuria	B-DISEASE
has	O
been	O
reported	O
as	O
a	O
consequence	O
of	O
sirolimus	B-CHEMICAL
therapy	O
,	O
although	O
the	O
mechanism	O
has	O
remained	O
unclear	O
.	O
We	O
retrospectively	O
examined	O
the	O
records	O
of	O
25	O
renal	O
transplant	O
patients	O
,	O
who	O
developed	O
or	O
displayed	O
increased	O
proteinuria	B-DISEASE
after	O
SRL	O
conversion	O
.	O
The	O
patient	O
cohort	O
(	O
14	O
men	O
,	O
11	O
women	O
)	O
was	O
treated	O
with	O
SRL	O
as	O
conversion	O
therapy	O
,	O
due	O
to	O
chronic	B-DISEASE
allograft	I-DISEASE
nephropathy	I-DISEASE
(	O
CAN	O
)	O
(	O
n	O
=	O
15	O
)	O
neoplasia	O
(	O
n	O
=	O
8)	O
;	O
Kaposi	B-DISEASE
's	I-DISEASE
sarcoma	I-DISEASE
,	O
Four	O
skin	O
cancers	B-DISEASE
,	O
One	O
intestinal	O
tumors	B-DISEASE
,	O
One	O
renal	O
cell	O
carsinom	O
)	O
or	O
BK	O
virus	O
nephropathy	B-DISEASE
(	O
n	O
=	O
2	O
)	O
.	O
SRL	O
was	O
started	O
at	O
a	O
mean	O
of	O
78	O
+	O
/-	O
42	O
(	O
15	O
to	O
163	O
)	O
months	O
after	O
transplantation	O
.	O
Mean	O
follow	O
-	O
up	O
on	O
SRL	O
therapy	O
was	O
20	O
+	O
/-	O
12	O
(	O
6	O
to	O
43	O
)	O
months	O
.	O
Proteinuria	B-DISEASE
increased	O
from	O
0.445	O
(	O
0	O
to	O
1.5	O
)	O
g	O
/	O
d	O
before	O
conversion	O
to	O
3.2	O
g	O
/	O
dL	O
(	O
0.2	O
to	O
12	O
)	O
after	O
conversion	O
(	O
P	O
=	O
0.001	O
)	O
.	O
Before	O
conversion	O
8	O
(	O
32	O
%	O
)	O
patients	O
had	O
no	O
proteinuria	B-DISEASE
,	O
whereas	O
afterwards	O
all	O
patients	O
had	O
proteinuria	B-DISEASE
.	O
In	O
28	O
%	O
of	O
patients	O
proteinuria	B-DISEASE
remained	O
unchanged	O
,	O
whereas	O
it	O
increased	O
in	O
68	O
%	O
of	O
patients	O
.	O
In	O
40	O
%	O
it	O
increased	O
by	O
more	O
than	O
100	O
%	O
.	O
Twenty	O
-	O
eight	O
percent	O
of	O
patients	O
showed	O
increased	O
proteinuria	B-DISEASE
to	O
the	O
nephrotic	B-DISEASE
range	O
.	O
Biopsies	O
performed	O
in	O
five	O
patients	O
revealed	O
new	O
pathological	O
changes	O
:	O
One	O
membranoproliferative	O
glomerulopathy	O
and	O
interstitial	B-DISEASE
nephritis	I-DISEASE
.	O
These	O
patients	O
showed	O
persistently	O
good	O
graft	O
function	O
.	O
Serum	O
creatinine	B-CHEMICAL
values	O
did	O
not	O
change	O
significantly	O
:	O
1.98	O
+	O
/-	O
0.8	O
mg	O
/	O
dL	O
before	O
SRL	O
therapy	O
and	O
2.53	O
+	O
/-	O
1.9	O
mg	O
/	O
dL	O
at	O
last	O
follow	O
-	O
up	O
(	O
P	O
=	O
.14	O
)	O
.	O
Five	O
grafts	O
were	O
lost	O
and	O
the	O
patients	O
returned	O
to	O
dialysis	O
.	O
Five	O
patients	O
displayed	O
CAN	O
and	O
Kaposi	B-DISEASE
's	I-DISEASE
sarcoma	I-DISEASE
.	O
Mean	O
urinary	O
protein	O
of	O
patients	O
who	O
returned	O
to	O
dialysis	O
was	O
1.26	O
(	O
0.5	O
to	O
3.5	O
)	O
g	O
/	O
d	O
before	O
and	O
4.7	O
(	O
3	O
to	O
12	O
)	O
g	O
/	O
d	O
after	O
conversion	O
(	O
P	O
=	O
.01	O
)	O
.	O
Mean	O
serum	O
creatinine	B-CHEMICAL
level	O
before	O
conversion	O
was	O
2.21	O
mg	O
/	O
dL	O
and	O
thereafter	O
,	O
4.93	O
mg	O
/	O
dL	O
(	O
P	O
=	O
.02	O
)	O
.	O
Heavy	O
proteinuria	B-DISEASE
was	O
common	O
after	O
the	O
use	O
of	O
SRL	O
as	O
rescue	O
therapy	O
for	O
renal	O
transplantation	O
.	O
Therefore	O
,	O
conversion	O
should	O
be	O
considered	O
for	O
patients	O
who	O
have	O
not	O
developed	O
advanced	O
CAN	O
and	O
proteinuria	B-DISEASE
.	O
The	O
possibility	O
of	O
de	O
novo	O
glomerular	O
pathology	O
under	O
SRL	O
treatment	O
requires	O
further	O
investigation	O
by	O
renal	O
biopsy	O
.	O

In	O
vitro	O
characterization	O
of	O
parasympathetic	O
and	O
sympathetic	O
responses	O
in	O
cyclophosphamide	B-CHEMICAL
-	O
induced	O
cystitis	B-DISEASE
in	O
the	O
rat	O
.	O
In	O
cyclophosphamide	B-CHEMICAL
-	O
induced	O
cystitis	B-DISEASE
in	O
the	O
rat	O
,	O
detrusor	O
function	O
is	O
impaired	O
and	O
the	O
expression	O
and	O
effects	O
of	O
muscarinic	O
receptors	O
altered	O
.	O
Whether	O
or	O
not	O
the	O
neuronal	O
transmission	O
may	O
be	O
affected	O
by	O
cystitis	B-DISEASE
was	O
presently	O
investigated	O
.	O
Responses	O
of	O
urinary	O
strip	O
preparations	O
from	O
control	O
and	O
cyclophosphamide	B-CHEMICAL
-	O
pretreated	O
rats	O
to	O
electrical	O
field	O
stimulation	O
and	O
to	O
agonists	O
were	O
assessed	O
in	O
the	O
absence	O
and	O
presence	O
of	O
muscarinic	O
,	O
adrenergic	O
and	O
purinergic	O
receptor	O
antagonists	O
.	O
Generally	O
,	O
atropine	O
reduced	O
contractions	O
,	O
but	O
in	O
contrast	O
to	O
controls	O
,	O
it	O
also	O
reduced	O
responses	O
to	O
low	O
electrical	O
field	O
stimulation	O
intensity	O
(	O
1	O
-	O
5	O
Hz	O
)	O
in	O
inflamed	O
preparations	O
.	O
In	O
both	O
types	O
,	O
purinoceptor	O
desensitization	O
with	O
alpha	O
,	O
beta	O
-	O
methylene	O
adenosine-5'-triphosphate	O
(	O
alpha	O
,	O
beta	O
-	O
meATP	O
)	O
caused	O
further	O
reductions	O
at	O
low	O
frequencies	O
(	O
<	O
10	O
Hz	O
)	O
.	O
The	O
muscarinic	O
receptor	O
antagonists	O
atropine	O
,	O
4	B-CHEMICAL
-	I-CHEMICAL
diphenylacetoxy	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
methylpiperidine	I-CHEMICAL
(	O
4	B-CHEMICAL
-	I-CHEMICAL
DAMP	I-CHEMICAL
)	O
(	O
'	O
M(1)/M(3)/M(5)-selective	O
'	O
)	O
,	O
methoctramine	O
(	O
'	O
M(2)-selective	O
'	O
)	O
and	O
pirenzepine	O
(	O
'	O
M(1)-selective	O
'	O
)	O
antagonized	O
the	O
tonic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation	O
-	O
evoked	O
contractile	O
response	O
more	O
potently	O
than	O
the	O
phasic	O
component	O
.	O
4	B-CHEMICAL
-	I-CHEMICAL
DAMP	I-CHEMICAL
inhibited	O
the	O
tonic	O
contractions	O
in	O
controls	O
more	O
potently	O
than	O
methoctramine	O
and	O
pirenzepine	O
.	O
In	O
inflamed	O
preparations	O
,	O
the	O
muscarinic	O
receptor	O
antagonism	O
on	O
the	O
phasic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation	O
-	O
evoked	O
contraction	O
was	O
decreased	O
and	O
the	O
pirenzepine	O
and	O
4	B-CHEMICAL
-	I-CHEMICAL
DAMP	I-CHEMICAL
antagonism	O
on	O
the	O
tonic	O
component	O
was	O
much	O
less	O
efficient	O
than	O
in	O
controls	O
.	O
In	O
contrast	O
to	O
controls	O
,	O
methoctramine	O
increased	O
--	O
instead	O
of	O
decreased	O
--	O
the	O
tonic	O
responses	O
at	O
high	O
frequencies	O
.	O
While	O
contractions	O
to	O
carbachol	O
and	O
ATP	B-CHEMICAL
were	O
the	O
same	O
in	O
inflamed	O
and	O
in	O
control	O
strips	O
when	O
related	O
to	O
a	O
reference	O
potassium	B-CHEMICAL
response	O
,	O
isoprenaline	B-CHEMICAL
-	O
induced	O
relaxations	O
were	O
smaller	O
in	O
inflamed	O
strips	O
.	O
Thus	O
,	O
in	O
cystitis	B-DISEASE
substantial	O
changes	O
of	O
the	O
efferent	O
functional	O
responses	O
occur	O
.	O
While	O
postjunctional	O
beta	O
-	O
adrenoceptor	O
-	O
mediated	O
relaxations	O
are	O
reduced	O
,	O
effects	O
by	O
prejunctional	O
inhibitory	O
muscarinic	O
receptors	O
may	O
be	O
increased	O
.	O

Associations	O
between	O
use	O
of	O
benzodiazepines	O
or	O
related	O
drugs	O
and	O
health	O
,	O
physical	O
abilities	O
and	O
cognitive	O
function	O
:	O
a	O
non	O
-	O
randomised	O
clinical	O
study	O
in	O
the	O
elderly	O
.	O
OBJECTIVE	O
:	O
To	O
describe	O
associations	O
between	O
the	O
use	O
of	O
benzodiazepines	O
or	O
related	O
drugs	O
(	O
BZDs	B-CHEMICAL
/	O
RDs	O
)	O
and	O
health	O
,	O
functional	O
abilities	O
and	O
cognitive	O
function	O
in	O
the	O
elderly	O
.	O
METHODS	O
:	O
A	O
non	O
-	O
randomised	O
clinical	O
study	O
of	O
patients	O
aged	O
>	O
or	O
=	O
65	O
years	O
admitted	O
to	O
acute	O
hospital	O
wards	O
during	O
1	O
month	O
.	O
164	O
patients	O
(	O
mean	O
age	O
+	O
/-	O
standard	O
deviation	O
[	O
SD	B-DISEASE
]	O
81.6	O
+	O
/-	O
6.8	O
years	O
)	O
were	O
admitted	O
.	O
Of	O
these	O
,	O
nearly	O
half	O
(	O
n	O
=	O
78	O
)	O
had	O
used	O
BZDs	B-CHEMICAL
/	O
RDs	O
before	O
admission	O
,	O
and	O
the	O
remainder	O
(	O
n	O
=	O
86	O
)	O
were	O
non	O
-	O
users	O
.	O
Cognitive	O
ability	O
was	O
assessed	O
by	O
the	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
.	O
Patients	O
scoring	O
>	O
or	O
=	O
20	O
MMSE	O
sum	O
points	O
were	O
interviewed	O
(	O
n	O
=	O
79	O
)	O
and	O
questioned	O
regarding	O
symptoms	O
and	O
functional	O
abilities	O
during	O
the	O
week	O
prior	O
to	O
admission	O
.	O
Data	O
on	O
use	O
of	O
BZDs	B-CHEMICAL
/	O
RDs	O
before	O
admission	O
,	O
current	O
medications	O
and	O
discharge	O
diagnoses	O
were	O
collected	O
from	O
medical	O
records	O
.	O
Health	O
,	O
physical	O
abilities	O
and	O
cognitive	O
function	O
were	O
compared	O
between	O
BZD	O
/	O
RD	O
users	O
and	O
non	O
-	O
users	O
,	O
and	O
adjustments	O
were	O
made	O
for	O
confounding	O
variables	O
.	O
The	O
residual	O
serum	O
concentrations	O
of	O
oxazepam	O
,	O
temazepam	O
and	O
zopiclone	O
were	O
analysed	O
.	O
RESULTS	O
:	O
The	O
mean	O
+	O
/-	O
SD	B-DISEASE
duration	O
of	O
BZD	O
/	O
RD	O
use	O
was	O
7	O
+	O
/-	O
7	O
years	O
(	O
range	O
1	O
-	O
31	O
)	O
.	O
Two	O
or	O
three	O
BZDs	B-CHEMICAL
/	O
RDs	O
were	O
concomitantly	O
taken	O
by	O
26	O
%	O
of	O
users	O
(	O
n	O
=	O
20	O
)	O
.	O
Long	O
-	O
term	O
use	O
of	O
these	O
drugs	O
was	O
associated	O
with	O
female	O
sex	O
and	O
use	O
of	O
a	O
higher	O
number	O
of	O
drugs	O
with	O
effects	O
on	O
the	O
CNS	O
,	O
which	O
tended	O
to	O
be	O
related	O
to	O
diagnosed	O
dementia	B-DISEASE
.	O
After	O
adjustment	O
for	O
these	O
variables	O
as	O
confounders	O
,	O
use	O
of	O
BZDs	B-CHEMICAL
/	O
RDs	O
was	O
not	O
associated	O
with	O
cognitive	O
function	O
as	O
measured	O
by	O
the	O
MMSE	O
.	O
However	O
,	O
use	O
of	O
BZDs	B-CHEMICAL
/	O
RDs	O
was	O
associated	O
with	O
dizziness	B-DISEASE
,	O
inability	O
to	O
sleep	O
after	O
awaking	O
at	O
night	O
and	O
tiredness	O
in	O
the	O
mornings	O
during	O
the	O
week	O
prior	O
to	O
admission	O
and	O
with	O
stronger	O
depressive	B-DISEASE
symptoms	I-DISEASE
measured	O
at	O
the	O
beginning	O
of	O
the	O
hospital	O
stay	O
.	O
Use	O
of	O
BZDs	B-CHEMICAL
/	O
RDs	O
tended	O
to	O
be	O
associated	O
with	O
a	O
reduced	O
ability	O
to	O
walk	O
and	O
shorter	O
night	O
-	O
time	O
sleep	O
during	O
the	O
week	O
prior	O
to	O
admission	O
.	O
A	O
higher	O
residual	O
serum	O
concentration	O
of	O
temazepam	O
correlated	O
with	O
a	O
lower	O
MMSE	O
sum	O
score	O
after	O
adjustment	O
for	O
confounding	O
variables	O
.	O
CONCLUSIONS	O
:	O
Long	O
-	O
term	O
use	O
and	O
concomitant	O
use	O
of	O
more	O
than	O
one	O
BZD	O
/	O
RD	O
were	O
common	O
in	O
elderly	O
patients	O
hospitalised	O
because	O
of	O
acute	O
illnesses	O
.	O
Long	O
-	O
term	O
use	O
was	O
associated	O
with	O
daytime	O
and	O
night	O
-	O
time	O
symptoms	O
indicative	O
of	O
poorer	O
health	O
and	O
potentially	O
caused	O
by	O
the	O
adverse	O
effects	O
of	O
these	O
drugs	O
.	O

Acute	O
vocal	B-DISEASE
fold	I-DISEASE
palsy	I-DISEASE
after	O
acute	O
disulfiram	B-CHEMICAL
intoxication	O
.	O
Acute	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
caused	O
by	O
a	O
disulfiram	B-CHEMICAL
overdose	B-DISEASE
is	O
very	O
rare	O
and	O
there	O
is	O
no	O
report	O
of	O
it	O
leading	O
to	O
vocal	B-DISEASE
fold	I-DISEASE
palsy	I-DISEASE
.	O
A	O
49	O
-	O
year	O
-	O
old	O
woman	O
was	O
transferred	O
to	O
our	O
department	O
because	O
of	O
quadriparesis	O
,	O
lancinating	O
pain	B-DISEASE
,	O
sensory	O
loss	O
,	O
and	O
paresthesia	B-DISEASE
of	O
the	O
distal	O
limbs	O
.	O
One	O
month	O
previously	O
,	O
she	O
had	O
taken	O
a	O
single	O
high	O
dose	O
of	O
disulfiram	B-CHEMICAL
(	O
130	O
tablets	O
of	O
ALCOHOL	O
STOP	O
TAB	O
,	O
Shin	O
-	O
Poong	O
Pharm	O
.	O
Co.	O
,	O
Ansan	O
,	O
Korea	O
)	O
in	O
a	O
suicide	B-DISEASE
attempt	O
.	O
She	O
was	O
not	O
an	O
alcoholic	O
.	O
For	O
the	O
first	O
few	O
days	O
after	O
ingestion	O
,	O
she	O
was	O
in	O
a	O
confused	O
state	O
and	O
had	O
mild	O
to	O
moderate	O
ataxia	B-DISEASE
and	O
giddiness	O
.	O
She	O
noticed	O
hoarseness	B-DISEASE
and	O
distally	O
accentuated	O
motor	O
and	O
sensory	O
dysfunction	O
after	O
she	O
had	O
recovered	O
from	O
this	O
state	O
.	O
A	O
nerve	O
conduction	O
study	O
was	O
consistent	O
with	O
severe	O
sensorimotor	O
axonal	O
polyneuropathy	B-DISEASE
.	O
Laryngeal	O
electromyography	O
(	O
thyroarytenoid	O
muscle	O
)	O
showed	O
ample	O
denervation	O
potentials	O
.	O
Laryngoscopy	O
revealed	O
asymmetric	O
vocal	O
fold	O
movements	O
during	O
phonation	O
.	O
Her	O
vocal	O
change	O
and	O
weakness	B-DISEASE
began	O
to	O
improve	O
spontaneously	O
about	O
3	O
weeks	O
after	O
transfer	O
.	O
This	O
was	O
a	O
case	O
of	O
acute	O
palsy	O
of	O
the	O
recurrent	O
laryngeal	O
nerve	O
and	O
superimposed	O
severe	O
acute	O
sensorimotor	O
axonal	O
polyneuropathy	B-DISEASE
caused	O
by	O
high	O
-	O
dose	O
disulfiram	B-CHEMICAL
intoxication	O
.	O

Higher	O
optical	O
density	O
of	O
an	O
antigen	O
assay	O
predicts	O
thrombosis	B-DISEASE
in	O
patients	O
with	O
heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-DISEASE
.	O
OBJECTIVES	O
:	O
To	O
correlate	O
optical	O
density	O
and	O
percent	O
inhibition	O
of	O
a	O
two	O
-	O
step	O
heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-DISEASE
(	O
HIT	O
)	O
antigen	O
assay	O
with	O
thrombosis	B-DISEASE
;	O
the	O
assay	O
utilizes	O
reaction	O
inhibition	O
characteristics	O
of	O
a	O
high	O
heparin	B-CHEMICAL
concentration	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Patients	O
with	O
more	O
than	O
50	O
%	O
decrease	O
in	O
platelet	O
count	O
or	O
thrombocytopenia	B-DISEASE
(	O
<	O
150	O
x	O
10(9)/L	O
)	O
after	O
exposure	O
to	O
heparin	B-CHEMICAL
,	O
who	O
had	O
a	O
positive	O
two	O
-	O
step	O
antigen	O
assay	O
[	O
optical	O
density	O
(	O
OD	O
)	O
>	O
0.4	O
and	O
>	O
50	O
inhibition	O
with	O
high	O
concentration	O
of	O
heparin	B-CHEMICAL
]	O
were	O
included	O
in	O
the	O
study	O
.	O
RESULTS	O
:	O
Forty	O
of	O
94	O
HIT	O
patients	O
had	O
thrombosis	B-DISEASE
at	O
diagnosis	O
;	O
54/94	O
had	O
isolated	O
-	O
HIT	O
without	O
thrombosis	B-DISEASE
.	O
Eight	O
of	O
the	O
isolated	O
-	O
HIT	O
patients	O
developed	O
thrombosis	B-DISEASE
within	O
the	O
next	O
30	O
d	O
;	O
thus	O
,	O
a	O
total	O
of	O
48	O
patients	O
had	O
thrombosis	B-DISEASE
at	O
day	O
30	O
.	O
At	O
diagnosis	O
there	O
was	O
no	O
significant	O
difference	O
in	O
OD	O
between	O
HIT	O
patients	O
with	O
thrombosis	B-DISEASE
and	O
those	O
with	O
isolated	O
-	O
HIT	O
.	O
However	O
,	O
OD	O
was	O
significantly	O
higher	O
in	O
all	O
patients	O
with	O
thrombosis	B-DISEASE
(	O
n	O
=	O
48	O
,	O
1.34	O
+	O
/-	O
0.89	O
)	O
,	O
including	O
isolated	O
-	O
HIT	O
patients	O
who	O
later	O
developed	O
thrombosis	B-DISEASE
within	O
30	O
d	O
(	O
n	O
=	O
8	O
,	O
1.84	O
+	O
/-	O
0.64	O
)	O
as	O
compared	O
to	O
isolated	O
-	O
HIT	O
patients	O
who	O
did	O
not	O
develop	O
thrombosis	B-DISEASE
(	O
0.96	O
+	O
/-	O
0.75	O
;	O
P	O
=	O
0.011	O
and	O
P	O
=	O
0.008	O
)	O
.	O
The	O
Receiver	O
Operative	O
Characteristic	O
Curve	O
showed	O
that	O
OD	O
>	O
1.27	O
in	O
the	O
isolated	O
-	O
HIT	O
group	O
had	O
a	O
significantly	O
higher	O
chance	O
of	O
developing	O
thrombosis	B-DISEASE
by	O
day	O
30	O
.	O
None	O
of	O
these	O
groups	O
showed	O
significant	O
difference	O
in	O
percent	O
inhibition	O
.	O
Multivariate	O
analysis	O
showed	O
a	O
2.8	O
-	O
fold	O
increased	O
risk	O
of	O
thrombosis	B-DISEASE
in	O
females	O
.	O
Similarly	O
,	O
thrombotic	B-DISEASE
risk	O
increased	O
with	O
age	O
and	O
OD	O
values	O
.	O
CONCLUSION	O
:	O
Higher	O
OD	O
is	O
associated	O
with	O
significant	O
risk	O
of	O
subsequent	O
thrombosis	B-DISEASE
in	O
patients	O
with	O
isolated	O
-	O
HIT	O
;	O
percent	O
inhibition	O
,	O
however	O
,	O
was	O
not	O
predictive	O
.	O

Central	B-DISEASE
retinal	I-DISEASE
vein	I-DISEASE
occlusion	I-DISEASE
associated	O
with	O
clomiphene	O
-	O
induced	O
ovulation	O
.	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
central	B-DISEASE
retinal	I-DISEASE
vein	I-DISEASE
occlusion	I-DISEASE
associated	O
with	O
clomiphene	O
citrate	O
(	O
CC	B-CHEMICAL
)	O
.	O
DESIGN	O
:	O
Case	O
study	O
.	O
SETTING	O
:	O
Ophthalmology	O
clinic	O
of	O
an	O
academic	O
hospital	O
.	O
PATIENT(S	O
):	O
A	O
36	O
-	O
year	O
-	O
old	O
woman	O
referred	O
from	O
the	O
infertility	B-DISEASE
clinic	O
for	O
blurred	B-DISEASE
vision	I-DISEASE
.	O
INTERVENTION(S	O
):	O
Ophthalmic	O
examination	O
after	O
CC	B-CHEMICAL
therapy	O
.	O
MAIN	O
OUTCOME	O
MEASURE(S	O
):	O
Central	B-DISEASE
retinal	I-DISEASE
vein	I-DISEASE
occlusion	I-DISEASE
after	O
ovulation	O
induction	O
with	O
CC	B-CHEMICAL
.	O
RESULT(S	O
):	O
A	O
36	O
-	O
year	O
-	O
old	O
Chinese	O
woman	O
developed	O
central	B-DISEASE
retinal	I-DISEASE
vein	I-DISEASE
occlusion	I-DISEASE
after	O
eight	O
courses	O
of	O
CC	B-CHEMICAL
.	O
A	O
search	O
of	O
the	O
literature	O
on	O
the	O
thromboembolic	B-DISEASE
complications	B-DISEASE
of	O
CC	B-CHEMICAL
does	O
not	O
include	O
this	O
severe	O
ophthalmic	O
complication	O
,	O
although	O
mild	O
visual	O
disturbance	O
after	O
CC	B-CHEMICAL
intake	O
is	O
not	O
uncommon	O
.	O
CONCLUSION(S	O
):	O
This	O
is	O
the	O
first	O
reported	O
case	O
of	O
central	B-DISEASE
retinal	I-DISEASE
vein	I-DISEASE
occlusion	I-DISEASE
after	O
treatment	O
with	O
CC	B-CHEMICAL
.	O
Extra	O
caution	O
is	O
warranted	O
in	O
treating	O
infertility	B-DISEASE
patients	O
with	O
CC	B-CHEMICAL
,	O
and	O
patients	O
should	O
be	O
well	O
informed	O
of	O
this	O
side	O
effect	O
before	O
commencement	O
of	O
therapy	O
.	O

Nicotine	B-CHEMICAL
-	O
induced	O
nystagmus	O
correlates	O
with	O
midpontine	O
activation	O
.	O
The	O
pathomechanism	O
of	O
nicotine	B-CHEMICAL
-	O
induced	O
nystagmus	O
(	O
NIN	O
)	O
is	O
unknown	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
delineate	O
brain	O
structures	O
that	O
are	O
involved	O
in	O
NIN	O
generation	O
.	O
Eight	O
healthy	O
volunteers	O
inhaled	O
nicotine	B-CHEMICAL
in	O
darkness	O
during	O
a	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
experiment	O
;	O
eye	O
movements	O
were	O
registered	O
using	O
video	O
-	O
oculography	O
.	O
NIN	O
correlated	O
with	O
blood	O
oxygen	B-CHEMICAL
level	O
-	O
dependent	O
(	O
BOLD	O
)	O
activity	O
levels	O
in	O
a	O
midpontine	O
site	O
in	O
the	O
posterior	O
basis	O
pontis	O
.	O
NIN	O
-	O
induced	O
midpontine	O
activation	O
may	O
correspond	O
to	O
activation	O
of	O
the	O
dorsomedial	O
pontine	O
nuclei	O
and	O
the	O
nucleus	O
reticularis	O
tegmenti	O
pontis	O
,	O
structures	O
known	O
to	O
participate	O
in	O
the	O
generation	O
of	O
multidirectional	O
saccades	O
and	O
smooth	O
pursuit	O
eye	O
movements	O
.	O

Protective	O
effect	O
of	O
verapamil	B-CHEMICAL
on	O
gastric	O
hemorrhagic	O
ulcers	B-DISEASE
in	O
severe	O
atherosclerotic	B-DISEASE
rats	O
.	O
Studies	O
concerning	O
with	O
pathogenesis	O
of	O
gastric	O
hemorrhage	B-DISEASE
and	O
mucosal	O
ulceration	O
produced	O
in	O
atherosclerotic	B-DISEASE
rats	O
are	O
lacking	O
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
role	O
of	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
mast	O
cell	O
histamine	B-CHEMICAL
release	O
,	O
lipid	O
peroxide	O
(	O
LPO	O
)	O
generation	O
and	O
mucosal	O
microvascular	O
permeability	O
in	O
modulating	O
gastric	O
hemorrhage	B-DISEASE
and	O
ulcer	B-DISEASE
in	O
rats	O
with	O
atherosclerosis	B-DISEASE
induced	O
by	O
coadministration	O
of	O
vitamin	O
D2	O
and	O
cholesterol	B-CHEMICAL
.	O
Additionally	O
,	O
the	O
protective	O
effect	O
of	O
verapamil	B-CHEMICAL
on	O
this	O
ulcer	B-DISEASE
model	O
was	O
evaluated	O
.	O
Male	O
Wistar	O
rats	O
were	O
challenged	O
intragastrically	O
once	O
daily	O
for	O
9	O
days	O
with	O
1.0	O
ml	O
/	O
kg	O
of	O
corn	O
oil	O
containing	O
vitamin	O
D2	O
and	O
cholesterol	B-CHEMICAL
to	O
induce	O
atherosclerosis	B-DISEASE
.	O
Control	O
rats	O
received	O
corn	O
oil	O
only	O
.	O
After	O
gastric	O
surgery	O
,	O
rat	O
stomachs	O
were	O
irrigated	O
for	O
3	O
h	O
with	O
either	O
simulated	O
gastric	O
juice	O
or	O
normal	O
saline	O
.	O
Gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
mucosal	O
LPO	O
generation	O
,	O
histamine	B-CHEMICAL
concentration	O
,	O
microvascular	O
permeability	O
,	O
luminal	B-CHEMICAL
hemoglobin	O
content	O
and	O
ulcer	B-DISEASE
areas	O
were	O
determined	O
.	O
Elevated	O
atherosclerotic	B-DISEASE
parameters	O
,	O
such	O
as	O
serum	O
calcium	B-CHEMICAL
,	O
total	O
cholesterol	B-CHEMICAL
and	O
low	O
-	O
density	O
lipoprotein	O
concentration	O
were	O
obtained	O
in	O
atherosclerotic	B-DISEASE
rats	O
.	O
Severe	O
gastric	O
ulcers	B-DISEASE
accompanied	O
with	O
increased	O
ulcerogenic	O
factors	O
,	O
including	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
histamine	B-CHEMICAL
release	O
,	O
LPO	O
generation	O
and	O
luminal	B-CHEMICAL
hemoglobin	O
content	O
were	O
also	O
observed	O
in	O
these	O
rats	O
.	O
Moreover	O
,	O
a	O
positive	O
correlation	O
of	O
histamine	B-CHEMICAL
to	O
gastric	O
hemorrhage	B-DISEASE
and	O
to	O
ulcer	B-DISEASE
was	O
found	O
in	O
those	O
atherosclerotic	B-DISEASE
rats	O
.	O
This	O
hemorrhagic	O
ulcer	B-DISEASE
and	O
various	O
ulcerogenic	O
parameters	O
were	O
dose	O
-	O
dependently	O
ameliorated	O
by	O
daily	O
intragastric	O
verapamil	B-CHEMICAL
.	O
Atherosclerosis	B-DISEASE
could	O
produce	O
gastric	O
hemorrhagic	O
ulcer	B-DISEASE
via	O
aggravation	O
of	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
LPO	O
generation	O
,	O
histamine	B-CHEMICAL
release	O
and	O
microvascular	O
permeability	O
that	O
could	O
be	O
ameliorated	O
by	O
verapamil	B-CHEMICAL
in	O
rats	O
.	O

Adriamycin	B-CHEMICAL
-	O
induced	O
autophagic	O
cardiomyocyte	O
death	B-DISEASE
plays	O
a	O
pathogenic	O
role	O
in	O
a	O
rat	O
model	O
of	O
heart	B-DISEASE
failure	I-DISEASE
.	O
BACKGROUND	O
:	O
The	O
mechanisms	O
underlying	O
heart	B-DISEASE
failure	I-DISEASE
induced	O
by	O
adriamycin	B-CHEMICAL
are	O
very	O
complicated	O
and	O
still	O
unclear	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
autophagy	O
was	O
involved	O
in	O
the	O
progression	O
of	O
heart	B-DISEASE
failure	I-DISEASE
induced	O
by	O
adriamycin	B-CHEMICAL
,	O
so	O
that	O
we	O
can	O
develop	O
a	O
novel	O
treatment	O
strategy	O
for	O
heart	B-DISEASE
failure	I-DISEASE
.	O
METHODS	O
:	O
3	B-CHEMICAL
-	I-CHEMICAL
methyladenine	I-CHEMICAL
(	O
3MA	B-CHEMICAL
)	O
,	O
a	O
specific	O
inhibitor	O
on	O
autophagy	O
was	O
used	O
in	O
a	O
heart	B-DISEASE
failure	I-DISEASE
model	O
of	O
rats	O
induced	O
by	O
adriamycin	B-CHEMICAL
.	O
Neonatal	O
cardiomyocytes	O
were	O
isolated	O
from	O
Sprague	O
-	O
Dawley	O
rat	O
hearts	O
and	O
randomly	O
divided	O
into	O
controls	O
,	O
an	O
adriamycin	B-CHEMICAL
-	O
treated	O
group	O
,	O
and	O
a	O
3MA	B-CHEMICAL
plus	O
adriamycin	B-CHEMICAL
-	O
treated	O
group	O
.	O
We	O
then	O
examined	O
the	O
morphology	O
,	O
expression	O
of	O
beclin	O
1	O
gene	O
,	O
mitochondrial	O
permeability	O
transition	O
(	O
MPT	O
)	O
,	O
and	O
Na+-K+	O
ATPase	O
activity	O
in	O
vivo	O
.	O
We	O
also	O
assessed	O
cell	O
viability	O
,	O
mitochondrial	O
membrane	O
potential	O
changes	O
and	O
counted	O
autophagic	O
vacuoles	O
in	O
cultured	O
cardiomyocytes	O
.	O
In	O
addition	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
autophagy	O
associated	O
gene	O
,	O
beclin	O
1	O
using	O
RT	O
-	O
PCR	O
and	O
Western	O
blotting	O
in	O
an	O
animal	O
model	O
.	O
RESULTS	O
:	O
3MA	B-CHEMICAL
significantly	O
improved	O
cardiac	O
function	O
and	O
reduced	O
mitochondrial	O
injury	O
.	O
Furthermore	O
,	O
adriamycin	B-CHEMICAL
induced	O
the	O
formation	O
of	O
autophagic	O
vacuoles	O
,	O
and	O
3MA	B-CHEMICAL
strongly	O
downregulated	O
the	O
expression	O
of	O
beclin	O
1	O
in	O
adriamycin	B-CHEMICAL
-	O
induced	O
failing	O
heart	O
and	O
inhibited	O
the	O
formation	O
of	O
autophagic	O
vacuoles	O
.	O
CONCLUSION	O
:	O
Autophagic	O
cardiomyocyte	O
death	B-DISEASE
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
heart	B-DISEASE
failure	I-DISEASE
in	O
rats	O
induced	O
by	O
adriamycin	B-CHEMICAL
.	O
Mitochondrial	O
injury	O
may	O
be	O
involved	O
in	O
the	O
progression	O
of	O
heart	B-DISEASE
failure	I-DISEASE
caused	O
by	O
adriamycin	B-CHEMICAL
via	O
the	O
autophagy	O
pathway	O
.	O

Confusion	B-DISEASE
,	O
a	O
rather	O
serious	O
adverse	B-DISEASE
drug	I-DISEASE
reaction	I-DISEASE
with	O
valproic	O
acid	O
:	O
a	O
review	O
of	O
the	O
French	O
Pharmacovigilance	O
database	O
.	O
INTRODUCTION	O
:	O
Confusion	B-DISEASE
is	O
an	O
adverse	B-DISEASE
drug	I-DISEASE
reaction	I-DISEASE
frequently	O
observed	O
with	O
valproic	O
acid	O
.	O
Some	O
case	O
reports	O
are	O
published	O
in	O
the	O
literature	O
but	O
no	O
systematic	O
study	O
from	O
a	O
sample	O
of	O
patients	O
has	O
been	O
published	O
.	O
We	O
performed	O
this	O
study	O
in	O
order	O
to	O
describe	O
the	O
main	O
characteristics	O
of	O
this	O
adverse	B-DISEASE
drug	I-DISEASE
reaction	I-DISEASE
.	O
METHODS	O
:	O
Using	O
the	O
French	O
Pharmacovigilance	O
database	O
,	O
we	O
selected	O
the	O
cases	O
of	O
confusion	B-DISEASE
reported	O
since	O
1985	O
with	O
valproic	O
acid	O
.	O
RESULTS	O
:	O
272	O
cases	O
of	O
confusion	B-DISEASE
were	O
reported	O
with	O
valproic	O
acid	O
:	O
153	O
women	O
and	O
119	O
men	O
.	O
Confusion	B-DISEASE
mostly	O
occurred	O
during	O
the	O
two	O
first	O
weeks	O
following	O
valproic	O
acid	O
exposure	O
(	O
39.7	O
%	O
)	O
.	O
It	O
was	O
"	O
serious	O
"	O
for	O
almost	O
2/3	O
of	O
the	O
patients	O
(	O
62.5	O
%	O
)	O
and	O
its	O
outcome	O
favourable	O
in	O
most	O
of	O
the	O
cases	O
(	O
82	O
%	O
)	O
.	O
The	O
occurrence	O
of	O
this	O
ADR	B-CHEMICAL
was	O
more	O
frequent	O
in	O
patients	O
aged	O
between	O
61	O
and	O
80	O
years	O
.	O
CONCLUSION	O
:	O
This	O
work	O
shows	O
that	O
confusion	B-DISEASE
with	O
valproic	O
acid	O
is	O
a	O
serious	O
,	O
rather	O
frequent	O
but	O
reversible	O
adverse	B-DISEASE
drug	I-DISEASE
reaction	I-DISEASE
.	O
It	O
occurs	O
especially	O
in	O
older	O
patients	O
and	O
during	O
the	O
first	O
two	O
weeks	O
of	O
treatment	O
.	O

Learning	O
and	O
memory	O
deficits	O
in	O
ecstasy	B-CHEMICAL
users	O
and	O
their	O
neural	O
correlates	O
during	O
a	O
face	O
-	O
learning	O
task	O
.	O
It	O
has	O
been	O
consistently	O
shown	O
that	O
ecstasy	B-CHEMICAL
users	O
display	O
impairments	O
in	O
learning	O
and	O
memory	O
performance	O
.	O
In	O
addition	O
,	O
working	O
memory	O
processing	O
in	O
ecstasy	B-CHEMICAL
users	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
neural	O
alterations	O
in	O
hippocampal	O
and/or	O
cortical	O
regions	O
as	O
measured	O
by	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
.	O
Using	O
functional	O
imaging	O
and	O
a	O
face	O
-	O
learning	O
task	O
,	O
we	O
investigated	O
neural	O
correlates	O
of	O
encoding	O
and	O
recalling	O
face	O
-	O
name	O
associations	O
in	O
20	O
recreational	O
drug	O
users	O
whose	O
predominant	O
drug	O
use	O
was	O
ecstasy	B-CHEMICAL
and	O
20	O
controls	O
.	O
To	O
address	O
the	O
potential	O
confounding	O
effects	O
of	O
the	O
cannabis	O
use	O
of	O
the	O
ecstasy	B-CHEMICAL
using	O
group	O
,	O
a	O
second	O
analysis	O
included	O
14	O
previously	O
tested	O
cannabis	O
users	O
(	O
Nestor	O
,	O
L.	O
,	O
Roberts	O
,	O
G.	O
,	O
Garavan	O
,	O
H.	O
,	O
Hester	O
,	O
R.	O
,	O
2008	O
.	O
Deficits	O
in	O
learning	O
and	O
memory	O
:	O
parahippocampal	O
hyperactivity	O
and	O
frontocortical	O
hypoactivity	O
in	O
cannabis	O
users	O
.	O
Neuroimage	O
40	O
,	O
1328	O
-	O
1339	O
)	O
.	O
Ecstasy	B-CHEMICAL
users	O
performed	O
significantly	O
worse	O
in	O
learning	O
and	O
memory	O
compared	O
to	O
controls	O
and	O
cannabis	O
users	O
.	O
A	O
conjunction	O
analysis	O
of	O
the	O
encode	O
and	O
recall	O
phases	O
of	O
the	O
task	O
revealed	O
ecstasy	B-CHEMICAL
-	O
specific	O
hyperactivity	O
in	O
bilateral	O
frontal	O
regions	O
,	O
left	O
temporal	O
,	O
right	O
parietal	O
,	O
bilateral	O
temporal	O
,	O
and	O
bilateral	O
occipital	O
brain	O
regions	O
.	O
Ecstasy	B-CHEMICAL
-	O
specific	O
hypoactivity	O
was	O
evident	O
in	O
the	O
right	O
dorsal	O
anterior	O
cingulated	O
cortex	O
(	O
ACC	O
)	O
and	O
left	O
posterior	O
cingulated	O
cortex	O
.	O
In	O
both	O
ecstasy	B-CHEMICAL
and	O
cannabis	O
groups	O
brain	O
activation	O
was	O
decreased	O
in	O
the	O
right	O
medial	O
frontal	O
gyrus	O
,	O
left	O
parahippocampal	O
gyrus	O
,	O
left	O
dorsal	O
cingulate	O
gyrus	O
,	O
and	O
left	O
caudate	O
.	O
These	O
results	O
elucidated	O
ecstasy	B-CHEMICAL
-	O
related	O
deficits	O
,	O
only	O
some	O
of	O
which	O
might	O
be	O
attributed	O
to	O
cannabis	O
use	O
.	O
These	O
ecstasy	B-CHEMICAL
-	O
specific	O
effects	O
may	O
be	O
related	O
to	O
the	O
vulnerability	O
of	O
isocortical	O
and	O
allocortical	O
regions	O
to	O
the	O
neurotoxic	B-DISEASE
effects	O
of	O
ecstasy	B-CHEMICAL
.	O

Prolonged	O
elevation	O
of	O
plasma	O
argatroban	O
in	O
a	O
cardiac	O
transplant	O
patient	O
with	O
a	O
suspected	O
history	O
of	O
heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-DISEASE
with	O
thrombosis	B-DISEASE
.	O
BACKGROUND	O
:	O
Direct	O
thrombin	O
inhibitors	O
(	O
DTIs	O
)	O
provide	O
an	O
alternative	O
method	O
of	O
anticoagulation	O
for	O
patients	O
with	O
a	O
history	O
of	O
heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-DISEASE
(	O
HIT	O
)	O
or	O
HIT	O
with	O
thrombosis	B-DISEASE
(	O
HITT	O
)	O
undergoing	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
.	O
In	O
the	O
following	O
report	O
,	O
a	O
65	O
-	O
year	O
-	O
old	O
critically	B-DISEASE
ill	I-DISEASE
patient	O
with	O
a	O
suspected	O
history	O
of	O
HITT	O
was	O
administered	O
argatroban	O
for	O
anticoagulation	O
on	O
bypass	O
during	O
heart	O
transplantation	O
.	O
The	O
patient	O
required	O
massive	O
transfusion	O
support	O
(	O
55	O
units	O
of	O
red	O
blood	O
cells	O
,	O
42	O
units	O
of	O
fresh	O
-	O
frozen	O
plasma	O
,	O
40	O
units	O
of	O
cryoprecipitate	O
,	O
40	O
units	O
of	O
platelets	O
,	O
and	O
three	O
doses	O
of	O
recombinant	O
Factor	O
VIIa	O
)	O
for	O
severe	O
intraoperative	O
and	O
postoperative	O
bleeding	B-DISEASE
.	O
STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
Plasma	O
samples	O
from	O
before	O
and	O
after	O
CPB	O
were	O
analyzed	O
postoperatively	O
for	O
argatroban	O
concentration	O
using	O
a	O
modified	O
ecarin	O
clotting	O
time	O
(	O
ECT	O
)	O
assay	O
.	O
RESULTS	O
:	O
Unexpectedly	O
high	O
concentrations	O
of	O
argatroban	O
were	O
measured	O
in	O
these	O
samples	O
(	O
range	O
,	O
0	O
-	O
32	O
microg	O
/	O
mL	O
)	O
,	O
and	O
a	O
prolonged	O
plasma	O
argatroban	O
half	O
life	O
(	O
t(1/2	O
)	O
)	O
of	O
514	O
minutes	O
was	O
observed	O
(	O
published	O
elimination	O
t(1/2	O
)	O
is	O
39	O
-	O
51	O
minutes	O
[	O
<	O
or	O
=	O
181	O
minutes	O
with	O
hepatic	O
impairment	O
]	O
)	O
.	O
CONCLUSIONS	O
:	O
Correlation	O
of	O
plasma	O
argatroban	O
concentration	O
versus	O
the	O
patient	O
's	O
coagulation	O
variables	O
and	O
clinical	O
course	O
suggest	O
that	O
prolonged	O
elevated	O
levels	O
of	O
plasma	O
argatroban	O
may	O
have	O
contributed	O
to	O
the	O
patient	O
's	O
extended	O
coagulopathy	B-DISEASE
.	O
Because	O
DTIs	O
do	O
not	O
have	O
reversal	O
agents	O
,	O
surgical	O
teams	O
and	O
transfusion	O
services	O
should	O
remain	O
aware	O
of	O
the	O
possibility	O
of	O
massive	O
transfusion	O
events	O
during	O
anticoagulation	O
with	O
these	O
agents	O
.	O
This	O
is	O
the	O
first	O
report	O
to	O
measure	O
plasma	O
argatroban	O
concentration	O
in	O
the	O
context	O
of	O
CPB	O
and	O
extended	O
coagulopathy	B-DISEASE
.	O

Antituberculosis	O
therapy	O
-	O
induced	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
:	O
magnitude	O
,	O
profile	O
,	O
prognosis	O
,	O
and	O
predictors	O
of	O
outcome	O
.	O
Antituberculosis	O
therapy	O
(	O
ATT)-associated	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
(	O
ATT	O
-	O
ALF	B-DISEASE
)	O
is	O
the	O
commonest	O
drug	O
-	O
induced	O
ALF	B-DISEASE
in	O
South	O
Asia	O
.	O
Prospective	O
studies	O
on	O
ATT	O
-	O
ALF	B-DISEASE
are	O
lacking	O
.	O
The	O
current	O
study	O
prospectively	O
evaluated	O
the	O
magnitude	O
,	O
clinical	O
course	O
,	O
outcome	O
,	O
and	O
prognostic	O
factors	O
in	O
ATT	O
-	O
ALF	B-DISEASE
.	O
From	O
January	O
1986	O
to	O
January	O
2009	O
,	O
1223	O
consecutive	O
ALF	B-DISEASE
patients	O
were	O
evaluated	O
:	O
ATT	O
alone	O
was	O
the	O
cause	O
in	O
70	O
(	O
5.7	O
%	O
)	O
patients	O
.	O
Another	O
15	O
(	O
1.2	O
%	O
)	O
had	O
ATT	O
and	O
simultaneous	O
hepatitis	B-DISEASE
virus	O
infection	B-DISEASE
.	O
In	O
44	O
(	O
62.8	O
%	O
)	O
patients	O
,	O
ATT	O
was	O
prescribed	O
empirically	O
without	O
definitive	O
evidence	O
of	O
tuberculosis	B-DISEASE
.	O
ATT	O
-	O
ALF	B-DISEASE
patients	O
were	O
younger	O
(	O
32.87	O
[	O
+	O
/-15.8	O
]	O
years	O
)	O
,	O
and	O
49	O
(	O
70	O
%	O
)	O
of	O
them	O
were	O
women	O
.	O
Most	O
had	O
hyperacute	O
presentation	O
;	O
the	O
median	O
icterus	O
encephalopathy	B-DISEASE
interval	O
was	O
4.5	O
(	O
0	O
-	O
30	O
)	O
days	O
.	O
The	O
median	O
duration	O
of	O
ATT	O
before	O
ALF	B-DISEASE
was	O
30	O
(	O
7	O
-	O
350	O
)	O
days	O
.	O
At	O
presentation	O
,	O
advanced	O
encephalopathy	B-DISEASE
and	O
cerebral	B-DISEASE
edema	I-DISEASE
were	O
present	O
in	O
51	O
(	O
76	O
%	O
)	O
and	O
29	O
(	O
41.4	O
%	O
)	O
patients	O
,	O
respectively	O
.	O
Gastrointestinal	O
bleed	O
,	O
seizures	B-DISEASE
,	O
infection	B-DISEASE
,	O
and	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
were	O
documented	O
in	O
seven	O
(	O
10	O
%	O
)	O
,	O
five	O
(	O
7.1	O
%	O
)	O
,	O
26	O
(	O
37.1	O
%	O
)	O
,	O
and	O
seven	O
(	O
10	O
%	O
)	O
patients	O
,	O
respectively	O
.	O
Compared	O
with	O
hepatitis	B-DISEASE
E	I-DISEASE
virus	O
(	O
HEV	O
)	O
and	O
non	O
-	O
A	O
non	O
-	O
E	O
-	O
induced	O
ALF	B-DISEASE
,	O
ATT	O
-	O
ALF	B-DISEASE
patients	O
had	O
nearly	O
similar	O
presentations	O
except	O
for	O
older	O
age	O
and	O
less	O
elevation	O
of	O
liver	O
enzymes	O
.	O
The	O
mortality	O
rate	O
among	O
patients	O
with	O
ATT	O
-	O
ALF	B-DISEASE
was	O
high	O
(	O
67.1	O
%	O
,	O
n	O
=	O
47	O
)	O
,	O
and	O
only	O
23	O
(	O
32.9	O
%	O
)	O
patients	O
recovered	O
with	O
medical	O
treatment	O
.	O
In	O
multivariate	O
analysis	O
,	O
three	O
factors	O
independently	O
predicted	O
mortality	O
:	O
serum	O
bilirubin	O
(	O
>	O
or=10.8	O
mg	O
/	O
dL	O
)	O
,	O
prothrombin	O
time	O
(	O
PT	O
)	O
prolongation	O
(	O
>	O
or=26	O
seconds	O
)	O
,	O
and	O
grade	O
III	O
/	O
IV	O
encephalopathy	B-DISEASE
at	O
presentation	O
.	O
CONCLUSION	O
:	O
ATT	O
-	O
ALF	B-DISEASE
constituted	O
5.7	O
%	O
of	O
ALF	B-DISEASE
at	O
our	O
center	O
and	O
had	O
a	O
high	O
mortality	O
rate	O
.	O
Because	O
the	O
mortality	O
rate	O
is	O
so	O
high	O
,	O
determining	O
which	O
factors	O
are	O
predictors	O
is	O
less	O
important	O
.	O
A	O
high	O
proportion	O
of	O
patients	O
had	O
consumed	O
ATT	O
empirically	O
,	O
which	O
could	O
have	O
been	O
prevented	O
.	O

Central	O
nervous	O
system	O
complications	B-DISEASE
during	O
treatment	O
of	O
acute	B-DISEASE
lymphoblastic	I-DISEASE
leukemia	I-DISEASE
in	O
a	O
single	O
pediatric	O
institution	O
.	O
Central	O
nervous	O
system	O
(	O
CNS	O
)	O
complications	B-DISEASE
during	O
treatment	O
of	O
childhood	O
acute	B-DISEASE
lymphoblastic	I-DISEASE
leukemia	I-DISEASE
(	O
ALL	O
)	O
remain	O
a	O
challenging	O
clinical	O
problem	O
.	O
Outcome	O
improvement	O
with	O
more	O
intensive	O
chemotherapy	O
has	O
significantly	O
increased	O
the	O
incidence	O
and	O
severity	O
of	O
adverse	O
events	O
.	O
This	O
study	O
analyzed	O
the	O
incidence	O
of	O
neurological	O
complications	B-DISEASE
during	O
ALL	O
treatment	O
in	O
a	O
single	O
pediatric	O
institution	O
,	O
focusing	O
on	O
clinical	O
,	O
radiological	O
,	O
and	O
electrophysiological	O
findings	O
.	O
Exclusion	O
criteria	O
included	O
CNS	O
leukemic	B-DISEASE
infiltration	I-DISEASE
at	O
diagnosis	O
,	O
therapy	O
-	O
related	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
,	O
late	O
-	O
onset	O
encephalopathy	B-DISEASE
,	O
or	O
long	O
-	O
term	O
neurocognitive	O
defects	O
.	O
During	O
a	O
9	O
-	O
year	O
period	O
,	O
we	O
retrospectively	O
collected	O
27	O
neurological	O
events	O
(	O
11	O
%	O
)	O
in	O
as	O
many	O
patients	O
,	O
from	O
253	O
children	O
enrolled	O
in	O
the	O
ALL	O
front	O
-	O
line	O
protocol	O
.	O
CNS	O
complications	B-DISEASE
included	O
posterior	O
reversible	O
leukoencephalopathy	B-DISEASE
syndrome	B-DISEASE
(	O
n	O
=	O
10	O
)	O
,	O
stroke	B-DISEASE
(	O
n	O
=	O
5	O
)	O
,	O
temporal	B-DISEASE
lobe	I-DISEASE
epilepsy	I-DISEASE
(	O
n	O
=	O
2	O
)	O
,	O
high	O
-	O
dose	O
methotrexate	B-CHEMICAL
toxicity	B-DISEASE
(	O
n	O
=	O
2	O
)	O
,	O
syndrome	B-DISEASE
of	I-DISEASE
inappropriate	I-DISEASE
antidiuretic	I-DISEASE
hormone	I-DISEASE
secretion	O
(	O
n	O
=	O
1	O
)	O
,	O
and	O
other	O
unclassified	O
events	O
(	O
n	O
=	O
7	O
)	O
.	O
In	O
conclusion	O
,	O
CNS	O
complications	B-DISEASE
are	O
frequent	O
events	O
during	O
ALL	O
therapy	O
,	O
and	O
require	O
rapid	O
detection	O
and	O
prompt	O
treatment	O
to	O
limit	O
permanent	O
damage	O
.	O

Safety	O
of	O
capecitabine	O
:	O
a	O
review	O
.	O
IMPORTANCE	O
OF	O
THE	O
FIELD	O
:	O
Fluoropyrimidines	O
,	O
in	O
particular	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
)	O
,	O
have	O
been	O
the	O
mainstay	O
of	O
treatment	O
for	O
several	O
solid	O
tumors	B-DISEASE
,	O
including	O
colorectal	O
,	O
breast	O
and	O
head	O
and	O
neck	O
cancers	B-DISEASE
,	O
for	O
>	O
40	O
years	O
.	O
AREAS	O
COVERED	O
IN	O
THIS	O
REVIEW	O
:	O
This	O
article	O
reviews	O
the	O
pharmacology	O
and	O
efficacy	O
of	O
capecitabine	O
with	O
a	O
special	O
emphasis	O
on	O
its	O
safety	O
.	O
WHAT	O
THE	O
READER	O
WILL	O
GAIN	O
:	O
The	O
reader	O
will	O
gain	O
better	O
insight	O
into	O
the	O
safety	O
of	O
capecitabine	O
in	O
special	O
populations	O
such	O
as	O
patients	O
with	O
advanced	O
age	O
,	O
renal	O
and	O
kidney	O
disease	B-DISEASE
.	O
We	O
also	O
explore	O
different	O
dosing	O
and	O
schedules	O
of	O
capecitabine	O
administration	O
.	O
TAKE	O
HOME	O
MESSAGE	O
:	O
Capecitabine	O
is	O
an	O
oral	O
prodrug	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
and	O
was	O
developed	O
to	O
fulfill	O
the	O
need	O
for	O
a	O
more	O
convenient	O
therapy	O
and	O
provide	O
an	O
improved	O
safety	O
/	O
efficacy	O
profile	O
.	O
It	O
has	O
shown	O
promising	O
results	O
alone	O
or	O
in	O
combination	O
with	O
other	O
chemotherapeutic	O
agents	O
in	O
colorectal	O
,	O
breast	O
,	O
pancreaticobiliary	O
,	O
gastric	O
,	O
renal	O
cell	O
and	O
head	O
and	O
neck	O
cancers	B-DISEASE
.	O
The	O
most	O
commonly	O
reported	O
toxic	O
effects	O
of	O
capecitabine	O
are	O
diarrhea	B-DISEASE
,	O
nausea	B-DISEASE
,	O
vomiting	B-DISEASE
,	O
stomatitis	B-DISEASE
and	O
hand	B-DISEASE
-	I-DISEASE
foot	I-DISEASE
syndrome	I-DISEASE
.	O
Capecitabine	O
has	O
a	O
well	O
-	O
established	O
safety	O
profile	O
and	O
can	O
be	O
given	O
safely	O
to	O
patients	O
with	O
advanced	O
age	O
,	O
hepatic	O
and	O
renal	O
dysfunctions	O
.	O

Effects	O
of	O
pallidal	O
neurotensin	B-CHEMICAL
on	O
haloperidol	B-CHEMICAL
-	O
induced	O
parkinsonian	B-DISEASE
catalepsy	B-DISEASE
:	O
behavioral	O
and	O
electrophysiological	O
studies	O
.	O
OBJECTIVE	O
:	O
The	O
globus	B-DISEASE
pallidus	O
plays	O
a	O
critical	O
role	O
in	O
movement	O
regulation	O
.	O
Previous	O
studies	O
have	O
indicated	O
that	O
the	O
globus	B-DISEASE
pallidus	O
receives	O
neurotensinergic	O
innervation	O
from	O
the	O
striatum	O
,	O
and	O
systemic	O
administration	O
of	O
a	O
neurotensin	B-CHEMICAL
analog	O
could	O
produce	O
antiparkinsonian	O
effects	O
.	O
The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
pallidal	O
neurotensin	B-CHEMICAL
on	O
haloperidol	B-CHEMICAL
-	O
induced	O
parkinsonian	B-DISEASE
symptoms	O
.	O
METHODS	O
:	O
Behavioral	O
experiments	O
and	O
electrophysiological	O
recordings	O
were	O
performed	O
in	O
the	O
present	O
study	O
.	O
RESULTS	O
:	O
Bilateral	O
infusions	O
of	O
neurotensin	B-CHEMICAL
into	O
the	O
globus	B-DISEASE
pallidus	O
reversed	O
haloperidol	B-CHEMICAL
-	O
induced	O
parkinsonian	B-DISEASE
catalepsy	B-DISEASE
in	O
rats	O
.	O
Electrophysiological	O
recordings	O
showed	O
that	O
microinjection	O
of	O
neurotensin	B-CHEMICAL
induced	O
excitation	O
of	O
pallidal	O
neurons	O
in	O
the	O
presence	O
of	O
systemic	O
haloperidol	B-CHEMICAL
administration	O
.	O
The	O
neurotensin	B-CHEMICAL
type-1	O
receptor	O
antagonist	O
SR48692	O
blocked	O
both	O
the	O
behavioral	O
and	O
the	O
electrophysiological	O
effects	O
induced	O
by	O
neurotensin	B-CHEMICAL
.	O
CONCLUSION	O
:	O
Activation	O
of	O
pallidal	O
neurotensin	B-CHEMICAL
receptors	O
may	O
be	O
involved	O
in	O
neurotensin	B-CHEMICAL
-	O
induced	O
antiparkinsonian	O
effects	O
.	O

Antihypertensive	B-CHEMICAL
drugs	I-CHEMICAL
and	O
depression	B-DISEASE
:	O
a	O
reappraisal	O
.	O
Eighty	O
-	O
nine	O
new	O
referral	O
hypertensive	B-DISEASE
out	O
-	O
patients	O
and	O
46	O
new	O
referral	O
non	O
-	O
hypertensive	B-DISEASE
chronically	O
physically	O
ill	O
out	O
-	O
patients	O
completed	O
a	O
mood	O
rating	O
scale	O
at	O
regular	O
intervals	O
for	O
one	O
year	O
.	O
The	O
results	O
showed	O
a	O
high	O
prevalence	O
of	O
depression	B-DISEASE
in	O
both	O
groups	O
of	O
patients	O
,	O
with	O
no	O
preponderance	O
in	O
the	O
hypertensive	B-DISEASE
group	O
.	O
Hypertensive	B-DISEASE
patients	O
with	O
psychiatric	B-DISEASE
histories	O
had	O
a	O
higher	O
prevalence	O
of	O
depression	B-DISEASE
than	O
the	O
comparison	O
patients	O
.	O
This	O
was	O
accounted	O
for	O
by	O
a	O
significant	O
number	O
of	O
depressions	B-DISEASE
occurring	O
in	O
methyl	O
dopa	O
treated	O
patients	O
with	O
psychiatric	B-DISEASE
histories	O
.	O

Pulmonary	O
shunt	O
and	O
cardiovascular	O
responses	O
to	O
CPAP	O
during	O
nitroprusside	B-CHEMICAL
-	O
induced	O
hypotension	B-DISEASE
.	O
The	O
effects	O
of	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
on	O
cardiovascular	O
dynamics	O
and	O
pulmonary	O
shunt	O
(	O
QS	O
/	O
QT	O
)	O
were	O
investigated	O
in	O
12	O
dogs	O
before	O
and	O
during	O
sodium	B-CHEMICAL
nitroprusside	I-CHEMICAL
infusion	O
that	O
decreased	O
mean	O
arterial	O
blood	O
pressure	O
40	O
-	O
50	O
per	O
cent	O
.	O
Before	O
nitroprusside	B-CHEMICAL
infusion	O
,	O
5	O
cm	B-DISEASE
H2O	O
CPAP	O
significantly	O
,	O
P	O
less	O
than	O
.05	O
,	O
decreased	O
arterial	O
blood	O
pressure	O
,	O
but	O
did	O
not	O
significantly	O
alter	O
heart	O
rate	O
,	O
cardiac	O
output	O
,	O
systemic	O
vascular	O
resistance	O
,	O
or	O
QS	O
/	O
QT	O
.	O
Ten	O
cm	B-DISEASE
H2O	O
CPAP	O
before	O
nitroprusside	B-CHEMICAL
infusion	O
produced	O
a	O
further	O
decrease	B-DISEASE
in	I-DISEASE
arterial	I-DISEASE
blood	I-DISEASE
pressure	I-DISEASE
and	O
significantly	O
increased	O
heart	O
rate	O
and	O
decreased	B-DISEASE
cardiac	I-DISEASE
output	I-DISEASE
and	O
QS	O
/	O
QT	O
.	O
Nitroprusside	B-CHEMICAL
caused	O
significant	O
decreases	B-DISEASE
in	I-DISEASE
arterial	I-DISEASE
blood	I-DISEASE
pressure	I-DISEASE
and	O
systemic	O
vascular	O
resistance	O
and	O
increases	O
in	O
heart	O
rate	O
,	O
but	O
did	O
not	O
change	O
cardiac	O
output	O
or	O
QS	O
/	O
QT	O
.	O
Five	O
cm	B-DISEASE
H2O	O
CPAP	O
during	O
nitroprusside	B-CHEMICAL
did	O
not	O
further	O
alter	O
any	O
of	O
the	O
above	O
-	O
mentioned	O
variables	O
.	O
However	O
,	O
10	O
cm	B-DISEASE
H2O	O
CPAP	O
decreased	O
arterial	O
blood	O
pressure	O
,	O
cardiac	O
output	O
,	O
and	O
QS	O
/	O
QT	O
.	O
These	O
data	O
indicate	O
that	O
nitroprusside	B-CHEMICAL
infusion	O
rates	O
that	O
decrease	O
mean	O
arterial	O
blood	O
pressure	O
by	O
40	O
-	O
50	O
per	O
cent	O
do	O
not	O
change	O
cardiac	O
output	O
or	O
QS	O
/	O
QT	O
.	O
During	O
nitroprusside	B-CHEMICAL
infusion	O
low	O
levels	O
of	O
CPAP	O
do	O
not	O
markedly	O
alter	O
cardiovascular	O
dynamics	O
,	O
but	O
high	O
levels	O
of	O
CPAP	O
(	O
10	O
cm	B-DISEASE
H2O	O
)	O
,	O
while	O
decreasing	O
QS	O
/	O
QT	O
,	O
produce	O
marked	O
decreases	B-DISEASE
in	I-DISEASE
arterial	I-DISEASE
blood	I-DISEASE
pressure	I-DISEASE
and	O
cardiac	O
output	O
.	O

Mediation	O
of	O
enhanced	O
reflex	O
vagal	O
bradycardia	B-DISEASE
by	O
L	O
-	O
dopa	O
via	O
central	O
dopamine	B-CHEMICAL
formation	O
in	O
dogs	O
.	O
L	O
-	O
Dopa	O
(	O
5	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
decreased	O
blood	O
pressure	O
and	O
heart	O
rate	O
after	O
extracerebral	O
decarboxylase	O
inhibition	O
with	O
MK-486	O
(	O
25	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
in	O
anesthetize	O
MAO	O
-	O
inhibited	O
dogs	O
.	O
In	O
addition	O
,	O
reflex	O
bradycardia	B-DISEASE
caused	O
by	O
injected	O
norepinephrine	B-CHEMICAL
was	O
significantly	O
enhanced	O
by	O
L	O
-	O
dopa	O
,	O
DL	O
-	O
Threo	O
-	O
dihydroxyphenylserine	O
had	O
no	O
effect	O
on	O
blood	O
pressure	O
,	O
heart	O
rate	O
or	O
reflex	O
responses	O
to	O
norepinephrine	B-CHEMICAL
.	O
FLA-63	O
,	O
a	O
dopamine	B-CHEMICAL
-	O
beta	O
-	O
oxidase	O
inhibitor	O
,	O
did	O
not	O
have	O
any	O
effect	O
on	O
the	O
hypotension	B-DISEASE
,	O
bradycardia	B-DISEASE
or	O
reflex	O
-	O
enhancing	O
effect	O
of	O
L	O
-	O
dopa	O
.	O
Pimozide	O
did	O
not	O
affect	O
the	O
actions	O
of	O
L	O
-	O
dopa	O
on	O
blood	O
pressure	O
and	O
heart	O
rate	O
but	O
completely	O
blocked	O
the	O
enhancement	O
of	O
reflexes	O
.	O
Removal	O
of	O
the	O
carotid	O
sinuses	O
caused	O
an	O
elevation	O
blood	O
pressure	O
and	O
heart	O
rate	O
and	O
abolished	O
the	O
negative	O
chronotropic	O
effect	O
of	O
norepinephrine	B-CHEMICAL
.	O
However	O
,	O
L	O
-	O
dopa	O
restored	O
the	O
bradycardia	B-DISEASE
caused	O
by	O
norepinephrine	B-CHEMICAL
in	O
addition	O
to	O
decreasing	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O
5	B-CHEMICAL
-	I-CHEMICAL
HTP	I-CHEMICAL
(	O
5	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
decreased	O
blood	O
pressure	O
and	O
heart	O
rate	O
and	O
decreased	O
the	O
reflex	O
bradycardia	B-DISEASE
to	O
norepinephrine	B-CHEMICAL
.	O
It	O
is	O
concluded	O
that	O
L	O
-	O
dopa	O
enhances	O
reflex	O
bradycardia	B-DISEASE
through	O
central	O
alpha	O
-	O
receptor	O
stimulation	O
.	O
Furthermore	O
,	O
the	O
effects	O
are	O
mediated	O
through	O
dopamine	B-CHEMICAL
rather	O
than	O
norepinephrine	B-CHEMICAL
and	O
do	O
not	O
require	O
the	O
carotid	O
sinus	O
baroreceptors	O
.	O

Cocaine	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
:	O
clinical	O
observations	O
and	O
pathogenetic	O
considerations	O
.	O
Clinical	O
and	O
experimental	O
data	O
published	O
to	O
date	O
suggest	O
several	O
possible	O
mechanisms	O
by	O
which	O
cocaine	B-CHEMICAL
may	O
result	O
in	O
acute	B-DISEASE
myocardial	I-DISEASE
infarction	I-DISEASE
.	O
In	O
individuals	O
with	O
preexisting	O
,	O
high	O
-	O
grade	O
coronary	O
arterial	O
narrowing	O
,	O
acute	B-DISEASE
myocardial	I-DISEASE
infarction	I-DISEASE
may	O
result	O
from	O
an	O
increase	O
in	O
myocardial	O
oxygen	B-CHEMICAL
demand	O
associated	O
with	O
cocaine	B-CHEMICAL
-	O
induced	O
increase	O
in	O
rate	O
-	O
pressure	O
product	O
.	O
In	O
other	O
individuals	O
with	O
no	O
underlying	O
atherosclerotic	B-DISEASE
obstruction	I-DISEASE
,	O
coronary	B-DISEASE
occlusion	I-DISEASE
may	O
be	O
due	O
to	O
spasm	B-DISEASE
,	O
thrombus	O
,	O
or	O
both	O
.	O
With	O
regard	O
to	O
spasm	B-DISEASE
,	O
the	O
clinical	O
findings	O
are	O
largely	O
circumstantial	O
,	O
and	O
the	O
locus	O
of	O
cocaine	B-CHEMICAL
-	O
induced	O
vasoconstriction	O
remains	O
speculative	O
.	O
Although	O
certain	O
clinical	O
and	O
experimental	O
findings	O
support	O
the	O
hypothesis	O
that	O
spasm	B-DISEASE
involves	O
the	O
epicardial	O
,	O
medium	O
-	O
size	O
vessels	O
,	O
other	O
data	O
suggest	O
intramural	O
vasoconstriction	O
.	O
Diffuse	O
intramural	O
vasoconstriction	O
is	O
not	O
consistent	O
with	O
reports	O
of	O
segmental	O
,	O
discrete	O
infarction	B-DISEASE
.	O
Whereas	O
certain	O
in	O
vivo	O
data	O
suggest	O
that	O
these	O
effects	O
are	O
alpha	O
-	O
mediated	O
,	O
other	O
in	O
vitro	O
data	O
suggest	O
the	O
opposite	O
.	O
The	O
finding	O
of	O
cocaine	B-CHEMICAL
-	O
induced	O
vasoconstriction	O
in	O
segments	O
of	O
(	O
noninnervated	O
)	O
human	O
umbilical	O
artery	O
suggests	O
that	O
the	O
presence	O
or	O
absence	O
of	O
intact	O
innervation	O
is	O
not	O
sufficient	O
to	O
explain	O
the	O
discrepant	O
data	O
involving	O
the	O
possibility	O
of	O
alpha	O
-	O
mediated	O
effects	O
.	O
Finally	O
,	O
the	O
contribution	O
of	O
a	O
primary	O
,	O
thrombotic	B-DISEASE
effect	O
of	O
cocaine	B-CHEMICAL
has	O
not	O
been	O
excluded	O
.	O

Rabbit	B-DISEASE
syndrome	I-DISEASE
,	O
antidepressant	O
use	O
,	O
and	O
cerebral	O
perfusion	O
SPECT	O
scan	O
findings	O
.	O
The	O
rabbit	B-DISEASE
syndrome	I-DISEASE
is	O
an	O
extrapyramidal	O
side	O
effect	O
associated	O
with	O
chronic	O
neuroleptic	O
therapy	O
.	O
Its	O
occurrence	O
in	O
a	O
patient	O
being	O
treated	O
with	O
imipramine	O
is	O
described	O
,	O
representing	O
the	O
first	O
reported	O
case	O
of	O
this	O
syndrome	B-DISEASE
in	O
conjunction	O
with	O
antidepressants	O
.	O
Repeated	O
cerebral	O
perfusion	O
SPECT	O
scans	O
revealed	O
decreased	B-DISEASE
basal	I-DISEASE
ganglia	I-DISEASE
perfusion	I-DISEASE
while	O
the	O
movement	O
disorder	O
was	O
present	O
,	O
and	O
a	O
return	O
to	O
normal	O
perfusion	O
when	O
the	O
rabbit	B-DISEASE
syndrome	I-DISEASE
resolved	O
.	O

Acute	O
bronchodilating	O
effects	O
of	O
ipratropium	O
bromide	O
and	O
theophylline	B-CHEMICAL
in	O
chronic	B-DISEASE
obstructive	I-DISEASE
pulmonary	I-DISEASE
disease	I-DISEASE
.	O
The	O
bronchodilator	O
effects	O
of	O
a	O
single	O
dose	O
of	O
ipratropium	O
bromide	O
aerosol	O
(	O
36	O
micrograms	O
)	O
and	O
short	O
-	O
acting	O
theophylline	B-CHEMICAL
tablets	O
(	O
dose	O
titrated	O
to	O
produce	O
serum	O
levels	O
of	O
10	O
-	O
20	O
micrograms	O
/	O
mL	O
)	O
were	O
compared	O
in	O
a	O
double	O
-	O
blind	B-DISEASE
,	O
placebo	O
-	O
controlled	O
crossover	O
study	O
in	O
21	O
patients	O
with	O
stable	O
,	O
chronic	B-DISEASE
obstructive	I-DISEASE
pulmonary	I-DISEASE
disease	I-DISEASE
.	O
Mean	O
peak	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
(	O
FEV1	O
)	O
increases	O
over	O
baseline	O
and	O
the	O
proportion	O
of	O
patients	O
attaining	O
at	O
least	O
a	O
15	O
%	O
increase	O
in	O
the	O
FEV1	O
(	O
responders	O
)	O
were	O
31	O
%	O
and	O
90	O
%	O
,	O
respectively	O
,	O
for	O
ipratropium	O
and	O
17	O
%	O
and	O
50	O
%	O
,	O
respectively	O
,	O
for	O
theophylline	B-CHEMICAL
.	O
The	O
average	O
FEV1	O
increases	O
during	O
the	O
6	O
-	O
hour	O
observation	O
period	O
were	O
18	O
%	O
for	O
ipratropium	O
and	O
8	O
%	O
for	O
theophylline	B-CHEMICAL
.	O
The	O
mean	O
duration	O
of	O
action	O
was	O
3.8	O
hours	O
with	O
ipratropium	O
and	O
2.4	O
hours	O
with	O
theophylline	B-CHEMICAL
.	O
While	O
side	O
effects	O
were	O
rare	O
,	O
those	O
experienced	O
after	O
theophylline	B-CHEMICAL
use	O
did	O
involve	O
the	O
cardiovascular	O
and	O
gastrointestinal	O
systems	O
.	O
These	O
results	O
show	O
that	O
ipratropium	O
is	O
a	O
more	O
potent	O
bronchodilator	O
than	O
oral	O
theophylline	B-CHEMICAL
in	O
patients	O
with	O
chronic	B-DISEASE
airflow	I-DISEASE
obstruction	I-DISEASE
.	O

Irreversible	O
damage	O
to	O
the	O
medullary	O
interstitium	O
in	O
experimental	O
analgesic	O
nephropathy	B-DISEASE
in	O
F344	O
rats	O
.	O
Renal	B-DISEASE
papillary	I-DISEASE
necrosis	I-DISEASE
(	O
RPN	B-DISEASE
)	O
and	O
a	O
decreased	O
urinary	O
concentrating	O
ability	O
developed	O
during	O
continuous	O
long	O
-	O
term	O
treatment	O
with	O
aspirin	O
and	O
paracetamol	B-CHEMICAL
in	O
female	O
Fischer	O
344	O
rats	O
.	O
Renal	O
structure	O
and	O
concentrating	O
ability	O
were	O
examined	O
after	O
a	O
recovery	O
period	O
of	O
up	O
to	O
18	O
weeks	O
,	O
when	O
no	O
analgesics	O
were	O
given	O
,	O
to	O
investigate	O
whether	O
the	O
analgesic	O
-	O
induced	O
changes	O
were	O
reversible	O
.	O
There	O
was	O
no	O
evidence	O
of	O
repair	O
to	O
the	O
damaged	O
medullary	O
interstitial	O
matrix	O
,	O
or	O
proliferation	O
of	O
remaining	O
undamaged	O
type	O
1	O
medullary	O
interstitial	O
cells	O
after	O
the	O
recovery	O
period	O
following	O
analgesic	O
treatment	O
.	O
The	O
recovery	O
of	O
urinary	O
concentrating	O
ability	O
was	O
related	O
to	O
the	O
length	O
of	O
analgesic	O
treatment	O
and	O
the	O
extent	O
of	O
the	O
resulting	O
inner	O
medullary	O
structural	O
damage	O
.	O
During	O
the	O
early	O
stages	O
of	O
analgesic	O
treatment	O
,	O
the	O
changes	O
in	O
urinary	O
concentrating	O
ability	O
were	O
reversible	O
,	O
but	O
after	O
prolonged	O
analgesic	O
treatment	O
,	O
maximum	O
urinary	O
concentrating	O
ability	O
failed	O
to	O
recover	O
.	O
This	O
study	O
shows	O
that	O
prolonged	O
analgesic	O
treatment	O
in	O
Fischer	O
344	O
rats	O
causes	O
progressive	O
and	O
irreversible	O
damage	O
to	O
the	O
interstitial	O
matrix	O
and	O
type	O
1	O
interstitial	O
cells	O
leading	O
to	O
RPN	B-DISEASE
.	O
The	O
associated	O
urinary	O
concentrating	O
defect	O
is	O
reversible	O
only	O
during	O
the	O
early	O
stages	O
of	O
structural	O
damage	O
to	O
the	O
inner	O
medulla	O
.	O

Less	O
frequent	O
lithium	B-CHEMICAL
administration	O
and	O
lower	O
urine	O
volume	O
.	O
OBJECTIVE	O
:	O
This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
patients	O
maintained	O
on	O
a	O
regimen	O
of	O
lithium	B-CHEMICAL
on	O
a	O
once	O
-	O
per	O
-	O
day	O
schedule	O
have	O
lower	O
urine	O
volumes	O
than	O
do	O
patients	O
receiving	O
multiple	O
doses	O
per	O
day	O
.	O
METHOD	O
:	O
This	O
was	O
a	O
cross	O
-	O
sectional	O
study	O
of	O
85	O
patients	O
from	O
a	O
lithium	B-CHEMICAL
clinic	O
who	O
received	O
different	O
dose	O
schedules	O
.	O
Patients	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
measurement	O
of	O
lithium	B-CHEMICAL
level	O
,	O
creatinine	B-CHEMICAL
clearance	O
,	O
urine	O
volume	O
,	O
and	O
maximum	O
osmolality	O
.	O
RESULTS	O
:	O
Multiple	O
daily	O
doses	O
of	O
lithium	B-CHEMICAL
were	O
associated	O
with	O
higher	O
urine	O
volumes	O
.	O
The	O
dosing	O
schedule	O
,	O
duration	O
of	O
lithium	B-CHEMICAL
treatment	O
,	O
and	O
daily	O
dose	O
of	O
lithium	B-CHEMICAL
did	O
not	O
affect	O
maximum	O
osmolality	O
or	O
creatinine	B-CHEMICAL
clearance	O
.	O
CONCLUSIONS	O
:	O
Urine	O
volume	O
can	O
be	O
reduced	O
by	O
giving	O
lithium	B-CHEMICAL
once	O
daily	O
and/or	O
by	O
lowering	O
the	O
total	O
daily	O
dose	O
.	O
Lithium	B-CHEMICAL
-	O
induced	O
polyuria	B-DISEASE
seems	O
to	O
be	O
related	O
to	O
extrarenal	O
as	O
well	O
as	O
to	O
renal	O
effects	O
.	O

Effect	O
of	O
adriamycin	B-CHEMICAL
combined	O
with	O
whole	O
body	O
hyperthermia	B-DISEASE
on	O
tumor	B-DISEASE
and	O
normal	O
tissues	O
.	O
Thermal	O
enhancement	O
of	O
Adriamycin	B-CHEMICAL
-	O
mediated	O
antitumor	O
activity	O
and	O
normal	O
tissue	O
toxicities	B-DISEASE
by	O
whole	O
body	O
hyperthermia	B-DISEASE
were	O
compared	O
using	O
a	O
F344	O
rat	O
model	O
.	O
Antitumor	O
activity	O
was	O
studied	O
using	O
a	O
tumor	B-DISEASE
growth	O
delay	O
assay	O
.	O
Acute	O
normal	O
tissue	O
toxicities	B-DISEASE
(	O
i.e.	O
,	O
leukopenia	B-DISEASE
and	O
thrombocytopenia	B-DISEASE
)	O
and	O
late	O
normal	O
tissue	O
toxicities	B-DISEASE
(	O
i.e.	O
,	O
myocardial	O
and	O
kidney	O
injury	O
)	O
were	O
evaluated	O
by	O
functional	O
/	O
physiological	O
assays	O
and	O
by	O
morphological	O
techniques	O
.	O
Whole	O
body	O
hyperthermia	B-DISEASE
(	O
120	O
min	O
at	O
41.5	O
degrees	O
C	O
)	O
enhanced	O
both	O
Adriamycin	B-CHEMICAL
-	O
mediated	O
antitumor	O
activity	O
and	O
toxic	O
side	O
effects	O
.	O
The	O
thermal	O
enhancement	O
ratio	O
calculated	O
for	O
antitumor	O
activity	O
was	O
1.6	O
.	O
Thermal	O
enhancement	O
ratios	O
estimated	O
for	O
"	O
acute	O
"	O
hematological	O
changes	O
were	O
1.3	O
,	O
whereas	O
those	O
estimated	O
for	O
"	O
late	O
"	O
damage	O
(	O
based	O
on	O
morphological	O
cardiac	O
and	O
renal	B-DISEASE
lesions	I-DISEASE
)	O
varied	O
between	O
2.4	O
and	O
4.3	O
.	O
Thus	O
,	O
while	O
whole	O
body	O
hyperthermia	B-DISEASE
enhances	O
Adriamycin	B-CHEMICAL
-	O
mediated	O
antitumor	O
effect	O
,	O
normal	O
tissue	O
toxicity	B-DISEASE
is	O
also	O
increased	O
,	O
and	O
the	O
potential	O
therapeutic	O
gain	O
of	O
the	O
combined	O
modality	O
treatment	O
is	O
eroded	O
.	O

Prazosin	B-CHEMICAL
-	O
induced	O
stress	B-DISEASE
incontinence	I-DISEASE
.	O
A	O
case	O
of	O
genuine	O
stress	B-DISEASE
incontinence	I-DISEASE
due	O
to	O
prazosin	B-CHEMICAL
,	O
a	O
common	O
antihypertensive	O
drug	O
,	O
is	O
presented	O
.	O
Prazosin	B-CHEMICAL
exerts	O
its	O
antihypertensive	O
effects	O
through	O
vasodilatation	O
caused	O
by	O
selective	O
blockade	O
of	O
postsynaptic	O
alpha-1	O
adrenergic	O
receptors	O
.	O
As	O
an	O
alpha	O
-	O
blocker	O
,	O
it	O
also	O
exerts	O
a	O
significant	O
relaxant	O
effect	O
on	O
the	O
bladder	O
neck	O
and	O
urethra	O
.	O
The	O
patient	O
's	O
clinical	O
course	O
is	O
described	O
and	O
correlated	O
with	O
initial	O
urodynamic	O
studies	O
while	O
on	O
prazosin	B-CHEMICAL
and	O
subsequent	O
studies	O
while	O
taking	O
verapamil	B-CHEMICAL
.	O
Her	O
incontinence	B-DISEASE
resolved	O
with	O
the	O
change	O
of	O
medication	O
.	O
The	O
restoration	O
of	O
continence	O
was	O
accompanied	O
by	O
a	O
substantial	O
rise	O
in	O
maximum	O
urethral	O
pressure	O
,	O
maximum	O
urethral	O
closure	O
pressure	O
,	O
and	O
functional	O
urethral	O
length	O
.	O
Patients	O
who	O
present	O
with	O
stress	B-DISEASE
incontinence	I-DISEASE
while	O
taking	O
prazosin	B-CHEMICAL
should	O
change	O
their	O
antihypertensive	O
medication	O
before	O
considering	O
surgery	O
,	O
because	O
their	O
incontinence	B-DISEASE
may	O
resolve	O
spontaneously	O
with	O
a	O
change	O
in	O
drug	O
therapy	O
.	O

Myocardial	B-DISEASE
infarction	I-DISEASE
following	O
sublingual	O
administration	O
of	O
isosorbide	O
dinitrate	O
.	O
A	O
78	O
-	O
year	O
-	O
old	O
with	O
healed	O
septal	O
necrosis	B-DISEASE
suffered	O
a	O
recurrent	O
myocardial	B-DISEASE
infarction	I-DISEASE
of	O
the	O
anterior	O
wall	O
following	O
the	O
administration	O
of	O
isosorbide	O
dinitrate	O
5	O
mg	O
sublingually	O
.	O
After	O
detailing	O
the	O
course	O
of	O
events	O
,	O
we	O
discuss	O
the	O
role	O
of	O
paradoxical	O
coronary	B-DISEASE
spasm	I-DISEASE
and	O
hypotension	B-DISEASE
-	O
mediated	O
myocardial	B-DISEASE
ischemia	I-DISEASE
occurring	O
downstream	O
to	O
significant	O
coronary	B-DISEASE
arterial	I-DISEASE
stenosis	I-DISEASE
in	O
the	O
pathophysiology	O
of	O
acute	B-DISEASE
coronary	I-DISEASE
insufficiency	I-DISEASE
.	O

Fluoxetine	B-CHEMICAL
-	O
induced	O
akathisia	O
:	O
clinical	O
and	O
theoretical	O
implications	O
.	O
Five	O
patients	O
receiving	O
fluoxetine	B-CHEMICAL
for	O
the	O
treatment	O
of	O
obsessive	B-DISEASE
compulsive	I-DISEASE
disorder	I-DISEASE
or	O
major	B-DISEASE
depression	I-DISEASE
developed	O
akathisia	O
.	O
The	O
typical	O
fluoxetine	B-CHEMICAL
-	O
induced	O
symptoms	O
of	O
restlessness	B-DISEASE
,	O
constant	O
pacing	O
,	O
purposeless	O
movements	O
of	O
the	O
feet	O
and	O
legs	O
,	O
and	O
marked	O
anxiety	B-DISEASE
were	O
indistinguishable	O
from	O
those	O
of	O
neuroleptic	O
-	O
induced	O
akathisia	O
.	O
Three	O
patients	O
who	O
had	O
experienced	O
neuroleptic	O
-	O
induced	O
akathisia	O
in	O
the	O
past	O
reported	O
that	O
the	O
symptoms	O
of	O
fluoxetine	B-CHEMICAL
-	O
induced	O
akathisia	O
were	O
identical	O
,	O
although	O
somewhat	O
milder	O
.	O
Akathisia	O
appeared	O
to	O
be	O
a	O
common	O
side	O
effect	O
of	O
fluoxetine	B-CHEMICAL
and	O
generally	O
responded	O
well	O
to	O
treatment	O
with	O
the	O
beta	O
-	O
adrenergic	B-CHEMICAL
antagonist	I-CHEMICAL
propranolol	B-CHEMICAL
,	O
dose	O
reduction	O
,	O
or	O
both	O
.	O
The	O
authors	O
suggest	O
that	O
fluoxetine	B-CHEMICAL
-	O
induced	O
akathisia	O
may	O
be	O
caused	O
by	O
serotonergically	O
mediated	O
inhibition	O
of	O
dopaminergic	O
neurotransmission	O
and	O
that	O
the	O
pathophysiology	O
of	O
fluoxetine	B-CHEMICAL
-	O
induced	O
akathisia	O
and	O
tricyclic	O
antidepressant	O
-	O
induced	O
"	O
jitteriness	O
"	O
may	O
be	O
identical	O
.	O

Chronic	B-DISEASE
active	I-DISEASE
hepatitis	I-DISEASE
associated	O
with	O
diclofenac	B-CHEMICAL
sodium	I-CHEMICAL
therapy	O
.	O
Diclofenac	B-CHEMICAL
sodium	I-CHEMICAL
(	O
Voltarol	O
,	O
Geigy	O
Pharmaceuticals	O
)	O
is	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
derivative	O
of	O
phenylacetic	B-CHEMICAL
acid	I-CHEMICAL
.	O
Although	O
generally	O
well	O
-	O
tolerated	O
,	O
asymptomatic	O
abnormalities	B-DISEASE
of	I-DISEASE
liver	I-DISEASE
function	I-DISEASE
have	O
been	O
recorded	O
and	O
,	O
less	O
commonly	O
,	O
severe	O
hepatitis	B-DISEASE
induced	O
by	O
diclofenac	B-CHEMICAL
.	O
The	O
patient	O
described	O
developed	O
chronic	B-DISEASE
active	I-DISEASE
hepatitis	I-DISEASE
after	O
six	O
months	O
therapy	O
with	O
diclofenac	B-CHEMICAL
sodium	I-CHEMICAL
which	O
progressed	O
despite	O
the	O
withdrawal	O
of	O
the	O
drug	O
,	O
a	O
finding	O
not	O
previously	O
reported	O
.	O

Stroke	B-DISEASE
associated	O
with	O
cocaine	B-CHEMICAL
use	O
.	O
We	O
describe	O
eight	O
patients	O
in	O
whom	O
cocaine	B-CHEMICAL
use	O
was	O
related	O
to	O
stroke	B-DISEASE
and	O
review	O
39	O
cases	O
from	O
the	O
literature	O
.	O
Among	O
these	O
47	O
patients	O
the	O
mean	O
(	O
+	O
/-	O
SD	B-DISEASE
)	O
age	O
was	O
32.5	O
+	O
/-	O
12.1	O
years	O
;	O
76	O
%	O
(	O
34/45	O
)	O
were	O
men	O
.	O
Stroke	B-DISEASE
followed	O
cocaine	B-CHEMICAL
use	O
by	O
inhalation	O
,	O
intranasal	O
,	O
intravenous	O
,	O
and	O
intramuscular	O
routes	O
.	O
Intracranial	B-DISEASE
aneurysms	I-DISEASE
or	O
arteriovenous	B-DISEASE
malformations	I-DISEASE
were	O
present	O
in	O
17	O
of	O
32	O
patients	O
studied	O
angiographically	O
or	O
at	O
autopsy	O
;	O
cerebral	B-DISEASE
vasculitis	I-DISEASE
was	O
present	O
in	O
two	O
patients	O
.	O
Cerebral	B-DISEASE
infarction	I-DISEASE
occurred	O
in	O
10	O
patients	O
(	O
22	O
%	O
)	O
,	O
intracerebral	O
hemorrhage	B-DISEASE
in	O
22	O
(	O
49	O
%	O
)	O
,	O
and	O
subarachnoid	B-DISEASE
hemorrhage	I-DISEASE
in	O
13	O
(	O
29	O
%	O
)	O
.	O
These	O
data	O
indicate	O
that	O
(	O
1	O
)	O
the	O
apparent	O
incidence	O
of	O
stroke	B-DISEASE
related	O
to	O
cocaine	B-CHEMICAL
use	O
is	O
increasing	O
;	O
(	O
2	O
)	O
cocaine	B-CHEMICAL
-	O
associated	O
stroke	B-DISEASE
occurs	O
primarily	O
in	O
young	O
adults	O
;	O
(	O
3	O
)	O
stroke	B-DISEASE
may	O
follow	O
any	O
route	O
of	O
cocaine	B-CHEMICAL
administration	O
;	O
(	O
4	O
)	O
stroke	B-DISEASE
after	O
cocaine	B-CHEMICAL
use	O
is	O
frequently	O
associated	O
with	O
intracranial	B-DISEASE
aneurysms	I-DISEASE
and	O
arteriovenous	B-DISEASE
malformations	I-DISEASE
;	O
and	O
(	O
5	O
)	O
in	O
cocaine	B-CHEMICAL
-	O
associated	O
stroke	B-DISEASE
,	O
the	O
frequency	O
of	O
intracranial	O
hemorrhage	B-DISEASE
exceeds	O
that	O
of	O
cerebral	B-DISEASE
infarction	I-DISEASE
.	O

Glyburide	O
-	O
induced	O
hepatitis	B-DISEASE
.	O
Drug	O
-	O
induced	O
hepatotoxicity	O
,	O
although	O
common	O
,	O
has	O
been	O
reported	O
only	O
infrequently	O
with	O
sulfonylureas	O
.	O
For	O
glyburide	O
,	O
a	O
second	O
-	O
generation	O
sulfonylurea	O
,	O
only	O
two	O
brief	O
reports	O
of	O
hepatotoxicity	O
exist	O
.	O
Two	O
patients	O
with	O
type	O
II	O
diabetes	B-DISEASE
mellitus	I-DISEASE
developed	O
an	O
acute	B-DISEASE
hepatitis	I-DISEASE
-	I-DISEASE
like	I-DISEASE
syndrome	I-DISEASE
soon	O
after	O
initiation	O
of	O
glyburide	O
therapy	O
.	O
There	O
was	O
no	O
serologic	O
evidence	O
of	O
viral	O
infection	B-DISEASE
,	O
and	O
a	O
liver	O
biopsy	O
sample	O
showed	O
a	O
histologic	O
pattern	O
consistent	O
with	O
drug	B-DISEASE
-	I-DISEASE
induced	I-DISEASE
hepatitis	I-DISEASE
.	O
Both	O
patients	O
recovered	O
quickly	O
after	O
stopping	O
glyburide	O
therapy	O
and	O
have	O
remained	O
well	O
for	O
a	O
follow	O
-	O
up	O
period	O
of	O
1	O
year	O
.	O
Glyburide	O
can	O
produce	O
an	O
acute	B-DISEASE
hepatitis	I-DISEASE
-	I-DISEASE
like	I-DISEASE
illness	I-DISEASE
in	O
some	O
persons	O
.	O

Systolic	O
pressure	O
variation	O
is	O
greater	O
during	O
hemorrhage	B-DISEASE
than	O
during	O
sodium	B-CHEMICAL
nitroprusside	I-CHEMICAL
-	O
induced	O
hypotension	B-DISEASE
in	O
ventilated	O
dogs	O
.	O
The	O
systolic	O
pressure	O
variation	O
(	O
SPV	O
)	O
,	O
which	O
is	O
the	O
difference	O
between	O
the	O
maximal	O
and	O
minimal	O
values	O
of	O
the	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
after	O
one	O
positive	O
-	O
pressure	O
breath	O
,	O
was	O
studied	O
in	O
ventilated	O
dogs	O
subjected	O
to	O
hypotension	B-DISEASE
.	O
Mean	O
arterial	O
pressure	O
was	O
decreased	O
to	O
50	O
mm	O
Hg	O
for	O
30	O
minutes	O
either	O
by	O
hemorrhage	B-DISEASE
(	O
HEM	O
,	O
n	O
=	O
7	O
)	O
or	O
by	O
continuous	O
infusion	O
of	O
sodium	B-CHEMICAL
nitroprusside	I-CHEMICAL
(	O
SNP	O
,	O
n	O
=	O
7	O
)	O
.	O
During	O
HEM	O
-	O
induced	O
hypotension	B-DISEASE
the	O
cardiac	O
output	O
was	O
significantly	O
lower	O
and	O
systemic	O
vascular	O
resistance	O
higher	O
compared	O
with	O
that	O
in	O
the	O
SNP	O
group	O
.	O
The	O
systemic	O
,	O
central	O
venous	O
,	O
pulmonary	O
capillary	O
wedge	O
pressures	O
,	O
and	O
heart	O
rates	O
,	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O
Analysis	O
of	O
the	O
respiratory	O
changes	O
in	O
the	O
arterial	O
pressure	O
waveform	O
enabled	O
differentiation	O
between	O
the	O
two	O
groups	O
.	O
The	O
SPV	O
during	O
hypotension	B-DISEASE
was	O
15.7	O
+	O
/-	O
6.7	O
mm	O
Hg	O
in	O
the	O
HEM	O
group	O
,	O
compared	O
with	O
9.1	O
+	O
/-	O
2.0	O
mm	O
Hg	O
in	O
the	O
SNP	O
group	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O
The	O
delta	O
down	O
,	O
which	O
is	O
the	O
measure	O
of	O
decrease	O
of	O
SBP	O
after	O
a	O
mechanical	O
breath	O
,	O
was	O
20.3	O
+	O
/-	O
8.4	O
and	O
10.1	O
+	O
/-	O
3.8	O
mm	O
Hg	O
in	O
the	O
HEM	O
and	O
SNP	O
groups	O
,	O
respectively	O
,	O
during	O
hypotension	B-DISEASE
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O
It	O
is	O
concluded	O
that	O
increases	O
in	O
the	O
SPV	O
and	O
the	O
delta	O
down	O
are	O
characteristic	O
of	O
a	O
hypotensive	B-DISEASE
state	O
due	O
to	O
a	O
predominant	O
decrease	O
in	O
preload	O
.	O
They	O
are	O
thus	O
more	O
important	O
during	O
absolute	O
hypovolemia	B-DISEASE
than	O
during	O
deliberate	O
hypotension	B-DISEASE
.	O

Drug	O
-	O
induced	O
arterial	O
spasm	B-DISEASE
relieved	O
by	O
lidocaine	B-CHEMICAL
.	O
Case	O
report	O
.	O
Following	O
major	O
intracranial	O
surgery	O
in	O
a	O
35	O
-	O
year	O
-	O
old	O
man	O
,	O
sodium	B-CHEMICAL
pentothal	O
was	O
intravenously	O
infused	O
to	O
minimize	O
cerebral	B-DISEASE
ischaemia	I-DISEASE
.	O
Intense	O
vasospasm	B-DISEASE
with	O
threatened	O
gangrene	B-DISEASE
arose	O
in	O
the	O
arm	O
used	O
for	O
the	O
infusion	O
.	O
Since	O
the	O
cranial	O
condition	O
precluded	O
use	O
of	O
more	O
usual	O
methods	O
,	O
lidocaine	B-CHEMICAL
was	O
given	O
intra	O
-	O
arterially	O
,	O
with	O
careful	O
cardiovascular	O
monitoring	O
,	O
to	O
counteract	O
the	O
vasospasm	B-DISEASE
.	O
The	O
treatment	O
was	O
rapidly	O
successful	O
.	O

Cerebral	O
blood	O
flow	O
and	O
metabolism	O
during	O
isoflurane	B-CHEMICAL
-	O
induced	O
hypotension	B-DISEASE
in	O
patients	O
subjected	O
to	O
surgery	O
for	O
cerebral	B-DISEASE
aneurysms	I-DISEASE
.	O
Cerebral	O
blood	O
flow	O
and	O
cerebral	O
metabolic	O
rate	O
for	O
oxygen	B-CHEMICAL
were	O
measured	O
during	O
isoflurane	B-CHEMICAL
-	O
induced	O
hypotension	B-DISEASE
in	O
10	O
patients	O
subjected	O
to	O
craniotomy	O
for	O
clipping	O
of	O
a	O
cerebral	B-DISEASE
aneurysm	I-DISEASE
.	O
Flow	O
and	O
metabolism	O
were	O
measured	O
5	O
-	O
13	O
days	O
after	O
the	O
subarachnoid	O
haemorrhage	O
by	O
a	O
modification	O
of	O
the	O
classical	O
Kety	O
-	O
Schmidt	O
technique	O
using	O
xenon-133	O
i.v	O
.	O
Anaesthesia	O
was	O
maintained	O
with	O
an	O
inspired	O
isoflurane	B-CHEMICAL
concentration	O
of	O
0.75	O
%	O
(	O
plus	O
67	O
%	O
nitrous	O
oxide	O
in	O
oxygen	B-CHEMICAL
)	O
,	O
during	O
which	O
CBF	O
and	O
CMRO2	O
were	O
34.3	O
+	O
/-	O
2.1	O
ml/100	O
g	O
min-1	O
and	O
2.32	O
+	O
/-	O
0.16	O
ml/100	O
g	O
min-1	O
at	O
PaCO2	O
4.1	O
+	O
/-	O
0.1	O
kPa	O
(	O
mean	O
+	O
/-	O
SEM	O
)	O
.	O
Controlled	O
hypotension	B-DISEASE
to	O
an	O
average	O
MAP	O
of	O
50	O
-	O
55	O
mm	O
Hg	O
was	O
induced	O
by	O
increasing	O
the	O
dose	O
of	O
isoflurane	B-CHEMICAL
,	O
and	O
maintained	O
at	O
an	O
inspired	O
concentration	O
of	O
2.2	O
+	O
/-	O
0.2	O
%	O
.	O
This	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
CMRO2	O
(	O
to	O
1.73	O
+	O
/-	O
0.16	O
ml/100	O
g	O
min-1	O
)	O
,	O
while	O
CBF	O
was	O
unchanged	O
.	O
After	O
the	O
clipping	O
of	O
the	O
aneurysm	B-DISEASE
the	O
isoflurane	B-CHEMICAL
concentration	O
was	O
reduced	O
to	O
0.75	O
%	O
.	O
There	O
was	O
a	O
significant	O
increase	O
in	O
CBF	O
,	O
although	O
CMRO2	O
was	O
unchanged	O
,	O
compared	O
with	O
pre	O
-	O
hypotensive	B-DISEASE
values	O
.	O
These	O
changes	O
might	O
offer	O
protection	O
to	O
brain	O
tissue	O
during	O
periods	O
of	O
induced	O
hypotension	B-DISEASE
.	O

Allergic	B-DISEASE
reaction	I-DISEASE
to	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
infusion	O
.	O
An	O
allergic	B-DISEASE
reaction	I-DISEASE
consisting	O
of	O
angioneurotic	B-DISEASE
edema	I-DISEASE
secondary	O
to	O
continuous	O
infusion	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
occurred	O
in	O
a	O
patient	O
with	O
recurrent	O
carcinoma	B-DISEASE
of	I-DISEASE
the	I-DISEASE
oral	I-DISEASE
cavity	I-DISEASE
,	O
cirrhosis	B-DISEASE
,	O
and	O
cisplatin	B-CHEMICAL
-	O
induced	O
impaired	O
renal	O
function	O
.	O
This	O
reaction	O
occurred	O
during	O
the	O
sixth	O
and	O
seventh	O
courses	O
of	O
infusional	O
chemotherapy	O
.	O
Oral	O
diphenhydramine	B-CHEMICAL
and	O
prednisone	B-CHEMICAL
were	O
ineffective	O
in	O
preventing	O
the	O
recurrence	B-DISEASE
of	O
the	O
allergic	B-DISEASE
reaction	I-DISEASE
.	O
Discontinuance	O
of	O
effective	O
chemotherapy	O
in	O
this	O
patient	O
during	O
partial	O
remission	O
resulted	O
in	O
fatal	O
disease	B-DISEASE
progression	I-DISEASE
.	O

Amiodarone	B-CHEMICAL
-	O
induced	O
sinoatrial	B-DISEASE
block	I-DISEASE
.	O
We	O
observed	O
sinoatrial	B-DISEASE
block	I-DISEASE
due	O
to	O
chronic	O
amiodarone	B-CHEMICAL
administration	O
in	O
a	O
5	O
-	O
year	O
-	O
old	O
boy	O
with	O
primary	O
cardiomyopathy	B-DISEASE
,	O
Wolff	B-DISEASE
-	I-DISEASE
Parkinson	I-DISEASE
-	I-DISEASE
White	I-DISEASE
syndrome	I-DISEASE
and	O
supraventricular	B-DISEASE
tachycardia	I-DISEASE
.	O
Reduction	O
in	O
the	O
dosage	O
of	O
amiodarone	B-CHEMICAL
resulted	O
in	O
the	O
disappearance	O
of	O
the	O
sinoatrial	B-DISEASE
block	I-DISEASE
and	O
the	O
persistence	O
of	O
asymptomatic	O
sinus	B-DISEASE
bradycardia	I-DISEASE
.	O

Possible	O
teratogenicity	O
of	O
sulphasalazine	B-CHEMICAL
.	O
Three	O
infants	O
,	O
born	O
of	O
two	O
mothers	O
with	O
inflammatory	O
bowel	O
disease	B-DISEASE
who	O
received	O
treatment	O
with	O
sulphasalazine	B-CHEMICAL
throughout	O
pregnancy	O
,	O
were	O
found	O
to	O
have	O
major	O
congenital	B-DISEASE
anomalies	I-DISEASE
.	O
In	O
the	O
singleton	O
pregnancy	O
,	O
the	O
mother	O
had	O
ulcerative	B-DISEASE
colitis	I-DISEASE
,	O
and	O
the	O
infant	O
,	O
a	O
male	O
,	O
had	O
coarctation	B-DISEASE
of	I-DISEASE
the	I-DISEASE
aorta	I-DISEASE
and	O
a	O
ventricular	O
septal	O
defect	O
.	O
In	O
the	O
twin	O
pregnancy	O
,	O
the	O
mother	O
had	O
Crohn	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
.	O
The	O
first	O
twin	O
,	O
a	O
female	O
,	O
had	O
a	O
left	O
Potter	B-DISEASE
-	I-DISEASE
type	I-DISEASE
IIa	I-DISEASE
polycystic	I-DISEASE
kidney	I-DISEASE
and	O
a	O
rudimentary	O
left	O
uterine	O
cornu	O
.	O
The	O
second	O
twin	O
,	O
a	O
male	O
,	O
had	O
some	O
features	O
of	O
Potter	B-DISEASE
's	I-DISEASE
facies	I-DISEASE
,	O
hypoplastic	O
lungs	O
,	O
absent	B-DISEASE
kidneys	I-DISEASE
and	I-DISEASE
ureters	I-DISEASE
,	O
and	O
talipes	B-DISEASE
equinovarus	O
.	O
Despite	O
reports	O
to	O
the	O
contrary	O
,	O
it	O
is	O
suggested	O
that	O
sulphasalazine	B-CHEMICAL
may	O
be	O
teratogenic	O
.	O

Veno	B-DISEASE
-	I-DISEASE
occlusive	I-DISEASE
liver	I-DISEASE
disease	I-DISEASE
after	O
dacarbazine	O
therapy	O
(	O
DTIC	O
)	O
for	O
melanoma	B-DISEASE
.	O
A	O
case	O
of	O
veno	O
-	O
occlusive	O
disease	B-DISEASE
of	O
the	O
liver	O
with	O
fatal	O
outcome	O
after	O
dacarbazine	O
(	O
DTIC	O
)	O
therapy	O
for	O
melanoma	B-DISEASE
is	O
reported	O
.	O
There	O
was	O
a	O
fulminant	O
clinical	O
course	O
from	O
start	O
of	O
symptoms	O
until	O
death	B-DISEASE
.	O
At	O
autopsy	O
the	O
liver	O
was	O
enlarged	O
and	O
firm	O
with	O
signs	O
of	O
venous	B-DISEASE
congestion	I-DISEASE
.	O
Small-	O
and	O
medium	O
-	O
sized	O
hepatic	O
veins	O
were	O
blocked	O
by	O
thrombosis	B-DISEASE
.	O
Eosinophilic	B-DISEASE
infiltrations	O
were	O
found	O
around	O
the	O
vessels	O
.	O
Published	O
cases	O
from	O
the	O
literature	O
are	O
reviewed	O
and	O
pertinent	O
features	O
discussed	O
.	O

A	O
case	O
of	O
tardive	B-DISEASE
dyskinesia	I-DISEASE
caused	O
by	O
metoclopramide	B-CHEMICAL
.	O
Abnormal	B-DISEASE
involuntary	I-DISEASE
movements	I-DISEASE
appeared	O
in	O
the	O
mouth	O
,	O
tongue	O
,	O
neck	O
and	O
abdomen	O
of	O
a	O
64	O
-	O
year	O
-	O
old	O
male	O
patient	O
after	O
he	O
took	O
metoclopramide	B-CHEMICAL
for	O
gastrointestinal	O
disorder	O
in	O
a	O
regimen	O
of	O
30	O
mg	O
per	O
day	O
for	O
a	O
total	O
of	O
about	O
260	O
days	O
.	O
The	O
symptoms	O
exacerbated	O
to	O
a	O
maximum	O
in	O
a	O
month	O
.	O
When	O
the	O
metoclopramide	B-CHEMICAL
administration	O
was	O
discontinued	O
,	O
the	O
abnormal	B-DISEASE
movements	I-DISEASE
gradually	O
improved	O
to	O
a	O
considerable	O
extent	O
.	O
Attention	O
to	O
the	O
possible	O
induction	O
of	O
specific	O
tardive	B-DISEASE
dyskinesia	I-DISEASE
is	O
called	O
for	O
in	O
the	O
use	O
of	O
this	O
drug	O
.	O

Further	O
observations	O
on	O
the	O
electrophysiologic	O
effects	O
of	O
oral	O
amiodarone	B-CHEMICAL
therapy	O
.	O
A	O
case	O
is	O
presented	O
of	O
a	O
reversible	O
intra	O
-	O
Hisian	O
block	O
occurring	O
under	O
amiodarone	B-CHEMICAL
treatment	O
for	O
atrial	B-DISEASE
tachycardia	I-DISEASE
in	O
a	O
patient	O
without	O
clear	O
intraventricular	O
conduction	O
abnormalities	O
.	O
His	O
bundle	O
recordings	O
showed	O
an	O
atrial	B-DISEASE
tachycardia	I-DISEASE
with	O
intermittent	O
exit	O
block	O
and	O
greatly	O
prolonged	O
BH	O
and	O
HV	O
intervals	O
(	O
40	O
and	O
100	O
msec	O
,	O
respectively	O
)	O
.	O
Thirty	O
days	O
after	O
amiodarone	B-CHEMICAL
discontinuation	O
,	O
His	O
bundle	O
electrograms	O
showed	O
atrial	B-DISEASE
flutter	I-DISEASE
without	O
intra	O
-	O
Hisian	O
or	O
infra	O
-	O
Hisian	O
delay	O
.	O
Amiodarone	B-CHEMICAL
should	O
be	O
used	O
with	O
caution	O
during	O
long	O
-	O
term	O
oral	O
therapy	O
in	O
patients	O
with	O
or	O
without	O
clear	O
intraventricular	O
conduction	O
defects	O
.	O

Busulfan	B-CHEMICAL
-	O
induced	O
hemorrhagic	O
cystitis	B-DISEASE
.	O
A	O
case	O
of	O
a	O
busulfan	B-CHEMICAL
-	O
induced	O
hemorrhage	B-DISEASE
cystitis	B-DISEASE
is	O
reported	O
.	O
Spontaneous	O
resolution	O
occurred	O
following	O
cessation	O
of	O
the	O
drug	O
.	O
The	O
similarity	O
between	O
the	O
histologic	O
appearances	O
of	O
busulfan	B-CHEMICAL
cystitis	B-DISEASE
and	O
both	O
radiation	O
and	O
cyclophosphamide	B-CHEMICAL
-	O
induced	O
cystitis	B-DISEASE
is	O
discussed	O
and	O
the	O
world	O
literature	O
reviewed	O
.	O
In	O
view	O
of	O
the	O
known	O
tendency	O
of	O
busulfan	B-CHEMICAL
to	O
induce	O
cellular	O
atypia	O
and	O
carcinoma	B-DISEASE
in	O
other	O
sites	O
,	O
periodic	O
urinary	O
cytology	O
is	O
suggested	O
in	O
patients	O
on	O
long	O
-	O
term	O
therapy	O
.	O

Rebound	O
hypertensive	B-DISEASE
after	O
sodium	B-CHEMICAL
nitroprusside	I-CHEMICAL
prevented	O
by	O
saralasin	B-CHEMICAL
in	O
rats	O
.	O
The	O
role	O
of	O
the	O
renin	O
--	O
angiotensin	O
system	O
in	O
the	O
maintenance	O
of	O
blood	O
pressure	O
during	O
halothane	B-CHEMICAL
anesthesia	O
and	O
sodium	B-CHEMICAL
nitroprusside	I-CHEMICAL
(	O
SNP)-induced	O
hypotension	B-DISEASE
was	O
evaluated	O
.	O
Control	O
rats	O
received	O
halothane	B-CHEMICAL
anesthesia	O
(	O
1	O
MAC	O
)	O
for	O
one	O
hour	O
,	O
followed	O
by	O
SNP	O
infusion	O
,	O
40	O
microgram	O
/	O
kg	O
/	O
min	O
,	O
for	O
30	O
min	O
,	O
followed	O
by	O
a	O
30	O
-	O
min	O
recovery	O
period	O
.	O
A	O
second	O
group	O
of	O
rats	O
was	O
treated	O
identically	O
and	O
,	O
in	O
addition	O
,	O
received	O
an	O
infusion	O
of	O
saralasin	B-CHEMICAL
(	O
a	O
competitive	O
inhibitor	O
of	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
)	O
throughout	O
the	O
experimental	O
period	O
.	O
In	O
each	O
group	O
,	O
SNP	O
infusion	O
resulted	O
in	O
an	O
initial	O
decrease	O
in	O
blood	O
pressure	O
from	O
86	O
torr	O
and	O
83	O
torr	O
,	O
respectively	O
,	O
to	O
48	O
torr	O
.	O
During	O
the	O
SNP	O
infusion	O
the	O
control	O
animals	O
demonstrated	O
a	O
progressive	O
increase	O
in	O
blood	O
pressure	O
to	O
61	O
torr	O
,	O
whereas	O
the	O
saralasin	B-CHEMICAL
-	O
treated	O
animals	O
showed	O
no	O
change	O
.	O
Following	O
discontinuation	O
of	O
SNP	O
,	O
blood	O
pressure	O
in	O
the	O
control	O
animals	O
rebounded	O
to	O
94	O
torr	O
,	O
as	O
compared	O
with	O
78	O
torr	O
in	O
the	O
saralasin	B-CHEMICAL
-	O
treated	O
rats	O
.	O
This	O
study	O
indicates	O
that	O
with	O
stable	O
halothane	B-CHEMICAL
anesthesia	O
,	O
the	O
partial	O
recovery	O
of	O
blood	O
pressure	O
during	O
SNP	O
infusion	O
and	O
the	O
post	O
-	O
SNP	O
rebound	O
of	O
blood	O
pressure	O
can	O
be	O
completely	O
blocked	O
by	O
saralasin	B-CHEMICAL
.	O
This	O
demonstrates	O
the	O
participation	O
of	O
the	O
renin	O
--	O
angiotensin	O
system	O
in	O
antagonizing	O
the	O
combined	O
hypotensive	B-DISEASE
effects	O
of	O
halothane	B-CHEMICAL
and	O
SNP	O
.	O

Toxic	B-DISEASE
hepatitis	I-DISEASE
induced	O
by	O
antithyroid	B-CHEMICAL
drugs	I-CHEMICAL
:	O
four	O
cases	O
including	O
one	O
with	O
cross	O
-	O
reactivity	O
between	O
carbimazole	O
and	O
benzylthiouracil	O
.	O
OBJECTIVE	O
:	O
This	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
occurrence	O
of	O
hepatic	O
adverse	O
effects	O
encountered	O
with	O
antithyroid	B-CHEMICAL
drugs	I-CHEMICAL
.	O
METHODS	O
:	O
Retrospective	O
review	O
of	O
medical	O
records	O
of	O
236	O
patients	O
with	O
hyperthyroidism	B-DISEASE
admitted	O
in	O
our	O
department	O
(	O
in-	O
or	O
out	O
-	O
patients	O
)	O
from	O
1986	O
to	O
1992	O
.	O
RESULTS	O
:	O
Four	O
patients	O
(	O
1.7	O
%	O
)	O
were	O
identified	O
with	O
toxic	B-DISEASE
hepatitis	I-DISEASE
which	O
could	O
reasonably	O
be	O
attributed	O
to	O
the	O
use	O
of	O
antithyroid	O
agent	O
.	O
Two	O
patients	O
had	O
a	O
cholestatic	B-DISEASE
hepatitis	B-DISEASE
induced	O
by	O
carbimazole	O
(	O
N	O
 	O
omercazole	O
)	O
.	O
Two	O
others	O
had	O
a	O
mixed	O
(	O
cholestatic	B-DISEASE
and	O
cytolytic	O
)	O
hepatitis	B-DISEASE
following	O
carbimazole	O
.	O
One	O
of	O
the	O
latter	O
two	O
patients	O
further	O
experienced	O
a	O
cytolytic	O
hepatitis	B-DISEASE
which	O
appeared	O
after	O
Benzylthiouracil	O
(	O
Basd	O
 	O
ne	O
)	O
had	O
replaced	O
carbimazole	O
.	O
Biological	O
features	O
of	O
hepatitis	B-DISEASE
disappeared	O
in	O
all	O
cases	O
after	O
cessation	O
of	O
the	O
incriminated	O
drug	O
,	O
while	O
biliary	O
,	O
viral	O
and	O
immunological	O
searches	O
were	O
negative	O
.	O
Only	O
2	O
patients	O
of	O
our	O
retrospective	O
study	O
experienced	O
a	O
mild	O
or	O
severe	O
neutropenia	B-DISEASE
.	O
CONCLUSION	O
:	O
Toxic	B-DISEASE
hepatitis	I-DISEASE
is	O
a	O
potential	O
adverse	O
effect	O
of	O
antithyroid	B-CHEMICAL
drugs	I-CHEMICAL
which	O
warrants	O
,	O
as	O
for	O
haematological	O
disturbances	O
,	O
a	O
pre	O
-	O
therapeutic	O
determination	O
and	O
a	O
careful	O
follow	O
-	O
up	O
of	O
relevant	O
biological	O
markers	O
.	O
Moreover	O
,	O
hepatotoxicity	O
may	O
not	O
be	O
restricted	O
to	O
one	O
class	O
of	O
antithyroid	B-CHEMICAL
agents	I-CHEMICAL
.	O

Study	O
of	O
the	O
role	O
of	O
vitamin	B-CHEMICAL
B12	I-CHEMICAL
and	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
supplementation	O
in	O
preventing	O
hematologic	O
toxicity	B-DISEASE
of	O
zidovudine	B-CHEMICAL
.	O
A	O
prospective	O
,	O
randomized	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
role	O
of	O
vitamin	B-CHEMICAL
B12	I-CHEMICAL
and	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
supplementation	O
in	O
preventing	O
zidovudine	B-CHEMICAL
(	O
ZDV)-induced	O
bone	B-DISEASE
marrow	I-DISEASE
suppression	I-DISEASE
.	O
Seventy	O
-	O
five	O
human	O
immunodeficiency	O
virus	O
(	O
HIV)-infected	O
patients	O
with	O
CD4	O
+	O
cell	O
counts	O
<	O
500	O
/	O
mm3	O
were	O
randomized	O
to	O
receive	O
either	O
ZDV	O
(	O
500	O
mg	O
daily	O
)	O
alone	O
(	O
group	O
I	O
,	O
n	O
=	O
38	O
)	O
or	O
in	O
combination	O
with	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
(	O
15	O
mg	O
daily	O
)	O
and	O
intramascular	O
vitamin	B-CHEMICAL
B12	I-CHEMICAL
(	O
1000	O
micrograms	O
monthly	O
)	O
(	O
group	O
II	O
,	O
n	O
=	O
37	O
)	O
.	O
Finally	O
,	O
15	O
patients	O
were	O
excluded	O
from	O
the	O
study	O
(	O
noncompliance	O
14	O
,	O
death	B-DISEASE
1	O
)	O
;	O
thus	O
,	O
60	O
patients	O
(	O
31	O
in	O
group	O
I	O
and	O
29	O
in	O
group	O
II	O
)	O
were	O
eligible	O
for	O
analysis	O
.	O
No	O
significant	O
differences	O
between	O
groups	O
were	O
found	O
at	O
enrollment	O
.	O
During	O
the	O
study	O
,	O
vitamin	B-CHEMICAL
B12	I-CHEMICAL
and	O
folate	O
levels	O
were	O
significantly	O
higher	O
in	O
group	O
II	O
patients	O
;	O
however	O
,	O
no	O
differences	O
in	O
hemoglobin	O
,	O
hematocrit	O
,	O
mean	O
corpuscular	O
volume	O
,	O
and	O
white	O
-	O
cell	O
,	O
neutrophil	O
and	O
platelet	O
counts	O
were	O
observed	O
between	O
groups	O
at	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	O
.	O
Severe	O
hematologic	O
toxicity	B-DISEASE
(	O
neutrophil	O
count	O
<	O
1000	O
/	O
mm3	O
and/or	O
hemoglobin	O
<	O
8	O
g	O
/	O
dl	O
)	O
occurred	O
in	O
4	O
patients	O
assigned	O
to	O
group	O
I	O
and	O
7	O
assigned	O
to	O
group	O
II	O
.	O
There	O
was	O
no	O
correlation	O
between	O
vitamin	B-CHEMICAL
B12	I-CHEMICAL
or	O
folate	O
levels	O
and	O
development	O
of	O
myelosuppression	B-DISEASE
.	O
Vitamin	B-CHEMICAL
B12	I-CHEMICAL
and	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
supplementation	O
of	O
ZDV	O
therapy	O
does	O
not	O
seem	O
useful	O
in	O
preventing	O
or	O
reducing	O
ZDV	O
-	O
induced	O
myelotoxicity	O
in	O
the	O
overall	O
treated	O
population	O
,	O
although	O
a	O
beneficial	O
effect	O
in	O
certain	O
subgroups	O
of	O
patients	O
can	O
not	O
be	O
excluded	O
.	O

Acute	O
confusion	B-DISEASE
induced	O
by	O
a	O
high	O
-	O
dose	O
infusion	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
and	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
.	O
A	O
61	O
-	O
year	O
-	O
old	O
man	O
was	O
treated	O
with	O
combination	O
chemotherapy	O
incorporating	O
cisplatinum	O
,	O
etoposide	B-CHEMICAL
,	O
high	O
-	O
dose	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
(	O
2,250	O
mg	O
/	O
m2/24	O
hours	O
)	O
and	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
for	O
an	O
inoperable	O
gastric	O
adenocarcinoma	B-DISEASE
.	O
He	O
developed	O
acute	O
neurologic	O
symptoms	O
of	O
mental	O
confusion	B-DISEASE
,	O
disorientation	B-DISEASE
and	O
irritability	B-DISEASE
,	O
and	O
then	O
lapsed	O
into	O
a	O
deep	O
coma	B-DISEASE
,	O
lasting	O
for	O
approximately	O
40	O
hours	O
during	O
the	O
first	O
dose	O
(	O
day	O
2	O
)	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
and	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
infusion	O
.	O
This	O
complication	O
reappeared	O
on	O
day	O
25	O
during	O
the	O
second	O
dose	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
and	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
,	O
which	O
were	O
then	O
the	O
only	O
drugs	O
given	O
.	O
Because	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
was	O
unlikely	O
to	O
be	O
associated	O
with	O
this	O
condition	O
,	O
neurotoxicity	B-DISEASE
due	O
to	O
high	O
-	O
dose	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
was	O
highly	O
suspected	O
.	O
The	O
pathogenesis	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
neurotoxicity	B-DISEASE
may	O
be	O
due	O
to	O
a	O
Krebs	O
cycle	O
blockade	O
by	O
fluoroacetate	O
and	O
fluorocitrate	O
,	O
thiamine	B-DISEASE
deficiency	I-DISEASE
,	O
or	O
dihydrouracil	B-CHEMICAL
dehydrogenase	O
deficiency	O
.	O
High	O
-	O
dose	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
/	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
infusion	O
therapy	O
has	O
recently	O
become	O
a	O
popular	O
regimen	O
for	O
various	O
cancers	B-DISEASE
.	O
It	O
is	O
necessary	O
that	O
both	O
oncologists	O
and	O
neurologists	O
be	O
fully	O
aware	O
of	O
this	O
unusual	O
complication	O
.	O

Effect	O
of	O
switching	O
carbamazepine	B-CHEMICAL
to	O
oxcarbazepine	O
on	O
the	O
plasma	O
levels	O
of	O
neuroleptics	B-CHEMICAL
.	O
A	O
case	O
report	O
.	O
Carbamazepine	B-CHEMICAL
was	O
switched	O
to	O
its	O
10	O
-	O
keto	O
analogue	O
oxcarbazepine	O
among	O
six	O
difficult	O
-	O
to	O
-	O
treat	O
schizophrenic	B-DISEASE
or	O
organic	O
psychotic	O
patients	O
using	O
concomitantly	O
haloperidol	B-CHEMICAL
,	O
chlorpromazine	B-CHEMICAL
or	O
clozapine	B-CHEMICAL
.	O
This	O
change	O
resulted	O
within	O
2	O
-	O
4	O
weeks	O
in	O
the	O
50	O
-	O
200	O
%	O
increase	O
in	O
the	O
plasma	O
levels	O
of	O
these	O
neuroleptics	B-CHEMICAL
and	O
the	O
appearance	O
of	O
extrapyramidal	B-DISEASE
symptoms	I-DISEASE
.	O
None	O
of	O
the	O
patients	O
showed	O
any	O
clinical	O
deteriotation	O
during	O
the	O
following	O
3	O
-	O
6	O
months	O
.	O
The	O
results	O
of	O
this	O
case	O
report	O
support	O
the	O
idea	O
that	O
in	O
contrast	O
with	O
carbamazepine	B-CHEMICAL
oxcarbazepine	O
does	O
not	O
induce	O
the	O
hepatic	O
microsomal	O
enzyme	O
systems	O
regulating	O
the	O
inactivation	O
of	O
antipsychotic	B-CHEMICAL
drugs	I-CHEMICAL
.	O

Erythema	B-DISEASE
multiforme	I-DISEASE
and	O
hypersensitivity	B-DISEASE
myocarditis	B-DISEASE
caused	O
by	O
ampicillin	O
.	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
erythema	B-DISEASE
multiforme	I-DISEASE
and	O
hypersensitivity	B-DISEASE
myocarditis	B-DISEASE
caused	O
by	O
ampicillin	O
.	O
CASE	O
SUMMARY	O
:	O
A	O
13	O
-	O
year	O
-	O
old	O
boy	O
was	O
treated	O
with	O
ampicillin	O
and	O
gentamicin	B-CHEMICAL
because	O
of	O
suspected	O
septicemia	O
.	O
Medications	O
were	O
discontinued	O
when	O
erythema	B-DISEASE
multiforme	I-DISEASE
and	O
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
caused	O
by	O
myocarditis	B-DISEASE
occurred	O
.	O
The	O
patient	O
was	O
treated	O
with	O
methylprednisolone	B-CHEMICAL
and	O
gradually	O
improved	O
.	O
Macrophage	O
-	O
migration	O
inhibition	O
(	O
MIF	O
)	O
test	O
with	O
ampicillin	O
was	O
positive	O
.	O
DISCUSSION	O
:	O
After	O
most	O
infections	B-DISEASE
causing	O
erythema	B-DISEASE
multiforme	I-DISEASE
and	O
myocarditis	B-DISEASE
were	O
ruled	O
out	O
,	O
a	O
drug	B-DISEASE
-	I-DISEASE
induced	I-DISEASE
allergic	I-DISEASE
reaction	I-DISEASE
was	O
suspected	O
.	O
Positive	O
MIF	O
test	O
for	O
ampicillin	O
showed	O
sensitization	O
of	O
the	O
patient	O
's	O
lymphocytes	O
to	O
ampicillin	O
.	O
CONCLUSIONS	O
:	O
Hypersensitivity	B-DISEASE
myocarditis	B-DISEASE
is	O
a	O
rare	O
and	O
dangerous	O
manifestation	O
of	O
allergy	B-DISEASE
to	O
penicillins	O
.	O

Immediate	O
allergic	B-DISEASE
reactions	I-DISEASE
to	O
amoxicillin	O
.	O
A	O
large	O
group	O
of	O
patients	O
with	O
suspected	O
allergic	B-DISEASE
reactions	I-DISEASE
to	O
beta	O
-	O
lactam	O
antibiotics	O
was	O
evaluated	O
.	O
A	O
detailed	O
clinical	O
history	O
,	O
together	O
with	O
skin	O
tests	O
,	O
RAST	O
(	O
radioallergosorbent	O
test	O
)	O
,	O
and	O
controlled	O
challenge	O
tests	O
,	O
was	O
used	O
to	O
establish	O
whether	O
patients	O
allergic	B-DISEASE
to	O
beta	O
-	O
lactam	O
antibiotics	O
had	O
selective	O
immediate	O
allergic	B-DISEASE
responses	O
to	O
amoxicillin	O
(	O
AX	B-CHEMICAL
)	O
or	O
were	O
cross	O
-	O
reacting	O
with	O
other	O
penicillin	B-CHEMICAL
derivatives	O
.	O
Skin	O
tests	O
were	O
performed	O
with	O
benzylpenicilloyl	O
-	O
poly	O
-	O
L	O
-	O
lysine	O
(	O
BPO	O
-	O
PLL	O
)	O
,	O
benzylpenicilloate	O
,	O
benzylpenicillin	O
(	O
PG	O
)	O
,	O
ampicillin	O
(	O
AMP	B-CHEMICAL
)	O
,	O
and	O
AX	B-CHEMICAL
.	O
RAST	O
for	O
BPO	O
-	O
PLL	O
and	O
AX	B-CHEMICAL
-	O
PLL	O
was	O
done	O
.	O
When	O
both	O
skin	O
test	O
and	O
RAST	O
for	O
BPO	O
were	O
negative	O
,	O
single	O
-	O
blind	B-DISEASE
,	O
placebo	O
-	O
controlled	O
challenge	O
tests	O
were	O
done	O
to	O
ensure	O
tolerance	O
of	O
PG	O
or	O
sensitivity	O
to	O
AX	B-CHEMICAL
.	O
A	O
total	O
of	O
177	O
patients	O
were	O
diagnosed	O
as	O
allergic	B-DISEASE
to	O
beta	O
-	O
lactam	O
antibiotics	O
.	O
We	O
selected	O
the	O
54	O
(	O
30.5	O
%	O
)	O
cases	O
of	O
immediate	O
AX	B-CHEMICAL
allergy	B-DISEASE
with	O
good	O
tolerance	O
of	O
PG	O
.	O
Anaphylaxis	B-DISEASE
was	O
seen	O
in	O
37	O
patients	O
(	O
69	O
%	O
)	O
,	O
the	O
other	O
17	O
(	O
31	O
%	O
)	O
having	O
urticaria	B-DISEASE
and/or	O
angioedema	B-DISEASE
.	O
All	O
the	O
patients	O
were	O
skin	O
test	O
negative	O
to	O
BPO	O
;	O
49	O
of	O
51	O
(	O
96	O
%	O
)	O
were	O
also	O
negative	O
to	O
MDM	O
,	O
and	O
44	O
of	O
46	O
(	O
96	O
%	O
)	O
to	O
PG	O
.	O
Skin	O
tests	O
with	O
AX	B-CHEMICAL
were	O
positive	O
in	O
34	O
(	O
63	O
%	O
)	O
patients	O
.	O
RAST	O
was	O
positive	O
for	O
AX	B-CHEMICAL
in	O
22	O
patients	O
(	O
41	O
%	O
)	O
and	O
to	O
BPO	O
in	O
just	O
5	O
(	O
9	O
%	O
)	O
.	O
None	O
of	O
the	O
sera	O
with	O
negative	O
RAST	O
for	O
AX	B-CHEMICAL
were	O
positive	O
to	O
BPO	O
.	O
Challenge	O
tests	O
with	O
AX	B-CHEMICAL
were	O
performed	O
in	O
23	O
subjects	O
(	O
43	O
%	O
)	O
to	O
establish	O
the	O
diagnosis	O
of	O
immediate	O
allergic	B-DISEASE
reaction	I-DISEASE
to	O
AX	B-CHEMICAL
,	O
and	O
in	O
15	O
cases	O
(	O
28	O
%	O
)	O
both	O
skin	O
test	O
and	O
RAST	O
for	O
AX	B-CHEMICAL
were	O
negative	O
.	O
PG	O
was	O
well	O
tolerated	O
by	O
all	O
54	O
patients	O
.	O
We	O
describe	O
the	O
largest	O
group	O
of	O
AX	B-CHEMICAL
-	O
allergic	B-DISEASE
patients	O
who	O
have	O
tolerated	O
PG	O
reported	O
so	O
far	O
.	O
Diagnosis	O
of	O
these	O
patients	O
can	O
be	O
achieved	O
only	O
if	O
specific	O
AX	B-CHEMICAL
-	O
related	O
reagents	O
are	O
employed	O
.	O
Further	O
studies	O
are	O
necessary	O
to	O
determine	O
the	O
exact	O
extent	O
of	O
this	O
problem	O
and	O
to	O
improve	O
the	O
efficacy	O
of	O
diagnostic	O
methods	O
.	O

Persistent	O
paralysis	B-DISEASE
after	O
prolonged	O
use	O
of	O
atracurium	B-CHEMICAL
in	O
the	O
absence	O
of	O
corticosteroids	B-CHEMICAL
.	O
Neuromuscular	O
blocking	O
agents	O
(	O
NMBAs	O
)	O
are	O
often	O
used	O
for	O
patients	O
requiring	O
prolonged	O
mechanical	O
ventilation	O
.	O
Reports	O
of	O
persistent	O
paralysis	B-DISEASE
after	O
the	O
discontinuance	O
of	O
these	O
drugs	O
have	O
most	O
often	O
involved	O
aminosteroid	O
-	O
based	O
NMBAs	O
such	O
as	O
vecuronium	O
bromide	O
,	O
especially	O
when	O
used	O
in	O
conjunction	O
with	O
corticosteroids	B-CHEMICAL
.	O
Atracurium	B-CHEMICAL
besylate	O
,	O
a	O
short	O
-	O
acting	O
benzylisoquinolinium	O
NMBA	O
that	O
is	O
eliminated	O
independently	O
of	O
renal	O
or	O
hepatic	O
function	O
,	O
has	O
also	O
been	O
associated	O
with	O
persistent	O
paralysis	B-DISEASE
,	O
but	O
only	O
when	O
used	O
with	O
corticosteroids	B-CHEMICAL
.	O
We	O
report	O
a	O
case	O
of	O
atracurium	B-CHEMICAL
-	O
related	O
paralysis	B-DISEASE
persisting	O
for	O
approximately	O
50	O
hours	O
in	O
a	O
patient	O
who	O
was	O
not	O
treated	O
with	O
corticosteroids	B-CHEMICAL
.	O

Habitual	O
use	O
of	O
acetaminophen	B-CHEMICAL
as	O
a	O
risk	O
factor	O
for	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
:	O
a	O
comparison	O
with	O
phenacetin	B-CHEMICAL
.	O
Six	O
epidemiologic	O
studies	O
in	O
the	O
United	O
States	O
and	O
Europe	O
indicate	O
that	O
habitual	O
use	O
of	O
phenacetin	B-CHEMICAL
is	O
associated	O
with	O
the	O
development	O
of	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
and	O
end	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
renal	I-DISEASE
disease	I-DISEASE
(	O
ESRD	B-DISEASE
)	O
,	O
with	O
a	O
relative	O
risk	O
in	O
the	O
range	O
of	O
4	O
to	O
19	O
.	O
As	O
a	O
result	O
of	O
these	O
and	O
other	O
studies	O
,	O
phenacetin	B-CHEMICAL
has	O
now	O
been	O
withdrawn	O
from	O
the	O
market	O
in	O
most	O
countries	O
.	O
However	O
,	O
three	O
case	O
control	O
studies	O
,	O
one	O
each	O
in	O
North	O
Carolina	O
,	O
northern	O
Maryland	O
,	O
and	O
West	O
Berlin	O
,	O
Germany	O
,	O
showed	O
that	O
habitual	O
use	O
of	O
acetaminophen	B-CHEMICAL
is	O
also	O
associated	O
with	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
and	O
ESRD	B-DISEASE
,	O
with	O
a	O
relative	O
risk	O
in	O
the	O
range	O
of	O
2	O
to	O
4	O
.	O
These	O
studies	O
suggest	O
that	O
both	O
phenacetin	B-CHEMICAL
and	O
acetaminophen	B-CHEMICAL
may	O
contribute	O
to	O
the	O
burden	O
of	O
ESRD	B-DISEASE
,	O
with	O
the	O
risk	O
of	O
the	O
latter	O
being	O
somewhat	O
less	O
than	O
that	O
of	O
the	O
former	O
.	O
This	O
apparent	O
difference	O
in	O
risk	O
may	O
not	O
be	O
due	O
to	O
differences	O
in	O
nephrotoxic	B-DISEASE
potential	O
of	O
the	O
drugs	O
themselves	O
.	O
A	O
lower	O
relative	O
risk	O
would	O
be	O
expected	O
for	O
acetaminophen	B-CHEMICAL
if	O
the	O
risk	O
of	O
both	O
drugs	O
in	O
combination	O
with	O
other	O
analgesics	O
was	O
higher	O
than	O
the	O
risk	O
of	O
either	O
agent	O
alone	O
.	O
Thus	O
,	O
acetaminophen	B-CHEMICAL
has	O
been	O
used	O
both	O
as	O
a	O
single	O
agent	O
and	O
in	O
combination	O
with	O
other	O
analgesics	O
,	O
whereas	O
phenacetin	B-CHEMICAL
was	O
available	O
only	O
in	O
combinations	O
.	O
The	O
possibility	O
that	O
habitual	O
use	O
of	O
acetaminophen	B-CHEMICAL
alone	O
increases	O
the	O
risk	O
of	O
ESRD	B-DISEASE
has	O
not	O
been	O
clearly	O
demonstrated	O
,	O
but	O
can	O
not	O
be	O
dismissed	O
.	O

Reduction	O
of	O
heparan	O
sulphate	O
-	O
associated	O
anionic	O
sites	O
in	O
the	O
glomerular	O
basement	O
membrane	O
of	O
rats	O
with	O
streptozotocin	B-CHEMICAL
-	O
induced	O
diabetic	B-DISEASE
nephropathy	I-DISEASE
.	O
Heparan	O
sulphate	O
-	O
associated	O
anionic	O
sites	O
in	O
the	O
glomerular	O
basement	O
membrane	O
were	O
studied	O
in	O
rats	O
8	O
months	O
after	O
induction	O
of	O
diabetes	B-DISEASE
by	O
streptozotocin	B-CHEMICAL
and	O
in	O
age-	O
adn	O
sex	O
-	O
matched	O
control	O
rats	O
,	O
employing	O
the	O
cationic	O
dye	O
cuprolinic	O
blue	O
.	O
Morphometric	O
analysis	O
at	O
the	O
ultrastructural	O
level	O
was	O
performed	O
using	O
a	O
computerized	O
image	O
processor	O
.	O
The	O
heparan	O
sulphate	O
specificity	O
of	O
the	O
cuprolinic	O
blue	O
staining	O
was	O
demonstrated	O
by	O
glycosaminoglycan	O
-	O
degrading	O
enzymes	O
,	O
showing	O
that	O
pretreatment	O
of	O
the	O
sections	O
with	O
heparitinase	O
abolished	O
all	O
staining	O
,	O
whereas	O
chondroitinase	O
ABC	O
had	O
no	O
effect	O
.	O
The	O
majority	O
of	O
anionic	O
sites	O
(	O
74	O
%	O
in	O
diabetic	B-DISEASE
and	O
81	O
%	O
in	O
control	O
rats	O
)	O
were	O
found	O
within	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
.	O
A	O
minority	O
of	O
anionic	O
sites	O
were	O
scattered	O
throughout	O
the	O
lamina	O
densa	O
and	O
lamina	O
rara	O
interna	O
,	O
and	O
were	O
significantly	O
smaller	O
than	O
those	O
in	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
(	O
p<0.001	O
and	O
p<0.01	O
for	O
diabetic	B-DISEASE
and	O
control	O
rats	O
,	O
respectively	O
)	O
.	O
Diabetic	B-DISEASE
rats	O
progressively	O
developed	O
albuminuria	B-DISEASE
reaching	O
40.3	O
(	O
32.2	O
-	O
62.0	O
)	O
mg/24	O
h	O
after	O
8	O
months	O
in	O
contrast	O
to	O
the	O
control	O
animals	O
(	O
0.8	O
(	O
0.2	O
-	O
0.9	O
)	O
mg/24	O
h	O
,	O
p<0.002	O
)	O
.	O
At	O
the	O
same	O
time	O
,	O
the	O
number	O
of	O
heparan	O
sulphate	O
anionic	O
sites	O
and	O
the	O
total	O
anionic	O
site	O
surface	O
(	O
number	O
of	O
anionic	O
sites	O
x	O
mean	O
anionic	O
site	O
surface	O
)	O
in	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
was	O
reduced	O
by	O
19	O
%	O
(	O
p<0.021	O
)	O
and	O
by	O
26	O
%	O
(	O
p<0.02	O
)	O
,	O
respectively	O
.	O
Number	O
and	O
total	O
anionic	O
site	O
surface	O
in	O
the	O
remaining	O
part	O
of	O
the	O
glomerular	O
basement	O
membrane	O
(	O
lamina	O
densa	O
and	O
lamina	O
rara	O
interna	O
)	O
were	O
not	O
significantly	O
changed	O
.	O
We	O
conclude	O
that	O
in	O
streptozotocin	B-CHEMICAL
-	O
diabetic	B-DISEASE
rats	O
with	O
an	O
increased	O
urinary	O
albumin	O
excretion	O
,	O
a	O
reduced	O
heparan	O
sulphate	O
charge	O
barrier	O
/	O
density	O
is	O
found	O
at	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
.	O

Effect	O
of	O
some	O
anticancer	O
drugs	O
and	O
combined	O
chemotherapy	O
on	O
renal	B-DISEASE
toxicity	I-DISEASE
.	O
The	O
nephrotoxic	B-DISEASE
action	O
of	O
anticancer	O
drugs	O
such	O
as	O
nitrogranulogen	O
(	O
NG	O
)	O
,	O
methotrexate	B-CHEMICAL
(	O
MTX	O
)	O
,	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
)	O
and	O
cyclophosphamide	B-CHEMICAL
(	O
CY	B-CHEMICAL
)	O
administered	O
alone	O
or	O
in	O
combination	O
[	O
MTX	O
+	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
+	O
CY	B-CHEMICAL
(	O
CMF	O
)	O
]	O
was	O
evaluated	O
in	O
experiments	O
on	O
Wistar	O
rats	O
.	O
After	O
drug	O
administration	O
,	O
creatinine	B-CHEMICAL
concentrations	O
in	O
the	O
plasma	O
and	O
in	O
the	O
urine	O
of	O
the	O
rats	O
were	O
determined	O
,	O
as	O
well	O
as	O
creatinine	B-CHEMICAL
clearance	O
.	O
Histopathologic	O
evaluation	O
of	O
the	O
kidneys	O
was	O
also	O
performed	O
.	O
After	O
MTX	O
administration	O
a	O
significant	O
increase	O
(	O
p	O
=	O
0.0228	O
)	O
in	O
the	O
plasma	O
creatinine	B-CHEMICAL
concentration	O
and	O
a	O
significant	O
(	O
p	O
=	O
0.0001	O
)	O
decrease	O
in	O
creatinine	B-CHEMICAL
clearance	O
was	O
noted	O
compared	O
to	O
controls	O
.	O
After	O
the	O
administration	O
of	O
NG	O
,	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
and	O
CY	B-CHEMICAL
neither	O
a	O
statistically	O
significant	O
increase	O
in	O
creatinine	B-CHEMICAL
concentration	O
nor	O
an	O
increase	O
in	O
creatinine	B-CHEMICAL
clearance	O
was	O
observed	O
compared	O
to	O
the	O
group	O
receiving	O
no	O
cytostatics	O
.	O
Following	O
polytherapy	O
according	O
to	O
the	O
CMF	B-CHEMICAL
regimen	I-CHEMICAL
,	O
a	O
statistically	O
significant	O
decrease	O
(	O
p	O
=	O
0.0343	O
)	O
in	O
creatinine	B-CHEMICAL
clearance	O
was	O
found	O
,	O
but	O
creatinine	B-CHEMICAL
concentration	O
did	O
not	O
increase	O
significantly	O
compared	O
to	O
controls	O
.	O
CY	B-CHEMICAL
caused	O
hemorrhagic	O
cystitis	B-DISEASE
in	O
40	O
%	O
of	O
rats	O
,	O
but	O
it	O
did	O
not	O
cause	O
this	O
complication	O
when	O
combined	O
with	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
and	O
MTX	O
.	O
Histologic	O
changes	O
were	O
found	O
in	O
rat	O
kidneys	O
after	O
administration	O
of	O
MTX	O
,	O
CY	B-CHEMICAL
and	O
NG	O
,	O
while	O
no	O
such	O
change	O
was	O
observed	O
after	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
and	O
joint	O
administration	O
of	O
MTX	O
+	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
+	O
CY	B-CHEMICAL
compared	O
to	O
controls	O
.	O
Our	O
studies	O
indicate	O
that	O
nephrotoxicity	B-DISEASE
of	O
MTX	O
+	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
+	O
CY	B-CHEMICAL
administered	O
jointly	O
is	O
lower	O
than	O
in	O
monotherapy	O
.	O

Lithium	B-CHEMICAL
-	O
associated	O
cognitive	B-DISEASE
and	I-DISEASE
functional	I-DISEASE
deficits	I-DISEASE
reduced	O
by	O
a	O
switch	O
to	O
divalproex	O
sodium	B-CHEMICAL
:	O
a	O
case	O
series	O
.	O
BACKGROUND	O
:	O
Lithium	B-CHEMICAL
remains	O
a	O
first	O
-	O
line	O
treatment	O
for	O
the	O
acute	O
and	O
maintenance	O
treatment	O
of	O
bipolar	B-DISEASE
disorder	I-DISEASE
.	O
Although	O
much	O
has	O
been	O
written	O
about	O
the	O
management	O
of	O
the	O
more	O
common	O
adverse	O
effects	O
of	O
lithium	B-CHEMICAL
,	O
such	O
as	O
polyuria	B-DISEASE
and	O
tremor	B-DISEASE
,	O
more	O
subtle	O
lithium	B-CHEMICAL
side	O
effects	O
such	O
as	O
cognitive	B-DISEASE
deficits	I-DISEASE
,	O
loss	O
of	O
creativity	O
,	O
and	O
functional	O
impairments	O
remain	O
understudied	O
.	O
This	O
report	O
summarizes	O
our	O
experience	O
in	O
switching	O
bipolar	B-DISEASE
patients	O
from	O
lithium	B-CHEMICAL
to	O
divalproex	O
sodium	B-CHEMICAL
to	O
alleviate	O
such	O
cognitive	B-DISEASE
and	I-DISEASE
functional	I-DISEASE
impairments	I-DISEASE
.	O
METHOD	O
:	O
Open	O
,	O
case	O
series	O
design	O
.	O
RESULTS	O
:	O
We	O
report	O
seven	O
cases	O
where	O
substitution	O
of	O
lithium	B-CHEMICAL
,	O
either	O
fully	O
or	O
partially	O
,	O
with	O
divalproex	O
sodium	B-CHEMICAL
was	O
extremely	O
helpful	O
in	O
reducing	O
the	O
cognitive	B-DISEASE
,	I-DISEASE
motivational	I-DISEASE
,	I-DISEASE
or	I-DISEASE
creative	I-DISEASE
deficits	I-DISEASE
attributed	O
to	O
lithium	B-CHEMICAL
in	O
our	O
bipolar	B-DISEASE
patients	O
.	O
CONCLUSION	O
:	O
In	O
this	O
preliminary	O
report	O
,	O
divalproex	O
sodium	B-CHEMICAL
was	O
a	O
superior	O
alternative	O
to	O
lithium	B-CHEMICAL
in	O
bipolar	B-DISEASE
patients	O
experiencing	O
cognitive	B-DISEASE
deficits	I-DISEASE
,	O
loss	O
of	O
creativity	O
,	O
and	O
functional	O
impairments	O
.	O

Treatment	O
of	O
previously	O
treated	O
metastatic	O
breast	B-DISEASE
cancer	I-DISEASE
by	O
mitoxantrone	B-CHEMICAL
and	O
48	O
-	O
hour	O
continuous	O
infusion	O
of	O
high	O
-	O
dose	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
and	O
leucovorin	O
(	O
MFL	O
):	O
low	O
palliative	O
benefit	O
and	O
high	O
treatment	O
-	O
related	O
toxicity	B-DISEASE
.	O
For	O
previously	O
treated	O
advanced	O
breast	B-DISEASE
cancer	I-DISEASE
,	O
there	O
is	O
no	O
standard	O
second	O
-	O
line	O
therapy	O
.	O
Combination	O
chemotherapy	O
with	O
mitoxantrone	B-CHEMICAL
,	O
high	O
-	O
dose	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
)	O
and	O
leucovorin	O
(	O
MFL	O
regimen	O
)	O
had	O
been	O
reported	O
as	O
an	O
effective	O
and	O
well	O
tolerated	O
regimen	O
.	O
From	O
October	O
1993	O
to	O
November	O
1995	O
,	O
we	O
treated	O
13	O
patients	O
with	O
previously	O
chemotherapy	O
-	O
treated	O
metastatic	O
breast	B-DISEASE
cancer	I-DISEASE
by	O
mitoxantrone	B-CHEMICAL
,	O
12	O
mg	O
/	O
m2	O
,	O
on	O
day	O
1	O
and	O
continuous	O
infusion	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
,	O
3000	O
mg	O
/	O
m2	O
,	O
together	O
with	O
leucovorin	O
,	O
300	O
mg	O
/	O
m2	O
,	O
for	O
48	O
h	O
from	O
day	O
1	O
to	O
2	O
.	O
Each	O
course	O
of	O
chemotherapy	O
was	O
given	O
every	O
4	O
weeks	O
.	O
Most	O
of	O
these	O
patients	O
had	O
more	O
than	O
two	O
metastatic	O
sites	O
,	O
with	O
lung	O
metastasis	O
predominant	O
.	O
Seven	O
patients	O
had	O
been	O
treated	O
with	O
anthracycline	O
.	O
Seven	O
patients	O
had	O
previously	O
received	O
radiotherapy	O
and	O
seven	O
had	O
received	O
hormone	O
therapy	O
.	O
Median	O
number	O
of	O
courses	O
of	O
MFL	O
regimen	O
given	O
was	O
six	O
and	O
the	O
median	O
cumulative	O
dose	O
of	O
mitoxantrone	B-CHEMICAL
was	O
68.35	O
mg	O
/	O
m2	O
.	O
One	O
patient	O
had	O
complete	O
response	O
,	O
seven	O
had	O
stable	O
disease	B-DISEASE
,	O
none	O
had	O
partial	O
response	O
and	O
five	O
had	O
progressive	O
disease	B-DISEASE
.	O
The	O
overall	O
objective	O
response	O
rate	O
was	O
7.6	O
%	O
.	O
The	O
median	O
follow	O
-	O
up	O
period	O
was	O
14	O
months	O
.	O
Median	O
survival	O
was	O
16	O
months	O
.	O
Median	O
progression	O
-	O
free	O
survival	O
was	O
5	O
months	O
.	O
A	O
complete	O
responder	O
had	O
relapse	O
-	O
free	O
survival	O
up	O
to	O
17	O
months	O
.	O
Major	O
toxicities	B-DISEASE
were	O
cardiotoxicity	B-DISEASE
and	O
leukopenia	B-DISEASE
.	O
Eight	O
patients	O
were	O
dead	O
in	O
the	O
last	O
follow	O
-	O
up	O
;	O
two	O
of	O
them	O
died	O
of	O
treatment	O
-	O
related	O
toxicity	B-DISEASE
.	O
The	O
MFL	O
regimen	O
achieves	O
little	O
palliative	O
benefit	O
and	O
induces	O
severe	O
toxicity	B-DISEASE
at	O
a	O
fairly	O
high	O
rate	O
.	O
Administration	O
of	O
this	O
regimen	O
to	O
breast	B-DISEASE
cancer	I-DISEASE
patients	O
who	O
have	O
been	O
treated	O
by	O
chemotherapy	O
and	O
those	O
with	O
impaired	O
heart	O
function	O
requires	O
careful	O
attention	O
.	O

Upregulation	O
of	O
the	O
expression	O
of	O
vasopressin	B-CHEMICAL
gene	O
in	O
the	O
paraventricular	O
and	O
supraoptic	O
nuclei	O
of	O
the	O
lithium	B-CHEMICAL
-	O
induced	O
diabetes	B-DISEASE
insipidus	I-DISEASE
rat	O
.	O
The	O
expression	O
of	O
arginine	B-CHEMICAL
vasopressin	I-CHEMICAL
(	O
AVP	B-CHEMICAL
)	O
gene	O
in	O
the	O
paraventricular	O
(	O
PVN	O
)	O
and	O
supraoptic	O
nuclei	O
(	O
SON	O
)	O
was	O
investigated	O
in	O
rats	O
with	O
lithium	B-CHEMICAL
(	O
Li)-induced	O
polyuria	B-DISEASE
,	O
using	O
in	O
situ	O
hybridization	O
histochemistry	O
and	O
radioimmunoassay	O
.	O
The	O
male	O
Wistar	O
rats	O
consuming	O
a	O
diet	O
that	O
contained	O
LiCl	O
(	O
60	O
mmol	O
/	O
kg	O
)	O
for	O
4	O
weeks	O
developed	O
marked	O
polyuria	B-DISEASE
.	O
The	O
Li	O
-	O
treated	O
rats	O
produced	O
a	O
large	O
volume	O
of	O
hypotonic	O
urine	O
with	O
low	O
ionic	O
concentrations	O
.	O
Plasma	O
sodium	B-CHEMICAL
concentrations	O
were	O
found	O
to	O
be	O
slightly	O
increased	O
in	O
the	O
Li	O
-	O
treated	O
rats	O
compared	O
with	O
those	O
in	O
controls	O
.	O
Plasma	O
concentration	O
of	O
AVP	B-CHEMICAL
and	O
transcripts	O
of	O
AVP	B-CHEMICAL
gene	O
in	O
the	O
PVN	O
and	O
SON	O
were	O
significantly	O
increased	O
in	O
the	O
Li	O
-	O
treated	O
rats	O
compared	O
with	O
controls	O
.	O
These	O
results	O
suggest	O
that	O
dehydration	B-DISEASE
and/or	O
the	O
activation	O
of	O
visceral	O
afferent	O
inputs	O
may	O
contribute	O
to	O
the	O
elevation	O
of	O
plasma	O
AVP	B-CHEMICAL
and	O
the	O
upregulation	O
of	O
AVP	B-CHEMICAL
gene	O
expression	O
in	O
the	O
PVN	O
and	O
the	O
SON	O
of	O
the	O
Li	O
-	O
induced	O
diabetes	B-DISEASE
insipidus	I-DISEASE
rat	O
.	O

Suxamethonium	B-CHEMICAL
-	O
induced	O
cardiac	B-DISEASE
arrest	I-DISEASE
and	O
death	B-DISEASE
following	O
5	O
days	O
of	O
immobilization	O
.	O
The	O
present	O
report	O
describes	O
a	O
case	O
of	O
cardiac	B-DISEASE
arrest	I-DISEASE
and	O
subsequent	O
death	B-DISEASE
as	O
a	O
result	O
of	O
hyperkalaemia	O
following	O
the	O
use	O
of	O
suxamethonium	B-CHEMICAL
in	O
a	O
23	O
-	O
year	O
-	O
old	O
Malawian	O
woman	O
.	O
Five	O
days	O
after	O
the	O
onset	O
of	O
the	O
symptoms	O
of	O
meningitis	B-DISEASE
,	O
the	O
patient	O
aspirated	O
stomach	O
contents	O
and	O
needed	O
endotracheal	O
intubation	O
.	O
Forty	O
seconds	O
after	O
injection	O
of	O
suxamethonium	B-CHEMICAL
,	O
bradycardia	B-DISEASE
and	O
cardiac	B-DISEASE
arrest	I-DISEASE
occurred	O
.	O
Attempts	O
to	O
resuscitate	O
the	O
patient	O
were	O
not	O
successful	O
.	O
The	O
serum	O
level	O
of	O
potassium	B-CHEMICAL
was	O
observed	O
to	O
be	O
8.4	O
mequiv	O
L-1	O
.	O
Apart	O
from	O
the	O
reduction	O
in	O
the	O
patient	O
's	O
level	O
of	O
consciousness	O
,	O
there	O
were	O
no	O
signs	O
of	O
motor	O
neurone	O
damage	O
or	O
of	O
any	O
of	O
the	O
other	O
known	O
predisposing	O
conditions	O
for	O
hyperkalaemia	O
following	O
the	O
administration	O
of	O
suxamethonium	B-CHEMICAL
.	O
It	O
is	O
postulated	O
that	O
her	O
death	B-DISEASE
was	O
caused	O
by	O
hypersensitivity	B-DISEASE
to	O
suxamethonium	B-CHEMICAL
,	O
associated	O
with	O
her	O
5	O
-	O
day	O
immobilization	O
.	O

An	O
unusual	O
toxic	O
reaction	O
to	O
axillary	O
block	O
by	O
mepivacaine	O
with	O
adrenaline	B-CHEMICAL
.	O
An	O
increase	O
in	O
blood	O
pressure	O
,	O
accompanied	O
by	O
atrial	B-DISEASE
fibrillation	I-DISEASE
,	O
agitation	B-DISEASE
,	O
incomprehensible	O
shouts	O
and	O
loss	O
of	O
consciousness	O
,	O
was	O
observed	O
in	O
an	O
elderly	O
,	O
ASA	B-CHEMICAL
classification	O
group	O
II	O
,	O
cardiovascularly	O
medicated	O
male	O
,	O
12	O
min	O
after	O
performance	O
of	O
axillary	O
block	O
with	O
mepivacaine	O
850	O
mg	O
containing	O
adrenaline	B-CHEMICAL
0.225	O
mg	O
,	O
for	O
correction	O
of	O
Dupuytren	O
's	O
contracture	B-DISEASE
.	O
After	O
intravenous	O
administration	O
of	O
labetalol	B-CHEMICAL
,	O
metoprolol	B-CHEMICAL
and	O
midazolam	B-CHEMICAL
the	O
patient	O
's	O
condition	O
improved	O
,	O
and	O
15	O
min	O
later	O
he	O
woke	O
up	O
.	O
The	O
block	O
was	O
successful	O
and	O
surgery	O
was	O
conducted	O
as	O
scheduled	O
despite	O
persisting	O
atrial	B-DISEASE
fibrillation	I-DISEASE
.	O
Postoperatively	O
,	O
the	O
patient	O
refused	O
DC	O
cardioversion	O
and	O
was	O
treated	O
medically	O
.	O
Both	O
the	O
temporal	O
relationship	O
of	O
events	O
and	O
the	O
response	O
to	O
treatment	O
suggest	O
that	O
a	O
rapid	O
systemic	O
absorption	O
of	O
mepivacaine	O
with	O
adrenaline	B-CHEMICAL
and/or	O
interaction	O
of	O
these	O
drugs	O
with	O
the	O
patient	O
's	O
cardiovascular	O
medications	O
were	O
responsible	O
for	O
the	O
perioperative	O
complications	B-DISEASE
.	O

Clinical	O
and	O
histopathologic	O
examination	O
of	O
renal	O
allografts	O
treated	O
with	O
tacrolimus	B-CHEMICAL
(	O
FK506	O
)	O
for	O
at	O
least	O
one	O
year	O
.	O
BACKGROUND	O
:	O
We	O
clinically	O
and	O
pathologically	O
analyzed	O
renal	O
allografts	O
from	O
1	O
9	O
renal	O
transplant	O
patients	O
treated	O
with	O
tacrolimus	B-CHEMICAL
(	O
FK506	O
)	O
for	O
more	O
than	O
1	O
year	O
.	O
METHODS	O
:	O
Twenty	O
-	O
six	O
renal	O
allograft	O
biopsy	O
specimens	O
from	O
1	O
9	O
renal	O
transplant	O
patients	O
who	O
underwent	O
transplantations	O
between	O
1991	O
and	O
1993	O
were	O
evaluated	O
.	O
Thirteen	O
biopsies	O
were	O
performed	O
from	O
stable	O
functioning	O
renal	O
allografts	O
with	O
informed	O
consent	O
(	O
nonepisode	O
biopsy	O
)	O
and	O
the	O
other	O
13	O
were	O
from	O
dysfunctional	O
renal	O
allografts	O
with	O
a	O
clinical	O
indication	O
for	O
biopsy	O
(	O
episode	O
biopsy	O
)	O
.	O
RESULTS	O
:	O
The	O
main	O
pathologic	O
diagnoses	O
(	O
some	O
overlap	O
)	O
were	O
acute	O
rejection	O
(	O
AR	O
;	O
n	O
=	O
4	O
)	O
,	O
chronic	O
rejection	O
(	O
CR	O
;	O
n=5	O
)	O
,	O
AR+CR	O
(	O
n	O
=	O
4	O
)	O
,	O
recurrent	O
IgA	O
nephropathy	B-DISEASE
(	O
n	O
=	O
5	O
)	O
,	O
normal	O
findings	O
(	O
n	O
=	O
2	O
)	O
,	O
minimal	O
-	O
type	O
chronic	O
FK506	O
nephropathy	B-DISEASE
(	O
n	O
=	O
9	O
)	O
,	O
and	O
mild	O
-	O
type	O
FK506	O
nephropathy	B-DISEASE
(	O
n	O
=	O
11	O
)	O
.	O
Of	O
the	O
nonepisode	O
biopsies	O
,	O
7	O
and	O
4	O
biopsies	O
showed	O
minimal	O
-	O
type	O
and	O
mild	O
-	O
type	O
chronic	O
FK506	O
nephropathy	B-DISEASE
,	O
respectively	O
.	O
Chronic	O
FK506	O
nephropathy	B-DISEASE
consisted	O
of	O
rough	O
and	O
foamy	O
tubular	O
vacuolization	O
(	O
5	O
biopsies	O
)	O
,	O
arteriolopathy	O
(	O
angiodegeneration	O
of	O
the	O
arteriolar	O
wall	O
;	O
20	O
biopsies	O
)	O
,	O
focal	O
segmental	B-DISEASE
glomerulosclerosis	I-DISEASE
(	O
4	O
biopsies	O
)	O
and	O
the	O
striped	O
form	O
of	O
interstitial	O
fibrosis	B-DISEASE
(	O
11	O
biopsies	O
)	O
.	O
The	O
serum	O
creatinine	B-CHEMICAL
levels	O
of	O
patients	O
in	O
the	O
mild	O
-	O
type	O
chronic	O
FK506	O
nephropathy	B-DISEASE
group	O
,	O
which	O
included	O
7	O
episode	O
biopsies	O
,	O
were	O
statistically	O
higher	O
than	O
those	O
in	O
the	O
minimum	O
-	O
type	O
chronic	O
FK506	O
-	O
nephropathy	B-DISEASE
group	O
(	O
P	O
<	O
0.001	O
)	O
.	O
CONCLUSIONS	O
:	O
This	O
study	O
demonstrates	O
that	O
chronic	O
FK506	O
nephropathy	B-DISEASE
consists	O
primarily	O
of	O
arteriolopathy	O
manifesting	O
as	O
insudative	O
hyalinosis	O
of	O
the	O
arteriolar	O
wall	O
,	O
and	O
suggests	O
that	O
mild	O
-	O
type	O
chronic	O
FK506	O
nephropathy	B-DISEASE
is	O
a	O
condition	O
which	O
may	O
lead	O
to	O
deterioration	O
of	O
renal	O
allograft	O
function	O
.	O

Memory	O
facilitation	O
and	O
stimulation	O
of	O
endogenous	O
nerve	O
growth	O
factor	O
synthesis	O
by	O
the	O
acetylcholine	O
releaser	O
PG-9	O
.	O
The	O
effects	O
of	O
PG-9	O
(	O
3alpha	B-CHEMICAL
-	I-CHEMICAL
tropyl	I-CHEMICAL
2-(p	I-CHEMICAL
-	I-CHEMICAL
bromophenyl)propionate	I-CHEMICAL
)	O
,	O
the	O
acetylcholine	O
releaser	O
,	O
on	O
memory	O
processes	O
and	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
synthesis	O
were	O
evaluated	O
.	O
In	O
the	O
mouse	O
passive	O
-	O
avoidance	O
test	O
,	O
PG-9	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
,	O
administered	O
20	O
min	O
before	O
the	O
training	O
session	O
,	O
prevented	O
amnesia	B-DISEASE
induced	O
by	O
both	O
the	O
non	O
selective	O
antimuscarinic	O
drug	O
scopolamine	B-CHEMICAL
and	O
the	O
M1	O
-	O
selective	O
antagonist	O
S-(-)-ET-126	O
.	O
In	O
the	O
same	O
experimental	O
conditions	O
,	O
PG-9	O
(	O
5	O
-	O
20	O
microg	O
per	O
mouse	O
,	O
i.c.v	O
.	O
)	O
was	O
also	O
able	O
to	O
prevent	O
antimuscarine	O
-	O
induced	O
amnesia	B-DISEASE
,	O
demonstrating	O
a	O
central	O
localization	O
of	O
the	O
activity	O
.	O
At	O
the	O
highest	O
effective	O
doses	O
,	O
PG-9	O
did	O
not	O
produce	O
any	O
collateral	O
symptoms	O
as	O
revealed	O
by	O
the	O
Irwin	O
test	O
,	O
and	O
it	O
did	O
not	O
modify	O
spontaneous	O
motility	O
and	O
inspection	O
activity	O
,	O
as	O
revealed	O
by	O
the	O
hole	O
-	O
board	O
test	O
.	O
PG-9	O
was	O
also	O
able	O
to	O
increase	O
the	O
amount	O
of	O
NGF	O
secreted	O
in	O
vitro	O
by	O
astrocytes	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
The	O
maximal	O
NGF	O
contents	O
obtained	O
by	O
PG-9	O
were	O
17.6	O
-	O
fold	O
of	O
the	O
control	O
value	O
.	O
During	O
culture	O
,	O
no	O
morphological	O
changes	O
were	O
found	O
at	O
effective	O
concentrations	O
of	O
PG-9	O
.	O
The	O
current	O
work	O
indicates	O
the	O
ability	O
of	O
PG-9	O
to	O
induce	O
beneficial	O
effects	O
on	O
cognitive	O
processes	O
and	O
stimulate	O
activity	O
of	O
NGF	O
synthesis	O
in	O
astroglial	O
cells	O
.	O
Therefore	O
,	O
PG-9	O
could	O
represent	O
a	O
potential	O
useful	O
drug	O
able	O
to	O
improve	O
the	O
function	O
of	O
impaired	O
cognitive	O
processes	O
.	O

Angioedema	B-DISEASE
due	O
to	O
ACE	O
inhibitors	O
:	O
common	O
and	O
inadequately	O
diagnosed	O
.	O
The	O
estimated	O
incidence	O
of	O
angioedema	B-DISEASE
during	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
treatment	O
is	O
between	O
1	O
and	O
7	O
per	O
thousand	O
patients	O
.	O
This	O
potentially	O
serious	O
adverse	O
effect	O
is	O
often	O
preceded	O
by	O
minor	O
manifestations	O
that	O
may	O
serve	O
as	O
a	O
warning	O
.	O

Recurarization	O
in	O
the	O
recovery	O
room	O
.	O
A	O
case	O
of	O
recurarization	O
in	O
the	O
recovery	O
room	O
is	O
reported	O
.	O
Accumulation	O
of	O
atracurium	B-CHEMICAL
in	O
the	O
intravenous	O
line	O
led	O
to	O
recurarization	O
after	O
flushing	B-DISEASE
the	O
line	O
in	O
the	O
recovery	O
room	O
.	O
A	O
respiratory	O
arrest	O
with	O
severe	O
desaturation	B-DISEASE
and	O
bradycardia	B-DISEASE
occurred	O
.	O
Circumstances	O
leading	O
to	O
this	O
event	O
and	O
the	O
mechanisms	O
enabling	O
a	O
neuromuscular	O
blockade	O
to	O
occur	O
,	O
following	O
the	O
administration	O
of	O
a	O
small	O
dose	O
of	O
relaxant	O
,	O
are	O
discussed	O
.	O

Recurrent	O
use	O
of	O
newer	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
and	O
the	O
risk	O
of	O
venous	B-DISEASE
thromboembolism	I-DISEASE
.	O
The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	O
of	O
venous	B-DISEASE
thromboembolism	I-DISEASE
(	O
VTE	B-DISEASE
)	O
associated	O
with	O
newer	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
(	O
OC	O
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	O
use	O
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O
Data	O
from	O
a	O
Transnational	O
case	O
-	O
control	O
study	O
were	O
used	O
to	O
assess	O
the	O
risk	O
of	O
VTE	B-DISEASE
for	O
the	O
latter	O
patterns	O
of	O
use	O
,	O
while	O
accounting	O
for	O
duration	O
of	O
use	O
.	O
Over	O
the	O
period	O
1993	O
-	O
1996	O
,	O
551	O
cases	O
of	O
VTE	B-DISEASE
were	O
identified	O
in	O
Germany	O
and	O
the	O
UK	O
along	O
with	O
2066	O
controls	O
.	O
Totals	O
of	O
128	O
cases	O
and	O
650	O
controls	O
were	O
analysed	O
for	O
repeat	O
use	O
and	O
135	O
cases	O
and	O
622	O
controls	O
for	O
switching	O
patterns	O
.	O
The	O
adjusted	O
rate	O
ratio	O
of	O
VTE	B-DISEASE
for	O
repeat	O
users	O
of	O
third	O
generation	O
OC	O
was	O
0.6	O
(	O
95	O
%	O
CI:0.3	O
-	O
1.2	O
)	O
relative	O
to	O
repeat	O
users	O
of	O
second	O
generation	O
pills	O
,	O
whereas	O
it	O
was	O
1.3	O
(	O
95	O
%	O
CI:0.7	O
-	O
2.4	O
)	O
for	O
switchers	O
from	O
second	O
to	O
third	O
generation	O
pills	O
relative	O
to	O
switchers	O
from	O
third	O
to	O
second	O
generation	O
pills	O
.	O
We	O
conclude	O
that	O
second	O
and	O
third	O
generation	O
agents	O
are	O
associated	O
with	O
equivalent	O
risks	O
of	O
VTE	B-DISEASE
when	O
the	O
same	O
agent	O
is	O
used	O
repeatedly	O
after	O
interruption	O
periods	O
or	O
when	O
users	O
are	O
switched	O
between	O
the	O
two	O
generations	O
of	O
pills	O
.	O
These	O
analyses	O
suggest	O
that	O
the	O
higher	O
risk	O
observed	O
for	O
the	O
newer	O
OC	O
in	O
other	O
studies	O
may	O
be	O
the	O
result	O
of	O
inadequate	O
comparisons	O
of	O
pill	O
users	O
with	O
different	O
patterns	O
of	O
pill	O
use	O
.	O

Development	O
of	O
apomorphine	O
-	O
induced	O
aggressive	B-DISEASE
behavior	I-DISEASE
:	O
comparison	O
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
.	O
The	O
development	O
of	O
apomorphine	O
-	O
induced	O
(	O
1.0	O
mg	O
/	O
kg	O
s.c	O
.	O
once	O
daily	O
)	O
aggressive	B-DISEASE
behavior	I-DISEASE
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
obtained	O
from	O
the	O
same	O
breeder	O
was	O
studied	O
in	O
two	O
consecutive	O
sets	O
.	O
In	O
male	O
animals	O
,	O
repeated	O
apomorphine	O
treatment	O
induced	O
a	O
gradual	O
development	O
of	O
aggressive	B-DISEASE
behavior	I-DISEASE
as	O
evidenced	O
by	O
the	O
increased	O
intensity	O
of	O
aggressiveness	B-DISEASE
and	O
shortened	O
latency	O
before	O
the	O
first	O
attack	O
toward	O
the	O
opponent	O
.	O
In	O
female	O
rats	O
,	O
only	O
a	O
weak	O
tendency	O
toward	O
aggressiveness	B-DISEASE
was	O
found	O
.	O
In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrates	O
gender	O
differences	O
in	O
the	O
development	O
of	O
the	O
apomorphine	O
-	O
induced	O
aggressive	B-DISEASE
behavior	I-DISEASE
and	O
indicates	O
that	O
the	O
female	O
rats	O
do	O
not	O
fill	O
the	O
validation	O
criteria	O
for	O
use	O
in	O
this	O
method	O
.	O

Serotonergic	O
antidepressants	O
and	O
urinary	B-DISEASE
incontinence	I-DISEASE
.	O
Many	O
new	O
serotonergic	O
antidepressants	O
have	O
been	O
introduced	O
over	O
the	O
past	O
decade	O
.	O
Although	O
urinary	B-DISEASE
incontinence	I-DISEASE
is	O
listed	O
as	O
one	O
side	O
effect	O
of	O
these	O
drugs	O
in	O
their	O
package	O
inserts	O
there	O
is	O
only	O
one	O
report	O
in	O
the	O
literature	O
.	O
This	O
concerns	O
2	O
male	O
patients	O
who	O
experienced	O
incontinence	B-DISEASE
while	O
taking	O
venlafaxine	B-CHEMICAL
.	O
In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	O
incontinence	B-DISEASE
secondary	O
to	O
the	O
selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitors	O
paroxetine	B-CHEMICAL
and	O
sertraline	B-CHEMICAL
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	B-CHEMICAL
.	O
In	O
2	O
of	O
the	O
3	O
cases	O
the	O
patients	O
were	O
also	O
taking	O
lithium	B-CHEMICAL
carbonate	O
and	O
beta	O
-	O
blockers	O
,	O
both	O
of	O
which	O
could	O
have	O
contributed	O
to	O
the	O
incontinence	B-DISEASE
.	O
Animal	O
studies	O
suggest	O
that	O
incontinence	B-DISEASE
secondary	O
to	O
serotonergic	O
antidepressants	O
could	O
be	O
mediated	O
by	O
the	O
5HT4	O
receptors	O
found	O
on	O
the	O
bladder	O
.	O
Further	O
research	O
is	O
needed	O
to	O
delineate	O
the	O
frequency	O
of	O
this	O
troubling	O
side	O
effect	O
and	O
how	O
best	O
to	O
treat	O
it	O
.	O

Hypotension	B-DISEASE
following	O
the	O
initiation	O
of	O
tizanidine	O
in	O
a	O
patient	O
treated	O
with	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
for	O
chronic	O
hypertension	B-DISEASE
.	O
Centrally	O
acting	O
alpha-2	O
adrenergic	B-CHEMICAL
agonists	I-CHEMICAL
are	O
one	O
of	O
several	O
pharmacologic	O
agents	O
used	O
in	O
the	O
treatment	O
of	O
spasticity	O
related	O
to	O
disorders	B-DISEASE
of	I-DISEASE
the	I-DISEASE
central	I-DISEASE
nervous	I-DISEASE
system	I-DISEASE
.	O
In	O
addition	O
to	O
their	O
effects	O
on	O
spasticity	O
,	O
certain	O
adverse	O
cardiorespiratory	O
effects	O
have	O
been	O
reported	O
.	O
Adults	O
chronically	O
treated	O
with	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
may	O
have	O
a	O
limited	O
ability	O
to	O
respond	O
to	O
hypotension	B-DISEASE
when	O
the	O
sympathetic	O
response	O
is	O
simultaneously	O
blocked	O
.	O
The	O
authors	O
present	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	O
,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	B-DISEASE
who	O
developed	O
hypotension	B-DISEASE
following	O
the	O
addition	O
of	O
tizanidine	O
,	O
an	O
alpha-2	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	O
.	O
The	O
possible	O
interaction	O
of	O
tizanidine	O
and	O
other	O
antihypertensive	B-CHEMICAL
agents	I-CHEMICAL
should	O
be	O
kept	O
in	O
mind	O
when	O
prescribing	O
therapy	O
to	O
treat	O
either	O
hypertension	B-DISEASE
or	O
spasticity	O
in	O
such	O
patients	O
.	O

Peritubular	O
capillary	O
basement	O
membrane	O
reduplication	O
in	O
allografts	O
and	O
native	O
kidney	O
disease	B-DISEASE
:	O
a	O
clinicopathologic	O
study	O
of	O
278	O
consecutive	O
renal	O
specimens	O
.	O
BACKGROUND	O
:	O
An	O
association	O
has	O
been	O
found	O
between	O
transplant	O
glomerulopathy	O
(	O
TG	O
)	O
and	O
reduplication	O
of	O
peritubular	O
capillary	O
basement	O
membranes	O
(	O
PTCR	O
)	O
.	O
Although	O
such	O
an	O
association	O
is	O
of	O
practical	O
and	O
theoretical	O
importance	O
,	O
only	O
one	O
prospective	O
study	O
has	O
tried	O
to	O
confirm	O
it	O
.	O
METHODS	O
:	O
We	O
examined	O
278	O
consecutive	O
renal	O
specimens	O
(	O
from	O
135	O
transplants	O
and	O
143	O
native	O
kidneys	O
)	O
for	O
ultrastructural	O
evidence	O
of	O
PTCR	O
.	O
In	O
addition	O
to	O
renal	O
allografts	O
with	O
TG	O
,	O
we	O
also	O
examined	O
grafts	O
with	O
acute	O
rejection	O
,	O
recurrent	O
glomerulonephritis	B-DISEASE
,	O
chronic	B-DISEASE
allograft	I-DISEASE
nephropathy	I-DISEASE
and	O
stable	O
grafts	O
(	O
"	O
protocol	O
biopsies	O
"	O
)	O
.	O
Native	O
kidney	O
specimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulopathies	O
as	O
well	O
as	O
cases	O
of	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
,	O
malignant	O
hypertension	B-DISEASE
,	O
acute	O
interstitial	B-DISEASE
nephritis	I-DISEASE
,	O
and	O
acute	B-DISEASE
tubular	I-DISEASE
necrosis	I-DISEASE
.	O
RESULTS	O
:	O
We	O
found	O
PTCR	O
in	O
14	O
of	O
15	O
cases	O
of	O
TG	O
,	O
in	O
7	O
transplant	O
biopsy	O
specimens	O
without	O
TG	O
,	O
and	O
in	O
13	O
of	O
143	O
native	O
kidney	O
biopsy	O
specimens	O
.	O
These	O
13	O
included	O
cases	O
of	O
malignant	O
hypertension	B-DISEASE
,	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
,	O
lupus	B-DISEASE
nephritis	I-DISEASE
,	O
Henoch	O
-	O
Schonlein	O
nephritis	B-DISEASE
,	O
crescentic	O
glomerulonephritis	B-DISEASE
,	O
and	O
cocaine	B-CHEMICAL
-	O
related	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
.	O
Mild	O
PTCR	O
in	O
allografts	O
without	O
TG	O
did	O
not	O
predict	O
renal	B-DISEASE
failure	I-DISEASE
or	O
significant	O
proteinuria	B-DISEASE
after	O
follow	O
-	O
up	O
periods	O
of	O
between	O
3	O
months	O
and	O
1	O
year	O
.	O
CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
in	O
transplants	O
,	O
there	O
is	O
a	O
strong	O
association	O
between	O
well	O
-	O
developed	O
PTCR	O
and	O
TG	O
,	O
while	O
the	O
significance	O
of	O
mild	O
PTCR	O
and	O
its	O
predictive	O
value	O
in	O
the	O
absence	O
of	O
TG	O
is	O
unclear	O
.	O
PTCR	O
also	O
occurs	O
in	O
certain	O
native	O
kidney	B-DISEASE
diseases	I-DISEASE
,	O
though	O
the	O
association	O
is	O
not	O
as	O
strong	O
as	O
that	O
for	O
TG	O
.	O
We	O
suggest	O
that	O
repeated	O
endothelial	B-DISEASE
injury	I-DISEASE
,	O
including	O
immunologic	O
injury	O
,	O
may	O
be	O
the	O
cause	O
of	O
this	O
lesion	O
both	O
in	O
allografts	O
and	O
native	O
kidneys	O
.	O

Conformationally	O
restricted	O
analogs	O
of	O
BD1008	O
and	O
an	O
antisense	O
oligodeoxynucleotide	O
targeting	O
sigma1	O
receptors	O
produce	O
anti	O
-	O
cocaine	B-CHEMICAL
effects	O
in	O
mice	O
.	O
Cocaine	B-CHEMICAL
's	O
ability	O
to	O
interact	O
with	O
sigma	O
receptors	O
suggests	O
that	O
these	O
proteins	O
mediate	O
some	O
of	O
its	O
behavioral	O
effects	O
.	O
Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	O
in	O
Swiss	O
Webster	O
mice	O
:	O
BD1018	O
(	O
3S-1-[2-(3,4	B-CHEMICAL
-	I-CHEMICAL
dichlorophenyl)ethyl]-1,4	I-CHEMICAL
-	I-CHEMICAL
diazabicyclo[4.3.0]nonane	I-CHEMICAL
)	O
,	O
BD1063	O
(	O
1-[2-(3,4	B-CHEMICAL
-	I-CHEMICAL
dichlorophenyl)ethyl]-4	I-CHEMICAL
-	I-CHEMICAL
methylpiperazine	I-CHEMICAL
)	O
,	O
and	O
LR132	O
(	O
1R,2S-(+)-cis	O
-	O
N-[2-(3,4	O
-	O
dichlorophenyl)ethyl]-2-(1	O
-	O
pyrrolidinyl)cyclohexylamine	O
)	O
.	O
Competition	O
binding	O
assays	O
demonstrated	O
that	O
all	O
three	O
compounds	O
have	O
high	O
affinities	O
for	O
sigma1	O
receptors	O
.	O
The	O
three	O
compounds	O
vary	O
in	O
their	O
affinities	O
for	O
sigma2	O
receptors	O
and	O
exhibit	O
negligible	O
affinities	O
for	O
dopamine	B-CHEMICAL
,	O
opioid	O
,	O
GABA(A	O
)	O
and	O
NMDA	O
receptors	O
.	O
In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	O
of	O
mice	O
with	O
BD1018	O
,	O
BD1063	O
,	O
or	O
LR132	O
significantly	O
attenuated	O
cocaine	B-CHEMICAL
-	O
induced	O
convulsions	B-DISEASE
and	O
lethality	O
.	O
Moreover	O
,	O
post	O
-	O
treatment	O
with	O
LR132	O
prevented	O
cocaine	B-CHEMICAL
-	O
induced	O
lethality	O
in	O
a	O
significant	O
proportion	O
of	O
animals	O
.	O
In	O
contrast	O
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	O
-	O
o	O
-	O
tolylguanidine	O
(	O
DTG	O
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD1031	O
(	O
3R-1-[2-(3,4	B-CHEMICAL
-	I-CHEMICAL
dichlorophenyl)ethyl]-1,4	I-CHEMICAL
-	I-CHEMICAL
diazabicyclo[4.3.0]nonane	I-CHEMICAL
)	O
each	O
worsened	O
the	O
behavioral	O
toxicity	B-DISEASE
of	O
cocaine	B-CHEMICAL
.	O
At	O
doses	O
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	O
effects	O
on	O
locomotion	O
,	O
BD1018	O
,	O
BD1063	O
and	O
LR132	O
significantly	O
attenuated	O
the	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	B-CHEMICAL
.	O
To	O
further	O
validate	O
the	O
hypothesis	O
that	O
the	O
anti	O
-	O
cocaine	B-CHEMICAL
effects	O
of	O
the	O
novel	O
ligands	O
involved	O
antagonism	O
of	O
sigma	O
receptors	O
,	O
an	O
antisense	O
oligodeoxynucleotide	O
against	O
sigma1	O
receptors	O
was	O
also	O
shown	O
to	O
significantly	O
attenuate	O
the	O
convulsive	B-DISEASE
and	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	B-CHEMICAL
.	O
Together	O
,	O
the	O
data	O
suggests	O
that	O
functional	O
antagonism	O
of	O
sigma	O
receptors	O
is	O
capable	O
of	O
attenuating	O
a	O
number	O
of	O
cocaine	B-CHEMICAL
-	O
induced	O
behaviors	O
.	O

Pharmacokinetic	O
/	O
pharmacodynamic	O
assessment	O
of	O
the	O
effects	O
of	O
E4031	O
,	O
cisapride	B-CHEMICAL
,	O
terfenadine	B-CHEMICAL
and	O
terodiline	B-CHEMICAL
on	O
monophasic	O
action	O
potential	O
duration	O
in	O
dog	O
.	O
1	O
.	O
Torsades	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
(	O
TDP	B-DISEASE
)	O
is	O
a	O
potentially	O
fatal	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
associated	O
with	O
increases	O
in	O
QT	O
interval	O
and	O
monophasic	O
action	O
potential	O
duration	O
(	O
MAPD	O
)	O
.	O
TDP	B-DISEASE
is	O
a	O
side	O
-	O
effect	O
that	O
has	O
led	O
to	O
withdrawal	O
of	O
several	O
drugs	O
from	O
the	O
market	O
(	O
e.g.	O
terfenadine	B-CHEMICAL
and	O
terodiline	B-CHEMICAL
)	O
.	O
2	O
.	O
The	O
potential	O
of	O
compounds	O
to	O
cause	O
TDP	B-DISEASE
was	O
evaluated	O
by	O
monitoring	O
their	O
effects	O
on	O
MAPD	O
in	O
dog	O
.	O
Four	O
compounds	O
known	O
to	O
increase	O
QT	O
interval	O
and	O
cause	O
TDP	B-DISEASE
were	O
investigated	O
:	O
terfenadine	B-CHEMICAL
,	O
terodiline	B-CHEMICAL
,	O
cisapride	B-CHEMICAL
and	O
E4031	O
.	O
On	O
the	O
basis	O
that	O
only	O
free	O
drug	O
in	O
the	O
systemic	O
circulation	O
will	O
elicit	O
a	O
pharmacological	O
response	O
target	O
,	O
free	O
concentrations	O
in	O
plasma	O
were	O
selected	O
to	O
mimic	O
the	O
free	O
drug	O
exposures	O
in	O
man	O
.	O
Infusion	O
regimens	O
were	O
designed	O
that	O
rapidly	O
achieved	O
and	O
maintained	O
target	O
-	O
free	O
concentrations	O
of	O
these	O
drugs	O
in	O
plasma	O
and	O
data	O
on	O
the	O
relationship	O
between	O
free	O
concentration	O
and	O
changes	O
in	O
MAPD	O
were	O
obtained	O
for	O
these	O
compounds	O
.	O
3	O
.	O
These	O
data	O
indicate	O
that	O
the	O
free	O
ED50	O
in	O
plasma	O
for	O
terfenadine	B-CHEMICAL
(	O
1.9	O
nM	O
)	O
,	O
terodiline	B-CHEMICAL
(	O
76	O
nM	O
)	O
,	O
cisapride	B-CHEMICAL
(	O
11	O
nM	O
)	O
and	O
E4031	O
(	O
1.9	O
nM	O
)	O
closely	O
correlate	O
with	O
the	O
free	O
concentration	O
in	O
man	O
causing	O
QT	O
effects	O
.	O
For	O
compounds	O
that	O
have	O
shown	O
TDP	B-DISEASE
in	O
the	O
clinic	O
(	O
terfenadine	B-CHEMICAL
,	O
terodiline	B-CHEMICAL
,	O
cisapride	B-CHEMICAL
)	O
there	O
is	O
little	O
differentiation	O
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficacious	O
free	O
plasma	O
concentrations	O
in	O
man	O
(	O
<	O
10	O
-	O
fold	O
)	O
reflecting	O
their	O
limited	O
safety	O
margins	O
.	O
These	O
data	O
underline	O
the	O
need	O
to	O
maximize	O
the	O
therapeutic	O
ratio	O
with	O
respect	O
to	O
TDP	B-DISEASE
in	O
potential	O
development	O
candidates	O
and	O
the	O
importance	O
of	O
using	O
free	O
drug	O
concentrations	O
in	O
pharmacokinetic	O
/	O
pharmacodynamic	O
studies	O
.	O

Fatal	O
myeloencephalopathy	O
due	O
to	O
accidental	O
intrathecal	O
vincristin	O
administration	O
:	O
a	O
report	O
of	O
two	O
cases	O
.	O
We	O
report	O
on	O
two	O
fatal	O
cases	O
of	O
accidental	O
intrathecal	O
vincristine	B-CHEMICAL
instillation	O
in	O
a	O
5	O
-	O
year	O
old	O
girl	O
with	O
recurrent	O
acute	B-DISEASE
lymphoblastic	I-DISEASE
leucemia	I-DISEASE
and	O
a	O
57	O
-	O
year	O
old	O
man	O
with	O
lymphoblastic	O
lymphoma	B-DISEASE
.	O
The	O
girl	O
died	O
seven	O
days	O
,	O
the	O
man	O
four	O
weeks	O
after	O
intrathecal	O
injection	O
of	O
vincristine	B-CHEMICAL
.	O
Clinically	O
,	O
the	O
onset	O
was	O
characterized	O
by	O
the	O
signs	O
of	O
opistothonus	O
,	O
sensory	O
and	O
motor	O
dysfunction	O
and	O
ascending	O
paralysis	B-DISEASE
.	O
Histological	O
and	O
immunohistochemical	O
investigations	O
(	O
HE	O
-	O
LFB	O
,	O
CD-68	O
,	O
Neurofilament	O
)	O
revealed	O
degeneration	O
of	O
myelin	O
and	O
axons	O
as	O
well	O
as	O
pseudocystic	O
transformation	O
in	O
areas	O
exposed	O
to	O
vincristine	B-CHEMICAL
,	O
accompanied	O
by	O
secondary	O
changes	O
with	O
numerous	O
prominent	O
macrophages	O
.	O
The	O
clinical	O
course	O
and	O
histopathological	O
results	O
of	O
the	O
two	O
cases	O
are	O
presented	O
.	O
A	O
review	O
of	O
all	O
reported	O
cases	O
in	O
the	O
literature	O
is	O
given	O
.	O
A	O
better	O
controlled	O
regimen	O
for	O
administering	O
vincristine	B-CHEMICAL
and	O
intrathecal	O
chemotherapy	O
is	O
recommended	O
.	O

Intravenous	O
administration	O
of	O
prochlorperazine	B-CHEMICAL
by	O
15	O
-	O
minute	O
infusion	O
versus	O
2	O
-	O
minute	O
bolus	O
does	O
not	O
affect	O
the	O
incidence	O
of	O
akathisia	O
:	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O
STUDY	O
OBJECTIVE	O
:	O
We	O
sought	O
to	O
compare	O
the	O
rate	O
of	O
akathisia	O
after	O
administration	O
of	O
intravenous	O
prochlorperazine	B-CHEMICAL
as	O
a	O
2	O
-	O
minute	O
bolus	O
or	O
15	O
-	O
minute	O
infusion	O
.	O
METHODS	O
:	O
We	O
conducted	O
a	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	B-DISEASE
study	O
in	O
the	O
emergency	B-DISEASE
department	I-DISEASE
of	O
a	O
central	O
-	O
city	O
teaching	O
hospital	O
.	O
Patients	O
aged	O
18	O
years	O
or	O
older	O
treated	O
with	O
prochlorperazine	B-CHEMICAL
for	O
headache	B-DISEASE
,	O
nausea	B-DISEASE
,	O
or	O
vomiting	B-DISEASE
were	O
eligible	O
for	O
inclusion	O
.	O
Study	O
participants	O
were	O
randomized	O
to	O
receive	O
10	O
mg	O
of	O
prochlorperazine	B-CHEMICAL
administered	O
intravenously	O
by	O
means	O
of	O
2	O
-	O
minute	O
push	O
(	O
bolus	O
group	O
)	O
or	O
10	O
mg	O
diluted	O
in	O
50	O
mL	O
of	O
normal	O
saline	O
solution	O
administered	O
by	O
means	O
of	O
intravenous	O
infusion	O
during	O
a	O
15	O
-	O
minute	O
period	O
(	O
infusion	O
group	O
)	O
.	O
The	O
main	O
outcome	O
was	O
the	O
number	O
of	O
study	O
participants	O
experiencing	O
akathisia	O
within	O
60	O
minutes	O
of	O
administration	O
.	O
Akathisia	O
was	O
defined	O
as	O
either	O
a	O
spontaneous	O
report	O
of	O
restlessness	B-DISEASE
or	O
agitation	B-DISEASE
or	O
a	O
change	O
of	O
2	O
or	O
more	O
in	O
the	O
patient	O
-	O
reported	O
akathisia	O
rating	O
scale	O
and	O
a	O
change	O
of	O
at	O
least	O
1	O
in	O
the	O
investigator	O
-	O
observed	O
akathisia	O
rating	O
scale	O
.	O
The	O
intensity	O
of	O
headache	B-DISEASE
and	O
nausea	B-DISEASE
was	O
measured	O
with	O
a	O
100	O
-	O
mm	O
visual	O
analog	O
scale	O
.	O
RESULTS	O
:	O
One	O
hundred	O
patients	O
were	O
enrolled	O
.	O
One	O
study	O
participant	O
was	O
excluded	O
after	O
protocol	O
violation	O
.	O
Seventy	O
-	O
three	O
percent	O
(	O
73/99	O
)	O
of	O
the	O
study	O
participants	O
were	O
treated	O
for	O
headache	B-DISEASE
and	O
70	O
%	O
(	O
70/99	O
)	O
for	O
nausea	B-DISEASE
.	O
In	O
the	O
bolus	O
group	O
,	O
26.0	O
%	O
(	O
13/50	O
)	O
had	O
akathisia	O
compared	O
with	O
32.7	O
%	O
(	O
16/49	O
)	O
in	O
the	O
infusion	O
group	O
(	O
Delta=-6.7	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
-24.6	O
%	O
to	O
11.2	O
%	O
)	O
.	O
The	O
difference	O
between	O
the	O
bolus	O
and	O
infusion	O
groups	O
in	O
the	O
percentage	O
of	O
participants	O
who	O
saw	O
a	O
50	O
%	O
reduction	O
in	O
their	O
headache	B-DISEASE
intensity	O
within	O
30	O
minutes	O
was	O
11.8	O
%	O
(	O
95	O
%	O
CI	O
-9.6	O
%	O
to	O
33.3	O
%	O
)	O
.	O
The	O
difference	O
in	O
the	O
percentage	O
of	O
patients	O
with	O
a	O
50	O
%	O
reduction	O
in	O
their	O
nausea	B-DISEASE
was	O
12.6	O
%	O
(	O
95	O
%	O
CI	O
-4.6	O
%	O
to	O
29.8	O
%	O
)	O
.	O
CONCLUSION	O
:	O
A	O
50	O
%	O
reduction	O
in	O
the	O
incidence	O
of	O
akathisia	O
when	O
prochlorperazine	B-CHEMICAL
was	O
administered	O
by	O
means	O
of	O
15	O
-	O
minute	O
intravenous	O
infusion	O
versus	O
a	O
2	O
-	O
minute	O
intravenous	O
push	O
was	O
not	O
detected	O
.	O
The	O
efficacy	O
of	O
prochlorperazine	B-CHEMICAL
in	O
the	O
treatment	O
of	O
headache	B-DISEASE
and	O
nausea	B-DISEASE
likewise	O
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
rate	O
of	O
administration	O
,	O
although	O
no	O
formal	O
statistical	O
comparisons	O
were	O
made	O
.	O

Antithymocyte	O
globulin	O
in	O
the	O
treatment	O
of	O
D	O
-	O
penicillamine	B-CHEMICAL
-	O
induced	O
aplastic	B-DISEASE
anemia	I-DISEASE
.	O
A	O
patient	O
who	O
received	O
antithymocyte	O
globulin	O
therapy	O
for	O
aplastic	B-DISEASE
anemia	I-DISEASE
due	O
to	O
D	O
-	O
penicillamine	B-CHEMICAL
therapy	O
is	O
described	O
.	O
Bone	O
marrow	O
recovery	O
and	O
peripheral	O
blood	O
recovery	O
were	O
complete	O
1	O
month	O
and	O
3	O
months	O
,	O
respectively	O
,	O
after	O
treatment	O
,	O
and	O
blood	O
transfusion	O
or	O
other	O
therapies	O
were	O
not	O
necessary	O
in	O
a	O
follow	O
-	O
up	O
period	O
of	O
more	O
than	O
2	O
years	O
.	O
Use	O
of	O
antithymocyte	O
globulin	O
may	O
be	O
the	O
optimal	O
treatment	O
of	O
D	O
-	O
penicillamine	B-CHEMICAL
-	O
induced	O
aplastic	B-DISEASE
anemia	I-DISEASE
.	O

The	O
relationship	O
between	O
hippocampal	O
acetylcholine	O
release	O
and	O
cholinergic	O
convulsant	O
sensitivity	O
in	O
withdrawal	O
seizure	B-DISEASE
-	O
prone	O
and	O
withdrawal	O
seizure	B-DISEASE
-	O
resistant	O
selected	O
mouse	O
lines	O
.	O
BACKGROUND	O
:	O
The	O
septo	O
-	O
hippocampal	O
cholinergic	O
pathway	O
has	O
been	O
implicated	O
in	O
epileptogenesis	O
,	O
and	O
genetic	O
factors	O
influence	O
the	O
response	O
to	O
cholinergic	B-CHEMICAL
agents	I-CHEMICAL
,	O
but	O
limited	O
data	O
are	O
available	O
on	O
cholinergic	O
involvement	O
in	O
alcohol	O
withdrawal	O
severity	O
.	O
Thus	O
,	O
the	O
relationship	O
between	O
cholinergic	O
activity	O
and	O
responsiveness	O
and	O
alcohol	O
withdrawal	O
was	O
investigated	O
in	O
a	O
genetic	O
animal	O
model	O
of	O
ethanol	B-CHEMICAL
withdrawal	O
severity	O
.	O
METHODS	O
:	O
Cholinergic	O
convulsant	O
sensitivity	O
was	O
examined	O
in	O
alcohol	O
-	O
na	O
 	O
ve	O
Withdrawal	O
Seizure	B-DISEASE
-	O
Prone	O
(	O
WSP	O
)	O
and	O
-	O
Resistant	O
(	O
WSR	O
)	O
mice	O
.	O
Animals	O
were	O
administered	O
nicotine	B-CHEMICAL
,	O
carbachol	O
,	O
or	O
neostigmine	O
via	O
timed	O
tail	O
vein	O
infusion	O
,	O
and	O
the	O
latencies	O
to	O
onset	O
of	O
tremor	B-DISEASE
and	O
clonus	O
were	O
recorded	O
and	O
converted	O
to	O
threshold	O
dose	O
.	O
We	O
also	O
used	O
microdialysis	O
to	O
measure	O
basal	O
and	O
potassium	B-CHEMICAL
-	O
stimulated	O
acetylcholine	O
(	O
ACh	B-CHEMICAL
)	O
release	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
.	O
Potassium	B-CHEMICAL
was	O
applied	O
by	O
reverse	O
dialysis	O
twice	O
,	O
separated	O
by	O
75	O
min	O
.	O
Hippocampal	O
ACh	B-CHEMICAL
also	O
was	O
measured	O
during	O
testing	O
for	O
handling	O
-	O
induced	O
convulsions	B-DISEASE
.	O
RESULTS	O
:	O
Sensitivity	O
to	O
several	O
convulsion	B-DISEASE
endpoints	O
induced	O
by	O
nicotine	B-CHEMICAL
,	O
carbachol	O
,	O
and	O
neostigmine	O
were	O
significantly	O
greater	O
in	O
WSR	O
versus	O
WSP	O
mice	O
.	O
In	O
microdialysis	O
experiments	O
,	O
the	O
lines	O
did	O
not	O
differ	O
in	O
basal	O
release	O
of	O
ACh	B-CHEMICAL
,	O
and	O
50	O
mM	O
KCl	O
increased	O
ACh	B-CHEMICAL
output	O
in	O
both	O
lines	O
of	O
mice	O
.	O
However	O
,	O
the	O
increase	O
in	O
release	O
of	O
ACh	B-CHEMICAL
produced	O
by	O
the	O
first	O
application	O
of	O
KCl	O
was	O
2	O
-	O
fold	O
higher	O
in	O
WSP	O
versus	O
WSR	O
mice	O
.	O
When	O
hippocampal	O
ACh	B-CHEMICAL
was	O
measured	O
during	O
testing	O
for	O
handling	O
-	O
induced	O
convulsions	B-DISEASE
,	O
extracellular	O
ACh	B-CHEMICAL
was	O
significantly	O
elevated	O
(	O
192	O
%	O
)	O
in	O
WSP	O
mice	O
,	O
but	O
was	O
nonsignificantly	O
elevated	O
(	O
59	O
%	O
)	O
in	O
WSR	O
mice	O
.	O
CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
differences	O
in	O
cholinergic	O
activity	O
and	O
postsynaptic	O
sensitivity	O
to	O
cholinergic	O
convulsants	B-DISEASE
may	O
be	O
associated	O
with	O
ethanol	B-CHEMICAL
withdrawal	O
severity	O
and	O
implicate	O
cholinergic	O
mechanisms	O
in	O
alcohol	O
withdrawal	O
.	O
Specifically	O
,	O
WSP	O
mice	O
may	O
have	O
lower	O
sensitivity	O
to	O
cholinergic	O
convulsants	B-DISEASE
compared	O
with	O
WSR	O
because	O
of	O
postsynaptic	O
receptor	O
desensitization	O
brought	O
on	O
by	O
higher	O
activity	O
of	O
cholinergic	O
neurons	O
.	O

Prenatal	O
dexamethasone	B-CHEMICAL
programs	O
hypertension	B-DISEASE
and	O
renal	B-DISEASE
injury	I-DISEASE
in	O
the	O
rat	O
.	O
Dexamethasone	B-CHEMICAL
is	O
frequently	O
administered	O
to	O
the	O
developing	O
fetus	O
to	O
accelerate	O
pulmonary	O
development	O
.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
prenatal	O
dexamethasone	B-CHEMICAL
programmed	O
a	O
progressive	O
increase	O
in	O
blood	O
pressure	O
and	O
renal	B-DISEASE
injury	I-DISEASE
in	O
rats	O
.	O
Pregnant	O
rats	O
were	O
given	O
either	O
vehicle	O
or	O
2	O
daily	O
intraperitoneal	O
injections	O
of	O
dexamethasone	B-CHEMICAL
(	O
0.2	O
mg	O
/	O
kg	O
body	B-DISEASE
weight	I-DISEASE
)	O
on	O
gestational	O
days	O
11	O
and	O
12	O
,	O
13	O
and	O
14	O
,	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
or	O
19	O
and	O
20	O
.	O
Offspring	O
of	O
rats	O
administered	O
dexamethasone	B-CHEMICAL
on	O
days	O
15	O
and	O
16	O
gestation	O
had	O
a	O
20	O
%	O
reduction	B-DISEASE
in	I-DISEASE
glomerular	I-DISEASE
number	I-DISEASE
compared	O
with	O
control	O
at	O
6	O
to	O
9	O
months	O
of	O
age	O
(	O
22	O
527+/-509	O
versus	O
28	O
050+/-561	O
,	O
P<0.05	O
)	O
,	O
which	O
was	O
comparable	O
to	O
the	O
percent	O
reduction	O
in	O
glomeruli	O
measured	O
at	O
3	O
weeks	O
of	O
age	O
.	O
Six-	O
to	O
9	O
-	O
month	O
old	O
rats	O
receiving	O
prenatal	O
dexamethasone	B-CHEMICAL
on	O
days	O
17	O
and	O
18	O
of	O
gestation	O
had	O
a	B-CHEMICAL
17	I-CHEMICAL
%	O
reduction	O
in	O
glomeruli	O
(	O
23	O
380+/-587	O
)	O
compared	O
with	O
control	O
rats	O
(	O
P<0.05	O
)	O
.	O
Male	O
rats	O
that	O
received	O
prenatal	O
dexamethasone	B-CHEMICAL
on	O
days	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
and	O
13	O
and	O
14	O
of	O
gestation	O
had	O
elevated	B-DISEASE
blood	I-DISEASE
pressures	I-DISEASE
at	O
6	O
months	O
of	O
age	O
;	O
the	O
latter	O
group	O
did	O
not	O
have	O
a	O
reduction	B-DISEASE
in	I-DISEASE
glomerular	I-DISEASE
number	I-DISEASE
.	O
Adult	O
rats	O
given	O
dexamethasone	B-CHEMICAL
on	O
days	O
15	O
and	O
16	O
of	O
gestation	O
had	O
more	O
glomeruli	O
with	O
glomerulosclerosis	O
than	O
control	O
rats	O
.	O
This	O
study	O
shows	O
that	O
prenatal	O
dexamethasone	B-CHEMICAL
in	O
rats	O
results	O
in	O
a	O
reduction	B-DISEASE
in	I-DISEASE
glomerular	I-DISEASE
number	I-DISEASE
,	O
glomerulosclerosis	O
,	O
and	O
hypertension	B-DISEASE
when	O
administered	O
at	O
specific	O
points	O
during	O
gestation	O
.	O
Hypertension	B-DISEASE
was	O
observed	O
in	O
animals	O
that	O
had	O
a	O
reduction	O
in	O
glomeruli	O
as	O
well	O
as	O
in	O
a	O
group	O
that	O
did	O
not	O
have	O
a	O
reduction	B-DISEASE
in	I-DISEASE
glomerular	I-DISEASE
number	I-DISEASE
,	O
suggesting	O
that	O
a	O
reduction	B-DISEASE
in	I-DISEASE
glomerular	I-DISEASE
number	I-DISEASE
is	O
not	O
the	O
sole	O
cause	O
for	O
the	O
development	O
of	O
hypertension	B-DISEASE
.	O

The	O
risk	O
of	O
venous	B-DISEASE
thromboembolism	I-DISEASE
in	O
women	O
prescribed	O
cyproterone	O
acetate	O
in	O
combination	O
with	O
ethinyl	O
estradiol	B-CHEMICAL
:	O
a	O
nested	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
.	O
BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	O
with	O
ethinyl	O
estradiol	B-CHEMICAL
(	O
CPA	B-CHEMICAL
/	O
EE	O
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	B-DISEASE
and	O
hirsutism	B-DISEASE
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	B-DISEASE
ovary	I-DISEASE
syndrome	I-DISEASE
(	O
PCOS	B-DISEASE
)	O
.	O
Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
venous	B-DISEASE
thromboembolism	I-DISEASE
(	O
VTE	B-DISEASE
)	O
associated	O
with	O
CPA	B-CHEMICAL
/	O
EE	O
compared	O
with	O
conventional	O
combined	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
(	O
COCs	O
)	O
.	O
We	O
believe	O
the	O
results	O
of	O
those	O
studies	O
may	O
have	O
been	O
affected	O
by	O
residual	O
confounding	O
.	O
METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
15	O
and	O
39	O
years	O
with	O
acne	B-DISEASE
,	O
hirsutism	B-DISEASE
or	O
PCOS	B-DISEASE
to	O
estimate	O
the	O
risk	O
of	O
VTE	B-DISEASE
associated	O
with	O
CPA	B-CHEMICAL
/	O
EE	O
.	O
RESULTS	O
:	O
The	O
age	O
-	O
adjusted	O
incidence	O
rate	O
ratio	O
for	O
CPA	B-CHEMICAL
/	O
EE	O
versus	O
conventional	O
COCs	O
was	O
2.20	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.35	O
-	O
3.58	O
]	O
.	O
Using	O
as	O
the	O
reference	O
group	O
women	O
who	O
were	O
not	O
using	O
oral	O
contraception	O
,	O
had	O
no	O
recent	O
pregnancy	O
or	O
menopausal	O
symptoms	O
,	O
the	O
case	O
-	O
control	O
analysis	O
gave	O
an	O
adjusted	O
odds	O
ratio	O
(	O
OR(adj	O
)	O
)	O
of	O
7.44	O
(	O
95	O
%	O
CI	O
3.67	O
-	O
15.08	O
)	O
for	O
CPA	B-CHEMICAL
/	O
EE	O
use	O
compared	O
with	O
an	O
OR(adj	O
)	O
of	O
2.58	O
(	O
95	O
%	O
CI	O
1.60	O
-	O
4.18	O
)	O
for	O
use	O
of	O
conventional	O
COCs	O
.	O
CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	B-DISEASE
associated	O
with	O
the	O
use	O
of	O
CPA	B-CHEMICAL
/	O
EE	O
in	O
women	O
with	O
acne	B-DISEASE
,	O
hirsutism	B-DISEASE
or	O
PCOS	B-DISEASE
although	O
residual	O
confounding	O
by	O
indication	O
can	O
not	O
be	O
excluded	O
.	O

Pseudoacromegaly	B-DISEASE
induced	O
by	O
the	O
long	O
-	O
term	O
use	O
of	O
minoxidil	O
.	O
Acromegaly	B-DISEASE
is	O
an	O
endocrine	B-DISEASE
disorder	I-DISEASE
caused	O
by	O
chronic	O
excessive	O
growth	O
hormone	O
secretion	O
from	O
the	O
anterior	O
pituitary	O
gland	O
.	O
Significant	O
disfiguring	O
changes	O
occur	O
as	O
a	O
result	O
of	O
bone	O
,	O
cartilage	O
,	O
and	O
soft	O
tissue	O
hypertrophy	B-DISEASE
,	O
including	O
the	O
thickening	O
of	O
the	O
skin	O
,	O
coarsening	O
of	O
facial	O
features	O
,	O
and	O
cutis	B-DISEASE
verticis	I-DISEASE
gyrata	I-DISEASE
.	O
Pseudoacromegaly	B-DISEASE
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
the	O
presence	O
of	O
similar	O
acromegaloid	O
features	O
in	O
the	O
absence	O
of	O
elevated	O
growth	O
hormone	O
or	O
insulin	O
-	O
like	O
growth	O
factor	O
levels	O
.	O
We	O
present	O
a	O
patient	O
with	O
pseudoacromegaly	B-DISEASE
that	O
resulted	O
from	O
the	O
long	O
-	O
term	O
use	O
of	O
minoxidil	O
at	O
an	O
unusually	O
high	O
dose	O
.	O
This	O
is	O
the	O
first	O
case	O
report	O
of	O
pseudoacromegaly	B-DISEASE
as	O
a	O
side	O
effect	O
of	O
minoxidil	O
use	O
.	O

Combined	O
androgen	O
blockade	O
-	O
induced	O
anemia	B-DISEASE
in	O
prostate	B-DISEASE
cancer	I-DISEASE
patients	O
without	O
bone	O
involvement	O
.	O
BACKGROUND	O
:	O
To	O
determine	O
the	O
onset	O
and	O
extent	O
of	O
combined	O
androgen	O
blockade	O
(	O
CAB)-induced	O
anemia	B-DISEASE
in	O
prostate	B-DISEASE
cancer	I-DISEASE
patients	O
without	O
bone	O
involvement	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
two	O
patients	O
with	O
biopsy	O
-	O
proven	O
prostatic	O
adenocarcinoma	B-DISEASE
[	O
26	O
with	O
stage	O
C	O
(	O
T3N0M0	O
)	O
and	O
16	O
with	O
stage	O
D1	O
(	O
T3N1M0	O
)	O
]	O
were	O
included	O
in	O
this	O
study	O
.	O
All	O
patients	O
received	O
CAB	O
[	O
leuprolide	O
acetate	O
(	O
LHRH	O
-	O
A	O
)	O
3.75	O
mg	O
,	O
intramuscularly	O
,	O
every	O
28	O
days	O
plus	O
250	O
mg	O
flutamide	O
,	O
tid	O
,	O
per	O
Os	O
]	O
and	O
were	O
evaluated	O
for	O
anemia	B-DISEASE
by	O
physical	O
examination	O
and	O
laboratory	O
tests	O
at	O
baseline	O
and	O
4	O
subsequent	O
intervals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
CAB	O
)	O
.	O
Hb	O
,	O
PSA	O
and	O
Testosterone	B-CHEMICAL
measurements	O
were	O
recorded	O
.	O
Patients	O
with	O
stage	O
D2	O
-	O
3	O
disease	B-DISEASE
,	O
abnormal	O
hemoglobin	O
level	O
or	O
renal	O
and	O
liver	O
function	O
tests	O
that	O
were	O
higher	O
than	O
the	O
upper	O
limits	O
were	O
excluded	O
from	O
the	O
study	O
.	O
The	O
duration	O
of	O
the	O
study	O
was	O
six	O
months	O
.	O
RESULTS	O
:	O
The	O
mean	O
hemoglobin	O
(	O
Hb	O
)	O
levels	O
were	O
significantly	O
declined	O
in	O
all	O
patients	O
from	O
baseline	O
of	O
14.2	O
g	O
/	O
dl	O
to	O
14.0	O
g	O
/	O
dl	O
,	O
13.5	O
g	O
/	O
dl	O
,	O
13.2	O
g	O
/	O
dl	O
and	O
12.7	O
g	O
/	O
dl	O
at	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
CAB	O
,	O
respectively	O
.	O
Severe	O
and	O
clinically	O
evident	O
anemia	B-DISEASE
of	O
Hb	O
<	O
11	O
g	O
/	O
dl	O
with	O
clinical	O
symptoms	O
was	O
detected	O
in	O
6	O
patients	O
(	O
14.3	O
%	O
)	O
.	O
This	O
CAB	O
-	O
induced	O
anemia	B-DISEASE
was	O
normochromic	O
and	O
normocytic	O
.	O
At	O
six	O
months	O
post	O
-	O
CAB	O
,	O
patients	O
with	O
severe	O
anemia	B-DISEASE
had	O
a	O
Hb	O
mean	O
value	O
of	O
10.2	O
+	O
/-	O
0.1	O
g	O
/	O
dl	O
(	O
X	O
+	O
/-	O
SE	B-DISEASE
)	O
,	O
whereas	O
the	O
other	O
patients	O
had	O
mild	O
anemia	B-DISEASE
with	O
Hb	O
mean	O
value	O
of	O
13.2	O
+	O
/-	O
0.17	O
(	O
X	O
+	O
/-	O
SE	B-DISEASE
)	O
.	O
The	O
development	O
of	O
severe	O
anemia	B-DISEASE
at	O
6	O
months	O
post	O
-	O
CAB	O
was	O
predictable	O
by	O
the	O
reduction	O
of	O
Hb	O
baseline	O
value	O
of	O
more	O
than	O
2.5	O
g	O
/	O
dl	O
after	O
3	O
months	O
of	O
CAB	O
(	O
p	O
=	O
0.01	O
)	O
.	O
The	O
development	O
of	O
severe	O
CAB	O
-	O
induced	O
anemia	B-DISEASE
in	O
prostate	B-DISEASE
cancer	I-DISEASE
patients	O
did	O
not	O
correlate	O
with	O
T	O
baseline	O
values	O
(	O
T	O
<	O
3	O
ng	O
/	O
ml	O
versus	O
T	O
>	O
or	O
=	O
3	O
ng	O
/	O
ml	O
)	O
,	O
with	O
age	O
(	O
<	O
76	O
yrs	O
versus	O
>	O
or	O
=	O
76	O
yrs	O
)	O
,	O
and	O
clinical	O
stage	O
(	O
stage	O
C	O
versus	O
stage	O
D1	O
)	O
.	O
Severe	O
and	O
clinically	O
evident	O
anemia	B-DISEASE
was	O
easily	O
corrected	O
by	O
subcutaneous	O
injections	O
(	O
3	O
times	O
/	O
week	O
for	O
1	O
month	O
)	O
of	O
recombinant	O
erythropoietin	O
(	O
rHuEPO	O
-	O
beta	O
)	O
.	O
CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
rHuEPO	O
-	O
beta	O
correctable	O
CAB	O
-	O
induced	O
anemia	B-DISEASE
occurs	O
in	O
14.3	O
%	O
of	O
prostate	B-DISEASE
cancer	I-DISEASE
patients	O
after	O
6	O
months	O
of	O
therapy	O
.	O

Reversible	O
dilated	B-DISEASE
cardiomyopathy	I-DISEASE
related	O
to	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
therapy	O
.	O
We	O
describe	O
a	O
patient	O
who	O
developed	O
dilated	B-DISEASE
cardiomyopathy	I-DISEASE
and	O
clinical	O
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
after	O
2	O
months	O
of	O
therapy	O
with	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
(	O
AmB	B-CHEMICAL
)	O
for	O
disseminated	O
coccidioidomycosis	B-DISEASE
.	O
His	O
echocardiographic	O
abnormalities	O
and	O
heart	B-DISEASE
failure	I-DISEASE
resolved	O
after	O
posaconazole	O
was	O
substituted	O
for	O
AmB.	O
It	O
is	O
important	O
to	O
recognize	O
the	O
rare	O
and	O
potentially	O
reversible	O
toxicity	B-DISEASE
of	O
AmB.	O

Risks	O
of	O
the	O
consumption	O
of	O
beverages	O
containing	O
quinine	B-CHEMICAL
.	O
Although	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
banned	O
its	O
use	O
for	O
nocturnal	O
leg	B-DISEASE
cramps	I-DISEASE
due	O
to	O
lack	O
of	O
safety	O
and	O
efficacy	O
,	O
quinine	B-CHEMICAL
is	O
widely	O
available	O
in	O
beverages	O
including	O
tonic	O
water	O
and	O
bitter	O
lemon	O
.	O
Numerous	O
anecdotal	O
reports	O
suggest	O
that	O
products	O
containing	O
quinine	B-CHEMICAL
may	O
produce	O
neurological	O
complications	B-DISEASE
,	O
including	O
confusion	B-DISEASE
,	O
altered	O
mental	O
status	O
,	O
seizures	B-DISEASE
,	O
and	O
coma	B-DISEASE
,	O
particularly	O
in	O
older	O
women	O
.	O
Psychologists	O
need	O
to	O
inquire	O
about	O
consumption	O
of	O
quinine	B-CHEMICAL
-	O
containing	O
beverages	O
as	O
part	O
of	O
an	O
evaluation	O
process	O
.	O

Organophosphate	O
-	O
induced	O
convulsions	B-DISEASE
and	O
prevention	O
of	O
neuropathological	O
damages	O
.	O
Such	O
organophosphorus	O
(	O
OP	O
)	O
compounds	O
as	O
diisopropylfluorophosphate	B-CHEMICAL
(	O
DFP	O
)	O
,	O
sarin	O
and	O
soman	O
are	O
potent	O
inhibitors	O
of	O
acetylcholinesterases	O
(	O
AChEs	O
)	O
and	O
butyrylcholinesterases	O
(	O
BChEs	O
)	O
.	O
The	O
acute	O
toxicity	B-DISEASE
of	O
OPs	O
is	O
the	O
result	O
of	O
their	O
irreversible	O
binding	O
with	O
AChEs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
which	O
elevates	O
acetylcholine	O
(	O
ACh	B-CHEMICAL
)	O
levels	O
.	O
The	O
protective	O
action	O
of	O
subcutaneously	O
(	O
SC	O
)	O
administered	O
antidotes	O
or	O
their	O
combinations	O
in	O
DFP	O
(	O
2.0	O
mg	O
/	O
kg	O
BW	O
)	O
intoxication	O
was	O
studied	O
in	O
9	O
-	O
10	O
-	O
weeks	O
-	O
old	O
Han	O
-	O
Wistar	O
male	O
rats	O
.	O
The	O
rats	O
received	O
AChE	O
reactivator	O
pralidoxime-2	O
-	O
chloride	O
(	O
2PAM	B-CHEMICAL
)	O
(	O
30.0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
anticonvulsant	O
diazepam	B-CHEMICAL
(	O
2.0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
A(1)-adenosine	O
receptor	O
agonist	O
N(6)-cyclopentyl	O
adenosine	O
(	O
CPA	B-CHEMICAL
)	O
(	O
2.0	O
mg	O
/	O
kg	O
BW	O
)	O
,	O
NMDA	O
-	O
receptor	O
antagonist	O
dizocilpine	O
maleate	O
(	O
+	O
-MK801	O
hydrogen	O
maleate	O
)	O
(	O
2.0	O
mg	O
/	O
kg	O
BW	O
)	O
or	O
their	O
combinations	O
with	O
cholinolytic	O
drug	O
atropine	O
sulfate	O
(	O
50.0	O
mg	O
/	O
kg	O
BW	O
)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injection	O
of	O
DFP	O
.	O
The	O
control	O
rats	O
received	O
atropine	O
sulfate	O
,	O
but	O
also	O
saline	O
and	O
olive	O
oil	O
instead	O
of	O
other	O
antidotes	O
and	O
DFP	O
,	O
respectively	O
.	O
All	O
rats	O
were	O
terminated	O
either	O
24	O
h	O
or	O
3	O
weeks	O
after	O
the	O
DFP	O
injection	O
.	O
The	O
rats	O
treated	O
with	O
DFP	O
-	O
atropine	O
showed	O
severe	O
typical	O
OP	O
-	O
induced	O
toxicity	B-DISEASE
signs	O
.	O
When	O
CPA	B-CHEMICAL
,	O
diazepam	B-CHEMICAL
or	O
2PAM	B-CHEMICAL
was	O
given	O
immediately	O
after	O
DFP	O
-	O
atropine	O
,	O
these	O
treatments	O
prevented	O
,	O
delayed	O
or	O
shortened	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	B-DISEASE
.	O
Atropine	O
-	O
MK801	O
did	O
not	O
offer	O
any	O
additional	O
protection	O
against	O
DFP	O
toxicity	B-DISEASE
.	O
In	O
conclusion	O
,	O
CPA	B-CHEMICAL
,	O
diazepam	B-CHEMICAL
and	O
2PAM	B-CHEMICAL
in	O
combination	O
with	O
atropine	O
prevented	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	B-DISEASE
and	O
thus	O
reduced	O
the	O
toxicity	B-DISEASE
of	O
DFP	O
in	O
rat	O
.	O

Differential	O
modulation	O
by	O
estrogen	B-CHEMICAL
of	O
alpha2	O
-	O
adrenergic	O
and	O
I1	O
-	O
imidazoline	O
receptor	O
-	O
mediated	O
hypotension	B-DISEASE
in	O
female	O
rats	O
.	O
We	O
have	O
recently	O
shown	O
that	O
estrogen	B-CHEMICAL
negatively	O
modulates	O
the	O
hypotensive	B-DISEASE
effect	O
of	O
clonidine	B-CHEMICAL
(	O
mixed	O
alpha2-/I1	O
-	O
receptor	O
agonist	O
)	O
in	O
female	O
rats	O
and	O
implicates	O
the	O
cardiovascular	O
autonomic	O
control	O
in	O
this	O
interaction	O
.	O
The	O
present	O
study	O
investigated	O
whether	O
this	O
effect	O
of	O
estrogen	B-CHEMICAL
involves	O
interaction	O
with	O
alpha2-	O
and/or	O
I1	O
-	O
receptors	O
.	O
Changes	O
evoked	O
by	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
rilmenidine	O
(	O
600	O
microg	O
/	O
kg	O
)	O
or	O
alpha	O
-	O
methyldopa	B-CHEMICAL
(	O
100	O
mg	O
/	O
kg	O
)	O
,	O
selective	O
I1-	O
and	O
alpha2	O
-	O
receptor	O
agonists	O
,	O
respectively	O
,	O
in	O
blood	O
pressure	O
,	O
hemodynamic	O
variability	O
,	O
and	O
locomotor	O
activity	O
were	O
assessed	O
in	O
radiotelemetered	O
sham	O
-	O
operated	O
and	O
ovariectomized	O
(	O
Ovx	O
)	O
Sprague	O
-	O
Dawley	O
female	O
rats	O
with	O
or	O
without	O
12	O
-	O
wk	O
estrogen	B-CHEMICAL
replacement	O
.	O
Three	O
time	O
domain	O
indexes	O
of	O
hemodynamic	O
variability	O
were	O
employed	O
:	O
the	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure	O
as	O
a	O
measure	O
of	O
blood	O
pressure	O
variability	O
and	O
the	O
standard	O
deviation	O
of	O
beat	O
-	O
to	O
-	O
beat	O
intervals	O
(	O
SDRR	O
)	O
and	O
the	O
root	O
mean	O
square	O
of	O
successive	O
differences	O
in	O
R	O
-	O
wave	O
-	O
to	O
-	O
R	O
-	O
wave	O
intervals	O
as	O
measures	O
of	O
heart	O
rate	O
variability	O
.	O
In	O
sham	O
-	O
operated	O
rats	O
,	O
rilmenidine	O
or	O
alpha	O
-	O
methyldopa	B-CHEMICAL
elicited	O
similar	O
hypotension	B-DISEASE
that	O
lasted	O
at	O
least	O
5	O
h	O
and	O
was	O
associated	O
with	O
reductions	O
in	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure	O
.	O
SDRR	O
was	O
reduced	O
only	O
by	O
alpha	O
-	O
methyldopa	B-CHEMICAL
.	O
Ovx	O
significantly	O
enhanced	O
the	O
hypotensive	B-DISEASE
response	O
to	O
alpha	O
-	O
methyldopa	B-CHEMICAL
,	O
in	O
contrast	O
to	O
no	O
effect	O
on	O
rilmenidine	O
hypotension	B-DISEASE
.	O
The	O
enhanced	O
alpha	O
-	O
methyldopa	B-CHEMICAL
hypotension	B-DISEASE
in	O
Ovx	O
rats	O
was	O
paralleled	O
with	O
further	O
reduction	O
in	O
SDRR	O
and	O
a	B-DISEASE
reduced	I-DISEASE
locomotor	I-DISEASE
activity	I-DISEASE
.	O
Estrogen	B-CHEMICAL
replacement	O
(	O
17beta	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
subcutaneous	O
pellet	O
,	O
14.2	O
microg	O
/	O
day	O
,	O
12	O
wk	O
)	O
of	O
Ovx	O
rats	O
restored	O
the	O
hemodynamic	O
and	O
locomotor	O
effects	O
of	O
alpha	O
-	O
methyldopa	B-CHEMICAL
to	O
sham	O
-	O
operated	O
levels	O
.	O
These	O
findings	O
suggest	O
that	O
estrogen	B-CHEMICAL
downregulates	O
alpha2-	O
but	O
not	O
I1	O
-	O
receptor	O
-	O
mediated	O
hypotension	B-DISEASE
and	O
highlight	O
a	O
role	O
for	O
the	O
cardiac	O
autonomic	O
control	O
in	O
alpha	O
-	O
methyldopa	B-CHEMICAL
-	O
estrogen	B-CHEMICAL
interaction	O
.	O

Cardioprotective	O
effect	O
of	O
tincture	O
of	O
Crataegus	O
on	O
isoproterenol	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
in	O
rats	O
.	O
Tincture	O
of	O
Crataegus	O
(	O
TCR	O
)	O
,	O
an	O
alcoholic	O
extract	O
of	O
the	O
berries	O
of	O
hawthorn	O
(	O
Crataegus	O
oxycantha	O
)	O
,	O
is	O
used	O
in	O
herbal	O
and	O
homeopathic	O
medicine	O
.	O
The	O
present	O
study	O
was	O
done	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
TCR	O
on	O
experimentally	O
induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
in	O
rats	O
.	O
Pretreatment	O
of	O
TCR	O
,	O
at	O
a	O
dose	O
of	O
0.5	O
mL/100	O
g	O
bodyweight	O
per	O
day	O
,	O
orally	O
for	O
30	O
days	O
,	O
prevented	O
the	O
increase	O
in	O
lipid	O
peroxidation	O
and	O
activity	O
of	O
marker	O
enzymes	O
observed	O
in	O
isoproterenol	B-CHEMICAL
-	O
induced	O
rats	O
(	O
85	O
mg	O
kg(-1	O
)	O
s.	O
c.	O
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
)	O
.	O
TCR	O
prevented	O
the	O
isoproterenol	B-CHEMICAL
-	O
induced	O
decrease	O
in	O
antioxidant	O
enzymes	O
in	O
the	O
heart	O
and	O
increased	O
the	O
rate	O
of	O
ADP	B-CHEMICAL
-	O
stimulated	O
oxygen	B-CHEMICAL
uptake	O
and	O
respiratory	O
coupling	O
ratio	O
.	O
TCR	O
protected	O
against	O
pathological	O
changes	O
induced	O
by	O
isoproterenol	B-CHEMICAL
in	O
rat	O
heart	O
.	O
The	O
results	O
show	O
that	O
pretreatment	O
with	O
TCR	O
may	O
be	O
useful	O
in	O
preventing	O
the	O
damage	O
induced	O
by	O
isoproterenol	B-CHEMICAL
in	O
rat	O
heart	O
.	O

Safety	O
and	O
adverse	O
effects	O
associated	O
with	O
raloxifene	O
:	O
multiple	O
outcomes	O
of	O
raloxifene	O
evaluation	O
.	O
OBJECTIVE	O
:	O
To	O
examine	O
the	O
effect	O
of	O
raloxifene	O
on	O
major	O
adverse	O
events	O
that	O
occur	O
with	O
postmenopausal	O
estrogen	B-CHEMICAL
therapy	O
or	O
tamoxifen	B-CHEMICAL
.	O
METHODS	O
:	O
The	O
Multiple	O
Outcomes	O
of	O
Raloxifene	O
Evaluation	O
,	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	B-DISEASE
trial	O
,	O
enrolled	O
7,705	O
postmenopausal	O
women	O
with	O
osteoporosis	B-DISEASE
.	O
Women	O
were	O
randomly	O
assigned	O
to	O
raloxifene	O
60	O
mg	O
/	O
d	O
or	O
120	O
mg	O
/	O
d	O
or	O
placebo	O
.	O
Outcomes	O
included	O
venous	B-DISEASE
thromboembolism	I-DISEASE
,	O
cataracts	B-DISEASE
,	O
gallbladder	O
disease	B-DISEASE
,	O
and	O
endometrial	B-DISEASE
hyperplasia	I-DISEASE
or	O
cancer	B-DISEASE
.	O
RESULTS	O
:	O
During	O
a	O
mean	O
follow	O
-	O
up	O
of	O
3.3	O
years	O
,	O
raloxifene	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	B-DISEASE
thromboembolism	I-DISEASE
(	O
relative	O
risk	O
[	O
RR	O
]	O
2.1	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.2	O
-	O
3.8	O
)	O
.	O
The	O
excess	O
event	O
rate	O
was	O
1.8	O
per	O
1,000	O
woman	O
-	O
years	O
(	O
95	O
%	O
CI	O
-0.5	O
-	O
4.1	O
)	O
,	O
and	O
the	O
number	O
needed	O
to	O
treat	O
to	O
cause	O
1	O
event	O
was	O
170	O
(	O
95	O
%	O
CI	O
100	O
-	O
582	O
)	O
over	O
3.3	O
years	O
.	O
Risk	O
in	O
the	O
raloxifene	O
group	O
was	O
higher	O
than	O
in	O
the	O
placebo	O
group	O
for	O
the	O
first	O
2	O
years	O
,	O
but	O
decreased	O
to	O
about	O
the	O
same	O
rate	O
as	O
in	O
the	O
placebo	O
group	O
thereafter	O
.	O
Raloxifene	O
did	O
not	O
increase	O
risk	O
for	O
cataracts	B-DISEASE
(	O
RR	O
0.9	O
;	O
95	O
%	O
CI	O
0.8	O
-	O
1.1	O
)	O
,	O
gallbladder	O
disease	B-DISEASE
(	O
RR	O
1.0	O
;	O
95	O
%	O
CI	O
0.7	O
-	O
1.3	O
)	O
,	O
endometrial	B-DISEASE
hyperplasia	I-DISEASE
(	O
RR	O
1.3	O
;	O
95	O
%	O
CI	O
0.4	O
-	O
5.1	O
)	O
,	O
or	O
endometrial	B-DISEASE
cancer	I-DISEASE
(	O
RR	O
0.9	O
;	O
95	O
%	O
CI	O
0.3	O
-	O
2.7	O
)	O
.	O
CONCLUSION	O
:	O
Raloxifene	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	B-DISEASE
thromboembolism	I-DISEASE
,	O
but	O
there	O
was	O
no	O
increased	O
risk	O
for	O
cataracts	B-DISEASE
,	O
gallbladder	O
disease	B-DISEASE
,	O
endometrial	B-DISEASE
hyperplasia	I-DISEASE
,	O
or	O
endometrial	B-DISEASE
cancer	I-DISEASE
.	O
LEVEL	O
OF	O
EVIDENCE	O
:	O
I	O

Ceftriaxone	B-CHEMICAL
-	O
associated	O
biliary	B-DISEASE
pseudolithiasis	I-DISEASE
in	O
paediatric	O
surgical	O
patients	O
.	O
It	O
is	O
well	O
known	O
that	O
ceftriaxone	B-CHEMICAL
leads	O
to	O
pseudolithiasis	B-DISEASE
in	O
some	O
patients	O
.	O
Clinical	O
and	O
experimental	O
studies	O
also	O
suggest	O
that	O
situations	O
causing	O
gallbladder	O
dysfunction	O
,	O
such	O
as	O
fasting	O
,	O
may	O
have	O
a	O
role	O
for	O
the	O
development	O
of	O
pseudolithiasis	B-DISEASE
.	O
In	O
this	O
study	O
,	O
we	O
prospectively	O
evaluated	O
the	O
incidence	O
and	O
clinical	O
importance	O
of	O
pseudolithiasis	B-DISEASE
in	O
paediatric	O
surgical	O
patients	O
receiving	O
ceftriaxone	B-CHEMICAL
treatment	O
,	O
who	O
often	O
had	O
to	O
fast	O
in	O
the	O
post	O
-	O
operative	O
period	O
.	O
Fifty	O
children	O
who	O
were	O
given	O
ceftriaxone	B-CHEMICAL
were	O
evaluated	O
by	O
serial	O
abdominal	O
sonograms	O
.	O
Of	O
those	O
,	O
13	O
(	O
26	O
%	O
)	O
developed	O
biliary	O
pathology	O
.	O
Comparison	O
of	O
the	O
patients	O
with	O
or	O
without	O
pseudolithiasis	B-DISEASE
revealed	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
age	O
,	O
sex	O
,	O
duration	O
of	O
the	O
treatment	O
and	O
starvation	B-DISEASE
variables	O
.	O
After	O
cessation	O
of	O
the	O
treatment	O
,	O
pseudolithiasis	B-DISEASE
resolved	O
spontaneously	O
within	O
a	O
short	O
period	O
.	O
The	O
incidence	O
of	O
pseudolithiasis	B-DISEASE
is	O
not	O
affected	O
by	O
fasting	O
.	O

Evaluation	O
of	O
the	O
anticocaine	O
monoclonal	O
antibody	O
GNC92H2	O
as	O
an	O
immunotherapy	O
for	O
cocaine	B-DISEASE
overdose	I-DISEASE
.	O
The	O
illicit	O
use	O
of	O
cocaine	B-CHEMICAL
continues	O
in	O
epidemic	O
proportions	O
and	O
treatment	O
for	O
cocaine	B-DISEASE
overdose	I-DISEASE
remains	O
elusive	O
.	O
Current	O
protein	O
-	O
based	O
technology	O
offers	O
a	O
new	O
therapeutic	O
venue	O
by	O
which	O
antibodies	O
bind	O
the	O
drug	O
in	O
the	O
blood	O
stream	O
,	O
inactivating	O
its	O
toxic	O
effects	O
.	O
The	O
therapeutic	O
potential	O
of	O
the	O
anticocaine	O
antibody	O
GNC92H2	O
was	O
examined	O
using	O
a	O
model	O
of	O
cocaine	B-DISEASE
overdose	I-DISEASE
.	O
Swiss	O
albino	O
mice	O
prepared	O
with	O
intrajugular	O
catheters	O
were	O
tested	O
in	O
photocell	O
cages	O
after	O
administration	O
of	O
93	O
mg	O
/	O
kg	O
(	O
LD50	O
)	O
of	O
cocaine	B-CHEMICAL
and	O
GNC92H2	O
infusions	O
ranging	O
from	O
30	O
to	O
190	O
mg	O
/	O
kg	O
.	O
GNC92H2	O
was	O
delivered	O
30	O
min	O
before	O
,	O
concomitantly	O
or	O
3	O
min	O
after	O
cocaine	B-CHEMICAL
treatment	O
.	O
Significant	O
blockade	O
of	O
cocaine	B-CHEMICAL
toxicity	B-DISEASE
was	O
observed	O
with	O
the	O
higher	O
dose	O
of	O
GNC92H2	O
(	O
190	O
mg	O
/	O
kg	O
)	O
,	O
where	O
premorbid	O
behaviors	O
were	O
reduced	O
up	O
to	O
40	O
%	O
,	O
seizures	B-DISEASE
up	O
to	O
77	O
%	O
and	O
death	B-DISEASE
by	O
72	O
%	O
.	O
Importantly	O
,	O
GNC92H2	O
prevented	O
death	B-DISEASE
even	O
post	O
-	O
cocaine	B-CHEMICAL
injection	O
.	O
The	O
results	O
support	O
the	O
important	O
potential	O
of	O
GNC92H2	O
as	O
a	O
therapeutic	O
tool	O
against	O
cocaine	B-DISEASE
overdose	I-DISEASE
.	O

The	O
effects	O
of	O
short	O
-	O
term	O
raloxifene	O
therapy	O
on	O
fibrinolysis	O
markers	O
:	O
TAFI	O
,	O
tPA	O
,	O
and	O
PAI-1	O
.	O
BACKGROUND	O
:	O
Markers	O
of	O
fibrinolysis	O
,	O
thrombin	O
-	O
activatable	O
fibrinolysis	O
inhibitor	O
(	O
TAFI	O
)	O
,	O
tissue	O
-	O
type	O
plasminogen	O
activator	O
(	O
tPA	O
)	O
,	O
and	O
plasminogen	O
activator	O
inhibitor-1	O
(	O
PAI-1	O
)	O
levels	O
were	O
studied	O
for	O
the	O
evaluation	O
of	O
short	O
-	O
term	O
effects	O
of	O
raloxifene	O
administration	O
in	O
postmenopausal	O
women	O
.	O
METHODS	O
:	O
Thirty	O
-	O
nine	O
postmenopausal	O
women	O
with	O
osteopenia	O
or	O
osteoporosis	B-DISEASE
were	O
included	O
in	O
this	O
prospective	O
,	O
controlled	O
clinical	O
study	O
.	O
Twenty	O
-	O
five	O
women	O
were	O
given	O
raloxifene	O
hydrochloride	O
(	O
60	O
mg	O
/	O
day	O
)	O
plus	O
calcium	B-CHEMICAL
(	O
500	O
mg	O
/	O
day	O
)	O
.	O
Age	O
-	O
matched	O
controls	O
(	O
n	O
=	O
14	O
)	O
were	O
given	O
only	O
calcium	B-CHEMICAL
.	O
Plasma	O
TAFI	O
,	O
tPA	O
,	O
and	O
PAI-1	O
antigen	O
levels	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
3	O
months	O
of	O
treatment	O
by	O
commercially	O
available	O
ELISA	O
kits	O
.	O
Variations	O
of	O
individuals	O
were	O
assessed	O
by	O
Wilcoxon	O
's	O
test	O
.	O
Relationship	O
between	O
those	O
markers	O
and	O
demographic	O
characteristics	O
were	O
investigated	O
.	O
RESULTS	O
:	O
Three	O
months	O
of	O
raloxifene	O
treatment	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	O
TAFI	O
antigen	O
concentrations	O
(	O
16	O
%	O
change	O
,	O
P	O
<	O
0.01	O
)	O
,	O
and	O
a	O
significant	O
increase	O
in	O
tPA	O
antigen	O
concentrations	O
(	O
25	O
%	O
change	O
,	O
P	O
<	O
0.05	O
)	O
.	O
A	O
significant	O
correlation	O
was	O
found	O
between	O
baseline	O
TAFI	O
antigen	O
concentrations	O
and	O
the	O
duration	O
of	O
amenorrhea	B-DISEASE
(	O
P	O
<	O
0.05	O
;	O
r	O
=	O
0.33	O
)	O
.	O
CONCLUSION	O
:	O
We	O
suggest	O
that	O
the	O
increased	O
risk	O
of	O
venous	B-DISEASE
thromboembolism	I-DISEASE
due	O
to	O
raloxifene	O
treatment	O
may	O
be	O
related	O
to	O
increased	O
tPA	O
levels	O
,	O
but	O
not	O
TAFI	O
levels	O
.	O

Ketoconazole	B-CHEMICAL
induced	O
torsades	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
without	O
concomitant	O
use	O
of	O
QT	O
interval	O
-	O
prolonging	O
drug	O
.	O
Ketoconazole	B-CHEMICAL
is	O
not	O
known	O
to	O
be	O
proarrhythmic	O
without	O
concomitant	O
use	O
of	O
QT	O
interval	O
-	O
prolonging	O
drugs	O
.	O
We	O
report	O
a	O
woman	O
with	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
who	O
developed	O
a	O
markedly	O
prolonged	O
QT	O
interval	O
and	O
torsades	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
(	O
TdP	B-DISEASE
)	O
after	O
taking	O
ketoconazole	B-CHEMICAL
for	O
treatment	O
of	O
fungal	O
infection	B-DISEASE
.	O
Her	O
QT	O
interval	O
returned	O
to	O
normal	O
upon	O
withdrawal	O
of	O
ketoconazole	B-CHEMICAL
.	O
Genetic	O
study	O
did	O
not	O
find	O
any	O
mutation	O
in	O
her	O
genes	O
that	O
encode	O
cardiac	O
IKr	O
channel	O
proteins	O
.	O
We	O
postulate	O
that	O
by	O
virtue	O
of	O
its	O
direct	O
blocking	O
action	O
on	O
IKr	O
,	O
ketoconazole	B-CHEMICAL
alone	O
may	O
prolong	O
QT	O
interval	O
and	O
induce	O
TdP.	O
This	O
calls	O
for	O
attention	O
when	O
ketoconazole	B-CHEMICAL
is	O
administered	O
to	O
patients	O
with	O
risk	O
factors	O
for	O
acquired	O
long	B-DISEASE
QT	I-DISEASE
syndrome	I-DISEASE
.	O

Pharmacological	O
evidence	O
for	O
the	O
potential	O
of	O
Daucus	O
carota	O
in	O
the	O
management	O
of	O
cognitive	O
dysfunctions	O
.	O
The	O
present	O
study	O
was	O
aimed	O
at	O
investigating	O
the	O
effects	O
of	O
Daucus	O
carota	O
seeds	O
on	O
cognitive	O
functions	O
,	O
total	O
serum	O
cholesterol	B-CHEMICAL
levels	O
and	O
brain	O
cholinesterase	O
activity	O
in	O
mice	O
.	O
The	O
ethanolic	O
extract	O
of	O
Daucus	O
carota	O
seeds	O
(	O
DCE	O
)	O
was	O
administered	O
orally	O
in	O
three	O
doses	O
(	O
100	O
,	O
200	O
,	O
400	O
mg	O
/	O
kg	O
)	O
for	O
seven	O
successive	O
days	O
to	O
different	O
groups	O
of	O
young	O
and	O
aged	O
mice	O
.	O
Elevated	O
plus	O
maze	O
and	O
passive	O
avoidance	O
apparatus	O
served	O
as	O
the	O
exteroceptive	O
behavioral	O
models	O
for	O
testing	O
memory	O
.	O
Diazepam-	O
,	O
scopolamine-	O
and	O
ageing	O
-	O
induced	O
amnesia	B-DISEASE
served	O
as	O
the	O
interoceptive	O
behavioral	O
models	O
.	O
DCE	O
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
showed	O
significant	O
improvement	O
in	O
memory	O
scores	O
of	O
young	O
and	O
aged	O
mice	O
.	O
The	O
extent	O
of	O
memory	O
improvement	O
evoked	O
by	O
DCE	O
was	O
23	O
%	O
at	O
the	O
dose	O
of	O
200	O
mg	O
/	O
kg	O
and	O
35	O
%	O
at	O
the	O
dose	O
of	O
400	O
mg	O
/	O
kg	O
in	O
young	O
mice	O
using	O
elevated	O
plus	O
maze	O
.	O
Similarly	O
,	O
significant	O
improvements	O
in	O
memory	O
scores	O
were	O
observed	O
using	O
passive	O
avoidance	O
apparatus	O
and	O
aged	O
mice	O
.	O
Furthermore	O
,	O
DCE	O
reversed	O
the	O
amnesia	B-DISEASE
induced	O
by	O
scopolamine	B-CHEMICAL
(	O
0.4	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
and	O
diazepam	B-CHEMICAL
(	O
1	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O
Daucus	O
carota	O
extract	O
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
reduced	O
significantly	O
the	O
brain	O
acetylcholinesterase	O
activity	O
and	O
cholesterol	B-CHEMICAL
levels	O
in	O
young	O
and	O
aged	O
mice	O
.	O
The	O
extent	O
of	O
inhibition	O
of	O
brain	O
cholinesterase	O
activity	O
evoked	O
by	O
DCE	O
at	O
the	O
dose	O
of	O
400	O
mg	O
/	O
kg	O
was	O
22	O
%	O
in	O
young	O
and	O
19	O
%	O
in	O
aged	O
mice	O
.	O
There	O
was	O
a	O
remarkable	O
reduction	O
in	O
total	O
cholesterol	B-CHEMICAL
level	O
as	O
well	O
,	O
to	O
the	O
extent	O
of	O
23	O
%	O
in	O
young	O
and	O
21	O
%	O
in	O
aged	O
animals	O
with	O
this	O
dose	O
of	O
DCE	O
.	O
Therefore	O
,	O
DCE	O
may	O
prove	O
to	O
be	O
a	O
useful	O
remedy	O
for	O
the	O
management	O
of	O
cognitive	O
dysfunctions	O
on	O
account	O
of	O
its	O
multifarious	O
beneficial	O
effects	O
such	O
as	O
,	O
memory	O
improving	O
property	O
,	O
cholesterol	B-CHEMICAL
lowering	O
property	O
and	O
anticholinesterase	O
activity	O
.	O

Cauda	B-DISEASE
equina	I-DISEASE
syndrome	I-DISEASE
after	O
epidural	O
steroid	B-CHEMICAL
injection	O
:	O
a	O
case	O
report	O
.	O
OBJECTIVE	O
:	O
Conventional	O
treatment	O
methods	O
of	O
lumbusacral	O
radiculopathy	B-DISEASE
are	O
physical	O
therapy	O
,	O
epidural	O
steroid	B-CHEMICAL
injections	O
,	O
oral	O
medications	O
,	O
and	O
spinal	O
manipulative	O
therapy	O
.	O
Cauda	B-DISEASE
equina	I-DISEASE
syndrome	I-DISEASE
is	O
a	O
rare	O
complication	O
of	O
epidural	O
anesthesia	O
.	O
The	O
following	O
case	O
is	O
a	O
report	O
of	O
cauda	B-DISEASE
equina	I-DISEASE
syndrome	I-DISEASE
possibly	O
caused	O
by	O
epidural	O
injection	O
of	O
triamcinolone	O
and	O
bupivacaine	O
.	O
CLINICAL	O
FEATURES	O
:	O
A	O
50	O
-	O
year	O
-	O
old	O
woman	O
with	O
low	O
back	O
and	O
right	O
leg	O
pain	B-DISEASE
was	O
scheduled	O
for	O
epidural	O
steroid	B-CHEMICAL
injection	O
.	O
INTERVENTION	O
AND	O
OUTCOME	O
:	O
An	O
18	O
-	O
gauge	O
Touhy	O
needle	O
was	O
inserted	O
until	O
loss	O
of	O
resistance	O
occurred	O
at	O
the	O
L4	O
-	O
5	O
level	O
.	O
Spread	O
of	O
the	O
contrast	O
medium	O
within	O
the	O
epidural	O
space	O
was	O
determined	O
by	O
radiographic	O
imaging	O
.	O
After	O
verifying	O
the	O
epidural	O
space	O
,	O
bupivacaine	O
and	O
triamcinolone	B-CHEMICAL
diacetate	I-CHEMICAL
were	O
injected	O
.	O
After	O
the	O
injection	O
,	O
there	O
was	O
a	O
reduction	O
in	O
radicular	O
symptoms	O
.	O
Three	O
hours	O
later	O
,	O
she	O
complained	O
of	O
perineal	O
numbness	O
and	O
lower	O
extremity	O
weakness	B-DISEASE
.	O
The	O
neurologic	O
evaluation	O
revealed	O
loss	O
of	O
sensation	O
in	O
the	O
saddle	O
area	O
and	O
medial	O
aspect	O
of	O
her	O
right	O
leg	O
.	O
There	O
was	O
a	O
decrease	O
in	O
the	O
perception	O
of	O
pinprick	O
test	O
.	O
Deep	O
-	O
tendon	O
reflexes	O
were	O
decreased	O
especially	O
in	O
the	O
right	O
leg	O
.	O
She	O
was	O
unable	O
to	O
urinate	O
.	O
The	O
patient	O
's	O
symptoms	O
improved	O
slightly	O
over	O
the	O
next	O
few	O
hours	O
.	O
She	O
had	O
a	O
gradual	O
return	O
of	O
motor	O
function	O
and	O
ability	O
of	O
feeling	O
Foley	O
catheter	O
.	O
All	O
of	O
the	O
symptoms	O
were	O
completely	O
resolved	O
over	O
the	O
next	O
8	O
hours	O
.	O
CONCLUSION	O
:	O
Complications	B-DISEASE
associated	O
with	O
epidural	O
steroid	B-CHEMICAL
injections	O
are	O
rare	O
.	O
Clinical	O
examination	O
and	O
continued	O
vigilance	O
for	O
neurologic	O
deterioration	O
after	O
epidural	O
steroid	B-CHEMICAL
injections	O
is	O
important	O
.	O

High	O
-	O
dose	O
testosterone	B-CHEMICAL
is	O
associated	O
with	O
atherosclerosis	B-DISEASE
in	O
postmenopausal	O
women	O
.	O
OBJECTIVES	O
:	O
To	O
study	O
the	O
long	O
-	O
term	O
effects	O
of	O
androgen	O
treatment	O
on	O
atherosclerosis	B-DISEASE
in	O
postmenopausal	O
women	O
.	O
METHODS	O
:	O
In	O
a	O
population	O
-	O
based	O
study	O
in	O
513	O
naturally	O
postmenopausal	O
women	O
aged	O
54	O
-	O
67	O
years	O
,	O
we	O
studied	O
the	O
association	O
between	O
self	O
-	O
reported	O
intramuscularly	O
administered	O
high	O
-	O
dose	O
estrogen	B-CHEMICAL
-	O
testosterone	B-CHEMICAL
therapy	O
(	O
estradiol-	O
and	O
testosterone	B-CHEMICAL
esters	O
)	O
and	O
aortic	O
atherosclerosis	B-DISEASE
.	O
Aortic	O
atherosclerosis	B-DISEASE
was	O
diagnosed	O
by	O
radiographic	O
detection	O
of	O
calcified	O
deposits	O
in	O
the	O
abdominal	O
aorta	O
,	O
which	O
have	O
been	O
shown	O
to	O
reflect	O
intima	O
atherosclerosis	B-DISEASE
.	O
Hormone	O
therapy	O
users	O
were	O
compared	O
with	O
never	O
users	O
.	O
RESULTS	O
:	O
Intramuscular	O
hormone	O
therapy	O
use	O
for	O
1	O
year	O
or	O
longer	O
was	O
reported	O
by	O
25	O
women	O
.	O
In	O
almost	O
half	O
of	O
these	O
women	O
severe	O
atherosclerosis	B-DISEASE
of	O
the	O
aorta	O
was	O
present	O
(	O
n=11	O
)	O
,	O
while	O
in	O
women	O
without	O
hormone	O
use	O
severe	O
atherosclerosis	B-DISEASE
of	O
the	O
aorta	O
was	O
present	O
in	O
less	O
than	O
20	O
%	O
(	O
OR	O
3.1	O
;	O
95	O
%	O
CI	O
,	O
1.1	O
-	O
8.5	O
,	O
adjusted	O
for	O
age	O
,	O
years	O
since	O
menopause	B-DISEASE
,	O
smoking	B-CHEMICAL
,	O
and	O
body	O
mass	O
index	O
)	O
.	O
The	O
association	O
remained	O
after	O
additional	O
adjustment	O
for	O
diabetes	B-DISEASE
,	O
cholesterol	B-CHEMICAL
level	O
,	O
systolic	O
blood	O
pressure	O
,	O
or	O
alcohol	O
use	O
.	O
No	O
association	O
was	O
found	O
for	O
hormone	O
use	O
less	O
than	O
1	O
year	O
.	O
CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
high	O
-	O
dose	O
testosterone	B-CHEMICAL
therapy	O
may	O
adversely	O
affect	O
atherosclerosis	B-DISEASE
in	O
postmenopausal	O
women	O
and	O
indicate	O
that	O
androgen	O
replacement	O
in	O
these	O
women	O
may	O
not	O
be	O
harmless	O
.	O

Sirolimus	B-CHEMICAL
-	O
associated	O
proteinuria	B-DISEASE
and	O
renal	B-DISEASE
dysfunction	I-DISEASE
.	O
Sirolimus	B-CHEMICAL
is	O
a	O
novel	O
immunosuppressant	O
with	O
potent	O
antiproliferative	O
actions	O
through	O
its	O
ability	O
to	O
inhibit	O
the	O
raptor	O
-	O
containing	O
mammalian	O
target	O
of	O
rapamycin	B-CHEMICAL
protein	O
kinase	O
.	O
Sirolimus	B-CHEMICAL
represents	O
a	O
major	O
therapeutic	O
advance	O
in	O
the	O
prevention	O
of	O
acute	O
renal	O
allograft	O
rejection	O
and	O
chronic	B-DISEASE
allograft	I-DISEASE
nephropathy	I-DISEASE
.	O
Its	O
role	O
in	O
the	O
therapy	O
of	O
glomerulonephritis	B-DISEASE
,	O
autoimmunity	B-DISEASE
,	O
cystic	B-DISEASE
renal	I-DISEASE
diseases	I-DISEASE
and	O
renal	O
cancer	B-DISEASE
is	O
under	O
investigation	O
.	O
Because	O
sirolimus	B-CHEMICAL
does	O
not	O
share	O
the	O
vasomotor	O
renal	O
adverse	O
effects	O
exhibited	O
by	O
calcineurin	B-CHEMICAL
inhibitors	I-CHEMICAL
,	O
it	O
has	O
been	O
designated	O
a	O
'	O
non	O
-	O
nephrotoxic	B-DISEASE
drug	O
'	O
.	O
However	O
,	O
clinical	O
reports	O
suggest	O
that	O
,	O
under	O
some	O
circumstances	O
,	O
sirolimus	B-CHEMICAL
is	O
associated	O
with	O
proteinuria	B-DISEASE
and	O
acute	B-DISEASE
renal	I-DISEASE
dysfunction	I-DISEASE
.	O
A	O
common	O
risk	O
factor	O
appears	O
to	O
be	O
presence	O
of	O
pre	O
-	O
existing	O
chronic	B-DISEASE
renal	I-DISEASE
damage	I-DISEASE
.	O
The	O
mechanisms	O
of	O
sirolimus	B-CHEMICAL
-	O
associated	O
proteinuria	B-DISEASE
are	O
multifactorial	O
and	O
may	O
be	O
due	O
to	O
an	O
increase	O
in	O
glomerular	O
capillary	O
pressure	O
following	O
calcineurin	O
inhibitor	O
withdrawal	O
.	O
It	O
has	O
also	O
been	O
suggested	O
that	O
sirolimus	B-CHEMICAL
directly	O
causes	O
increased	O
glomerular	O
permeability	O
/	O
injury	O
,	O
but	O
evidence	O
for	O
this	O
mechanism	O
is	O
currently	O
inconclusive	O
.	O
The	O
acute	B-DISEASE
renal	I-DISEASE
dysfunction	I-DISEASE
associated	O
with	O
sirolimus	B-CHEMICAL
(	O
such	O
as	O
in	O
delayed	B-DISEASE
graft	I-DISEASE
function	I-DISEASE
)	O
may	O
be	O
due	O
to	O
suppression	O
of	O
compensatory	O
renal	O
cell	O
proliferation	O
and	O
survival	O
/	O
repair	O
processes	O
.	O
Although	O
these	O
adverse	O
effects	O
occur	O
in	O
some	O
patients	O
,	O
their	O
occurrence	O
could	O
be	O
minimised	O
by	O
knowledge	O
of	O
the	O
molecular	O
effects	O
of	O
sirolimus	B-CHEMICAL
on	O
the	O
kidney	O
,	O
the	O
use	O
of	O
sirolimus	B-CHEMICAL
in	O
appropriate	O
patient	O
populations	O
,	O
close	O
monitoring	O
of	O
proteinuria	B-DISEASE
and	O
renal	O
function	O
,	O
use	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitors	O
or	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
receptor	O
blockers	O
if	O
proteinuria	B-DISEASE
occurs	O
and	O
withdrawal	O
if	O
needed	O
.	O
Further	O
long	O
-	O
term	O
analysis	O
of	O
renal	O
allograft	O
studies	O
using	O
sirolimus	B-CHEMICAL
as	O
de	O
novo	O
immunosuppression	O
along	O
with	O
clinical	O
and	O
laboratory	O
studies	O
will	O
refine	O
these	O
issues	O
in	O
the	O
future	O
.	O

Progressive	O
myopathy	B-DISEASE
with	O
up	O
-	O
regulation	O
of	O
MHC	O
-	O
I	O
associated	O
with	O
statin	B-CHEMICAL
therapy	O
.	O
Statins	B-CHEMICAL
can	O
cause	O
a	O
necrotizing	O
myopathy	B-DISEASE
and	O
hyperCKaemia	O
which	O
is	O
reversible	O
on	O
cessation	O
of	O
the	O
drug	O
.	O
What	O
is	O
less	O
well	O
known	O
is	O
a	O
phenomenon	O
whereby	O
statins	B-CHEMICAL
may	O
induce	O
a	O
myopathy	B-DISEASE
,	O
which	O
persists	O
or	O
may	O
progress	O
after	O
stopping	O
the	O
drug	O
.	O
We	O
investigated	O
the	O
muscle	O
pathology	O
in	O
8	O
such	O
cases	O
.	O
All	O
had	O
myofibre	O
necrosis	B-DISEASE
but	O
only	O
3	O
had	O
an	O
inflammatory	O
infiltrate	O
.	O
In	O
all	O
cases	O
there	O
was	O
diffuse	O
or	O
multifocal	O
up	O
-	O
regulation	O
of	O
MHC	O
-	O
I	O
expression	O
even	O
in	O
non	O
-	O
necrotic	B-DISEASE
fibres	O
.	O
Progressive	O
improvement	O
occurred	O
in	O
7	O
cases	O
after	O
commencement	O
of	O
prednisolone	B-CHEMICAL
and	O
methotrexate	B-CHEMICAL
,	O
and	O
in	O
one	O
case	O
spontaneously	O
.	O
These	O
observations	O
suggest	O
that	O
statins	B-CHEMICAL
may	O
initiate	O
an	O
immune	O
-	O
mediated	O
myopathy	B-DISEASE
that	O
persists	O
after	O
withdrawal	O
of	O
the	O
drug	O
and	O
responds	O
to	O
immunosuppressive	O
therapy	O
.	O
The	O
mechanism	O
of	O
this	O
myopathy	B-DISEASE
is	O
uncertain	O
but	O
may	O
involve	O
the	O
induction	O
by	O
statins	B-CHEMICAL
of	O
an	O
endoplasmic	O
reticulum	O
stress	B-DISEASE
response	O
with	O
associated	O
up	O
-	O
regulation	O
of	O
MHC	O
-	O
I	O
expression	O
and	O
antigen	O
presentation	O
by	O
muscle	O
fibres	O
.	O

Direct	O
inhibition	O
of	O
cardiac	O
hyperpolarization	O
-	O
activated	O
cyclic	O
nucleotide	O
-	O
gated	O
pacemaker	O
channels	O
by	O
clonidine	B-CHEMICAL
.	O
BACKGROUND	O
:	O
Inhibition	O
of	O
cardiac	O
sympathetic	O
tone	O
represents	O
an	O
important	O
strategy	O
for	O
treatment	O
of	O
cardiovascular	B-DISEASE
disease	I-DISEASE
,	O
including	O
arrhythmia	B-DISEASE
,	O
coronary	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
,	O
and	O
chronic	O
heart	B-DISEASE
failure	I-DISEASE
.	O
Activation	O
of	O
presynaptic	O
alpha2	O
-	O
adrenoceptors	O
is	O
the	O
most	O
widely	O
accepted	O
mechanism	O
of	O
action	O
of	O
the	O
antisympathetic	O
drug	O
clonidine	B-CHEMICAL
;	O
however	O
,	O
other	O
target	O
proteins	O
have	O
been	O
postulated	O
to	O
contribute	O
to	O
the	O
in	O
vivo	O
actions	O
of	O
clonidine	B-CHEMICAL
.	O
METHODS	O
AND	O
RESULTS	O
:	O
To	O
test	O
whether	O
clonidine	B-CHEMICAL
elicits	O
pharmacological	O
effects	O
independent	O
of	O
alpha2	O
-	O
adrenoceptors	O
,	O
we	O
have	O
generated	O
mice	O
with	O
a	O
targeted	O
deletion	O
of	O
all	O
3	O
alpha2	O
-	O
adrenoceptor	O
subtypes	O
(	O
alpha2ABC-/-	O
)	O
.	O
Alpha2ABC-/-	O
mice	O
were	O
completely	O
unresponsive	O
to	O
the	O
analgesic	O
and	O
hypnotic	O
effects	O
of	O
clonidine	B-CHEMICAL
;	O
however	O
,	O
clonidine	B-CHEMICAL
significantly	O
lowered	O
heart	O
rate	O
in	O
alpha2ABC-/-	O
mice	O
by	O
up	O
to	O
150	O
bpm	O
.	O
Clonidine	B-CHEMICAL
-	O
induced	O
bradycardia	B-DISEASE
in	O
conscious	O
alpha2ABC-/-	O
mice	O
was	O
32.3	O
%	O
(	O
10	O
microg	O
/	O
kg	O
)	O
and	O
26.6	O
%	O
(	O
100	O
microg	O
/	O
kg	O
)	O
of	O
the	O
effect	O
in	O
wild	O
-	O
type	O
mice	O
.	O
A	O
similar	O
bradycardic	B-DISEASE
effect	O
of	O
clonidine	B-CHEMICAL
was	O
observed	O
in	O
isolated	O
spontaneously	O
beating	O
right	O
atria	O
from	O
alpha2ABC	O
-	O
knockout	O
and	O
wild	O
-	O
type	O
mice	O
.	O
Clonidine	B-CHEMICAL
inhibited	O
the	O
native	O
pacemaker	O
current	O
(	O
I(f	O
)	O
)	O
in	O
isolated	O
sinoatrial	O
node	O
pacemaker	O
cells	O
and	O
the	O
I(f)-generating	O
hyperpolarization	O
-	O
activated	O
cyclic	O
nucleotide	O
-	O
gated	O
(	O
HCN	O
)	O
2	O
and	O
HCN4	O
channels	O
in	O
transfected	O
HEK293	O
cells	O
.	O
As	O
a	O
consequence	O
of	O
blocking	O
I(f	O
)	O
,	O
clonidine	B-CHEMICAL
reduced	O
the	O
slope	O
of	O
the	O
diastolic	O
depolarization	O
and	O
the	O
frequency	O
of	O
pacemaker	O
potentials	O
in	O
sinoatrial	O
node	O
cells	O
from	O
wild	O
-	O
type	O
and	O
alpha2ABC	O
-	O
knockout	O
mice	O
.	O
CONCLUSIONS	O
:	O
Direct	O
inhibition	O
of	O
cardiac	O
HCN	O
pacemaker	O
channels	O
contributes	O
to	O
the	O
bradycardic	B-DISEASE
effects	O
of	O
clonidine	B-CHEMICAL
gene	O
-	O
targeted	O
mice	O
in	O
vivo	O
,	O
and	O
thus	O
,	O
clonidine	B-CHEMICAL
-	O
like	O
drugs	O
represent	O
novel	O
structures	O
for	O
future	O
HCN	O
channel	O
inhibitors	O
.	O

Influence	O
of	O
smoking	B-CHEMICAL
on	O
developing	O
cochlea	O
.	O
Does	O
smoking	B-CHEMICAL
during	O
pregnancy	O
affect	O
the	O
amplitudes	O
of	O
transient	O
evoked	O
otoacoustic	O
emissions	O
in	O
newborns	O
?	O
OBJECTIVE	O
:	O
Maternal	O
tobacco	O
smoking	B-CHEMICAL
has	O
negative	O
effects	O
on	O
fetal	O
growth	O
.	O
The	O
influence	O
of	O
smoking	B-CHEMICAL
during	O
pregnancy	O
on	O
the	O
developing	O
cochlea	O
has	O
not	O
been	O
estimated	O
,	O
although	O
smoking	B-CHEMICAL
has	O
been	O
positively	O
associated	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
adults	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
maternal	O
smoking	B-CHEMICAL
on	O
transient	O
evoked	O
otoacoustic	O
emissions	O
(	O
TEOAEs	O
)	O
of	O
healthy	O
neonates	O
.	O
METHODS	O
:	O
This	O
study	O
was	O
undertaken	O
as	O
part	O
of	O
neonatal	O
screening	O
for	O
hearing	O
impairment	O
and	O
involved	O
both	O
ears	O
of	O
200	O
newborns	O
.	O
Newborns	O
whose	O
mothers	O
reported	O
smoking	B-CHEMICAL
during	O
pregnancy	O
(	O
n=200	O
ears	O
)	O
were	O
compared	O
to	O
a	O
control	O
group	O
of	O
newborns	O
(	O
n=200	O
ears	O
)	O
,	O
whose	O
mothers	O
were	O
non	O
-	O
smokers	O
.	O
Exposure	O
to	O
tobacco	O
was	O
characterized	O
as	O
low	O
(	O
<	O
5	O
cigarettes	O
per	O
day	O
,	O
n=88	O
ears	O
)	O
,	O
moderate	O
(	O
5	O
<	O
or	O
=	O
cigarettes	O
per	O
day<10	O
,	O
n=76	O
)	O
or	O
high	O
(	O
>	O
or	O
=	O
10	O
cigarettes	O
per	O
day	O
,	O
n=36	O
)	O
.	O
RESULTS	O
:	O
In	O
exposed	O
neonates	O
,	O
TEOAEs	O
mean	O
response	O
(	O
across	O
frequency	O
)	O
and	O
mean	O
amplitude	O
at	O
4000Hz	O
was	O
significantly	O
lower	O
than	O
in	O
non	O
-	O
exposed	O
neonates	O
.	O
Comparisons	O
between	O
exposed	O
newborns	O
'	O
subgroups	O
revealed	O
no	O
significant	O
differences	O
.	O
However	O
,	O
by	O
comparing	O
each	O
subgroup	O
to	O
control	O
group	O
,	O
we	O
found	O
statistically	O
significant	O
decreases	B-DISEASE
of	I-DISEASE
TEOAEs	I-DISEASE
amplitudes	I-DISEASE
at	O
4000Hz	O
for	O
all	O
three	O
groups	O
.	O
Mean	O
TEOAEs	O
responses	O
of	O
highly	O
exposed	O
newborns	O
were	O
also	O
significantly	O
lower	O
in	O
comparison	O
to	O
our	O
control	O
group	O
.	O
CONCLUSION	O
:	O
In	O
utero	O
,	O
exposure	O
to	O
tobacco	O
smoking	B-CHEMICAL
seems	O
to	O
have	O
a	O
small	O
impact	O
on	O
outer	O
hair	O
cells	O
.	O
These	O
effects	O
seem	O
to	O
be	O
equally	O
true	O
for	O
all	O
exposed	O
newborns	O
,	O
regardless	O
of	O
the	O
degree	O
of	O
exposure	O
.	O
Further	O
studies	O
are	O
needed	O
in	O
order	O
to	O
establish	O
a	O
potential	O
negative	O
effect	O
of	O
maternal	O
smoking	B-CHEMICAL
on	O
the	O
neonate	O
's	O
hearing	O
acuity	O
.	O

Neuroinflammation	O
and	O
behavioral	B-DISEASE
abnormalities	I-DISEASE
after	O
neonatal	O
terbutaline	B-CHEMICAL
treatment	O
in	O
rats	O
:	O
implications	O
for	O
autism	B-DISEASE
.	O
Autism	B-DISEASE
is	O
a	O
neurodevelopmental	O
disorder	O
presenting	O
before	O
3	O
years	O
of	O
age	O
with	O
deficits	B-DISEASE
in	I-DISEASE
communication	I-DISEASE
and	I-DISEASE
social	I-DISEASE
skills	I-DISEASE
and	O
repetitive	O
behaviors	O
.	O
In	O
addition	O
to	O
genetic	O
influences	O
,	O
recent	O
studies	O
suggest	O
that	O
prenatal	O
drug	O
or	O
chemical	O
exposures	O
are	O
risk	O
factors	O
for	O
autism	B-DISEASE
.	O
Terbutaline	B-CHEMICAL
,	O
a	O
beta2	O
-	O
adrenoceptor	O
agonist	O
used	O
to	O
arrest	O
preterm	O
labor	O
,	O
has	O
been	O
associated	O
with	O
increased	O
concordance	O
for	O
autism	B-DISEASE
in	O
dizygotic	O
twins	O
.	O
We	O
studied	O
the	O
effects	O
of	O
terbutaline	B-CHEMICAL
on	O
microglial	O
activation	O
in	O
different	O
brain	O
regions	O
and	O
behavioral	O
outcomes	O
in	O
developing	O
rats	O
.	O
Newborn	O
rats	O
were	O
given	O
terbutaline	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
)	O
daily	O
on	O
postnatal	O
days	O
(	O
PN	O
)	O
2	O
to	O
5	O
or	O
PN	O
11	O
to	O
14	O
and	O
examined	O
24	O
h	O
after	O
the	O
last	O
dose	O
and	O
at	O
PN	O
30	O
.	O
Immunohistochemical	O
studies	O
showed	O
that	O
administration	O
of	O
terbutaline	B-CHEMICAL
on	O
PN	O
2	O
to	O
5	O
produced	O
a	O
robust	O
increase	O
in	O
microglial	O
activation	O
on	O
PN	O
30	O
in	O
the	O
cerebral	O
cortex	O
,	O
as	O
well	O
as	O
in	O
cerebellar	O
and	O
cerebrocortical	O
white	O
matter	O
.	O
None	O
of	O
these	O
effects	O
occurred	O
in	O
animals	O
given	O
terbutaline	B-CHEMICAL
on	O
PN	O
11	O
to	O
14	O
.	O
In	O
behavioral	O
tests	O
,	O
animals	O
treated	O
with	O
terbutaline	B-CHEMICAL
on	O
PN	O
2	O
to	O
5	O
showed	O
consistent	O
patterns	O
of	O
hyper	O
-	O
reactivity	O
to	O
novelty	O
and	O
aversive	O
stimuli	O
when	O
assessed	O
in	O
a	O
novel	O
open	O
field	O
,	O
as	O
well	O
as	O
in	O
the	O
acoustic	O
startle	O
response	O
test	O
.	O
Our	O
findings	O
indicate	O
that	O
beta2	O
-	O
adrenoceptor	O
overstimulation	O
during	O
an	O
early	O
critical	O
period	O
results	O
in	O
microglial	O
activation	O
associated	O
with	O
innate	O
neuroinflammatory	O
pathways	O
and	O
behavioral	B-DISEASE
abnormalities	I-DISEASE
,	O
similar	O
to	O
those	O
described	O
in	O
autism	B-DISEASE
.	O
This	O
study	O
provides	O
a	O
useful	O
animal	O
model	O
for	O
understanding	O
the	O
neuropathological	O
processes	O
underlying	O
autism	B-DISEASE
spectrum	I-DISEASE
disorders	I-DISEASE
.	O

Acute	O
myocarditis	B-DISEASE
associated	O
with	O
clozapine	B-CHEMICAL
.	O
OBJECTIVE	O
:	O
A	O
case	O
of	O
acute	O
myocarditis	B-DISEASE
associated	O
with	O
the	O
commencement	O
of	O
clozapine	B-CHEMICAL
is	O
described	O
,	O
highlighting	O
the	O
onset	O
,	O
course	O
and	O
possible	O
contributing	O
factors	O
.	O
There	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareness	O
about	O
this	O
potentially	O
fatal	O
complication	O
of	O
clozapine	B-CHEMICAL
use	O
.	O
RESULTS	O
:	O
A	O
20	O
-	O
year	O
-	O
old	O
male	O
with	O
schizophrenia	B-DISEASE
developed	O
a	O
sudden	O
onset	O
of	O
myocarditis	B-DISEASE
after	O
commencement	O
of	O
clozapine	B-CHEMICAL
.	O
The	O
patient	O
recovered	O
with	O
intensive	O
medical	O
support	O
.	O
The	O
symptoms	O
occurred	O
around	O
2	O
weeks	O
after	O
starting	O
clozapine	B-CHEMICAL
in	O
an	O
inpatient	O
setting	O
.	O
Possible	O
contributing	O
factors	O
may	O
have	O
been	O
concomitant	O
antidepressant	O
use	O
and	O
unaccustomed	O
physical	O
activity	O
.	O
CONCLUSIONS	O
:	O
Myocarditis	B-DISEASE
is	O
an	O
increasingly	O
recognized	O
complication	O
associated	O
with	O
the	O
use	O
of	O
clozapine	B-CHEMICAL
.	O
It	O
can	O
be	O
fatal	O
if	O
not	O
recognized	O
and	O
treated	O
early	O
.	O
Considering	O
that	O
clozapine	B-CHEMICAL
remains	O
the	O
gold	O
standard	O
in	O
treatment	O
of	O
resistant	O
psychosis	B-DISEASE
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareness	O
among	O
medical	O
and	O
paramedical	O
staff	O
involved	O
in	O
the	O
care	O
of	O
these	O
patients	O
.	O
There	O
are	O
also	O
implications	O
for	O
recommendations	O
and	O
regulations	O
regarding	O
the	O
use	O
of	O
clozapine	B-CHEMICAL
.	O

Encephalopathy	B-DISEASE
induced	O
by	O
levetiracetam	B-CHEMICAL
added	O
to	O
valproate	O
.	O
BACKGROUND	O
:	O
We	O
report	O
on	O
the	O
manifestation	O
of	O
a	O
levetiracetam	B-CHEMICAL
(	O
LEV)-induced	O
encephalopathy	B-DISEASE
.	O
FINDINGS	O
:	O
A	O
28	O
-	O
year	O
-	O
old	O
man	O
suffering	O
from	O
idiopathic	B-DISEASE
epilepsy	I-DISEASE
with	O
generalized	O
seizures	B-DISEASE
was	O
treated	O
with	O
LEV	O
(	O
3000	O
mg	O
)	O
added	O
to	O
valproate	O
(	O
VPA	O
)	O
(	O
2000	O
mg	O
)	O
.	O
Frequency	O
of	O
generalized	O
tonic	B-DISEASE
-	I-DISEASE
clonic	I-DISEASE
seizures	I-DISEASE
increased	O
from	O
one	O
per	O
6	O
months	O
to	O
two	O
per	O
month	O
.	O
Neuropsychological	O
testing	O
showed	O
impaired	O
word	O
fluency	O
,	O
psychomotor	O
speed	O
and	O
working	O
memory	O
.	O
The	O
interictal	O
electroencephalogram	O
(	O
EEG	O
)	O
showed	O
a	O
generalized	O
slowing	O
to	O
5	O
per	O
second	O
theta	O
rhythms	O
with	O
bilateral	O
generalized	O
high	O
-	O
amplitude	O
discharges	O
.	O
OUTCOME	O
:	O
Following	O
discontinuation	O
of	O
LEV	O
,	O
EEG	O
and	O
neuropsychological	O
findings	O
improved	O
and	O
seizure	B-DISEASE
frequency	O
decreased	O
.	O

Norepinephrine	B-CHEMICAL
signaling	O
through	O
beta	O
-	O
adrenergic	O
receptors	O
is	O
critical	O
for	O
expression	O
of	O
cocaine	B-CHEMICAL
-	O
induced	O
anxiety	B-DISEASE
.	O
BACKGROUND	O
:	O
Cocaine	B-CHEMICAL
is	O
a	O
widely	O
abused	O
psychostimulant	O
that	O
has	O
both	O
rewarding	O
and	O
aversive	O
properties	O
.	O
While	O
the	O
mechanisms	O
underlying	O
cocaine	B-CHEMICAL
's	O
rewarding	O
effects	O
have	O
been	O
studied	O
extensively	O
,	O
less	O
attention	O
has	O
been	O
paid	O
to	O
the	O
unpleasant	O
behavioral	O
states	O
induced	O
by	O
cocaine	B-CHEMICAL
,	O
such	O
as	O
anxiety	B-DISEASE
.	O
METHODS	O
:	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
performance	O
of	O
dopamine	B-CHEMICAL
beta	O
-	O
hydroxylase	O
knockout	O
(	O
Dbh	O
-/-	O
)	O
mice	O
,	O
which	O
lack	O
norepinephrine	B-CHEMICAL
(	O
NE	O
)	O
,	O
in	O
the	O
elevated	O
plus	O
maze	O
(	O
EPM	O
)	O
to	O
examine	O
the	O
contribution	O
of	O
noradrenergic	O
signaling	O
to	O
cocaine	B-CHEMICAL
-	O
induced	O
anxiety	B-DISEASE
.	O
RESULTS	O
:	O
We	O
found	O
that	O
cocaine	B-CHEMICAL
dose	O
-	O
dependently	O
increased	O
anxiety	B-DISEASE
-	O
like	O
behavior	O
in	O
control	O
(	O
Dbh	O
+	O
/-	O
)	O
mice	O
,	O
as	O
measured	O
by	O
a	O
decrease	O
in	O
open	O
arm	O
exploration	O
.	O
The	O
Dbh	O
-/-	O
mice	O
had	O
normal	O
baseline	O
performance	O
in	O
the	O
EPM	O
but	O
were	O
completely	O
resistant	O
to	O
the	O
anxiogenic	O
effects	O
of	O
cocaine	B-CHEMICAL
.	O
Cocaine	B-CHEMICAL
-	O
induced	O
anxiety	B-DISEASE
was	O
also	O
attenuated	O
in	O
Dbh	O
+	O
/-	O
mice	O
following	O
administration	O
of	O
disulfiram	B-CHEMICAL
,	O
a	O
dopamine	B-CHEMICAL
beta	O
-	O
hydroxylase	O
(	O
DBH	O
)	O
inhibitor	O
.	O
In	O
experiments	O
using	O
specific	O
adrenergic	B-CHEMICAL
antagonists	I-CHEMICAL
,	O
we	O
found	O
that	O
pretreatment	O
with	O
the	O
beta	O
-	O
adrenergic	O
receptor	O
antagonist	O
propranolol	B-CHEMICAL
blocked	O
cocaine	B-CHEMICAL
-	O
induced	O
anxiety	B-DISEASE
-	O
like	O
behavior	O
in	O
Dbh	O
+	O
/-	O
and	O
wild	O
-	O
type	O
C57BL6	O
/	O
J	O
mice	O
,	O
while	O
the	O
alpha(1	O
)	O
antagonist	O
prazosin	B-CHEMICAL
and	O
the	O
alpha(2	O
)	O
antagonist	O
yohimbine	B-CHEMICAL
had	O
no	O
effect	O
.	O
CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
noradrenergic	O
signaling	O
via	O
beta	O
-	O
adrenergic	O
receptors	O
is	O
required	O
for	O
cocaine	B-CHEMICAL
-	O
induced	O
anxiety	B-DISEASE
in	O
mice	O
.	O

Clonidine	B-CHEMICAL
for	O
attention	B-DISEASE
-	I-DISEASE
deficit	I-DISEASE
/	I-DISEASE
hyperactivity	I-DISEASE
disorder	I-DISEASE
:	O
II	O
.	O
ECG	O
changes	O
and	O
adverse	O
events	O
analysis	O
.	O
OBJECTIVE	O
:	O
To	O
examine	O
the	O
safety	O
and	O
tolerability	O
of	O
clonidine	B-CHEMICAL
used	O
alone	O
or	O
with	O
methylphenidate	B-CHEMICAL
in	O
children	O
with	O
attention	B-DISEASE
-	I-DISEASE
deficit	I-DISEASE
/	I-DISEASE
hyperactivity	I-DISEASE
disorder	I-DISEASE
(	O
ADHD	B-DISEASE
)	O
.	O
METHOD	O
:	O
In	O
a	O
16	O
-	O
week	O
multicenter	O
,	O
double	O
-	O
blind	B-DISEASE
trial	O
,	O
122	O
children	O
with	O
ADHD	B-DISEASE
were	O
randomly	O
assigned	O
to	O
clonidine	B-CHEMICAL
(	O
n	O
=	O
31	O
)	O
,	O
methylphenidate	B-CHEMICAL
(	O
n	O
=	O
29	O
)	O
,	O
clonidine	B-CHEMICAL
and	O
methylphenidate	B-CHEMICAL
(	O
n	O
=	O
32	O
)	O
,	O
or	O
placebo	O
(	O
n	O
=	O
30	O
)	O
.	O
Doses	O
were	O
flexibly	O
titrated	O
up	O
to	O
0.6	O
mg	O
/	O
day	O
for	O
clonidine	B-CHEMICAL
and	O
60	O
mg	O
/	O
day	O
for	O
methylphenidate	B-CHEMICAL
(	O
both	O
with	O
divided	O
dosing	O
)	O
.	O
Groups	O
were	O
compared	O
regarding	O
adverse	O
events	O
and	O
changes	O
from	O
baseline	O
to	O
week	O
16	O
in	O
electrocardiograms	O
and	O
vital	O
signs	O
.	O
RESULTS	O
:	O
There	O
were	O
more	O
incidents	O
of	O
bradycardia	B-DISEASE
in	O
subjects	O
treated	O
with	O
clonidine	B-CHEMICAL
compared	O
with	O
those	O
not	O
treated	O
with	O
clonidine	B-CHEMICAL
(	O
17.5	O
%	O
versus	O
3.4	O
%	O
;	O
p	O
=	O
.02	O
)	O
,	O
but	O
no	O
other	O
significant	O
group	O
differences	O
regarding	O
electrocardiogram	O
and	O
other	O
cardiovascular	O
outcomes	O
.	O
There	O
were	O
no	O
suggestions	O
of	O
interactions	O
between	O
clonidine	B-CHEMICAL
and	O
methylphenidate	B-CHEMICAL
regarding	O
cardiovascular	O
outcomes	O
.	O
Moderate	O
or	O
severe	O
adverse	O
events	O
were	O
more	O
common	O
in	O
subjects	O
on	O
clonidine	B-CHEMICAL
(	O
79.4	O
%	O
versus	O
49.2	O
%	O
;	O
p	O
=	O
.0006	O
)	O
but	O
not	O
associated	O
with	O
higher	O
rates	O
of	O
early	O
study	O
withdrawal	O
.	O
Drowsiness	B-DISEASE
was	O
common	O
on	O
clonidine	B-CHEMICAL
,	O
but	O
generally	O
resolved	O
by	O
6	O
to	O
8	O
weeks	O
.	O
CONCLUSIONS	O
:	O
Clonidine	B-CHEMICAL
,	O
used	O
alone	O
or	O
with	O
methylphenidate	B-CHEMICAL
,	O
appears	O
safe	O
and	O
well	O
tolerated	O
in	O
childhood	O
ADHD	B-DISEASE
.	O
Physicians	O
prescribing	O
clonidine	B-CHEMICAL
should	O
monitor	O
for	O
bradycardia	B-DISEASE
and	O
advise	O
patients	O
about	O
the	O
high	O
likelihood	O
of	O
initial	O
drowsiness	B-DISEASE
.	O

Thalidomide	B-CHEMICAL
has	O
limited	O
single	O
-	O
agent	O
activity	O
in	O
relapsed	O
or	O
refractory	O
indolent	O
non	O
-	O
Hodgkin	O
lymphomas	O
:	O
a	O
phase	O
II	O
trial	O
of	O
the	O
Cancer	B-DISEASE
and	O
Leukemia	B-DISEASE
Group	O
B.	O
Thalidomide	B-CHEMICAL
is	O
an	O
immunomodulatory	O
agent	O
with	O
demonstrated	O
activity	O
in	O
multiple	B-DISEASE
myeloma	I-DISEASE
,	O
mantle	O
cell	O
lymphoma	B-DISEASE
and	O
lymphoplasmacytic	O
lymphoma	B-DISEASE
.	O
Its	O
activity	O
is	O
believed	O
to	O
be	O
due	O
modulation	O
of	O
the	O
tumour	O
milieu	O
,	O
including	O
downregulation	O
of	O
angiogenesis	O
and	O
inflammatory	O
cytokines	O
.	O
Between	O
July	O
2001	O
and	O
April	O
2004	O
,	O
24	O
patients	O
with	O
relapsed	O
/	O
refractory	O
indolent	O
lymphomas	O
received	O
thalidomide	B-CHEMICAL
200	O
mg	O
daily	O
with	O
escalation	O
by	O
100	O
mg	O
daily	O
every	O
1	O
-	O
2	O
weeks	O
as	O
tolerated	O
,	O
up	O
to	O
a	O
maximum	O
of	O
800	O
mg	O
daily	O
.	O
Patients	O
had	O
received	O
a	O
median	O
of	O
2	O
(	O
range	O
,	O
1	O
-	O
4	O
)	O
prior	O
regimens	O
.	O
Of	O
24	O
evaluable	O
patients	O
,	O
two	O
achieved	O
a	O
complete	O
remission	O
and	O
one	O
achieved	O
a	O
partial	O
remission	O
for	O
an	O
overall	O
response	O
rate	O
of	O
12.5	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
2.6	O
-	O
32.4	O
%	O
)	O
.	O
Eleven	O
patients	O
progressed	O
during	O
therapy	O
.	O
Grade	O
3	O
-	O
4	O
adverse	O
effects	O
included	O
myelosuppression	B-DISEASE
,	O
fatigue	B-DISEASE
,	O
somnolence	B-DISEASE
/	O
depressed	B-DISEASE
mood	I-DISEASE
,	O
neuropathy	B-DISEASE
and	O
dyspnea	B-DISEASE
.	O
Of	O
concern	O
was	O
the	O
occurrence	O
of	O
four	O
thromboembolic	B-DISEASE
events	O
.	O
Our	O
results	O
failed	O
to	O
demonstrate	O
an	O
important	O
response	O
rate	O
to	O
single	O
agent	O
thalidomide	B-CHEMICAL
in	O
indolent	O
lymphomas	O
and	O
contrast	O
with	O
the	O
higher	O
activity	O
level	O
reported	O
with	O
the	O
second	O
generation	O
immunomodulatory	O
agent	O
,	O
lenalidomide	O
.	O

Intracavernous	O
epinephrine	B-CHEMICAL
:	O
a	O
minimally	O
invasive	O
treatment	O
for	O
priapism	B-DISEASE
in	O
the	O
emergency	B-DISEASE
department	I-DISEASE
.	O
Priapism	B-DISEASE
is	O
the	O
prolonged	O
erection	O
of	O
the	O
penis	O
in	O
the	O
absence	O
of	O
sexual	O
arousal	O
.	O
A	O
45	O
-	O
year	O
-	O
old	O
man	O
,	O
an	O
admitted	O
frequent	O
cocaine	B-CHEMICAL
user	O
,	O
presented	O
to	O
the	O
Emergency	B-DISEASE
Department	I-DISEASE
(	O
ED	O
)	O
on	O
two	O
separate	O
occasions	O
with	O
a	O
history	O
of	O
priapism	B-DISEASE
after	O
cocaine	B-CHEMICAL
use	O
.	O
The	O
management	O
options	O
in	O
the	O
ED	O
,	O
as	O
exemplified	O
by	O
four	O
individual	O
case	O
reports	O
,	O
in	O
particular	O
the	O
use	O
of	O
a	O
minimally	O
invasive	O
method	O
of	O
intracorporal	O
epinephrine	B-CHEMICAL
instillation	O
,	O
are	O
discussed	O
.	O

Effect	O
of	O
green	B-CHEMICAL
tea	I-CHEMICAL
and	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
combination	O
in	O
isoproterenol	B-CHEMICAL
induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
in	O
rats	O
.	O
The	O
present	O
study	O
was	O
aimed	O
to	O
investigate	O
the	O
combined	O
effects	O
of	O
green	B-CHEMICAL
tea	I-CHEMICAL
and	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
on	O
heart	O
weight	O
,	O
body	B-DISEASE
weight	I-DISEASE
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
,	O
endogenous	O
antioxidants	B-CHEMICAL
and	O
membrane	O
bound	O
ATPases	O
in	O
isoproterenol	B-CHEMICAL
(	O
ISO)-induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
in	O
rats	O
.	O
Adult	O
male	O
albino	O
rats	O
,	O
treated	O
with	O
ISO	O
(	O
200	O
mg	O
/	O
kg	O
,	O
s.c	O
.	O
)	O
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
caused	O
a	O
significant	O
(	O
P<0.05	O
)	O
elevation	O
of	O
heart	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
and	O
Ca+2	O
ATPase	O
level	O
whereas	O
there	O
was	O
a	O
significant	O
(	O
P<0.05	O
)	O
decrease	O
in	O
body	B-DISEASE
weight	I-DISEASE
,	O
endogenous	O
antioxidants	B-CHEMICAL
,	O
Na+/	O
K+	O
ATPase	O
and	O
Mg+2	O
ATPase	O
levels	O
.	O
Administration	O
of	O
green	B-CHEMICAL
tea	I-CHEMICAL
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
p.o	O
.	O
)	O
and	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
p.o	O
.	O
)	O
together	O
for	O
30	O
consecutive	O
days	O
and	O
challenged	O
with	O
ISO	O
on	O
the	O
day	O
29th	O
and	O
30th	O
,	O
showed	O
a	O
significant	O
(	O
P<0.05	O
)	O
decrease	O
in	O
heart	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	O
peroxidation	O
,	O
Ca+2	O
ATPase	O
and	O
a	O
significant	O
increase	O
in	O
the	O
body	B-DISEASE
weight	I-DISEASE
,	O
endogenous	O
antioxidants	B-CHEMICAL
,	O
Na+/K+	O
ATPase	O
and	O
Mg+2	O
ATPase	O
when	O
compared	O
with	O
ISO	O
treated	O
group	O
and	O
green	B-CHEMICAL
tea	I-CHEMICAL
or	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
alone	O
treated	O
groups	O
.	O
These	O
findings	O
indicate	O
the	O
synergistic	O
protective	O
effect	O
of	O
green	B-CHEMICAL
tea	I-CHEMICAL
and	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
during	O
ISO	O
induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
in	O
rats	O
.	O

Development	O
of	O
ocular	O
myasthenia	O
during	O
pegylated	O
interferon	O
and	O
ribavirin	B-CHEMICAL
treatment	O
for	O
chronic	B-DISEASE
hepatitis	I-DISEASE
C.	O
A	O
63	O
-	O
year	O
-	O
old	O
male	O
experienced	O
sudden	O
diplopia	B-DISEASE
after	O
9	O
weeks	O
of	O
administration	O
of	O
pegylated	O
interferon	O
(	O
IFN	O
)	O
alpha-2b	O
and	O
ribavirin	B-CHEMICAL
for	O
chronic	B-DISEASE
hepatitis	I-DISEASE
C	I-DISEASE
(	O
CHC	O
)	O
.	O
Ophthalmologic	O
examinations	O
showed	O
ptosis	O
on	O
the	O
right	O
upper	O
lid	O
and	O
restricted	O
right	O
eye	O
movement	O
without	O
any	O
other	O
neurological	O
signs	O
.	O
A	O
brain	O
imaging	O
study	O
and	O
repetitive	O
nerve	O
stimulation	O
test	O
indicated	O
no	O
abnormality	O
.	O
The	O
acetylcholine	O
receptor	O
antibody	O
titer	O
and	O
response	O
to	O
acetylcholinesterase	O
inhibitors	O
were	O
negative	O
,	O
and	O
the	O
results	O
of	O
thyroid	O
function	O
tests	O
were	O
normal	O
.	O
The	O
patient	O
's	O
ophthalmological	O
symptoms	O
improved	O
rapidly	O
3	O
weeks	O
after	O
discontinuation	O
of	O
pegylated	O
IFN	O
alpha-2b	O
and	O
ribavirin	B-CHEMICAL
.	O
The	O
ocular	O
myasthenia	O
associated	O
with	O
combination	O
therapy	O
of	O
pegylated	O
IFN	O
alpha-2b	O
and	O
ribavirin	B-CHEMICAL
for	O
CHC	O
is	O
very	O
rarely	O
reported	O
;	O
therefore	O
,	O
we	O
present	O
this	O
case	O
with	O
a	O
review	O
of	O
the	O
various	O
eye	O
complications	B-DISEASE
of	O
IFN	O
therapy	O
.	O

The	O
glycine	B-CHEMICAL
transporter-1	O
inhibitor	O
SSR103800	O
displays	O
a	O
selective	O
and	O
specific	O
antipsychotic	O
-	O
like	O
profile	O
in	O
normal	O
and	O
transgenic	O
mice	O
.	O
Schizophrenia	B-DISEASE
has	O
been	O
initially	O
associated	O
with	O
dysfunction	O
in	O
dopamine	B-CHEMICAL
neurotransmission	O
.	O
However	O
,	O
the	O
observation	O
that	O
antagonists	O
of	O
the	O
glutamate	B-CHEMICAL
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptor	O
produce	O
schizophrenic	B-DISEASE
-	O
like	O
symptoms	O
in	O
humans	O
has	O
led	O
to	O
the	O
idea	O
of	O
a	O
dysfunctioning	O
of	O
the	O
glutamatergic	O
system	O
via	O
its	O
NMDA	O
receptor	O
.	O
As	O
a	O
result	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
development	O
of	O
pharmacological	O
agents	O
with	O
potential	O
antipsychotic	O
properties	O
that	O
enhance	O
the	O
activity	O
of	O
the	O
glutamatergic	O
system	O
via	O
a	O
modulation	O
of	O
the	O
NMDA	O
receptor	O
.	O
Among	O
them	O
are	O
glycine	B-CHEMICAL
transporter-1	O
(	O
GlyT1	O
)	O
inhibitors	O
such	O
as	O
SSR103800	O
,	O
which	O
indirectly	O
enhance	O
NMDA	O
receptor	O
function	O
by	O
increasing	O
the	O
glycine	B-CHEMICAL
(	O
a	O
co	B-CHEMICAL
-	O
agonist	O
for	O
the	O
NMDA	O
receptor	O
)	O
levels	O
in	O
the	O
synapse	O
.	O
This	O
study	O
aimed	O
at	O
investigating	O
the	O
potential	O
antipsychotic	O
-	O
like	O
properties	O
of	O
SSR103800	O
,	O
with	O
a	O
particular	O
focus	O
on	O
models	O
of	O
hyperactivity	O
,	O
involving	O
either	O
drug	O
challenge	O
(	O
ie	O
,	O
amphetamine	O
and	O
MK-801	O
)	O
or	O
transgenic	O
mice	O
(	O
ie	O
,	O
NMDA	O
Nr1(neo-/-	O
)	O
and	O
DAT(-/-	O
)	O
)	O
.	O
Results	O
showed	O
that	O
SSR103800	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p.o	O
.	O
)	O
blocked	O
hyperactivity	O
induced	O
by	O
the	O
non	O
-	O
competitive	O
NMDA	O
receptor	O
antagonist	O
,	O
MK-801	O
and	O
partially	O
reversed	O
spontaneous	O
hyperactivity	O
of	O
NMDA	O
Nr1(neo-/-	O
)	O
mice	O
.	O
In	O
contrast	O
,	O
SSR103800	O
failed	O
to	O
affect	O
hyperactivity	O
induced	O
by	O
amphetamine	O
or	O
naturally	O
observed	O
in	O
dopamine	B-CHEMICAL
transporter	O
(	O
DAT(-/-	O
)	O
)	O
knockout	O
mice	O
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p.o	O
.	O
)	O
.	O
Importantly	O
,	O
both	O
classical	O
(	O
haloperidol	B-CHEMICAL
)	O
and	O
atypical	O
(	O
olanzapine	B-CHEMICAL
,	O
clozapine	B-CHEMICAL
and	O
aripiprazole	O
)	O
antipsychotics	B-CHEMICAL
were	O
effective	O
in	O
all	O
these	O
models	O
of	O
hyperactivity	O
.	O
However	O
,	O
unlike	O
these	O
latter	O
,	O
SSR103800	O
did	O
not	O
produce	O
catalepsy	B-DISEASE
(	O
retention	O
on	O
the	O
bar	O
test	O
)	O
up	O
to	O
30	O
mg	O
/	O
kg	O
p.o	O
.	O
Together	O
these	O
findings	O
show	O
that	O
the	O
GlyT1	O
inhibitor	O
,	O
SSR103800	O
,	O
produces	O
antipsychotic	O
-	O
like	O
effects	O
,	O
which	O
differ	O
from	O
those	O
observed	O
with	O
compounds	O
primarily	O
targeting	O
the	O
dopaminergic	O
system	O
,	O
and	O
has	O
a	O
reduced	O
side	O
-	O
effect	O
potential	O
as	O
compared	O
with	O
these	O
latter	O
drugs	O
.	O

Phenylephrine	B-CHEMICAL
but	O
not	O
ephedrine	B-CHEMICAL
reduces	O
frontal	O
lobe	O
oxygenation	O
following	O
anesthesia	O
-	O
induced	O
hypotension	B-DISEASE
.	O
BACKGROUND	O
:	O
Vasopressor	O
agents	O
are	O
used	O
to	O
correct	O
anesthesia	O
-	O
induced	O
hypotension	B-DISEASE
.	O
We	O
describe	O
the	O
effect	O
of	O
phenylephrine	B-CHEMICAL
and	O
ephedrine	B-CHEMICAL
on	O
frontal	O
lobe	O
oxygenation	O
(	O
S(c)O(2	O
)	O
)	O
following	O
anesthesia	O
-	O
induced	O
hypotension	B-DISEASE
.	O
METHODS	O
:	O
Following	O
induction	O
of	O
anesthesia	O
by	O
fentanyl	B-CHEMICAL
(	O
0.15	O
mg	O
kg(-1	O
)	O
)	O
and	O
propofol	B-CHEMICAL
(	O
2.0	O
mg	O
kg(-1	O
)	O
)	O
,	O
13	O
patients	O
received	O
phenylephrine	B-CHEMICAL
(	O
0.1	O
mg	O
iv	O
)	O
and	O
12	O
patients	O
received	O
ephedrine	B-CHEMICAL
(	O
10	O
mg	O
iv	O
)	O
to	O
restore	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
.	O
Heart	O
rate	O
(	O
HR	O
)	O
,	O
MAP	O
,	O
stroke	B-DISEASE
volume	O
(	O
SV	O
)	O
,	O
cardiac	O
output	O
(	O
CO	B-CHEMICAL
)	O
,	O
and	O
frontal	O
lobe	O
oxygenation	O
(	O
S(c)O(2	O
)	O
)	O
were	O
registered	O
.	O
RESULTS	O
:	O
Induction	O
of	O
anesthesia	O
was	O
followed	O
by	O
a	O
decrease	O
in	O
MAP	O
,	O
HR	O
,	O
SV	O
,	O
and	O
CO	B-CHEMICAL
concomitant	O
with	O
an	O
elevation	O
in	O
S(c)O(2	O
)	O
.	O
After	O
administration	O
of	O
phenylephrine	B-CHEMICAL
,	O
MAP	O
increased	O
(	O
51	O
+	O
/-	O
12	O
to	O
81	O
+	O
/-	O
13	O
mmHg	O
;	O
P	O
<	O
0.001	O
;	O
mean	O
+	O
/-	O
SD	B-DISEASE
)	O
.	O
However	O
,	O
a	O
14	O
%	O
(	O
from	O
70	O
+	O
/-	O
8	O
%	O
to	O
60	O
+	O
/-	O
7	O
%	O
)	O
reduction	O
in	O
S(c)O(2	O
)	O
(	O
P	O
<	O
0.05	O
)	O
followed	O
with	O
no	O
change	O
in	O
CO	B-CHEMICAL
(	O
3.7	O
+	O
/-	O
1.1	O
to	O
3.4	O
+	O
/-	O
0.9	O
l	O
min(-1	O
)	O
)	O
.	O
The	O
administration	O
of	O
ephedrine	B-CHEMICAL
led	O
to	O
a	O
similar	O
increase	O
in	O
MAP	O
(	O
53	O
+	O
/-	O
9	O
to	O
79	O
+	O
/-	O
8	O
mmHg	O
;	O
P	O
<	O
0.001	O
)	O
,	O
restored	O
CO	B-CHEMICAL
(	O
3.2	O
+	O
/-	O
1.2	O
to	O
5.0	O
+	O
/-	O
1.3	O
l	O
min(-1	O
)	O
)	O
,	O
and	O
preserved	O
S(c)O(2	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
utilization	O
of	O
phenylephrine	B-CHEMICAL
to	O
correct	O
hypotension	B-DISEASE
induced	O
by	O
anesthesia	O
has	O
a	O
negative	O
impact	O
on	O
S(c)O(2	O
)	O
while	O
ephedrine	B-CHEMICAL
maintains	O
frontal	O
lobe	O
oxygenation	O
potentially	O
related	O
to	O
an	O
increase	O
in	O
CO	B-CHEMICAL
.	O

A	O
novel	O
,	O
multiple	O
symptom	O
model	O
of	O
obsessive	O
-	O
compulsive	O
-	O
like	O
behaviors	O
in	O
animals	O
.	O
BACKGROUND	O
:	O
Current	O
animal	O
models	O
of	O
obsessive	B-DISEASE
-	I-DISEASE
compulsive	I-DISEASE
disorder	I-DISEASE
(	O
OCD	B-DISEASE
)	O
typically	O
involve	O
acute	O
,	O
drug	O
-	O
induced	O
symptom	O
provocation	O
or	O
a	O
genetic	O
association	O
with	O
stereotypies	O
or	O
anxiety	B-DISEASE
.	O
None	O
of	O
these	O
current	O
models	O
demonstrate	O
multiple	O
OCD	B-DISEASE
-	O
like	O
behaviors	O
.	O
METHODS	O
:	O
Neonatal	O
rats	O
were	O
treated	O
with	O
the	O
tricyclic	O
antidepressant	O
clomipramine	B-CHEMICAL
or	O
vehicle	O
between	O
days	O
9	O
and	O
16	O
twice	O
daily	O
and	O
behaviorally	O
tested	O
in	O
adulthood	O
.	O
RESULTS	O
:	O
Clomipramine	B-CHEMICAL
exposure	O
in	O
immature	O
rats	O
produced	O
significant	O
behavioral	O
and	O
biochemical	O
changes	O
that	O
include	O
enhanced	O
anxiety	B-DISEASE
(	O
elevated	O
plus	O
maze	O
and	O
marble	B-CHEMICAL
burying	O
)	O
,	O
behavioral	B-DISEASE
inflexibility	I-DISEASE
(	O
perseveration	O
in	O
the	O
spontaneous	O
alternation	O
task	O
and	O
impaired	O
reversal	O
learning	O
)	O
,	O
working	O
memory	B-DISEASE
impairment	I-DISEASE
(	O
e.g.	O
,	O
win	O
-	O
shift	O
paradigm	O
)	O
,	O
hoarding	O
,	O
and	O
corticostriatal	B-DISEASE
dysfunction	I-DISEASE
.	O
Dopamine	B-CHEMICAL
D2	O
receptors	O
were	O
elevated	O
in	O
the	O
striatum	O
,	O
whereas	O
serotonin	B-CHEMICAL
2C	O
,	O
but	O
not	O
serotonin	B-CHEMICAL
1A	O
,	O
receptors	O
were	O
elevated	O
in	O
the	O
orbital	O
frontal	O
cortex	O
.	O
CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
multiple	O
symptoms	O
consistent	O
with	O
an	O
OCD	B-DISEASE
-	O
like	O
profile	O
in	O
animals	O
.	O
Moreover	O
,	O
these	O
behaviors	O
are	O
accompanied	O
by	O
biochemical	O
changes	O
in	O
brain	O
regions	O
previously	O
identified	O
as	O
relevant	O
to	O
OCD	B-DISEASE
.	O
This	O
novel	O
model	O
of	O
OCD	B-DISEASE
demonstrates	O
that	O
drug	O
exposure	O
during	O
a	O
sensitive	O
period	O
can	O
program	O
disease	B-DISEASE
-	O
like	O
systems	O
permanently	O
,	O
which	O
could	O
have	O
implications	O
for	O
current	O
and	O
future	O
therapeutic	O
strategies	O
for	O
this	O
and	O
other	O
psychiatric	B-DISEASE
disorders	O
.	O

Late	O
recovery	O
of	O
renal	O
function	O
in	O
a	O
woman	O
with	O
the	O
hemolytic	B-DISEASE
uremic	I-DISEASE
syndrome	I-DISEASE
.	O
A	O
case	O
is	O
reported	O
of	O
the	O
hemolytic	B-DISEASE
uremic	I-DISEASE
syndrome	I-DISEASE
(	O
HUS	O
)	O
in	O
a	O
woman	O
taking	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
.	O
She	O
was	O
treated	O
with	O
heparin	B-CHEMICAL
,	O
dipyridamole	B-CHEMICAL
and	O
hemodialysis	O
;	O
and	O
after	O
more	O
than	O
three	O
months	O
,	O
her	O
urinary	O
output	O
rose	O
above	O
500	O
ml	O
;	O
and	O
six	O
months	O
after	O
the	O
onset	O
of	O
anuria	B-DISEASE
,	O
dialysis	O
treatment	O
was	O
stopped	O
.	O
This	O
case	O
emphasizes	O
the	O
possibility	O
that	O
HUS	O
in	O
adults	O
is	O
not	O
invariably	O
irreversible	O
and	O
that	O
,	O
despite	O
prolonged	O
oliguria	B-DISEASE
,	O
recovery	O
of	O
renal	O
function	O
can	O
be	O
obtained	O
.	O
Therefore	O
,	O
in	O
adult	O
patients	O
affected	O
by	O
HUS	O
,	O
dialysis	O
should	O
not	O
be	O
discontinued	O
prematurely	O
;	O
moreover	O
,	O
bilateral	O
nephrectomy	O
,	O
for	O
treatment	O
of	O
severe	O
hypertension	B-DISEASE
and	O
microangiopathic	O
hemolytic	O
anemia	B-DISEASE
,	O
should	O
be	O
performed	O
with	O
caution	O
.	O

Effects	O
of	O
acetylsalicylic	O
acid	O
,	O
dipyridamole	B-CHEMICAL
,	O
and	O
hydrocortisone	B-CHEMICAL
on	O
epinephrine	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
injury	I-DISEASE
in	O
dogs	O
.	O
A	O
reproducible	O
model	O
for	O
producing	O
diffuse	O
myocardial	B-DISEASE
injury	I-DISEASE
(	O
epinephrine	B-CHEMICAL
infusion	O
)	O
has	O
been	O
developed	O
to	O
study	O
the	O
cardioprotective	O
effects	O
of	O
agents	O
or	O
maneuvers	O
which	O
might	O
alter	O
the	O
evolution	O
of	O
acute	B-DISEASE
myocardial	I-DISEASE
infarction	I-DISEASE
.	O
Infusions	O
of	O
epinephrine	B-CHEMICAL
(	O
4	O
mug	O
per	O
kilogram	O
per	O
minute	O
for	O
6	O
hours	O
)	O
increased	O
radiocalcium	O
uptakes	O
into	O
intact	O
myocardium	O
and	O
each	O
of	O
its	O
subcellular	O
components	O
with	O
the	O
mitochondrial	O
fraction	O
showing	O
the	O
most	O
consistent	O
changes	O
when	O
compared	O
to	O
saline	O
-	O
infused	O
control	O
animals	O
(	O
4,957	O
vs.	O
827	O
counts	O
per	O
minute	O
per	O
gram	O
of	O
dried	O
tissue	O
or	O
fraction	O
)	O
.	O
Myocardial	O
concentrations	O
of	O
calcium	B-CHEMICAL
also	O
increased	O
significantly	O
(	O
12.0	O
vs.	O
5.0	O
mg.per	O
100	O
Gm	O
.	O
of	O
fat	O
-	O
free	O
dry	O
weight	O
)	O
.	O
Infusions	O
of	O
calcium	B-CHEMICAL
chloride	I-CHEMICAL
sufficient	O
to	O
raise	O
serum	O
calcium	B-CHEMICAL
concentrations	O
2	O
mEq	O
.	O
per	O
liter	O
failed	O
to	O
increase	O
calcium	B-CHEMICAL
influx	O
into	O
the	O
myocardial	O
cell	O
.	O
Mitochondrial	O
radiocalcium	O
uptakes	O
were	O
significantly	O
decreased	O
in	O
animals	O
pretreated	O
with	O
acetylsalicylic	O
acid	O
or	O
dipyridamole	B-CHEMICAL
or	O
when	O
hydrocortisone	B-CHEMICAL
was	O
added	O
to	O
the	O
epinephrine	B-CHEMICAL
infusion	O
(	O
2,682,2,803	O
,	O
and	O
3,424	O
counts	O
per	O
minute	O
per	O
gram	O
of	O
dried	O
fraction	O
,	O
respectively	O
)	O
.	O
Myocardial	O
calcium	B-CHEMICAL
concentrations	O
also	O
were	O
decreased	O
(	O
11.2	O
,	O
8.3	O
,	O
and	O
8.9	O
mg	O
.	O
per	O
100	O
Gm	O
.	O
of	O
fat	O
-	O
free	O
dry	O
weight	O
,	O
respectively	O
)	O
in	O
the	O
three	O
treatment	O
groups	O
,	O
being	O
significantly	O
decreased	O
only	O
in	O
the	O
last	O
two	O
.	O
Evidence	O
of	O
microscopic	O
damage	O
was	O
graded	O
as	O
less	O
severe	O
in	O
the	O
three	O
treatment	O
groups	O
.	O
Acetylsalicylic	O
acid	O
,	O
dipyridamole	B-CHEMICAL
,	O
and	O
hydrocortisone	B-CHEMICAL
all	O
appear	O
to	O
have	O
cardioprotective	O
effects	O
when	O
tested	O
in	O
this	O
model	O
.	O

Changes	O
in	O
depressive	B-DISEASE
status	O
associated	O
with	O
topical	O
beta	O
-	O
blockers	O
.	O
Depression	B-DISEASE
and	O
sexual	B-DISEASE
dysfunction	I-DISEASE
have	O
been	O
related	O
to	O
side	O
effects	O
of	O
topical	O
beta	O
-	O
blockers	O
.	O
We	O
performed	O
a	O
preliminary	O
study	O
in	O
order	O
to	O
determine	O
any	O
difference	O
between	O
a	O
non	O
selective	O
beta	O
-	O
blocker	O
(	O
timolol	B-CHEMICAL
)	O
and	O
a	O
selective	O
beta	O
-	O
blocker	O
(	O
betaxolol	B-CHEMICAL
)	O
regarding	O
CNS	O
side	O
effects	O
.	O
Eight	O
glaucomatous	O
patients	O
chronically	O
treated	O
with	O
timolol	B-CHEMICAL
0.5%/12h	O
,	O
suffering	O
from	O
depression	B-DISEASE
diagnosed	O
through	O
DMS	O
-	O
III	O
-	O
R	O
criteria	O
,	O
were	O
included	O
in	O
the	O
study	O
.	O
During	O
the	O
six	O
-	O
month	O
follow	O
up	O
,	O
depression	B-DISEASE
was	O
quantified	O
through	O
the	O
Beck	O
and	O
Zung	O
-	O
Conde	O
scales	O
every	O
two	O
months	O
.	O
In	O
a	O
double	O
blind	B-DISEASE
cross	O
-	O
over	O
study	O
with	O
control	O
group	O
,	O
the	O
patients	O
under	O
timolol	B-CHEMICAL
treatment	O
presented	O
higher	O
depression	B-DISEASE
values	O
measured	O
through	O
the	O
Beck	O
and	O
the	O
Zung	O
-	O
Conde	O
scales	O
(	O
p	O
<	O
0.001	O
vs	O
control	O
)	O
.	O
These	O
results	O
suggest	O
that	O
betaxolol	B-CHEMICAL
could	O
be	O
less	O
of	O
a	O
depression	B-DISEASE
-	O
inducer	O
than	O
timolol	B-CHEMICAL
in	O
predisposed	O
patients	O
.	O

Long	O
-	O
term	O
follow	O
-	O
up	O
of	O
ifosfamide	B-CHEMICAL
renal	B-DISEASE
toxicity	I-DISEASE
in	O
children	O
treated	O
for	O
malignant	O
mesenchymal	O
tumors	B-DISEASE
:	O
an	O
International	O
Society	O
of	O
Pediatric	O
Oncology	O
report	O
.	O
The	O
renal	O
function	O
of	O
74	O
children	O
with	O
malignant	O
mesenchymal	O
tumors	B-DISEASE
in	O
complete	O
remission	O
and	O
who	O
have	O
received	O
the	O
same	O
ifosfamide	B-CHEMICAL
chemotherapy	O
protocol	O
(	O
International	O
Society	O
of	O
Pediatric	O
Oncology	O
Malignant	B-DISEASE
Mesenchymal	I-DISEASE
Tumor	I-DISEASE
Study	O
84	O
[	O
SIOP	O
MMT	O
84	O
]	O
)	O
were	O
studied	O
1	O
year	O
after	O
the	O
completion	O
of	O
treatment	O
.	O
Total	O
cumulative	O
doses	O
were	O
36	O
or	O
60	O
g	O
/	O
m2	O
of	O
ifosfamide	B-CHEMICAL
(	O
six	O
or	O
10	O
cycles	O
of	O
ifosfamide	B-CHEMICAL
,	O
vincristine	B-CHEMICAL
,	O
and	O
dactinomycin	O
[	O
IVA	O
]	O
)	O
.	O
None	O
of	O
them	O
had	O
received	O
cisplatin	B-CHEMICAL
chemotherapy	O
.	O
Ages	O
ranged	O
from	O
4	O
months	O
to	O
17	O
years	O
;	O
58	O
patients	O
were	O
males	O
and	O
42	O
females	O
.	O
The	O
most	O
common	O
primary	O
tumor	B-DISEASE
site	O
was	O
the	O
head	O
and	O
neck	O
.	O
Renal	O
function	O
was	O
investigated	O
by	O
measuring	O
plasma	O
and	O
urinary	O
electrolytes	O
,	O
glucosuria	O
,	O
proteinuria	B-DISEASE
,	O
aminoaciduria	B-DISEASE
,	O
urinary	O
pH	O
,	O
osmolarity	O
,	O
creatinine	B-CHEMICAL
clearance	O
,	O
phosphate	B-CHEMICAL
tubular	O
reabsorption	O
,	O
beta	O
2	O
microglobulinuria	O
,	O
and	O
lysozymuria	O
.	O
Fifty	O
-	O
eight	O
patients	O
(	O
78	O
%	O
)	O
had	O
normal	O
renal	O
tests	O
,	O
whereas	O
16	O
patients	O
(	O
22	O
%	O
)	O
had	O
renal	O
abnormalities	O
.	O
Two	O
subsets	O
of	O
patients	O
were	O
identified	O
from	O
this	O
latter	O
group	O
:	O
the	O
first	O
included	O
four	O
patients	O
(	O
5	O
%	O
of	O
the	O
total	O
population	O
)	O
who	O
developed	O
major	O
toxicity	B-DISEASE
resulting	O
in	O
Fanconi	O
's	O
syndrome	B-DISEASE
(	O
TDFS	B-DISEASE
)	O
;	O
and	O
the	O
second	O
group	O
included	O
five	O
patients	O
with	O
elevated	O
beta	O
2	O
microglobulinuria	O
and	O
low	O
phosphate	B-CHEMICAL
reabsorption	O
.	O
The	O
remaining	O
seven	O
patients	O
had	O
isolated	O
beta	O
2	O
microglobulinuria	O
.	O
Severe	O
toxicity	B-DISEASE
was	O
correlated	O
with	O
the	O
higher	O
cumulative	O
dose	O
of	O
60	O
g	O
/	O
m2	O
of	O
ifosfamide	B-CHEMICAL
,	O
a	O
younger	O
age	O
(	O
less	O
than	O
2	O
1/2	O
years	O
old	O
)	O
,	O
and	O
a	O
predominance	O
of	O
vesicoprostatic	O
tumor	B-DISEASE
involvement	O
.	O
This	O
low	O
percentage	O
(	O
5	O
%	O
)	O
of	O
TDFS	B-DISEASE
must	O
be	O
evaluated	O
with	O
respect	O
to	O
the	O
efficacy	O
of	O
ifosfamide	B-CHEMICAL
in	O
the	O
treatment	O
of	O
mesenchymal	O
tumors	B-DISEASE
in	O
children	O
.	O

Evidence	O
for	O
an	O
involvement	O
of	O
D1	O
and	O
D2	O
dopamine	B-CHEMICAL
receptors	O
in	O
mediating	O
nicotine	B-CHEMICAL
-	O
induced	O
hyperactivity	O
in	O
rats	O
.	O
Previous	O
studies	O
have	O
suggested	O
that	O
repeated	O
exposure	O
of	O
rats	O
to	O
the	O
drug	O
or	O
to	O
the	O
experimental	O
environment	O
is	O
necessary	O
to	O
observe	O
nicotine	B-CHEMICAL
-	O
induced	O
locomotor	O
stimulation	O
.	O
In	O
the	O
present	O
study	O
the	O
role	O
of	O
habituation	O
to	O
the	O
experimental	O
environment	O
on	O
the	O
stimulant	O
effect	O
of	O
nicotine	B-CHEMICAL
in	O
rats	O
was	O
examined	O
.	O
In	O
addition	O
,	O
the	O
role	O
of	O
dopamine	B-CHEMICAL
receptors	O
in	O
mediating	O
nicotine	B-CHEMICAL
-	O
induced	O
locomotor	O
stimulation	O
was	O
investigated	O
by	O
examining	O
the	O
effects	O
of	O
selective	O
D1	O
and	O
D2	O
dopamine	B-CHEMICAL
receptor	O
antagonists	O
on	O
activity	O
induced	O
by	O
nicotine	B-CHEMICAL
.	O
Locomotor	O
activity	O
was	O
assessed	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
tested	O
in	O
photocell	O
cages	O
.	O
Nicotine	B-CHEMICAL
(	O
1.0	O
mg	O
/	O
kg	O
)	O
caused	O
a	O
significant	O
increase	O
in	O
locomotor	O
activity	O
in	O
rats	O
that	O
were	O
habituated	O
to	O
the	O
test	O
environment	O
,	O
but	O
had	O
only	O
a	O
weak	O
and	O
delayed	O
stimulant	O
action	O
in	O
rats	O
that	O
were	O
unfamiliar	O
with	O
the	O
test	O
environment	O
.	O
The	O
stimulant	O
action	O
of	O
nicotine	B-CHEMICAL
was	O
blocked	O
by	O
the	O
central	O
nicotinic	O
antagonist	O
mecamylamine	O
but	O
not	O
by	O
the	O
peripheral	O
nicotinic	O
blocker	O
hexamethonium	B-CHEMICAL
,	O
indicating	O
that	O
the	O
response	O
is	O
probably	O
mediated	O
by	O
central	O
nicotinic	O
receptors	O
.	O
Nicotine	B-CHEMICAL
-	O
induced	O
hyperactivity	O
was	O
blocked	O
by	O
the	O
selective	O
D1	O
antagonist	O
SCH	O
23390	O
,	O
the	O
selective	O
D2	O
antagonist	O
raclopride	O
and	O
the	O
D1	O
/	O
D2	O
antagonist	O
fluphenazine	O
.	O
Pretreatment	O
with	O
the	O
D2	O
agonist	O
PHNO	O
enhanced	O
nicotine	B-CHEMICAL
-	O
induced	O
hyperactivity	O
,	O
whereas	O
the	O
D1	O
agonist	O
SKF	O
38393	O
had	O
no	O
effect	O
.	O
The	O
results	O
indicate	O
that	O
acute	O
nicotine	B-CHEMICAL
injection	O
induces	O
a	O
pronounced	O
hyperactivity	O
in	O
rats	O
habituated	O
to	O
the	O
test	O
environment	O
.	O
The	O
effect	O
appears	O
to	O
be	O
mediated	O
by	O
central	O
nicotine	B-CHEMICAL
receptors	O
,	O
possibly	O
located	O
on	O
dopaminergic	O
neurons	O
,	O
and	O
also	O
requires	O
the	O
activation	O
of	O
both	O
D1	O
and	O
D2	O
dopamine	B-CHEMICAL
receptors	O
.	O

Neuropsychiatric	O
side	O
effects	O
after	O
the	O
use	O
of	O
mefloquine	B-CHEMICAL
.	O
This	O
study	O
describes	O
neuropsychiatric	O
side	O
effects	O
in	O
patients	O
after	O
treatment	O
with	O
mefloquine	B-CHEMICAL
.	O
Reactions	O
consisted	O
mainly	O
of	O
seizures	B-DISEASE
,	O
acute	O
psychoses	B-DISEASE
,	O
anxiety	B-DISEASE
neurosis	I-DISEASE
,	O
and	O
major	O
disturbances	B-DISEASE
of	I-DISEASE
sleep	I-DISEASE
-	I-DISEASE
wake	I-DISEASE
rhythm	I-DISEASE
.	O
Side	O
effects	O
occurred	O
after	O
both	O
therapeutic	O
and	O
prophylactic	O
intake	O
and	O
were	O
graded	O
from	O
moderate	O
to	O
severe	O
.	O
In	O
a	O
risk	O
analysis	O
of	O
neuropsychiatric	O
side	O
effects	O
in	O
Germany	O
,	O
it	O
is	O
estimated	O
that	O
one	O
of	O
8,000	O
mefloquine	B-CHEMICAL
users	O
suffers	O
from	O
such	O
reactions	O
.	O
The	O
incidence	O
calculation	O
revealed	O
that	O
one	O
of	O
215	O
therapeutic	O
users	O
had	O
reactions	O
,	O
compared	O
with	O
one	O
of	O
13,000	O
in	O
the	O
prophylaxis	O
group	O
,	O
making	O
the	O
risk	O
of	O
neuropsychiatric	O
reactions	O
after	O
mefloquine	B-CHEMICAL
treatment	O
60	O
times	O
higher	O
than	O
after	O
prophylaxis	O
.	O
Therefore	O
,	O
certain	O
limitations	O
for	O
malaria	B-DISEASE
prophylaxis	O
and	O
treatment	O
with	O
mefloquine	B-CHEMICAL
are	O
recommended	O
.	O

Reduction	O
in	O
injection	O
pain	B-DISEASE
using	O
buffered	O
lidocaine	B-CHEMICAL
as	O
a	O
local	O
anesthetic	O
before	O
cardiac	O
catheterization	O
.	O
Previous	O
reports	O
have	O
suggested	O
that	O
pain	B-DISEASE
associated	O
with	O
the	O
injection	O
of	O
lidocaine	B-CHEMICAL
is	O
related	O
to	O
the	O
acidic	O
pH	O
of	O
the	O
solution	O
.	O
To	O
determine	O
if	O
the	O
addition	O
of	O
a	O
buffering	O
solution	O
to	O
adjust	O
the	O
pH	O
of	O
lidocaine	B-CHEMICAL
into	O
the	O
physiologic	O
range	O
would	O
reduce	O
pain	B-DISEASE
during	O
injection	O
,	O
we	O
performed	O
a	O
blinded	O
randomized	O
study	O
in	O
patients	O
undergoing	O
cardiac	O
catheterization	O
.	O
Twenty	O
patients	O
were	O
asked	O
to	O
quantify	O
the	O
severity	O
of	O
pain	B-DISEASE
after	O
receiving	O
standard	O
lidocaine	B-CHEMICAL
in	O
one	O
femoral	O
area	O
and	O
buffered	O
lidocaine	B-CHEMICAL
in	O
the	O
opposite	O
femoral	O
area	O
.	O
The	O
mean	O
pain	B-DISEASE
score	O
for	O
buffered	O
lidocaine	B-CHEMICAL
was	O
significantly	O
lower	O
than	O
the	O
mean	O
score	O
for	O
standard	O
lidocaine	B-CHEMICAL
(	O
2.7	O
+	O
/-	O
1.9	O
vs.	O
3.8	O
+	O
/-	O
2.2	O
,	O
P	O
=	O
0.03	O
)	O
.	O
The	O
pH	O
adjustment	O
of	O
standard	O
lidocaine	B-CHEMICAL
can	O
be	O
accomplished	O
easily	O
in	O
the	O
catheterization	O
laboratory	O
before	O
injection	O
and	O
results	O
in	O
a	O
reduction	O
of	O
the	O
pain	B-DISEASE
occurring	O
during	O
the	O
infiltration	O
of	O
tissues	O
.	O

Randomized	O
,	O
double	O
-	O
blind	B-DISEASE
trial	O
of	O
mazindol	B-CHEMICAL
in	O
Duchenne	O
dystrophy	O
.	O
There	O
is	O
evidence	O
that	O
growth	O
hormone	O
may	O
be	O
related	O
to	O
the	O
progression	O
of	O
weakness	B-DISEASE
in	O
Duchenne	O
dystrophy	O
.	O
We	O
conducted	O
a	O
12	O
-	O
month	O
controlled	O
trial	O
of	O
mazindol	B-CHEMICAL
,	O
a	O
putative	O
growth	O
hormone	O
secretion	O
inhibitor	O
,	O
in	O
83	O
boys	O
with	O
Duchenne	O
dystrophy	O
.	O
Muscle	O
strength	O
,	O
contractures	B-DISEASE
,	O
functional	O
ability	O
and	O
pulmonary	B-DISEASE
function	I-DISEASE
were	O
tested	O
at	O
baseline	O
,	O
and	O
6	O
and	O
12	O
months	O
after	O
treatment	O
with	O
mazindol	B-CHEMICAL
(	O
3	O
mg	O
/	O
d	O
)	O
or	O
placebo	O
.	O
The	O
study	O
was	O
designed	O
to	O
have	O
a	O
power	O
of	O
greater	O
than	O
0.90	O
to	O
detect	O
a	O
slowing	O
to	O
25	O
%	O
of	O
the	O
expected	O
rate	O
of	O
progression	O
of	O
weakness	B-DISEASE
at	O
P	O
less	O
than	O
0.05	O
.	O
Mazindol	B-CHEMICAL
did	O
not	O
benefit	O
strength	O
at	O
any	O
point	O
in	O
the	O
study	O
.	O
Side	O
effects	O
attributable	O
to	O
mazindol	B-CHEMICAL
included	O
decreased	B-DISEASE
appetite	I-DISEASE
(	O
36	O
%	O
)	O
,	O
dry	B-DISEASE
mouth	I-DISEASE
(	O
10	O
%	O
)	O
,	O
behavioral	O
change	O
(	O
22	O
%	O
)	O
,	O
and	O
gastrointestinal	O
symptoms	O
(	O
18	O
%	O
)	O
;	O
mazindol	B-CHEMICAL
dosage	O
was	O
reduced	O
in	O
43	O
%	O
of	O
patients	O
.	O
The	O
effect	O
of	O
mazindol	B-CHEMICAL
on	O
GH	O
secretion	O
was	O
estimated	O
indirectly	O
by	O
comparing	O
the	O
postabsorptive	O
IGF	O
-	O
I	O
levels	O
obtained	O
following	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
months	O
in	O
the	O
mazindol	B-CHEMICAL
treated	O
to	O
those	O
in	O
the	O
placebo	O
groups	O
.	O
Although	O
mazindol	B-CHEMICAL
-	O
treated	O
patients	O
gained	O
less	O
weight	O
and	O
height	O
than	O
placebo	O
-	O
treated	O
patients	O
,	O
no	O
significant	O
effect	O
on	O
IGF	O
-	O
I	O
levels	O
was	O
observed	O
.	O
Mazindol	B-CHEMICAL
doses	O
not	O
slow	O
the	O
progression	O
of	O
weakness	B-DISEASE
in	O
Duchenne	O
dystrophy	O
.	O

Pentoxifylline	B-CHEMICAL
(	O
Trental	O
)	O
does	O
not	O
inhibit	O
dipyridamole	B-CHEMICAL
-	O
induced	O
coronary	O
hyperemia	B-DISEASE
:	O
implications	O
for	O
dipyridamole	B-CHEMICAL
-	O
thallium-201	O
myocardial	O
imaging	O
.	O
Dipyridamole	B-CHEMICAL
-	O
thallium-201	O
imaging	O
is	O
often	O
performed	O
in	O
patients	O
unable	O
to	O
exercise	O
because	O
of	O
peripheral	B-DISEASE
vascular	I-DISEASE
disease	I-DISEASE
.	O
Many	O
of	O
these	O
patients	O
are	O
taking	O
pentoxifylline	B-CHEMICAL
(	O
Trental	O
)	O
,	O
a	O
methylxanthine	O
derivative	O
which	O
may	O
improve	O
intermittent	B-DISEASE
claudication	I-DISEASE
.	O
Whether	O
pentoxifylline	B-CHEMICAL
inhibits	O
dipyridamole	B-CHEMICAL
-	O
induced	O
coronary	O
hyperemia	B-DISEASE
like	O
other	O
methylxanthines	O
such	O
as	O
theophylline	B-CHEMICAL
and	O
should	O
be	O
stopped	O
prior	O
to	O
dipyridamole	B-CHEMICAL
-	O
thallium-201	O
imaging	O
is	O
unknown	O
.	O
Therefore	O
,	O
we	O
studied	O
the	O
hyperemic	O
response	O
to	O
dipyridamole	B-CHEMICAL
in	O
seven	O
open	O
-	O
chest	O
anesthetized	O
dogs	O
after	O
pretreatment	O
with	O
either	O
pentoxifylline	B-CHEMICAL
(	O
0	O
,	O
7.5	O
,	O
or	O
15	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
or	O
theophylline	B-CHEMICAL
(	O
3	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
.	O
Baseline	O
circumflex	O
coronary	O
blood	O
flows	O
did	O
not	O
differ	O
significantly	O
among	O
treatment	O
groups	O
.	O
Dipyridamole	B-CHEMICAL
significantly	O
increased	O
coronary	O
blood	O
flow	O
before	O
and	O
after	O
7.5	O
or	O
15	O
mm	O
/	O
kg	O
i.v	O
.	O
pentoxifylline	B-CHEMICAL
(	O
p	O
less	O
than	O
0.002	O
)	O
.	O
Neither	O
dose	O
of	O
pentoxifylline	B-CHEMICAL
significantly	O
decreased	O
the	O
dipyridamole	B-CHEMICAL
-	O
induced	O
hyperemia	B-DISEASE
,	O
while	O
peak	O
coronary	O
blood	O
flow	O
was	O
significantly	O
lower	O
after	O
theophylline	B-CHEMICAL
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O
We	O
conclude	O
that	O
pentoxyifylline	O
does	O
not	O
inhibit	O
dipyridamole	B-CHEMICAL
-	O
induced	O
coronary	O
hyperemia	B-DISEASE
even	O
at	O
high	O
doses	O
.	O

Cause	O
of	O
death	B-DISEASE
among	O
patients	O
with	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
:	O
a	O
rare	O
mortality	O
due	O
to	O
cerebral	B-DISEASE
haemorrhage	I-DISEASE
.	O
Causes	O
of	O
death	B-DISEASE
,	O
with	O
special	O
reference	O
to	O
cerebral	B-DISEASE
haemorrhage	I-DISEASE
,	O
among	O
240	O
patients	O
with	O
pathologically	O
verified	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
were	O
investigated	O
using	O
the	O
Annuals	O
of	O
the	O
Pathological	O
Autopsy	O
Cases	O
in	O
Japan	O
from	O
1981	O
to	O
1985	O
.	O
The	O
leading	O
causes	O
of	O
death	B-DISEASE
were	O
pneumonia	B-DISEASE
and	O
bronchitis	B-DISEASE
(	O
44.1	O
%	O
)	O
,	O
malignant	O
neoplasms	B-DISEASE
(	O
11.6	O
%	O
)	O
,	O
heart	B-DISEASE
diseases	I-DISEASE
(	O
4.1	O
%	O
)	O
,	O
cerebral	B-DISEASE
infarction	I-DISEASE
(	O
3.7	O
%	O
)	O
and	O
septicaemia	O
(	O
3.3	O
%	O
)	O
.	O
Cerebral	B-DISEASE
haemorrhage	I-DISEASE
was	O
the	O
11th	O
most	O
frequent	O
cause	O
of	O
death	B-DISEASE
,	O
accounting	O
for	O
only	O
0.8	O
%	O
of	O
deaths	B-DISEASE
among	O
the	O
patients	O
,	O
whereas	O
it	O
was	O
the	O
5th	O
most	O
common	O
cause	O
of	O
death	B-DISEASE
among	O
the	O
Japanese	O
general	O
population	O
in	O
1985	O
.	O
The	O
low	O
incidence	O
of	O
cerebral	B-DISEASE
haemorrhage	I-DISEASE
as	O
a	O
cause	O
of	O
death	B-DISEASE
in	O
patients	O
with	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
may	O
reflect	O
the	O
hypotensive	B-DISEASE
effect	O
of	O
levodopa	B-CHEMICAL
and	O
a	O
hypotensive	B-DISEASE
mechanism	O
due	O
to	O
reduced	O
noradrenaline	B-CHEMICAL
levels	O
in	O
the	O
parkinsonian	B-DISEASE
brain	O
.	O

Tolerance	O
and	O
antiviral	O
effect	O
of	O
ribavirin	B-CHEMICAL
in	O
patients	O
with	O
Argentine	O
hemorrhagic	O
fever	B-DISEASE
.	O
Tolerance	O
and	O
antiviral	O
effect	O
of	O
ribavirin	B-CHEMICAL
was	O
studied	O
in	O
6	O
patients	O
with	O
Argentine	O
hemorrhagic	O
fever	B-DISEASE
(	O
AHF	O
)	O
of	O
more	O
than	O
8	O
days	O
of	O
evolution	O
.	O
Administration	O
of	O
ribavirin	B-CHEMICAL
resulted	O
in	O
a	O
neutralization	O
of	O
viremia	B-DISEASE
and	O
a	O
drop	O
of	O
endogenous	O
interferon	O
titers	O
.	O
The	O
average	O
time	O
of	O
death	B-DISEASE
was	O
delayed	O
.	O
A	O
reversible	O
anemia	B-DISEASE
was	O
the	O
only	O
adverse	O
effect	O
observed	O
.	O
From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
ribavirin	B-CHEMICAL
has	O
an	O
antiviral	O
effect	O
in	O
advanced	O
cases	O
of	O
AHF	O
,	O
and	O
that	O
anemia	B-DISEASE
,	O
the	O
only	O
secondary	O
reaction	O
observed	O
,	O
can	O
be	O
easily	O
managed	O
.	O
The	O
possible	O
beneficial	O
effect	O
of	O
ribavirin	B-CHEMICAL
during	O
the	O
initial	O
days	O
of	O
AHF	O
is	O
discussed	O
.	O

Dipyridamole	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
ischemia	I-DISEASE
.	O
Angina	B-DISEASE
and	O
ischemic	B-DISEASE
electrocardiographic	O
changes	O
occurred	O
after	O
administration	O
of	O
oral	O
dipyridamole	B-CHEMICAL
in	O
four	O
patients	O
awaiting	O
urgent	O
myocardial	O
revascularization	O
procedures	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
has	O
not	O
previously	O
been	O
reported	O
as	O
a	O
side	O
effect	O
of	O
preoperative	O
dipyridamole	B-CHEMICAL
therapy	O
,	O
although	O
dipyridamole	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
ischemia	I-DISEASE
has	O
been	O
demonstrated	O
to	O
occur	O
in	O
animals	O
and	O
humans	O
with	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
.	O
Epicardial	O
coronary	O
collateral	O
vessels	O
were	O
demonstrated	O
in	O
all	O
four	O
patients	O
;	O
a	O
coronary	O
"	O
steal	O
"	O
phenomenon	O
may	O
be	O
the	O
mechanism	O
of	O
the	O
dipyridamole	B-CHEMICAL
-	O
induced	O
ischemia	B-DISEASE
observed	O
.	O

Inhibition	O
of	O
immunoreactive	O
corticotropin	O
-	O
releasing	O
factor	O
secretion	O
into	O
the	O
hypophysial	O
-	O
portal	O
circulation	O
by	O
delayed	O
glucocorticoid	O
feedback	O
.	O
Nitroprusside	B-CHEMICAL
-	O
induced	O
hypotension	B-DISEASE
evokes	O
ACTH	O
secretion	O
which	O
is	O
primarily	O
mediated	O
by	O
enhanced	O
secretion	O
of	O
immunoreactive	O
corticotropin	O
-	O
releasing	O
factor	O
(	O
irCRF	O
)	O
into	O
the	O
hypophysial	O
-	O
portal	O
circulation	O
.	O
Portal	O
plasma	O
concentrations	O
of	O
neither	O
arginine	B-CHEMICAL
vasopressin	I-CHEMICAL
nor	O
oxytocin	B-CHEMICAL
are	O
significantly	O
altered	O
in	O
this	O
paradigm	O
.	O
Application	O
of	O
a	O
delayed	O
feedback	O
signal	O
,	O
in	O
the	O
form	O
of	O
a	O
2	O
-	O
h	O
systemic	O
corticosterone	B-CHEMICAL
infusion	O
in	O
urethane	O
-	O
anesthetized	O
rats	O
with	O
pharmacological	O
blockade	O
of	O
glucocorticoid	O
synthesis	O
,	O
is	O
without	O
effect	O
on	O
the	O
resting	O
secretion	O
of	O
arginine	B-CHEMICAL
vasopressin	I-CHEMICAL
and	O
oxytocin	B-CHEMICAL
at	O
any	O
corticosterone	B-CHEMICAL
feedback	O
dose	O
tested	O
.	O
Resting	O
irCRF	O
levels	O
are	O
suppressed	O
only	O
at	O
the	O
highest	O
corticosterone	B-CHEMICAL
infusion	O
rate	O
,	O
which	O
resulted	O
in	O
systemic	O
corticosterone	B-CHEMICAL
levels	O
of	O
40	O
micrograms	O
/	O
dl	O
.	O
Suppression	O
of	O
irCRF	O
secretion	O
in	O
response	O
to	O
nitroprusside	B-CHEMICAL
-	O
induced	O
hypotension	B-DISEASE
is	O
observed	O
and	O
occurs	O
at	O
a	O
plasma	O
corticosterone	B-CHEMICAL
level	O
between	O
8	O
-	O
12	O
micrograms	O
/	O
dl	O
.	O
These	O
studies	O
provide	O
further	O
evidence	O
for	O
a	O
strong	O
central	O
component	O
of	O
the	O
delayed	O
feedback	O
process	O
which	O
is	O
mediated	O
by	O
modulation	O
of	O
irCRF	O
release	O
.	O

Noradrenergic	O
involvement	O
in	O
catalepsy	B-DISEASE
induced	O
by	O
delta	O
9	O
-	O
tetrahydrocannabinol	O
.	O
In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
the	O
catecholaminergic	O
system	O
in	O
the	O
cataleptogenic	O
effect	O
of	O
delta	O
9	O
-	O
tetrahydrocannabinol	O
(	O
THC	O
)	O
,	O
the	O
effect	O
of	O
pretreatment	O
with	O
6	B-CHEMICAL
-	I-CHEMICAL
hydroxydopamine	I-CHEMICAL
(	O
6	B-CHEMICAL
-	I-CHEMICAL
OHDA	I-CHEMICAL
)	O
or	O
with	O
desipramine	B-CHEMICAL
and	O
6	B-CHEMICAL
-	I-CHEMICAL
OHDA	I-CHEMICAL
and	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
were	O
investigated	O
in	O
rats	O
.	O
The	O
cataleptogenic	O
effect	O
of	O
THC	O
was	O
significantly	O
reduced	O
in	O
rats	O
treated	O
with	O
6	B-CHEMICAL
-	I-CHEMICAL
OHDA	I-CHEMICAL
and	O
in	O
rats	O
with	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
but	O
not	O
in	O
rats	O
treated	O
with	O
desipramine	B-CHEMICAL
and	O
6	B-CHEMICAL
-	I-CHEMICAL
OHDA	I-CHEMICAL
,	O
as	O
compared	O
with	O
control	O
rats	O
.	O
On	O
the	O
contrary	O
,	O
the	O
cataleptogenic	O
effect	O
of	O
haloperidol	B-CHEMICAL
was	O
significantly	O
reduced	O
in	O
rats	O
treated	O
with	O
desipramine	B-CHEMICAL
and	O
6	B-CHEMICAL
-	I-CHEMICAL
OHDA	I-CHEMICAL
but	O
not	O
in	O
rats	O
treated	O
with	O
6	B-CHEMICAL
-	I-CHEMICAL
OHDA	I-CHEMICAL
or	O
in	O
rats	O
with	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
.	O
These	O
results	O
indicate	O
that	O
noradrenergic	O
neurons	O
have	O
an	O
important	O
role	O
in	O
the	O
manifestation	O
of	O
catalepsy	B-DISEASE
induced	O
by	O
THC	O
,	O
whereas	O
dopaminergic	O
neurons	O
are	O
important	O
in	O
catalepsy	B-DISEASE
induced	O
by	O
haloperidol	B-CHEMICAL
.	O

Intracranial	O
pressure	O
increases	O
during	O
alfentanil	O
-	O
induced	O
rigidity	B-DISEASE
.	O
Intracranial	O
pressure	O
(	O
ICP	O
)	O
was	O
measured	O
during	O
alfentanil	O
-	O
induced	O
rigidity	B-DISEASE
in	O
rats	O
.	O
Ten	O
rats	O
had	O
arterial	O
,	O
central	O
venous	O
(	O
CVP	O
)	O
,	O
and	O
subdural	O
cannulae	O
inserted	O
under	O
halothane	B-CHEMICAL
anesthesia	O
.	O
The	O
animals	O
were	O
mechanically	O
ventilated	O
to	O
achieve	O
normocarbia	O
(	O
PCO2	O
=	O
42	O
+	O
/-	O
1	O
mmHg	O
,	O
mean	O
+	O
/-	O
SE	B-DISEASE
)	O
.	O
Following	O
instrumentation	O
,	O
halothane	B-CHEMICAL
was	O
discontinued	O
and	O
alfentanil	O
(	O
125	O
mu	O
/	O
kg	O
)	O
administered	O
iv	O
during	O
emergence	O
from	O
halothane	B-CHEMICAL
anesthesia	O
.	O
In	O
the	O
five	O
rats	O
that	O
developed	O
somatic	O
rigidity	B-DISEASE
,	O
ICP	O
and	O
CVP	O
increased	O
significantly	O
above	O
baseline	O
(	O
delta	O
ICP	O
7.5	O
+	O
/-	O
1.0	O
mmHg	O
,	O
delta	O
CVP	O
5.9	O
+	O
/-	O
1.3	O
mmHg	O
)	O
.	O
These	O
variables	O
returned	O
to	O
baseline	O
when	O
rigidity	B-DISEASE
was	O
abolished	O
with	O
metocurine	O
.	O
In	O
five	O
rats	O
that	O
did	O
not	O
become	O
rigid	O
,	O
ICP	O
and	O
CVP	O
did	O
not	O
change	O
following	O
alfentanil	O
.	O
These	O
observations	O
suggest	O
that	O
rigidity	B-DISEASE
should	O
be	O
prevented	O
when	O
alfentanil	O
,	O
and	O
,	O
presumably	O
,	O
other	O
opiates	B-CHEMICAL
,	O
are	O
used	O
in	O
the	O
anesthetic	O
management	O
of	O
patients	O
with	O
ICP	O
problems	O
.	O

Adverse	O
cardiac	O
effects	O
during	O
induction	O
chemotherapy	O
treatment	O
with	O
cis	O
-	O
platin	O
and	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
.	O
Survival	O
for	O
patients	O
with	O
advanced	O
head	O
and	O
neck	O
carcinoma	B-DISEASE
and	O
esophageal	B-DISEASE
carcinoma	I-DISEASE
is	O
poor	O
with	O
radiotherapy	O
and/or	O
surgery	O
.	O
Obviously	O
,	O
there	O
is	O
a	O
need	O
for	O
effective	O
chemotherapy	O
.	O
In	O
the	O
present	O
study	O
,	O
cis	O
-	O
platin	O
(	O
80	O
-	O
120	O
mg	O
/	O
m2BSA	O
)	O
and	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
(	O
1000	O
mg	O
/	O
m2BSA	O
daily	O
as	O
a	O
continuous	O
infusion	O
during	O
5	O
days	O
)	O
were	O
given	O
to	O
76	O
patients	O
before	O
radiotherapy	O
and	O
surgery	O
.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
clarify	O
the	O
incidence	O
and	O
severity	O
of	O
adverse	O
cardiac	O
effects	O
to	O
this	O
treatment	O
.	O
Before	O
treatment	O
all	O
patients	O
had	O
a	O
cardiac	O
evaluation	O
and	O
during	O
treatment	O
serial	O
ECG	O
recordings	O
were	O
performed	O
.	O
In	O
the	O
pre	O
-	O
treatment	O
evaluation	O
,	O
signs	O
of	O
cardiovascular	B-DISEASE
disease	I-DISEASE
were	O
found	O
in	O
33	O
patients	O
(	O
43	O
%	O
)	O
.	O
During	O
treatment	O
,	O
adverse	O
cardiac	O
effects	O
were	O
observed	O
in	O
14	O
patients	O
(	O
18	O
%	O
)	O
.	O
The	O
mean	O
age	O
of	O
these	O
patients	O
was	O
the	O
same	O
as	O
for	O
the	O
entire	O
group	O
,	O
64	O
years	O
.	O
The	O
incidence	O
of	O
cardiotoxicity	B-DISEASE
was	O
not	O
higher	O
in	O
patients	O
with	O
signs	O
of	O
cardiovascular	B-DISEASE
disease	I-DISEASE
than	O
in	O
those	O
without	O
in	O
the	O
pre	O
-	O
treatment	O
evaluation	O
.	O
The	O
most	O
common	O
signs	O
of	O
cardiotoxicity	B-DISEASE
were	O
chest	B-DISEASE
pain	I-DISEASE
,	O
ST	O
-	O
T	O
wave	O
changes	O
and	O
atrial	B-DISEASE
fibrillation	I-DISEASE
.	O
This	O
was	O
followed	O
by	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
in	O
one	O
patient	O
and	O
sudden	O
death	B-DISEASE
in	O
another	O
.	O
It	O
is	O
concluded	O
that	O
patients	O
on	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
treatment	O
should	O
be	O
under	O
close	O
supervision	O
and	O
that	O
the	O
treatment	O
should	O
be	O
discontinued	O
if	O
chest	B-DISEASE
pain	I-DISEASE
or	O
tachyarrhythmia	O
is	O
observed	O
.	O

Verapamil	B-CHEMICAL
-	O
induced	O
carbamazepine	B-CHEMICAL
neurotoxicity	B-DISEASE
.	O
A	O
report	O
of	O
two	O
cases	O
.	O
Two	O
patients	O
with	O
signs	O
of	O
carbamazepine	B-CHEMICAL
neurotoxicity	B-DISEASE
after	O
combined	O
treatment	O
with	O
verapamil	B-CHEMICAL
showed	O
complete	O
recovery	O
after	O
discontinuation	O
of	O
the	O
calcium	B-CHEMICAL
entry	O
blocker	O
.	O
Use	O
of	O
verapamil	B-CHEMICAL
in	O
combination	O
with	O
carbamazepine	B-CHEMICAL
should	O
either	O
be	O
avoided	O
or	O
prescribed	O
only	O
with	O
appropriate	O
adjustment	O
of	O
the	O
carbamazepine	B-CHEMICAL
dose	O
(	O
usually	O
reduction	O
of	O
the	O
carbamazepine	B-CHEMICAL
dose	O
by	O
one	O
half	O
)	O
.	O

Serial	O
studies	O
of	O
auditory	B-DISEASE
neurotoxicity	I-DISEASE
in	O
patients	O
receiving	O
deferoxamine	B-CHEMICAL
therapy	O
.	O
Visual	O
and	O
auditory	B-DISEASE
neurotoxicity	I-DISEASE
was	O
previously	O
documented	O
in	O
42	O
of	O
89	O
patients	O
with	O
transfusion	O
-	O
dependent	O
anemia	B-DISEASE
who	O
were	O
receiving	O
iron	B-CHEMICAL
chelation	O
therapy	O
with	O
daily	O
subcutaneous	O
deferoxamine	B-CHEMICAL
.	O
Twenty	O
-	O
two	O
patients	O
in	O
the	O
affected	O
group	O
had	O
abnormal	B-DISEASE
audiograms	I-DISEASE
with	I-DISEASE
deficits	I-DISEASE
mostly	I-DISEASE
in	I-DISEASE
the	I-DISEASE
high	I-DISEASE
frequency	I-DISEASE
range	I-DISEASE
of	I-DISEASE
4,000	I-DISEASE
to	I-DISEASE
8,000	I-DISEASE
Hz	I-DISEASE
and	O
in	O
the	O
hearing	O
threshold	O
levels	O
of	O
30	O
to	O
100	O
decibels	O
.	O
When	O
deferoxamine	B-CHEMICAL
therapy	O
was	O
discontinued	O
and	O
serial	O
studies	O
were	O
performed	O
,	O
audiograms	O
in	O
seven	O
cases	O
reverted	O
to	O
normal	O
or	O
near	O
normal	O
within	O
two	O
to	O
three	O
weeks	O
,	O
and	O
nine	O
of	O
13	O
patients	O
with	O
symptoms	O
became	O
asymptomatic	O
.	O
Audiograms	O
from	O
15	O
patients	O
remained	O
abnormal	O
and	O
four	O
patients	O
required	O
hearing	O
aids	B-DISEASE
because	O
of	O
permanent	O
disability	O
.	O
Since	O
18	O
of	O
the	O
22	O
patients	O
were	O
initially	O
receiving	O
deferoxamine	B-CHEMICAL
doses	O
in	O
excess	O
of	O
the	O
commonly	O
recommended	O
50	O
mg	O
/	O
kg	O
per	O
dose	O
,	O
therapy	O
was	O
restarted	O
with	O
lower	O
doses	O
,	O
usually	O
50	O
mg	O
/	O
kg	O
per	O
dose	O
or	O
less	O
depending	O
on	O
the	O
degree	O
of	O
auditory	B-DISEASE
abnormality	I-DISEASE
,	O
and	O
with	O
the	O
exception	O
of	O
two	O
cases	O
no	O
further	O
toxicity	B-DISEASE
was	O
demonstrated	O
.	O
Auditory	O
deterioration	O
and	O
improvement	O
,	O
demonstrated	O
serially	O
in	O
individual	O
patients	O
receiving	O
and	O
not	O
receiving	O
deferoxamine	B-CHEMICAL
,	O
respectively	O
,	O
provided	O
convincing	O
evidence	O
for	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relation	O
between	O
deferoxamine	B-CHEMICAL
administration	O
and	O
ototoxicity	B-DISEASE
.	O
Based	O
on	O
these	O
data	O
,	O
a	O
plan	O
of	O
management	O
was	O
developed	O
that	O
allows	O
effective	O
yet	O
safe	O
administration	O
of	O
deferoxamine	B-CHEMICAL
.	O
A	O
dose	O
of	O
50	O
mg	O
/	O
kg	O
is	O
recommended	O
in	O
those	O
without	O
audiogram	O
abnormalities	O
.	O
With	O
mild	O
toxicity	B-DISEASE
,	O
a	O
reduction	O
to	O
30	O
or	O
40	O
mg	O
/	O
kg	O
per	O
dose	O
should	O
result	O
in	O
a	O
reversal	O
of	O
the	O
abnormal	O
results	O
to	O
normal	O
within	O
four	O
weeks	O
.	O
Moderate	O
abnormalities	O
require	O
a	O
reduction	O
of	O
deferoxamine	B-CHEMICAL
to	O
25	O
mg	O
/	O
kg	O
per	O
dose	O
with	O
careful	O
monitoring	O
.	O
In	O
those	O
with	O
symptoms	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
the	O
drug	O
should	O
be	O
stopped	O
for	O
four	O
weeks	O
,	O
and	O
when	O
the	O
audiogram	O
is	O
stable	O
or	O
improved	O
,	O
therapy	O
should	O
be	O
restarted	O
at	O
10	O
to	O
25	O
mg	O
/	O
kg	O
per	O
dose	O
.	O
Serial	O
audiograms	O
should	O
be	O
performed	O
every	O
six	O
months	O
in	O
those	O
without	O
problems	O
and	O
more	O
frequently	O
in	O
young	O
patients	O
with	O
normal	O
serum	O
ferritin	O
values	O
and	O
in	O
those	O
with	O
auditory	B-DISEASE
dysfunction	I-DISEASE
.	O

Flurbiprofen	O
in	O
the	O
treatment	O
of	O
juvenile	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
.	O
Thirty	O
-	O
four	O
patients	O
with	O
juvenile	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
,	O
who	O
were	O
treated	O
with	O
flurbiprofen	O
at	O
a	O
maximum	O
dose	O
of	O
4	O
mg	O
/	O
kg	O
/	O
day	O
,	O
had	O
statistically	O
significant	O
decreases	O
from	O
baseline	O
in	O
6	O
arthritis	B-DISEASE
indices	O
after	O
12	O
weeks	O
of	O
treatment	O
.	O
Improvements	O
were	O
seen	O
in	O
the	O
number	O
of	O
tender	O
joints	O
,	O
the	O
severity	O
of	O
swelling	B-DISEASE
and	O
tenderness	O
,	O
the	O
time	O
of	O
walk	O
50	O
feet	O
,	O
the	O
duration	O
of	O
morning	O
stiffness	O
and	O
the	O
circumference	O
of	O
the	O
left	O
knee	O
.	O
The	O
most	O
frequently	O
observed	O
side	O
effect	O
was	O
fecal	B-DISEASE
occult	I-DISEASE
blood	I-DISEASE
(	O
25	O
%	O
of	O
patients	O
)	O
;	O
however	O
,	O
there	O
was	O
no	O
other	O
evidence	O
of	O
gastrointestinal	O
(	O
GI	O
)	O
bleeding	B-DISEASE
in	O
these	O
patients	O
.	O
One	O
patient	O
was	O
prematurely	O
discontinued	O
from	O
the	O
study	O
for	O
severe	O
headache	B-DISEASE
and	O
abdominal	B-DISEASE
pain	I-DISEASE
.	O
Most	O
side	O
effects	O
were	O
mild	O
and	O
related	O
to	O
the	O
GI	O
tract	O
.	O

The	O
correlation	O
between	O
neurotoxic	B-DISEASE
esterase	O
inhibition	O
and	O
mipafox	O
-	O
induced	O
neuropathic	O
damage	O
in	O
rats	O
.	O
The	O
correlation	O
between	O
neuropathic	O
damage	O
and	O
inhibition	O
of	O
neurotoxic	B-DISEASE
esterase	O
or	O
neuropathy	B-DISEASE
target	O
enzyme	O
(	O
NTE	O
)	O
was	O
examined	O
in	O
rats	O
acutely	O
exposed	O
to	O
Mipafox	O
(	O
N	O
,	O
N'-diisopropylphosphorodiamidofluoridate	O
)	O
,	O
a	O
neurotoxic	B-DISEASE
organophosphate	O
.	O
Brain	O
and	O
spinal	O
cord	O
NTE	O
activities	O
were	O
measured	O
in	O
Long	O
-	O
Evans	O
male	O
rats	O
1	O
hr	O
post	O
-	O
exposure	O
to	O
various	O
dosages	O
of	O
Mipafox	O
(	O
ip	O
,	O
1	O
-	O
15	O
mg	O
/	O
kg	O
)	O
.	O
These	O
data	O
were	O
correlated	O
with	O
histologically	O
scored	O
cervical	O
cord	B-DISEASE
damage	I-DISEASE
in	O
a	O
separate	O
group	O
of	O
similarly	O
dosed	O
rats	O
sampled	O
14	O
-	O
21	O
days	O
post	O
-	O
exposure	O
.	O
Those	O
dosages	O
(	O
greater	O
than	O
or	O
equal	O
to	O
10	O
mg	O
/	O
kg	O
)	O
that	O
inhibited	O
mean	O
NTE	O
activity	O
in	O
the	O
spinal	O
cord	O
greater	O
than	O
or	O
equal	O
to	O
73	O
%	O
and	O
brain	O
greater	O
than	O
or	O
equal	O
to	O
67	O
%	O
of	O
control	O
values	O
produced	O
severe	O
(	O
greater	O
than	O
or	O
equal	O
to	O
3	O
)	O
cervical	O
cord	O
pathology	O
in	O
85	O
%	O
of	O
the	O
rats	O
.	O
In	O
contrast	O
,	O
dosages	O
of	O
Mipafox	O
(	O
less	O
than	O
or	O
equal	O
to	O
5	O
mg	O
/	O
kg	O
)	O
which	O
inhibited	O
mean	O
NTE	O
activity	O
in	O
spinal	O
cord	O
less	O
than	O
or	O
equal	O
to	O
61	O
%	O
and	O
brain	O
less	O
than	O
or	O
equal	O
to	O
60	O
%	O
produced	O
this	O
degree	O
of	O
cord	B-DISEASE
damage	I-DISEASE
in	O
only	O
9	O
%	O
of	O
the	O
animals	O
.	O
These	O
data	O
indicate	O
that	O
a	O
critical	O
percentage	O
of	O
NTE	O
inhibition	O
in	O
brain	O
and	O
spinal	O
cord	O
sampled	O
shortly	O
after	O
Mipafox	O
exposure	O
can	O
predict	O
neuropathic	O
damage	O
in	O
rats	O
several	O
weeks	O
later	O
.	O

Cerebral	B-DISEASE
infarction	I-DISEASE
with	O
a	O
single	O
oral	O
dose	O
of	O
phenylpropanolamine	B-CHEMICAL
.	O
Phenylpropanolamine	B-CHEMICAL
(	O
PPA	O
)	O
,	O
a	O
synthetic	O
sympathomimetic	O
that	O
is	O
structurally	O
similar	O
to	O
amphetamine	O
,	O
is	O
available	O
over	O
the	O
counter	O
in	O
anorectics	O
,	O
nasal	O
congestants	O
,	O
and	O
cold	O
preparations	O
.	O
Its	O
prolonged	O
use	O
or	O
overuse	O
has	O
been	O
associated	O
with	O
seizures	B-DISEASE
,	O
intracerebral	O
hemorrhage	B-DISEASE
,	O
neuropsychiatric	O
symptoms	O
,	O
and	O
nonhemorrhagic	O
cerebral	B-DISEASE
infarction	I-DISEASE
.	O
We	O
report	O
the	O
case	O
of	O
a	O
young	O
woman	O
who	O
suffered	O
a	O
cerebral	B-DISEASE
infarction	I-DISEASE
after	O
taking	O
a	O
single	O
oral	O
dose	O
of	O
PPA	O
.	O

Treatment	O
of	O
psoriasis	B-DISEASE
with	O
azathioprine	B-CHEMICAL
.	O
Azathioprine	B-CHEMICAL
treatment	O
benefited	O
19	O
(	O
66	O
%	O
)	O
out	O
of	O
29	O
patients	O
suffering	O
from	O
severe	O
psoriasis	B-DISEASE
.	O
Haematological	O
complications	B-DISEASE
were	O
not	O
troublesome	O
and	O
results	O
of	O
biochemical	O
liver	O
function	O
tests	O
remained	O
normal	O
.	O
Minimal	O
cholestasis	B-DISEASE
was	O
seen	O
in	O
two	O
cases	O
and	O
portal	O
fibrosis	B-DISEASE
of	O
a	O
reversible	O
degree	O
in	O
eight	O
.	O
Liver	O
biopsies	O
should	O
be	O
undertaken	O
at	O
regular	O
intervals	O
if	O
azathioprine	B-CHEMICAL
therapy	O
is	O
continued	O
so	O
that	O
structural	O
liver	B-DISEASE
damage	I-DISEASE
may	O
be	O
detected	O
at	O
an	O
early	O
and	O
reversible	O
stage	O
.	O

Maternal	O
lithium	B-CHEMICAL
and	O
neonatal	O
Ebstein	B-DISEASE
's	I-DISEASE
anomaly	I-DISEASE
:	O
evaluation	O
with	O
cross	O
-	O
sectional	O
echocardiography	O
.	O
Cross	O
-	O
sectional	O
echocardiography	O
was	O
used	O
to	O
evaluate	O
two	O
neonates	O
whose	O
mothers	O
ingested	O
lithium	B-CHEMICAL
during	O
pregnancy	O
.	O
In	O
one	O
infant	O
,	O
Ebstein	B-DISEASE
's	I-DISEASE
anomaly	I-DISEASE
of	O
the	O
tricuspid	O
valve	O
was	O
identified	O
.	O
In	O
the	O
other	O
infant	O
cross	O
-	O
sectional	O
echocardiography	O
provided	O
reassurance	O
that	O
the	O
infant	O
did	O
not	O
have	O
Ebstein	B-DISEASE
's	I-DISEASE
anomaly	I-DISEASE
.	O
Cross	O
-	O
sectional	O
echocardiographic	O
screening	O
of	O
newborns	O
exposed	O
to	O
lithium	B-CHEMICAL
during	O
gestation	O
can	O
provide	O
highly	O
accurate	O
,	O
noninvasive	O
assessment	O
of	O
the	O
presence	O
or	O
absence	O
of	O
lithium	B-CHEMICAL
-	O
induced	O
cardiac	B-DISEASE
malformations	I-DISEASE
.	O

Effects	O
of	O
training	O
on	O
the	O
extent	O
of	O
experimental	O
myocardial	B-DISEASE
infarction	I-DISEASE
in	O
aging	O
rats	O
.	O
The	O
effects	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
were	O
studied	O
in	O
female	O
albino	O
rats	O
of	O
20,40,60	O
and	O
80	O
weeks	O
of	O
age	O
.	O
The	O
rats	O
were	O
trained	O
to	O
swim	O
for	O
a	O
specific	O
duration	O
and	O
for	O
a	O
particular	O
period	O
.	O
The	O
occurrence	O
of	O
infarcts	O
were	O
confirmed	O
by	O
histological	O
methods	O
.	O
Elevations	O
in	O
the	O
serum	O
GOT	O
and	O
GPT	O
were	O
maximum	O
in	O
the	O
sedentary	O
-	O
isoproterenols	O
and	O
minimum	O
in	O
the	O
exercise	O
-	O
controls	O
.	O
These	O
changes	O
in	O
the	O
serum	O
transaminases	O
were	O
associated	O
with	O
corresponding	O
depletions	O
in	O
the	O
cardiac	O
GOT	O
and	O
GPT	O
.	O
However	O
,	O
age	O
was	O
seen	O
to	O
interfere	O
with	O
the	O
responses	O
exhibited	O
by	O
the	O
young	O
and	O
old	O
rats	O
.	O
Studies	O
dealing	O
with	O
myocardial	B-DISEASE
infarction	I-DISEASE
are	O
more	O
informative	O
when	O
dealt	O
with	O
age	O
.	O

Effect	O
of	O
polyethylene	B-CHEMICAL
glycol	I-CHEMICAL
400	I-CHEMICAL
on	O
adriamycin	B-CHEMICAL
toxicity	B-DISEASE
in	O
mice	O
.	O
The	O
effect	O
of	O
a	O
widely	O
used	O
organic	O
solvent	O
,	O
polyethylene	B-CHEMICAL
glycol	I-CHEMICAL
400	I-CHEMICAL
(	O
PEG	B-CHEMICAL
400	I-CHEMICAL
)	O
,	O
on	O
the	O
toxic	O
action	O
of	O
an	O
acute	O
or	O
chronic	O
treatment	O
with	O
adriamycin	B-CHEMICAL
(	O
ADR	B-CHEMICAL
)	O
was	O
evaluated	O
in	O
mice	O
.	O
PEG	B-CHEMICAL
400	I-CHEMICAL
impressively	O
decreased	O
both	O
acute	O
high	O
-	O
dose	O
and	O
chronic	O
low	O
-	O
dose	O
-	O
ADR	B-CHEMICAL
-	O
associated	O
lethality	O
.	O
Light	O
microscopic	O
analysis	O
showed	O
a	O
significant	O
protection	O
against	O
ADR	B-CHEMICAL
-	O
induced	O
cardiac	B-DISEASE
morphological	I-DISEASE
alterations	I-DISEASE
.	O
Such	O
treatment	O
did	O
not	O
diminish	O
the	O
ADR	B-CHEMICAL
antitumor	O
activity	O
in	O
L1210	O
leukemia	B-DISEASE
and	O
in	O
Ehrlich	O
ascites	B-DISEASE
tumor	B-DISEASE
.	O

Intra	O
-	O
arterial	O
BCNU	B-CHEMICAL
chemotherapy	O
for	O
treatment	O
of	O
malignant	O
gliomas	O
of	O
the	O
central	O
nervous	O
system	O
.	O
Because	O
of	O
the	O
rapid	O
systemic	O
clearance	O
of	O
BCNU	B-CHEMICAL
(	O
1,3	B-CHEMICAL
-	I-CHEMICAL
bis-(2	I-CHEMICAL
-	I-CHEMICAL
chloroethyl)-1	I-CHEMICAL
-	I-CHEMICAL
nitrosourea	I-CHEMICAL
)	O
,	O
intra	O
-	O
arterial	O
administration	O
should	O
provide	O
a	O
substantial	O
advantage	O
over	O
intravenous	O
administration	O
for	O
the	O
treatment	O
of	O
malignant	O
gliomas	O
.	O
Thirty	O
-	O
six	O
patients	O
were	O
treated	O
with	O
BCNU	B-CHEMICAL
every	O
6	O
to	O
8	O
weeks	O
,	O
either	O
by	O
transfemoral	O
catheterization	O
of	O
the	O
internal	O
carotid	O
or	O
vertebral	O
artery	O
or	O
through	O
a	O
fully	O
implantable	O
intracarotid	O
drug	O
delivery	O
system	O
,	O
beginning	O
with	O
a	O
dose	O
of	O
200	O
mg	O
/	O
sq	O
m	O
body	O
surface	O
area	O
.	O
Twelve	O
patients	O
with	O
Grade	O
III	O
or	O
IV	O
astrocytomas	B-DISEASE
were	O
treated	O
after	O
partial	O
resection	O
of	O
the	O
tumor	B-DISEASE
without	O
prior	O
radiation	O
therapy	O
.	O
After	O
two	O
to	O
seven	O
cycles	O
of	O
chemotherapy	O
,	O
nine	O
patients	O
showed	O
a	O
decrease	O
in	O
tumor	B-DISEASE
size	O
and	O
surrounding	O
edema	B-DISEASE
on	O
contrast	O
-	O
enhanced	O
computerized	O
tomography	O
scans	O
.	O
In	O
the	O
nine	O
responders	O
,	O
median	O
duration	O
of	O
chemotherapy	O
response	O
from	O
the	O
time	O
of	O
operation	O
was	O
25	O
weeks	O
(	O
range	O
12	O
to	O
more	O
than	O
91	O
weeks	O
)	O
.	O
The	O
median	O
duration	O
of	O
survival	O
in	O
the	O
12	O
patients	O
was	O
54	O
weeks	O
(	O
range	O
21	O
to	O
more	O
than	O
156	O
weeks	O
)	O
,	O
with	O
an	O
18	O
-	O
month	O
survival	O
rate	O
of	O
42	O
%	O
.	O
Twenty	O
-	O
four	O
patients	O
with	O
recurrent	O
Grade	O
I	O
to	O
IV	O
astrocytomas	B-DISEASE
,	O
whose	O
resection	O
and	O
irradiation	O
therapy	O
had	O
failed	O
,	O
received	O
two	O
to	O
eight	O
courses	O
of	O
intra	O
-	O
arterial	O
BCNU	B-CHEMICAL
therapy	O
.	O
Seventeen	O
of	O
these	O
had	O
a	O
response	O
or	O
were	O
stable	O
for	O
a	O
median	O
of	O
20	O
weeks	O
(	O
range	O
6	O
to	O
more	O
than	O
66	O
weeks	O
)	O
.	O
The	O
catheterization	O
procedure	O
is	O
safe	O
,	O
with	O
no	O
immediate	O
complication	O
in	O
111	O
infusions	O
of	O
BCNU	B-CHEMICAL
.	O
A	O
delayed	O
complication	O
in	O
nine	O
patients	O
has	O
been	O
unilateral	O
loss	O
of	O
vision	O
secondary	O
to	O
a	O
retinal	B-DISEASE
vasculitis	I-DISEASE
.	O
The	O
frequency	O
of	O
visual	B-DISEASE
loss	I-DISEASE
decreased	O
after	O
the	O
concentration	O
of	O
the	O
ethanol	B-CHEMICAL
diluent	O
was	O
lowered	O
.	O

Blood	O
pressure	O
response	O
to	O
chronic	O
low	O
-	O
dose	O
intrarenal	O
noradrenaline	B-CHEMICAL
infusion	O
in	O
conscious	O
rats	O
.	O
Sodium	B-CHEMICAL
chloride	O
solution	O
(	O
0.9	O
%	O
)	O
or	O
noradrenaline	B-CHEMICAL
in	O
doses	O
of	O
4	O
,	O
12	O
and	O
36	O
micrograms	O
h-1	O
kg-1	O
was	O
infused	O
for	O
five	O
consecutive	O
days	O
,	O
either	O
intrarenally	O
(	O
by	O
a	O
new	O
technique	O
)	O
or	O
intravenously	O
into	O
rats	O
with	O
one	O
kidney	O
removed	O
.	O
Intrarenal	O
infusion	O
of	O
noradrenaline	B-CHEMICAL
caused	O
hypertension	B-DISEASE
at	O
doses	O
which	O
did	O
not	O
do	O
so	O
when	O
infused	O
intravenously	O
.	O
Intrarenal	O
compared	O
with	O
intravenous	O
infusion	O
of	O
noradrenaline	B-CHEMICAL
caused	O
higher	O
plasma	O
noradrenaline	B-CHEMICAL
concentrations	O
and	O
a	O
shift	O
of	O
the	O
plasma	O
noradrenaline	B-CHEMICAL
concentration	O
-	O
blood	O
pressure	O
effect	O
curve	O
towards	O
lower	O
plasma	O
noradrenaline	B-CHEMICAL
levels	O
.	O
These	O
results	O
suggest	O
that	O
hypertension	B-DISEASE
after	O
chronic	O
intrarenal	O
noradrenaline	B-CHEMICAL
infusion	O
is	O
produced	O
by	O
relatively	O
higher	O
levels	O
of	O
circulating	O
noradrenaline	B-CHEMICAL
and	O
by	O
triggering	O
of	O
an	O
additional	O
intrarenal	O
pressor	O
mechanism	O
.	O

Age	O
and	O
renal	O
clearance	O
of	O
cimetidine	B-CHEMICAL
.	O
In	O
35	O
patients	O
(	O
ages	O
20	O
to	O
86	O
yr	O
)	O
receiving	O
cimetidine	B-CHEMICAL
therapeutically	O
two	O
serum	O
samples	O
and	O
all	O
urine	O
formed	O
in	O
the	O
interim	O
were	O
collected	O
for	O
analysis	O
of	O
cimetidine	B-CHEMICAL
by	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
and	O
for	O
creatinine	B-CHEMICAL
.	O
Cimetidine	B-CHEMICAL
clearance	O
decreased	O
with	O
age	O
.	O
The	O
extrapolated	O
6	O
-	O
hr	O
serum	O
concentration	O
of	O
cimetidine	B-CHEMICAL
per	O
unit	O
dose	O
,	O
after	O
intravenous	O
cimetidine	B-CHEMICAL
,	O
increased	O
with	O
age	O
of	O
the	O
patients	O
.	O
The	O
ratio	O
of	O
cimetidine	B-CHEMICAL
clearance	O
to	O
creatinine	B-CHEMICAL
clearance	O
(	O
Rc	O
)	O
averaged	O
4.8	O
+	O
/-	O
2.0	O
,	O
indicating	O
net	O
tubular	O
secretion	O
for	O
cimetidine	B-CHEMICAL
.	O
Rc	O
seemed	O
to	O
be	O
independent	O
of	O
age	O
and	O
decreased	O
with	O
increasing	O
serum	O
concentration	O
of	O
cimetidine	B-CHEMICAL
,	O
suggesting	O
that	O
secretion	O
of	O
cimetidine	B-CHEMICAL
is	O
a	O
saturable	O
process	O
.	O
There	O
was	O
only	O
one	O
case	O
of	O
dementia	B-DISEASE
possibly	O
due	O
to	O
cimetidine	B-CHEMICAL
(	O
with	O
a	O
drug	O
level	O
of	O
1.9	O
microgram	O
/	O
ml	O
6	O
hr	O
after	O
a	O
dose	O
)	O
in	O
a	O
group	O
of	O
13	O
patients	O
without	O
liver	O
or	O
kidney	O
disease	B-DISEASE
who	O
had	O
cimetidine	B-CHEMICAL
levels	O
above	O
1.25	O
microgram	O
/	O
ml	O
.	O
Thus	O
,	O
high	O
cimetidine	B-CHEMICAL
levels	O
alone	O
do	O
not	O
always	O
induce	O
dementia	B-DISEASE
.	O

Development	O
of	O
clear	B-DISEASE
cell	I-DISEASE
adenocarcinoma	I-DISEASE
in	O
DES	O
-	O
exposed	O
offspring	O
under	O
observation	O
.	O
Two	O
cases	O
of	O
clear	B-DISEASE
cell	I-DISEASE
adenocarcinoma	I-DISEASE
of	O
the	O
vagina	O
detected	O
at	O
follow	O
-	O
up	O
in	O
young	O
women	O
exposed	O
in	O
utero	O
to	O
diethylstilbestrol	B-CHEMICAL
are	O
reported	O
.	O
One	O
patient	O
,	O
aged	O
23	O
,	O
had	O
been	O
followed	O
for	O
2	O
years	O
before	O
carcinoma	B-DISEASE
was	O
diagnosed	O
;	O
the	O
second	O
patient	O
,	O
aged	O
22	O
,	O
had	O
been	O
seen	O
on	O
a	O
regular	O
basis	O
for	O
5	O
years	O
,	O
8	O
months	O
.	O
In	O
both	O
instances	O
,	O
suspicion	O
of	O
the	O
presence	O
of	O
carcinoma	B-DISEASE
was	O
aroused	O
by	O
the	O
palpation	O
of	O
a	O
small	O
nodule	O
in	O
the	O
vaginal	O
fornix	O
.	O
Hysterosalpingography	O
was	O
performed	O
on	O
both	O
patients	O
and	O
,	O
in	O
1	O
instance	O
,	O
an	O
abnormal	O
x	O
-	O
ray	O
film	O
was	O
reflected	O
by	O
the	O
gross	O
appearance	O
of	O
the	O
uterine	O
cavity	O
found	O
in	O
the	O
surgical	O
specimen	O
.	O

Phenobarbitone	B-CHEMICAL
-	O
induced	O
enlargement	B-DISEASE
of	I-DISEASE
the	I-DISEASE
liver	I-DISEASE
in	O
the	O
rat	O
:	O
its	O
relationship	O
to	O
carbon	B-CHEMICAL
tetrachloride	I-CHEMICAL
-	O
induced	O
cirrhosis	B-DISEASE
.	O
The	O
yield	O
of	O
severe	O
cirrhosis	B-DISEASE
of	I-DISEASE
the	I-DISEASE
liver	I-DISEASE
(	O
defined	O
as	O
a	O
shrunken	O
finely	O
nodular	O
liver	O
with	O
micronodular	O
histology	O
,	O
ascites	B-DISEASE
greater	O
than	O
30	O
ml	O
,	O
plasma	O
albumin	O
less	O
than	O
2.2	O
g	O
/	O
dl	O
,	O
splenomegaly	B-DISEASE
2	O
-	O
3	O
times	O
normal	O
,	O
and	O
testicular	O
atrophy	B-DISEASE
approximately	O
half	O
normal	O
weight	O
)	O
after	O
12	O
doses	O
of	O
carbon	B-CHEMICAL
tetrachloride	I-CHEMICAL
given	O
intragastrically	O
in	O
the	O
phenobarbitone	B-CHEMICAL
-	O
primed	O
rat	O
was	O
increased	O
from	O
25	O
%	O
to	O
56	O
%	O
by	O
giving	O
the	O
initial	O
"	O
calibrating	O
"	O
dose	O
of	O
carbon	B-CHEMICAL
tetrachloride	I-CHEMICAL
at	O
the	O
peak	O
of	O
the	O
phenobarbitone	B-CHEMICAL
-	O
induced	O
enlargement	B-DISEASE
of	I-DISEASE
the	I-DISEASE
liver	I-DISEASE
.	O
At	O
this	O
point	O
it	O
was	O
assumed	O
that	O
the	O
cytochrome	O
P450	O
/	O
CCl4	O
toxic	O
state	O
was	O
both	O
maximal	O
and	O
stable	O
.	O
The	O
optimal	O
rat	O
size	O
to	O
begin	O
phenobarbitone	B-CHEMICAL
was	O
determined	O
as	O
100	O
g	O
,	O
and	O
this	O
size	O
as	O
a	O
group	O
had	O
a	O
mean	O
maximum	O
relative	O
liver	O
weight	O
increase	O
47	O
%	O
greater	O
than	O
normal	O
rats	O
of	O
the	O
same	O
body	B-DISEASE
weight	I-DISEASE
.	O
The	O
optimal	O
time	O
for	O
the	O
initial	O
dose	O
of	O
carbon	B-CHEMICAL
tetrachloride	I-CHEMICAL
was	O
after	O
14	O
days	O
on	O
phenobarbitone	B-CHEMICAL
.	O

Attenuation	O
of	O
the	O
lithium	B-CHEMICAL
-	O
induced	O
diabetes	B-DISEASE
-	I-DISEASE
insipidus	I-DISEASE
-	I-DISEASE
like	I-DISEASE
syndrome	I-DISEASE
by	O
amiloride	O
in	O
rats	O
.	O
The	O
effect	O
of	O
amiloride	O
on	O
lithium	B-CHEMICAL
-	O
induced	O
polydipsia	B-DISEASE
and	O
polyuria	B-DISEASE
and	O
on	O
the	O
lithium	B-CHEMICAL
concentration	O
in	O
the	O
plasma	O
,	O
brain	O
,	O
kidney	O
,	O
thyroid	O
and	O
red	O
blood	O
cells	O
was	O
investigated	O
in	O
rats	O
,	O
chronically	O
treated	O
with	O
LiCl	O
.	O
Amiloride	O
reduced	O
the	O
drinking	O
and	O
urine	O
volume	O
of	O
rats	O
in	O
an	O
acute	O
(	O
6	O
or	O
12	O
h	O
)	O
and	O
a	O
subacute	O
(	O
3	O
days	O
)	O
experiment	O
.	O
6	O
h	O
after	O
the	O
administration	O
of	O
amiloride	O
,	O
a	O
reduction	O
was	O
observed	O
in	O
the	O
lithium	B-CHEMICAL
content	O
of	O
the	O
renal	O
medulla	O
but	O
not	O
in	O
the	O
other	O
organs	O
studied	O
.	O
At	O
12	O
h	O
,	O
all	O
the	O
tissues	O
showed	O
a	O
slight	O
increase	O
in	O
lithium	B-CHEMICAL
levels	O
.	O
After	O
3	O
days	O
of	O
combined	O
treatment	O
,	O
a	O
marked	O
elevation	O
in	O
plasma	O
and	O
tissue	O
lithium	B-CHEMICAL
levels	O
accompanied	O
a	O
reduction	O
in	O
water	O
intake	O
.	O
In	O
all	O
the	O
experiments	O
,	O
the	O
attenuation	O
of	O
the	O
lithium	B-CHEMICAL
-	O
induced	O
diabetes	B-DISEASE
-	I-DISEASE
insipidus	I-DISEASE
-	I-DISEASE
like	I-DISEASE
syndrome	I-DISEASE
by	O
amiloride	O
was	O
accompanied	O
by	O
a	O
reduction	O
of	O
the	O
ratio	O
between	O
the	O
lithium	B-CHEMICAL
concentration	O
in	O
the	O
renal	O
medulla	O
and	O
its	O
levels	O
in	O
the	O
blood	O
and	O
an	O
elevation	O
in	O
the	O
plasma	O
potassium	B-CHEMICAL
level	O
.	O
It	O
is	O
concluded	O
that	O
acute	O
amiloride	O
administration	O
to	O
lithium	B-CHEMICAL
-	O
treated	O
patients	O
suffering	O
from	O
polydipsia	B-DISEASE
and	O
polyuria	B-DISEASE
might	O
relieve	O
these	O
patients	O
but	O
prolonged	O
amiloride	O
supplementation	O
would	O
result	O
in	O
elevated	O
lithium	B-CHEMICAL
levels	O
and	O
might	O
be	O
hazardous	O
.	O

Safety	O
and	O
side	O
-	O
effects	O
of	O
alprazolam	B-CHEMICAL
.	O
Controlled	O
study	O
in	O
agoraphobia	B-DISEASE
with	O
panic	B-DISEASE
disorder	I-DISEASE
.	O
BACKGROUND	O
:	O
The	O
widespread	O
use	O
of	O
benzodiazepines	O
has	O
led	O
to	O
increasing	O
recognition	O
of	O
their	O
unwanted	O
effects	O
.	O
The	O
efficacy	O
of	O
alprazolam	B-CHEMICAL
and	O
placebo	O
in	O
panic	B-DISEASE
disorder	I-DISEASE
with	O
agoraphobia	B-DISEASE
,	O
and	O
the	O
side	O
-	O
effect	O
and	O
adverse	O
effect	O
profiles	O
of	O
both	O
drug	O
groups	O
were	O
measured	O
.	O
METHOD	O
:	O
In	O
London	O
and	O
Toronto	O
154	O
patients	O
who	O
met	O
DSM	O
-	O
III	O
criteria	O
for	O
panic	B-DISEASE
disorder	I-DISEASE
with	O
agoraphobia	B-DISEASE
were	O
randomised	O
to	O
alprazolam	B-CHEMICAL
or	O
placebo	O
.	O
Subjects	O
in	O
each	O
drug	O
group	O
also	O
received	O
either	O
exposure	O
or	O
relaxation	O
.	O
Treatment	O
was	O
from	O
weeks	O
0	O
to	O
8	O
and	O
was	O
then	O
tapered	O
from	O
weeks	O
8	O
to	O
16	O
.	O
RESULTS	O
:	O
Mean	O
alprazolam	B-CHEMICAL
dose	O
was	O
5	O
mg	O
daily	O
.	O
Compared	O
with	O
placebo	O
subjects	O
,	O
alprazolam	B-CHEMICAL
patients	O
developed	O
more	O
adverse	O
reactions	O
(	O
21	O
%	O
v.	O
0	O
%	O
)	O
of	O
depression	B-DISEASE
,	O
enuresis	B-DISEASE
,	O
disinhibition	O
and	O
aggression	B-DISEASE
;	O
and	O
more	O
side	O
-	O
effects	O
,	O
particularly	O
sedation	O
,	O
irritability	B-DISEASE
,	O
impaired	O
memory	O
,	O
weight	B-DISEASE
loss	I-DISEASE
and	O
ataxia	B-DISEASE
.	O
Side	O
-	O
effects	O
tended	O
to	O
diminish	O
during	O
treatment	O
but	O
remained	O
significant	O
at	O
week	O
8	O
.	O
Despite	O
this	O
,	O
the	O
drop	O
-	O
out	O
rate	O
was	O
low	O
.	O
CONCLUSIONS	O
:	O
Alprazolam	B-CHEMICAL
caused	O
side	O
-	O
effects	O
and	O
adverse	O
effects	O
during	O
treatment	O
but	O
many	O
patients	O
were	O
willing	O
to	O
accept	O
these	O
.	O

Dup	O
753	O
prevents	O
the	O
development	O
of	O
puromycin	O
aminonucleoside	O
-	O
induced	O
nephrosis	B-DISEASE
.	O
The	O
appearance	O
of	O
nephrotic	B-DISEASE
syndromes	O
such	O
as	O
proteinuria	B-DISEASE
,	O
hypoalbuminemia	B-DISEASE
,	O
hypercholesterolemia	B-DISEASE
and	O
increase	O
in	O
blood	O
nitrogen	O
urea	B-CHEMICAL
,	O
induced	O
in	O
rats	O
by	O
injection	O
of	O
puromycin	O
aminonucleoside	O
was	O
markedly	O
inhibited	O
by	O
oral	O
administration	O
of	O
Dup	O
753	O
(	O
losartan	B-CHEMICAL
)	O
,	O
a	O
novel	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
receptor	O
antagonist	O
,	O
at	O
a	O
dose	O
of	O
1	O
or	O
2	O
mg	O
/	O
kg	O
per	O
day	O
.	O
The	O
results	O
suggest	O
a	O
possible	O
involvement	O
of	O
the	O
renin	O
-	O
angiotensin	O
system	O
in	O
the	O
development	O
of	O
puromycin	O
aminonucleoside	O
-	O
induced	O
nephrosis	B-DISEASE
.	O

Sodium	B-CHEMICAL
bicarbonate	O
alleviates	O
penile	B-DISEASE
pain	I-DISEASE
induced	O
by	O
intracavernous	O
injections	O
for	O
erectile	B-DISEASE
dysfunction	I-DISEASE
.	O
In	O
an	O
attempt	O
to	O
determine	O
whether	O
penile	B-DISEASE
pain	I-DISEASE
associated	O
with	O
intracorporeal	O
injections	O
could	O
be	O
due	O
to	O
the	O
acidity	O
of	O
the	O
medication	O
,	O
we	O
performed	O
a	O
randomized	O
study	O
comparing	O
the	O
incidence	O
of	O
penile	B-DISEASE
pain	I-DISEASE
following	O
intracorporeal	O
injections	O
with	O
or	O
without	O
the	O
addition	O
of	O
sodium	B-CHEMICAL
bicarbonate	O
to	O
the	O
intracorporeal	O
medications	O
.	O
A	O
total	O
of	O
38	O
consecutive	O
patients	O
who	O
presented	O
to	O
our	O
clinic	O
with	O
impotence	B-DISEASE
received	O
0.2	O
ml	O
.	O
of	O
a	O
combination	O
of	O
3	O
drugs	O
:	O
6	O
mg	O
.	O
papaverine	B-CHEMICAL
,	O
100	O
micrograms	O
.	O
phentolamine	O
and	O
10	O
micrograms	O
.	O
prostaglandin	B-CHEMICAL
E1	I-CHEMICAL
with	O
(	O
pH	O
7.05	O
)	O
or	O
without	O
(	O
pH	O
4.17	O
)	O
the	O
addition	O
of	O
sodium	B-CHEMICAL
bicarbonate	O
(	O
0.03	O
mEq	O
.	O
)	O
.	O
Of	O
the	O
19	O
patients	O
without	O
sodium	B-CHEMICAL
bicarbonate	O
added	O
to	O
the	O
medication	O
11	O
(	O
58	O
%	O
)	O
complained	O
of	O
penile	B-DISEASE
pain	I-DISEASE
due	O
to	O
the	O
medication	O
,	O
while	O
only	O
1	O
of	O
the	O
19	O
men	O
(	O
5	O
%	O
)	O
who	O
received	O
sodium	B-CHEMICAL
bicarbonate	O
complained	O
of	O
penile	B-DISEASE
pain	I-DISEASE
.	O
From	O
these	O
data	O
we	O
conclude	O
that	O
the	O
penile	B-DISEASE
pain	I-DISEASE
following	O
intracorporeal	O
injections	O
is	O
most	O
likely	O
due	O
to	O
the	O
acidity	O
of	O
the	O
medication	O
,	O
which	O
can	O
be	O
overcome	O
by	O
elevating	O
the	O
pH	O
to	O
a	O
neutral	O
level	O
.	O

Prospective	O
study	O
of	O
the	O
long	O
-	O
term	O
effects	O
of	O
somatostatin	B-CHEMICAL
analog	O
(	O
octreotide	B-CHEMICAL
)	O
on	O
gallbladder	O
function	O
and	O
gallstone	O
formation	O
in	O
Chinese	O
acromegalic	B-DISEASE
patients	O
.	O
This	O
article	O
reports	O
the	O
changes	O
in	O
gallbladder	O
function	O
examined	O
by	O
ultrasonography	O
in	O
20	O
Chinese	O
patients	O
with	O
active	O
acromegaly	B-DISEASE
treated	O
with	O
sc	O
injection	O
of	O
the	O
somatostatin	B-CHEMICAL
analog	O
octreotide	B-CHEMICAL
in	O
dosages	O
of	O
300	O
-	O
1500	O
micrograms	O
/	O
day	O
for	O
a	O
mean	O
of	O
24.2	O
+	O
/-	O
13.9	O
months	O
.	O
During	O
treatment	O
with	O
octreotide	B-CHEMICAL
,	O
17	O
patients	O
developed	O
sludge	O
,	O
10	O
had	O
gallstones	B-DISEASE
,	O
and	O
1	O
developed	O
acute	B-DISEASE
cholecystitis	I-DISEASE
requiring	O
surgery	O
.	O
In	O
all	O
of	O
7	O
patients	O
examined	O
acutely	O
,	O
gallbladder	O
contractility	O
was	O
inhibited	O
after	O
a	O
single	O
100	O
-	O
micrograms	O
injection	O
.	O
In	O
8	O
patients	O
followed	O
for	O
24	O
weeks	O
,	O
gallbladder	O
contractility	O
remained	O
depressed	B-DISEASE
throughout	O
therapy	O
.	O
After	O
withdrawal	O
of	O
octreotide	B-CHEMICAL
in	O
10	O
patients	O
without	O
gallstones	B-DISEASE
,	O
8	O
patients	O
assessed	O
had	O
return	O
of	O
normal	O
gallbladder	O
contractility	O
within	O
1	O
month	O
.	O
In	O
8	O
of	O
the	O
remaining	O
10	O
patients	O
who	O
developed	O
gallstones	B-DISEASE
during	O
treatment	O
,	O
gallbladder	O
contractility	O
normalized	O
in	O
5	O
patients	O
(	O
3	O
of	O
whom	O
has	O
disappearance	O
of	O
their	O
stones	O
within	O
3	O
weeks	O
)	O
,	O
and	O
remained	O
depressed	B-DISEASE
in	O
3	O
(	O
2	O
of	O
whom	O
had	O
stones	O
present	O
at	O
6	O
months	O
)	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
suppression	O
of	O
gallbladder	O
contractility	O
is	O
the	O
cause	O
of	O
the	O
successive	O
formation	O
of	O
bile	O
sludge	O
,	O
gallstones	B-DISEASE
,	O
and	O
cholecystitis	B-DISEASE
during	O
octreotide	B-CHEMICAL
therapy	O
in	O
Chinese	O
acromegalic	B-DISEASE
patients	O
.	O
It	O
is	O
therefore	O
very	O
important	O
to	O
follow	O
the	O
changes	O
of	O
gallbladder	O
function	O
during	O
long	O
-	O
term	O
octreotide	B-CHEMICAL
therapy	O
of	O
acromegalic	B-DISEASE
patients	O
.	O

Improvement	O
of	O
levodopa	B-CHEMICAL
-	O
induced	O
dyskinesia	B-DISEASE
by	O
propranolol	B-CHEMICAL
in	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
.	O
Seven	O
patients	O
suffering	O
from	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
(	O
PD	O
)	O
with	O
severely	O
disabling	O
dyskinesia	B-DISEASE
received	O
low	O
-	O
dose	O
propranolol	B-CHEMICAL
as	O
an	O
adjunct	O
to	O
the	O
currently	O
used	O
medical	O
treatment	O
.	O
There	O
was	O
a	O
significant	O
40	O
%	O
improvement	O
in	O
the	O
dyskinesia	B-DISEASE
score	O
without	O
increase	O
of	O
parkinsonian	B-DISEASE
motor	B-DISEASE
disability	I-DISEASE
.	O
Ballistic	O
and	O
choreic	O
dyskinesia	B-DISEASE
were	O
markedly	O
ameliorated	O
,	O
whereas	O
dystonia	B-DISEASE
was	O
not	O
.	O
This	O
study	O
suggests	O
that	O
administration	O
of	O
low	O
doses	O
of	O
beta	O
-	O
blockers	O
may	O
improve	O
levodopa	B-CHEMICAL
-	O
induced	O
ballistic	O
and	O
choreic	O
dyskinesia	B-DISEASE
in	O
PD	O
.	O

Morphological	O
features	O
of	O
encephalopathy	B-DISEASE
after	O
chronic	O
administration	O
of	O
the	O
antiepileptic	O
drug	O
valproate	O
to	O
rats	O
.	O
A	O
transmission	O
electron	O
microscopic	O
study	O
of	O
capillaries	O
in	O
the	O
cerebellar	O
cortex	O
.	O
Long	O
-	O
term	O
intragastric	O
application	O
of	O
the	O
antiepileptic	O
drug	O
sodium	B-CHEMICAL
valproate	O
(	O
Vupral	O
"	O
Polfa	O
"	O
)	O
at	O
the	O
effective	O
dose	O
of	O
200	O
mg	O
/	O
kg	O
b.	O
w.	O
once	O
daily	O
to	O
rats	O
for	O
1	O
,	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	O
revealed	O
neurological	O
disorders	O
indicating	O
cerebellum	B-DISEASE
damage	I-DISEASE
(	O
"	O
valproate	O
encephalopathy	B-DISEASE
"	O
)	O
.	O
The	O
first	O
ultrastructural	O
changes	O
in	O
structural	O
elements	O
of	O
the	O
blood	O
-	O
brain	O
-	O
barrier	O
(	O
BBB	O
)	O
in	O
the	O
cerebellar	O
cortex	O
were	O
detectable	O
after	O
3	O
months	O
of	O
the	O
experiment	O
.	O
They	O
became	O
more	O
severe	O
in	O
the	O
later	O
months	O
of	O
the	O
experiment	O
,	O
and	O
were	O
most	O
severe	O
after	O
12	O
months	O
,	O
located	O
mainly	O
in	O
the	O
molecular	O
layer	O
of	O
the	O
cerebellar	O
cortex	O
.	O
Lesions	O
of	O
the	O
capillary	O
included	O
necrosis	B-DISEASE
of	O
endothelial	O
cells	O
.	O
Organelles	O
of	O
these	O
cells	O
,	O
in	O
particular	O
the	O
mitochondria	O
(	O
increased	O
number	O
and	O
size	O
,	O
distinct	O
degeneration	O
of	O
their	O
matrix	O
and	O
cristae	O
)	O
and	O
Golgi	O
apparatus	O
were	O
altered	O
.	O
Reduced	O
size	O
of	O
capillary	O
lumen	O
and	O
occlusion	O
were	O
caused	O
by	O
swollen	O
endothelial	O
cells	O
which	O
had	O
luminal	B-CHEMICAL
protrusions	O
and	O
swollen	O
microvilli	O
.	O
Pressure	O
on	O
the	O
vessel	O
wall	O
was	O
produced	O
by	O
enlarged	O
perivascular	O
astrocytic	O
processes	O
.	O
Fragments	O
of	O
necrotic	B-DISEASE
endothelial	O
cells	O
were	O
in	O
the	O
vascular	O
lumens	O
and	O
in	O
these	O
there	O
was	O
loosening	O
and	O
breaking	O
of	O
tight	O
cellular	O
junctions	O
.	O
Damage	O
to	O
the	O
vascular	O
basement	O
lamina	O
was	O
also	O
observed	O
.	O
Damage	O
to	O
the	O
capillary	O
was	O
accompanied	O
by	O
marked	O
damage	O
to	O
neuroglial	O
cells	O
,	O
mainly	O
to	O
perivascular	O
processes	O
of	O
astrocytes	O
.	O
The	O
proliferation	O
of	O
astrocytes	O
(	O
Bergmann	O
's	O
in	O
particular	O
)	O
and	O
occasionally	O
of	O
oligodendrocytes	O
was	O
found	O
.	O
Alterations	O
in	O
the	O
structural	O
elements	O
of	O
the	O
BBB	O
coexisted	O
with	O
marked	O
lesions	O
of	O
neurons	O
of	O
the	O
cerebellum	O
(	O
Purkinje	O
cells	O
are	O
earliest	O
)	O
.	O
In	O
electron	O
micrographs	O
both	O
luminal	B-CHEMICAL
and	O
antiluminal	O
sides	O
of	O
the	O
BBB	O
of	O
the	O
cerebellar	O
cortex	O
had	O
similar	O
lesions	O
.	O
The	O
possible	O
influence	O
of	O
the	O
hepatic	O
damage	O
,	O
mainly	O
hyperammonemia	B-DISEASE
,	O
upon	O
the	O
development	O
of	O
valproate	O
encephalopathy	B-DISEASE
is	O
discussed	O
.	O

Macula	O
toxicity	B-DISEASE
after	O
intravitreal	O
amikacin	O
.	O
BACKGROUND	O
:	O
Although	O
intravitreal	O
aminoglycosides	O
have	O
substantially	O
improved	O
visual	O
prognosis	O
in	O
endophthalmitis	B-DISEASE
,	O
macular	O
infarction	B-DISEASE
may	O
impair	O
full	O
visual	O
recovery	O
.	O
METHODS	O
:	O
We	O
present	O
a	O
case	O
of	O
presumed	O
amikacin	O
retinal	O
toxicity	B-DISEASE
following	O
treatment	O
with	O
amikacin	O
and	O
vancomycin	B-CHEMICAL
for	O
alpha	O
-	O
haemolytic	O
streptococcal	O
endophthalmitis	B-DISEASE
.	O
RESULTS	O
:	O
Endophthalmitis	B-DISEASE
resolved	O
with	O
improvement	O
in	O
visual	O
acuity	O
to	O
6/24	O
at	O
three	O
months	O
.	O
Fundus	O
fluorescein	B-CHEMICAL
angiography	O
confirmed	O
macular	O
capillary	O
closure	O
and	O
telangiectasis	B-DISEASE
.	O
CONCLUSIONS	O
:	O
Currently	O
accepted	O
intravitreal	O
antibiotic	O
regimens	O
may	O
cause	O
retinal	O
toxicity	B-DISEASE
and	O
macular	O
ischaemia	O
.	O
Treatment	O
strategies	O
aimed	O
at	O
avoiding	O
retinal	O
toxicity	B-DISEASE
are	O
discussed	O
.	O

Iatrogenically	O
induced	O
intractable	O
atrioventricular	B-DISEASE
reentrant	I-DISEASE
tachycardia	I-DISEASE
after	O
verapamil	B-CHEMICAL
and	O
catheter	O
ablation	O
in	O
a	O
patient	O
with	O
Wolff	B-DISEASE
-	I-DISEASE
Parkinson	I-DISEASE
-	I-DISEASE
White	I-DISEASE
syndrome	I-DISEASE
and	O
idiopathic	O
dilated	B-DISEASE
cardiomyopathy	I-DISEASE
.	O
In	O
a	O
patient	O
with	O
WPW	B-DISEASE
syndrome	I-DISEASE
and	O
idiopathic	O
dilated	B-DISEASE
cardiomyopathy	I-DISEASE
,	O
intractable	O
atrioventricular	B-DISEASE
reentrant	I-DISEASE
tachycardia	I-DISEASE
(	O
AVRT	O
)	O
was	O
iatrogenically	O
induced	O
.	O
QRS	O
without	O
preexcitation	O
,	O
caused	O
by	O
junctional	O
escape	O
beats	O
after	O
verapamil	B-CHEMICAL
or	O
unidirectional	O
antegrade	O
block	O
of	O
accessory	O
pathway	O
after	O
catheter	O
ablation	O
,	O
established	O
frequent	O
AVRT	O
attack	O
.	O

Epidemic	O
of	O
liver	B-DISEASE
disease	I-DISEASE
caused	O
by	O
hydrochlorofluorocarbons	O
used	O
as	O
ozone	O
-	O
sparing	O
substitutes	O
of	O
chlorofluorocarbons	O
.	O
BACKGROUND	O
:	O
Hydrochlorofluorocarbons	O
(	O
HCFCs	O
)	O
are	O
used	O
increasingly	O
in	O
industry	O
as	O
substitutes	O
for	O
ozone	O
-	O
depleting	O
chlorofluorocarbons	O
(	O
CFCs	O
)	O
.	O
Limited	O
studies	O
in	O
animals	O
indicate	O
potential	O
hepatotoxicity	O
of	O
some	O
of	O
these	O
compounds	O
.	O
We	O
investigated	O
an	O
epidemic	O
of	O
liver	B-DISEASE
disease	I-DISEASE
in	O
nine	O
industrial	O
workers	O
who	O
had	O
had	O
repeated	O
accidental	O
exposure	O
to	O
a	O
mixture	O
of	O
1,1	B-CHEMICAL
-	I-CHEMICAL
dichloro-2,2,2	I-CHEMICAL
-	I-CHEMICAL
trifluoroethane	I-CHEMICAL
(	O
HCFC	O
123	O
)	O
and	O
1	B-CHEMICAL
-	I-CHEMICAL
chloro-1,2,2,2	I-CHEMICAL
-	I-CHEMICAL
tetrafluoroethane	I-CHEMICAL
(	O
HCFC	O
124	O
)	O
.	O
All	O
nine	O
exposed	O
workers	O
were	O
affected	O
to	O
various	O
degrees	O
.	O
Both	O
compounds	O
are	O
metabolised	O
in	O
the	O
same	O
way	O
as	O
1	B-CHEMICAL
-	I-CHEMICAL
bromo-1	I-CHEMICAL
-	I-CHEMICAL
chloro-2,2,2	I-CHEMICAL
-	I-CHEMICAL
trifluoroethane	I-CHEMICAL
(	O
halothane	B-CHEMICAL
)	O
to	O
form	O
reactive	O
trifluoroacetyl	O
halide	O
intermediates	O
,	O
which	O
have	O
been	O
implicated	O
in	O
the	O
hepatotoxicity	O
of	O
halothane	B-CHEMICAL
.	O
We	O
aimed	O
to	O
test	O
whether	O
HCFCs	O
123	O
and	O
124	O
can	O
result	O
in	O
serious	O
liver	B-DISEASE
disease	I-DISEASE
.	O
METHODS	O
:	O
For	O
one	O
severely	O
affected	O
worker	O
liver	O
biopsy	O
and	O
immunohistochemical	O
stainings	O
for	O
the	O
presence	O
of	O
trifluoroacetyl	O
protein	O
adducts	O
were	O
done	O
.	O
The	O
serum	O
of	O
six	O
affected	O
workers	O
and	O
five	O
controls	O
was	O
tested	O
for	O
autoantibodies	O
that	O
react	O
with	O
human	O
liver	O
cytochrome	O
-	O
P450	O
2E1	O
(	O
P450	O
2E1	O
)	O
and	O
P58	O
protein	O
disulphide	O
isomerase	O
isoform	O
(	O
P58	O
)	O
.	O
FINDINGS	O
:	O
The	O
liver	O
biopsy	O
sample	O
showed	O
hepatocellular	O
necrosis	B-DISEASE
which	O
was	O
prominent	O
in	O
perivenular	O
zone	O
three	O
and	O
extended	O
focally	O
from	O
portal	O
tracts	O
to	O
portal	O
tracts	O
and	O
centrilobular	O
areas	O
(	O
bridging	O
necrosis	B-DISEASE
)	O
.	O
Trifluoroacetyl	O
-	O
adducted	O
proteins	O
were	O
detected	O
in	O
surviving	O
hepatocytes	O
.	O
Autoantibodies	O
against	O
P450	O
2E1	O
or	O
P58	O
,	O
previously	O
associated	O
with	O
halothane	B-DISEASE
hepatitis	I-DISEASE
,	O
were	O
detected	O
in	O
the	O
serum	O
of	O
five	O
affected	O
workers	O
.	O
INTERPRETATION	O
:	O
Repeated	O
exposure	O
of	O
human	O
beings	O
to	O
HCFCs	O
123	O
and	O
124	O
can	O
result	O
in	O
serious	O
liver	B-DISEASE
injury	I-DISEASE
in	O
a	O
large	O
proportion	O
of	O
the	O
exposed	O
population	O
.	O
Although	O
the	O
exact	O
mechanism	O
of	O
hepatotoxicity	O
of	O
these	O
agents	O
is	O
not	O
known	O
,	O
the	O
results	O
suggest	O
that	O
trifluoroacetyl	O
-	O
altered	O
liver	O
proteins	O
are	O
involved	O
.	O
In	O
view	O
of	O
the	O
potentially	O
widespread	O
use	O
of	O
these	O
compounds	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
safer	O
alternatives	O
.	O

The	O
effect	O
of	O
different	O
anaesthetic	O
agents	O
in	O
hearing	B-DISEASE
loss	I-DISEASE
following	O
spinal	O
anaesthesia	O
.	O
The	O
cause	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
after	O
spinal	O
anaesthesia	O
is	O
unknown	O
.	O
Up	O
until	O
now	O
,	O
the	O
only	O
factor	O
studied	O
has	O
been	O
the	O
effect	O
of	O
the	O
diameter	O
of	O
the	O
spinal	O
needle	O
on	O
post	O
-	O
operative	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
this	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
to	O
investigate	O
other	O
factors	O
influencing	O
the	O
degree	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
.	O
Two	O
groups	O
of	O
22	O
similar	O
patients	O
were	O
studied	O
:	O
one	O
group	O
received	O
6	O
mL	O
prilocaine	B-CHEMICAL
2	O
%	O
;	O
and	O
the	O
other	O
received	O
3	O
mL	O
bupivacaine	O
0.5	O
%	O
.	O
Patients	O
given	O
prilocaine	B-CHEMICAL
were	O
more	O
likely	O
to	O
develop	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
10	O
out	O
of	O
22	O
)	O
than	O
those	O
given	O
bupivacaine	O
(	O
4	O
out	O
of	O
22	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O
The	O
average	O
hearing	B-DISEASE
loss	I-DISEASE
for	O
speech	O
frequencies	O
was	O
about	O
10	O
dB	O
after	O
prilocaine	B-CHEMICAL
and	O
15	O
dB	O
after	O
bupivacaine	O
.	O
None	O
of	O
the	O
patients	O
complained	O
of	O
subjective	O
hearing	B-DISEASE
loss	I-DISEASE
.	O
Long	O
-	O
term	O
follow	O
-	O
up	O
of	O
the	O
patients	O
was	O
not	O
possible	O
.	O

A	O
transient	O
neurological	O
deficit	O
following	O
intrathecal	O
injection	O
of	O
1	O
%	O
hyperbaric	O
bupivacaine	O
for	O
unilateral	O
spinal	O
anaesthesia	O
.	O
We	O
describe	O
a	O
case	O
of	O
transient	O
neurological	O
deficit	O
that	O
occurred	O
after	O
unilateral	O
spinal	O
anaesthesia	O
with	O
8	O
mg	O
of	O
1	O
%	O
hyperbaric	O
bupivacaine	O
slowly	O
injected	O
through	O
a	O
25	O
-	O
gauge	O
pencil	O
-	O
point	O
spinal	O
needle	O
.	O
The	O
surgery	O
and	O
anaesthesia	O
were	O
uneventful	O
,	O
but	O
3	O
days	O
after	O
surgery	O
,	O
the	O
patient	O
reported	O
an	O
area	O
of	O
hypoaesthesia	O
over	O
L3	O
-	O
L4	O
dermatomes	O
of	O
the	O
leg	O
which	O
had	O
been	O
operated	O
on	O
(	O
loss	O
of	O
pinprick	O
sensation	O
)	O
without	O
reduction	O
in	O
muscular	O
strength	O
.	O
Sensation	O
in	O
this	O
area	O
returned	O
to	O
normal	O
over	O
the	O
following	O
2	O
weeks	O
.	O
Prospective	O
multicentre	O
studies	O
with	O
a	O
large	O
population	O
and	O
a	O
long	O
follow	O
-	O
up	O
should	O
be	O
performed	O
in	O
order	O
to	O
evaluate	O
the	O
incidence	O
of	O
this	O
unusual	O
side	O
effect	O
.	O
However	O
,	O
we	O
suggest	O
that	O
a	O
low	O
solution	O
concentration	O
should	O
be	O
preferred	O
for	O
unilateral	O
spinal	O
anaesthesia	O
with	O
a	O
hyperbaric	O
anaesthetic	O
solution	O
(	O
if	O
pencil	O
-	O
point	O
needle	O
and	O
slow	O
injection	O
rate	O
are	O
employed	O
)	O
,	O
in	O
order	O
to	O
minimize	O
the	O
risk	O
of	O
a	O
localized	O
high	O
peak	O
anaesthetic	O
concentration	O
,	O
which	O
might	O
lead	O
to	O
a	O
transient	O
neurological	O
deficit	O
.	O

Pethidine	B-CHEMICAL
-	O
associated	O
seizure	B-DISEASE
in	O
a	O
healthy	O
adolescent	O
receiving	O
pethidine	B-CHEMICAL
for	O
postoperative	O
pain	B-DISEASE
control	O
.	O
A	O
healthy	O
17	O
-	O
year	O
-	O
old	O
male	O
received	O
standard	O
intermittent	O
doses	O
of	O
pethidine	B-CHEMICAL
via	O
a	O
patient	O
-	O
controlled	O
analgesia	B-DISEASE
(	O
PCA	O
)	O
pump	O
for	O
management	O
of	O
postoperative	O
pain	B-DISEASE
control	O
.	O
Twenty	O
-	O
three	O
h	O
postoperatively	O
he	O
developed	O
a	O
brief	O
self	O
-	O
limited	O
seizure	B-DISEASE
.	O
Both	O
plasma	O
pethidine	B-CHEMICAL
and	O
norpethidine	O
were	O
elevated	O
in	O
the	O
range	O
associated	O
with	O
clinical	O
manifestations	O
of	O
central	O
nervous	O
system	O
excitation	O
.	O
No	O
other	O
risk	O
factors	O
for	O
CNS	O
toxicity	B-DISEASE
were	O
identified	O
.	O
This	O
method	O
allowed	O
frequent	O
self	O
-	O
dosing	O
of	O
pethidine	B-CHEMICAL
at	O
short	O
time	O
intervals	O
and	O
rapid	O
accumulation	O
of	O
pethidine	B-CHEMICAL
and	O
norpethidine	O
.	O
The	O
routine	O
use	O
of	O
pethidine	B-CHEMICAL
via	O
PCA	O
even	O
for	O
a	O
brief	O
postoperative	O
analgesia	B-DISEASE
should	O
be	O
reconsidered	O
.	O

Drug	O
-	O
associated	O
acute	O
-	O
onset	O
vanishing	O
bile	O
duct	O
and	O
Stevens	B-DISEASE
-	I-DISEASE
Johnson	I-DISEASE
syndromes	I-DISEASE
in	O
a	O
child	O
.	O
Acute	O
vanishing	O
bile	O
duct	O
syndrome	B-DISEASE
is	O
a	O
rare	O
but	O
established	O
cause	O
of	O
progressive	O
cholestasis	B-DISEASE
in	O
adults	O
,	O
is	O
most	O
often	O
drug	O
or	O
toxin	O
related	O
,	O
and	O
is	O
of	O
unknown	O
pathogenesis	O
.	O
It	O
has	O
not	O
been	O
reported	O
previously	O
in	O
children	O
.	O
Stevens	B-DISEASE
-	I-DISEASE
Johnson	I-DISEASE
syndrome	I-DISEASE
is	O
a	O
well	O
-	O
recognized	O
immune	O
complex	O
-	O
mediated	O
hypersensitivity	B-DISEASE
reaction	O
that	O
affects	O
all	O
age	O
groups	O
,	O
is	O
drug	O
or	O
infection	B-DISEASE
induced	O
,	O
and	O
has	O
classic	O
systemic	O
,	O
mucosal	O
,	O
and	O
dermatologic	O
manifestations	O
.	O
A	O
previously	O
healthy	O
child	O
who	O
developed	O
acute	O
,	O
severe	O
,	O
rapidly	O
progressive	O
vanishing	O
bile	O
duct	O
syndrome	B-DISEASE
shortly	O
after	O
Stevens	B-DISEASE
-	I-DISEASE
Johnson	I-DISEASE
syndrome	I-DISEASE
is	O
described	O
;	O
this	O
was	O
temporally	O
associated	O
with	O
ibuprofen	B-CHEMICAL
use	O
.	O
Despite	O
therapy	O
with	O
ursodeoxycholic	B-CHEMICAL
acid	I-CHEMICAL
,	O
prednisone	B-CHEMICAL
,	O
and	O
then	O
tacrolimus	B-CHEMICAL
,	O
her	O
cholestatic	B-DISEASE
disease	I-DISEASE
was	O
unrelenting	O
,	O
with	O
cirrhosis	B-DISEASE
shown	O
by	O
biopsy	O
6	O
months	O
after	O
presentation	O
.	O
This	O
case	O
documents	O
acute	O
drug	O
-	O
related	O
vanishing	O
bile	O
duct	O
syndrome	B-DISEASE
in	O
the	O
pediatric	O
age	O
group	O
and	O
suggests	O
shared	O
immune	O
mechanisms	O
in	O
the	O
pathogenesis	O
of	O
both	O
Stevens	B-DISEASE
-	I-DISEASE
Johnson	I-DISEASE
syndrome	I-DISEASE
and	O
vanishing	O
bile	O
duct	O
syndrome	B-DISEASE
.	O

High	O
incidence	O
of	O
primary	B-DISEASE
pulmonary	I-DISEASE
hypertension	I-DISEASE
associated	O
with	O
appetite	O
suppressants	O
in	O
Belgium	O
.	O
Primary	B-DISEASE
pulmonary	I-DISEASE
hypertension	I-DISEASE
is	O
a	O
rare	O
,	O
progressive	O
and	O
incurable	O
disease	B-DISEASE
,	O
which	O
has	O
been	O
associated	O
with	O
the	O
intake	O
of	O
appetite	O
suppressant	O
drugs	O
.	O
The	O
importance	O
of	O
this	O
association	O
was	O
evaluated	O
in	O
Belgium	O
while	O
this	O
country	O
still	O
had	O
no	O
restriction	O
on	O
the	O
prescription	O
of	O
appetite	O
suppressants	O
.	O
Thirty	O
-	O
five	O
patients	O
with	O
primary	B-DISEASE
pulmonary	I-DISEASE
hypertension	I-DISEASE
and	O
85	O
matched	O
controls	O
were	O
recruited	O
over	O
32	O
months	O
(	O
1992	O
-	O
1994	O
)	O
in	O
Belgium	O
.	O
Exposure	O
to	O
appetite	O
-	O
suppressants	O
was	O
assessed	O
on	O
the	O
basis	O
of	O
hospital	O
records	O
and	O
standardized	O
interview	O
.	O
Twenty	O
-	O
three	O
of	O
the	O
patients	O
had	O
previously	O
taken	O
appetite	O
suppressants	O
,	O
mainly	O
fenfluramines	O
,	O
as	O
compared	O
with	O
only	O
5	O
of	O
the	O
controls	O
(	O
66	O
versus	O
6	O
%	O
,	O
p<0.0001	O
)	O
.	O
Five	O
patients	O
died	O
before	O
the	O
interview	O
,	O
all	O
of	O
them	O
had	O
taken	O
appetite	O
suppressants	O
.	O
In	O
8	O
patients	O
the	O
diagnosis	O
of	O
primary	B-DISEASE
pulmonary	I-DISEASE
hypertension	I-DISEASE
was	O
uncertain	O
,	O
5	O
of	O
them	O
had	O
taken	O
appetite	O
suppressants	O
.	O
The	O
patients	O
who	O
had	O
been	O
exposed	O
to	O
appetite	O
suppressants	O
tended	O
to	O
be	O
on	O
average	O
more	O
severely	O
ill	O
,	O
and	O
to	O
have	O
a	O
shorter	O
median	O
delay	O
between	O
onset	O
of	O
symptoms	O
and	O
diagnosis	O
.	O
A	O
policy	O
of	O
unrestricted	O
prescription	O
of	O
appetite	O
suppressants	O
may	O
lead	O
to	O
a	O
high	O
incidence	O
of	O
associated	O
primary	B-DISEASE
pulmonary	I-DISEASE
hypertension	I-DISEASE
.	O
Intake	O
of	O
appetite	O
suppressants	O
may	O
accelerate	O
the	O
progression	O
of	O
the	O
disease	B-DISEASE
.	O

Choreoathetoid	B-DISEASE
movements	I-DISEASE
associated	O
with	O
rapid	O
adjustment	O
to	O
methadone	B-CHEMICAL
.	O
Choreatiform	O
hyperkinesias	O
are	O
known	O
to	O
be	O
occasional	O
movement	O
abnormalities	O
during	O
intoxications	O
with	O
cocaine	B-CHEMICAL
but	O
not	O
opiates	B-CHEMICAL
.	O
This	O
is	O
a	O
case	O
report	O
of	O
euphoria	O
and	O
choreoathetoid	B-DISEASE
movements	I-DISEASE
both	O
transiently	O
induced	O
by	O
rapid	O
adjustment	O
to	O
the	O
selective	O
mu	O
-	O
opioid	O
receptor	O
agonist	O
methadone	B-CHEMICAL
in	O
an	O
inpatient	O
previously	O
abusing	O
heroine	O
and	O
cocaine	B-CHEMICAL
.	O
In	O
addition	O
,	O
minor	O
EEG	O
abnormalities	O
occurred	O
.	O
Possible	O
underlying	O
neurobiological	O
phenomena	O
are	O
discussed	O
.	O

Cocaine	B-CHEMICAL
-	O
induced	O
mood	O
disorder	O
:	O
prevalence	O
rates	O
and	O
psychiatric	B-DISEASE
symptoms	O
in	O
an	O
outpatient	O
cocaine	B-CHEMICAL
-	O
dependent	O
sample	O
.	O
This	O
paper	O
attempts	O
to	O
examine	O
and	O
compare	O
prevalence	O
rates	O
and	O
symptom	O
patterns	O
of	O
DSM	O
substance	O
-	O
induced	O
and	O
other	O
mood	B-DISEASE
disorders	I-DISEASE
.	O
243	O
cocaine	B-CHEMICAL
-	O
dependent	O
outpatients	O
with	O
cocaine	B-CHEMICAL
-	O
induced	O
mood	O
disorder	O
(	O
CIMD	B-DISEASE
)	O
,	O
other	O
mood	B-DISEASE
disorders	I-DISEASE
,	O
or	O
no	O
mood	O
disorder	O
were	O
compared	O
on	O
measures	O
of	O
psychiatric	B-DISEASE
symptoms	O
.	O
The	O
prevalence	O
rate	O
for	O
CIMD	B-DISEASE
was	O
12	O
%	O
at	O
baseline	O
.	O
Introduction	O
of	O
the	O
DSM	O
-	O
IV	O
diagnosis	O
of	O
CIMD	B-DISEASE
did	O
not	O
substantially	O
affect	O
rates	O
of	O
the	O
other	O
depressive	B-DISEASE
disorders	O
.	O
Patients	O
with	O
CIMD	B-DISEASE
had	O
symptom	O
severity	O
levels	O
between	O
those	O
of	O
patients	O
with	O
and	O
without	O
a	O
mood	O
disorder	O
.	O
These	O
findings	O
suggest	O
some	O
validity	O
for	O
the	O
new	O
DSM	O
-	O
IV	O
diagnosis	O
of	O
CIMD	B-DISEASE
,	O
but	O
also	O
suggest	O
that	O
it	O
requires	O
further	O
specification	O
and	O
replication	O
.	O

Hemolysis	B-DISEASE
of	O
human	O
erythrocytes	O
induced	O
by	O
tamoxifen	B-CHEMICAL
is	O
related	O
to	O
disruption	O
of	O
membrane	O
structure	O
.	O
Tamoxifen	B-CHEMICAL
(	O
TAM	O
)	O
,	O
the	O
antiestrogenic	O
drug	O
most	O
widely	O
prescribed	O
in	O
the	O
chemotherapy	O
of	O
breast	B-DISEASE
cancer	I-DISEASE
,	O
induces	O
changes	O
in	O
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	O
anemia	B-DISEASE
.	O
This	O
work	O
evaluates	O
the	O
effects	O
of	O
TAM	O
on	O
isolated	O
human	O
erythrocytes	O
,	O
attempting	O
to	O
identify	O
the	O
underlying	O
mechanisms	O
on	O
TAM	O
-	O
induced	O
hemolytic	O
anemia	B-DISEASE
and	O
the	O
involvement	O
of	O
biomembranes	O
in	O
its	O
cytostatic	O
action	O
mechanisms	O
.	O
TAM	O
induces	O
hemolysis	B-DISEASE
of	O
erythrocytes	O
as	O
a	O
function	O
of	O
concentration	O
.	O
The	O
extension	O
of	O
hemolysis	B-DISEASE
is	O
variable	O
with	O
erythrocyte	O
samples	O
,	O
but	O
12.5	O
microM	O
TAM	O
induces	O
total	O
hemolysis	B-DISEASE
of	O
all	O
tested	O
suspensions	O
.	O
Despite	O
inducing	O
extensive	O
erythrocyte	O
lysis	O
,	O
TAM	O
does	O
not	O
shift	O
the	O
osmotic	O
fragility	O
curves	O
of	O
erythrocytes	O
.	O
The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	O
-	O
induced	O
hemolysis	B-DISEASE
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O
This	O
was	O
further	O
evidenced	O
by	O
absence	O
of	O
oxygen	B-CHEMICAL
consumption	O
and	O
hemoglobin	O
oxidation	O
both	O
determined	O
in	O
parallel	O
with	O
TAM	O
-	O
induced	O
hemolysis	B-DISEASE
.	O
Furthermore	O
,	O
it	O
was	O
observed	O
that	O
TAM	O
inhibits	O
the	O
peroxidation	O
of	O
human	O
erythrocytes	O
induced	O
by	O
AAPH	O
,	O
thus	O
ruling	O
out	O
TAM	O
-	O
induced	O
cell	O
oxidative	O
stress	B-DISEASE
.	O
Hemolysis	B-DISEASE
caused	O
by	O
TAM	O
was	O
not	O
preceded	O
by	O
the	O
leakage	O
of	O
K(+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	O
mechanism	O
of	O
hemolysis	B-DISEASE
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves	O
.	O
However	O
,	O
TAM	O
induces	O
release	O
of	O
peripheral	O
proteins	O
of	O
membrane	O
-	O
cytoskeleton	O
and	O
cytosol	O
proteins	O
essentially	O
bound	O
to	O
band	O
3	O
.	O
Either	O
alpha	O
-	O
T	O
or	O
alpha	O
-	O
TAc	O
increases	O
membrane	O
packing	O
and	O
prevents	O
TAM	O
partition	O
into	O
model	O
membranes	O
.	O
These	O
effects	O
suggest	O
that	O
the	O
protection	O
from	O
hemolysis	B-DISEASE
by	O
tocopherols	O
is	O
related	O
to	O
a	O
decreased	O
TAM	O
incorporation	O
in	O
condensed	O
membranes	O
and	O
the	O
structural	O
damage	O
of	O
the	O
erythrocyte	O
membrane	O
is	O
consequently	O
avoided	O
.	O
Therefore	O
,	O
TAM	O
-	O
induced	O
hemolysis	B-DISEASE
results	O
from	O
a	O
structural	O
perturbation	O
of	O
red	O
cell	O
membrane	O
,	O
leading	O
to	O
changes	O
in	O
the	O
framework	O
of	O
the	O
erythrocyte	O
membrane	O
and	O
its	O
cytoskeleton	O
caused	O
by	O
its	O
high	O
partition	O
in	O
the	O
membrane	O
.	O
These	O
defects	O
explain	O
the	O
abnormal	O
erythrocyte	O
shape	O
and	O
decreased	O
mechanical	O
stability	O
promoted	O
by	O
TAM	O
,	O
resulting	O
in	O
hemolytic	O
anemia	B-DISEASE
.	O
Additionally	O
,	O
since	O
membrane	O
leakage	O
is	O
a	O
final	O
stage	O
of	O
cytotoxicity	B-DISEASE
,	O
the	O
disruption	O
of	O
the	O
structural	O
characteristics	O
of	O
biomembranes	O
by	O
TAM	O
may	O
contribute	O
to	O
the	O
multiple	O
mechanisms	O
of	O
its	O
anticancer	O
action	O
.	O

Changes	O
of	O
sodium	B-CHEMICAL
and	O
ATP	B-CHEMICAL
affinities	O
of	O
the	O
cardiac	O
(	O
Na	O
,	O
K)-ATPase	O
during	O
and	O
after	O
nitric	O
oxide	O
deficient	O
hypertension	B-DISEASE
.	O
In	O
the	O
cardiovascular	O
system	O
,	O
NO	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
a	O
variety	O
of	O
functions	O
.	O
Inhibition	O
of	O
NO	O
synthesis	O
induces	O
sustained	O
hypertension	B-DISEASE
.	O
In	O
several	O
models	O
of	O
hypertension	B-DISEASE
,	O
elevation	O
of	O
intracellular	O
sodium	B-CHEMICAL
level	O
was	O
documented	O
in	O
cardiac	O
tissue	O
.	O
To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	O
,	O
K)-ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	B-DISEASE
induced	O
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N(G)-nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
4	O
four	O
weeks	O
.	O
After	O
4	O
-	O
week	O
administration	O
of	O
L	O
-	O
NAME	O
,	O
the	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
increased	O
by	O
36	O
%	O
.	O
Two	O
weeks	O
after	O
terminating	O
the	O
treatment	O
,	O
the	O
SBP	O
recovered	O
to	O
control	O
value	O
.	O
When	O
activating	O
the	O
(	O
Na	O
,	O
K)-ATPase	O
with	O
its	O
substrate	O
ATP	B-CHEMICAL
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O
During	O
activation	O
with	O
Na+	O
,	O
the	O
Vmax	O
remained	O
unchanged	O
,	O
however	O
the	O
K(Na	O
)	O
increased	O
by	O
50	O
%	O
,	O
indicating	O
a	O
profound	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
Na+-binding	O
site	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O
After	O
recovery	O
from	O
hypertension	B-DISEASE
,	O
the	O
activity	O
of	O
(	O
Na	O
,	O
K)-ATPase	O
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	B-CHEMICAL
-	O
binding	O
site	O
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	B-CHEMICAL
.	O
The	O
K(Na	O
)	O
value	O
for	O
Na+	O
returned	O
to	O
control	O
value	O
.	O
Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	O
a	O
reversible	O
hypertension	B-DISEASE
accompanied	O
by	O
depressed	B-DISEASE
Na+-extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na+-binding	O
properties	O
of	O
the	O
(	O
Na	O
,	O
K)-ATPase	O
.	O
After	O
recovery	O
of	O
blood	O
pressure	O
to	O
control	O
values	O
,	O
the	O
extrusion	O
of	O
Na+	O
from	O
cardiac	O
cells	O
was	O
normalized	O
,	O
as	O
revealed	O
by	O
restoration	O
of	O
the	O
(	O
Na	O
,	O
K)-ATPase	O
activity	O
.	O

Effects	O
of	O
long	O
-	O
term	O
pretreatment	O
with	O
isoproterenol	B-CHEMICAL
on	O
bromocriptine	O
-	O
induced	O
tachycardia	B-DISEASE
in	O
conscious	O
rats	O
.	O
It	O
has	O
been	O
shown	O
that	O
bromocriptine	O
-	O
induced	O
tachycardia	B-DISEASE
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	O
by	O
central	O
dopamine	B-CHEMICAL
D2	O
receptor	O
activation	O
and	O
(	O
ii	O
)	O
reduced	O
by	O
5	O
-	O
day	O
isoproterenol	B-CHEMICAL
pretreatment	O
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O
This	O
study	O
was	O
conducted	O
to	O
examine	O
whether	O
prolonged	O
pretreatment	O
with	O
isoproterenol	B-CHEMICAL
could	O
abolish	O
bromocriptine	O
-	O
induced	O
tachycardia	B-DISEASE
in	O
conscious	O
rats	O
.	O
Isoproterenol	B-CHEMICAL
pretreatment	O
for	O
15	O
days	O
caused	O
cardiac	B-DISEASE
hypertrophy	I-DISEASE
without	O
affecting	O
baseline	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O
In	O
control	O
rats	O
,	O
intravenous	O
bromocriptine	O
(	O
150	O
microg	O
/	O
kg	O
)	O
induced	O
significant	O
hypotension	B-DISEASE
and	O
tachycardia	B-DISEASE
.	O
Bromocriptine	O
-	O
induced	O
hypotension	B-DISEASE
was	O
unaffected	O
by	O
isoproterenol	B-CHEMICAL
pretreatment	O
,	O
while	O
tachycardia	B-DISEASE
was	O
reversed	O
to	O
significant	O
bradycardia	B-DISEASE
,	O
an	O
effect	O
that	O
was	O
partly	O
reduced	O
by	O
i.v	O
.	O
domperidone	B-CHEMICAL
(	O
0.5	O
mg	O
/	O
kg	O
)	O
.	O
Neither	O
cardiac	O
vagal	O
nor	O
sympathetic	O
tone	O
was	O
altered	O
by	O
isoproterenol	B-CHEMICAL
pretreatment	O
.	O
In	O
isolated	O
perfused	O
heart	O
preparations	O
from	O
isoproterenol	B-CHEMICAL
-	O
pretreated	O
rats	O
,	O
the	O
isoproterenol	B-CHEMICAL
-	O
induced	O
maximal	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
significantly	O
reduced	O
,	O
compared	O
with	O
saline	O
-	O
pretreated	O
rats	O
(	O
the	O
EC50	O
of	O
the	O
isoproterenol	B-CHEMICAL
-	O
induced	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
enhanced	O
approximately	O
22	O
-	O
fold	O
)	O
.	O
These	O
results	O
show	O
that	O
15	O
-	O
day	O
isoproterenol	B-CHEMICAL
pretreatment	O
not	O
only	O
abolished	O
but	O
reversed	O
bromocriptine	O
-	O
induced	O
tachycardia	B-DISEASE
to	O
bradycardia	B-DISEASE
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	O
beta	O
-	O
adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O
They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	O
central	O
tachycardia	B-DISEASE
of	O
bromocriptine	O
appears	O
to	O
predominate	O
and	O
to	O
mask	O
the	O
bradycardia	B-DISEASE
of	O
this	O
agonist	O
at	O
peripheral	O
dopamine	B-CHEMICAL
D2	O
receptors	O
.	O

A	O
developmental	O
analysis	O
of	O
clonidine	B-CHEMICAL
's	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
in	O
infant	O
rats	O
.	O
Under	O
controlled	O
conditions	O
,	O
infant	O
rats	O
emit	O
ultrasonic	O
vocalizations	O
during	O
extreme	O
cold	O
exposure	O
and	O
after	O
administration	O
of	O
the	O
alpha(2	O
)	O
adrenoceptor	O
agonist	O
,	O
clonidine	B-CHEMICAL
.	O
Previous	O
investigations	O
have	O
determined	O
that	O
,	O
in	O
response	O
to	O
clonidine	B-CHEMICAL
,	O
ultrasound	O
production	O
increases	O
through	O
the	O
2nd	O
-	O
week	O
postpartum	O
and	O
decreases	O
thereafter	O
.	O
Given	O
that	O
sympathetic	O
neural	O
dominance	O
exhibits	O
a	O
similar	O
developmental	O
pattern	O
,	O
and	O
given	O
that	O
clonidine	B-CHEMICAL
induces	O
sympathetic	O
withdrawal	O
and	O
bradycardia	B-DISEASE
,	O
we	O
hypothesized	O
that	O
clonidine	B-CHEMICAL
's	O
developmental	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
would	O
mirror	O
each	O
other	O
.	O
Therefore	O
,	O
in	O
the	O
present	O
experiment	O
,	O
the	O
effects	O
of	O
clonidine	B-CHEMICAL
administration	O
(	O
0.5	O
mg	O
/	O
kg	O
)	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
were	O
examined	O
in	O
2-	O
,	O
8-	O
,	O
15-	O
,	O
and	O
20	O
-	O
day	O
-	O
old	O
rats	O
.	O
Age	O
-	O
related	O
changes	O
in	O
ultrasound	O
production	O
corresponded	O
with	O
changes	O
in	O
cardiovascular	O
variables	O
,	O
including	O
baseline	O
cardiac	O
rate	O
and	O
clonidine	B-CHEMICAL
-	O
induced	O
bradycardia	B-DISEASE
.	O
This	O
experiment	O
is	O
discussed	O
with	O
regard	O
to	O
the	O
hypothesis	O
that	O
ultrasound	O
production	O
is	O
the	O
acoustic	O
by	O
-	O
product	O
of	O
a	O
physiological	O
maneuver	O
that	O
compensates	O
for	O
clonidine	B-CHEMICAL
's	O
detrimental	O
effects	O
on	O
cardiovascular	O
function	O
.	O

Differential	O
effects	O
of	O
systemically	O
administered	O
ketamine	B-CHEMICAL
and	O
lidocaine	B-CHEMICAL
on	O
dynamic	O
and	O
static	O
hyperalgesia	B-DISEASE
induced	O
by	O
intradermal	O
capsaicin	B-CHEMICAL
in	O
humans	O
.	O
We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	O
of	O
ketamine	B-CHEMICAL
and	O
lidocaine	B-CHEMICAL
on	O
brush	O
-	O
evoked	O
(	O
dynamic	O
)	O
pain	B-DISEASE
and	O
punctate	O
-	O
evoked	O
(	O
static	O
)	O
hyperalgesia	B-DISEASE
induced	O
by	O
capsaicin	B-CHEMICAL
.	O
In	O
a	O
randomized	O
,	O
double	O
-	O
blind	B-DISEASE
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
study	O
,	O
we	O
studied	O
12	O
volunteers	O
in	O
three	O
experiments	O
.	O
Capsaicin	B-CHEMICAL
100	O
micrograms	O
was	O
injected	O
intradermally	O
on	O
the	O
volar	O
forearm	O
followed	O
by	O
an	O
i.v	O
.	O
infusion	O
of	O
ketamine	B-CHEMICAL
(	O
bolus	O
0.1	O
mg	O
kg-1	O
over	O
10	O
min	O
followed	O
by	O
infusion	O
of	O
7	O
micrograms	O
kg-1	O
min-1	O
)	O
,	O
lidocaine	B-CHEMICAL
5	O
mg	O
kg-1	O
or	O
saline	O
for	O
50	O
min	O
.	O
Infusion	O
started	O
15	O
min	O
after	O
injection	O
of	O
capsaicin	B-CHEMICAL
.	O
The	O
following	O
were	O
measured	O
:	O
spontaneous	O
pain	B-DISEASE
,	O
pain	B-DISEASE
evoked	O
by	O
punctate	O
and	O
brush	O
stimuli	O
(	O
VAS	O
)	O
,	O
and	O
areas	O
of	O
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	O
hyperalgesia	B-DISEASE
.	O
Ketamine	B-CHEMICAL
reduced	O
both	O
the	O
area	O
of	O
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	O
hyperalgesia	B-DISEASE
significantly	O
and	O
it	O
tended	O
to	O
reduce	O
brush	O
-	O
evoked	O
pain	B-DISEASE
.	O
Lidocaine	B-CHEMICAL
reduced	O
the	O
area	O
of	O
punctate	O
-	O
evoked	O
hyperalgesia	B-DISEASE
significantly	O
.	O
It	O
tended	O
to	O
reduce	O
VAS	O
scores	O
of	O
spontaneous	O
pain	B-DISEASE
but	O
had	O
no	O
effect	O
on	O
evoked	O
pain	B-DISEASE
.	O
The	O
differential	O
effects	O
of	O
ketamine	B-CHEMICAL
and	O
lidocaine	B-CHEMICAL
on	O
static	O
and	O
dynamic	O
hyperalgesia	B-DISEASE
suggest	O
that	O
the	O
two	O
types	O
of	O
hyperalgesia	B-DISEASE
are	O
mediated	O
by	O
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O

Cyclosporine	B-CHEMICAL
and	O
tacrolimus	B-CHEMICAL
-	O
associated	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
.	O
The	O
development	O
of	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
(	O
TMA	B-DISEASE
)	O
associated	O
with	O
the	O
use	O
of	O
cyclosporine	B-CHEMICAL
has	O
been	O
well	O
documented	O
.	O
Treatments	O
have	O
included	O
discontinuation	O
or	O
reduction	O
of	O
cyclosporine	B-CHEMICAL
dose	O
with	O
or	O
without	O
concurrent	O
plasma	O
exchange	O
,	O
plasma	O
infusion	O
,	O
anticoagulation	O
,	O
and	O
intravenous	O
immunoglobulin	O
G	O
infusion	O
.	O
However	O
,	O
for	O
recipients	O
of	O
organ	O
transplantation	O
,	O
removing	O
the	O
inciting	O
agent	O
is	O
not	O
without	O
the	O
attendant	O
risk	O
of	O
precipitating	O
acute	O
rejection	O
and	O
graft	O
loss	O
.	O
The	O
last	O
decade	O
has	O
seen	O
the	O
emergence	O
of	O
tacrolimus	B-CHEMICAL
as	O
a	O
potent	O
immunosuppressive	O
agent	O
with	O
mechanisms	O
of	O
action	O
virtually	O
identical	O
to	O
those	O
of	O
cyclosporine	B-CHEMICAL
.	O
As	O
a	O
result	O
,	O
switching	O
to	O
tacrolimus	B-CHEMICAL
has	O
been	O
reported	O
to	O
be	O
a	O
viable	O
therapeutic	O
option	O
in	O
the	O
setting	O
of	O
cyclosporine	B-CHEMICAL
-	O
induced	O
TMA	B-DISEASE
.	O
With	O
the	O
more	O
widespread	O
application	O
of	O
tacrolimus	B-CHEMICAL
in	O
organ	O
transplantation	O
,	O
tacrolimus	B-CHEMICAL
-	O
associated	O
TMA	B-DISEASE
has	O
also	O
been	O
recognized	O
.	O
However	O
,	O
literature	O
regarding	O
the	O
incidence	O
of	O
the	O
recurrence	B-DISEASE
of	O
TMA	B-DISEASE
in	O
patients	O
exposed	O
sequentially	O
to	O
cyclosporine	B-CHEMICAL
and	O
tacrolimus	B-CHEMICAL
is	O
limited	O
.	O
We	O
report	O
a	O
case	O
of	O
a	O
living	O
donor	O
renal	O
transplant	O
recipient	O
who	O
developed	O
cyclosporine	B-CHEMICAL
-	O
induced	O
TMA	B-DISEASE
that	O
responded	O
to	O
the	O
withdrawal	O
of	O
cyclosporine	B-CHEMICAL
in	O
conjunction	O
with	O
plasmapheresis	O
and	O
fresh	O
frozen	O
plasma	O
replacement	O
therapy	O
.	O
Introduction	O
of	O
tacrolimus	B-CHEMICAL
as	O
an	O
alternative	O
immunosuppressive	O
agent	O
resulted	O
in	O
the	O
recurrence	B-DISEASE
of	O
TMA	B-DISEASE
and	O
the	O
subsequent	O
loss	O
of	O
the	O
renal	O
allograft	O
.	O
Patients	O
who	O
are	O
switched	O
from	O
cyclosporine	B-CHEMICAL
to	O
tacrolimus	B-CHEMICAL
or	O
vice	O
versa	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
signs	B-DISEASE
and	I-DISEASE
symptoms	I-DISEASE
of	O
recurrent	O
TMA	B-DISEASE
.	O

Repeated	O
transient	O
anuria	B-DISEASE
following	O
losartan	B-CHEMICAL
administration	O
in	O
a	O
patient	O
with	O
a	O
solitary	B-DISEASE
kidney	I-DISEASE
.	O
We	O
report	O
the	O
case	O
of	O
a	O
70	O
-	O
year	O
-	O
old	O
hypertensive	B-DISEASE
man	O
with	O
a	O
solitary	B-DISEASE
kidney	I-DISEASE
and	O
chronic	B-DISEASE
renal	I-DISEASE
insufficiency	I-DISEASE
who	O
developed	O
two	O
episodes	O
of	O
transient	O
anuria	B-DISEASE
after	O
losartan	B-CHEMICAL
administration	O
.	O
He	O
was	O
hospitalized	O
for	O
a	O
myocardial	B-DISEASE
infarction	I-DISEASE
with	O
pulmonary	B-DISEASE
edema	I-DISEASE
,	O
treated	O
with	O
high	O
-	O
dose	O
diuretics	O
.	O
Due	O
to	O
severe	O
systolic	O
dysfunction	O
losartan	B-CHEMICAL
was	O
prescribed	O
.	O
Surprisingly	O
,	O
the	O
first	O
dose	O
of	O
50	O
mg	O
of	O
losartan	B-CHEMICAL
resulted	O
in	O
a	O
sudden	O
anuria	B-DISEASE
,	O
which	O
lasted	O
eight	O
hours	O
despite	O
high	O
-	O
dose	O
furosemide	B-CHEMICAL
and	O
amine	O
infusion	O
.	O
One	O
week	O
later	O
,	O
by	O
mistake	O
,	O
losartan	B-CHEMICAL
was	O
prescribed	O
again	O
and	O
after	O
the	O
second	O
dose	O
of	O
50	O
mg	O
,	O
the	O
patient	O
developed	O
a	O
second	O
episode	O
of	O
transient	O
anuria	B-DISEASE
lasting	O
10	O
hours	O
.	O
During	O
these	O
two	O
episodes	O
,	O
his	O
blood	O
pressure	O
diminished	O
but	O
no	O
severe	O
hypotension	B-DISEASE
was	O
noted	O
.	O
Ultimately	O
,	O
an	O
arteriography	O
showed	O
a	O
70	O
-	O
80	O
%	O
renal	O
artery	O
stenosis	O
.	O
In	O
this	O
patient	O
,	O
renal	O
artery	O
stenosis	O
combined	O
with	O
heart	B-DISEASE
failure	I-DISEASE
and	O
diuretic	B-CHEMICAL
therapy	O
certainly	O
resulted	O
in	O
a	O
strong	O
activation	O
of	O
the	O
renin	O
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
.	O
Under	O
such	O
conditions	O
,	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
receptor	O
blockade	O
by	O
losartan	B-CHEMICAL
probably	O
induced	O
a	O
critical	O
fall	O
in	O
glomerular	O
filtration	O
pressure	O
.	O
This	O
case	O
report	O
highlights	O
the	O
fact	O
that	O
the	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
receptor	O
antagonist	O
losartan	B-CHEMICAL
can	O
cause	O
serious	O
unexpected	O
complications	B-DISEASE
in	O
patients	O
with	O
renovascular	O
disease	B-DISEASE
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
this	O
setting	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	B-DISEASE
cell	O
deaths	B-DISEASE
during	O
acetaminophen	B-CHEMICAL
-	O
induced	O
nephrotoxicity	B-DISEASE
,	O
amiodarone	B-CHEMICAL
-	O
induced	O
lung	O
toxicity	B-DISEASE
and	O
doxorubicin	B-CHEMICAL
-	O
induced	O
cardiotoxicity	B-DISEASE
by	O
a	O
novel	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O
Grape	O
seed	O
extract	O
,	O
primarily	O
a	O
mixture	O
of	O
proanthocyanidins	O
,	O
has	O
been	O
shown	O
to	O
modulate	O
a	O
wide	O
-	O
range	O
of	O
biological	O
,	O
pharmacological	O
and	O
toxicological	O
effects	O
which	O
are	O
mainly	O
cytoprotective	O
.	O
This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	O
acetaminophen	B-CHEMICAL
(	O
AAP)-induced	O
nephrotoxicity	B-DISEASE
,	O
amiodarone	B-CHEMICAL
(	O
AMI)-induced	O
lung	O
toxicity	B-DISEASE
,	O
and	O
doxorubicin	B-CHEMICAL
(	O
DOX)-induced	O
cardiotoxicity	B-DISEASE
in	O
mice	O
.	O
Experimental	O
design	O
consisted	O
of	O
four	O
groups	O
:	O
control	O
(	O
vehicle	O
alone	O
)	O
,	O
GSPE	O
alone	O
,	O
drug	O
alone	O
and	O
GSPE+drug	O
.	O
For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	O
gavaged	O
100	O
mg	O
/	O
Kg	O
GSPE	O
for	O
7	O
-	O
10	O
days	O
followed	O
by	O
i.p	O
.	O
injections	O
of	O
organ	O
specific	O
three	O
drugs	O
(	O
AAP	B-CHEMICAL
:	O
500	O
mg	O
/	O
Kg	O
for	O
24	O
h	O
;	O
AMI	B-CHEMICAL
:	O
50	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O
DOX	O
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O
Parameters	O
of	O
study	O
included	O
analysis	O
of	O
serum	O
chemistry	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
orderly	O
fragmentation	O
of	O
genomic	O
DNA	O
(	O
both	O
endonuclease	O
-	O
dependent	O
and	O
independent	O
)	O
in	O
addition	O
to	O
microscopic	O
evaluation	O
of	O
damage	O
and/or	O
protection	O
in	O
corresponding	O
PAS	O
stained	O
tissues	O
.	O
Results	O
indicate	O
that	O
GSPE	O
preexposure	O
prior	O
to	O
AAP	B-CHEMICAL
,	O
AMI	B-CHEMICAL
and	O
DOX	O
,	O
provided	O
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	O
DNA	O
fragmentation	O
.	O
Histopathological	O
examination	O
of	O
kidney	O
,	O
heart	O
and	O
lung	O
sections	O
revealed	O
moderate	O
to	O
massive	O
tissue	O
damage	O
with	O
a	O
variety	O
of	O
morphological	O
aberrations	O
by	O
all	O
the	O
three	O
drugs	O
in	O
the	O
absence	O
of	O
GSPE	O
preexposure	O
than	O
in	O
its	O
presence	O
.	O
GSPE+drug	O
exposed	O
tissues	O
exhibited	O
minor	O
residual	O
damage	O
or	O
near	O
total	O
recovery	O
.	O
Additionally	O
,	O
histopathological	O
alterations	O
mirrored	O
both	O
serum	O
chemistry	O
changes	O
and	O
the	O
pattern	O
of	O
DNA	O
fragmentation	O
.	O
Interestingly	O
,	O
all	O
the	O
drugs	O
,	O
such	O
as	O
,	O
AAP	B-CHEMICAL
,	O
AMI	B-CHEMICAL
and	O
DOX	O
induced	O
apoptotic	O
death	B-DISEASE
in	O
addition	O
to	O
necrosis	B-DISEASE
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	O
blocked	O
by	O
GSPE	O
.	O
Since	O
AAP	B-CHEMICAL
,	O
AMI	B-CHEMICAL
and	O
DOX	O
undergo	O
biotransformation	O
and	O
are	O
known	O
to	O
produce	O
damaging	O
radicals	O
in	O
vivo	O
,	O
the	O
protection	O
by	O
GSPE	O
may	O
be	O
linked	O
to	O
both	O
inhibition	O
of	O
metabolism	O
and/or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O
In	O
addition	O
,	O
its	O
'	O
presumed	O
contribution	O
to	O
DNA	O
repair	O
may	O
be	O
another	O
important	O
attribute	O
,	O
which	O
played	O
a	O
role	O
in	O
the	O
chemoprevention	O
process	O
.	O
Additionally	O
,	O
this	O
may	O
have	O
been	O
the	O
first	O
report	O
on	O
AMI	B-CHEMICAL
-	O
induced	O
apoptotic	O
death	B-DISEASE
in	O
the	O
lung	O
tissue	O
.	O
Taken	O
together	O
,	O
these	O
events	O
undoubtedly	O
establish	O
GSPE	O
's	O
abundant	O
bioavailability	O
,	O
and	O
the	O
power	O
to	O
defend	O
multiple	O
target	O
organs	O
from	O
toxic	O
assaults	O
induced	O
by	O
structurally	O
diverse	O
and	O
functionally	O
different	O
entities	O
in	O
vivo	O
.	O

Palpebral	O
twitching	O
in	O
a	O
depressed	B-DISEASE
adolescent	O
on	O
citalopram	B-CHEMICAL
.	O
Current	O
estimates	O
suggest	O
that	O
between	O
0.4	O
%	O
and	O
8.3	O
%	O
of	O
children	O
and	O
adolescents	O
are	O
affected	O
by	O
major	B-DISEASE
depression	I-DISEASE
.	O
We	O
report	O
a	O
favorable	O
response	O
to	O
treatment	O
with	O
citalopram	B-CHEMICAL
by	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
major	B-DISEASE
depression	I-DISEASE
who	O
exhibited	O
palpebral	O
twitching	O
during	O
his	O
first	O
2	O
weeks	O
of	O
treatment	O
.	O
This	O
may	O
have	O
been	O
a	O
side	O
effect	O
of	O
citalopram	B-CHEMICAL
as	O
it	O
remitted	O
with	O
redistribution	O
of	O
doses	O
.	O

Metamizol	O
potentiates	O
morphine	B-CHEMICAL
antinociception	O
but	O
not	O
constipation	B-DISEASE
after	O
chronic	O
treatment	O
.	O
This	O
work	O
evaluates	O
the	O
antinociceptive	O
and	O
constipating	B-DISEASE
effects	O
of	O
the	O
combination	O
of	O
3.2	O
mg	O
/	O
kg	O
s.c	O
.	O
morphine	B-CHEMICAL
with	O
177.8	O
mg	O
/	O
kg	O
s.c	O
.	O
metamizol	O
in	O
acutely	O
and	O
chronically	O
treated	O
(	O
once	O
a	O
day	O
for	O
12	O
days	O
)	O
rats	O
.	O
On	O
the	O
13th	O
day	O
,	O
antinociceptive	O
effects	O
were	O
assessed	O
using	O
a	O
model	O
of	O
inflammatory	O
nociception	O
,	O
pain	B-DISEASE
-	O
induced	O
functional	O
impairment	O
model	O
,	O
and	O
the	O
charcoal	O
meal	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
intestinal	O
transit	O
.	O
Simultaneous	O
administration	O
of	O
morphine	B-CHEMICAL
with	O
metamizol	O
resulted	O
in	O
a	O
markedly	O
antinociceptive	O
potentiation	O
and	O
an	O
increasing	O
of	O
the	O
duration	O
of	O
action	O
after	O
a	O
single	O
(	O
298+/-7	O
vs.	O
139+/-36	O
units	O
area	O
(	O
ua	O
)	O
;	O
P<0.001	O
)	O
and	O
repeated	O
administration	O
(	O
280+/-17	O
vs.	O
131+/-22	O
ua	O
;	O
P<0.001	O
)	O
.	O
Antinociceptive	O
effect	O
of	O
morphine	B-CHEMICAL
was	O
reduced	O
in	O
chronically	O
treated	O
rats	O
(	O
39+/-10	O
vs.	O
18+/-5	O
au	O
)	O
while	O
the	O
combination	O
-	O
induced	O
antinociception	O
was	O
remained	O
similar	O
as	O
an	O
acute	O
treatment	O
(	O
298+/-7	O
vs.	O
280+/-17	O
au	O
)	O
.	O
Acute	O
antinociceptive	O
effects	O
of	O
the	O
combination	O
were	O
partially	O
prevented	O
by	O
3.2	O
mg	O
/	O
kg	O
naloxone	B-CHEMICAL
s.c	O
.	O
(	O
P<0.05	O
)	O
,	O
suggesting	O
the	O
partial	O
involvement	O
of	O
the	O
opioidergic	O
system	O
in	O
the	O
synergism	O
observed	O
.	O
In	O
independent	O
groups	O
,	O
morphine	B-CHEMICAL
inhibited	O
the	O
intestinal	O
transit	O
in	O
48+/-4	O
%	O
and	O
38+/-4	O
%	O
after	O
acute	O
and	O
chronic	O
treatment	O
,	O
respectively	O
,	O
suggesting	O
that	O
tolerance	O
did	O
not	O
develop	O
to	O
the	O
constipating	B-DISEASE
effects	O
.	O
The	O
combination	O
inhibited	O
intestinal	O
transit	O
similar	O
to	O
that	O
produced	O
by	O
morphine	B-CHEMICAL
regardless	O
of	O
the	O
time	O
of	O
treatment	O
,	O
suggesting	O
that	O
metamizol	O
did	O
not	O
potentiate	O
morphine	B-CHEMICAL
-	O
induced	O
constipation	B-DISEASE
.	O
These	O
findings	O
show	O
a	O
significant	O
interaction	O
between	O
morphine	B-CHEMICAL
and	O
metamizol	O
in	O
chronically	O
treated	O
rats	O
,	O
suggesting	O
that	O
this	O
combination	O
could	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
chronic	B-DISEASE
pain	I-DISEASE
.	O

Ifosfamide	B-CHEMICAL
encephalopathy	B-DISEASE
presenting	O
with	O
asterixis	B-DISEASE
.	O
CNS	O
toxic	O
effects	O
of	O
the	O
antineoplastic	O
agent	O
ifosfamide	B-CHEMICAL
(	O
IFX	O
)	O
are	O
frequent	O
and	O
include	O
a	O
variety	O
of	O
neurological	O
symptoms	O
that	O
can	O
limit	O
drug	O
use	O
.	O
We	O
report	O
a	O
case	O
of	O
a	O
51	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
severe	O
,	O
disabling	O
negative	O
myoclonus	B-DISEASE
of	O
the	O
upper	O
and	O
lower	O
extremities	O
after	O
the	O
infusion	O
of	O
ifosfamide	B-CHEMICAL
for	O
plasmacytoma	B-DISEASE
.	O
He	O
was	O
awake	O
,	O
revealed	O
no	O
changes	O
of	O
mental	O
status	O
and	O
at	O
rest	O
there	O
were	O
no	O
further	O
motor	O
symptoms	O
.	O
Cranial	O
magnetic	O
resonance	O
imaging	O
and	O
extensive	O
laboratory	O
studies	O
failed	O
to	O
reveal	O
structural	O
lesions	O
of	O
the	O
brain	O
and	O
metabolic	O
abnormalities	O
.	O
An	O
electroencephalogram	O
showed	O
continuous	O
,	O
generalized	O
irregular	O
slowing	O
with	O
admixed	O
periodic	O
triphasic	O
waves	O
indicating	O
symptomatic	O
encephalopathy	B-DISEASE
.	O
The	O
administration	O
of	O
ifosfamide	B-CHEMICAL
was	O
discontinued	O
and	O
within	O
12	O
h	O
the	O
asterixis	B-DISEASE
resolved	O
completely	O
.	O
In	O
the	O
patient	O
described	O
,	O
the	O
presence	O
of	O
asterixis	B-DISEASE
during	O
infusion	O
of	O
ifosfamide	B-CHEMICAL
,	O
normal	O
laboratory	O
findings	O
and	O
imaging	O
studies	O
and	O
the	O
resolution	O
of	O
symptoms	O
following	O
the	O
discontinuation	O
of	O
the	O
drug	O
suggest	O
that	O
negative	O
myoclonus	B-DISEASE
is	O
associated	O
with	O
the	O
use	O
of	O
IFX	O
.	O

Sub	O
-	O
chronic	O
low	O
dose	O
gamma	O
-	O
vinyl	O
GABA	O
(	O
vigabatrin	B-CHEMICAL
)	O
inhibits	O
cocaine	B-CHEMICAL
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
dopamine	B-CHEMICAL
.	O
RATIONALE	O
:	O
gamma	O
-	O
Vinyl	O
GABA	O
(	O
GVG	O
)	O
irreversibly	O
inhibits	O
GABA	O
-	O
transaminase	O
.	O
This	O
non	O
-	O
receptor	O
mediated	O
inhibition	O
requires	O
de	O
novo	O
synthesis	O
for	O
restoration	O
of	O
functional	O
GABA	O
catabolism	O
.	O
OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	O
abuse	O
and	O
the	O
increased	O
risk	O
of	O
visual	B-DISEASE
field	I-DISEASE
defects	I-DISEASE
(	O
VFD	B-DISEASE
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	B-CHEMICAL
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	B-CHEMICAL
(	O
DA	O
)	O
.	O
METHODS	O
:	O
Using	O
in	O
vivo	O
microdialysis	O
,	O
we	O
compared	O
acute	O
exposure	O
(	O
450	O
mg	O
/	O
kg	O
)	O
to	O
an	O
identical	O
sub	O
-	O
chronic	O
exposure	O
(	O
150	O
mg	O
/	O
kg	O
per	O
day	O
for	O
3	O
days	O
)	O
,	O
followed	O
by	O
1-	O
or	O
3	O
-	O
day	O
washout	O
.	O
Finally	O
,	O
we	O
examined	O
the	O
low	O
dose	O
of	O
150	O
mg	O
/	O
kg	O
(	O
50	O
mg	O
/	O
kg	O
per	O
day	O
)	O
using	O
a	O
similar	O
washout	O
period	O
.	O
RESULTS	O
:	O
Sub	O
-	O
chronic	O
GVG	O
exposure	O
inhibited	O
the	O
effect	O
of	O
cocaine	B-CHEMICAL
for	O
3	O
days	O
,	O
which	O
exceeded	O
in	O
magnitude	O
and	O
duration	O
the	O
identical	O
acute	O
dose	O
.	O
CONCLUSIONS	O
:	O
Sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
potentiates	O
and	O
extends	O
the	O
inhibition	O
of	O
cocaine	B-CHEMICAL
-	O
induced	O
increases	O
in	O
dopamine	B-CHEMICAL
,	O
effectively	O
reducing	O
cumulative	O
exposures	O
and	O
the	O
risk	O
for	O
VFDS	O
.	O

Amount	O
of	O
bleeding	B-DISEASE
and	O
hematoma	B-DISEASE
size	O
in	O
the	O
collagenase	O
-	O
induced	O
intracerebral	O
hemorrhage	B-DISEASE
rat	O
model	O
.	O
The	O
aggravated	O
risk	O
on	O
intracerebral	O
hemorrhage	B-DISEASE
(	O
ICH	B-DISEASE
)	O
with	O
drugs	O
used	O
for	O
stroke	B-DISEASE
patients	O
should	O
be	O
estimated	O
carefully	O
.	O
We	O
therefore	O
established	O
sensitive	O
quantification	O
methods	O
and	O
provided	O
a	O
rat	O
ICH	B-DISEASE
model	O
for	O
detection	O
of	O
ICH	B-DISEASE
deterioration	O
.	O
In	O
ICH	B-DISEASE
intrastriatally	O
induced	O
by	O
0.014	O
-	O
unit	O
,	O
0.070	O
-	O
unit	O
,	O
and	O
0.350	O
-	O
unit	O
collagenase	O
,	O
the	O
amount	O
of	O
bleeding	B-DISEASE
was	O
measured	O
using	O
a	O
hemoglobin	O
assay	O
developed	O
in	O
the	O
present	O
study	O
and	O
was	O
compared	O
with	O
the	O
morphologically	O
determined	O
hematoma	B-DISEASE
volume	O
.	O
The	O
blood	O
amounts	O
and	O
hematoma	B-DISEASE
volumes	O
were	O
significantly	O
correlated	O
,	O
and	O
the	O
hematoma	B-DISEASE
induced	O
by	O
0.014	O
-	O
unit	O
collagenase	O
was	O
adequate	O
to	O
detect	O
ICH	B-DISEASE
deterioration	O
.	O
In	O
ICH	B-DISEASE
induction	O
using	O
0.014	O
-	O
unit	O
collagenase	O
,	O
heparin	B-CHEMICAL
enhanced	O
the	O
hematoma	B-DISEASE
volume	O
3.4	O
-	O
fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	B-DISEASE
animals	O
and	O
the	O
bleeding	B-DISEASE
7.6	O
-	O
fold	O
.	O
Data	O
suggest	O
that	O
this	O
sensitive	O
hemoglobin	O
assay	O
is	O
useful	O
for	O
ICH	B-DISEASE
detection	O
,	O
and	O
that	O
a	O
model	O
with	O
a	O
small	O
ICH	B-DISEASE
induced	O
with	O
a	O
low	O
-	O
dose	O
collagenase	O
should	O
be	O
used	O
for	O
evaluation	O
of	O
drugs	O
that	O
may	O
affect	O
ICH	B-DISEASE
.	O

Estradiol	B-CHEMICAL
reduces	O
seizure	B-DISEASE
-	O
induced	O
hippocampal	O
injury	O
in	O
ovariectomized	O
female	O
but	O
not	O
in	O
male	O
rats	O
.	O
Estrogens	O
protect	O
ovariectomized	O
rats	O
from	O
hippocampal	O
injury	O
induced	O
by	O
kainic	O
acid	O
-	O
induced	O
status	B-DISEASE
epilepticus	I-DISEASE
(	O
SE	B-DISEASE
)	O
.	O
We	O
compared	O
the	O
effects	O
of	O
17beta	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
in	O
adult	O
male	O
and	O
ovariectomized	O
female	O
rats	O
subjected	O
to	O
lithium	B-CHEMICAL
-	O
pilocarpine	B-CHEMICAL
-	O
induced	O
SE	B-DISEASE
.	O
Rats	O
received	O
subcutaneous	O
injections	O
of	O
17beta	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
(	O
2	O
microg	O
/	O
rat	O
)	O
or	O
oil	O
once	O
daily	O
for	O
four	O
consecutive	O
days	O
.	O
SE	B-DISEASE
was	O
induced	O
20	O
h	O
following	O
the	O
second	O
injection	O
and	O
terminated	O
3	O
h	O
later	O
.	O
The	O
extent	O
of	O
silver	O
-	O
stained	O
CA3	O
and	O
CA1	O
hippocampal	O
neurons	O
was	O
evaluated	O
2	O
days	O
after	O
SE	B-DISEASE
.	O
17beta	B-CHEMICAL
-	I-CHEMICAL
Estradiol	I-CHEMICAL
did	O
not	O
alter	O
the	O
onset	O
of	O
first	O
clonus	O
in	O
ovariectomized	O
rats	O
but	O
accelerated	O
it	O
in	O
males	O
.	O
17beta	B-CHEMICAL
-	I-CHEMICAL
Estradiol	I-CHEMICAL
reduced	O
the	O
argyrophilic	O
neurons	O
in	O
the	O
CA1	O
and	O
CA3	O
-	O
C	O
sectors	O
of	O
ovariectomized	O
rats	O
.	O
In	O
males	O
,	O
estradiol	B-CHEMICAL
increased	O
the	O
total	O
damage	O
score	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
effects	O
of	O
estradiol	B-CHEMICAL
on	O
seizure	B-DISEASE
threshold	O
and	O
damage	O
may	O
be	O
altered	O
by	O
sex	O
-	O
related	O
differences	O
in	O
the	O
hormonal	O
environment	O
.	O

Delirium	B-DISEASE
during	O
clozapine	B-CHEMICAL
treatment	O
:	O
incidence	O
and	O
associated	O
risk	O
factors	O
.	O
BACKGROUND	O
:	O
Incidence	O
and	O
risk	O
factors	O
for	O
delirium	B-DISEASE
during	O
clozapine	B-CHEMICAL
treatment	O
require	O
further	O
clarification	O
.	O
METHODS	O
:	O
We	O
used	O
computerized	O
pharmacy	O
records	O
to	O
identify	O
all	O
adult	O
psychiatric	B-DISEASE
inpatients	O
treated	O
with	O
clozapine	B-CHEMICAL
(	O
1995	O
-	O
96	O
)	O
,	O
reviewed	O
their	O
medical	O
records	O
to	O
score	O
incidence	O
and	O
severity	O
of	O
delirium	B-DISEASE
,	O
and	O
tested	O
associations	O
with	O
potential	O
risk	O
factors	O
.	O
RESULTS	O
:	O
Subjects	O
(	O
n	O
=	O
139	O
)	O
were	O
72	O
women	O
and	O
67	O
men	O
,	O
aged	O
40.8	O
+	O
/-	O
12.1	O
years	O
,	O
hospitalized	O
for	O
24.9	O
+	O
/-	O
23.3	O
days	O
,	O
and	O
given	O
clozapine	B-CHEMICAL
,	O
gradually	O
increased	O
to	O
an	O
average	O
daily	O
dose	O
of	O
282	O
+	O
/-	O
203	O
mg	O
(	O
3.45	O
+	O
/-	O
2.45	O
mg	O
/	O
kg	O
)	O
for	O
18.9	O
+	O
/-	O
16.4	O
days	O
.	O
Delirium	B-DISEASE
was	O
diagnosed	O
in	O
14	O
(	O
10.1	O
%	O
incidence	O
,	O
or	O
1.48	O
cases	O
/	O
person	O
-	O
years	O
of	O
exposure	O
)	O
;	O
71.4	O
%	O
of	O
cases	O
were	O
moderate	O
or	O
severe	O
.	O
Associated	O
factors	O
were	O
co	B-CHEMICAL
-	O
treatment	O
with	O
other	O
centrally	O
antimuscarinic	O
agents	O
,	O
poor	O
clinical	O
outcome	O
,	O
older	O
age	O
,	O
and	O
longer	O
hospitalization	O
(	O
by	O
17.5	O
days	O
,	O
increasing	O
cost	O
)	O
;	O
sex	O
,	O
diagnosis	O
or	O
medical	O
co	B-CHEMICAL
-	O
morbidity	O
,	O
and	O
daily	O
clozapine	B-CHEMICAL
dose	O
,	O
which	O
fell	O
with	O
age	O
,	O
were	O
unrelated	O
.	O
CONCLUSIONS	O
:	O
Delirium	B-DISEASE
was	O
found	O
in	O
10	O
%	O
of	O
clozapine	B-CHEMICAL
-	O
treated	O
inpatients	O
,	O
particularly	O
in	O
older	O
patients	O
exposed	O
to	O
other	O
central	O
anticholinergics	O
.	O
Delirium	B-DISEASE
was	O
inconsistently	O
recognized	O
clinically	O
in	O
milder	O
cases	O
and	O
was	O
associated	O
with	O
increased	O
length	O
-	O
of	O
-	O
stay	O
and	O
higher	O
costs	O
,	O
and	O
inferior	O
clinical	O
outcome	O
.	O

Ketoconazole	B-CHEMICAL
-	O
induced	O
neurologic	O
sequelae	O
.	O
A	O
77	O
-	O
y	O
-	O
old	O
patient	O
developed	O
weakness	B-DISEASE
of	O
extremities	O
,	O
legs	O
paralysis	B-DISEASE
,	O
dysarthria	B-DISEASE
and	O
tremor	B-DISEASE
1	O
h	O
after	O
ingestion	O
of	O
200	O
mg	O
ketoconazole	B-CHEMICAL
for	O
the	O
first	O
time	O
in	O
his	O
life	O
.	O
All	O
complaints	O
faded	O
away	O
within	O
24	O
h.	O
Few	O
days	O
later	O
,	O
the	O
patient	O
used	O
another	O
200	O
mg	O
ketoconazole	B-CHEMICAL
tablet	O
,	O
and	O
within	O
an	O
hour	O
experienced	O
a	O
similar	O
clinical	O
picture	O
,	O
which	O
resolved	O
again	O
spontaneously	O
within	O
hours	O
.	O
Laboratory	O
evaluations	O
,	O
including	O
head	O
CT	O
scan	O
,	O
were	O
normal	O
.	O
This	O
case	O
illustrates	O
the	O
need	O
for	O
close	O
vigilance	O
in	O
adverse	B-DISEASE
drug	I-DISEASE
reactions	I-DISEASE
,	O
particularly	O
in	O
the	O
elderly	O
.	O

Noxious	O
chemical	O
stimulation	O
of	O
rat	O
facial	O
mucosa	O
increases	O
intracranial	O
blood	O
flow	O
through	O
a	O
trigemino	O
-	O
parasympathetic	O
reflex	O
--	O
an	O
experimental	O
model	O
for	O
vascular	O
dysfunctions	O
in	O
cluster	B-DISEASE
headache	I-DISEASE
.	O
Cluster	B-DISEASE
headache	I-DISEASE
is	O
characterized	O
by	O
typical	O
autonomic	O
dysfunctions	O
including	O
facial	O
and	O
intracranial	O
vascular	O
disturbances	O
.	O
Both	O
the	O
trigeminal	O
and	O
the	O
cranial	O
parasympathetic	O
systems	O
may	O
be	O
involved	O
in	O
mediating	O
these	O
dysfunctions	O
.	O
An	O
experimental	O
model	O
was	O
developed	O
in	O
the	O
rat	O
to	O
measure	O
changes	O
in	O
lacrimation	O
and	O
intracranial	O
blood	O
flow	O
following	O
noxious	O
chemical	O
stimulation	O
of	O
facial	O
mucosa	O
.	O
Blood	O
flow	O
was	O
monitored	O
in	O
arteries	O
of	O
the	O
exposed	O
cranial	O
dura	O
mater	O
and	O
the	O
parietal	O
cortex	O
using	O
laser	O
Doppler	O
flowmetry	O
.	O
Capsaicin	B-CHEMICAL
(	O
0.01	O
-	O
1	O
mm	O
)	O
applied	O
to	O
oral	O
or	O
nasal	O
mucosa	O
induced	O
increases	O
in	O
dural	O
and	O
cortical	O
blood	O
flow	O
and	O
provoked	O
lacrimation	O
.	O
These	O
responses	O
were	O
blocked	O
by	O
systemic	O
pre	O
-	O
administration	O
of	O
hexamethonium	B-CHEMICAL
chloride	O
(	O
20	O
mg	O
/	O
kg	O
)	O
.	O
The	O
evoked	O
increases	O
in	O
dural	O
blood	O
flow	O
were	O
also	O
abolished	O
by	O
topical	O
pre	O
-	O
administration	O
of	O
atropine	O
(	O
1	O
mm	O
)	O
and	O
[	O
Lys1	O
,	O
Pro2,5	O
,	O
Arg3,4	O
,	O
Tyr6]-VIP	O
(	O
0.1	O
mm	O
)	O
,	O
a	O
vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
antagonist	O
,	O
onto	O
the	O
exposed	O
dura	O
mater	O
.	O
We	O
conclude	O
that	O
noxious	O
stimulation	O
of	O
facial	O
mucosa	O
increases	O
intracranial	O
blood	O
flow	O
and	O
lacrimation	O
via	O
a	O
trigemino	O
-	O
parasympathetic	O
reflex	O
.	O
The	O
blood	O
flow	O
responses	O
seem	O
to	O
be	O
mediated	O
by	O
the	O
release	O
of	O
acetylcholine	O
and	O
VIP	O
within	O
the	O
meninges	O
.	O
Similar	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
cluster	B-DISEASE
headache	I-DISEASE
.	O

Recurrent	O
excitation	O
in	O
the	O
dentate	O
gyrus	O
of	O
a	O
murine	O
model	O
of	O
temporal	B-DISEASE
lobe	I-DISEASE
epilepsy	I-DISEASE
.	O
Similar	O
to	O
rats	O
,	O
systemic	O
pilocarpine	B-CHEMICAL
injection	O
causes	O
status	B-DISEASE
epilepticus	I-DISEASE
(	O
SE	B-DISEASE
)	O
and	O
the	O
eventual	O
development	O
of	O
spontaneous	O
seizures	B-DISEASE
and	O
mossy	O
fiber	O
sprouting	O
in	O
C57BL/6	O
and	O
CD1	O
mice	O
,	O
but	O
the	O
physiological	O
correlates	O
of	O
these	O
events	O
have	O
not	O
been	O
identified	O
in	O
mice	O
.	O
Population	O
responses	O
in	O
granule	O
cells	O
of	O
the	O
dentate	O
gyrus	O
were	O
examined	O
in	O
transverse	O
slices	O
of	O
the	O
ventral	O
hippocampus	O
from	O
pilocarpine	B-CHEMICAL
-	O
treated	O
and	O
untreated	O
mice	O
.	O
In	O
Mg(2+)-free	O
bathing	O
medium	O
containing	O
bicuculline	O
,	O
conditions	O
designed	O
to	O
increase	O
excitability	O
in	O
the	O
slices	O
,	O
electrical	O
stimulation	O
of	O
the	O
hilus	O
resulted	O
in	O
a	O
single	O
population	O
spike	O
in	O
granule	O
cells	O
from	O
control	O
mice	O
and	O
pilocarpine	B-CHEMICAL
-	O
treated	O
mice	O
that	O
did	O
not	O
experience	O
SE	B-DISEASE
.	O
In	O
SE	B-DISEASE
survivors	O
,	O
similar	O
stimulation	O
resulted	O
in	O
a	O
population	O
spike	O
followed	O
,	O
at	O
a	O
variable	O
latency	O
,	O
by	O
negative	O
DC	O
shifts	O
and	O
repetitive	O
afterdischarges	O
of	O
3	O
-	O
60	O
s	O
duration	O
,	O
which	O
were	O
blocked	O
by	O
ionotropic	O
glutamate	B-CHEMICAL
receptor	O
antagonists	O
.	O
Focal	O
glutamate	B-CHEMICAL
photostimulation	O
of	O
the	O
granule	O
cell	O
layer	O
at	O
sites	O
distant	O
from	O
the	O
recording	O
pipette	O
resulted	O
in	O
population	O
responses	O
of	O
1	O
-	O
30	O
s	O
duration	O
in	O
slices	O
from	O
SE	B-DISEASE
survivors	O
but	O
not	O
other	O
groups	O
.	O
These	O
data	O
support	O
the	O
hypothesis	O
that	O
SE	B-DISEASE
-	O
induced	O
mossy	O
fiber	O
sprouting	O
and	O
synaptic	O
reorganization	O
are	O
relevant	O
characteristics	O
of	O
seizure	B-DISEASE
development	O
in	O
these	O
murine	O
strains	O
,	O
resembling	O
rat	O
models	O
of	O
human	O
temporal	B-DISEASE
lobe	I-DISEASE
epilepsy	I-DISEASE
.	O

The	O
alpha3	O
and	O
beta4	O
nicotinic	O
acetylcholine	O
receptor	O
subunits	O
are	O
necessary	O
for	O
nicotine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
and	O
hypolocomotion	O
in	O
mice	O
.	O
Binding	O
of	O
nicotine	B-CHEMICAL
to	O
nicotinic	O
acetylcholine	O
receptors	O
(	O
nAChRs	O
)	O
elicits	O
a	O
series	O
of	O
dose	O
-	O
dependent	O
behaviors	O
that	O
go	O
from	O
altered	O
exploration	O
,	O
sedation	O
,	O
and	O
tremors	B-DISEASE
,	O
to	O
seizures	B-DISEASE
and	O
death	B-DISEASE
.	O
nAChRs	O
are	O
pentameric	O
ion	O
channels	O
usually	O
composed	O
of	O
alpha	O
and	O
beta	O
subunits	O
.	O
A	O
gene	O
cluster	O
comprises	O
the	O
alpha3	O
,	O
alpha5	O
and	O
beta4	O
subunits	O
,	O
which	O
coassemble	O
to	O
form	O
functional	O
receptors	O
.	O
We	O
examined	O
the	O
role	O
of	O
the	O
beta4	O
subunits	O
in	O
nicotine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
and	O
hypolocomotion	O
in	O
beta4	O
homozygous	O
null	O
(	O
beta4	O
-/-	O
)	O
and	O
alpha3	O
heterozygous	O
(	O
+	O
/-	O
)	O
mice	O
.	O
beta4	O
-/-	O
mice	O
were	O
less	O
sensitive	O
to	O
the	O
effects	O
of	O
nicotine	B-CHEMICAL
both	O
at	O
low	O
doses	O
,	O
measured	O
as	O
decreased	O
exploration	O
in	O
an	O
open	O
field	O
,	O
and	O
at	O
high	O
doses	O
,	O
measured	O
as	O
sensitivity	O
to	O
nicotine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
.	O
Using	O
in	O
situ	O
hybridization	O
probes	O
for	O
the	O
alpha3	O
and	O
alpha5	O
subunits	O
,	O
we	O
showed	O
that	O
alpha5	O
mRNA	O
levels	O
are	O
unchanged	O
,	O
whereas	O
alpha3	O
mRNA	O
levels	O
are	O
selectively	O
decreased	O
in	O
the	O
mitral	O
cell	O
layer	O
of	O
the	O
olfactory	O
bulb	O
,	O
and	O
the	O
inferior	O
and	O
the	O
superior	O
colliculus	O
of	O
beta4	O
-/-	O
brains	O
.	O
alpha3	O
+	O
/-	O
mice	O
were	O
partially	O
resistant	O
to	O
nicotine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
when	O
compared	O
to	O
wild	O
-	O
type	O
littermates	O
.	O
mRNA	O
levels	O
for	O
the	O
alpha5	O
and	O
the	O
beta4	O
subunits	O
were	O
unchanged	O
in	O
alpha3	O
+	O
/-	O
brains	O
.	O
Together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
beta4	O
and	O
the	O
alpha3	O
subunits	O
are	O
mediators	O
of	O
nicotine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
and	O
hypolocomotion	O
.	O

Recurrent	O
acute	O
interstitial	B-DISEASE
nephritis	I-DISEASE
induced	O
by	O
azithromycin	O
.	O
A	O
14	O
-	O
year	O
-	O
old	O
girl	O
is	O
reported	O
with	O
recurrent	O
,	O
azithromycin	O
-	O
induced	O
,	O
acute	O
interstitial	B-DISEASE
nephritis	I-DISEASE
.	O
The	O
second	O
episode	O
was	O
more	O
severe	O
than	O
the	O
first	O
;	O
and	O
although	O
both	O
were	O
treated	O
with	O
intensive	O
corticosteroid	O
therapy	O
,	O
renal	O
function	O
remained	O
impaired	O
.	O
Although	O
most	O
cases	O
of	O
antibiotic	O
induced	O
acute	O
interstitial	B-DISEASE
nephritis	I-DISEASE
are	O
benign	O
and	O
self	O
-	O
limited	O
,	O
some	O
patients	O
are	O
at	O
risk	O
for	O
permanent	O
renal	B-DISEASE
injury	I-DISEASE
.	O

Valproate	O
-	O
induced	O
encephalopathy	B-DISEASE
.	O
Valproate	O
-	O
induced	O
encephalopathy	B-DISEASE
is	O
a	O
rare	O
syndrome	B-DISEASE
that	O
may	O
manifest	O
in	O
otherwise	O
normal	O
epileptic	B-DISEASE
individuals	O
.	O
It	O
may	O
even	O
present	O
in	O
patients	O
who	O
have	O
tolerated	O
this	O
medicine	O
well	O
in	O
the	O
past	O
.	O
It	O
is	O
usually	O
but	O
not	O
necessarily	O
associated	O
with	O
hyperammonemia	B-DISEASE
.	O
The	O
EEG	O
shows	O
characteristic	O
triphasic	O
waves	O
in	O
most	O
patients	O
with	O
this	O
complication	O
.	O
A	O
case	O
of	O
valproate	O
-	O
induced	O
encephalopathy	B-DISEASE
is	O
presented	O
.	O
The	O
problems	O
in	O
diagnosing	O
this	O
condition	O
are	O
subsequently	O
discussed	O
.	O

Nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
:	O
a	O
potential	O
protector	O
against	O
gentamicin	B-CHEMICAL
ototoxicity	B-DISEASE
.	O
The	O
nitric	O
oxide	O
(	O
NO	O
)	O
inhibitor	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
may	O
act	O
as	O
an	O
otoprotectant	O
against	O
high	O
-	O
frequency	O
hearing	B-DISEASE
loss	I-DISEASE
caused	O
by	O
gentamicin	B-CHEMICAL
,	O
but	O
further	O
studies	O
are	O
needed	O
to	O
confirm	O
this	O
.	O
Aminoglycoside	O
antibiotics	O
are	O
still	O
widely	O
used	O
by	O
virtue	O
of	O
their	O
efficacy	O
and	O
low	O
cost	O
.	O
Their	O
ototoxicity	B-DISEASE
is	O
a	O
serious	O
health	O
problem	O
and	O
,	O
as	O
their	O
ototoxic	O
mechanism	O
involves	O
the	O
production	O
of	O
NO	O
,	O
we	O
need	O
to	O
assess	O
the	O
use	O
of	O
NO	O
inhibitors	O
for	O
the	O
prevention	O
of	O
aminoglycoside	O
-	O
induced	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O
In	O
this	O
experimental	O
study	O
we	O
used	O
30	O
Sprague	O
-	O
Dawley	O
rats	O
,	O
27	O
of	O
which	O
had	O
gentamicin	B-CHEMICAL
instilled	O
into	O
the	O
middle	O
ear	O
.	O
The	O
otoprotectant	O
L	O
-	O
NAME	O
was	O
administered	O
topically	O
to	O
12/27	O
animals	O
.	O
Its	O
effect	O
was	O
determined	O
in	O
terms	O
of	O
attenuation	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
measured	O
by	O
shifts	O
in	O
the	O
auditory	O
brainstem	O
response	O
threshold	O
.	O
L	O
-	O
NAME	O
reduced	O
gentamicin	B-CHEMICAL
-	O
induced	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
high	O
-	O
frequency	O
range	O
,	O
but	O
gave	O
no	O
protection	O
in	O
the	O
middle	O
or	O
low	O
frequencies	O
.	O

Cerebral	B-DISEASE
vasculitis	I-DISEASE
following	O
oral	O
methylphenidate	B-CHEMICAL
intake	O
in	O
an	O
adult	O
:	O
a	O
case	O
report	O
.	O
Methylphenidate	B-CHEMICAL
is	O
structurally	O
and	O
functionally	O
similar	O
to	O
amphetamine	O
.	O
Cerebral	B-DISEASE
vasculitis	I-DISEASE
associated	O
with	O
amphetamine	B-DISEASE
abuse	I-DISEASE
is	O
well	O
documented	O
,	O
and	O
in	O
rare	O
cases	O
ischaemic	O
stroke	B-DISEASE
has	O
been	O
reported	O
after	O
methylphenidate	B-CHEMICAL
intake	O
in	O
children	O
.	O
We	O
report	O
the	O
case	O
of	O
a	O
63	O
-	O
year	O
-	O
old	O
female	O
who	O
was	O
treated	O
with	O
methylphenidate	B-CHEMICAL
due	O
to	O
hyperactivity	O
and	O
suffered	O
from	O
multiple	O
ischaemic	O
strokes	B-DISEASE
.	O
We	O
consider	O
drug	O
-	O
induced	O
cerebral	B-DISEASE
vasculitis	I-DISEASE
as	O
the	O
most	O
likely	O
cause	O
of	O
recurrent	O
ischaemic	O
strokes	B-DISEASE
in	O
the	O
absence	O
of	O
any	O
pathological	O
findings	O
during	O
the	O
diagnostic	O
work	O
-	O
up	O
.	O
We	O
conclude	O
that	O
methylphenidate	B-CHEMICAL
mediated	O
vasculitis	B-DISEASE
should	O
be	O
considered	O
in	O
patients	O
with	O
neurological	O
symptoms	O
and	O
a	O
history	O
of	O
methylphenidate	B-CHEMICAL
therapy	O
.	O
This	O
potential	O
side	O
-	O
effect	O
,	O
though	O
very	O
rare	O
,	O
represents	O
one	O
more	O
reason	O
to	O
be	O
very	O
restrictive	O
in	O
the	O
use	O
of	O
methylphenidate	B-CHEMICAL
.	O

Cerebral	B-DISEASE
haemorrhage	I-DISEASE
induced	O
by	O
warfarin	B-CHEMICAL
-	O
the	O
influence	O
of	O
drug	O
-	O
drug	O
interactions	O
.	O
PURPOSE	O
:	O
To	O
evaluate	O
the	O
frequency	O
,	O
severity	O
and	O
preventability	O
of	O
warfarin	B-CHEMICAL
-	O
induced	O
cerebral	B-DISEASE
haemorrhages	I-DISEASE
due	O
to	O
warfarin	B-CHEMICAL
and	O
warfarin	B-CHEMICAL
-	O
drug	O
interactions	O
in	O
patients	O
living	O
in	O
the	O
county	O
of	O
Osterg	O
 	O
tland	O
,	O
Sweden	O
.	O
METHODS	O
:	O
All	O
patients	O
with	O
a	O
diagnosed	O
cerebral	B-DISEASE
haemorrhage	I-DISEASE
at	O
three	O
hospitals	O
during	O
the	O
period	O
2000	O
-	O
2002	O
were	O
identified	O
.	O
Medical	O
records	O
were	O
studied	O
retrospectively	O
to	O
evaluate	O
whether	O
warfarin	B-CHEMICAL
and	O
warfarin	B-CHEMICAL
-	O
drug	O
interactions	O
could	O
have	O
caused	O
the	O
cerebral	B-DISEASE
haemorrhage	I-DISEASE
.	O
The	O
proportion	O
of	O
possibly	O
avoidable	O
cases	O
due	O
to	O
drug	O
interactions	O
was	O
estimated	O
.	O
RESULTS	O
:	O
Among	O
593	O
patients	O
with	O
cerebral	B-DISEASE
haemorrhage	I-DISEASE
,	O
59	O
(	O
10	O
%	O
)	O
were	O
assessed	O
as	O
related	O
to	O
warfarin	B-CHEMICAL
treatment	O
.	O
This	O
imply	O
an	O
incidence	O
of	O
1.7/100,000	O
treatment	O
years	O
.	O
Of	O
the	O
59	O
cases	O
,	O
26	O
(	O
44	O
%	O
)	O
had	O
a	O
fatal	O
outcome	O
,	O
compared	O
to	O
136	O
(	O
25	O
%	O
)	O
among	O
the	O
non	O
-	O
warfarin	B-CHEMICAL
patients	O
(	O
p	O
<	O
0.01	O
)	O
.	O
A	O
warfarin	B-CHEMICAL
-	O
drug	O
interaction	O
could	O
have	O
contributed	O
to	O
the	O
haemorrhage	O
in	O
24	O
(	O
41	O
%	O
)	O
of	O
the	O
warfarin	B-CHEMICAL
patients	O
and	O
in	O
7	O
of	O
these	O
(	O
12	O
%	O
)	O
the	O
bleeding	B-DISEASE
complication	O
was	O
considered	O
being	O
possible	O
to	O
avoid	O
.	O
CONCLUSIONS	O
:	O
Warfarin	B-CHEMICAL
-	O
induced	O
cerebral	B-DISEASE
haemorrhages	I-DISEASE
are	O
a	O
major	O
clinical	O
problem	O
with	O
a	O
high	O
fatality	O
rate	O
.	O
Almost	O
half	O
of	O
the	O
cases	O
was	O
related	O
to	O
a	O
warfarin	B-CHEMICAL
-	O
drug	O
interaction	O
.	O
A	O
significant	O
proportion	O
of	O
warfarin	B-CHEMICAL
-	O
related	O
cerebral	B-DISEASE
haemorrhages	I-DISEASE
might	O
have	O
been	O
prevented	O
if	O
greater	O
caution	O
had	O
been	O
taken	O
when	O
prescribing	O
drugs	O
known	O
to	O
interact	O
with	O
warfarin	B-CHEMICAL
.	O

Side	O
effects	O
of	O
postoperative	O
administration	O
of	O
methylprednisolone	B-CHEMICAL
and	O
gentamicin	B-CHEMICAL
into	O
the	O
posterior	O
sub	O
-	O
Tenon	O
's	O
space	O
.	O
PURPOSE	O
:	O
To	O
assess	O
the	O
incidence	O
of	O
postoperative	O
emetic	O
side	O
effects	O
after	O
the	O
administration	O
of	O
methylprednisolone	B-CHEMICAL
and	O
gentamicin	B-CHEMICAL
into	O
the	O
posterior	O
sub	O
-	O
Tenon	O
's	O
space	O
at	O
the	O
end	O
of	O
routine	O
cataract	B-DISEASE
surgery	O
.	O
SETTING	O
:	O
St.	O
Luke	O
's	O
Hospital	O
,	O
Gwardamangia	O
,	O
Malta	O
.	O
METHODS	O
:	O
A	O
double	O
-	O
blind	B-DISEASE
double	O
-	O
armed	O
prospective	O
study	O
comprised	O
40	O
patients	O
who	O
had	O
uneventful	O
sutureless	O
phacoemulsification	O
under	O
sub	O
-	O
Tenon	O
's	O
local	O
infiltration	O
of	O
3	O
mL	O
of	O
plain	O
lignocaine	B-CHEMICAL
.	O
At	O
the	O
end	O
of	O
the	O
procedure	O
,	O
Group	O
A	O
(	O
n	O
=	O
20	O
)	O
had	O
20	O
mg/0.5	O
mL	O
of	O
methylprednisolone	B-CHEMICAL
and	O
10	O
mg/0.5	O
mL	O
of	O
gentamicin	B-CHEMICAL
injected	O
into	O
the	O
posterior	O
sub	O
-	O
Tenon	O
's	O
space	O
and	O
Group	O
B	O
(	O
n	O
=	O
20	O
)	O
had	O
the	O
same	O
combination	O
injected	O
into	O
the	O
anterior	O
sub	O
-	O
Tenon	O
's	O
space	O
.	O
Postoperatively	O
,	O
all	O
patients	O
were	O
assessed	O
for	O
symptoms	O
of	O
nausea	B-DISEASE
,	O
vomiting	B-DISEASE
,	O
and	O
headache	B-DISEASE
.	O
A	O
chi	O
-	O
square	O
test	O
was	O
used	O
to	O
assess	O
the	O
statistical	O
significance	O
of	O
results	O
.	O
RESULTS	O
:	O
Sixty	O
percent	O
in	O
Group	O
A	O
developed	O
postoperative	O
emetic	O
symptoms	O
,	O
headache	B-DISEASE
,	O
or	O
both	O
;	O
1	O
patient	O
in	O
Group	O
B	O
developed	O
symptoms	O
.	O
CONCLUSIONS	O
:	O
The	O
administration	O
of	O
methylprednisolone	B-CHEMICAL
and	O
gentamicin	B-CHEMICAL
in	O
the	O
posterior	O
sub	O
-	O
Tenon	O
's	O
space	O
was	O
related	O
to	O
a	O
high	O
incidence	O
of	O
side	O
effects	O
including	O
nausea	B-DISEASE
,	O
vomiting	B-DISEASE
,	O
and	O
headache	B-DISEASE
.	O
All	O
adverse	O
effects	O
were	O
self	O
-	O
limiting	O
.	O

Cardiac	O
Angiography	O
in	O
Renally	O
Impaired	O
Patients	O
(	O
CARE	O
)	O
study	O
:	O
a	O
randomized	O
double	O
-	O
blind	B-DISEASE
trial	O
of	O
contrast	O
-	O
induced	O
nephropathy	B-DISEASE
in	O
patients	O
with	O
chronic	B-DISEASE
kidney	I-DISEASE
disease	I-DISEASE
.	O
BACKGROUND	O
:	O
No	O
direct	O
comparisons	O
exist	O
of	O
the	O
renal	O
tolerability	O
of	O
the	O
low	O
-	O
osmolality	O
contrast	O
medium	O
iopamidol	B-CHEMICAL
with	O
that	O
of	O
the	O
iso	O
-	O
osmolality	O
contrast	O
medium	O
iodixanol	B-CHEMICAL
in	O
high	O
-	O
risk	O
patients	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
The	O
present	O
study	O
is	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	B-DISEASE
comparison	O
of	O
iopamidol	B-CHEMICAL
and	O
iodixanol	B-CHEMICAL
in	O
patients	O
with	O
chronic	B-DISEASE
kidney	I-DISEASE
disease	I-DISEASE
(	O
estimated	O
glomerular	O
filtration	O
rate	O
,	O
20	O
to	O
59	O
mL	O
/	O
min	O
)	O
who	O
underwent	O
cardiac	O
angiography	O
or	O
percutaneous	O
coronary	O
interventions	O
.	O
Serum	O
creatinine	B-CHEMICAL
(	O
SCr	O
)	O
levels	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
were	O
assessed	O
at	O
baseline	O
and	O
2	O
to	O
5	O
days	O
after	O
receiving	O
medications	O
.	O
The	O
primary	O
outcome	O
was	O
a	O
postdose	O
SCr	O
increase	O
>	O
or	O
=	O
0.5	O
mg	O
/	O
dL	O
(	O
44.2	O
micromol	O
/	O
L	O
)	O
over	O
baseline	O
.	O
Secondary	O
outcomes	O
were	O
a	O
postdose	O
SCr	O
increase	O
>	O
or	O
=	O
25	O
%	O
,	O
a	O
postdose	O
estimated	O
glomerular	O
filtration	O
rate	O
decrease	O
of	O
>	O
or	O
=	O
25	O
%	O
,	O
and	O
the	O
mean	O
peak	O
change	O
in	O
SCr	O
.	O
In	O
414	O
patients	O
,	O
contrast	O
volume	O
,	O
presence	O
of	O
diabetes	B-DISEASE
mellitus	I-DISEASE
,	O
use	O
of	O
N	O
-	O
acetylcysteine	B-CHEMICAL
,	O
mean	O
baseline	O
SCr	O
,	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
were	O
comparable	O
in	O
the	O
2	O
groups	O
.	O
SCr	O
increases	O
>	O
or	O
=	O
0.5	O
mg	O
/	O
dL	O
occurred	O
in	O
4.4	O
%	O
(	O
9	O
of	O
204	O
patients	O
)	O
after	O
iopamidol	B-CHEMICAL
and	O
6.7	O
%	O
(	O
14	O
of	O
210	O
patients	O
)	O
after	O
iodixanol	B-CHEMICAL
(	O
P=0.39	O
)	O
,	O
whereas	O
rates	O
of	O
SCr	O
increases	O
>	O
or	O
=	O
25	O
%	O
were	O
9.8	O
%	O
and	O
12.4	O
%	O
,	O
respectively	O
(	O
P=0.44	O
)	O
.	O
In	O
patients	O
with	O
diabetes	B-DISEASE
,	O
SCr	O
increases	O
>	O
or	O
=	O
0.5	O
mg	O
/	O
dL	O
were	O
5.1	O
%	O
(	O
4	O
of	O
78	O
patients	O
)	O
with	O
iopamidol	B-CHEMICAL
and	O
13.0	O
%	O
(	O
12	O
of	O
92	O
patients	O
)	O
with	O
iodixanol	B-CHEMICAL
(	O
P=0.11	O
)	O
,	O
whereas	O
SCr	O
increases	O
>	O
or	O
=	O
25	O
%	O
were	O
10.3	O
%	O
and	O
15.2	O
%	O
,	O
respectively	O
(	O
P=0.37	O
)	O
.	O
Mean	O
post	O
-	O
SCr	O
increases	O
were	O
significantly	O
less	O
with	O
iopamidol	B-CHEMICAL
(	O
all	O
patients	O
:	O
0.07	O
versus	O
0.12	O
mg	O
/	O
dL	O
,	O
6.2	O
versus	O
10.6	O
micromol	O
/	O
L	O
,	O
P=0.03	O
;	O
patients	O
with	O
diabetes	B-DISEASE
:	O
0.07	O
versus	O
0.16	O
mg	O
/	O
dL	O
,	O
6.2	O
versus	O
14.1	O
micromol	O
/	O
L	O
,	O
P=0.01	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
rate	O
of	O
contrast	O
-	O
induced	O
nephropathy	B-DISEASE
,	O
defined	O
by	O
multiple	O
end	O
points	O
,	O
is	O
not	O
statistically	O
different	O
after	O
the	O
intraarterial	O
administration	O
of	O
iopamidol	B-CHEMICAL
or	O
iodixanol	B-CHEMICAL
to	O
high	O
-	O
risk	O
patients	O
,	O
with	O
or	O
without	O
diabetes	B-DISEASE
mellitus	I-DISEASE
.	O
Any	O
true	O
difference	O
between	O
the	O
agents	O
is	O
small	O
and	O
not	O
likely	O
to	O
be	O
clinically	O
significant	O
.	O

A	O
novel	O
compound	O
,	O
maltolyl	B-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
coumarate	I-CHEMICAL
,	O
attenuates	O
cognitive	B-DISEASE
deficits	I-DISEASE
and	O
shows	O
neuroprotective	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
dementia	B-DISEASE
models	O
.	O
To	O
develop	O
a	O
novel	O
and	O
effective	O
drug	O
that	O
could	O
enhance	O
cognitive	O
function	O
and	O
neuroprotection	O
,	O
we	O
newly	O
synthesized	O
maltolyl	B-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
coumarate	I-CHEMICAL
by	O
the	O
esterification	O
of	O
maltol	O
and	O
p	O
-	O
coumaric	O
acid	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
maltolyl	B-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
coumarate	I-CHEMICAL
could	O
improve	O
cognitive	O
decline	O
in	O
scopolamine	B-CHEMICAL
-	O
injected	O
rats	O
and	O
in	O
amyloid	O
beta	O
peptide(1	O
-	O
42)-infused	O
rats	O
.	O
Maltolyl	B-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
coumarate	I-CHEMICAL
was	O
found	O
to	O
attenuate	O
cognitive	B-DISEASE
deficits	I-DISEASE
in	O
both	O
rat	O
models	O
using	O
passive	O
avoidance	O
test	O
and	O
to	O
reduce	O
apoptotic	O
cell	O
death	B-DISEASE
observed	O
in	O
the	O
hippocampus	O
of	O
the	O
amyloid	O
beta	O
peptide(1	O
-	O
42)-infused	O
rats	O
.	O
We	O
also	O
examined	O
the	O
neuroprotective	O
effects	O
of	O
maltolyl	B-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
coumarate	I-CHEMICAL
in	O
vitro	O
using	O
SH	O
-	O
SY5Y	O
cells	O
.	O
Cells	O
were	O
pretreated	O
with	O
maltolyl	B-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
coumarate	I-CHEMICAL
,	O
before	O
exposed	O
to	O
amyloid	O
beta	O
peptide(1	O
-	O
42	O
)	O
,	O
glutamate	B-CHEMICAL
or	O
H2O2	O
.	O
We	O
found	O
that	O
maltolyl	B-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
coumarate	I-CHEMICAL
significantly	O
decreased	O
apoptotic	O
cell	O
death	B-DISEASE
and	O
reduced	O
reactive	O
oxygen	B-CHEMICAL
species	O
,	O
cytochrome	O
c	O
release	O
,	O
and	O
caspase	B-CHEMICAL
3	I-CHEMICAL
activation	O
.	O
Taking	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
together	O
,	O
our	O
study	O
suggests	O
that	O
maltolyl	B-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
coumarate	I-CHEMICAL
is	O
a	O
potentially	O
effective	O
candidate	O
against	O
Alzheimer	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
that	O
is	O
characterized	O
by	O
wide	O
spread	O
neuronal	O
death	B-DISEASE
and	O
progressive	O
decline	B-DISEASE
of	I-DISEASE
cognitive	I-DISEASE
function	I-DISEASE
.	O

Interaction	O
between	O
warfarin	B-CHEMICAL
and	O
levofloxacin	B-CHEMICAL
:	O
case	O
series	O
.	O
Warfarin	B-CHEMICAL
is	O
the	O
most	O
widely	O
used	O
oral	O
anticoagulant	O
and	O
is	O
indicated	O
for	O
many	O
clinical	O
conditions	O
.	O
Levofloxacin	B-CHEMICAL
,	O
a	O
fluoroquinolone	O
,	O
is	O
one	O
of	O
the	O
most	O
commonly	O
prescribed	O
antibiotics	O
in	O
clinical	O
practice	O
and	O
is	O
effective	O
against	O
Gram	O
-	O
positive	O
,	O
Gram	O
-	O
negative	O
,	O
and	O
atypical	O
bacteria	O
.	O
While	O
small	O
prospective	O
studies	O
have	O
not	O
revealed	O
any	O
significant	O
drug	O
-	O
drug	O
interaction	O
between	O
warfarin	B-CHEMICAL
and	O
levofloxacin	B-CHEMICAL
,	O
several	O
case	O
reports	O
have	O
indicated	O
that	O
levofloxacin	B-CHEMICAL
may	O
significantly	O
potentiate	O
the	O
anticoagulation	O
effect	O
of	O
warfarin	B-CHEMICAL
.	O
We	O
report	O
3	O
cases	O
of	O
serious	O
bleeding	B-DISEASE
complications	B-DISEASE
that	O
appear	O
to	O
be	O
the	O
result	O
of	O
the	O
interaction	O
between	O
warfarin	B-CHEMICAL
and	O
levofloxacin	B-CHEMICAL
.	O
Physicians	O
should	O
be	O
aware	O
of	O
this	O
potential	O
interaction	O
and	O
use	O
caution	O
when	O
prescribing	O
levofloxacin	B-CHEMICAL
to	O
patients	O
taking	O
warfarin	B-CHEMICAL
.	O

Mutations	O
associated	O
with	O
lamivudine	B-CHEMICAL
-	O
resistance	O
in	O
therapy	O
-	O
na	O
 	O
ve	O
hepatitis	B-DISEASE
B	I-DISEASE
virus	O
(	O
HBV	O
)	O
infected	O
patients	O
with	O
and	O
without	O
HIV	B-DISEASE
co	B-CHEMICAL
-	O
infection	B-DISEASE
:	O
implications	O
for	O
antiretroviral	O
therapy	O
in	O
HBV	O
and	O
HIV	B-DISEASE
co	B-CHEMICAL
-	O
infected	O
South	O
African	O
patients	O
.	O
This	O
was	O
an	O
exploratory	O
study	O
to	O
investigate	O
lamivudine	B-CHEMICAL
-	O
resistant	O
hepatitis	B-DISEASE
B	I-DISEASE
virus	O
(	O
HBV	O
)	O
strains	O
in	O
selected	O
lamivudine	B-CHEMICAL
-	O
na	O
 	O
ve	O
HBV	O
carriers	O
with	O
and	O
without	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	B-DISEASE
)	O
co	B-CHEMICAL
-	O
infection	B-DISEASE
in	O
South	O
African	O
patients	O
.	O
Thirty	O
-	O
five	O
lamivudine	B-CHEMICAL
-	O
na	O
 	O
ve	O
HBV	O
infected	O
patients	O
with	O
or	O
without	O
HIV	B-DISEASE
co	B-CHEMICAL
-	O
infection	B-DISEASE
were	O
studied	O
:	O
15	O
chronic	O
HBV	O
mono	O
-	O
infected	O
patients	O
and	O
20	O
HBV	O
-	O
HIV	B-DISEASE
co	B-CHEMICAL
-	O
infected	O
patients	O
.	O
The	O
latter	O
group	O
was	O
further	O
sub	O
-	O
divided	O
into	O
13	O
occult	O
HBV	O
(	O
HBsAg	O
-	O
negative	O
)	O
and	O
7	O
overt	O
HBV	O
(	O
HBsAg-	O
positive	O
)	O
patients	O
.	O
HBsAg	O
,	O
anti	O
-	O
HBs	O
,	O
anti	O
-	O
HBc	O
,	O
and	O
anti	O
-	O
HIV	B-DISEASE
1/2	O
were	O
determined	O
as	O
part	O
of	O
routine	O
diagnosis	O
using	O
Axsym	O
assays	O
(	O
Abbott	O
Laboratories	O
,	O
North	O
Chicago	O
,	O
IL	O
)	O
.	O
Serum	O
samples	O
were	O
PCR	O
amplified	O
with	O
HBV	O
reverse	O
transcriptase	O
(	O
RT	O
)	O
primers	O
,	O
followed	O
by	O
direct	O
sequencing	O
across	O
the	O
tyrosine	B-CHEMICAL
-	O
methionine	O
-	O
aspartate	O
-	O
aspartate	O
(	O
YMDD	O
)	O
motif	O
of	O
the	O
major	O
catalytic	O
region	O
in	O
the	O
C	O
domain	O
of	O
the	O
HBV	O
RT	O
enzyme	O
.	O
HBV	O
viral	O
load	O
was	O
performed	O
with	O
Amplicor	O
HBV	O
Monitor	O
test	O
v2.0	O
(	O
Roche	O
Diagnostics	O
,	O
Penzberg	O
,	O
Germany	O
)	O
.	O
HBV	O
lamivudine	B-CHEMICAL
-	O
resistant	O
strains	O
were	O
detected	O
in	O
3	O
of	O
15	O
mono	O
-	O
infected	O
chronic	B-DISEASE
hepatitis	I-DISEASE
B	I-DISEASE
patients	O
and	O
10	O
of	O
20	O
HBV	O
-	O
HIV	B-DISEASE
co	B-CHEMICAL
-	O
infected	O
patients	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
constitutes	O
the	O
first	O
report	O
of	O
HBV	O
lamivudine	B-CHEMICAL
-	O
resistant	O
strains	O
in	O
therapy	O
-	O
na	O
 	O
ve	O
HBV	O
-	O
HIV	B-DISEASE
co	B-CHEMICAL
-	O
infected	O
patients	O
.	O
The	O
HBV	O
viral	O
loads	O
for	O
mono	O
-	O
infected	O
and	O
co	B-CHEMICAL
-	O
infected	O
patients	O
ranged	O
from	O
3.32	O
x	O
10(2	O
)	O
to	O
3.82	O
x	O
10(7	O
)	O
and	O
<	O
200	O
to	O
4.40	O
x	O
10(3	O
)	O
copies	O
/	O
ml	O
,	O
respectively	O
.	O
It	O
remains	O
to	O
be	O
seen	O
whether	O
such	O
pre	O
-	O
existing	O
antiviral	O
mutations	O
could	O
result	O
in	O
widespread	O
emergence	O
of	O
HBV	O
resistant	O
strains	O
when	O
lamivudine	B-CHEMICAL
-	O
containing	O
highly	O
active	O
antiretroviral	O
(	O
ARV	O
)	O
treatment	O
(	O
HAART	O
)	O
regimens	O
become	O
widely	O
applied	O
in	O
South	O
Africa	O
,	O
as	O
this	O
is	O
likely	O
to	O
have	O
potential	O
implications	O
in	O
the	O
management	O
of	O
HBV	O
-	O
HIV	B-DISEASE
co	B-CHEMICAL
-	O
infected	O
patients	O
.	O

Sex	O
differences	O
in	O
NMDA	O
antagonist	O
enhancement	O
of	O
morphine	B-CHEMICAL
antihyperalgesia	O
in	O
a	O
capsaicin	B-CHEMICAL
model	O
of	O
persistent	O
pain	B-DISEASE
:	O
comparisons	O
to	O
two	O
models	O
of	O
acute	B-DISEASE
pain	I-DISEASE
.	O
In	O
acute	B-DISEASE
pain	I-DISEASE
models	O
,	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
antagonists	O
enhance	O
the	O
antinociceptive	O
effects	O
of	O
morphine	B-CHEMICAL
to	O
a	O
greater	O
extent	O
in	O
males	O
than	O
females	O
.	O
The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
extend	O
these	O
findings	O
to	O
a	O
persistent	O
pain	B-DISEASE
model	O
which	O
could	O
be	O
distinguished	O
from	O
acute	B-DISEASE
pain	I-DISEASE
models	O
on	O
the	O
basis	O
of	O
the	O
nociceptive	O
fibers	O
activated	O
,	O
neurochemical	O
substrates	O
,	O
and	O
duration	O
of	O
the	O
nociceptive	O
stimulus	O
.	O
To	O
this	O
end	O
,	O
persistent	O
hyperalgesia	B-DISEASE
was	O
induced	O
by	O
administration	O
of	O
capsaicin	B-CHEMICAL
in	O
the	O
tail	O
of	O
gonadally	O
intact	O
F344	O
rats	O
,	O
following	O
which	O
the	O
tail	O
was	O
immersed	O
in	O
a	O
mildly	O
noxious	O
thermal	O
stimulus	O
,	O
and	O
tail	O
-	O
withdrawal	O
latencies	O
measured	O
.	O
For	O
comparison	O
,	O
tests	O
were	O
conducted	O
in	O
two	O
acute	B-DISEASE
pain	I-DISEASE
models	O
,	O
the	O
hotplate	O
and	O
warm	O
water	O
tail	O
-	O
withdrawal	O
procedures	O
.	O
In	O
males	O
,	O
the	O
non	O
-	O
competitive	O
NMDA	O
antagonist	O
dextromethorphan	B-CHEMICAL
enhanced	O
the	O
antihyperalgesic	O
effect	O
of	O
low	O
to	O
moderate	O
doses	O
of	O
morphine	B-CHEMICAL
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O
Across	O
the	O
doses	O
and	O
pretreatment	O
times	O
examined	O
,	O
enhancement	O
was	O
not	O
observed	O
in	O
females	O
.	O
Enhancement	O
of	O
morphine	B-CHEMICAL
antinociception	O
by	O
dextromethorphan	B-CHEMICAL
was	O
seen	O
in	O
both	O
males	O
and	O
females	O
in	O
the	O
acute	B-DISEASE
pain	I-DISEASE
models	O
,	O
with	O
the	O
magnitude	O
of	O
this	O
effect	O
being	O
greater	O
in	O
males	O
.	O
These	O
findings	O
demonstrate	O
a	O
sexually	O
-	O
dimorphic	O
interaction	O
between	O
NMDA	O
antagonists	O
and	O
morphine	B-CHEMICAL
in	O
a	O
persistent	O
pain	B-DISEASE
model	O
that	O
can	O
be	O
distinguished	O
from	O
those	O
observed	O
in	O
acute	B-DISEASE
pain	I-DISEASE
models	O
.	O

Development	O
of	O
proteinuria	B-DISEASE
after	O
switch	O
to	O
sirolimus	B-CHEMICAL
-	O
based	O
immunosuppression	O
in	O
long	O
-	O
term	O
cardiac	O
transplant	O
patients	O
.	O
Calcineurin	O
-	O
inhibitor	O
therapy	O
can	O
lead	O
to	O
renal	B-DISEASE
dysfunction	I-DISEASE
in	O
heart	O
transplantation	O
patients	O
.	O
The	O
novel	O
immunosuppressive	O
(	O
IS	O
)	O
drug	O
sirolmus	O
(	O
Srl	O
)	O
lacks	O
nephrotoxic	B-DISEASE
effects	O
;	O
however	O
,	O
proteinuria	B-DISEASE
associated	O
with	O
Srl	O
has	O
been	O
reported	O
following	O
renal	O
transplantation	O
.	O
In	O
cardiac	O
transplantation	O
,	O
the	O
incidence	O
of	O
proteinuria	B-DISEASE
associated	O
with	O
Srl	O
is	O
unknown	O
.	O
In	O
this	O
study	O
,	O
long	O
-	O
term	O
cardiac	O
transplant	O
patients	O
were	O
switched	O
from	O
cyclosporine	B-CHEMICAL
to	O
Srl	O
-	O
based	O
IS	O
.	O
Concomitant	O
IS	O
consisted	O
of	O
mycophenolate	O
mofetil	O
+	O
/-	O
steroids	B-CHEMICAL
.	O
Proteinuria	B-DISEASE
increased	O
significantly	O
from	O
a	O
median	O
of	O
0.13	O
g	O
/	O
day	O
(	O
range	O
0	O
-	O
5.7	O
)	O
preswitch	O
to	O
0.23	O
g	O
/	O
day	O
(	O
0	O
-	O
9.88	O
)	O
at	O
24	O
months	O
postswitch	O
(	O
p	O
=	O
0.0024	O
)	O
.	O
Before	O
the	O
switch	O
,	O
11.5	O
%	O
of	O
patients	O
had	O
high	O
-	O
grade	O
proteinuria	B-DISEASE
(	O
>	O
1.0	O
g	O
/	O
day	O
)	O
;	O
this	O
increased	O
to	O
22.9	O
%	O
postswitch	O
(	O
p	O
=	O
0.006	O
)	O
.	O
ACE	B-CHEMICAL
inhibitor	I-CHEMICAL
and	O
angiotensin	O
-	O
releasing	O
blocker	O
(	O
ARB	O
)	O
therapy	O
reduced	O
proteinuria	B-DISEASE
development	O
.	O
Patients	O
without	O
proteinuria	B-DISEASE
had	O
increased	O
renal	O
function	O
(	O
median	O
42.5	O
vs.	O
64.1	O
,	O
p	O
=	O
0.25	O
)	O
,	O
whereas	O
patients	O
who	O
developed	O
high	O
-	O
grade	O
proteinuria	B-DISEASE
showed	O
decreased	B-DISEASE
renal	I-DISEASE
function	I-DISEASE
at	O
the	O
end	O
of	O
follow	O
-	O
up	O
(	O
median	O
39.6	O
vs.	O
29.2	O
,	O
p	O
=	O
0.125	O
)	O
.	O
Thus	O
,	O
proteinuria	B-DISEASE
may	O
develop	O
in	O
cardiac	O
transplant	O
patients	O
after	O
switch	O
to	O
Srl	O
,	O
which	O
may	O
have	O
an	O
adverse	O
effect	O
on	O
renal	O
function	O
in	O
these	O
patients	O
.	O
Srl	O
should	O
be	O
used	O
with	O
ACEi	O
/	O
ARB	O
therapy	O
and	O
patients	O
monitored	O
for	O
proteinuria	B-DISEASE
and	O
increased	O
renal	B-DISEASE
dysfunction	I-DISEASE
.	O

Synthesis	O
of	O
N	O
-	O
pyrimidinyl-2	O
-	O
phenoxyacetamides	O
as	O
adenosine	O
A2A	O
receptor	O
antagonists	O
.	O
A	O
series	O
of	O
N	O
-	O
pyrimidinyl-2	O
-	O
phenoxyacetamide	O
adenosine	O
A(2A	O
)	O
antagonists	O
is	O
described	O
.	O
SAR	O
studies	O
led	O
to	O
compound	O
14	O
with	O
excellent	O
potency	O
(	O
K(i	O
)	O
=	O
0.4	O
nM	O
)	O
,	O
selectivity	O
(	O
A(1)/A(2A	O
)	O
>	O
100	O
)	O
,	O
and	O
efficacy	O
(	O
MED	O
10	O
mg	O
/	O
kg	O
p.o	O
.	O
)	O
in	O
the	O
rat	O
haloperidol	B-CHEMICAL
-	O
induced	O
catalepsy	B-DISEASE
model	O
for	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
.	O

Methamphetamine	B-CHEMICAL
-	O
induced	O
neurotoxicity	B-DISEASE
and	O
microglial	O
activation	O
are	O
not	O
mediated	O
by	O
fractalkine	O
receptor	O
signaling	O
.	O
Methamphetamine	B-CHEMICAL
(	O
METH	O
)	O
damages	O
dopamine	B-CHEMICAL
(	O
DA	O
)	O
nerve	O
endings	O
by	O
a	O
process	O
that	O
has	O
been	O
linked	O
to	O
microglial	O
activation	O
but	O
the	O
signaling	O
pathways	O
that	O
mediate	O
this	O
response	O
have	O
not	O
yet	O
been	O
delineated	O
.	O
Cardona	O
et	O
al	O
.	O
[	O
Nat	O
.	O
Neurosci	O
.	O
9	O
(	O
2006	O
)	O
,	O
917	O
]	O
recently	O
identified	O
the	O
microglial	O
-	O
specific	O
fractalkine	O
receptor	O
(	O
CX3CR1	O
)	O
as	O
an	O
important	O
mediator	O
of	O
MPTP	O
-	O
induced	O
neurodegeneration	O
of	O
DA	O
neurons	O
.	O
Because	O
the	O
CNS	O
damage	O
caused	O
by	O
METH	O
and	O
MPTP	O
is	O
highly	O
selective	O
for	O
the	O
DA	O
neuronal	O
system	O
in	O
mouse	O
models	O
of	O
neurotoxicity	B-DISEASE
,	O
we	O
hypothesized	O
that	O
the	O
CX3CR1	O
plays	O
a	O
role	O
in	O
METH	O
-	O
induced	O
neurotoxicity	B-DISEASE
and	O
microglial	O
activation	O
.	O
Mice	O
in	O
which	O
the	O
CX3CR1	O
gene	O
has	O
been	O
deleted	O
and	O
replaced	O
with	O
a	O
cDNA	O
encoding	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
eGFP	O
)	O
were	O
treated	O
with	O
METH	O
and	O
examined	O
for	O
striatal	O
neurotoxicity	B-DISEASE
.	O
METH	O
depleted	O
DA	O
,	O
caused	O
microglial	O
activation	O
,	O
and	O
increased	O
body	O
temperature	O
in	O
CX3CR1	O
knockout	O
mice	O
to	O
the	O
same	O
extent	O
and	O
over	O
the	O
same	O
time	O
course	O
seen	O
in	O
wild	O
-	O
type	O
controls	O
.	O
The	O
effects	O
of	O
METH	O
in	O
CX3CR1	O
knockout	O
mice	O
were	O
not	O
gender	O
-	O
dependent	O
and	O
did	O
not	O
extend	O
beyond	O
the	O
striatum	O
.	O
Striatal	O
microglia	O
expressing	O
eGFP	O
constitutively	O
show	O
morphological	O
changes	O
after	O
METH	O
that	O
are	O
characteristic	O
of	O
activation	O
.	O
This	O
response	O
was	O
restricted	O
to	O
the	O
striatum	O
and	O
contrasted	O
sharply	O
with	O
unresponsive	O
eGFP	O
-	O
microglia	O
in	O
surrounding	O
brain	O
areas	O
that	O
are	O
not	O
damaged	O
by	O
METH	O
.	O
We	O
conclude	O
from	O
these	O
studies	O
that	O
CX3CR1	O
signaling	O
does	O
not	O
modulate	O
METH	O
neurotoxicity	B-DISEASE
or	O
microglial	O
activation	O
.	O
Furthermore	O
,	O
it	O
appears	O
that	O
striatal	O
-	O
resident	O
microglia	O
respond	O
to	O
METH	O
with	O
an	O
activation	O
cascade	O
and	O
then	O
return	O
to	O
a	O
surveying	O
state	O
without	O
undergoing	O
apoptosis	O
or	O
migration	O
.	O

Recovery	O
of	O
tacrolimus	B-CHEMICAL
-	O
associated	O
brachial	B-DISEASE
neuritis	I-DISEASE
after	O
conversion	O
to	O
everolimus	B-CHEMICAL
in	O
a	O
pediatric	O
renal	O
transplant	O
recipient	O
--	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O
TAC	O
has	O
been	O
shown	O
to	O
be	O
a	O
potent	O
immunosuppressive	O
agent	O
for	O
solid	O
organ	O
transplantation	O
in	O
pediatrics	O
.	O
Neurotoxicity	B-DISEASE
is	O
a	O
potentially	O
serious	O
toxic	O
effect	O
.	O
It	O
is	O
characterized	O
by	O
encephalopathy	B-DISEASE
,	O
headaches	B-DISEASE
,	O
seizures	B-DISEASE
,	O
or	O
neurological	O
deficits	O
.	O
Here	O
,	O
we	O
describe	O
an	O
eight	O
-	O
and	O
-	O
a	O
-	O
half	O
-	O
yr	O
-	O
old	O
male	O
renal	O
transplant	O
recipient	O
with	O
right	O
BN	O
.	O
MRI	O
demonstrated	O
hyperintense	O
T2	O
signals	O
in	O
the	O
cervical	O
cord	O
and	O
right	O
brachial	O
plexus	O
roots	O
indicative	O
of	O
both	O
myelitis	B-DISEASE
and	O
right	O
brachial	B-DISEASE
plexitis	I-DISEASE
.	O
Symptoms	O
persisted	O
for	O
three	O
months	O
despite	O
TAC	O
dose	O
reduction	O
,	O
administration	O
of	O
IVIG	O
and	O
four	O
doses	O
of	O
methylprednisolone	B-CHEMICAL
pulse	O
therapy	O
.	O
Improvement	O
and	O
eventually	O
full	O
recovery	O
only	O
occurred	O
after	O
TAC	O
was	O
completely	O
discontinued	O
and	O
successfully	O
replaced	O
by	O
everolimus	B-CHEMICAL
.	O

Valvular	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
in	O
patients	O
with	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
treated	O
with	O
pergolide	B-CHEMICAL
.	O
Course	O
following	O
treatment	O
modifications	O
.	O
Valvular	B-DISEASE
heart	I-DISEASE
abnormalities	I-DISEASE
have	O
been	O
reported	O
in	O
patients	O
with	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
(	O
PD	O
)	O
treated	O
with	O
pergolide	B-CHEMICAL
.	O
However	O
,	O
the	O
incidence	O
and	O
severity	O
of	O
these	O
abnormalities	O
vary	O
from	O
study	O
to	O
study	O
and	O
their	O
course	O
after	O
drug	O
withdrawal	O
has	O
not	O
been	O
systematically	O
assessed	O
.	O
OBJECTIVES	O
:	O
To	O
estimate	O
the	O
frequency	O
and	O
severity	O
of	O
valvular	O
heart	O
abnormality	O
and	O
its	O
possible	O
reversibility	O
after	O
drug	O
withdrawal	O
in	O
a	O
case	O
-	O
control	O
study	O
.	O
METHODS	O
:	O
All	O
PD	O
patients	O
in	O
the	O
Amiens	O
area	O
treated	O
with	O
pergolide	B-CHEMICAL
were	O
invited	O
to	O
attend	O
a	O
cardiologic	O
assessment	O
including	O
transthoracic	O
echocardiography	O
.	O
Thirty	O
PD	O
patients	O
participated	O
in	O
the	O
study	O
.	O
A	O
second	O
echocardiography	O
was	O
performed	O
(	O
median	O
interval	O
:	O
13	O
months	O
)	O
after	O
pergolide	B-CHEMICAL
withdrawal	O
(	O
n=10	O
patients	O
)	O
.	O
Controls	O
were	O
age-	O
and	O
sex	O
-	O
matched	O
non	O
-	O
PD	O
patients	O
referred	O
to	O
the	O
cardiology	O
department	O
.	O
RESULTS	O
:	O
Compared	O
to	O
controls	O
,	O
aortic	B-DISEASE
regurgitation	I-DISEASE
(	O
OR	O
:	O
3.1	O
;	O
95	O
%	O
IC	O
:	O
1.1	O
-	O
8.8	O
)	O
and	O
mitral	B-DISEASE
regurgitation	I-DISEASE
(	O
OR	O
:	O
10.7	O
;	O
95	O
%	O
IC	O
:	O
2.1	O
-	O
53	O
)	O
were	O
more	O
frequent	O
in	O
PD	O
patients	O
(	O
tricuspid	O
:	O
NS	O
)	O
.	O
The	O
number	O
of	O
affected	O
valves	O
(	O
n=2.4+/-0.7	O
)	O
and	O
the	O
sum	O
of	O
regurgitation	O
grades	O
(	O
n=2.8+/-1.09	O
)	O
were	O
higher	O
(	O
p=0.008	O
and	O
p=0.006	O
,	O
respectively	O
)	O
in	O
the	O
pergolide	B-CHEMICAL
group	O
.	O
Severity	O
of	O
regurgitation	O
was	O
not	O
correlated	O
with	O
pergolide	B-CHEMICAL
cumulative	O
dose	O
.	O
A	O
restrictive	O
pattern	O
of	O
valvular	O
regurgitation	O
,	O
suggestive	O
of	O
the	O
role	O
of	O
pergolide	B-CHEMICAL
,	O
was	O
observed	O
in	O
12/30	O
(	O
40	O
%	O
)	O
patients	O
including	O
two	O
with	O
heart	B-DISEASE
failure	I-DISEASE
.	O
Pergolide	B-CHEMICAL
was	O
discontinued	O
in	O
10	O
patients	O
with	O
valvular	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
,	O
resulting	O
in	O
a	O
lower	O
regurgitation	O
grade	O
(	O
p=0.01	O
)	O
at	O
the	O
second	O
transthoracic	O
echocardiography	O
and	O
the	O
two	O
patients	O
with	O
heart	B-DISEASE
failure	I-DISEASE
returned	O
to	O
nearly	O
normal	O
clinical	O
examination	O
.	O
This	O
study	O
supports	O
the	O
high	O
frequency	O
of	O
restrictive	O
valve	O
regurgitation	O
in	O
PD	O
patients	O
treated	O
with	O
pergolide	B-CHEMICAL
and	O
reveals	O
that	O
a	O
significant	O
improvement	O
is	O
usual	O
when	O
the	O
treatment	O
is	O
converted	O
to	O
non	O
-	O
ergot	O
dopamine	B-CHEMICAL
agonists	O
.	O

Adverse	O
effects	O
of	O
topical	O
papaverine	B-CHEMICAL
on	O
auditory	O
nerve	O
function	O
.	O
BACKGROUND	O
:	O
Papaverine	B-CHEMICAL
hydrochloride	O
is	O
a	O
direct	O
-	O
acting	O
vasodilator	O
used	O
to	O
manage	O
vasospasm	B-DISEASE
during	O
various	O
neurosurgical	O
operations	O
.	O
Transient	O
cranial	B-DISEASE
nerve	I-DISEASE
dysfunction	I-DISEASE
has	O
been	O
described	O
in	O
a	O
few	O
cases	O
with	O
topical	O
papaverine	B-CHEMICAL
.	O
This	O
study	O
supports	O
previous	O
reports	O
and	O
provides	O
neurophysiological	O
evidence	O
of	O
an	O
adverse	O
effect	O
on	O
the	O
auditory	O
nerve	O
.	O
METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
review	O
of	O
70	O
consecutive	O
microvascular	O
decompression	O
operations	O
and	O
studied	O
those	O
patients	O
who	O
received	O
topical	O
papaverine	B-CHEMICAL
for	O
vasospasm	B-DISEASE
.	O
Topical	O
papaverine	B-CHEMICAL
was	O
used	O
as	O
a	O
direct	O
therapeutic	O
action	O
to	O
manage	O
vasospasm	B-DISEASE
in	O
a	O
total	O
of	O
11	O
patients	O
.	O
The	O
timing	O
of	O
papaverine	B-CHEMICAL
application	O
and	O
ongoing	O
operative	O
events	O
was	O
reviewed	O
relative	O
to	O
changes	O
in	O
neurophysiological	O
recordings	O
.	O
Brainstem	O
auditory	O
evoked	O
potentials	O
(	O
BAEPs	O
)	O
were	O
routinely	O
used	O
to	O
monitor	O
cochlear	O
nerve	O
function	O
during	O
these	O
operations	O
.	O
FINDINGS	O
:	O
A	O
temporal	O
relationship	O
was	O
found	O
between	O
topical	O
papaverine	B-CHEMICAL
and	O
BAEP	O
changes	O
leading	O
to	O
complete	O
waveform	O
loss	O
.	O
The	O
average	O
temporal	O
delay	O
between	O
papaverine	B-CHEMICAL
and	O
the	O
onset	O
of	O
an	O
adverse	O
BAEP	O
change	O
was	O
5	O
min	O
.	O
In	O
10	O
of	O
11	O
patients	O
,	O
BAEP	O
waves	O
II	O
/	O
III	O
-	O
V	O
completely	O
disappeared	O
within	O
2	O
to	O
25	O
min	O
after	O
papaverine	B-CHEMICAL
.	O
Eight	O
of	O
these	O
10	O
patients	O
had	O
complete	O
loss	O
of	O
BAEP	O
waveforms	O
within	O
10	O
min	O
.	O
One	O
patient	O
showed	O
no	O
recovery	O
of	O
later	O
waves	O
and	O
a	O
delayed	O
profound	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O
The	O
average	O
recovery	O
time	O
of	O
BAEP	O
waveforms	O
to	O
pre	O
-	O
papaverine	B-CHEMICAL
baseline	O
values	O
was	O
39	O
min	O
.	O
CONCLUSIONS	O
:	O
Topical	O
papaverine	B-CHEMICAL
for	O
the	O
treatment	O
of	O
vasospasm	B-DISEASE
was	O
associated	O
with	O
the	O
onset	O
of	O
a	O
transient	O
disturbance	O
in	O
neurophysiological	O
function	O
of	O
the	O
ascending	O
auditory	O
brainstem	O
pathway	O
.	O
The	O
complete	O
disappearance	O
of	O
BAEP	O
waveforms	O
with	O
a	O
consistent	O
temporal	O
delay	O
suggests	O
a	O
possible	O
adverse	B-DISEASE
effect	I-DISEASE
on	I-DISEASE
the	I-DISEASE
proximal	I-DISEASE
eighth	I-DISEASE
nerve	I-DISEASE
.	O
Recommendations	O
to	O
avoid	O
potential	O
cranial	B-DISEASE
nerve	I-DISEASE
deficits	I-DISEASE
from	O
papaverine	B-CHEMICAL
are	O
provided	O
.	O

Massive	O
proteinuria	B-DISEASE
and	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
after	O
oral	O
bisphosphonate	O
(	O
alendronate	B-CHEMICAL
)	O
administration	O
in	O
a	O
patient	O
with	O
focal	O
segmental	B-DISEASE
glomerulosclerosis	I-DISEASE
.	O
A	O
61	O
-	O
year	O
-	O
old	O
Japanese	O
man	O
with	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
due	O
to	O
focal	O
segmental	B-DISEASE
glomerulosclerosis	I-DISEASE
was	O
initially	O
responding	O
well	O
to	O
steroid	B-CHEMICAL
therapy	O
.	O
The	O
amount	O
of	O
daily	O
urinary	O
protein	O
decreased	O
from	O
15.6	O
to	O
2.8	O
g.	O
Within	O
14	O
days	O
of	O
the	O
oral	O
bisphosphonate	O
(	O
alendronate	B-CHEMICAL
sodium	B-CHEMICAL
)	O
administration	O
,	O
the	O
amount	O
of	O
daily	O
urinary	O
protein	O
increased	O
rapidly	O
up	O
to	O
12.8	O
g	O
with	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
.	O
After	O
discontinuing	O
the	O
oral	O
alendronate	B-CHEMICAL
,	O
the	O
patient	O
underwent	O
six	O
cycles	O
of	O
hemodialysis	O
and	O
four	O
cycles	O
of	O
LDL	O
apheresis	O
.	O
Urinary	O
volume	O
and	O
serum	O
creatinine	B-CHEMICAL
levels	O
recovered	O
to	O
the	O
normal	O
range	O
,	O
with	O
urinary	O
protein	O
disappearing	O
completely	O
within	O
40	O
days	O
.	O
This	O
report	O
demonstrates	O
that	O
not	O
only	O
intravenous	O
,	O
but	O
also	O
oral	O
bisphosphonates	O
can	O
aggravate	O
proteinuria	B-DISEASE
and	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
.	O

Serum-	O
and	O
glucocorticoid	O
-	O
inducible	O
kinase	O
1	O
in	O
doxorubicin	B-CHEMICAL
-	O
induced	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
.	O
Doxorubicin	B-CHEMICAL
-	O
induced	O
nephropathy	B-DISEASE
leads	O
to	O
epithelial	O
sodium	B-CHEMICAL
channel	O
(	O
ENaC)-dependent	O
volume	O
retention	O
and	O
renal	O
fibrosis	B-DISEASE
.	O
The	O
aldosterone	O
-	O
sensitive	O
serum-	O
and	O
glucocorticoid	O
-	O
inducible	O
kinase	O
SGK1	O
has	O
been	O
shown	O
to	O
participate	O
in	O
the	O
stimulation	O
of	O
ENaC	O
and	O
to	O
mediate	O
renal	O
fibrosis	B-DISEASE
following	O
mineralocorticoid	O
and	O
salt	B-CHEMICAL
excess	O
.	O
The	O
present	O
study	O
was	O
performed	O
to	O
elucidate	O
the	O
role	O
of	O
SGK1	O
in	O
the	O
volume	O
retention	O
and	O
fibrosis	B-DISEASE
during	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
.	O
To	O
this	O
end	O
,	O
doxorubicin	B-CHEMICAL
(	O
15	O
mug	O
/	O
g	O
body	O
wt	O
)	O
was	O
injected	O
intravenously	O
into	O
gene	O
-	O
targeted	O
mice	O
lacking	O
SGK1	O
(	O
sgk1(-/-	O
)	O
)	O
and	O
their	O
wild	O
-	O
type	O
littermates	O
(	O
sgk1(+/+	O
)	O
)	O
.	O
Doxorubicin	B-CHEMICAL
treatment	O
resulted	O
in	O
heavy	O
proteinuria	B-DISEASE
(	O
>	O
100	O
mg	O
protein	O
/	O
mg	O
crea	O
)	O
in	O
15/44	O
of	O
sgk1(+/+	O
)	O
and	O
15/44	O
of	O
sgk1(-/-	O
)	O
mice	O
leading	O
to	O
severe	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
with	O
ascites	B-DISEASE
,	O
lipidemia	O
,	O
and	O
hypoalbuminemia	B-DISEASE
in	O
both	O
genotypes	O
.	O
Plasma	O
aldosterone	O
levels	O
increased	O
in	O
nephrotic	B-DISEASE
mice	O
of	O
both	O
genotypes	O
and	O
was	O
followed	O
by	O
increased	O
SGK1	O
protein	O
expression	O
in	O
sgk1(+/+	O
)	O
mice	O
.	O
Urinary	O
sodium	B-CHEMICAL
excretion	O
reached	O
signficantly	O
lower	O
values	O
in	O
sgk1(+/+	O
)	O
mice	O
(	O
15	O
+	O
/-	O
5	O
mumol	O
/	O
mg	O
crea	O
)	O
than	O
in	O
sgk1(-/-	O
)	O
mice	O
(	O
35	O
+	O
/-	O
5	O
mumol	O
/	O
mg	O
crea	O
)	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
higher	O
body	B-DISEASE
weight	I-DISEASE
gain	O
in	O
sgk1(+/+	O
)	O
compared	O
with	O
sgk1(-/-	O
)	O
mice	O
(	O
+6.6	O
+	O
/-	O
0.7	O
vs.	O
+4.1	O
+	O
/-	O
0.8	O
g	O
)	O
.	O
During	O
the	O
course	O
of	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
,	O
serum	O
urea	B-CHEMICAL
concentrations	O
increased	O
significantly	O
faster	O
in	O
sgk1(-/-	O
)	O
mice	O
than	O
in	O
sgk1(+/+	O
)	O
mice	O
leading	O
to	O
uremia	B-DISEASE
and	O
a	O
reduced	O
median	O
survival	O
in	O
sgk1(-/-	O
)	O
mice	O
(	O
29	O
vs.	O
40	O
days	O
in	O
sgk1(+/+	O
)	O
mice	O
)	O
.	O
In	O
conclusion	O
,	O
gene	O
-	O
targeted	O
mice	O
lacking	O
SGK1	O
showed	O
blunted	O
volume	O
retention	O
,	O
yet	O
were	O
not	O
protected	O
against	O
renal	O
fibrosis	B-DISEASE
during	O
experimental	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
.	O

Severe	O
and	O
long	O
lasting	O
cholestasis	B-DISEASE
after	O
high	O
-	O
dose	O
co	B-CHEMICAL
-	O
trimoxazole	O
treatment	O
for	O
Pneumocystis	B-DISEASE
pneumonia	I-DISEASE
in	O
HIV	B-DISEASE
-	O
infected	O
patients	O
--	O
a	O
report	O
of	O
two	O
cases	O
.	O
Pneumocystis	B-DISEASE
pneumonia	I-DISEASE
(	O
PCP	O
)	O
,	O
a	O
common	O
opportunistic	O
infection	B-DISEASE
in	O
HIV	B-DISEASE
-	O
infected	O
individuals	O
,	O
is	O
generally	O
treated	O
with	O
high	O
doses	O
of	O
co	B-CHEMICAL
-	O
trimoxazole	O
.	O
However	O
,	O
treatment	O
is	O
often	O
limited	O
by	O
adverse	O
effects	O
.	O
Here	O
,	O
we	O
report	O
two	O
cases	O
of	O
severely	O
immunocompromised	O
HIV	B-DISEASE
-	O
infected	O
patients	O
who	O
developed	O
severe	O
intrahepatic	O
cholestasis	B-DISEASE
,	O
and	O
in	O
one	O
patient	O
lesions	O
mimicking	O
liver	B-DISEASE
abscess	I-DISEASE
formation	O
on	O
radiologic	O
exams	O
,	O
during	O
co	B-CHEMICAL
-	O
trimoxazole	O
treatment	O
for	O
PCP	O
.	O
Whereas	O
patient	O
1	O
showed	O
lesions	O
of	O
up	O
to	O
1	O
cm	B-DISEASE
readily	O
detectable	O
on	O
magnetic	O
resonance	O
imaging	O
under	O
prolonged	O
co	B-CHEMICAL
-	O
trimoxazole	O
treatment	O
,	O
therapy	O
of	O
patient	O
2	O
was	O
switched	O
early	O
.	O

Clinically	O
significant	O
proteinuria	B-DISEASE
following	O
the	O
administration	O
of	O
sirolimus	B-CHEMICAL
to	O
renal	O
transplant	O
recipients	O
.	O
BACKGROUND	O
:	O
Sirolimus	B-CHEMICAL
is	O
the	O
latest	O
immunosuppressive	O
agent	O
used	O
to	O
prevent	O
rejection	O
,	O
and	O
may	O
have	O
less	O
nephrotoxicity	B-DISEASE
than	O
calcineurin	O
inhibitor	O
(	O
CNI)-based	O
regimens	O
.	O
To	O
date	O
there	O
has	O
been	O
little	O
documentation	O
of	O
clinically	O
significant	O
proteinuria	B-DISEASE
linked	O
with	O
the	O
use	O
of	O
sirolimus	B-CHEMICAL
.	O
We	O
have	O
encountered	O
several	O
patients	O
who	O
developed	O
substantial	O
proteinuria	B-DISEASE
associated	O
with	O
sirolimus	B-CHEMICAL
use	O
.	O
In	O
each	O
patient	O
,	O
the	O
close	O
temporal	O
association	O
between	O
the	O
commencement	O
of	O
sirolimus	B-CHEMICAL
therapy	O
and	O
proteinuria	B-DISEASE
implicated	O
sirolimus	B-CHEMICAL
as	O
the	O
most	O
likely	O
etiology	O
of	O
the	O
proteinuria	B-DISEASE
.	O
METHODS	O
:	O
We	O
analyzed	O
the	O
clinical	O
and	O
laboratory	O
information	O
available	O
for	O
all	O
119	O
patients	O
transplanted	O
at	O
the	O
Washington	O
Hospital	O
Center	O
between	O
1999	O
-	O
2003	O
for	O
whom	O
sirolimus	B-CHEMICAL
was	O
a	O
component	O
of	O
their	O
immunosuppressant	O
regimen	O
.	O
In	O
these	O
patients	O
,	O
the	O
magnitude	O
of	O
proteinuria	B-DISEASE
was	O
assessed	O
on	O
morning	O
urine	O
samples	O
by	O
turbidometric	O
measurement	O
or	O
random	O
urine	O
protein	O
:	O
creatinine	B-CHEMICAL
ratios	O
,	O
an	O
estimate	O
of	O
grams	O
of	O
proteinuria	B-DISEASE
/	O
day	O
.	O
Laboratory	O
results	O
were	O
compared	O
between	O
prior	O
,	O
during	O
and	O
following	O
sirolimus	B-CHEMICAL
use	O
.	O
RESULTS	O
:	O
Twenty	O
-	O
eight	O
patients	O
(	O
24	O
%	O
)	O
developed	O
increased	O
proteinuria	B-DISEASE
from	O
baseline	O
during	O
their	O
post	O
-	O
transplantation	O
course	O
.	O
In	O
21	O
patients	O
an	O
alternative	O
cause	O
of	O
proteinuria	B-DISEASE
was	O
either	O
obvious	O
or	O
insufficient	O
data	O
was	O
available	O
to	O
be	O
conclusive	O
.	O
In	O
7	O
of	O
the	O
28	O
patients	O
there	O
was	O
a	O
striking	O
temporal	O
association	O
between	O
the	O
initiation	O
of	O
sirolimus	B-CHEMICAL
and	O
the	O
development	O
of	O
nephrotic	B-DISEASE
-	O
range	O
proteinuria	B-DISEASE
.	O
Proteinuria	B-DISEASE
correlated	O
most	O
strongly	O
with	O
sirolimus	B-CHEMICAL
therapy	O
when	O
compared	O
to	O
other	O
demographic	O
and	O
clinical	O
variables	O
.	O
In	O
most	O
patients	O
,	O
discontinuation	O
of	O
sirolimus	B-CHEMICAL
resulted	O
in	O
a	O
decrease	O
,	O
but	O
not	O
resolution	O
,	O
of	O
proteinuria	B-DISEASE
.	O
CONCLUSIONS	O
:	O
Sirolimus	B-CHEMICAL
induces	O
or	O
aggravates	O
pre	O
-	O
existing	O
proteinuria	B-DISEASE
in	O
an	O
unpredictable	O
subset	O
of	O
renal	O
allograft	O
recipients	O
.	O
Proteinuria	B-DISEASE
may	O
improve	O
,	O
but	O
does	O
not	O
resolve	O
,	O
when	O
sirolimus	B-CHEMICAL
is	O
withdrawn	O
.	O

Comparative	O
cognitive	O
and	O
subjective	O
side	O
effects	O
of	O
immediate	O
-	O
release	O
oxycodone	B-CHEMICAL
in	O
healthy	O
middle	O
-	O
aged	O
and	O
older	O
adults	O
.	O
This	O
study	O
measured	O
the	O
objective	O
and	O
subjective	O
neurocognitive	O
effects	O
of	O
a	O
single	O
10	O
-	O
mg	O
dose	O
of	O
immediate	O
-	O
release	O
oxycodone	B-CHEMICAL
in	O
healthy	O
,	O
older	O
(	O
>	O
65	O
years	O
)	O
,	O
and	O
middle	O
-	O
aged	O
(	O
35	O
to	O
55	O
years	O
)	O
adults	O
who	O
were	O
not	O
suffering	O
from	O
chronic	O
or	O
significant	O
daily	O
pain	B-DISEASE
.	O
Seventy	O
-	O
one	O
participants	O
completed	O
2	O
separate	O
study	O
days	O
and	O
were	O
blind	B-DISEASE
to	O
medication	O
condition	O
(	O
placebo	O
,	O
10	O
-	O
mg	O
oxycodone	B-CHEMICAL
)	O
.	O
Plasma	O
oxycodone	B-CHEMICAL
concentration	O
peaked	O
between	O
60	O
and	O
90	O
minutes	O
postdose	O
(	O
P	O
<	O
.01	O
)	O
and	O
pupil	O
size	O
,	O
an	O
indication	O
of	O
physiological	O
effects	O
of	O
the	O
medication	O
,	O
peaked	O
at	O
approximately	O
90	O
to	O
120	O
minutes	O
postdose	O
(	O
P	O
<	O
.01	O
)	O
.	O
Significant	O
declines	O
in	O
simple	O
and	O
sustained	O
attention	O
,	O
working	O
memory	O
,	O
and	O
verbal	O
memory	O
were	O
observed	O
at	O
1	O
hour	O
postdose	O
compared	O
to	O
baseline	O
for	O
both	O
age	O
groups	O
with	O
a	O
trend	O
toward	O
return	O
to	O
baseline	O
by	O
5	O
hours	O
postdose	O
.	O
For	O
almost	O
all	O
cognitive	O
measures	O
,	O
there	O
were	O
no	O
medication	O
by	O
age	O
-	O
interaction	O
effects	O
,	O
which	O
indicates	O
that	O
the	O
2	O
age	O
groups	O
exhibited	O
similar	O
responses	O
to	O
the	O
medication	O
challenge	O
.	O
This	O
study	O
suggests	O
that	O
for	O
healthy	O
older	O
adults	O
who	O
are	O
not	O
suffering	O
from	O
chronic	B-DISEASE
pain	I-DISEASE
,	O
neurocognitive	O
and	O
pharmacodynamic	O
changes	O
in	O
response	O
to	O
a	O
10	O
-	O
mg	O
dose	O
of	O
immediate	O
-	O
release	O
oxycodone	B-CHEMICAL
are	O
similar	O
to	O
those	O
observed	O
for	O
middle	O
-	O
aged	O
adults	O
.	O
PERSPECTIVE	O
:	O
Study	O
findings	O
indicate	O
that	O
the	O
metabolism	O
,	O
neurocognitive	O
effects	O
,	O
and	O
physical	O
side	O
effects	O
of	O
oral	O
oxycodone	B-CHEMICAL
are	O
similar	O
for	O
healthy	O
middle	O
-	O
aged	O
and	O
older	O
adults	O
.	O
Therefore	O
,	O
clinicians	O
should	O
not	O
avoid	O
prescribing	O
oral	O
opioids	O
to	O
older	O
adults	O
based	O
on	O
the	O
belief	O
that	O
older	O
adults	O
are	O
at	O
higher	O
risk	O
for	O
side	O
effects	O
than	O
younger	O
adults	O
.	O

Normalizing	O
effects	O
of	O
modafinil	B-CHEMICAL
on	O
sleep	O
in	O
chronic	O
cocaine	B-CHEMICAL
users	O
.	O
OBJECTIVE	O
:	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
morning	O
-	O
dosed	O
modafinil	B-CHEMICAL
on	O
sleep	O
and	O
daytime	B-DISEASE
sleepiness	I-DISEASE
in	O
chronic	O
cocaine	B-CHEMICAL
users	O
.	O
METHOD	O
:	O
Twenty	O
cocaine	B-CHEMICAL
-	O
dependent	O
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
modafinil	B-CHEMICAL
,	O
400	O
mg	O
(	O
N=10	O
)	O
,	O
or	O
placebo	O
(	O
N=10	O
)	O
every	O
morning	O
at	O
7:30	O
a.m.	O
for	O
16	O
days	O
in	O
an	O
inpatient	O
,	O
double	O
-	O
blind	B-DISEASE
randomized	O
trial	O
.	O
Participants	O
underwent	O
polysomnographic	O
sleep	O
recordings	O
on	O
days	O
1	O
to	O
3	O
,	O
7	O
to	O
9	O
,	O
and	O
14	O
to	O
16	O
(	O
first	O
,	O
second	O
,	O
and	O
third	O
weeks	O
of	O
abstinence	O
)	O
.	O
The	O
Multiple	O
Sleep	O
Latency	O
Test	O
was	O
performed	O
at	O
11:30	O
a.m.	O
,	O
2:00	O
p.m.	O
,	O
and	O
4:30	O
p.m.	O
on	O
days	O
2	O
,	O
8	O
,	O
and	O
15	O
.	O
For	O
comparison	O
of	O
sleep	O
architecture	O
variables	O
,	O
12	O
healthy	O
comparison	O
participants	O
underwent	O
a	O
single	O
night	O
of	O
experimental	O
polysomnography	O
that	O
followed	O
1	O
night	O
of	O
accommodation	O
polysomnography	O
.	O
RESULTS	O
:	O
Progressive	O
abstinence	O
from	O
cocaine	B-CHEMICAL
was	O
associated	O
with	O
worsening	O
of	O
all	O
measured	O
polysomnographic	O
sleep	O
outcomes	O
.	O
Compared	O
with	O
placebo	O
,	O
modafinil	B-CHEMICAL
decreased	O
nighttime	O
sleep	O
latency	O
and	O
increased	O
slow	O
-	O
wave	O
sleep	O
time	O
in	O
cocaine	B-CHEMICAL
-	O
dependent	O
participants	O
.	O
The	O
effect	O
of	O
modafinil	B-CHEMICAL
interacted	O
with	O
the	O
abstinence	O
week	O
and	O
was	O
associated	O
with	O
longer	O
total	O
sleep	O
time	O
and	O
shorter	O
REM	O
sleep	O
latency	O
in	O
the	O
third	O
week	O
of	O
abstinence	O
.	O
Comparison	O
of	O
slow	O
-	O
wave	O
sleep	O
time	O
,	O
total	O
sleep	O
time	O
,	O
and	O
sleep	O
latency	O
in	O
cocaine	B-CHEMICAL
-	O
dependent	O
and	O
healthy	O
participants	O
revealed	O
a	O
normalizing	O
effect	O
of	O
modafinil	B-CHEMICAL
in	O
cocaine	B-CHEMICAL
-	O
dependent	O
participants	O
.	O
Modafinil	B-CHEMICAL
was	O
associated	O
with	O
increased	O
daytime	O
sleep	O
latency	O
,	O
as	O
measured	O
by	O
the	O
Multiple	O
Sleep	O
Latency	O
Test	O
,	O
and	O
a	O
nearly	O
significant	O
decrease	O
in	O
subjective	O
daytime	B-DISEASE
sleepiness	I-DISEASE
.	O
CONCLUSIONS	O
:	O
Morning	O
-	O
dosed	O
modafinil	B-CHEMICAL
promotes	O
nocturnal	O
sleep	O
,	O
normalizes	O
sleep	O
architecture	O
,	O
and	O
decreases	O
daytime	B-DISEASE
sleepiness	I-DISEASE
in	O
abstinent	O
cocaine	B-CHEMICAL
users	O
.	O
These	O
effects	O
may	O
be	O
relevant	O
in	O
the	O
treatment	O
of	O
cocaine	B-CHEMICAL
dependence	O
.	O

Efficacy	O
and	O
safety	O
of	O
asenapine	O
in	O
a	O
placebo-	O
and	O
haloperidol	B-CHEMICAL
-	O
controlled	O
trial	O
in	O
patients	O
with	O
acute	O
exacerbation	O
of	O
schizophrenia	B-DISEASE
.	O
Asenapine	O
is	O
approved	O
by	O
the	O
Food	O
and	O
Drugs	O
Administration	O
in	O
adults	O
for	O
acute	O
treatment	O
of	O
schizophrenia	B-DISEASE
or	O
of	O
manic	B-DISEASE
or	O
mixed	O
episodes	O
associated	O
with	O
bipolar	B-DISEASE
I	I-DISEASE
disorder	I-DISEASE
with	O
or	O
without	O
psychotic	O
features	O
.	O
In	O
a	O
double	O
-	O
blind	B-DISEASE
6	O
-	O
week	O
trial	O
,	O
458	O
patients	O
with	O
acute	O
schizophrenia	B-DISEASE
were	O
randomly	O
assigned	O
to	O
fixed	O
-	O
dose	O
treatment	O
with	O
asenapine	O
at	O
5	O
mg	O
twice	O
daily	O
(	O
BID	O
)	O
,	O
asenapine	O
at	O
10	O
mg	O
BID	O
,	O
placebo	O
,	O
or	O
haloperidol	B-CHEMICAL
at	O
4	O
mg	O
BID	O
(	O
to	O
verify	O
assay	O
sensitivity	O
)	O
.	O
With	O
last	O
observations	O
carried	O
forward	O
(	O
LOCF	O
)	O
,	O
mean	O
Positive	O
and	O
Negative	O
Syndrome	B-DISEASE
Scale	O
total	O
score	O
reductions	O
from	O
baseline	O
to	O
endpoint	O
were	O
significantly	O
greater	O
with	O
asenapine	O
at	O
5	O
mg	O
BID	O
(	O
-16.2	O
)	O
and	O
haloperidol	B-CHEMICAL
(	O
-15.4	O
)	O
than	O
placebo	O
(	O
-10.7	O
;	O
both	O
P	O
<	O
0.05	O
)	O
;	O
using	O
mixed	O
model	O
for	O
repeated	O
measures	O
(	O
MMRM	O
)	O
,	O
changes	O
at	O
day	O
42	O
were	O
significantly	O
greater	O
with	O
asenapine	O
at	O
5	O
and	O
10	O
mg	O
BID	O
(	O
-21.3	O
and	O
-19.4	O
,	O
respectively	O
)	O
and	O
haloperidol	B-CHEMICAL
(	O
-20.0	O
)	O
than	O
placebo	O
(	O
-14.6	O
;	O
all	O
P	O
<	O
0.05	O
)	O
.	O
On	O
the	O
Positive	O
and	O
Negative	O
Syndrome	B-DISEASE
Scale	O
positive	O
subscale	O
,	O
all	O
treatments	O
were	O
superior	O
to	O
placebo	O
with	O
LOCF	O
and	O
MMRM	O
;	O
asenapine	O
at	O
5	O
mg	O
BID	O
was	O
superior	O
to	O
placebo	O
on	O
the	O
negative	O
subscale	O
with	O
MMRM	O
and	O
on	O
the	O
general	O
psychopathology	O
subscale	O
with	O
LOCF	O
and	O
MMRM	O
.	O
Treatment	O
-	O
related	O
adverse	O
events	O
(	O
AEs	O
)	O
occurred	O
in	O
44	O
%	O
and	O
52	O
%	O
,	O
57	O
%	O
,	O
and	O
41	O
%	O
of	O
the	O
asenapine	O
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidol	B-CHEMICAL
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O
Extrapyramidal	B-DISEASE
symptoms	I-DISEASE
reported	O
as	O
AEs	O
occurred	O
in	O
15	O
%	O
and	O
18	O
%	O
,	O
34	O
%	O
,	O
and	O
10	O
%	O
of	O
the	O
asenapine	O
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidol	B-CHEMICAL
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O
Across	O
all	O
groups	O
,	O
no	O
more	O
than	O
5	O
%	O
of	O
patients	O
had	O
clinically	O
significant	O
weight	O
change	O
.	O
Post	O
hoc	O
analyses	O
indicated	O
that	O
efficacy	O
was	O
similar	O
with	O
asenapine	O
and	O
haloperidol	B-CHEMICAL
;	O
greater	O
contrasts	O
were	O
seen	O
in	O
AEs	O
,	O
especially	O
extrapyramidal	B-DISEASE
symptoms	I-DISEASE
.	O

Permeability	O
,	O
ultrastructural	O
changes	O
,	O
and	O
distribution	O
of	O
novel	O
proteins	O
in	O
the	O
glomerular	O
barrier	O
in	O
early	O
puromycin	O
aminonucleoside	O
nephrosis	B-DISEASE
.	O
BACKGROUND	O
/	O
AIMS	O
:	O
It	O
is	O
still	O
unclear	O
what	O
happens	O
in	O
the	O
glomerulus	O
when	O
proteinuria	B-DISEASE
starts	O
.	O
Using	O
puromycin	O
aminonucleoside	O
nephrosis	B-DISEASE
(	O
PAN	O
)	O
rats	O
,	O
we	O
studied	O
early	O
ultrastructural	O
and	O
permeability	O
changes	O
in	O
relation	O
to	O
the	O
expression	O
of	O
the	O
podocyte	O
-	O
associated	O
molecules	O
nephrin	O
,	O
a	O
-	O
actinin	O
,	O
dendrin	O
,	O
and	O
plekhh2	O
,	O
the	O
last	O
two	O
of	O
which	O
were	O
only	O
recently	O
discovered	O
in	O
podocytes	O
.	O
METHODS	O
:	O
Using	O
immune	O
stainings	O
,	O
semiquantitative	O
measurement	O
was	O
performed	O
under	O
the	O
electron	O
microscope	O
.	O
Permeability	O
was	O
assessed	O
using	O
isolated	O
kidney	O
perfusion	O
with	O
tracers	O
.	O
Possible	O
effects	O
of	O
ACE	O
inhibition	O
were	O
tested	O
.	O
RESULTS	O
:	O
By	O
day	O
2	O
,	O
some	O
patchy	O
foot	O
process	O
effacement	O
,	O
but	O
no	O
proteinuria	B-DISEASE
,	O
appeared	O
.	O
The	O
amount	O
of	O
nephrin	O
was	O
reduced	O
in	O
both	O
diseased	O
and	O
normal	O
areas	O
.	O
The	O
other	O
proteins	O
showed	O
few	O
changes	O
,	O
which	O
were	O
limited	O
to	O
diseased	O
areas	O
.	O
By	O
day	O
4	O
,	O
foot	O
process	O
effacement	O
was	O
complete	O
and	O
proteinuria	B-DISEASE
appeared	O
in	O
parallel	O
with	O
signs	O
of	O
size	O
barrier	O
damage	O
.	O
Nephrin	O
decreased	O
further	O
,	O
while	O
dendrin	O
and	O
plekhh2	O
also	O
decreased	O
but	O
a	O
-	O
actinin	O
remained	O
unchanged	O
.	O
ACE	O
inhibition	O
had	O
no	O
significant	O
protective	O
effect	O
.	O
CONCLUSIONS	O
:	O
PAN	O
glomeruli	O
already	O
showed	O
significant	O
pathology	O
by	O
day	O
4	O
,	O
despite	O
relatively	O
mild	O
proteinuria	B-DISEASE
.	O
This	O
was	O
preceded	O
by	O
altered	O
nephrin	O
expression	O
,	O
supporting	O
its	O
pivotal	O
role	O
in	O
podocyte	O
morphology	O
.	O
The	O
novel	O
proteins	O
dendrin	O
and	O
plekhh2	O
were	O
both	O
reduced	O
,	O
suggesting	O
roles	O
in	O
PAN	O
,	O
whereas	O
a	O
-	O
actinin	O
was	O
unchanged	O
.	O

Twin	O
preterm	O
neonates	O
with	O
cardiac	B-DISEASE
toxicity	I-DISEASE
related	O
to	O
lopinavir	O
/	O
ritonavir	B-CHEMICAL
therapy	O
.	O
We	O
report	O
twin	O
neonates	O
who	O
were	O
born	O
prematurely	O
at	O
32	O
weeks	O
of	O
gestation	O
to	O
a	O
mother	O
with	O
human	O
immunodeficiency	O
virus	O
infection	B-DISEASE
.	O
One	O
of	O
the	O
twins	O
developed	O
complete	O
heart	B-DISEASE
block	I-DISEASE
and	O
dilated	B-DISEASE
cardiomyopathy	I-DISEASE
related	O
to	O
lopinavir	O
/	O
ritonavir	B-CHEMICAL
therapy	O
,	O
a	O
boosted	O
protease	O
-	O
inhibitor	O
agent	O
,	O
while	O
the	O
other	O
twin	O
developed	O
mild	O
bradycardia	B-DISEASE
.	O
We	O
recommend	O
caution	O
in	O
the	O
use	O
of	O
lopinavir	O
/	O
ritonavir	B-CHEMICAL
in	O
the	O
immediate	O
neonatal	O
period	O
.	O

Learning	O
of	O
rats	O
under	O
amnesia	B-DISEASE
caused	O
by	O
pentobarbital	B-CHEMICAL
.	O
Dissociated	O
learning	O
of	O
rats	O
in	O
the	O
normal	O
state	O
and	O
the	O
state	O
of	O
amnesia	B-DISEASE
produced	O
by	O
pentobarbital	B-CHEMICAL
(	O
15	O
mg	O
/	O
kg	O
,	O
ip	O
)	O
was	O
carried	O
out	O
.	O
Rats	O
were	O
trained	O
to	O
approach	O
a	O
shelf	O
where	O
they	O
received	O
food	O
reinforcement	O
.	O
In	O
Group	O
1	O
the	O
rats	O
were	O
trained	O
under	O
the	O
influence	O
of	O
pentobarbital	B-CHEMICAL
to	O
run	O
to	O
the	O
same	O
shelf	O
as	O
in	O
the	O
normal	O
state	O
.	O
In	O
Group	O
2	O
the	O
rats	O
were	O
trained	O
to	O
approach	O
different	O
shelves	O
in	O
different	O
drug	O
states	O
.	O
It	O
was	O
shown	O
that	O
memory	O
dissociation	O
occurred	O
in	O
both	O
groups	O
.	O
Differences	O
in	O
the	O
parameters	O
of	O
training	O
under	O
the	O
influence	O
of	O
pentobarbital	B-CHEMICAL
between	O
Groups	O
1	O
and	O
2	O
were	O
revealed	O
.	O
These	O
findings	O
show	O
that	O
the	O
brain	O
-	O
dissociated	O
state	O
induced	O
by	O
pentobarbital	B-CHEMICAL
is	O
formed	O
with	O
the	O
participation	O
of	O
the	O
mechanisms	O
of	O
information	O
perception	O
.	O

Angiosarcoma	O
of	O
the	O
liver	O
associated	O
with	O
diethylstilbestrol	B-CHEMICAL
.	O
Angiosarcoma	O
of	O
the	O
liver	O
occurred	O
in	O
a	O
76	O
-	O
year	O
-	O
old	O
man	O
who	O
had	O
been	O
treated	O
for	O
a	O
well	O
-	O
differentiated	O
adenocarcinoma	B-DISEASE
of	O
the	O
liver	O
with	O
diethylstilbestrol	B-CHEMICAL
for	O
13	O
years	O
.	O
Angiosarcoma	O
was	O
also	O
present	O
within	O
pulmonary	O
and	O
renal	O
arteries	O
.	O
The	O
possibility	O
that	O
the	O
intraarterial	O
lesions	O
might	O
represent	O
independent	O
primary	O
tumors	B-DISEASE
is	O
considered	O
.	O

Role	O
of	O
xanthine	O
oxidase	O
in	O
dexamethasone	B-CHEMICAL
-	O
induced	O
hypertension	B-DISEASE
in	O
rats	O
.	O
1	O
.	O
Glucocorticoid	O
-	O
induced	O
hypertension	B-DISEASE
(	O
GC	O
-	O
HT	O
)	O
in	O
the	O
rat	O
is	O
associated	O
with	O
nitric	O
oxide	O
-	O
redox	O
imbalance	O
.	O
2	O
.	O
We	O
studied	O
the	O
role	O
of	O
xanthine	O
oxidase	O
(	O
XO	O
)	O
,	O
which	O
is	O
implicated	O
in	O
the	O
production	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
,	O
in	O
dexamethasone	B-CHEMICAL
-	O
induced	O
hypertension	B-DISEASE
(	O
dex	B-CHEMICAL
-	O
HT	O
)	O
.	O
3	O
.	O
Thirty	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
divided	O
randomly	O
into	O
four	O
treatment	O
groups	O
:	O
saline	O
,	O
dexamethasone	B-CHEMICAL
(	O
dex	B-CHEMICAL
)	O
,	O
allopurinol	O
plus	O
saline	O
,	O
and	O
allopurinol	O
plus	O
dex	B-CHEMICAL
.	O
4	O
.	O
Systolic	O
blood	O
pressures	O
(	O
SBP	O
)	O
and	O
bodyweights	O
were	O
recorded	O
each	O
alternate	O
day	O
.	O
Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	O
activity	O
,	O
and	O
serum	O
urate	O
to	O
assess	O
XO	O
inhibition	O
.	O
5	O
.	O
Dex	B-CHEMICAL
increased	O
SBP	O
(	O
110	O
+	O
/-	O
2	O
-	O
126	O
+	O
/-	O
3	O
mmHg	O
;	O
P	O
<	O
0.001	O
)	O
and	O
decreased	B-DISEASE
thymus	I-DISEASE
(	I-DISEASE
P	I-DISEASE
<	I-DISEASE
0.001	I-DISEASE
)	I-DISEASE
and	I-DISEASE
bodyweights	I-DISEASE
(	O
P	O
"	O
<	O
0.01	O
)	O
.	O
Allopurinol	O
decreased	O
serum	O
urate	O
from	O
76	O
+	O
/-	O
5	O
to	O
30	O
+	O
/-	O
3	O
micromol	O
/	O
L	O
(	O
P	O
<	O
0.001	O
)	O
in	O
saline	O
and	O
from	O
84	O
+	O
/-	O
13	O
to	O
28	O
+	O
/-	O
2	O
micromol	O
/	O
L	O
in	O
dex	B-CHEMICAL
-	O
treated	O
(	O
P	O
<	O
0.01	O
)	O
groups	O
.	O
6	O
.	O
Allopurinol	O
did	O
not	O
prevent	O
dex	B-CHEMICAL
-	O
HT	O
.	O
This	O
,	O
together	O
with	O
our	O
previous	O
findings	O
that	O
allopurinol	O
failed	O
to	O
prevent	O
adrenocorticotrophic	O
hormone	O
induced	O
hypertension	B-DISEASE
,	O
suggests	O
that	O
XO	O
activity	O
is	O
not	O
a	O
major	O
determinant	O
of	O
GC	O
-	O
HT	O
in	O
the	O
rat	O
.	O

Extrapyramidal	O
side	O
effects	O
with	O
risperidone	B-CHEMICAL
and	O
haloperidol	B-CHEMICAL
at	O
comparable	O
D2	O
receptor	O
occupancy	O
levels	O
.	O
Risperidone	B-CHEMICAL
is	O
an	O
antipsychotic	O
drug	O
with	O
high	O
affinity	O
at	O
dopamine	B-CHEMICAL
D2	O
and	O
serotonin	B-CHEMICAL
5	O
-	O
HT2	O
receptors	O
.	O
Previous	O
clinical	O
studies	O
have	O
proposed	O
that	O
risperidone	B-CHEMICAL
's	O
pharmacologic	O
profile	O
may	O
produce	O
improved	O
efficacy	O
for	O
negative	O
psychotic	B-DISEASE
symptoms	I-DISEASE
and	O
decreased	O
propensity	O
for	O
extrapyramidal	O
side	O
effects	O
;	O
features	O
shared	O
by	O
so	O
-	O
called	O
'	O
atypical	O
'	O
neuroleptics	B-CHEMICAL
.	O
To	O
determine	O
if	O
routine	O
risperidone	B-CHEMICAL
treatment	O
is	O
associated	O
with	O
a	O
unique	O
degree	O
of	O
D2	O
receptor	O
occupancy	O
and	O
pattern	O
of	O
clinical	O
effects	O
,	O
we	O
used	O
[	O
123I]IBZM	O
SPECT	O
to	O
determine	O
D2	O
occupancy	O
in	O
subjects	O
treated	O
with	O
routine	O
clinical	O
doses	O
of	O
risperidone	B-CHEMICAL
(	O
n	O
=	O
12	O
)	O
or	O
haloperidol	B-CHEMICAL
(	O
n	O
=	O
7	O
)	O
.	O
Both	O
risperidone	B-CHEMICAL
and	O
haloperidol	B-CHEMICAL
produced	O
D2	O
occupancy	O
levels	O
between	O
approximately	O
60	O
and	O
90	O
%	O
at	O
standard	O
clinical	O
doses	O
.	O
There	O
was	O
no	O
significant	O
difference	O
between	O
occupancy	O
levels	O
obtained	O
with	O
haloperidol	B-CHEMICAL
or	O
risperidone	B-CHEMICAL
.	O
Drug	O
-	O
induced	O
parkinsonism	B-DISEASE
was	O
observed	O
in	O
subjects	O
treated	O
with	O
risperidone	B-CHEMICAL
(	O
42	O
%	O
)	O
and	O
haloperidol	B-CHEMICAL
(	O
29	O
%	O
)	O
and	O
was	O
observed	O
at	O
occupancy	O
levels	O
above	O
60	O
%	O
.	O
Based	O
on	O
these	O
observations	O
,	O
it	O
is	O
concluded	O
that	O
5	O
-	O
HT2	O
blockade	O
obtained	O
with	O
risperidone	B-CHEMICAL
at	O
D2	O
occupancy	O
rates	O
of	O
60	O
%	O
and	O
above	O
does	O
not	O
appear	O
to	O
protect	O
against	O
the	O
risk	O
for	O
extrapyramidal	O
side	O
effects	O
.	O

Simvastatin	B-CHEMICAL
-	O
ezetimibe	B-CHEMICAL
-	O
induced	O
hepatic	O
failure	O
necessitating	O
liver	O
transplantation	O
.	O
Abstract	O
Serum	O
aminotransferase	O
elevations	O
are	O
a	O
commonly	O
known	O
adverse	O
effect	O
of	O
3	O
-	O
hydroxy-3	O
-	O
methylglutaryl	O
coenzyme	O
A	O
reductase	O
inhibitor	O
(	O
statin	B-CHEMICAL
)	O
therapy	O
.	O
However	O
,	O
hepatotoxic	O
events	O
have	O
not	O
been	O
widely	O
published	O
with	O
ezetimibe	B-CHEMICAL
or	O
the	O
combination	O
agent	O
simvastatin	B-CHEMICAL
-	O
ezetimibe	B-CHEMICAL
.	O
We	O
describe	O
a	O
70	O
-	O
year	O
-	O
old	O
Hispanic	O
woman	O
who	O
developed	O
fulminant	O
hepatic	O
failure	O
necessitating	O
liver	O
transplantation	O
10	O
weeks	O
after	O
conversion	O
from	O
simvastatin	B-CHEMICAL
40	O
mg	O
/	O
day	O
to	O
simvastatin	B-CHEMICAL
10	O
mg	O
-	O
ezetimibe	B-CHEMICAL
40	O
mg	O
/	O
day	O
.	O
The	O
patient	O
's	O
lipid	O
panel	O
had	O
been	O
maintained	O
with	O
simvastatin	B-CHEMICAL
for	O
18	O
months	O
before	O
the	O
conversion	O
without	O
evidence	O
of	O
hepatotoxicity	O
.	O
A	O
routine	O
laboratory	O
work	O
-	O
up	O
10	O
weeks	O
after	O
conversion	O
revealed	O
elevated	O
serum	O
aminotransferase	O
levels	O
.	O
Simvastatinezetimibe	O
and	O
escitalopram	O
(	O
which	O
she	O
was	O
taking	O
for	O
depression	B-DISEASE
)	O
were	O
discontinued	O
,	O
and	O
other	O
potential	O
causes	O
of	O
hepatotoxicity	O
were	O
excluded	O
.	O
A	O
repeat	O
work	O
-	O
up	O
revealed	O
further	O
elevations	O
in	O
aminotransferase	O
levels	O
,	O
and	O
liver	O
biopsy	O
revealed	O
evidence	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
drug	B-DISEASE
toxicity	I-DISEASE
.	O
She	O
underwent	O
liver	O
transplantation	O
with	O
an	O
uneventful	O
postoperative	O
course	O
.	O
Her	O
aminotransferase	O
levels	O
returned	O
to	O
normal	O
by	O
postoperative	O
day	O
23	O
,	O
and	O
her	O
2	O
-	O
year	O
follow	O
-	O
up	O
showed	O
no	O
adverse	O
events	O
.	O
Ezetimibe	B-CHEMICAL
undergoes	O
extensive	O
glucuronidation	O
by	O
uridine	O
diphosphate	O
glucoronosyltransferases	O
(	O
UGT	O
)	O
in	O
the	O
intestine	O
and	O
liver	O
and	O
may	O
have	O
inhibited	O
the	O
glucuronidation	O
of	O
simvastatin	B-CHEMICAL
hydroxy	O
acid	O
,	O
resulting	O
in	O
increased	O
simvastatin	B-CHEMICAL
exposure	O
and	O
subsequent	O
hepatotoxicity	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
simvastatin	B-CHEMICAL
-	O
ezetimibe	B-CHEMICAL
-	O
induced	O
liver	B-DISEASE
failure	I-DISEASE
that	O
resulted	O
in	O
liver	O
transplantation	O
.	O
We	O
postulate	O
that	O
the	O
mechanism	O
of	O
the	O
simvastatinezetimibe	O
-	O
induced	O
hepatotoxicity	O
is	O
the	O
increased	O
simvastatin	B-CHEMICAL
exposure	O
by	O
ezetimibe	B-CHEMICAL
inhibition	O
of	O
UGT	O
enzymes	O
.	O
Clinicians	O
should	O
be	O
aware	O
of	O
potential	O
hepatotoxicity	O
with	O
simvastatin	B-CHEMICAL
-	O
ezetimibe	B-CHEMICAL
especially	O
in	O
elderly	O
patients	O
and	O
should	O
carefully	O
monitor	O
serum	O
aminotransferase	O
levels	O
when	O
starting	O
therapy	O
and	O
titrating	O
the	O
dosage	O
.	O

Oral	B-DISEASE
manifestations	I-DISEASE
of	O
"	O
meth	B-DISEASE
mouth	I-DISEASE
"	O
:	O
a	O
case	O
report	O
.	O
AIM	O
:	O
The	O
aim	O
of	O
the	O
documentation	O
of	O
this	O
clinical	O
case	O
is	O
to	O
make	O
clinicians	O
aware	O
of	O
"	O
meth	B-DISEASE
mouth	I-DISEASE
"	O
and	O
the	O
medical	O
risks	O
associated	O
with	O
this	O
serious	O
condition	O
.	O
BACKGROUND	O
:	O
Methamphetamine	B-CHEMICAL
is	O
a	O
very	O
addictive	O
,	O
powerful	O
stimulant	O
that	O
increases	O
wakefulness	O
and	O
physical	O
activity	O
and	O
can	O
produce	O
other	O
effects	O
such	O
as	O
cardiac	B-DISEASE
dysrhythmias	I-DISEASE
,	O
hypertension	B-DISEASE
,	O
hallucinations	B-DISEASE
,	O
and	O
violent	O
behavior	O
.	O
Dental	O
patients	O
abusing	O
methamphetamine	B-CHEMICAL
can	O
present	O
with	O
poor	O
oral	O
hygiene	O
,	O
xerostomia	B-DISEASE
,	O
rampant	O
caries	B-DISEASE
(	O
"	O
meth	B-DISEASE
mouth	I-DISEASE
"	O
)	O
,	O
and	O
excessive	O
tooth	B-DISEASE
wear	I-DISEASE
.	O
Oral	O
rehabilitation	O
of	O
patients	O
using	O
methamphetamine	B-CHEMICAL
can	O
be	O
challenging	O
.	O
CASE	O
DESCRIPTION	O
:	O
A	O
30	O
-	O
year	O
-	O
old	O
Caucasian	O
woman	O
presented	O
with	O
dental	O
pain	B-DISEASE
,	O
bad	B-DISEASE
breath	I-DISEASE
,	O
and	O
self	O
-	O
reported	O
poor	O
esthetics	O
.	O
A	O
comprehensive	O
examination	O
including	O
her	O
medical	O
history	O
,	O
panoramic	O
radiograph	O
,	O
and	O
intraoral	O
examination	O
revealed	O
19	O
carious	B-DISEASE
lesions	I-DISEASE
,	O
which	O
is	O
not	O
very	O
common	O
for	O
a	O
healthy	O
adult	O
.	O
She	O
reported	O
her	O
use	O
of	O
methamphetamine	B-CHEMICAL
for	O
five	O
years	O
and	O
had	O
not	O
experienced	O
any	O
major	O
carious	B-DISEASE
episodes	I-DISEASE
before	O
she	O
started	O
using	O
the	O
drug	O
.	O
SUMMARY	O
:	O
The	O
patient	O
's	O
medical	O
and	O
dental	O
histories	O
along	O
with	O
radiographic	O
and	O
clinical	O
findings	O
lead	O
to	O
a	O
diagnosis	O
of	O
"	O
meth	B-DISEASE
mouth	I-DISEASE
.	O
"	O
Although	O
three	O
different	O
dental	O
treatment	O
modalities	O
(	O
either	O
conventional	O
or	O
implant	O
-	O
supported	O
)	O
have	O
been	O
offered	O
to	O
the	O
patient	O
since	O
August	O
2007	O
,	O
the	O
patient	O
has	O
yet	O
to	O
initiate	O
any	O
treatment	O
.	O
CLINICAL	O
SIGNIFICANCE	O
:	O
This	O
clinical	O
case	O
showing	O
oral	B-DISEASE
manifestations	I-DISEASE
of	O
meth	B-DISEASE
mouth	I-DISEASE
was	O
presented	O
to	O
help	O
dental	O
practitioners	O
recognize	O
and	O
manage	O
patients	O
who	O
may	O
be	O
abusing	O
methamphetamines	O
.	O
Dental	O
practitioners	O
also	O
may	O
be	O
skeptical	O
about	O
the	O
reliability	O
of	O
appointment	O
keeping	O
by	O
these	O
patients	O
,	O
as	O
they	O
frequently	O
miss	O
their	O
appointments	O
without	O
reasonable	O
justification	O
.	O

Thyroxine	B-CHEMICAL
abuse	O
:	O
an	O
unusual	O
case	O
of	O
thyrotoxicosis	B-DISEASE
in	O
pregnancy	O
.	O
Eating	B-DISEASE
disorders	I-DISEASE
and	O
the	O
associated	O
behavioural	O
problems	O
and	O
drug	B-DISEASE
abuse	I-DISEASE
are	O
uncommon	O
in	O
pregnancy	O
.	O
When	O
they	O
do	O
occur	O
they	O
are	O
often	O
unrecognized	O
because	O
of	O
denial	O
but	O
when	O
significant	O
may	O
pose	O
a	O
risk	O
to	O
both	O
the	O
mother	O
and	O
her	O
fetus	O
.	O
This	O
case	O
illustrates	O
a	O
number	O
of	O
problems	O
that	O
may	O
be	O
encountered	O
in	O
women	O
with	O
eating	B-DISEASE
disorders	I-DISEASE
in	O
pregnancy	O
,	O
including	O
prolonged	O
and	O
recurrent	O
metabolic	O
disturbances	O
and	O
diuretic	B-CHEMICAL
abuse	O
.	O
In	O
particular	O
it	O
illustrates	O
the	O
derangements	O
of	O
thyroid	O
function	O
seen	O
in	O
pregnant	O
women	O
with	O
eating	B-DISEASE
disorders	I-DISEASE
and	O
reminds	O
us	O
that	O
when	O
a	O
cause	O
for	O
thyrotoxicosis	B-DISEASE
remains	O
obscure	O
,	O
thyroxine	B-CHEMICAL
abuse	O
should	O
be	O
considered	O
and	O
explored	O
.	O

Attenuation	O
of	O
methamphetamine	B-CHEMICAL
-	O
induced	O
nigrostriatal	O
dopaminergic	O
neurotoxicity	B-DISEASE
in	O
mice	O
by	O
lipopolysaccharide	B-CHEMICAL
pretreatment	O
.	O
Immunological	O
activation	O
has	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
methamphetamine	B-CHEMICAL
-	O
induced	O
dopaminergic	B-DISEASE
terminal	I-DISEASE
damage	I-DISEASE
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
roles	O
of	O
lipopolysaccharide	B-CHEMICAL
,	O
a	O
pro	O
-	O
inflammatory	O
and	O
inflammatory	O
factor	O
,	O
treatment	O
in	O
modulating	O
the	O
methamphetamine	B-CHEMICAL
-	O
induced	O
nigrostriatal	O
dopamine	B-CHEMICAL
neurotoxicity	B-DISEASE
.	O
Lipopolysaccharide	B-CHEMICAL
pretreatment	O
did	O
not	O
affect	O
the	O
basal	O
body	O
temperature	O
or	O
methamphetamine	B-CHEMICAL
-	O
elicited	O
hyperthermia	B-DISEASE
three	O
days	O
later	O
.	O
Such	O
systemic	O
lipopolysaccharide	B-CHEMICAL
treatment	O
mitigated	O
methamphetamine	B-CHEMICAL
-	O
induced	O
striatal	O
dopamine	B-CHEMICAL
and	O
3,4	B-CHEMICAL
-	I-CHEMICAL
dihydroxyphenylacetic	I-CHEMICAL
acid	I-CHEMICAL
depletions	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
As	O
the	O
most	O
potent	O
dose	O
(	O
1	O
mg	O
/	O
kg	O
)	O
of	O
lipopolysaccharide	B-CHEMICAL
was	O
administered	O
two	O
weeks	O
,	O
one	O
day	O
before	O
or	O
after	O
the	O
methamphetamine	B-CHEMICAL
dosing	O
regimen	O
,	O
methamphetamine	B-CHEMICAL
-	O
induced	O
striatal	O
dopamine	B-CHEMICAL
and	O
3,4	B-CHEMICAL
-	I-CHEMICAL
dihydroxyphenylacetic	I-CHEMICAL
acid	I-CHEMICAL
depletions	O
remained	O
unaltered	O
.	O
Moreover	O
,	O
systemic	O
lipopolysaccharide	B-CHEMICAL
pretreatment	O
(	O
1	O
mg	O
/	O
kg	O
)	O
attenuated	O
local	O
methamphetamine	B-CHEMICAL
infusion	O
-	O
produced	O
dopamine	B-CHEMICAL
and	O
3,4	B-CHEMICAL
-	I-CHEMICAL
dihydroxyphenylacetic	I-CHEMICAL
acid	I-CHEMICAL
depletions	O
in	O
the	O
striatum	O
,	O
indicating	O
that	O
the	O
protective	O
effect	O
of	O
lipopolysaccharide	B-CHEMICAL
is	O
less	O
likely	O
due	O
to	O
interrupted	O
peripheral	O
distribution	O
or	O
metabolism	O
of	O
methamphetamine	B-CHEMICAL
.	O
We	O
concluded	O
a	O
critical	O
time	O
window	O
for	O
systemic	O
lipopolysaccharide	B-CHEMICAL
pretreatment	O
in	O
exerting	O
effective	O
protection	O
against	O
methamphetamine	B-CHEMICAL
-	O
induced	O
nigrostriatal	O
dopamine	B-CHEMICAL
neurotoxicity	B-DISEASE
.	O

Effect	O
of	O
converting	O
enzyme	O
inhibition	O
on	O
the	O
course	O
of	O
adriamycin	B-CHEMICAL
-	O
induced	O
nephropathy	B-DISEASE
.	O
The	O
effect	O
of	O
the	O
converting	O
enzyme	O
inhibitor	O
(	O
CEI	O
)	O
enalapril	B-CHEMICAL
was	O
assessed	O
in	O
Munich	O
-	O
Wistar	O
rats	O
with	O
established	O
adriamycin	B-CHEMICAL
nephrosis	B-DISEASE
.	O
Rats	O
were	O
given	O
a	O
single	O
dose	O
of	O
adriamycin	B-CHEMICAL
and	O
one	O
month	O
later	O
divided	O
into	O
four	O
groups	O
matched	O
for	O
albuminuria	B-DISEASE
,	O
blood	O
pressure	O
,	O
and	O
plasma	O
albumin	O
concentration	O
.	O
Groups	O
1	O
and	O
3	O
remained	O
untreated	O
while	O
groups	O
2	O
and	O
4	O
received	O
enalapril	B-CHEMICAL
.	O
Groups	O
1	O
and	O
2	O
underwent	O
micropuncture	O
studies	O
after	O
10	O
days	O
.	O
These	O
short	O
-	O
term	O
studies	O
showed	O
that	O
enalapril	B-CHEMICAL
reduced	O
arterial	O
blood	O
pressure	O
(	O
101	O
+	O
/-	O
2	O
vs.	O
124	O
+	O
/-	O
3	O
mm	O
Hg	O
,	O
group	O
2	O
vs.	O
1	O
,	O
P	O
less	O
than	O
0.05	O
)	O
and	O
glomerular	O
capillary	O
pressure	O
(	O
54	O
+	O
/-	O
1	O
vs.	O
61	O
+	O
/-	O
2	O
mm	O
Hg	O
,	O
P	O
less	O
than	O
0.05	O
)	O
without	O
reducing	O
albuminuria	B-DISEASE
(	O
617	O
+	O
/-	O
50	O
vs.	O
570	O
+	O
/-	O
47	O
mg	O
/	O
day	O
)	O
or	O
GFR	O
(	O
1.03	O
+	O
/-	O
0.04	O
vs.	O
1.04	O
+	O
/-	O
0.11	O
ml	O
/	O
min	O
)	O
.	O
Groups	O
3	O
and	O
4	O
were	O
studied	O
at	O
four	O
and	O
at	O
six	O
months	O
to	O
assess	O
the	O
effect	O
of	O
enalapril	B-CHEMICAL
on	O
progression	O
of	O
renal	B-DISEASE
injury	I-DISEASE
in	O
adriamycin	B-CHEMICAL
nephrosis	B-DISEASE
.	O
Chronic	O
enalapril	B-CHEMICAL
treatment	O
reduced	O
blood	O
pressure	O
without	O
reducing	O
albuminuria	B-DISEASE
in	O
group	O
4	O
.	O
Untreated	O
group	O
3	O
rats	O
exhibited	O
a	O
progressive	O
reduction	O
in	O
GFR	O
(	O
0.35	O
+	O
/-	O
0.08	O
ml	O
/	O
min	O
at	O
4	O
months	O
,	O
0.27	O
+	O
/-	O
0.07	O
ml	O
/	O
min	O
at	O
6	O
months	O
)	O
.	O
Enalapril	B-CHEMICAL
treatment	O
blunted	O
but	O
did	O
not	O
prevent	O
reduction	O
in	O
GFR	O
in	O
group	O
4	O
(	O
0.86	O
+	O
/-	O
0.15	O
ml	O
/	O
min	O
at	O
4	O
months	O
,	O
0.69	O
+	O
/-	O
0.13	O
ml	O
/	O
min	O
at	O
6	O
months	O
,	O
both	O
P	O
less	O
than	O
0.05	O
vs.	O
group	O
3	O
)	O
.	O
Reduction	O
in	O
GFR	O
was	O
associated	O
with	O
the	O
development	O
of	O
glomerular	O
sclerosis	B-DISEASE
in	O
both	O
treated	O
and	O
untreated	O
rats.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Butyrylcholinesterase	O
gene	O
mutations	O
in	O
patients	O
with	O
prolonged	O
apnea	B-DISEASE
after	O
succinylcholine	B-CHEMICAL
for	O
electroconvulsive	O
therapy	O
.	O
BACKGROUND	O
:	O
patients	O
undergoing	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
often	O
receive	O
succinylcholine	B-CHEMICAL
as	O
part	O
of	O
the	O
anesthetic	O
procedure	O
.	O
The	O
duration	O
of	O
action	O
may	O
be	O
prolonged	O
in	O
patients	O
with	O
genetic	O
variants	O
of	O
the	O
butyrylcholinesterase	O
enzyme	O
(	O
BChE	O
)	O
,	O
the	O
most	O
common	O
being	O
the	O
K-	O
and	O
the	O
A	O
-	O
variants	O
.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
assess	O
the	O
clinical	O
significance	O
of	O
genetic	O
variants	O
in	O
butyrylcholinesterase	O
gene	O
(	O
BCHE	O
)	O
in	O
patients	O
with	O
a	O
suspected	O
prolonged	O
duration	O
of	O
action	O
of	O
succinylcholine	B-CHEMICAL
after	O
ECT	O
.	O
METHODS	O
:	O
a	O
total	O
of	O
13	O
patients	O
were	O
referred	O
to	O
the	O
Danish	O
Cholinesterase	O
Research	O
Unit	O
after	O
ECT	O
during	O
38	O
months	O
.	O
We	O
determined	O
the	O
BChE	O
activity	O
and	O
the	O
BCHE	O
genotype	O
using	O
molecular	O
genetic	O
methods	O
,	O
the	O
duration	O
of	O
apnea	B-DISEASE
,	O
time	O
to	O
sufficient	O
spontaneous	O
ventilation	O
and	O
whether	O
neuromuscular	O
monitoring	O
was	O
used	O
.	O
The	O
duration	O
of	O
apnea	B-DISEASE
was	O
compared	O
with	O
published	O
data	O
on	O
normal	O
subjects	O
.	O
RESULTS	O
:	O
in	O
11	O
patients	O
,	O
mutations	O
were	O
found	O
in	O
the	O
BCHE	O
gene	O
,	O
the	O
K	O
-	O
variant	O
being	O
the	O
most	O
frequent	O
.	O
The	O
duration	O
of	O
apnea	B-DISEASE
was	O
5	O
-	O
15	O
min	O
compared	O
with	O
3	O
-	O
5.3	O
min	O
from	O
the	O
literature	O
.	O
Severe	O
distress	O
was	O
noted	O
in	O
the	O
recovery	O
phase	O
in	O
two	O
patients	O
.	O
Neuromuscular	O
monitoring	O
was	O
used	O
in	O
two	O
patients	O
.	O
CONCLUSION	O
:	O
eleven	O
of	O
13	O
patients	O
with	O
a	O
prolonged	O
duration	O
of	O
action	O
of	O
succinylcholine	B-CHEMICAL
had	O
mutations	O
in	O
BCHE	O
,	O
indicating	O
that	O
this	O
is	O
the	O
possible	O
reason	O
for	O
a	O
prolonged	O
period	O
of	O
apnea	B-DISEASE
.	O
We	O
recommend	O
objective	O
neuromuscular	O
monitoring	O
during	O
the	O
first	O
ECT	O
.	O

Ketamine	B-CHEMICAL
sedation	O
for	O
the	O
reduction	O
of	O
children	O
's	O
fractures	B-DISEASE
in	O
the	O
emergency	B-DISEASE
department	I-DISEASE
.	O
BACKGROUND	O
:	O
There	O
recently	O
has	O
been	O
a	O
resurgence	O
in	O
the	O
utilization	O
of	O
ketamine	B-CHEMICAL
,	O
a	O
unique	O
anesthetic	O
,	O
for	O
emergency	O
-	O
department	O
procedures	O
requiring	O
sedation	O
.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
safety	O
and	O
efficacy	O
of	O
ketamine	B-CHEMICAL
for	O
sedation	O
in	O
the	O
treatment	O
of	O
children	O
's	O
fractures	B-DISEASE
in	O
the	O
emergency	B-DISEASE
department	I-DISEASE
.	O
METHODS	O
:	O
One	O
hundred	O
and	O
fourteen	O
children	O
(	O
average	O
age	O
,	O
5.3	O
years	O
;	O
range	O
,	O
twelve	O
months	O
to	O
ten	O
years	O
and	O
ten	O
months	O
)	O
who	O
underwent	O
closed	O
reduction	O
of	O
an	O
isolated	O
fracture	O
or	O
dislocation	B-DISEASE
in	O
the	O
emergency	B-DISEASE
department	I-DISEASE
at	O
a	O
level	O
-	O
I	O
trauma	O
center	O
were	O
prospectively	O
evaluated	O
.	O
Ketamine	B-CHEMICAL
hydrochloride	O
was	O
administered	O
intravenously	O
(	O
at	O
a	O
dose	O
of	O
two	O
milligrams	O
per	O
kilogram	O
of	O
body	B-DISEASE
weight	I-DISEASE
)	O
in	O
ninety	O
-	O
nine	O
of	O
the	O
patients	O
and	O
intramuscularly	O
(	O
at	O
a	O
dose	O
of	O
four	O
milligrams	O
per	O
kilogram	O
of	O
body	B-DISEASE
weight	I-DISEASE
)	O
in	O
the	O
other	O
fifteen	O
.	O
A	O
board	O
-	O
certified	O
emergency	O
physician	O
skilled	O
in	O
airway	O
management	O
supervised	O
administration	O
of	O
the	O
anesthetic	O
,	O
and	O
the	O
patients	O
were	O
monitored	O
by	O
a	O
registered	O
nurse	O
.	O
Any	O
pain	B-DISEASE
during	O
the	O
reduction	O
was	O
rated	O
by	O
the	O
orthopaedic	O
surgeon	O
treating	O
the	O
patient	O
according	O
to	O
the	O
Children	O
's	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	B-DISEASE
Scale	O
(	O
CHEOPS	O
)	O
.	O
RESULTS	O
:	O
The	O
average	O
time	O
from	O
intravenous	O
administration	O
of	O
ketamine	B-CHEMICAL
to	O
manipulation	O
of	O
the	O
fracture	O
or	O
dislocation	B-DISEASE
was	O
one	O
minute	O
and	O
thirty	O
-	O
six	O
seconds	O
(	O
range	O
,	O
twenty	O
seconds	O
to	O
five	O
minutes	O
)	O
,	O
and	O
the	O
average	O
time	O
from	O
intramuscular	O
administration	O
to	O
manipulation	O
was	O
four	O
minutes	O
and	O
forty	O
-	O
two	O
seconds	O
(	O
range	O
,	O
sixty	O
seconds	O
to	O
fifteen	O
minutes	O
)	O
.	O
The	O
average	O
score	O
according	O
to	O
the	O
Children	O
's	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	B-DISEASE
Scale	O
was	O
6.4	O
points	O
(	O
range	O
,	O
5	O
to	O
10	O
points	O
)	O
,	O
reflecting	O
minimal	O
or	O
no	O
pain	B-DISEASE
during	O
fracture	O
reduction	O
.	O
Adequate	O
fracture	O
reduction	O
was	O
obtained	O
in	O
111	O
of	O
the	O
children	O
.	O
Ninety	O
-	O
nine	O
percent	O
(	O
sixty	O
-	O
eight	O
)	O
of	O
the	O
sixty	O
-	O
nine	O
parents	O
present	O
during	O
the	O
reduction	O
were	O
pleased	O
with	O
the	O
sedation	O
and	O
would	O
allow	O
it	O
to	O
be	O
used	O
again	O
in	O
a	O
similar	O
situation	O
.	O
Patency	O
of	O
the	O
airway	O
and	O
independent	O
respiration	O
were	O
maintained	O
in	O
all	O
of	O
the	O
patients	O
.	O
Blood	O
pressure	O
and	O
heart	O
rate	O
remained	O
stable	O
.	O
Minor	O
side	O
effects	O
included	O
nausea	B-DISEASE
(	O
thirteen	O
patients	O
)	O
,	O
emesis	B-DISEASE
(	O
eight	O
of	O
the	O
thirteen	O
patients	O
with	O
nausea	B-DISEASE
)	O
,	O
clumsiness	B-DISEASE
(	O
evident	O
as	O
ataxic	B-DISEASE
movements	I-DISEASE
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	B-DISEASE
reaction	I-DISEASE
(	O
one	O
patient	O
)	O
.	O
No	O
long	O
-	O
term	O
sequelae	O
were	O
noted	O
,	O
and	O
no	O
patients	O
had	O
hallucinations	B-DISEASE
or	O
nightmares	O
.	O
CONCLUSIONS	O
:	O
Ketamine	B-CHEMICAL
reliably	O
,	O
safely	O
,	O
and	O
quickly	O
provided	O
adequate	O
sedation	O
to	O
effectively	O
facilitate	O
the	O
reduction	O
of	O
children	O
's	O
fractures	B-DISEASE
in	O
the	O
emergency	B-DISEASE
department	I-DISEASE
at	O
our	O
institution	O
.	O
Ketamine	B-CHEMICAL
should	O
only	O
be	O
used	O
in	O
an	O
environment	O
such	O
as	O
the	O
emergency	B-DISEASE
department	I-DISEASE
,	O
where	O
proper	O
one	O
-	O
on	O
-	O
one	O
monitoring	O
is	O
used	O
and	O
board	O
-	O
certified	O
physicians	O
skilled	O
in	O
airway	O
management	O
are	O
directly	O
involved	O
in	O
the	O
care	O
of	O
the	O
patient	O
.	O

Prophylactic	O
use	O
of	O
lamivudine	B-CHEMICAL
with	O
chronic	O
immunosuppressive	O
therapy	O
for	O
rheumatologic	O
disorders	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
report	O
our	O
experience	O
concerning	O
the	O
effectiveness	O
of	O
the	O
prophylactic	O
administration	O
of	O
lamivudine	B-CHEMICAL
in	O
hepatitis	B-DISEASE
B	I-DISEASE
virus	O
surface	O
antigen	O
(	O
HBs	O
Ag	O
)	O
positive	O
patients	O
with	O
rheumatologic	O
disease	B-DISEASE
.	O
From	O
June	O
2004	O
to	O
October	O
2006	O
,	O
11	O
HBs	O
Ag	O
positive	O
patients	O
with	O
rheumatologic	O
diseases	B-DISEASE
,	O
who	O
were	O
on	O
both	O
immunosuppressive	O
and	O
prophylactic	O
lamivudine	B-CHEMICAL
therapies	O
,	O
were	O
retrospectively	O
assessed	O
.	O
Liver	O
function	O
tests	O
,	O
hepatitis	B-DISEASE
B	I-DISEASE
virus	O
(	O
HBV	O
)	O
serologic	O
markers	O
,	O
and	O
HBV	O
DNA	O
levels	O
of	O
the	O
patients	O
during	O
follow	O
-	O
up	O
were	O
obtained	O
from	O
hospital	O
file	O
records	O
.	O
Eleven	O
patients	O
(	O
six	O
male	O
)	O
with	O
median	O
age	O
47	O
years	O
(	O
range	O
27	O
-	O
73	O
)	O
,	O
median	O
disease	B-DISEASE
duration	O
50	O
months	O
(	O
range	O
9	O
-	O
178	O
)	O
and	O
median	O
follow	O
-	O
up	O
period	O
of	O
patients	O
13.8	O
months	O
(	O
range	O
5	O
-	O
27	O
)	O
were	O
enrolled	O
in	O
this	O
study	O
.	O
Lamivudine	B-CHEMICAL
therapy	O
was	O
started	O
3	O
-	O
7	O
days	O
prior	O
to	O
immunosuppressive	O
therapy	O
in	O
all	O
patients	O
.	O
Baseline	O
,	O
liver	O
function	O
tests	O
were	O
elevated	O
in	O
two	O
patients	O
(	O
fourth	O
patient	O
:	O
ALT:122	O
IU	O
/	O
l	O
,	O
AST:111	O
IU	O
/	O
l	O
,	O
tenth	O
patient	O
:	O
ALT:294	O
IU	O
/	O
l	O
,	O
AST:274	O
IU	O
/	O
l	O
,	O
with	O
minimal	O
changes	O
in	O
the	O
liver	O
biopsy	O
in	O
both	O
)	O
.	O
Shortly	O
after	O
treatment	O
their	O
tests	O
normalized	O
and	O
during	O
follow	O
-	O
up	O
period	O
none	O
of	O
the	O
patients	O
had	O
abnormal	B-DISEASE
liver	I-DISEASE
function	I-DISEASE
tests	O
.	O
In	O
four	O
patients	O
HBV	O
DNA	O
levels	O
were	O
higher	O
than	O
normal	O
at	O
baseline	O
.	O
Two	O
of	O
these	O
normalized	O
and	O
the	O
others	O
increased	O
later	O
.	O
In	O
three	O
additional	O
patients	O
,	O
HBV	O
DNA	O
levels	O
were	O
increased	O
during	O
follow	O
-	O
up	O
.	O
None	O
of	O
the	O
patients	O
had	O
significant	O
clinical	O
sings	O
of	O
HBV	O
activation	O
.	O
Lamivudine	B-CHEMICAL
was	O
well	O
tolerated	O
and	O
was	O
continued	O
in	O
all	O
patients	O
.	O
Prophylactic	O
administration	O
of	O
lamivudine	B-CHEMICAL
in	O
patients	O
who	O
required	O
immunosuppressive	O
therapy	O
seems	O
to	O
be	O
safe	O
,	O
well	O
tolerated	O
and	O
effective	O
in	O
preventing	O
HBV	O
reactivation	O
.	O

Safety	O
of	O
transesophageal	O
echocardiography	O
in	O
adults	O
:	O
study	O
in	O
a	O
multidisciplinary	O
hospital	O
.	O
BACKGROUND	O
:	O
TEE	O
is	O
a	O
semi	O
-	O
invasive	O
tool	O
broadly	O
used	O
and	O
its	O
utilization	O
associated	O
to	O
sedatives	O
drugs	O
might	O
to	O
affect	O
the	O
procedure	O
safety	O
.	O
OBJECTIVE	O
:	O
to	O
analyze	O
aspects	O
of	O
TEE	O
safety	O
associated	O
to	O
the	O
use	O
of	O
Midazolan	O
(	O
MZ	O
)	O
and	O
Flumazenil	O
(	O
FL	O
)	O
and	O
the	O
influence	O
of	O
the	O
clinical	O
variables	O
on	O
the	O
event	O
rate	O
.	O
METHOD	O
:	O
prospective	O
study	O
with	O
137	O
patients	O
that	O
underwent	O
TEE	O
with	O
MZ	O
associated	O
to	O
moderate	O
sedation	O
.	O
We	O
analyzed	O
the	O
following	O
events	O
:	O
complications	B-DISEASE
related	O
with	O
the	O
topical	O
anesthesia	O
,	O
with	O
MZ	O
use	O
and	O
with	O
the	O
procedure	O
.	O
Uni-	O
and	O
multivariate	O
analyses	O
were	O
used	O
to	O
test	O
the	O
influence	O
of	O
the	O
clinical	O
variables	O
:	O
age	O
,	O
sex	O
,	O
stroke	B-DISEASE
,	O
myocardiopathy	O
(	O
MP	O
)	O
,	O
duration	O
of	O
the	O
test	O
,	O
mitral	B-DISEASE
regurgitation	I-DISEASE
(	O
MR	O
)	O
and	O
the	O
MZ	O
dose	O
.	O
RESULTS	O
:	O
All	O
patients	O
(	O
65+/-16	O
yrs	O
;	O
58	O
%	O
males	O
)	O
finished	O
the	O
examination	O
.	O
The	O
mean	O
doses	O
of	O
MZ	O
and	O
FL	O
were	O
4.3+/-1.9	O
mg	O
and	O
0.28+/-0.2	O
mg	O
,	O
respectively	O
.	O
The	O
duration	O
of	O
the	O
examination	O
and	O
the	O
mean	O
ejection	O
fraction	O
(	O
EF	O
)	O
were	O
16.4+/-6.1	O
minutes	O
and	O
60+/-9	O
%	O
,	O
respectively	O
.	O
Mild	O
hypoxia	B-DISEASE
(	O
SO2<90	O
%	O
)	O
was	O
the	O
most	O
common	O
event	O
(	O
11	O
patients	O
)	O
;	O
3	O
patients	O
(	O
2	O
%	O
)	O
presented	O
transient	O
hypoxia	B-DISEASE
due	O
to	O
upper	O
airway	B-DISEASE
obstruction	I-DISEASE
by	O
probe	O
introduction	O
and	O
8	O
(	O
5.8	O
%	O
)	O
due	O
to	O
hypoxia	B-DISEASE
caused	O
by	O
MZ	O
use	O
.	O
Transient	O
hypotension	B-DISEASE
(	O
SAP<90mmHg	O
)	O
occurred	O
in	O
1	O
patient	O
(	O
0.7	O
%	O
)	O
.	O
The	O
multivariate	O
analysis	O
showed	O
that	O
severe	O
MR	O
,	O
MP	O
(	O
EF<45	O
%	O
)	O
and	O
high	O
doses	O
of	O
MZ	O
(	O
>	O
5	O
mg	O
)	O
were	O
associated	O
with	O
events	O
(	O
p<0.001	O
)	O
.	O
The	O
EF	O
was	O
40	O
%	O
,	O
in	O
the	O
group	O
with	O
MP	O
and	O
44	O
%	O
in	O
the	O
group	O
with	O
severe	O
MR	O
and	O
it	O
can	O
be	O
a	O
factor	O
associated	O
with	O
clinical	O
events	O
in	O
the	O
last	O
group	O
.	O
CONCLUSION	O
:	O
TEE	O
with	O
sedation	O
presents	O
a	O
low	O
rate	O
of	O
events	O
.	O
There	O
were	O
no	O
severe	O
events	O
and	O
there	O
was	O
no	O
need	O
to	O
interrupt	O
the	O
examinations	O
.	O

Effects	O
of	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
on	O
bupivacaine	O
-	O
induced	O
toxicity	B-DISEASE
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
influence	O
of	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
on	O
bupivacaine	O
-	O
induced	O
acute	O
toxicity	B-DISEASE
.	O
For	O
each	O
of	O
the	O
three	O
tested	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
(	O
diltiazem	B-CHEMICAL
,	O
verapamil	B-CHEMICAL
and	O
bepridil	O
)	O
6	O
groups	O
of	O
mice	O
were	O
treated	O
by	O
two	O
different	O
doses	O
,	O
i.e.	O
2	O
and	O
10	O
mg	O
/	O
kg	O
/	O
i.p	O
.	O
,	O
or	O
an	O
equal	O
volume	O
of	O
saline	O
for	O
the	O
control	O
group	O
(	O
n	O
=	O
20	O
)	O
;	O
15	O
minutes	O
later	O
,	O
all	O
the	O
animals	O
were	O
injected	O
with	O
a	O
single	O
50	O
mg	O
/	O
kg	O
/	O
i.p	O
.	O
dose	O
of	O
bupivacaine	O
.	O
The	O
convulsant	O
activity	O
,	O
the	O
time	O
of	O
latency	O
to	O
convulse	O
and	O
the	O
mortality	O
rate	O
were	O
assessed	O
in	O
each	O
group	O
.	O
The	O
local	O
anesthetic	O
-	O
induced	O
mortality	O
was	O
significantly	O
increased	O
by	O
the	O
three	O
different	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
.	O
The	O
convulsant	O
activity	O
of	O
bupivacaine	O
was	O
not	O
significantly	O
modified	O
but	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
decreased	O
the	O
time	O
of	O
latency	O
to	O
obtain	O
bupivacaine	O
-	O
induced	O
convulsions	B-DISEASE
;	O
this	O
effect	O
was	O
less	O
pronounced	O
with	O
bepridil	O
.	O

Selegiline	B-CHEMICAL
-	O
induced	O
postural	O
hypotension	B-DISEASE
in	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
:	O
a	O
longitudinal	O
study	O
on	O
the	O
effects	O
of	O
drug	O
withdrawal	O
.	O
OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	B-DISEASE
's	I-DISEASE
Disease	I-DISEASE
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	O
patients	O
with	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
(	O
PD	O
)	O
randomized	O
to	O
receive	O
10	O
mg	O
selegiline	B-CHEMICAL
per	O
day	O
and	O
L	O
-	O
dopa	O
compared	O
with	O
those	O
taking	O
L	O
-	O
dopa	O
alone	O
.	O
Recently	O
,	O
we	O
found	O
that	O
therapy	O
with	O
selegiline	B-CHEMICAL
and	O
L	O
-	O
dopa	O
was	O
associated	O
with	O
selective	O
systolic	O
orthostatic	B-DISEASE
hypotension	I-DISEASE
which	O
was	O
abolished	O
by	O
withdrawal	O
of	O
selegiline	B-CHEMICAL
.	O
This	O
unwanted	O
effect	O
on	O
postural	O
blood	O
pressure	O
was	O
not	O
the	O
result	O
of	O
underlying	O
autonomic	O
failure	O
.	O
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
confirm	O
our	O
previous	O
findings	O
in	O
a	O
separate	O
cohort	O
of	O
patients	O
and	O
to	O
determine	O
the	O
time	O
course	O
of	O
the	O
cardiovascular	O
consequences	O
of	O
stopping	O
selegiline	B-CHEMICAL
in	O
the	O
expectation	O
that	O
this	O
might	O
shed	O
light	O
on	O
the	O
mechanisms	O
by	O
which	O
the	O
drug	O
causes	O
orthostatic	B-DISEASE
hypotension	I-DISEASE
.	O
METHODS	O
:	O
The	O
cardiovascular	O
responses	O
to	O
standing	O
and	O
head	O
-	O
up	O
tilt	O
were	O
studied	O
repeatedly	O
in	O
PD	O
patients	O
receiving	O
selegiline	B-CHEMICAL
and	O
as	O
the	O
drug	O
was	O
withdrawn	O
.	O
RESULTS	O
:	O
Head	O
-	O
up	O
tilt	O
caused	O
systolic	O
orthostatic	B-DISEASE
hypotension	I-DISEASE
which	O
was	O
marked	O
in	O
six	O
of	O
20	O
PD	O
patients	O
on	O
selegiline	B-CHEMICAL
,	O
one	O
of	O
whom	O
lost	O
consciousness	O
with	O
unrecordable	O
blood	O
pressures	O
.	O
A	O
lesser	O
degree	O
of	O
orthostatic	B-DISEASE
hypotension	I-DISEASE
occurred	O
with	O
standing	O
.	O
Orthostatic	B-DISEASE
hypotension	I-DISEASE
was	O
ameliorated	O
4	O
days	O
after	O
withdrawal	O
of	O
selegiline	B-CHEMICAL
and	O
totally	O
abolished	O
7	O
days	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O
Stopping	O
selegiline	B-CHEMICAL
also	O
significantly	O
reduced	O
the	O
supine	O
systolic	O
and	O
diastolic	O
blood	O
pressures	O
consistent	O
with	O
a	O
previously	O
undescribed	O
supine	O
pressor	O
action	O
.	O
CONCLUSION	O
:	O
This	O
study	O
confirms	O
our	O
previous	O
finding	O
that	O
selegiline	B-CHEMICAL
in	O
combination	O
with	O
L	O
-	O
dopa	O
is	O
associated	O
with	O
selective	O
orthostatic	B-DISEASE
hypotension	I-DISEASE
.	O
The	O
possibilities	O
that	O
these	O
cardiovascular	O
findings	O
might	O
be	O
the	O
result	O
of	O
non	O
-	O
selective	O
inhibition	O
of	O
monoamine	O
oxidase	O
or	O
of	O
amphetamine	O
and	O
metamphetamine	O
are	O
discussed	O
.	O

Explicit	O
episodic	O
memory	O
for	O
sensory	O
-	O
discriminative	O
components	O
of	O
capsaicin	B-CHEMICAL
-	O
induced	O
pain	B-DISEASE
:	O
immediate	O
and	O
delayed	O
ratings	O
.	O
Pain	B-DISEASE
memory	O
is	O
thought	O
to	O
affect	O
future	O
pain	B-DISEASE
sensitivity	O
and	O
thus	O
contribute	O
to	O
clinical	O
pain	B-DISEASE
conditions	O
.	O
Systematic	O
investigations	O
of	O
the	O
human	O
capacity	O
to	O
remember	O
sensory	O
features	O
of	O
experimental	O
pain	B-DISEASE
are	O
sparse	O
.	O
In	O
order	O
to	O
address	O
long	O
-	O
term	O
pain	B-DISEASE
memory	O
,	O
nine	O
healthy	O
male	O
volunteers	O
received	O
intradermal	O
injections	O
of	O
three	O
doses	O
of	O
capsaicin	B-CHEMICAL
(	O
0.05	O
,	O
1	O
and	O
20	O
microg	O
,	O
separated	O
by	O
15	O
min	O
breaks	O
)	O
,	O
each	O
given	O
three	O
times	O
in	O
a	O
balanced	O
design	O
across	O
three	O
sessions	O
at	O
one	O
week	O
intervals	O
.	O
Pain	B-DISEASE
rating	O
was	O
performed	O
using	O
a	O
computerized	O
visual	O
analogue	O
scale	O
(	O
0	O
-	O
100	O
)	O
digitized	O
at	O
1	O
/	O
s	O
,	O
either	O
immediately	O
online	O
or	O
one	O
hour	O
or	O
one	O
day	O
after	O
injection	O
.	O
Subjects	O
also	O
recalled	O
their	O
pains	O
one	O
week	O
later	O
.	O
Capsaicin	B-CHEMICAL
injection	O
reliably	O
induced	O
a	O
dose	O
-	O
dependent	O
flare	O
(	O
p<0.001	O
)	O
without	O
any	O
difference	O
within	O
or	O
across	O
sessions	O
.	O
The	O
strong	O
burning	O
pain	B-DISEASE
decayed	O
exponentially	O
within	O
a	O
few	O
minutes	O
.	O
Subjects	O
were	O
able	O
to	O
reliably	O
discriminate	O
pain	B-DISEASE
magnitude	O
and	O
duration	O
across	O
capsaicin	B-CHEMICAL
doses	O
(	O
both	O
p<0.001	O
)	O
,	O
regardless	O
of	O
whether	O
first	O
-	O
time	O
ratings	O
were	O
requested	O
immediately	O
,	O
after	O
one	O
hour	O
or	O
after	O
one	O
day	O
.	O
Pain	B-DISEASE
recall	O
after	O
one	O
week	O
was	O
similarly	O
precise	O
(	O
magnitude	O
:	O
p<0.01	O
,	O
duration	O
:	O
p<0.05	O
)	O
.	O
Correlation	O
with	O
rating	O
recall	O
after	O
one	O
week	O
was	O
best	O
when	O
first	O
-	O
time	O
ratings	O
were	O
requested	O
as	O
late	O
as	O
one	O
day	O
after	O
injection	O
(	O
R(2)=0.79	O
)	O
indicating	O
that	O
both	O
rating	O
retrievals	O
utilized	O
similar	O
memory	O
traces	O
.	O
These	O
results	O
indicate	O
a	O
reliable	O
memory	O
for	O
magnitude	O
and	O
duration	O
of	O
experimentally	O
induced	O
pain	B-DISEASE
.	O
The	O
data	O
further	O
suggest	O
that	O
the	O
consolidation	O
of	O
this	O
memory	O
is	O
an	O
important	O
interim	O
stage	O
,	O
and	O
may	O
take	O
up	O
to	O
one	O
day	O
.	O

Reversibility	O
of	O
captopril	B-CHEMICAL
-	O
induced	O
renal	B-DISEASE
insufficiency	I-DISEASE
after	O
prolonged	O
use	O
in	O
an	O
unusual	O
case	O
of	O
renovascular	O
hypertension	B-DISEASE
.	O
We	O
report	O
a	O
case	O
of	O
severe	O
hypertension	B-DISEASE
with	O
an	O
occluded	O
renal	O
artery	O
to	O
a	O
solitary	B-DISEASE
kidney	I-DISEASE
,	O
who	O
developed	O
sudden	O
deterioration	B-DISEASE
of	I-DISEASE
renal	I-DISEASE
function	I-DISEASE
following	O
treatment	O
with	O
captopril	B-CHEMICAL
.	O
His	O
renal	O
function	O
remained	O
impaired	O
but	O
stable	O
during	O
2	O
years	O
'	O
treatment	O
with	O
captopril	B-CHEMICAL
but	O
returned	O
to	O
pre	O
-	O
treatment	O
levels	O
soon	O
after	O
cessation	O
of	O
the	O
drug	O
.	O
This	O
indicates	O
reversibility	O
in	O
captopril	B-CHEMICAL
-	O
induced	O
renal	B-DISEASE
failure	I-DISEASE
even	O
after	O
its	O
prolonged	O
use	O
and	O
suggests	O
that	O
no	O
organic	O
damage	O
occurs	O
to	O
glomerular	O
arterioles	O
following	O
chronic	O
ACE	O
inhibition	O
.	O

Liver	B-DISEASE
disease	I-DISEASE
caused	O
by	O
propylthiouracil	B-CHEMICAL
.	O
This	O
report	O
presents	O
the	O
clinical	O
,	O
laboratory	O
,	O
and	O
light	O
and	O
electron	O
microscopic	O
observations	O
on	O
a	O
patient	O
with	O
chronic	B-DISEASE
active	I-DISEASE
(	I-DISEASE
aggressive	I-DISEASE
)	I-DISEASE
hepatitis	I-DISEASE
caused	O
by	O
the	O
administration	O
of	O
propylthiouracil	B-CHEMICAL
.	O
This	O
is	O
an	O
addition	O
to	O
the	O
list	O
of	O
drugs	O
that	O
must	O
be	O
considered	O
in	O
the	O
evaluation	O
of	O
chronic	B-DISEASE
liver	I-DISEASE
disease	I-DISEASE
.	O

Capsaicin	B-CHEMICAL
-	O
induced	O
muscle	O
pain	B-DISEASE
alters	O
the	O
excitability	O
of	O
the	O
human	O
jaw	O
-	O
stretch	O
reflex	O
.	O
The	O
pathophysiology	O
of	O
painful	O
temporomandibular	O
disorders	O
is	O
not	O
fully	O
understood	O
,	O
but	O
evidence	O
suggests	O
that	O
muscle	O
pain	B-DISEASE
modulates	O
motor	O
function	O
in	O
characteristic	O
ways	O
.	O
This	O
study	O
tested	O
the	O
hypothesis	O
that	O
activation	O
of	O
nociceptive	O
muscle	O
afferent	O
fibers	O
would	O
be	O
linked	O
to	O
an	O
increased	O
excitability	O
of	O
the	O
human	O
jaw	O
-	O
stretch	O
reflex	O
and	O
whether	O
this	O
process	O
would	O
be	O
sensitive	O
to	O
length	O
and	O
velocity	O
of	O
the	O
stretch	O
.	O
Capsaicin	B-CHEMICAL
(	O
10	O
micro	O
g	O
)	O
was	O
injected	O
into	O
the	O
masseter	O
muscle	O
to	O
induce	O
pain	B-DISEASE
in	O
11	O
healthy	O
volunteers	O
.	O
Short	O
-	O
latency	O
reflex	O
responses	O
were	O
evoked	O
in	O
the	O
masseter	O
and	O
temporalis	O
muscles	O
by	O
a	O
stretch	O
device	O
with	O
different	O
velocities	O
and	O
displacements	O
before	O
,	O
during	O
,	O
and	O
after	O
the	O
pain	B-DISEASE
.	O
The	O
normalized	O
reflex	O
amplitude	O
increased	O
with	O
an	O
increase	O
in	O
velocity	O
at	O
a	O
given	O
displacement	O
,	O
but	O
remained	O
constant	O
with	O
different	O
displacements	O
at	O
a	O
given	O
velocity	O
.	O
The	O
normalized	O
reflex	O
amplitude	O
was	O
significantly	O
higher	O
during	O
pain	B-DISEASE
,	O
but	O
only	O
at	O
faster	O
stretches	O
in	O
the	O
painful	O
muscle	O
.	O
Increased	O
sensitivity	O
of	O
the	O
fusimotor	O
system	O
during	O
acute	O
muscle	O
pain	B-DISEASE
could	O
be	O
one	O
likely	O
mechanism	O
to	O
explain	O
the	O
findings	O
.	O

Repetitive	O
transcranial	O
magnetic	O
stimulation	O
for	O
levodopa	B-CHEMICAL
-	O
induced	O
dyskinesias	B-DISEASE
in	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
.	O
In	O
a	O
placebo	O
-	O
controlled	O
,	O
single	O
-	O
blinded	O
,	O
crossover	O
study	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
"	O
real	O
"	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
versus	O
"	O
sham	O
"	O
rTMS	O
(	O
placebo	O
)	O
on	O
peak	O
dose	O
dyskinesias	B-DISEASE
in	O
patients	O
with	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
(	O
PD	O
)	O
.	O
Ten	O
patients	O
with	O
PD	O
and	O
prominent	O
dyskinesias	B-DISEASE
had	O
rTMS	O
(	O
1,800	O
pulses	O
;	O
1	O
Hz	O
rate	O
)	O
delivered	O
over	O
the	O
motor	O
cortex	O
for	O
4	O
consecutive	O
days	O
twice	O
,	O
once	O
real	O
stimuli	O
and	O
once	O
sham	O
stimulation	O
were	O
used	O
;	O
evaluations	O
were	O
done	O
at	O
the	O
baseline	O
and	O
1	O
day	O
after	O
the	O
end	O
of	O
each	O
of	O
the	O
treatment	O
series	O
.	O
Direct	O
comparison	O
between	O
sham	O
and	O
real	O
rTMS	O
effects	O
showed	O
no	O
significant	O
difference	O
in	O
clinician	O
-	O
assessed	O
dyskinesia	B-DISEASE
severity	O
.	O
However	O
,	O
comparison	O
with	O
the	O
baseline	O
showed	O
small	O
but	O
significant	O
reduction	O
in	O
dyskinesia	B-DISEASE
severity	O
following	O
real	O
rTMS	O
but	O
not	O
placebo	O
.	O
The	O
major	O
effect	O
was	O
on	O
dystonia	B-DISEASE
subscore	O
.	O
Similarly	O
,	O
in	O
patient	O
diaries	O
,	O
although	O
both	O
treatments	O
caused	O
reduction	O
in	O
subjective	O
dyskinesia	B-DISEASE
scores	O
during	O
the	O
days	O
of	O
intervention	O
,	O
the	O
effect	O
was	O
sustained	O
for	O
3	O
days	O
after	O
the	O
intervention	O
for	O
the	O
real	O
rTMS	O
only	O
.	O
Following	O
rTMS	O
,	O
no	O
side	O
effects	O
and	O
no	O
adverse	O
effects	O
on	O
motor	O
function	O
and	O
PD	O
symptoms	O
were	O
noted	O
.	O
The	O
results	O
suggest	O
the	O
existence	O
of	O
residual	O
beneficial	O
clinical	O
aftereffects	O
of	O
consecutive	O
daily	O
applications	O
of	O
low	O
-	O
frequency	O
rTMS	O
on	O
dyskinesias	B-DISEASE
in	O
PD	O
.	O
The	O
effects	O
may	O
be	O
further	O
exploited	O
for	O
potential	O
therapeutic	O
uses	O
.	O

Disulfiram	B-CHEMICAL
-	O
like	O
syndrome	B-DISEASE
after	O
hydrogen	O
cyanamide	O
professional	O
skin	O
exposure	O
:	O
two	O
case	O
reports	O
in	O
France	O
.	O
Hydrogen	O
cyanamide	O
is	O
a	O
plant	O
growth	O
regulator	O
used	O
in	O
agriculture	O
to	O
induce	O
bud	O
break	O
in	O
fruit	O
trees	O
.	O
Contact	O
with	O
the	O
skin	O
can	O
result	O
in	O
percutaneous	O
absorption	O
of	O
the	O
substance	O
that	O
inhibits	O
aldehyde	B-CHEMICAL
dehydrogenase	I-CHEMICAL
and	O
can	O
induce	O
acetaldehyde	O
syndrome	B-DISEASE
in	O
case	O
of	O
alcohol	O
use	O
.	O
The	O
purpose	O
of	O
this	O
report	O
is	O
to	O
describe	O
two	O
cases	O
of	O
a	O
disulfiram	B-CHEMICAL
-	O
like	O
syndrome	B-DISEASE
following	O
occupational	O
exposure	O
to	O
hydrogen	O
cyanamide	O
.	O
The	O
first	O
case	O
involved	O
a	O
59	O
-	O
year	O
-	O
old	O
man	O
who	O
used	O
Dormex	O
,	O
which	O
contains	O
hydrogen	O
cyanamide	O
,	O
without	O
protection	O
after	O
consuming	O
a	O
large	O
amount	O
of	O
alcohol	O
during	O
a	O
meal	O
.	O
In	O
less	O
than	O
1	O
hour	O
after	O
the	O
ingestion	O
of	O
alcohol	O
,	O
he	O
developed	O
malaise	O
with	O
flushing	B-DISEASE
of	O
the	O
face	O
,	O
tachycardia	B-DISEASE
,	O
and	O
dyspnea	B-DISEASE
.	O
Manifestations	O
regressed	O
spontaneously	O
under	O
surveillance	O
in	O
the	O
hospital	O
.	O
The	O
second	O
case	O
occurred	O
in	O
a	O
55	O
-	O
year	O
-	O
old	O
farmer	O
following	O
cutaneous	O
contact	O
with	O
Dormex	O
.	O
Five	O
hours	O
after	O
exposure	O
,	O
he	O
developed	O
disulfiram	B-CHEMICAL
-	O
like	O
syndrome	B-DISEASE
with	O
flushing	B-DISEASE
,	O
tachycardia	B-DISEASE
,	O
and	O
arterial	B-DISEASE
hypotension	I-DISEASE
after	O
consuming	O
three	O
glasses	O
of	O
wine	O
.	O
The	O
patient	O
recovered	O
spontaneously	O
in	O
3	O
hours	O
under	O
surveillance	O
in	O
the	O
hospital	O
.	O
These	O
cases	O
confirm	O
the	O
necessity	O
of	O
avoiding	O
alcohol	O
consumption	O
as	O
recommended	O
in	O
the	O
instructions	O
for	O
use	O
of	O
Dormex	O
and	O
of	O
preventing	O
cutaneous	O
contact	O
during	O
use	O
.	O

Repeated	O
trimipramine	O
induces	O
dopamine	B-CHEMICAL
D2	O
/	O
D3	O
and	O
alpha1	O
-	O
adrenergic	O
up	O
-	O
regulation	O
.	O
Trimipramine	O
(	O
TRI	O
)	O
,	O
which	O
shows	O
a	O
clinical	O
antidepressant	O
activity	O
,	O
is	O
chemically	O
related	O
to	O
imipramine	O
but	O
does	O
not	O
inhibit	O
the	O
reuptake	O
of	O
noradrenaline	B-CHEMICAL
and	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
,	O
nor	O
does	O
it	O
induce	O
beta	O
-	O
adrenergic	O
down	O
-	O
regulation	O
.	O
The	O
mechanism	O
of	O
its	O
antidepressant	O
activity	O
is	O
still	O
unknown	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
find	O
out	O
whether	O
TRI	O
given	O
repeatedly	O
was	O
able	O
to	O
induce	O
adaptive	O
changes	O
in	O
the	O
dopaminergic	O
and	O
alpha1	O
-	O
adrenergic	O
systems	O
,	O
demonstrated	O
by	O
us	O
previously	O
for	O
various	O
antidepressants	O
.	O
TRI	O
was	O
given	O
to	O
male	O
Wistar	O
rats	O
and	O
male	O
Albino	O
Swiss	O
mice	O
perorally	O
twice	O
daily	O
for	O
14	O
days	O
.	O
In	O
the	O
acute	O
experiment	O
TRI	O
(	O
given	O
i.p	O
.	O
)	O
does	O
not	O
antagonize	O
the	O
reserpine	B-CHEMICAL
hypothermia	B-DISEASE
in	O
mice	O
and	O
does	O
not	O
potentiate	O
the	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptophan	I-CHEMICAL
head	O
twitches	O
in	O
rats	O
.	O
TRI	O
given	O
repeatedly	O
to	O
rats	O
increases	O
the	O
locomotor	B-DISEASE
hyperactivity	I-DISEASE
induced	O
by	O
d	O
-	O
amphetamine	O
,	O
quinpirole	O
and	O
(	O
+	O
)	O
-7	O
-	O
hydroxy	O
-	O
dipropyloaminotetralin	O
(	O
dopamine	B-CHEMICAL
D2	O
and	O
D3	O
effects	O
)	O
.	O
The	O
stereotypies	O
induced	O
by	O
d	O
-	O
amphetamine	O
or	O
apomorphine	O
are	O
not	O
potentiated	O
by	O
TRI	O
.	O
It	O
increases	O
the	O
behaviour	O
stimulation	O
evoked	O
by	O
phenylephrine	B-CHEMICAL
(	O
given	O
intraventricularly	O
)	O
in	O
rats	O
,	O
evaluated	O
in	O
the	O
open	O
field	O
test	O
as	O
well	O
as	O
the	O
aggressiveness	B-DISEASE
evoked	O
by	O
clonidine	B-CHEMICAL
in	O
mice	O
,	O
both	O
these	O
effects	O
being	O
mediated	O
by	O
an	O
alpha1	O
-	O
adrenergic	O
receptor	O
.	O
It	O
may	O
be	O
concluded	O
that	O
,	O
like	O
other	O
tricyclic	O
antidepressants	O
studied	O
previously	O
,	O
TRI	O
given	O
repeatedly	O
increases	O
the	O
responsiveness	O
of	O
brain	O
dopamine	B-CHEMICAL
D2	O
and	O
D3	O
(	O
locomotor	O
activity	O
but	O
not	O
stereotypy	O
)	O
as	O
well	O
as	O
alpha1	O
-	O
adrenergic	O
receptors	O
to	O
their	O
agonists	O
.	O
A	O
question	O
arises	O
whether	O
the	O
reuptake	O
inhibition	O
is	O
of	O
any	O
importance	O
to	O
the	O
adaptive	O
changes	O
induced	O
by	O
repeated	O
antidepressants	O
,	O
suggested	O
to	O
be	O
responsible	O
for	O
the	O
antidepressant	O
activity	O
.	O

Ranitidine	B-CHEMICAL
-	O
induced	O
acute	O
interstitial	B-DISEASE
nephritis	I-DISEASE
in	O
a	O
cadaveric	O
renal	O
allograft	O
.	O
Ranitidine	B-CHEMICAL
frequently	O
is	O
used	O
for	O
preventing	O
peptic	O
ulceration	O
after	O
renal	O
transplantation	O
.	O
This	O
drug	O
occasionally	O
has	O
been	O
associated	O
with	O
acute	O
interstitial	B-DISEASE
nephritis	I-DISEASE
in	O
native	O
kidneys	O
.	O
There	O
are	O
no	O
similar	O
reports	O
with	O
renal	O
transplantation	O
.	O
We	O
report	O
a	O
case	O
of	O
ranitidine	B-CHEMICAL
-	O
induced	O
acute	O
interstitial	B-DISEASE
nephritis	I-DISEASE
in	O
a	O
recipient	O
of	O
a	O
cadaveric	O
renal	O
allograft	O
presenting	O
with	O
acute	O
allograft	O
dysfunction	O
within	O
48	O
hours	O
of	O
exposure	O
to	O
the	O
drug	O
.	O
The	O
biopsy	O
specimen	O
showed	O
pathognomonic	O
features	O
,	O
including	O
eosinophilic	B-DISEASE
infiltration	O
of	O
the	O
interstitial	O
compartment	O
.	O
Allograft	O
function	O
improved	O
rapidly	O
and	O
returned	O
to	O
baseline	O
after	O
stopping	O
the	O
drug	O
.	O

Late	O
,	O
late	O
doxorubicin	B-CHEMICAL
cardiotoxicity	B-DISEASE
.	O
Cardiac	B-DISEASE
toxicity	I-DISEASE
is	O
a	O
major	O
complication	O
which	O
limits	O
the	O
use	O
of	O
adriamycin	B-CHEMICAL
as	O
a	O
chemotherapeutic	O
agent	O
.	O
Cardiomyopathy	B-DISEASE
is	O
frequent	O
when	O
the	O
total	O
dose	O
exceeds	O
600	O
mg	O
/	O
m2	O
and	O
occurs	O
within	O
one	O
to	O
six	O
months	O
after	O
cessation	O
of	O
therapy	O
.	O
A	O
patient	O
is	O
reported	O
who	O
developed	O
progressive	O
cardiomyopathy	B-DISEASE
two	O
and	O
one	O
-	O
half	O
years	O
after	O
receiving	O
580	O
mg	O
/	O
m2	O
which	O
apparently	O
represents	O
late	O
,	O
late	O
cardiotoxicity	B-DISEASE
.	O

Acetazolamide	O
-	O
induced	O
nephrolithiasis	B-DISEASE
:	O
implications	O
for	O
treatment	O
of	O
neuromuscular	O
disorders	O
.	O
Carbonic	B-CHEMICAL
anhydrase	I-CHEMICAL
inhibitors	I-CHEMICAL
can	O
cause	O
nephrolithiasis	B-DISEASE
.	O
We	O
studied	O
20	O
patients	O
receiving	O
long	O
-	O
term	O
carbonic	O
anhydrase	O
inhibitor	O
treatment	O
for	O
periodic	O
paralysis	B-DISEASE
and	O
myotonia	B-DISEASE
.	O
Three	O
patients	O
on	O
acetazolamide	O
(	O
15	O
%	O
)	O
developed	O
renal	B-DISEASE
calculi	I-DISEASE
.	O
Extracorporeal	O
lithotripsy	O
successfully	O
removed	O
a	O
renal	B-DISEASE
calculus	I-DISEASE
in	O
one	O
patient	O
and	O
surgery	O
removed	O
a	O
staghorn	O
calculus	B-DISEASE
in	O
another	O
,	O
permitting	O
continued	O
treatment	O
.	O
Renal	O
function	O
remained	O
normal	O
in	O
all	O
patients	O
.	O
Nephrolithiasis	B-DISEASE
is	O
a	O
complication	O
of	O
acetazolamide	O
but	O
does	O
not	O
preclude	O
its	O
use	O
.	O

Is	O
the	O
treatment	O
of	O
scabies	B-DISEASE
hazardous	O
?	O
Treatment	O
for	O
scabies	B-DISEASE
is	O
usually	O
initiated	O
by	O
general	O
practitioners	O
;	O
most	O
consider	O
lindane	B-CHEMICAL
(	O
gamma	O
benzene	O
hexachloride	O
)	O
the	O
treatment	O
of	O
choice	O
.	O
Lindane	B-CHEMICAL
is	O
also	O
widely	O
used	O
as	O
an	O
agricultural	O
and	O
industrial	O
pesticide	O
,	O
and	O
as	O
a	O
result	O
the	O
toxic	O
profile	O
of	O
this	O
insecticide	O
is	O
well	O
understood	O
.	O
Evidence	O
is	O
accumulating	O
that	O
lindane	B-CHEMICAL
can	O
be	O
toxic	O
to	O
the	O
central	O
nervous	O
system	O
and	O
may	O
be	O
associated	O
with	O
aplastic	B-DISEASE
anaemia	I-DISEASE
.	O
Preparations	O
containing	O
lindane	B-CHEMICAL
continue	O
to	O
be	O
sold	O
over	O
the	O
counter	O
and	O
may	O
represent	O
a	O
hazard	O
to	O
poorly	O
informed	O
patients	O
.	O
This	O
literature	O
review	O
suggests	O
that	O
general	O
practitioners	O
should	O
prescribe	O
scabicides	O
with	O
increased	O
caution	O
for	O
certain	O
at	O
-	O
risk	O
groups	O
,	O
and	O
give	O
adequate	O
warnings	O
regarding	O
potential	O
toxicity	B-DISEASE
.	O

Anaesthetists	O
'	O
nightmare	O
:	O
masseter	O
spasm	B-DISEASE
after	O
induction	O
in	O
an	O
undiagnosed	O
case	O
of	O
myotonia	B-DISEASE
congenita	I-DISEASE
.	O
We	O
report	O
an	O
undiagnosed	O
case	O
of	O
myotonia	B-DISEASE
congenita	I-DISEASE
in	O
a	O
24	O
-	O
year	O
-	O
old	O
previously	O
healthy	O
primigravida	O
,	O
who	O
developed	O
life	O
threatening	O
masseter	O
spasm	B-DISEASE
following	O
a	O
standard	O
dose	O
of	O
intravenous	O
suxamethonium	B-CHEMICAL
for	O
induction	O
of	O
anaesthesia	O
.	O
Neither	O
the	O
patient	O
nor	O
the	O
anaesthetist	O
was	O
aware	O
of	O
the	O
diagnosis	O
before	O
this	O
potentially	O
lethal	O
complication	O
occurred	O
.	O

Toxicity	B-DISEASE
in	O
rhesus	O
monkeys	O
following	O
administration	O
of	O
the	O
8	B-CHEMICAL
-	I-CHEMICAL
aminoquinoline	I-CHEMICAL
8-[(4	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
l	I-CHEMICAL
-	I-CHEMICAL
methylbutyl)amino]-	I-CHEMICAL
5-(l	I-CHEMICAL
-	I-CHEMICAL
hexyloxy)-6	I-CHEMICAL
-	I-CHEMICAL
methoxy-4	I-CHEMICAL
-	I-CHEMICAL
methylquinoline	I-CHEMICAL
(	O
WR242511	O
)	O
.	O
INTRODUCTION	O
:	O
Many	O
substances	O
that	O
form	O
methemoglobin	O
(	O
MHb	O
)	O
effectively	O
counter	O
cyanide	O
(	O
CN	O
)	O
toxicity	B-DISEASE
.	O
Although	O
MHb	O
formers	O
are	O
generally	O
applied	O
as	O
treatments	O
for	O
CN	O
poisoning	B-DISEASE
,	O
it	O
has	O
been	O
proposed	O
that	O
a	O
stable	O
,	O
long	O
-	O
acting	O
MHb	O
former	O
could	O
serve	O
as	O
a	O
CN	O
pretreatment	O
.	O
Using	O
this	O
rationale	O
,	O
the	O
8	B-CHEMICAL
-	I-CHEMICAL
aminoquinoline	I-CHEMICAL
WR242511	O
,	O
a	O
potent	O
long	O
-	O
lasting	O
MHb	O
former	O
in	O
rodents	O
and	O
beagle	O
dogs	O
,	O
was	O
studied	O
in	O
the	O
rhesus	O
monkey	O
for	O
advanced	O
development	O
as	O
a	O
potential	O
CN	O
pretreatment	O
.	O
METHODS	O
:	O
In	O
this	O
study	O
,	O
WR242511	O
was	O
administered	O
intravenously	O
(	O
IV	O
)	O
in	O
2	O
female	O
and	O
4	O
male	O
rhesus	O
monkeys	O
in	O
doses	O
of	O
3.5	O
and/or	O
7.0	O
mg	O
/	O
kg	O
;	O
a	O
single	O
male	O
also	O
received	O
WR242511	O
orally	O
(	O
PO	O
)	O
at	O
7.0	O
mg	O
/	O
kg	O
.	O
Health	O
status	O
and	O
MHb	O
levels	O
were	O
monitored	O
following	O
exposure	O
.	O
RESULTS	O
:	O
The	O
selected	O
doses	O
of	O
WR242511	O
,	O
which	O
produced	O
significant	O
methemoglobinemia	B-DISEASE
in	O
beagle	O
dogs	O
in	O
earlier	O
studies	O
conducted	O
elsewhere	O
,	O
produced	O
very	O
little	O
MHb	O
(	O
mean	O
<	O
2.0	O
%	O
)	O
in	O
the	O
rhesus	O
monkey	O
.	O
Furthermore	O
,	O
transient	O
hemoglobinuria	B-DISEASE
was	O
noted	O
approximately	O
60	O
minutes	O
postinjection	O
of	O
WR242511	O
(	O
3.5	O
or	O
7.0	O
mg	O
/	O
kg	O
)	O
,	O
and	O
2	O
lethalities	O
occurred	O
(	O
one	O
IV	O
and	O
one	O
PO	O
)	O
following	O
the	O
7.0	O
mg	O
/	O
kg	O
dose	O
.	O
Myoglobinuria	B-DISEASE
was	O
also	O
observed	O
following	O
the	O
7.0	O
mg	O
/	O
kg	O
dose	O
.	O
Histopathology	O
analyses	O
in	O
the	O
2	O
animals	O
that	O
died	O
revealed	O
liver	O
and	O
kidney	O
toxicity	B-DISEASE
,	O
with	O
greater	O
severity	O
in	O
the	O
orally	O
-	O
treated	O
animal	O
.	O
CONCLUSIONS	O
:	O
These	O
data	O
demonstrate	O
direct	O
and/or	O
indirect	O
drug	O
-	O
induced	O
toxicity	B-DISEASE
.	O
It	O
is	O
concluded	O
that	O
WR242511	O
should	O
not	O
be	O
pursued	O
as	O
a	O
pretreatment	O
for	O
CN	O
poisoning	B-DISEASE
unless	O
the	O
anti	O
-	O
CN	O
characteristics	O
of	O
this	O
compound	O
can	O
be	O
successfully	O
dissociated	O
from	O
those	O
producing	O
undesirable	O
toxicity	B-DISEASE
.	O

Neuroplasticity	O
of	O
the	O
adult	O
primate	O
auditory	O
cortex	O
following	O
cochlear	O
hearing	B-DISEASE
loss	I-DISEASE
.	O
Tonotopic	O
organization	O
is	O
an	O
essential	O
feature	O
of	O
the	O
primary	O
auditory	O
area	O
(	O
A1	O
)	O
of	O
primate	O
cortex	O
.	O
In	O
A1	O
of	O
macaque	O
monkeys	O
,	O
low	O
frequencies	O
are	O
represented	O
rostrolaterally	O
and	O
high	O
frequencies	O
are	O
represented	O
caudomedially	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
changes	O
occur	O
in	O
this	O
tonotopic	O
organization	O
following	O
cochlear	O
hearing	B-DISEASE
loss	I-DISEASE
.	O
Under	O
anesthesia	O
,	O
the	O
superior	O
temporal	O
gyrus	O
of	O
adult	O
macaque	O
monkeys	O
was	O
exposed	O
,	O
and	O
the	O
tonotopic	O
organization	O
of	O
A1	O
was	O
mapped	O
using	O
conventional	O
microelectrode	O
recording	O
techniques	O
.	O
Following	O
recovery	O
,	O
the	O
monkeys	O
were	O
selectively	O
deafened	O
for	O
high	O
frequencies	O
using	O
kanamycin	B-CHEMICAL
and	O
furosemide	B-CHEMICAL
.	O
The	O
actual	O
frequencies	O
deafened	O
were	O
determined	O
by	O
the	O
loss	O
of	O
tone	O
-	O
burst	O
elicited	O
auditory	O
brainstem	O
responses	O
.	O
Three	O
months	O
after	O
deafening	O
,	O
A1	O
was	O
remapped	O
.	O
Postmortem	O
cytoarchitectural	O
features	O
identifying	O
A1	O
were	O
correlated	O
with	O
the	O
electrophysiologic	O
data	O
.	O
The	O
results	O
indicate	O
that	O
the	O
deprived	O
area	O
of	O
A1	O
undergoes	O
extensive	O
reorganization	O
and	O
becomes	O
responsive	O
to	O
intact	O
cochlear	O
frequencies	O
.	O
The	O
region	O
of	O
cortex	O
that	O
represents	O
the	O
low	O
frequencies	O
was	O
not	O
obviously	O
affected	O
by	O
the	O
cochlear	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

The	O
site	O
of	O
common	O
side	O
effects	O
of	O
sumatriptan	B-CHEMICAL
.	O
Atypical	O
sensations	O
following	O
the	O
use	O
of	O
subcutaneous	O
sumatriptan	B-CHEMICAL
are	O
common	O
,	O
but	O
of	O
uncertain	O
origin	O
.	O
They	O
are	O
almost	O
always	O
benign	O
,	O
but	O
can	O
be	O
mistaken	O
for	O
a	O
serious	O
adverse	O
event	O
by	O
the	O
patient	O
.	O
Two	O
patients	O
are	O
presented	O
with	O
tingling	O
or	O
burning	O
sensations	O
limited	O
to	O
areas	O
of	O
heat	O
exposure	O
or	O
sunburn	B-DISEASE
.	O
In	O
these	O
individuals	O
,	O
side	O
effects	O
are	O
most	O
likely	O
generated	O
superficially	O
in	O
the	O
skin	O
.	O

Tremor	B-DISEASE
side	O
effects	O
of	O
salbutamol	B-CHEMICAL
,	O
quantified	O
by	O
a	O
laser	O
pointer	O
technique	O
.	O
OBJECTIVE	O
:	O
To	O
study	O
tremor	B-DISEASE
side	O
effects	O
of	O
salbutamol	B-CHEMICAL
an	O
easily	O
applicable	O
,	O
quick	O
and	O
low	O
-	O
priced	O
method	O
is	O
needed	O
.	O
A	O
new	O
method	O
using	O
a	O
commercially	O
available	O
,	O
pen	O
-	O
shaped	O
laser	O
pointer	O
was	O
developed	O
.	O
Aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
sensitivity	O
,	O
reproducibility	O
,	O
reference	O
values	O
and	O
the	O
agreement	O
with	O
a	O
questionnaire	O
.	O
METHODS	O
:	O
Tremor	B-DISEASE
was	O
measured	O
using	O
a	O
laser	O
pointer	O
technique	O
.	O
To	O
determine	O
sensitivity	O
we	O
assessed	O
tremor	B-DISEASE
in	O
44	O
patients	O
with	O
obstructive	O
lung	B-DISEASE
disease	I-DISEASE
after	O
administration	O
of	O
cumulative	O
doses	O
of	O
salbutamol	B-CHEMICAL
.	O
Subjects	O
were	O
asked	O
to	O
aim	O
at	O
the	O
centre	O
of	O
a	O
target	O
,	O
subdivided	O
in	O
concentric	O
circles	O
,	O
from	O
5	O
m	O
distance	O
.	O
The	O
circle	O
in	O
which	O
the	O
participant	O
succeeded	O
to	O
aim	O
was	O
recorded	O
in	O
millimetres	O
radius	O
.	O
In	O
another	O
series	O
of	O
measurements	O
,	O
reproducibility	O
and	O
reference	O
values	O
of	O
the	O
tremor	B-DISEASE
was	O
assessed	O
in	O
65	O
healthy	O
subjects	O
in	O
three	O
sessions	O
,	O
at	O
9	O
a.m.	O
,	O
4	O
p.m.	O
and	O
9	O
a.m.	O
,	O
respectively	O
,	O
1	O
week	O
later	O
.	O
Postural	O
tremor	B-DISEASE
was	O
measured	O
with	O
the	O
arm	O
horizontally	O
outstretched	O
rest	O
tremor	B-DISEASE
with	O
the	O
arm	O
supported	O
by	O
an	O
armrest	O
and	O
finally	O
tremor	B-DISEASE
was	O
measured	O
after	O
holding	O
a	O
2	O
-	O
kg	O
weight	O
until	O
exhaustion	O
.	O
Inter	O
-	O
observer	O
variability	O
was	O
measured	O
in	O
a	O
series	O
of	O
10	O
healthy	O
subjects	O
.	O
Tremor	B-DISEASE
was	O
measured	O
simultaneously	O
by	O
two	O
independent	O
observers	O
.	O
RESULTS	O
:	O
Salbutamol	B-CHEMICAL
significantly	O
increased	O
tremor	B-DISEASE
severity	O
in	O
patients	O
in	O
a	O
dose	O
-	O
dependent	O
way	O
.	O
Within	O
healthy	O
adults	O
no	O
age	O
-	O
dependency	O
could	O
be	O
found	O
(	O
b	O
=	O
0.262	O
mm	O
/	O
year	O
;	O
P	O
=	O
0.72	O
)	O
.	O
There	O
was	O
no	O
agreement	O
between	O
the	O
questionnaire	O
and	O
tremor	B-DISEASE
severity	O
(	O
r	O
=	O
0.093	O
;	O
P	O
=	O
0.53	O
)	O
.	O
Postural	O
tremor	B-DISEASE
showed	O
no	O
significant	O
difference	O
between	O
the	O
first	O
and	O
third	O
session	O
(	O
P	O
=	O
0.07	O
)	O
.	O
Support	O
of	O
the	O
arm	O
decreased	O
tremor	B-DISEASE
severity	O
,	O
exhaustion	O
increased	O
tremor	B-DISEASE
severity	O
significantly	O
.	O
A	O
good	O
agreement	O
was	O
found	O
between	O
two	O
independent	O
observers	O
(	O
interclass	O
correlation	O
coefficient	O
0.72	O
)	O
.	O
DISCUSSION	O
:	O
Quantifying	O
tremor	B-DISEASE
by	O
using	O
an	O
inexpensive	O
laser	O
pointer	O
is	O
,	O
with	O
the	O
exception	O
of	O
children	O
(	O
<	O
12	O
years	O
)	O
a	O
sensitive	O
and	O
reproducible	O
method	O
.	O

Increased	O
frequency	O
of	O
venous	B-DISEASE
thromboembolism	I-DISEASE
with	O
the	O
combination	O
of	O
docetaxel	B-CHEMICAL
and	O
thalidomide	B-CHEMICAL
in	O
patients	O
with	O
metastatic	O
androgen	O
-	O
independent	O
prostate	B-DISEASE
cancer	I-DISEASE
.	O
STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
venous	B-DISEASE
thromboembolism	I-DISEASE
(	O
VTE	B-DISEASE
)	O
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	B-DISEASE
cancer	I-DISEASE
who	O
were	O
treated	O
with	O
docetaxel	B-CHEMICAL
alone	O
or	O
in	O
combination	O
with	O
thalidomide	B-CHEMICAL
.	O
DESIGN	O
:	O
Retrospective	O
analysis	O
of	O
a	O
randomized	O
phase	O
II	O
trial	O
.	O
SETTING	O
:	O
National	O
Institutes	O
of	O
Health	O
clinical	O
research	O
center	O
.	O
PATIENTS	O
:	O
Seventy	O
men	O
,	O
aged	O
50	O
-	O
80	O
years	O
,	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	B-DISEASE
cancer	I-DISEASE
.	O
INTERVENTION	O
:	O
Each	O
patient	O
received	O
either	O
intravenous	O
docetaxel	B-CHEMICAL
30	O
mg	O
/	O
m2	O
/	O
week	O
for	O
3	O
consecutive	O
weeks	O
,	O
followed	O
by	O
1	O
week	O
off	O
,	O
or	O
the	O
combination	O
of	O
continuous	O
oral	O
thalidomide	B-CHEMICAL
200	O
mg	O
every	O
evening	O
plus	O
the	O
same	O
docetaxel	B-CHEMICAL
regimen	O
.	O
This	O
4	O
-	O
week	O
cycle	O
was	O
repeated	O
until	O
there	O
was	O
evidence	O
of	O
excessive	O
toxicity	B-DISEASE
or	O
disease	B-DISEASE
progression	I-DISEASE
.	O
MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
23	O
patients	O
who	O
received	O
docetaxel	B-CHEMICAL
alone	O
developed	O
VTE	B-DISEASE
,	O
whereas	O
9	O
of	O
47	O
patients	O
(	O
19	O
%	O
)	O
who	O
received	O
docetaxel	B-CHEMICAL
plus	O
thalidomide	B-CHEMICAL
developed	O
VTE	B-DISEASE
(	O
p=0.025	O
)	O
.	O
CONCLUSION	O
:	O
The	O
addition	O
of	O
thalidomide	B-CHEMICAL
to	O
docetaxel	B-CHEMICAL
in	O
the	O
treatment	O
of	O
prostate	B-DISEASE
cancer	I-DISEASE
significantly	O
increases	O
the	O
frequency	O
of	O
VTE	B-DISEASE
.	O
Clinicians	O
should	O
be	O
aware	O
of	O
this	O
potential	O
complication	O
when	O
adding	O
thalidomide	B-CHEMICAL
to	O
chemotherapeutic	O
regimens	O
.	O

Sublingual	O
absorption	O
of	O
the	O
quaternary	O
ammonium	O
antiarrhythmic	O
agent	O
,	O
UM-272	O
.	O
UM-272	O
(	O
N	O
,	O
N	O
-	O
dimethylpropranolol	O
)	O
,	O
a	O
quaternary	O
antiarrhythmic	O
agent	O
,	O
was	O
administered	O
sublingually	O
to	O
dogs	O
with	O
ouabain	B-CHEMICAL
-	O
induced	O
ventricular	O
tachycardias	O
.	O
Both	O
anti	O
-	O
arrhythmic	B-DISEASE
efficacy	O
and	O
bioavailability	O
were	O
compared	O
to	O
oral	O
drug	O
.	O
Sublingual	O
UM-272	O
converted	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
to	O
sinus	O
rhythm	O
in	O
all	O
5	O
dogs	O
.	O
The	O
area	O
under	O
the	O
plasma	O
concentration	O
time	O
curve	O
at	O
90	O
min	O
was	O
4	O
-	O
12	O
times	O
greater	O
than	O
for	O
oral	O
drug	O
,	O
suggesting	O
the	O
existence	O
of	O
an	O
absorption	O
-	O
limiting	O
process	O
in	O
the	O
intestine	O
,	O
and	O
providing	O
an	O
alternate	O
form	O
of	O
administration	O
for	O
quaternary	O
drugs	O
.	O

Severe	O
thrombocytopenia	B-DISEASE
and	O
haemolytic	O
anaemia	B-DISEASE
associated	O
with	O
ciprofloxacin	B-CHEMICAL
:	O
a	O
case	O
report	O
with	O
fatal	O
outcome	O
.	O
Haematological	O
adverse	O
reactions	O
associated	O
with	O
fatal	O
outcome	O
are	O
rare	O
during	O
treatment	O
with	O
ciprofloxacin	B-CHEMICAL
.	O
A	O
30	O
-	O
year	O
old	O
Caucasian	O
man	O
reported	O
with	O
abdominal	B-DISEASE
pain	I-DISEASE
and	O
jaundice	B-DISEASE
after	O
3	O
-	O
day	O
administration	O
of	O
oral	O
ciprofloxacin	B-CHEMICAL
for	O
a	O
suspect	O
of	O
urinary	B-DISEASE
tract	I-DISEASE
infection	I-DISEASE
.	O
Clinical	O
evaluations	O
suggested	O
an	O
initial	O
diagnosis	O
of	O
severe	O
thrombocytopenia	B-DISEASE
and	O
haemolysis	B-DISEASE
.	O
The	O
patient	O
progressively	O
developed	O
petechiae	O
and	O
purpura	B-DISEASE
on	O
thorax	O
and	O
lower	O
limbs	O
.	O
Despite	O
pharmacological	O
and	O
supportive	O
interventions	O
,	O
laboratory	O
parameters	O
worsened	O
and	O
the	O
patient	O
died	O
17	O
hours	O
after	O
admission	O
.	O
An	O
accurate	O
autopsy	O
revealed	O
most	O
organs	O
with	O
diffuse	O
petechial	O
haemorrhages	O
.	O
No	O
signs	O
of	O
bone	B-DISEASE
marrow	I-DISEASE
depression	I-DISEASE
were	O
found	O
.	O
No	O
thrombi	B-DISEASE
or	O
signs	O
of	O
microangiopathies	O
were	O
observed	O
in	O
arterial	O
vessels	O
.	O
Blood	O
and	O
urine	O
cultures	O
did	O
not	O
show	O
any	O
bacterial	O
growth	O
.	O
This	O
case	O
report	O
shows	O
that	O
ciprofloxacin	B-CHEMICAL
may	O
precipitate	O
life	O
-	O
threatening	O
thrombocytopenia	B-DISEASE
and	O
haemolytic	O
anaemia	B-DISEASE
,	O
even	O
in	O
the	O
early	O
phases	O
of	O
treatment	O
and	O
without	O
apparent	O
previous	O
exposures	O
.	O

Simvastatin	B-CHEMICAL
-	O
induced	O
bilateral	O
leg	O
compartment	B-DISEASE
syndrome	I-DISEASE
and	O
myonecrosis	O
associated	O
with	O
hypothyroidism	B-DISEASE
.	O
A	O
54	O
-	O
year	O
-	O
old	O
hypothyroid	B-DISEASE
male	O
taking	O
thyroxine	B-CHEMICAL
and	O
simvastatin	B-CHEMICAL
presented	O
with	O
bilateral	O
leg	O
compartment	B-DISEASE
syndrome	I-DISEASE
and	O
myonecrosis	O
.	O
Urgent	O
fasciotomies	O
were	O
performed	O
and	O
the	O
patient	O
made	O
an	O
uneventful	O
recovery	O
with	O
the	O
withdrawal	O
of	O
simvastatin	B-CHEMICAL
.	O
It	O
is	O
likely	O
that	O
this	O
complication	O
will	O
be	O
seen	O
more	O
often	O
with	O
the	O
increased	O
worldwide	O
use	O
of	O
this	O
drug	O
and	O
its	O
approval	O
for	O
all	O
arteriopathic	B-DISEASE
patients	O
.	O

Bile	O
duct	O
hamartoma	B-DISEASE
occurring	O
in	O
association	O
with	O
long	O
-	O
term	O
treatment	O
with	O
danazol	B-CHEMICAL
.	O
We	O
report	O
a	O
case	O
of	O
bile	O
duct	O
hamartoma	B-DISEASE
which	O
developed	O
in	O
a	O
patient	O
who	O
had	O
been	O
on	O
long	O
-	O
term	O
danazol	B-CHEMICAL
treatment	O
.	O
Such	O
patients	O
should	O
be	O
under	O
close	O
follow	O
-	O
up	O
,	O
preferably	O
with	O
periodic	O
ultrasound	O
examination	O
of	O
the	O
liver	O
.	O
If	O
the	O
patient	O
develops	O
a	O
liver	O
mass	O
,	O
because	O
of	O
non	O
-	O
specific	O
clinical	O
features	O
and	O
imaging	O
appearances	O
,	O
biopsy	O
may	O
be	O
the	O
only	O
way	O
to	O
achieve	O
a	O
definitive	O
diagnosis	O
.	O

Granulomatous	O
hepatitis	B-DISEASE
due	O
to	O
combination	O
of	O
amoxicillin	O
and	O
clavulanic	B-CHEMICAL
acid	I-CHEMICAL
.	O
We	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
amoxicillin	O
-	O
clavulanic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
hepatitis	B-DISEASE
with	O
histologic	O
multiple	O
granulomas	O
.	O
This	O
type	O
of	O
lesion	O
broadens	O
the	O
spectrum	O
of	O
liver	B-DISEASE
injury	I-DISEASE
due	O
to	O
this	O
drug	O
combination	O
,	O
mainly	O
represented	O
by	O
a	O
benign	O
cholestatic	B-DISEASE
syndrome	I-DISEASE
.	O
The	O
association	O
of	O
granulomas	O
and	O
eosinophilia	B-DISEASE
favor	O
an	O
immunoallergic	O
mechanism	O
.	O
As	O
penicillin	B-CHEMICAL
derivatives	O
and	O
amoxicillin	O
alone	O
are	O
known	O
to	O
induce	O
such	O
types	O
of	O
lesions	O
,	O
the	O
amoxicillin	O
component	O
,	O
with	O
or	O
without	O
a	O
potentiating	O
effect	O
of	O
clavulanic	B-CHEMICAL
acid	I-CHEMICAL
,	O
might	O
have	O
a	O
major	O
role	O
.	O

Intracranial	B-DISEASE
aneurysms	I-DISEASE
and	O
cocaine	B-DISEASE
abuse	I-DISEASE
:	O
analysis	O
of	O
prognostic	O
indicators	O
.	O
OBJECTIVE	O
:	O
The	O
outcome	O
of	O
subarachnoid	B-DISEASE
hemorrhage	I-DISEASE
associated	O
with	O
cocaine	B-DISEASE
abuse	I-DISEASE
is	O
reportedly	O
poor	O
.	O
However	O
,	O
no	O
study	O
in	O
the	O
literature	O
has	O
reported	O
the	O
use	O
of	O
a	O
statistical	O
model	O
to	O
analyze	O
the	O
variables	O
that	O
influence	O
outcome	O
.	O
METHODS	O
:	O
A	O
review	O
of	O
admissions	O
during	O
a	O
6	O
-	O
year	O
period	O
revealed	O
14	O
patients	O
with	O
cocaine	B-CHEMICAL
-	O
related	O
aneurysms	B-DISEASE
.	O
This	O
group	O
was	O
compared	O
with	O
a	O
control	O
group	O
of	O
135	O
patients	O
with	O
ruptured	B-DISEASE
aneurysms	I-DISEASE
and	O
no	O
history	O
of	O
cocaine	B-DISEASE
abuse	I-DISEASE
.	O
Age	O
at	O
presentation	O
,	O
time	O
of	O
ictus	O
after	O
intoxication	O
,	O
Hunt	O
and	O
Hess	O
grade	O
of	O
subarachnoid	B-DISEASE
hemorrhage	I-DISEASE
,	O
size	O
of	O
the	O
aneurysm	B-DISEASE
,	O
location	O
of	O
the	O
aneurysm	B-DISEASE
,	O
and	O
the	O
Glasgow	O
Outcome	O
Scale	O
score	O
were	O
assessed	O
and	O
compared	O
.	O
RESULTS	O
:	O
The	O
patients	O
in	O
the	O
study	O
group	O
were	O
significantly	O
younger	O
than	O
the	O
patients	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.002	O
)	O
.	O
In	O
patients	O
in	O
the	O
study	O
group	O
,	O
all	O
aneurysms	B-DISEASE
were	O
located	O
in	O
the	O
anterior	O
circulation	O
.	O
The	O
majority	O
of	O
these	O
aneurysms	B-DISEASE
were	O
smaller	O
than	O
those	O
of	O
the	O
control	O
group	O
(	O
8	O
+	O
/-	O
6.08	O
mm	O
versus	O
11	O
+	O
/-	O
5.4	O
mm	O
;	O
P	O
=	O
0.05	O
)	O
.	O
The	O
differences	O
in	O
mortality	O
and	O
morbidity	O
between	O
the	O
two	O
groups	O
were	O
not	O
significant	O
.	O
Hunt	O
and	O
Hess	O
grade	O
(	O
P	O
<	O
0.005	O
)	O
and	O
age	O
(	O
P	O
<	O
0.007	O
)	O
were	O
significant	O
predictors	O
of	O
outcome	O
for	O
the	O
patients	O
with	O
cocaine	B-CHEMICAL
-	O
related	O
aneurysms	B-DISEASE
.	O
CONCLUSION	O
:	O
Cocaine	B-CHEMICAL
use	O
predisposed	O
aneurysmal	B-DISEASE
rupture	I-DISEASE
at	O
a	O
significantly	O
earlier	O
age	O
and	O
in	O
much	O
smaller	O
aneurysms	B-DISEASE
.	O
Contrary	O
to	O
the	O
published	O
literature	O
,	O
this	O
group	O
did	O
reasonably	O
well	O
with	O
aggressive	O
management	O
.	O

Anti	O
-	O
epileptic	B-DISEASE
drugs	O
-	O
induced	O
de	O
novo	O
absence	B-DISEASE
seizures	I-DISEASE
.	O
The	O
authors	O
present	O
three	O
patients	O
with	O
de	O
novo	O
absence	B-DISEASE
epilepsy	I-DISEASE
after	O
administration	O
of	O
carbamazepine	B-CHEMICAL
and	O
vigabatrin	B-CHEMICAL
.	O
Despite	O
the	O
underlying	O
diseases	B-DISEASE
,	O
the	O
prognosis	O
for	O
drug	O
-	O
induced	O
de	O
novo	O
absence	B-DISEASE
seizure	I-DISEASE
is	O
good	O
because	O
it	O
subsides	O
rapidly	O
after	O
discontinuing	O
the	O
use	O
of	O
the	O
offending	O
drugs	O
.	O
The	O
gamma	B-CHEMICAL
-	I-CHEMICAL
aminobutyric	I-CHEMICAL
acid	I-CHEMICAL
-	O
transmitted	O
thalamocortical	O
circuitry	O
accounts	O
for	O
a	O
major	O
part	O
of	O
the	O
underlying	O
neurophysiology	O
of	O
the	O
absence	B-DISEASE
epilepsy	I-DISEASE
.	O
Because	O
drug	O
-	O
induced	O
de	O
novo	O
absence	B-DISEASE
seizure	I-DISEASE
is	O
rare	O
,	O
pro	O
-	O
absence	O
drugs	O
can	O
only	O
be	O
considered	O
a	O
promoting	O
factor	O
.	O
The	O
underlying	O
epileptogenecity	O
of	O
the	O
patients	O
or	O
the	O
synergistic	O
effects	O
of	O
the	O
accompanying	O
drugs	O
is	O
required	O
to	O
trigger	O
the	O
de	O
novo	O
absence	B-DISEASE
seizure	I-DISEASE
.	O
The	O
possibility	O
of	O
drug	O
-	O
induced	O
aggravation	O
should	O
be	O
considered	O
whenever	O
an	O
unexpected	O
increase	O
in	O
seizure	B-DISEASE
frequency	O
and/or	O
new	O
seizure	B-DISEASE
types	O
appear	O
following	O
a	O
change	O
in	O
drug	O
treatment	O
.	O
By	O
understanding	O
the	O
underlying	O
mechanism	O
of	O
absence	B-DISEASE
epilepsy	I-DISEASE
,	O
we	O
can	O
avoid	O
the	O
inappropriate	O
use	O
of	O
anticonvulsants	O
in	O
children	O
with	O
epilepsy	B-DISEASE
and	O
prevent	O
drug	O
-	O
induced	O
absence	B-DISEASE
seizures	I-DISEASE
.	O

Procainamide	B-CHEMICAL
-	O
induced	O
polymorphous	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
.	O
Seven	O
cases	O
of	O
procainamide	B-CHEMICAL
-	O
induced	O
polymorphous	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
are	O
presented	O
.	O
In	O
four	O
patients	O
,	O
polymorphous	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
appeared	O
after	O
intravenous	O
administration	O
of	O
200	O
to	O
400	O
mg	O
of	O
procainamide	B-CHEMICAL
for	O
the	O
treatment	O
of	O
sustained	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
.	O
In	O
the	O
remaining	O
three	O
patients	O
,	O
procainamide	B-CHEMICAL
was	O
administered	O
orally	O
for	O
treatment	O
of	O
chronic	O
premature	O
ventricular	O
contractions	O
or	O
atrial	B-DISEASE
flutter	I-DISEASE
.	O
These	O
patients	O
had	O
Q	B-DISEASE
-	I-DISEASE
T	I-DISEASE
prolongation	I-DISEASE
and	O
recurrent	O
syncope	B-DISEASE
due	O
to	O
polymorphous	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
.	O
In	O
four	O
patients	O
,	O
the	O
arrhythmia	B-DISEASE
was	O
rapidly	O
diagnosed	O
and	O
treated	O
with	O
disappearance	O
of	O
further	O
episodes	O
of	O
the	O
arrhythmia	B-DISEASE
.	O
In	O
two	O
patients	O
,	O
the	O
arrhythmia	B-DISEASE
degenerated	O
into	O
irreversible	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
and	O
both	O
patients	O
died	O
.	O
In	O
the	O
seventh	O
patient	O
,	O
a	O
permanent	O
ventricular	O
pacemaker	O
was	O
inserted	O
and	O
,	O
despite	O
continuation	O
of	O
procainamide	B-CHEMICAL
therapy	O
,	O
polymorphous	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
did	O
not	O
reoccur	O
.	O
These	O
seven	O
cases	O
demonstrate	O
that	O
procainamide	B-CHEMICAL
can	O
produce	O
an	O
acquired	O
prolonged	O
Q	O
-	O
T	O
syndrome	B-DISEASE
with	O
polymorphous	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
.	O

Role	O
of	O
activation	O
of	O
bradykinin	B-CHEMICAL
B2	O
receptors	O
in	O
disruption	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B-DISEASE
.	O
Cellular	O
mechanisms	O
which	O
account	O
for	O
disruption	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B-DISEASE
are	O
not	O
clear	O
.	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
role	O
of	O
synthesis	O
/	O
release	O
of	O
bradykinin	B-CHEMICAL
to	O
activate	O
B2	O
receptors	O
in	O
disruption	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B-DISEASE
.	O
Permeability	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
was	O
quantitated	O
by	O
clearance	O
of	O
fluorescent	O
-	O
labeled	O
dextran	B-CHEMICAL
before	O
and	O
during	O
phenylephrine	B-CHEMICAL
-	O
induced	O
acute	O
hypertension	B-DISEASE
in	O
rats	O
treated	O
with	O
vehicle	O
and	O
Hoe-140	O
(	O
0.1	O
microM	O
)	O
.	O
Phenylephrine	B-CHEMICAL
infusion	O
increased	O
arterial	O
pressure	O
,	O
arteriolar	O
diameter	O
and	O
clearance	O
of	O
fluorescent	O
dextran	B-CHEMICAL
by	O
a	O
similar	O
magnitude	O
in	O
both	O
groups	O
.	O
These	O
findings	O
suggest	O
that	O
disruption	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B-DISEASE
is	O
not	O
related	O
to	O
the	O
synthesis	O
/	O
release	O
of	O
bradykinin	B-CHEMICAL
to	O
activate	O
B2	O
receptors	O
.	O

5	B-CHEMICAL
-	I-CHEMICAL
azacytidine	I-CHEMICAL
potentiates	O
initiation	O
induced	O
by	O
carcinogens	O
in	O
rat	O
liver	O
.	O
To	O
test	O
the	O
validity	O
of	O
the	O
hypothesis	O
that	O
hypomethylation	O
of	O
DNA	O
plays	O
an	O
important	O
role	O
in	O
the	O
initiation	O
of	O
carcinogenic	B-DISEASE
process	O
,	O
5	B-CHEMICAL
-	I-CHEMICAL
azacytidine	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
AzC	I-CHEMICAL
)	O
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
an	O
inhibitor	O
of	O
DNA	O
methylation	O
,	O
was	O
given	O
to	O
rats	O
during	O
the	O
phase	O
of	O
repair	O
synthesis	O
induced	O
by	O
the	O
three	O
carcinogens	O
,	O
benzo[a]-pyrene	O
(	O
200	O
mg	O
/	O
kg	O
)	O
,	O
N	O
-	O
methyl	O
-	O
N	O
-	O
nitrosourea	O
(	O
60	O
mg	O
/	O
kg	O
)	O
and	O
1,2	B-CHEMICAL
-	I-CHEMICAL
dimethylhydrazine	I-CHEMICAL
(	O
1,2	B-CHEMICAL
-	I-CHEMICAL
DMH	I-CHEMICAL
)	O
(	O
100	O
mg	O
/	O
kg	O
)	O
.	O
The	O
initiated	O
hepatocytes	O
in	O
the	O
liver	O
were	O
assayed	O
as	O
the	O
gamma	O
-	O
glutamyltransferase	O
(	O
gamma	O
-	O
GT	O
)	O
positive	O
foci	O
formed	O
following	O
a	O
2	O
-	O
week	O
selection	O
regimen	O
consisting	O
of	O
dietary	O
0.02	O
%	O
2	B-CHEMICAL
-	I-CHEMICAL
acetylaminofluorene	I-CHEMICAL
coupled	O
with	O
a	O
necrogenic	O
dose	O
of	O
CCl4	O
.	O
The	O
results	O
obtained	O
indicate	O
that	O
with	O
all	O
three	O
carcinogens	O
,	O
administration	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
AzC	I-CHEMICAL
during	O
repair	O
synthesis	O
increased	O
the	O
incidence	O
of	O
initiated	O
hepatocytes	O
,	O
for	O
example	O
10	O
-	O
20	O
foci	O
/	O
cm2	O
in	O
5	B-CHEMICAL
-	I-CHEMICAL
AzC	I-CHEMICAL
and	O
carcinogen	O
-	O
treated	O
rats	O
compared	O
with	O
3	O
-	O
5	O
foci	O
/	O
cm2	O
in	O
rats	O
treated	O
with	O
carcinogen	O
only	O
.	O
Administration	O
of	O
[	O
3H]-5	O
-	O
azadeoxycytidine	O
during	O
the	O
repair	O
synthesis	O
induced	O
by	O
1,2	B-CHEMICAL
-	I-CHEMICAL
DMH	I-CHEMICAL
further	O
showed	O
that	O
0.019	O
mol	O
%	O
of	O
cytosine	O
residues	O
in	O
DNA	O
were	O
substituted	O
by	O
the	O
analogue	O
,	O
indicating	O
that	O
incorporation	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
AzC	I-CHEMICAL
occurs	O
during	O
repair	O
synthesis	O
.	O
In	O
the	O
absence	O
of	O
the	O
carcinogen	O
,	O
5	B-CHEMICAL
-	I-CHEMICAL
AzC	I-CHEMICAL
given	O
after	O
a	O
two	O
thirds	O
partial	O
hepatectomy	O
,	O
when	O
its	O
incorporation	O
should	O
be	O
maximum	O
,	O
failed	O
to	O
induce	O
any	O
gamma	O
-	O
GT	O
positive	O
foci	O
.	O
The	O
results	O
suggest	O
that	O
hypomethylation	O
of	O
DNA	O
per	O
se	B-DISEASE
may	O
not	O
be	O
sufficient	O
for	O
initiation	O
.	O
Perhaps	O
two	O
events	O
might	O
be	O
necessary	O
for	O
initiation	O
,	O
the	O
first	O
caused	O
by	O
the	O
carcinogen	O
and	O
a	O
second	O
involving	O
hypomethylation	O
of	O
DNA	O
.	O

Withdrawal	O
-	O
emergent	O
rabbit	B-DISEASE
syndrome	I-DISEASE
during	O
dose	O
reduction	O
of	O
risperidone	B-CHEMICAL
.	O
Rabbit	B-DISEASE
syndrome	I-DISEASE
(	O
RS	B-DISEASE
)	O
is	O
a	O
rare	O
extrapyramidal	O
side	O
effect	O
caused	O
by	O
prolonged	O
neuroleptic	O
medication	O
.	O
Here	O
we	O
present	O
a	O
case	O
of	O
withdrawal	O
-	O
emergent	O
RS	B-DISEASE
,	O
which	O
is	O
the	O
first	O
of	O
its	O
kind	O
to	O
be	O
reported	O
.	O
The	O
patient	O
developed	O
RS	B-DISEASE
during	O
dose	O
reduction	O
of	O
risperidone	B-CHEMICAL
.	O
The	O
symptom	O
was	O
treated	O
successfully	O
with	O
trihexyphenidyl	B-CHEMICAL
anticholinergic	O
therapy	O
.	O
The	O
underlying	O
mechanism	O
of	O
withdrawal	O
-	O
emergent	O
RS	B-DISEASE
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	B-CHEMICAL
,	O
a	O
serotonin	B-CHEMICAL
-	O
dopamine	B-CHEMICAL
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	O
influence	O
of	O
the	O
serotonin	B-CHEMICAL
system	O
in	O
the	O
development	O
of	O
RS	B-DISEASE
.	O

Verapamil	B-CHEMICAL
withdrawal	O
as	O
a	O
possible	O
cause	O
of	O
myocardial	B-DISEASE
infarction	I-DISEASE
in	O
a	O
hypertensive	B-DISEASE
woman	O
with	O
a	O
normal	O
coronary	O
angiogram	O
.	O
Verapamil	B-CHEMICAL
is	O
an	O
effective	O
and	O
relatively	O
-	O
safe	O
antihypertensive	O
drug	O
.	O
Serious	O
adverse	O
effects	O
are	O
uncommon	O
and	O
mainly	O
have	O
been	O
related	O
to	O
the	O
depression	B-DISEASE
of	O
cardiac	O
contractility	O
and	O
conduction	O
,	O
especially	O
when	O
the	O
drug	O
is	O
combined	O
with	O
beta	O
-	O
blocking	O
agents	O
.	O
We	O
report	O
a	O
case	O
in	O
which	O
myocardial	B-DISEASE
infarction	I-DISEASE
coincided	O
with	O
the	O
introduction	O
of	O
captopril	B-CHEMICAL
and	O
the	O
withdrawal	O
of	O
verapamil	B-CHEMICAL
in	O
a	O
previously	O
asymptomatic	O
woman	O
with	O
severe	O
hypertension	B-DISEASE
.	O
Possible	O
mechanisms	O
that	O
involve	O
a	O
verapamil	B-CHEMICAL
-	O
related	O
increase	O
in	O
platelet	O
and/or	O
vascular	O
alpha	O
2	O
-	O
adrenoreceptor	O
affinity	O
for	O
catecholamines	O
are	O
discussed	O
.	O

Remission	O
induction	O
of	O
meningeal	O
leukemia	B-DISEASE
with	O
high	O
-	O
dose	O
intravenous	O
methotrexate	B-CHEMICAL
.	O
Twenty	O
children	O
with	O
acute	B-DISEASE
lymphoblastic	I-DISEASE
leukemia	I-DISEASE
who	O
developed	O
meningeal	O
disease	B-DISEASE
were	O
treated	O
with	O
a	O
high	O
-	O
dose	O
intravenous	O
methotrexate	B-CHEMICAL
regimen	O
that	O
was	O
designed	O
to	O
achieve	O
and	O
maintain	O
CSF	O
methotrexate	B-CHEMICAL
concentrations	O
of	O
10(-5	O
)	O
mol	O
/	O
L	O
without	O
the	O
need	O
for	O
concomitant	O
intrathecal	O
dosing	O
.	O
The	O
methotrexate	B-CHEMICAL
was	O
administered	O
as	O
a	O
loading	O
dose	O
of	O
6,000	O
mg	O
/	O
m2	O
for	O
a	O
period	O
of	O
one	O
hour	O
followed	O
by	O
an	O
infusion	O
of	O
1,200	O
mg	O
/	O
m2	O
/	O
h	O
for	O
23	O
hours	O
.	O
Leucovorin	O
rescue	O
was	O
initiated	O
12	O
hours	O
after	O
the	O
end	O
of	O
the	O
infusion	O
with	O
a	O
loading	O
dose	O
of	O
200	O
mg	O
/	O
m2	O
followed	O
by	O
12	O
mg	O
/	O
m2	O
every	O
three	O
hours	O
for	O
six	O
doses	O
and	O
then	O
every	O
six	O
hours	O
until	O
the	O
plasma	O
methotrexate	B-CHEMICAL
level	O
decreased	O
to	O
less	O
than	O
1	O
X	O
10(-7	O
)	O
mol	O
/	O
L.	O
The	O
mean	O
steady	O
-	O
state	O
plasma	O
and	O
CSF	O
methotrexate	B-CHEMICAL
concentrations	O
achieved	O
were	O
1.1	O
X	O
10(-3	O
)	O
mol	O
/	O
L	O
and	O
3.6	O
X	O
10(-5	O
)	O
mol	O
/	O
L	O
,	O
respectively	O
.	O
All	O
20	O
patients	O
responded	O
to	O
this	O
regimen	O
,	O
16/20	O
(	O
80	O
%	O
)	O
achieved	O
a	O
complete	O
remission	O
,	O
and	O
20	O
%	O
obtained	O
a	O
partial	O
remission	O
.	O
The	O
most	O
common	O
toxicities	B-DISEASE
encountered	O
were	O
transient	O
serum	O
transaminase	O
and	O
bilirubin	O
elevations	O
,	O
neutropenia	B-DISEASE
,	O
and	O
mucositis	B-DISEASE
.	O
One	O
patient	O
had	O
focal	O
seizures	B-DISEASE
and	O
transient	O
hemiparesis	O
but	O
recovered	O
completely	O
.	O
High	O
-	O
dose	O
intravenous	O
methotrexate	B-CHEMICAL
is	O
an	O
effective	O
treatment	O
for	O
the	O
induction	O
of	O
remission	O
after	O
meningeal	O
relapse	O
in	O
acute	B-DISEASE
lymphoblastic	I-DISEASE
leukemia	I-DISEASE
.	O

Hypersensitivity	B-DISEASE
to	O
carbamazepine	B-CHEMICAL
presenting	O
with	O
a	O
leukemoid	B-DISEASE
reaction	I-DISEASE
,	O
eosinophilia	B-DISEASE
,	O
erythroderma	B-DISEASE
,	O
and	O
renal	B-DISEASE
failure	I-DISEASE
.	O
We	O
report	O
a	O
patient	O
in	O
whom	O
hypersensitivity	B-DISEASE
to	O
carbamazepine	B-CHEMICAL
presented	O
with	O
generalized	O
erythroderma	B-DISEASE
,	O
a	O
severe	O
leukemoid	B-DISEASE
reaction	I-DISEASE
,	O
eosinophilia	B-DISEASE
,	O
hyponatremia	B-DISEASE
,	O
and	O
renal	B-DISEASE
failure	I-DISEASE
.	O
This	O
is	O
the	O
first	O
report	O
of	O
such	O
an	O
unusual	O
reaction	O
to	O
carbamazepine	B-CHEMICAL
.	O

The	O
interpeduncular	O
nucleus	O
regulates	O
nicotine	B-CHEMICAL
's	O
effects	O
on	O
free	O
-	O
field	O
activity	O
.	O
Partial	O
lesions	O
were	O
made	O
with	O
kainic	O
acid	O
in	O
the	O
interpeduncular	O
nucleus	O
of	O
the	O
ventral	O
midbrain	O
of	O
the	O
rat	O
.	O
Compared	O
with	O
sham	O
-	O
operated	O
controls	O
,	O
lesions	O
significantly	O
(	O
p	O
<	O
0.25	O
)	O
blunted	O
the	O
early	O
(	O
<	O
60	O
min	O
)	O
free	O
-	O
field	O
locomotor	O
hypoactivity	O
caused	O
by	O
nicotine	B-CHEMICAL
(	O
0.5	O
mg	O
kg(-1	O
)	O
,	O
i.m	O
.	O
)	O
,	O
enhanced	O
the	O
later	O
(	O
60	O
-	O
120	O
min	O
)	O
nicotine	B-CHEMICAL
-	O
induced	O
hyperactivity	O
,	O
and	O
raised	O
spontaneous	O
nocturnal	O
activity	O
.	O
Lesions	O
reduced	O
the	O
extent	O
of	O
immunohistological	O
staining	O
for	O
choline	B-CHEMICAL
acetyltransferase	O
in	O
the	O
interpeduncular	O
nucleus	O
(	O
p	O
<	O
0.025	O
)	O
,	O
but	O
not	O
for	O
tyrosine	B-CHEMICAL
hydroxylase	O
in	O
the	O
surrounding	O
catecholaminergic	O
A10	O
region	O
.	O
We	O
conclude	O
that	O
the	O
interpeduncular	O
nucleus	O
mediates	O
nicotinic	O
depression	B-DISEASE
of	O
locomotor	O
activity	O
and	O
dampens	O
nicotinic	O
arousal	O
mechanisms	O
located	O
elsewhere	O
in	O
the	O
brain	O
.	O

Assessment	O
of	O
a	O
new	O
non	O
-	O
invasive	O
index	O
of	O
cardiac	O
performance	O
for	O
detection	O
of	O
dobutamine	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
ischemia	I-DISEASE
.	O
BACKGROUND	O
:	O
Electrocardiography	O
has	O
a	O
very	O
low	O
sensitivity	O
in	O
detecting	O
dobutamine	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
ischemia	I-DISEASE
.	O
OBJECTIVES	O
:	O
To	O
assess	O
the	O
added	O
diagnostic	O
value	O
of	O
a	O
new	O
cardiac	O
performance	O
index	O
(	O
dP	O
/	O
dtejc	O
)	O
measurement	O
,	O
based	O
on	O
brachial	O
artery	O
flow	O
changes	O
,	O
as	O
compared	O
to	O
standard	O
12	O
-	O
lead	O
ECG	O
,	O
for	O
detecting	O
dobutamine	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
ischemia	I-DISEASE
,	O
using	O
Tc99m	O
-	O
Sestamibi	O
single	O
-	O
photon	O
emission	O
computed	O
tomography	O
as	O
the	O
gold	O
standard	O
of	O
comparison	O
to	O
assess	O
the	O
presence	O
or	O
absence	O
of	O
ischemia	B-DISEASE
.	O
METHODS	O
:	O
The	O
study	O
group	O
comprised	O
40	O
patients	O
undergoing	O
Sestamibi	O
-	O
SPECT	O
/	O
dobutamine	B-CHEMICAL
stress	B-DISEASE
test	O
.	O
Simultaneous	O
measurements	O
of	O
ECG	O
and	O
brachial	O
artery	O
dP	O
/	O
dtejc	O
were	O
performed	O
at	O
each	O
dobutamine	B-CHEMICAL
level	O
.	O
In	O
19	O
of	O
the	O
40	O
patients	O
perfusion	O
defects	O
compatible	O
with	O
ischemia	B-DISEASE
were	O
detected	O
on	O
SPECT	O
.	O
The	O
increase	O
in	O
dP	O
/	O
dtejc	O
during	O
infusion	O
of	O
dobutamine	B-CHEMICAL
in	O
this	O
group	O
was	O
severely	O
impaired	O
as	O
compared	O
to	O
the	O
non	O
-	O
ischemic	B-DISEASE
group	O
.	O
dP	O
/	O
dtejc	O
outcome	O
was	O
combined	O
with	O
the	O
ECG	O
results	O
,	O
giving	O
an	O
ECG	O
-	O
enhanced	O
value	O
,	O
and	O
compared	O
to	O
ECG	O
alone	O
.	O
RESULTS	O
:	O
The	O
sensitivity	O
improved	O
dramatically	O
from	O
16	O
%	O
to	O
79	O
%	O
,	O
positive	O
predictive	O
value	O
increased	O
from	O
60	O
%	O
to	O
68	O
%	O
and	O
negative	O
predictive	O
value	O
from	O
54	O
%	O
to	O
78	O
%	O
,	O
and	O
specificity	O
decreased	O
from	O
90	O
%	O
to	O
67	O
%	O
.	O
CONCLUSIONS	O
:	O
If	O
ECG	O
alone	O
is	O
used	O
for	O
specificity	O
,	O
the	O
combination	O
with	O
dP	O
/	O
dtejc	O
improved	O
the	O
sensitivity	O
of	O
the	O
test	O
and	O
could	O
be	O
a	O
cost	O
-	O
savings	O
alternative	O
to	O
cardiac	O
imaging	O
or	O
perfusion	O
studies	O
to	O
detect	O
myocardial	B-DISEASE
ischemia	I-DISEASE
,	O
especially	O
in	O
patients	O
unable	O
to	O
exercise	O
.	O

Acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
in	O
two	O
patients	O
with	O
regular	O
alcohol	O
consumption	O
ingesting	O
paracetamol	B-CHEMICAL
at	O
therapeutic	O
dosage	O
.	O
BACKGROUND	O
:	O
The	O
possible	O
role	O
of	O
alcohol	O
in	O
the	O
development	O
of	O
hepatotoxicity	O
associated	O
with	O
therapeutic	O
doses	O
of	O
paracetamol	B-CHEMICAL
(	O
acetaminophen	B-CHEMICAL
)	O
is	O
currently	O
debated	O
.	O
CASE	O
REPORT	O
:	O
We	O
describe	O
2	O
patients	O
who	O
were	O
regular	O
consumers	O
of	O
alcohol	O
and	O
who	O
developed	O
liver	B-DISEASE
failure	I-DISEASE
within	O
3	O
-	O
5	O
days	O
after	O
hospitalization	O
and	O
stopping	O
alcohol	O
consumption	O
while	O
being	O
treated	O
with	O
4	O
g	O
paracetamol	B-CHEMICAL
/	O
day	O
.	O
A	O
paracetamol	B-CHEMICAL
serum	O
level	O
obtained	O
in	O
one	O
of	O
these	O
patients	O
was	O
not	O
in	O
the	O
toxic	O
range	O
.	O
Possible	O
risk	O
factors	O
for	O
the	O
development	O
of	O
hepatotoxicity	O
in	O
patients	O
treated	O
with	O
therapeutic	O
doses	O
of	O
paracetamol	B-CHEMICAL
are	O
discussed	O
.	O
CONCLUSION	O
:	O
In	O
patients	O
with	O
risk	O
factors	O
,	O
e.g.	O
regular	O
consumption	O
of	O
alcohol	O
,	O
liver	B-DISEASE
failure	I-DISEASE
is	O
possible	O
when	O
therapeutic	O
doses	O
are	O
ingested	O
.	O
We	O
propose	O
that	O
the	O
paracetamol	B-CHEMICAL
dose	O
should	O
not	O
exceed	O
2	O
g	O
/	O
day	O
in	O
such	O
patients	O
and	O
that	O
their	O
liver	O
function	O
should	O
be	O
monitored	O
closely	O
while	O
being	O
treated	O
with	O
paracetamol	B-CHEMICAL
.	O

Cocaine	B-CHEMICAL
related	O
chest	B-DISEASE
pain	I-DISEASE
:	O
are	O
we	O
seeing	O
the	O
tip	O
of	O
an	O
iceberg	O
?	O
The	O
recreational	O
use	O
of	O
cocaine	B-CHEMICAL
is	O
on	O
the	O
increase	O
.	O
The	O
emergency	O
nurse	O
ought	O
to	O
be	O
familiar	O
with	O
some	O
of	O
the	O
cardiovascular	O
consequences	O
of	O
cocaine	B-CHEMICAL
use	O
.	O
In	O
particular	O
,	O
the	O
tendency	O
of	O
cocaine	B-CHEMICAL
to	O
produce	O
chest	B-DISEASE
pain	I-DISEASE
ought	O
to	O
be	O
in	O
the	O
mind	O
of	O
the	O
emergency	O
nurse	O
when	O
faced	O
with	O
a	O
young	O
victim	O
of	O
chest	B-DISEASE
pain	I-DISEASE
who	O
is	O
otherwise	O
at	O
low	O
risk	O
.	O
The	O
mechanism	O
of	O
chest	B-DISEASE
pain	I-DISEASE
related	O
to	O
cocaine	B-CHEMICAL
use	O
is	O
discussed	O
and	O
treatment	O
dilemmas	O
are	O
discussed	O
.	O
Finally	O
,	O
moral	O
issues	O
relating	O
to	O
the	O
testing	O
of	O
potential	O
cocaine	B-CHEMICAL
users	O
will	O
be	O
addressed	O
.	O

Severe	O
rhabdomyolysis	B-DISEASE
and	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
secondary	O
to	O
concomitant	O
use	O
of	O
simvastatin	B-CHEMICAL
,	O
amiodarone	B-CHEMICAL
,	O
and	O
atazanavir	O
.	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
a	O
severe	O
interaction	O
between	O
simvastatin	B-CHEMICAL
,	O
amiodarone	B-CHEMICAL
,	O
and	O
atazanavir	O
resulting	O
in	O
rhabdomyolysis	B-DISEASE
and	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
.	O
BACKGROUND	O
:	O
A	O
72	O
-	O
year	O
-	O
old	O
white	O
man	O
with	O
underlying	O
human	O
immunodeficiency	O
virus	O
,	O
atrial	B-DISEASE
fibrillation	I-DISEASE
,	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
,	O
and	O
hyperlipidemia	O
presented	O
with	O
generalized	O
pain	B-DISEASE
,	O
fatigue	B-DISEASE
,	O
and	O
dark	O
orange	O
urine	O
for	O
3	O
days	O
.	O
The	O
patient	O
was	O
taking	O
80	O
mg	O
simvastatin	B-CHEMICAL
at	O
bedtime	O
(	O
initiated	O
27	O
days	O
earlier	O
)	O
;	O
amiodarone	B-CHEMICAL
at	O
a	O
dose	O
of	O
400	O
mg	O
daily	O
for	O
7	O
days	O
,	O
then	O
200	O
mg	O
daily	O
(	O
initiated	O
19	O
days	O
earlier	O
)	O
;	O
and	O
400	O
mg	O
atazanavir	O
daily	O
(	O
initiated	O
at	O
least	O
2	O
years	O
previously	O
)	O
.	O
Laboratory	O
evaluation	O
revealed	O
66,680	O
U	O
/	O
L	O
creatine	B-CHEMICAL
kinase	O
,	O
93	O
mg	O
/	O
dL	O
blood	O
urea	B-CHEMICAL
nitrogen	O
,	O
4.6	O
mg	O
/	O
dL	O
creatinine	B-CHEMICAL
,	O
1579	O
U	O
/	O
L	O
aspartate	O
aminotransferase	O
,	O
and	O
738	O
U	O
/	O
L	O
alanine	O
aminotransferase	O
.	O
Simvastatin	B-CHEMICAL
,	O
amiodarone	B-CHEMICAL
,	O
and	O
the	O
patient	O
's	O
human	O
immunodeficiency	O
virus	O
medications	O
were	O
all	O
temporarily	O
discontinued	O
and	O
the	O
patient	O
was	O
given	O
forced	O
alkaline	O
diuresis	O
and	O
started	O
on	O
dialysis	O
.	O
Nine	O
days	O
later	O
the	O
patient	O
's	O
creatine	B-CHEMICAL
kinase	O
had	O
dropped	O
to	O
1695	O
U	O
/	O
L	O
and	O
creatinine	B-CHEMICAL
was	O
3.3	O
mg	O
/	O
dL.	O
The	O
patient	O
was	O
discharged	O
and	O
continued	O
outpatient	O
dialysis	O
for	O
1	O
month	O
until	O
his	O
renal	O
function	O
recovered	O
.	O
DISCUSSION	O
:	O
The	O
risk	O
of	O
rhabdomyolysis	B-DISEASE
is	O
increased	O
in	O
the	O
presence	O
of	O
concomitant	O
drugs	O
that	O
inhibit	O
simvastatin	B-CHEMICAL
metabolism	O
.	O
Simvastatin	B-CHEMICAL
is	O
metabolized	O
by	O
CYP3A4	O
.	O
Amiodarone	B-CHEMICAL
and	O
atazanavir	O
are	O
recognized	O
CYP3A4	O
inhibitors	O
.	O
CONCLUSIONS	O
:	O
Pharmacokinetic	O
differences	O
in	O
statins	B-CHEMICAL
are	O
an	O
important	O
consideration	O
for	O
assessing	O
the	O
risk	O
of	O
potential	O
drug	O
interactions	O
.	O
In	O
patients	O
requiring	O
the	O
concurrent	O
use	O
of	O
statins	B-CHEMICAL
and	O
CYP3A4	O
inhibitors	O
,	O
pravastatin	B-CHEMICAL
,	O
fluvastatin	O
,	O
and	O
rosuvastatin	O
carry	O
the	O
lowest	O
risk	O
of	O
drug	O
interactions	O
;	O
atorvastatin	O
carries	O
moderate	O
risk	O
,	O
whereas	O
simvastatin	B-CHEMICAL
and	O
lovastatin	B-CHEMICAL
have	O
the	O
highest	O
risk	O
and	O
should	O
be	O
avoided	O
in	O
patients	O
taking	O
concomitant	O
CYP3A4	O
inhibitors	O
.	O

Phase	O
II	O
trial	O
of	O
vinorelbine	B-CHEMICAL
in	O
metastatic	O
squamous	O
cell	O
esophageal	B-DISEASE
carcinoma	I-DISEASE
.	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	B-DISEASE
Gastrointestinal	O
Treat	O
Cancer	B-DISEASE
Cooperative	O
Group	O
.	O
PURPOSE	O
:	O
To	O
evaluate	O
the	O
response	O
rate	O
and	O
toxic	O
effects	O
of	O
vinorelbine	B-CHEMICAL
(	O
VNB	O
)	O
administered	O
as	O
a	O
single	O
agent	O
in	O
metastatic	O
squamous	O
cell	O
esophageal	B-DISEASE
carcinoma	I-DISEASE
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
six	O
eligible	O
patients	O
with	O
measurable	O
lesions	O
were	O
included	O
and	O
were	O
stratified	O
according	O
to	O
previous	O
chemotherapy	O
.	O
Thirty	O
patients	O
without	O
prior	O
chemotherapy	O
and	O
16	O
pretreated	O
with	O
cisplatin	B-CHEMICAL
-	O
based	O
chemotherapy	O
were	O
assessable	O
for	O
toxicity	B-DISEASE
and	O
response	O
.	O
VNB	O
was	O
administered	O
weekly	O
as	O
a	O
25	O
-	O
mg	O
/	O
m2	O
short	O
intravenous	O
(	O
i.v	O
.	O
)	O
infusion	O
.	O
RESULTS	O
:	O
Six	O
of	O
30	O
patients	O
(	O
20	O
%	O
)	O
without	O
prior	O
chemotherapy	O
achieved	O
a	O
partial	O
response	O
(	O
PR	O
)	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
8	O
%	O
to	O
39	O
%	O
)	O
.	O
The	O
median	O
duration	O
of	O
response	O
was	O
21	O
weeks	O
(	O
range	O
,	O
17	O
to	O
28	O
)	O
.	O
One	O
of	O
16	O
patients	O
(	O
6	O
%	O
)	O
with	O
prior	O
chemotherapy	O
had	O
a	O
complete	O
response	O
(	O
CR	O
)	O
of	O
31	O
weeks	O
'	O
duration	O
(	O
95	O
%	O
CI	O
,	O
0	O
%	O
to	O
30	O
%	O
)	O
.	O
The	O
overall	O
response	O
rate	O
(	O
World	O
Health	O
Organization	O
[	O
WHO	O
]	O
criteria	O
)	O
was	O
15	O
%	O
(	O
CR	O
,	O
2	O
%	O
;	O
PR	O
13	O
%	O
;	O
95	O
%	O
CI	O
,	O
6	O
%	O
to	O
29	O
%	O
)	O
.	O
The	O
median	O
dose	O
-	O
intensity	O
(	O
DI	O
)	O
was	O
20	O
mg	O
/	O
m2	O
/	O
wk	O
.	O
VNB	O
was	O
well	O
tolerated	O
and	O
zero	O
instances	O
of	O
WHO	O
grade	O
4	O
nonhematologic	O
toxicity	B-DISEASE
occurred	O
.	O
At	O
least	O
one	O
episode	O
of	O
grade	O
3	O
or	O
4	O
granulocytopenia	O
was	O
seen	O
in	O
59	O
%	O
of	O
patients	O
.	O
A	O
grade	O
2	O
or	O
3	O
infection	B-DISEASE
occurred	O
in	O
16	O
%	O
of	O
patients	O
,	O
but	O
no	O
toxic	O
deaths	B-DISEASE
occurred	O
.	O
Other	O
side	O
effects	O
were	O
rare	O
,	O
and	O
peripheral	O
neurotoxicity	B-DISEASE
has	O
been	O
minor	O
(	O
26	O
%	O
grade	O
1	O
)	O
.	O
CONCLUSION	O
:	O
These	O
data	O
indicate	O
that	O
VNB	O
is	O
an	O
active	O
agent	O
in	O
metastatic	O
esophageal	B-DISEASE
squamous	I-DISEASE
cell	I-DISEASE
carcinoma	I-DISEASE
.	O
Given	O
its	O
excellent	O
tolerance	O
profile	O
and	O
low	O
toxicity	B-DISEASE
,	O
further	O
evaluation	O
of	O
VNB	O
in	O
combination	O
therapy	O
is	O
warranted	O
.	O

Paclitaxel	B-CHEMICAL
,	O
cisplatin	B-CHEMICAL
,	O
and	O
gemcitabine	B-CHEMICAL
combination	O
chemotherapy	O
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	O
in	O
metastatic	O
nonsmall	O
cell	O
lung	O
carcinoma	B-DISEASE
.	O
BACKGROUND	O
:	O
Cisplatin	B-CHEMICAL
-	O
based	O
chemotherapy	O
combinations	O
improve	O
quality	O
of	O
life	O
and	O
survival	O
in	O
advanced	O
nonsmall	O
cell	O
lung	O
carcinoma	B-DISEASE
(	O
NSCLC	O
)	O
.	O
The	O
emergence	O
of	O
new	O
active	O
drugs	O
might	O
translate	O
into	O
more	O
effective	O
regimens	O
for	O
the	O
treatment	O
of	O
this	O
disease	B-DISEASE
.	O
METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	B-DISEASE
of	O
a	O
paclitaxel	B-CHEMICAL
,	O
cisplatin	B-CHEMICAL
,	O
and	O
gemcitabine	B-CHEMICAL
combination	O
to	O
treat	O
metastatic	O
NSCLC	O
.	O
Thirty	O
-	O
five	O
consecutive	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
Stage	O
IV	O
NSCLC	O
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
-	O
2	O
were	O
treated	O
with	O
a	O
combination	O
of	O
paclitaxel	B-CHEMICAL
(	O
135	O
mg	O
/	O
m(2	O
)	O
given	O
intravenously	O
in	O
3	O
hours	O
)	O
on	O
Day	O
1	O
,	O
cisplatin	B-CHEMICAL
(	O
120	O
mg	O
/	O
m(2	O
)	O
given	O
intravenously	O
in	O
6	O
hours	O
)	O
on	O
Day	O
1	O
,	O
and	O
gemcitabine	B-CHEMICAL
(	O
800	O
mg	O
/	O
m(2	O
)	O
given	O
intravenously	O
in	O
30	O
minutes	O
)	O
on	O
Days	O
1	O
and	O
8	O
,	O
every	O
4	O
weeks	O
.	O
Although	O
responding	O
patients	O
were	O
scheduled	O
to	O
receive	O
consolidation	O
radiotherapy	O
and	O
24	O
patients	O
received	O
preplanned	O
second	O
-	O
line	O
chemotherapy	O
after	O
disease	B-DISEASE
progression	I-DISEASE
,	O
the	O
response	O
and	O
toxicity	B-DISEASE
rates	O
reported	O
refer	O
only	O
to	O
the	O
chemotherapy	O
regimen	O
given	O
.	O
RESULTS	O
:	O
All	O
the	O
patients	O
were	O
examined	O
for	O
toxicity	B-DISEASE
;	O
34	O
were	O
examinable	O
for	O
response	O
.	O
An	O
objective	O
response	O
was	O
observed	O
in	O
73.5	O
%	O
of	O
the	O
patients	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
55.6	O
-	O
87.1	O
%	O
)	O
,	O
including	O
4	O
complete	O
responses	O
(	O
11.7	O
%	O
)	O
.	O
According	O
to	O
intention	O
-	O
to	O
-	O
treat	O
,	O
the	O
overall	O
response	O
rate	O
was	O
71.4	O
%	O
(	O
95	O
%	O
CI	O
,	O
53	O
.	O
7	O
-	O
85.4	O
%	O
)	O
.	O
After	O
154	O
courses	O
of	O
therapy	O
,	O
the	O
median	O
dose	O
intensity	O
was	O
131	O
mg	O
/	O
m(2	O
)	O
for	O
paclitaxel	B-CHEMICAL
(	O
97.3	O
%	O
)	O
,	O
117	O
mg	O
/	O
m(2	O
)	O
for	O
cisplatin	B-CHEMICAL
(	O
97.3	O
%	O
)	O
,	O
and	O
1378	O
mg	O
/	O
m(2	O
)	O
for	O
gemcitabine	B-CHEMICAL
(	O
86.2	O
%	O
)	O
.	O
World	O
Health	O
Organization	O
Grade	O
3	O
-	O
4	O
neutropenia	B-DISEASE
and	O
thrombocytopenia	B-DISEASE
occurred	O
in	O
39.9	O
%	O
and	O
11.4	O
%	O
of	O
patients	O
,	O
respectively	O
.	O
There	O
was	O
one	O
treatment	O
-	O
related	O
death	B-DISEASE
.	O
Nonhematologic	O
toxicities	B-DISEASE
were	O
mild	O
.	O
After	O
a	O
median	O
follow	O
-	O
up	O
of	O
22	O
months	O
,	O
the	O
median	O
progression	O
free	O
survival	O
rate	O
was	O
7	O
months	O
,	O
and	O
the	O
median	O
survival	O
time	O
was	O
16	O
months	O
.	O
CONCLUSIONS	O
:	O
The	O
combination	O
of	O
paclitaxel	B-CHEMICAL
,	O
cisplatin	B-CHEMICAL
,	O
and	O
gemcitabine	B-CHEMICAL
is	O
well	O
tolerated	O
and	O
shows	O
high	O
activity	O
in	O
metastatic	O
NSCLC	O
.	O
This	O
treatment	O
merits	O
further	O
comparison	O
with	O
other	O
cisplatin	B-CHEMICAL
-	O
based	O
regimens	O
.	O

Evaluation	O
of	O
adverse	O
reactions	O
of	O
aponidine	O
hydrochloride	O
ophthalmic	O
solution	O
.	O
We	O
prospectively	O
evaluated	O
the	O
adverse	O
reactions	O
of	O
apraclonidine	O
in	O
20	O
normal	O
volunteers	O
by	O
instilling	O
a	O
single	O
drop	O
of	O
1	O
%	O
apraclonidine	O
in	O
their	O
right	O
eyes	O
.	O
Examinations	O
,	O
including	O
blood	O
pressure	O
,	O
pulse	O
rate	O
,	O
conjunctiva	O
and	O
cornea	O
,	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
,	O
pupil	O
diameter	O
,	O
basal	O
tear	O
secretion	O
and	O
margin	O
reflex	O
distance	O
of	O
both	O
upper	O
and	O
lower	O
eyelids	O
,	O
were	O
performed	O
prior	O
to	O
entry	O
and	O
at	O
1	O
,	O
3	O
,	O
5	O
and	O
7	O
hours	O
after	O
instillation	O
.	O
The	O
ocular	O
hypotensive	B-DISEASE
effects	O
were	O
statistically	O
significant	O
for	O
apraclonidine	O
-	O
treated	O
eyes	O
throughout	O
the	O
study	O
and	O
also	O
statistically	O
significant	O
for	O
contralateral	O
eyes	O
from	O
three	O
hours	O
after	O
topical	O
administration	O
of	O
1	O
%	O
apraclonidine	O
.	O
Decreases	O
in	O
systolic	O
blood	O
pressure	O
were	O
statistically	O
,	O
but	O
not	O
clinically	O
,	O
significant	O
.	O
No	O
significant	O
changes	O
in	O
diastolic	O
blood	O
pressure	O
,	O
pulse	O
rate	O
and	O
basal	O
tear	O
secretion	O
were	O
noted	O
.	O
Conjunctival	O
blanching	O
and	O
mydriasis	B-DISEASE
were	O
commonly	O
found	O
.	O
Upper	O
lid	O
retraction	O
was	O
frequently	O
noted	O
.	O
While	O
the	O
elevations	O
of	O
the	O
upper	O
lid	O
margin	O
in	O
most	O
subjects	O
were	O
not	O
more	O
than	O
2	O
mm	O
and	O
did	O
not	O
cause	O
noticeable	O
change	O
in	O
appearance	O
,	O
one	O
subject	O
suffered	O
from	O
mechanical	O
entropion	B-DISEASE
and	O
marked	O
corneal	B-DISEASE
abrasion	I-DISEASE
3	O
hours	O
after	O
instillation	O
of	O
the	O
medication	O
.	O
This	O
may	O
well	O
be	O
a	O
particularly	O
notable	O
finding	O
in	O
Asian	O
people	O
.	O

Carmofur	O
-	O
induced	O
organic	O
mental	B-DISEASE
disorders	I-DISEASE
.	O
Organic	O
mental	O
disorder	O
was	O
observed	O
in	O
a	O
29	O
-	O
year	O
-	O
old	O
female	O
in	O
the	O
prognostic	O
period	O
after	O
the	O
onset	O
of	O
carmofur	O
-	O
induced	O
leukoencephalopathy	B-DISEASE
.	O
Symptoms	O
such	O
as	O
euphoria	O
,	O
emotional	O
lability	O
and	O
puerile	O
attitude	O
noted	O
in	O
the	O
patient	O
were	O
diagnosed	O
as	O
organic	O
personality	O
syndrome	B-DISEASE
according	O
to	O
the	O
criteria	O
defined	O
in	O
the	O
DSM	O
-	O
III	O
-	O
R.	O
It	O
is	O
referred	O
to	O
as	O
a	O
frontal	O
lobe	O
syndrome	B-DISEASE
.	O
Brain	O
CT	O
revealed	O
a	O
periventricular	O
low	O
density	O
area	O
in	O
the	O
frontal	O
white	O
matter	O
and	O
moderate	O
dilatation	O
of	O
the	O
lateral	O
ventricles	O
especially	O
at	O
the	O
bilateral	O
anterior	O
horns	O
.	O
Consequently	O
,	O
carmofur	O
-	O
induced	O
leukoencephalopathy	B-DISEASE
may	O
uncommonly	O
result	O
in	O
organic	O
personality	O
syndrome	B-DISEASE
in	O
the	O
residual	O
state	O
.	O
It	O
may	O
be	O
attributed	O
to	O
the	O
structural	O
damage	O
to	O
the	O
frontal	O
lobe	O
.	O

International	O
mexiletine	B-CHEMICAL
and	O
placebo	O
antiarrhythmic	O
coronary	O
trial	O
:	O
I.	O
Report	O
on	O
arrhythmia	B-DISEASE
and	O
other	O
findings	O
.	O
Impact	O
Research	O
Group	O
.	O
The	O
antiarrhythmic	O
effects	O
of	O
the	O
sustained	O
release	O
form	O
of	O
mexiletine	B-CHEMICAL
(	O
Mexitil	O
-	O
Perlongets	O
)	O
were	O
evaluated	O
in	O
a	O
double	O
-	O
blind	B-DISEASE
placebo	O
trial	O
in	O
630	O
patients	O
with	O
recent	O
documented	O
myocardial	B-DISEASE
infarction	I-DISEASE
.	O
The	O
primary	O
response	O
variable	O
was	O
based	O
on	O
central	O
reading	O
of	O
24	O
hour	O
ambulatory	O
electrocardiographic	O
recordings	O
and	O
was	O
defined	O
as	O
the	O
occurrence	O
of	O
30	O
or	O
more	O
single	O
premature	O
ventricular	O
complexes	O
in	O
any	O
two	O
consecutive	O
30	O
minute	O
blocks	O
or	O
one	O
or	O
more	O
runs	O
of	O
two	O
or	O
more	O
premature	O
ventricular	O
complexes	O
in	O
the	O
entire	O
24	O
hour	O
electrocardiographic	O
recording	O
.	O
Large	O
differences	O
,	O
regarded	O
as	O
statistically	O
significant	O
,	O
between	O
the	O
mexiletine	B-CHEMICAL
and	O
placebo	O
groups	O
were	O
noted	O
in	O
that	O
end	O
point	O
at	O
months	O
1	O
and	O
4	O
,	O
but	O
only	O
trends	O
were	O
observed	O
at	O
month	O
12	O
.	O
These	O
differences	O
were	O
observed	O
even	O
though	O
the	O
serum	O
mexiletine	B-CHEMICAL
levels	O
obtained	O
in	O
this	O
study	O
were	O
generally	O
lower	O
than	O
those	O
observed	O
in	O
studies	O
that	O
have	O
used	O
the	O
regular	O
form	O
of	O
the	O
drug	O
.	O
There	O
were	O
more	O
deaths	B-DISEASE
in	O
the	O
mexiletine	B-CHEMICAL
group	O
(	O
7.6	O
%	O
)	O
than	O
in	O
the	O
placebo	O
group	O
(	O
4.8	O
%	O
)	O
;	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O
The	O
incidence	O
of	O
coronary	O
events	O
was	O
similar	O
in	O
both	O
groups	O
.	O
Previously	O
recognized	O
side	O
effects	O
,	O
particularly	O
tremor	B-DISEASE
and	O
gastrointestinal	O
problems	O
,	O
were	O
more	O
frequent	O
in	O
the	O
mexiletine	B-CHEMICAL
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O

Regional	O
localization	O
of	O
the	O
antagonism	O
of	O
amphetamine	O
-	O
induced	O
hyperactivity	O
by	O
intracerebral	O
calcitonin	O
injections	O
.	O
Calcitonin	O
receptors	O
are	O
found	O
in	O
the	O
brain	O
,	O
and	O
intracerebral	O
infusions	O
of	O
calcitonin	O
can	O
produce	O
behavioral	O
effects	O
.	O
Among	O
these	O
behavioral	O
effects	O
are	O
decreases	O
in	O
food	O
intake	O
and	O
decreases	O
in	O
amphetamine	O
-	O
induced	O
locomotor	O
activity	O
.	O
In	O
previous	O
experiments	O
we	O
found	O
that	O
decreases	O
in	O
food	O
intake	O
were	O
induced	O
by	O
local	O
administration	O
of	O
calcitonin	O
into	O
several	O
hypothalamic	O
sites	O
and	O
into	O
the	O
nucleus	O
accumbens	O
.	O
In	O
the	O
present	O
experiment	O
calcitonin	O
decreased	O
locomotor	O
activity	O
when	O
locally	O
injected	O
into	O
the	O
same	O
sites	O
where	O
it	O
decreases	O
food	O
intake	O
.	O
The	O
areas	O
where	O
calcitonin	O
is	O
most	O
effective	O
in	O
decreasing	O
locomotor	O
activity	O
are	O
located	O
in	O
the	O
hypothalamus	O
and	O
nucleus	O
accumbens	O
,	O
suggesting	O
that	O
these	O
areas	O
are	O
the	O
major	O
sites	O
of	O
action	O
of	O
calcitonin	O
in	O
inhibiting	O
amphetamine	O
-	O
induced	O
locomotor	O
activity	O
.	O

Fatal	O
intracranial	O
bleeding	B-DISEASE
associated	O
with	O
prehospital	O
use	O
of	O
epinephrine	B-CHEMICAL
.	O
We	O
present	O
a	O
case	O
of	O
paramedic	O
misjudgment	O
in	O
the	O
execution	O
of	O
a	O
protocol	O
for	O
the	O
treatment	O
of	O
allergic	B-DISEASE
reaction	I-DISEASE
in	O
a	O
case	O
of	O
pulmonary	B-DISEASE
edema	I-DISEASE
with	O
wheezing	O
.	O
The	O
sudden	O
onset	O
of	O
respiratory	O
distress	O
,	O
rash	B-DISEASE
,	O
and	O
a	O
history	O
of	O
a	O
new	O
medicine	O
led	O
the	O
two	O
paramedics	O
on	O
the	O
scene	O
to	O
administer	O
subcutaneous	O
epinephrine	B-CHEMICAL
.	O
Subsequently	O
,	O
acute	O
cardiac	B-DISEASE
arrest	I-DISEASE
and	O
fatal	O
subarachnoid	B-DISEASE
hemorrhage	I-DISEASE
occurred	O
.	O
Epinephrine	B-CHEMICAL
has	O
a	O
proven	O
role	O
in	O
cardiac	B-DISEASE
arrest	I-DISEASE
in	O
prehospital	O
care	O
;	O
however	O
,	O
use	O
by	O
paramedics	O
in	O
patients	O
with	O
suspected	O
allergic	B-DISEASE
reaction	I-DISEASE
and	O
severe	O
hypertension	B-DISEASE
should	O
be	O
viewed	O
with	O
caution	O
.	O

A	O
case	O
of	O
massive	O
rhabdomyolysis	B-DISEASE
following	O
molindone	O
administration	O
.	O
Rhabdomyolysis	B-DISEASE
is	O
a	O
potentially	O
lethal	O
syndrome	B-DISEASE
that	O
psychiatric	B-DISEASE
patients	O
seem	O
predisposed	O
to	O
develop	O
.	O
The	O
clinical	O
signs	B-DISEASE
and	I-DISEASE
symptoms	I-DISEASE
,	O
typical	O
laboratory	O
features	O
,	O
and	O
complications	B-DISEASE
of	O
rhabdomyolysis	B-DISEASE
are	O
presented	O
.	O
The	O
case	O
of	O
a	O
schizophrenic	B-DISEASE
patient	O
is	O
reported	O
to	O
illustrate	O
massive	O
rhabdomyolysis	B-DISEASE
and	O
subsequent	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
following	O
molindone	O
administration	O
.	O
Physicians	O
who	O
prescribe	O
molindone	O
should	O
be	O
aware	O
of	O
this	O
reaction	O
.	O

Cardiovascular	B-DISEASE
alterations	I-DISEASE
in	O
rat	O
fetuses	O
exposed	O
to	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
.	O
Preclinical	O
toxicologic	O
investigation	O
suggested	O
that	O
a	O
new	O
calcium	B-CHEMICAL
channel	O
blocker	O
,	O
Ro	O
40	O
-	O
5967	O
,	O
induced	O
cardiovascular	B-DISEASE
alterations	I-DISEASE
in	O
rat	O
fetuses	O
exposed	O
to	O
this	O
agent	O
during	O
organogenesis	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
hypothesis	O
that	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
in	O
general	O
induce	O
cardiovascular	B-DISEASE
malformations	I-DISEASE
indicating	O
a	O
pharmacologic	O
class	O
effect	O
.	O
We	O
studied	O
three	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
of	O
different	O
structure	O
,	O
nifedipine	B-CHEMICAL
,	O
diltiazem	B-CHEMICAL
,	O
and	O
verapamil	B-CHEMICAL
,	O
along	O
with	O
the	O
new	O
agent	O
.	O
Pregnant	O
rats	O
were	O
administered	O
one	O
of	O
these	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
during	O
the	O
period	O
of	O
cardiac	O
morphogenesis	O
and	O
the	O
offspring	O
examined	O
on	O
day	O
20	O
of	O
gestation	O
for	O
cardiovascular	B-DISEASE
malformations	I-DISEASE
.	O
A	O
low	O
incidence	O
of	O
cardiovascular	B-DISEASE
malformations	I-DISEASE
was	O
observed	O
after	O
exposure	O
to	O
each	O
of	O
the	O
four	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
,	O
but	O
this	O
incidence	O
was	O
statistically	O
significant	O
only	O
for	O
verapamil	B-CHEMICAL
and	O
nifedipine	B-CHEMICAL
.	O
All	O
four	O
agents	O
were	O
associated	O
with	O
aortic	O
arch	O
branching	O
variants	O
,	O
although	O
significantly	O
increased	O
only	O
for	O
Ro	O
40	O
-	O
5967	O
and	O
verapamil	B-CHEMICAL
.	O

Differential	O
impact	O
of	O
immune	O
escape	O
mutations	O
G145R	O
and	O
P120	O
T	O
on	O
the	O
replication	O
of	O
lamivudine	B-CHEMICAL
-	O
resistant	O
hepatitis	B-DISEASE
B	I-DISEASE
virus	O
e	O
antigen	O
-	O
positive	O
and	O
-negative	O
strains	O
.	O
Immune	O
escape	O
variants	O
of	O
the	O
hepatitis	B-DISEASE
B	I-DISEASE
virus	O
(	O
HBV	O
)	O
represent	O
an	O
emerging	O
clinical	O
challenge	O
,	O
because	O
they	O
can	O
be	O
associated	O
with	O
vaccine	O
escape	O
,	O
HBV	O
reactivation	O
,	O
and	O
failure	O
of	O
diagnostic	O
tests	O
.	O
Recent	O
data	O
suggest	O
a	O
preferential	O
selection	O
of	O
immune	O
escape	O
mutants	O
in	O
distinct	O
peripheral	O
blood	O
leukocyte	O
compartments	O
of	O
infected	O
individuals	O
.	O
We	O
therefore	O
systematically	O
analyzed	O
the	O
functional	O
impact	O
of	O
the	O
most	O
prevalent	O
immune	O
escape	O
variants	O
,	O
the	O
sG145R	O
and	O
sP120	O
T	O
mutants	O
,	O
on	O
the	O
viral	O
replication	O
efficacy	O
and	O
antiviral	O
drug	O
susceptibility	O
of	O
common	O
treatment	O
-	O
associated	O
mutants	O
with	O
resistance	O
to	O
lamivudine	B-CHEMICAL
(	O
LAM	O
)	O
and/or	O
HBeAg	O
negativity	O
.	O
Replication	O
-	O
competent	O
HBV	O
strains	O
with	O
sG145R	O
or	O
sP120	O
T	O
and	O
LAM	O
resistance	O
(	O
rtM204I	O
or	O
rtL180M	O
/	O
rtM204V	O
)	O
were	O
generated	O
on	O
an	O
HBeAg	O
-	O
positive	O
and	O
an	O
HBeAg	O
-	O
negative	O
background	O
with	O
precore	O
(	O
PC	O
)	O
and	O
basal	O
core	O
promoter	O
(	O
BCP	O
)	O
mutants	O
.	O
The	O
sG145R	O
mutation	O
strongly	O
reduced	O
HBsAg	O
levels	O
and	O
was	O
able	O
to	O
fully	O
restore	O
the	O
impaired	O
replication	O
of	O
LAM	O
-	O
resistant	O
HBV	O
mutants	O
to	O
the	O
levels	O
of	O
wild	O
-	O
type	O
HBV	O
,	O
and	O
PC	O
or	O
BCP	O
mutations	O
further	O
enhanced	O
viral	O
replication	O
.	O
Although	O
the	O
sP120	O
T	O
substitution	O
also	O
impaired	O
HBsAg	O
secretion	O
,	O
it	O
did	O
not	O
enhance	O
the	O
replication	O
of	O
LAM	O
-	O
resistant	O
clones	O
.	O
However	O
,	O
the	O
concomitant	O
occurrence	O
of	O
HBeAg	O
negativity	O
(	O
PC	O
/	O
BCP	O
)	O
,	O
sP120	O
T	O
,	O
and	O
LAM	O
resistance	O
resulted	O
in	O
the	O
restoration	O
of	O
replication	O
to	O
levels	O
of	O
wild	O
-	O
type	O
HBV	O
.	O
In	O
all	O
clones	O
with	O
combined	O
immune	O
escape	O
and	O
LAM	O
resistance	O
mutations	O
,	O
the	O
nucleotide	O
analogues	O
adefovir	O
and	O
tenofovir	O
remained	O
effective	O
in	O
suppressing	O
viral	O
replication	O
in	O
vitro	O
.	O
These	O
findings	O
reveal	O
the	O
differential	O
impact	O
of	O
immune	O
escape	O
variants	O
on	O
the	O
replication	O
and	O
drug	O
susceptibility	O
of	O
complex	O
HBV	O
mutants	O
,	O
supporting	O
the	O
need	O
of	O
close	O
surveillance	O
and	O
treatment	O
adjustment	O
in	O
response	O
to	O
the	O
selection	O
of	O
distinct	O
mutational	O
patterns	O
.	O

The	O
effects	O
of	O
sevoflurane	B-CHEMICAL
on	O
lidocaine	B-CHEMICAL
-	O
induced	O
convulsions	B-DISEASE
.	O
The	O
influence	O
of	O
sevoflurane	B-CHEMICAL
on	O
lidocaine	B-CHEMICAL
-	O
induced	O
convulsions	B-DISEASE
was	O
studied	O
in	O
cats	O
.	O
The	O
convulsive	B-DISEASE
threshold	O
(	O
mean	O
+	O
/-	O
SD	B-DISEASE
)	O
was	O
41.4	O
+	O
/-	O
6.5	O
mg	O
.	O
l(-1	O
)	O
with	O
lidocaine	B-CHEMICAL
infusion	O
(	O
6	O
mg.kg(-1).min(-1	O
)	O
)	O
,	O
increasing	O
significantly	O
to	O
66.6	O
+	O
/-	O
10.9	O
mg	O
.	O
l(-1	O
)	O
when	O
the	O
end	O
-	O
tidal	O
concentration	O
of	O
sevoflurane	B-CHEMICAL
was	O
0.8	O
%	O
.	O
However	O
,	O
the	O
threshold	O
(	O
61.6	O
+	O
/-	O
8.7	O
mg	O
.	O
l(-1	O
)	O
)	O
during	O
1.6	O
%	O
sevoflurane	B-CHEMICAL
was	O
not	O
significant	O
from	O
that	O
during	O
0.8	O
%	O
sevoflurane	B-CHEMICAL
,	O
indicating	O
a	O
celling	O
effect	O
.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
convulsive	B-DISEASE
threshold	O
between	O
sevoflurane	B-CHEMICAL
and	O
enflurane	B-CHEMICAL
.	O
The	O
rise	O
in	O
blood	O
pressure	O
became	O
less	O
marked	O
when	O
higher	O
concentrations	O
of	O
sevoflurane	B-CHEMICAL
or	O
enflurane	B-CHEMICAL
were	O
administered	O
and	O
the	O
blood	O
pressure	O
at	O
convulsions	B-DISEASE
decreased	O
significantly	O
in	O
1.6	O
%	O
sevoflurane	B-CHEMICAL
,	O
and	O
in	O
0.8	O
%	O
and	O
1.6	O
%	O
enflurane	B-CHEMICAL
.	O
However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
lidocaine	B-CHEMICAL
concentrations	O
measured	O
when	O
the	O
systolic	O
blood	O
pressure	O
became	O
70	O
mmHg	O
.	O
Apamin	O
,	O
a	O
selective	O
blocker	O
of	O
calcium	B-CHEMICAL
-	O
dependent	O
potassium	B-CHEMICAL
channels	O
,	O
was	O
administered	O
intracerebroventricularly	O
in	O
rats	O
anesthetized	O
with	O
0.8	O
%	O
sevoflurane	B-CHEMICAL
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
anticonvulsive	O
effects	O
.	O
Apamin	O
(	O
10	O
ng	O
)	O
had	O
a	O
tendency	O
to	O
decrease	O
the	O
convulsive	B-DISEASE
threshold	O
(	O
21.6	O
+	O
/-	O
2.2	O
to	O
19.9	O
+	O
/-	O
2.5	O
mg	O
.	O
l(-1	O
)	O
)	O
but	O
this	O
was	O
not	O
statistically	O
significant	O
.	O
It	O
is	O
suggested	O
that	O
sevoflurane	B-CHEMICAL
reduces	O
the	O
convulsive	B-DISEASE
effect	O
of	O
lidocaine	B-CHEMICAL
toxicity	B-DISEASE
but	O
carries	O
some	O
risk	O
due	O
to	O
circulatory	O
depression	B-DISEASE
.	O

Anti	O
-	O
oxidant	O
effects	O
of	O
atorvastatin	O
in	O
dexamethasone	B-CHEMICAL
-	O
induced	O
hypertension	B-DISEASE
in	O
the	O
rat	O
.	O
1	O
.	O
Dexamethasone	B-CHEMICAL
(	O
Dex)-induced	O
hypertension	B-DISEASE
is	O
characterized	O
by	O
endothelial	O
dysfunction	O
associated	O
with	O
nitric	O
oxide	O
(	O
NO	O
)	O
deficiency	O
and	O
increased	O
superoxide	B-CHEMICAL
(	O
O2-	O
)	O
production	O
.	O
Atorvastatin	O
(	O
Ato	B-CHEMICAL
)	O
possesses	O
pleiotropic	O
properties	O
that	O
have	O
been	O
reported	O
to	O
improve	O
endothelial	O
function	O
through	O
increased	O
availability	O
of	O
NO	O
and	O
reduced	O
O2-	O
production	O
in	O
various	O
forms	O
of	O
hypertension	B-DISEASE
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
50	O
mg	O
/	O
kg	O
per	O
day	O
,	O
p.o	O
.	O
,	O
Ato	B-CHEMICAL
could	O
prevent	O
endothelial	O
NO	O
synthase	O
(	O
eNOS	O
)	O
downregulation	O
and	O
the	O
increase	O
in	O
O2-	O
in	O
Sprague	O
-	O
Dawley	O
(	O
SD	B-DISEASE
)	O
rats	O
,	O
thereby	O
reducing	O
blood	O
pressure	O
.	O
2	O
.	O
Male	O
SD	B-DISEASE
rats	O
(	O
n	O
=	O
30	O
)	O
were	O
treated	O
with	O
Ato	B-CHEMICAL
(	O
50	O
mg	O
/	O
kg	O
per	O
day	O
in	O
drinking	O
water	O
)	O
or	O
tap	O
water	O
for	O
15	O
days	O
.	O
Dexamethasone	B-CHEMICAL
(	O
10	O
microg	O
/	O
kg	O
per	O
day	O
,	O
s.c	O
.	O
)	O
or	O
saline	O
was	O
started	O
after	O
4	O
days	O
in	O
Ato	B-CHEMICAL
-	O
treated	O
and	O
non	O
-	O
treated	O
rats	O
and	O
continued	O
for	O
11	O
-	O
13	O
days	O
.	O
Systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
was	O
measured	O
on	O
alternate	O
days	O
using	O
the	O
tail	O
-	O
cuff	O
method	O
.	O
Endothelial	O
function	O
was	O
assessed	O
by	O
acetylcholine	O
-	O
induced	O
vasorelaxation	O
and	O
phenylephrine	B-CHEMICAL
-	O
induced	O
vasoconstriction	O
in	O
aortic	O
segments	O
.	O
Vascular	O
eNOS	O
mRNA	O
was	O
assessed	O
by	O
semi	O
-	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O
3	O
.	O
In	O
rats	O
treated	O
with	O
Dex	B-CHEMICAL
alone	O
,	O
SBP	O
was	O
increased	O
from	O
109	O
+	O
/-	O
2	O
to	O
133	O
+	O
/-	O
2	O
mmHg	O
on	O
Days	O
4	O
and	O
Day	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
.	O
In	O
the	O
Ato	B-CHEMICAL
+	O
Dex	B-CHEMICAL
group	O
,	O
SBP	O
was	O
increased	O
from	O
113	O
+	O
/-	O
2	O
to	O
119	O
+	O
/-	O
2	O
mmHg	O
on	O
Days	O
4	O
to	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
,	O
but	O
was	O
significantly	O
lower	O
than	O
SBP	O
in	O
the	O
group	O
treated	O
with	O
Dex	B-CHEMICAL
alone	O
(	O
P	O
<	O
0.05	O
)	O
.	O
Endothelial	O
-	O
dependent	O
relaxation	O
and	O
eNOS	O
mRNA	O
expression	O
were	O
greater	O
in	O
the	O
Dex	B-CHEMICAL
+	O
Ato	B-CHEMICAL
group	O
than	O
in	O
the	O
Dex	B-CHEMICAL
only	O
group	O
(	O
P	O
<	O
0.05	O
and	O
P	O
<	O
0.0001	O
,	O
respectively	O
)	O
.	O
Aortic	O
superoxide	B-CHEMICAL
production	O
was	O
lower	O
in	O
the	O
Dex	B-CHEMICAL
+	O
Ato	B-CHEMICAL
group	O
compared	O
with	O
the	O
group	O
treated	O
with	O
Dex	B-CHEMICAL
alone	O
(	O
P	O
<	O
0.0001	O
)	O
.	O
4	O
.	O
Treatment	O
with	O
Ato	B-CHEMICAL
improved	O
endothelial	O
function	O
,	O
reduced	O
superoxide	B-CHEMICAL
production	O
and	O
reduced	O
SBP	O
in	O
Dex	B-CHEMICAL
-	O
treated	O
SD	B-DISEASE
rats	O
.	O

99mTc	B-CHEMICAL
-	I-CHEMICAL
glucarate	I-CHEMICAL
for	O
detection	O
of	O
isoproterenol	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
in	O
rats	O
.	O
Infarct	O
-	O
avid	O
radiopharmaceuticals	O
are	O
necessary	O
for	O
rapid	O
and	O
timely	O
diagnosis	O
of	O
acute	B-DISEASE
myocardial	I-DISEASE
infarction	I-DISEASE
.	O
The	O
animal	O
model	O
used	O
to	O
produce	O
infarction	B-DISEASE
implies	O
artery	O
ligation	O
but	O
chemical	O
induction	O
can	O
be	O
easily	O
obtained	O
with	O
isoproterenol	B-CHEMICAL
.	O
A	O
new	O
infarct	O
-	O
avid	O
radiopharmaceutical	O
based	O
on	O
glucaric	O
acid	O
was	O
prepared	O
in	O
the	O
hospital	O
radiopharmacy	O
of	O
the	O
INCMNSZ	O
.	O
99mTc	B-CHEMICAL
-	I-CHEMICAL
glucarate	I-CHEMICAL
was	O
easy	O
to	O
prepare	O
,	O
stable	O
for	O
96	O
h	O
and	O
was	O
used	O
to	O
study	O
its	O
biodistribution	O
in	O
rats	O
with	O
isoproterenol	B-CHEMICAL
-	O
induced	O
acute	B-DISEASE
myocardial	I-DISEASE
infarction	I-DISEASE
.	O
Histological	O
studies	O
demonstrated	O
that	O
the	O
rats	O
developed	O
an	O
infarct	O
18	O
h	O
after	O
isoproterenol	B-CHEMICAL
administration	O
.	O
The	O
rat	O
biodistribution	O
studies	O
showed	O
a	O
rapid	O
blood	O
clearance	O
via	O
the	O
kidneys	O
.	O
Thirty	O
minutes	O
after	O
99mTc	B-CHEMICAL
-	I-CHEMICAL
glucarate	I-CHEMICAL
administration	O
the	O
standardised	O
heart	O
uptake	O
value	O
S(h)UV	O
was	O
4.7	O
in	O
infarcted	O
rat	O
heart	O
which	O
is	O
six	O
times	O
more	O
than	O
in	O
normal	O
rats	O
.	O
ROIs	O
drawn	O
over	O
the	O
gamma	O
camera	O
images	O
showed	O
a	O
ratio	O
of	O
4.4	O
.	O
The	O
high	O
image	O
quality	O
suggests	O
that	O
high	O
contrast	O
images	O
can	O
be	O
obtained	O
in	O
humans	O
and	O
the	O
96	O
h	O
stability	O
makes	O
it	O
an	O
ideal	O
agent	O
to	O
detect	O
,	O
in	O
patients	O
,	O
early	O
cardiac	B-DISEASE
infarction	I-DISEASE
.	O

A	O
randomized	O
,	O
placebo	O
-	O
controlled	O
dose	O
-	O
comparison	O
trial	O
of	O
haloperidol	B-CHEMICAL
for	O
psychosis	B-DISEASE
and	O
disruptive	B-DISEASE
behaviors	I-DISEASE
in	O
Alzheimer	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
.	O
OBJECTIVE	O
:	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
and	O
side	O
effects	O
of	O
two	O
doses	O
of	O
haloperidol	B-CHEMICAL
and	O
placebo	O
in	O
the	O
treatment	O
of	O
psychosis	B-DISEASE
and	O
disruptive	B-DISEASE
behaviors	I-DISEASE
in	O
patients	O
with	O
Alzheimer	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
.	O
METHOD	O
:	O
In	O
a	O
6	O
-	O
week	O
random	O
-	O
assignment	O
,	O
double	O
-	O
blind	B-DISEASE
,	O
placebo	O
-	O
controlled	O
trial	O
(	O
phase	O
A	O
)	O
,	O
haloperidol	B-CHEMICAL
,	O
2	O
-	O
3	O
mg	O
/	O
day	O
(	O
standard	O
dose	O
)	O
,	O
and	O
haloperidol	B-CHEMICAL
,	O
0.50	O
-	O
0.75	O
mg	O
/	O
day	O
(	O
low	O
dose	O
)	O
,	O
were	O
compared	O
in	O
71	O
outpatients	O
with	O
Alzheimer	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
.	O
For	O
the	O
subsequent	O
6	O
-	O
week	O
double	O
-	O
blind	B-DISEASE
crossover	O
phase	O
(	O
phase	O
B	O
)	O
,	O
patients	O
taking	O
standard-	O
or	O
low	O
-	O
dose	O
haloperidol	B-CHEMICAL
were	O
switched	O
to	O
placebo	O
,	O
and	O
patients	O
taking	O
placebo	O
were	O
randomly	O
assigned	O
to	O
standard-	O
or	O
low	O
-	O
dose	O
haloperidol	B-CHEMICAL
.	O
RESULTS	O
:	O
For	O
the	O
60	O
patients	O
who	O
completed	O
phase	O
A	O
,	O
standard	O
-	O
dose	O
haloperidol	B-CHEMICAL
was	O
efficacious	O
and	O
superior	O
to	O
both	O
low	O
-	O
dose	O
haloperidol	B-CHEMICAL
and	O
placebo	O
for	O
scores	O
on	O
the	O
Brief	O
Psychiatric	B-DISEASE
Rating	O
Scale	O
psychosis	B-DISEASE
factor	O
and	O
on	O
psychomotor	B-DISEASE
agitation	I-DISEASE
.	O
Response	O
rates	O
according	O
to	O
three	O
sets	O
of	O
criteria	O
were	O
greater	O
with	O
the	O
standard	O
dose	O
(	O
55%-60	O
%	O
)	O
than	O
the	O
low	O
dose	O
(	O
25%-35	O
%	O
)	O
and	O
placebo	O
(	O
25%-30	O
%	O
)	O
.	O
The	O
advantage	O
of	O
standard	O
dose	O
over	O
low	O
dose	O
was	O
replicated	O
in	O
phase	O
B.	O
In	O
phase	O
A	O
,	O
extrapyramidal	B-DISEASE
signs	I-DISEASE
tended	O
to	O
be	O
greater	O
with	O
the	O
standard	O
dose	O
than	O
in	O
the	O
other	O
two	O
conditions	O
,	O
primarily	O
because	O
of	O
a	O
subgroup	O
(	O
20	O
%	O
)	O
who	O
developed	O
moderate	O
to	O
severe	O
signs	O
.	O
Low	O
-	O
dose	O
haloperidol	B-CHEMICAL
did	O
not	O
differ	O
from	O
placebo	O
on	O
any	O
measure	O
of	O
efficacy	O
or	O
side	O
effects	O
.	O
CONCLUSIONS	O
:	O
The	O
results	O
indicated	O
a	O
favorable	O
therapeutic	O
profile	O
for	O
haloperidol	B-CHEMICAL
in	O
doses	O
of	O
2	O
-	O
3	O
mg	O
/	O
day	O
,	O
although	O
a	O
subgroup	O
developed	O
moderate	O
to	O
severe	O
extrapyramidal	B-DISEASE
signs	I-DISEASE
.	O
A	O
starting	O
dose	O
of	O
1	O
mg	O
/	O
day	O
with	O
gradual	O
,	O
upward	O
dose	O
titration	O
is	O
recommended	O
.	O
The	O
narrow	O
therapeutic	O
window	O
observed	O
with	O
haloperidol	B-CHEMICAL
may	O
also	O
apply	O
to	O
other	O
neuroleptics	B-CHEMICAL
used	O
in	O
Alzheimer	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
patients	O
with	O
psychosis	B-DISEASE
and	O
disruptive	B-DISEASE
behaviors	I-DISEASE
.	O

Individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
in	O
healthy	O
rats	O
predict	O
susceptibility	O
to	O
adriamycin	B-CHEMICAL
-	O
induced	O
renal	B-DISEASE
damage	I-DISEASE
.	O
BACKGROUND	O
:	O
In	O
man	O
,	O
differences	O
in	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
levels	O
,	O
related	O
to	O
ACE	O
(	O
I	O
/	O
D	O
)	O
genotype	O
,	O
are	O
associated	O
with	O
renal	O
prognosis	O
.	O
This	O
raises	O
the	O
hypothesis	O
that	O
individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
are	O
involved	O
in	O
renal	O
susceptibility	O
to	O
inflicted	O
damage	O
.	O
Therefore	O
,	O
we	O
studied	O
the	O
predictive	O
effect	O
of	O
renal	O
ACE	O
activity	O
for	O
the	O
severity	O
of	O
renal	B-DISEASE
damage	I-DISEASE
induced	O
by	O
a	O
single	O
injection	O
of	O
adriamycin	B-CHEMICAL
in	O
rats	O
.	O
METHODS	O
:	O
Renal	O
ACE	O
activity	O
(	O
Hip	O
-	O
His	O
-	O
Leu	O
cleavage	O
by	O
cortical	O
homogenates	O
)	O
was	O
determined	O
by	O
renal	O
biopsy	O
in	O
27	O
adult	O
male	O
Wistar	O
rats	O
.	O
After	O
1	O
week	O
of	O
recovery	O
,	O
proteinuria	B-DISEASE
was	O
induced	O
by	O
adriamycin	B-CHEMICAL
[	O
1.5	O
mg	O
/	O
kg	O
intravenously	O
(	O
i.v	O
.	O
)	O
n	O
=	O
18	O
;	O
controls	O
,	O
saline	O
i.v	O
.	O
n	O
=	O
9	O
]	O
.	O
Proteinuria	B-DISEASE
was	O
measured	O
every	O
2	O
weeks	O
.	O
After	O
12	O
weeks	O
,	O
rats	O
were	O
sacrificed	O
and	O
their	O
kidneys	O
harvested	O
.	O
RESULTS	O
:	O
As	O
anticipated	O
,	O
adriamycin	B-CHEMICAL
elicited	O
nephrotic	B-DISEASE
range	O
proteinuria	B-DISEASE
,	O
renal	O
interstitial	O
damage	O
and	O
mild	O
focal	O
glomerulosclerosis	O
.	O
Baseline	O
renal	O
ACE	O
positively	O
correlated	O
with	O
the	O
relative	O
rise	O
in	O
proteinuria	B-DISEASE
after	O
adriamycin	B-CHEMICAL
(	O
r	O
=	O
0.62	O
,	O
P<0.01	O
)	O
,	O
renal	O
interstitial	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
r	O
=	O
0.49	O
,	O
P<0.05	O
)	O
,	O
interstitial	O
macrophage	O
influx	O
(	O
r	O
=	O
0.56	O
,	O
P<0.05	O
)	O
,	O
interstitial	O
collagen	O
III	O
(	O
r	O
=	O
0.53	O
,	O
P<0.05	O
)	O
,	O
glomerular	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
r	O
=	O
0.74	O
,	O
P<0.01	O
)	O
and	O
glomerular	O
desmin	O
(	O
r	O
=	O
0.48	O
,	O
P<0.05	O
)	O
.	O
Baseline	O
renal	O
ACE	O
did	O
not	O
correlate	O
with	O
focal	O
glomerulosclerosis	O
(	O
r	O
=	O
0.22	O
,	O
NS	O
)	O
.	O
In	O
controls	O
,	O
no	O
predictive	O
values	O
for	O
renal	O
parameters	O
were	O
observed	O
.	O
CONCLUSION	O
:	O
Individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
predict	O
the	O
severity	O
of	O
adriamycin	B-CHEMICAL
-	O
induced	O
renal	B-DISEASE
damage	I-DISEASE
in	O
this	O
outbred	O
rat	O
strain	O
.	O
This	O
supports	O
the	O
assumption	O
that	O
differences	O
in	O
renal	O
ACE	O
activity	O
predispose	O
to	O
a	O
less	O
favourable	O
course	O
of	O
renal	B-DISEASE
damage	I-DISEASE
.	O

Clinical	O
nephrotoxicity	B-DISEASE
of	O
tobramycin	B-CHEMICAL
and	O
gentamicin	B-CHEMICAL
.	O
A	O
prospective	O
study	O
.	O
Nearly	O
3.2	O
million	O
people	O
in	O
this	O
country	O
receive	O
aminoglycoside	O
antibiotics	O
annually	O
.	O
Gentamicin	B-CHEMICAL
sulfate	O
and	O
tobramycin	B-CHEMICAL
sulfate	O
continue	O
to	O
demonstrate	O
ototoxicity	B-DISEASE
and	O
nephrotoxicity	B-DISEASE
in	O
both	O
animal	O
and	O
clinical	O
studies	O
.	O
In	O
this	O
study	O
,	O
62	O
patients	O
with	O
confirmed	O
initial	O
normal	O
renal	O
function	O
and	O
treated	O
with	O
2	O
to	O
5	O
mg	O
/	O
kg	O
/	O
day	O
of	O
gentamicin	B-CHEMICAL
sulfate	O
or	O
tobramycin	B-CHEMICAL
sulfate	O
for	O
a	O
minimum	O
of	O
seven	O
days	O
were	O
followed	O
up	O
prospectively	O
for	O
the	O
development	O
of	O
aminoglycoside	O
-	O
related	O
renal	B-DISEASE
failure	I-DISEASE
,	O
defined	O
as	O
at	O
least	O
a	O
one	O
-	O
third	O
reduction	O
in	O
renal	O
function	O
.	O
In	O
these	O
62	O
patients	O
,	O
no	O
other	O
causes	O
for	O
renal	B-DISEASE
failure	I-DISEASE
could	O
be	O
identified	O
.	O
Five	O
of	O
33	O
(	O
15	O
%	O
)	O
of	O
the	O
tobramycin	B-CHEMICAL
-	O
treated	O
patients	O
and	O
16	O
of	O
29	O
(	O
55.2	O
%	O
)	O
of	O
the	O
gentamicin	B-CHEMICAL
-	O
treated	O
patients	O
had	O
renal	B-DISEASE
failure	I-DISEASE
.	O
Thus	O
,	O
gentamicin	B-CHEMICAL
was	O
associated	O
with	O
renal	B-DISEASE
failure	I-DISEASE
more	O
than	O
three	O
times	O
as	O
often	O
as	O
was	O
tobramycin	B-CHEMICAL
.	O

Neuroprotective	O
action	O
of	O
MPEP	O
,	O
a	O
selective	O
mGluR5	O
antagonist	O
,	O
in	O
methamphetamine	B-CHEMICAL
-	O
induced	O
dopaminergic	O
neurotoxicity	B-DISEASE
is	O
associated	O
with	O
a	O
decrease	O
in	O
dopamine	B-CHEMICAL
outflow	O
and	O
inhibition	O
of	O
hyperthermia	B-DISEASE
in	O
rats	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
role	O
of	O
metabotropic	O
glutamate	B-CHEMICAL
receptor	O
5	O
(	O
mGluR5	O
)	O
in	O
the	O
toxic	O
action	O
of	O
methamphetamine	B-CHEMICAL
on	O
dopaminergic	O
neurones	O
in	O
rats	O
.	O
Methamphetamine	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
,	O
administered	O
five	O
times	O
,	O
reduced	O
the	O
levels	O
of	O
dopamine	B-CHEMICAL
and	O
its	O
metabolites	O
in	O
striatal	O
tissue	O
when	O
measured	O
72	O
h	O
after	O
the	O
last	O
injection	O
.	O
A	O
selective	O
antagonist	O
of	O
mGluR5	O
,	O
2	B-CHEMICAL
-	I-CHEMICAL
methyl-6-(phenylethynyl)pyridine	I-CHEMICAL
(	O
MPEP	O
;	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
when	O
administered	O
five	O
times	O
immediately	O
before	O
each	O
methamphetamine	B-CHEMICAL
injection	O
reversed	O
the	O
above	O
-	O
mentioned	O
methamphetamine	B-CHEMICAL
effects	O
.	O
A	O
single	O
MPEP	O
(	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	O
the	O
basal	O
extracellular	O
dopamine	B-CHEMICAL
level	O
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	B-CHEMICAL
release	O
stimulated	O
either	O
by	O
methamphetamine	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	O
(	O
100	O
microM	O
)	O
.	O
Moreover	O
,	O
it	O
transiently	O
diminished	O
the	O
methamphetamine	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
sc)-induced	O
hyperthermia	B-DISEASE
and	O
reduced	O
basal	O
body	O
temperature	O
.	O
MPEP	O
administered	O
into	O
the	O
striatum	O
at	O
high	O
concentrations	O
(	O
500	O
microM	O
)	O
increased	O
extracellular	O
dopamine	B-CHEMICAL
levels	O
,	O
while	O
lower	O
concentrations	O
(	O
50	O
-	O
100	O
microM	O
)	O
were	O
devoid	O
of	O
any	O
effect	O
.	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
blockade	O
of	O
mGluR5	O
by	O
MPEP	O
may	O
protect	O
dopaminergic	O
neurones	O
against	O
methamphetamine	B-CHEMICAL
-	O
induced	O
toxicity	B-DISEASE
.	O
Neuroprotection	O
rendered	O
by	O
MPEP	O
may	O
be	O
associated	O
with	O
the	O
reduction	O
of	O
the	O
methamphetamine	B-CHEMICAL
-	O
induced	O
dopamine	B-CHEMICAL
efflux	O
in	O
the	O
striatum	O
due	O
to	O
the	O
blockade	O
of	O
extrastriatal	O
mGluR5	O
,	O
and	O
with	O
a	O
decrease	O
in	O
hyperthermia	B-DISEASE
.	O

Pharmacokinetics	O
of	O
desipramine	B-CHEMICAL
HCl	O
when	O
administered	O
with	O
cinacalcet	B-CHEMICAL
HCl	O
.	O
OBJECTIVE	O
:	O
In	O
vitro	O
work	O
has	O
demonstrated	O
that	O
cinacalcet	B-CHEMICAL
is	O
a	O
strong	O
inhibitor	O
of	O
cytochrome	O
P450	O
isoenzyme	O
(	O
CYP	O
)	O
2D6	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
cinacalcet	B-CHEMICAL
on	O
CYP2D6	O
activity	O
,	O
using	O
desipramine	B-CHEMICAL
as	O
a	O
probe	O
substrate	O
,	O
in	O
healthy	O
subjects	O
.	O
METHODS	O
:	O
Seventeen	O
subjects	O
who	O
were	O
genotyped	O
as	O
CYP2D6	O
extensive	O
metabolizers	O
were	O
enrolled	O
in	O
this	O
randomized	O
,	O
open	O
-	O
label	O
,	O
crossover	O
study	O
to	O
receive	O
a	O
single	O
oral	O
dose	O
of	O
desipramine	B-CHEMICAL
(	O
50	O
mg	O
)	O
on	O
two	O
separate	O
occasions	O
,	O
once	O
alone	O
and	O
once	O
after	O
multiple	O
doses	O
of	O
cinacalcet	B-CHEMICAL
(	O
90	O
mg	O
for	O
7	O
days	O
)	O
.	O
Blood	O
samples	O
were	O
obtained	O
predose	O
and	O
up	O
to	O
72	O
h	O
postdose	O
.	O
RESULTS	O
:	O
Fourteen	O
subjects	O
completed	O
both	O
treatment	O
arms	O
.	O
Relative	O
to	O
desipramine	B-CHEMICAL
alone	O
,	O
mean	O
AUC	O
and	O
C(max	O
)	O
of	O
desipramine	B-CHEMICAL
increased	O
3.6-	O
and	O
1.8	O
-	O
fold	O
when	O
coadministered	O
with	O
cinacalcet	B-CHEMICAL
.	O
The	O
t	O
(	O
1/2,z	O
)	O
of	O
desipramine	B-CHEMICAL
was	O
longer	O
when	O
desipramine	B-CHEMICAL
was	O
coadministered	O
with	O
cinacalcet	B-CHEMICAL
(	O
21.0	O
versus	O
43.3	O
hs	O
)	O
.	O
The	O
t	O
(	O
max	O
)	O
was	O
similar	O
between	O
the	O
regimens	O
.	O
Fewer	O
subjects	O
reported	O
adverse	O
events	O
following	O
treatment	O
with	O
desipramine	B-CHEMICAL
alone	O
than	O
when	O
receiving	O
desipramine	B-CHEMICAL
with	O
cinacalcet	B-CHEMICAL
(	O
33	O
versus	O
86	O
%	O
)	O
,	O
the	O
most	O
frequent	O
of	O
which	O
(	O
nausea	B-DISEASE
and	O
headache	B-DISEASE
)	O
have	O
been	O
reported	O
for	O
patients	O
treated	O
with	O
either	O
desipramine	B-CHEMICAL
or	O
cinacalcet	B-CHEMICAL
.	O
CONCLUSION	O
:	O
This	O
study	O
demonstrates	O
that	O
cinacalcet	B-CHEMICAL
is	O
a	O
strong	O
inhibitor	O
of	O
CYP2D6	O
.	O
These	O
data	O
suggest	O
that	O
during	O
concomitant	O
treatment	O
with	O
cinacalcet	B-CHEMICAL
,	O
dose	O
adjustment	O
may	O
be	O
necessary	O
for	O
drugs	O
that	O
demonstrate	O
a	O
narrow	O
therapeutic	O
index	O
and	O
are	O
metabolized	O
by	O
CYP2D6	O
.	O

Proteomic	O
analysis	O
of	O
striatal	O
proteins	O
in	O
the	O
rat	O
model	O
of	O
L	O
-	O
DOPA	O
-	O
induced	O
dyskinesia	B-DISEASE
.	O
L	O
-	O
DOPA	O
-	O
induced	O
dyskinesia	B-DISEASE
(	O
LID	O
)	O
is	O
among	O
the	O
motor	O
complications	B-DISEASE
that	O
arise	O
in	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
(	O
PD	O
)	O
patients	O
after	O
a	O
prolonged	O
treatment	O
with	O
L	O
-	O
DOPA	O
.	O
To	O
this	O
day	O
,	O
transcriptome	O
analysis	O
has	O
been	O
performed	O
in	O
a	O
rat	O
model	O
of	O
LID	O
[	O
Neurobiol	O
.	O
Dis	O
.	O
,	O
17	O
(	O
2004	O
)	O
,	O
219	O
]	O
but	O
information	O
regarding	O
the	O
proteome	O
is	O
still	O
lacking	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
changes	O
occurring	O
at	O
the	O
protein	O
level	O
in	O
striatal	O
samples	O
obtained	O
from	O
the	O
unilaterally	O
6	B-CHEMICAL
-	I-CHEMICAL
hydroxydopamine	I-CHEMICAL
-	O
lesion	O
rat	O
model	O
of	O
PD	O
treated	O
with	O
saline	O
,	O
L	O
-	O
DOPA	O
or	O
bromocriptine	O
using	O
two	O
-	O
dimensional	O
difference	O
gel	O
electrophoresis	O
and	O
mass	O
spectrometry	O
(	O
MS	B-DISEASE
)	O
.	O
Rats	O
treated	O
with	O
L	O
-	O
DOPA	O
were	O
allocated	O
to	O
two	O
groups	O
based	O
on	O
the	O
presence	O
or	O
absence	O
of	O
LID	O
.	O
Among	O
the	O
2000	O
spots	O
compared	O
for	O
statistical	O
difference	O
,	O
67	O
spots	O
were	O
significantly	O
changed	O
in	O
abundance	O
and	O
identified	O
using	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
MS	B-DISEASE
,	O
atmospheric	O
pressure	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
and	O
HPLC	O
coupled	O
tandem	O
MS	B-DISEASE
(	O
LC	O
/	O
MS	B-DISEASE
/	O
MS	B-DISEASE
)	O
.	O
Out	O
of	O
these	O
67	O
proteins	O
,	O
LID	O
significantly	O
changed	O
the	O
expression	O
level	O
of	O
five	O
proteins	O
:	O
alphabeta	O
-	O
crystalin	O
,	O
gamma	O
-	O
enolase	O
,	O
guanidoacetate	O
methyltransferase	O
,	O
vinculin	O
,	O
and	O
proteasome	O
alpha-2	O
subunit	O
.	O
Complementary	O
techniques	O
such	O
as	O
western	O
immunoblotting	O
and	O
immunohistochemistry	O
were	O
performed	O
to	O
investigate	O
the	O
validity	O
of	O
the	O
data	O
obtained	O
using	O
the	O
proteomic	O
approach	O
.	O
In	O
conclusion	O
,	O
this	O
study	O
provides	O
new	O
insights	O
into	O
the	O
protein	O
changes	O
occurring	O
in	O
LID	O
.	O

Pseudo	O
-	O
allergic	B-DISEASE
reactions	I-DISEASE
to	O
corticosteroids	B-CHEMICAL
:	O
diagnosis	O
and	O
alternatives	O
.	O
Two	O
patients	O
treated	O
with	O
parenteral	O
paramethasone	B-CHEMICAL
(	O
Triniol	O
)	O
and	O
dexamethasone	B-CHEMICAL
(	O
Sedionbel	O
)	O
are	O
described	O
.	O
A	O
few	O
minutes	O
after	O
administration	O
of	O
the	O
drugs	O
,	O
they	O
presented	O
urticaria	B-DISEASE
(	O
patients	O
1	O
and	O
2	O
)	O
and	O
conjunctivitis	B-DISEASE
(	O
patient	O
1	O
)	O
.	O
The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
determine	O
the	O
cause	O
of	O
the	O
patients	O
'	O
reactions	O
,	O
the	O
immunological	O
mechanisms	O
involved	O
and	O
whether	O
these	O
patients	O
would	O
be	O
able	O
to	O
tolerate	O
any	O
kind	O
of	O
corticoid	O
.	O
Clinical	O
examinations	O
and	O
skin	O
,	O
oral	O
and	O
parenteral	O
challenges	O
with	O
different	O
corticosteroids	B-CHEMICAL
and	O
ELISA	O
tests	O
were	O
performed	O
.	O
In	O
the	O
two	O
patients	O
,	O
skin	O
and	O
ELISA	O
tests	O
with	O
paramethasone	B-CHEMICAL
were	O
negative	O
,	O
as	O
was	O
the	O
prick	O
test	O
with	O
each	O
of	O
its	O
excipients	B-CHEMICAL
.	O
A	O
single	O
-	O
blind	B-DISEASE
parenteral	O
challenge	O
with	O
Triniol	O
was	O
positive	O
in	O
both	O
patients	O
after	O
the	O
administration	O
of	O
1	O
ml	O
of	O
the	O
drug	O
,	O
and	O
negative	O
with	O
its	O
excipients	B-CHEMICAL
.	O
We	O
also	O
carried	O
out	O
oral	O
and	O
parenteral	O
challenges	O
with	O
other	O
corticosteroids	B-CHEMICAL
and	O
found	O
intolerance	O
to	O
some	O
of	O
them	O
.	O
These	O
results	O
suggest	O
that	O
paramethasone	B-CHEMICAL
caused	O
pseudoallergic	O
reactions	O
in	O
our	O
patients	O
.	O
Corticosteroids	B-CHEMICAL
different	O
from	O
paramethasone	B-CHEMICAL
also	O
produced	O
hypersensitivity	B-DISEASE
reactions	O
in	O
these	O
patients	O
;	O
however	O
,	O
a	O
few	O
of	O
them	O
were	O
tolerated	O
.	O
The	O
basic	O
mechanisms	O
of	O
those	O
reactions	O
are	O
not	O
yet	O
fully	O
understood	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
pseudo	O
-	O
allergy	B-DISEASE
caused	O
by	O
paramethasone	B-CHEMICAL
.	O

Valproic	O
acid	O
induced	O
encephalopathy--19	O
new	O
cases	O
in	O
Germany	O
from	O
1994	O
to	O
2003	O
-	O
-a	O
side	O
effect	O
associated	O
to	O
VPA	O
-	O
therapy	O
not	O
only	O
in	O
young	O
children	O
.	O
Valproic	O
acid	O
(	O
VPA	O
)	O
is	O
a	O
broad	O
-	O
spectrum	O
antiepileptic	O
drug	O
and	O
is	O
usually	O
well	O
-	O
tolerated	O
.	O
Rare	O
serious	O
complications	B-DISEASE
may	O
occur	O
in	O
some	O
patients	O
,	O
including	O
haemorrhagic	O
pancreatitis	B-DISEASE
,	O
bone	B-DISEASE
marrow	I-DISEASE
suppression	I-DISEASE
,	O
VPA	O
-	O
induced	O
hepatotoxicity	O
and	O
VPA	O
-	O
induced	O
encephalopathy	B-DISEASE
.	O
The	O
typical	O
signs	O
of	O
VPA	O
-	O
induced	O
encephalopathy	B-DISEASE
are	O
impaired	O
consciousness	O
,	O
sometimes	O
marked	O
EEG	O
background	O
slowing	O
,	O
increased	O
seizure	B-DISEASE
frequency	O
,	O
with	O
or	O
without	O
hyperammonemia	B-DISEASE
.	O
There	O
is	O
still	O
no	O
proof	O
of	O
causative	O
effect	O
of	O
VPA	O
in	O
patients	O
with	O
encephalopathy	B-DISEASE
,	O
but	O
only	O
of	O
an	O
association	O
with	O
an	O
assumed	O
causal	O
relation	O
.	O
We	O
report	O
19	O
patients	O
with	O
VPA	O
-	O
associated	O
encephalopathy	B-DISEASE
in	O
Germany	O
from	O
the	O
years	O
1994	O
to	O
2003	O
,	O
none	O
of	O
whom	O
had	O
been	O
published	O
previously	O
.	O

Haemolytic	O
-	O
uraemic	O
syndrome	B-DISEASE
after	O
treatment	O
with	O
metronidazole	B-CHEMICAL
.	O
This	O
paper	O
describes	O
the	O
clinical	O
features	O
of	O
six	O
children	O
who	O
developed	O
the	O
haemolytic	O
-	O
uraemic	O
syndrome	B-DISEASE
after	O
treatment	O
with	O
metronidazole	B-CHEMICAL
.	O
These	O
children	O
were	O
older	O
and	O
were	O
more	O
likely	O
to	O
have	O
undergone	O
recent	O
bowel	O
surgery	O
than	O
are	O
other	O
children	O
with	O
this	O
condition	O
.	O
While	O
the	O
involvement	O
of	O
metronidazole	B-CHEMICAL
in	O
the	O
aetiology	O
of	O
the	O
haemolytic	O
-	O
uraemic	O
syndrome	B-DISEASE
is	O
not	O
established	O
firmly	O
,	O
the	O
action	O
of	O
this	O
drug	O
in	O
sensitizing	O
tissues	O
to	O
oxidation	O
injury	O
and	O
the	O
reported	O
evidence	O
of	O
oxidation	O
changes	O
in	O
the	O
haemolytic	O
-	O
uraemic	O
syndrome	B-DISEASE
suggest	O
a	O
possible	O
link	O
between	O
metronidazole	B-CHEMICAL
treatment	O
and	O
some	O
cases	O
of	O
the	O
haemolytic	O
-	O
uraemic	O
syndrome	B-DISEASE
.	O

Risk	O
factors	O
of	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
in	O
preterm	O
infants	O
.	O
Among	O
547	O
preterm	O
infants	O
of	O
<	O
or	O
=	O
34	O
weeks	O
gestation	O
born	O
between	O
1987	O
and	O
1991	O
,	O
8	O
children	O
(	O
1.46	O
%	O
)	O
developed	O
severe	O
progressive	O
and	O
bilateral	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O
Perinatal	O
risk	O
factors	O
of	O
infants	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
were	O
compared	O
with	O
those	O
of	O
two	O
control	O
groups	O
matched	O
for	O
gestation	O
and	O
birth	B-DISEASE
weight	I-DISEASE
and	O
for	O
perinatal	O
complications	B-DISEASE
.	O
Our	O
observations	O
demonstrated	O
an	O
association	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
with	O
a	O
higher	O
incidence	O
of	O
perinatal	O
complications	B-DISEASE
.	O
Ototoxicity	B-DISEASE
appeared	O
closely	O
related	O
to	O
a	O
prolonged	O
administration	O
and	O
higher	O
total	O
dose	O
of	O
ototoxic	O
drugs	O
,	O
particularly	O
aminoglycosides	O
and	O
furosemide	B-CHEMICAL
.	O
Finally	O
,	O
we	O
strongly	O
recommend	O
to	O
prospectively	O
and	O
regularly	O
perform	O
audiologic	O
assessment	O
in	O
sick	O
preterm	O
children	O
as	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
of	O
delayed	O
onset	O
and	O
in	O
most	O
cases	O
bilateral	O
and	O
severe	O
.	O

Pharmacokinetic	O
and	O
clinical	O
studies	O
in	O
patients	O
with	O
cimetidine	B-CHEMICAL
-	O
associated	O
mental	O
confusion	B-DISEASE
.	O
15	O
cases	O
of	O
cimetidine	B-CHEMICAL
-	O
associated	O
mental	O
confusion	B-DISEASE
have	O
been	O
reported	O
.	O
In	O
order	O
that	O
this	O
syndrome	B-DISEASE
might	O
be	O
investigated	O
changes	O
in	O
mental	O
status	O
(	O
M.S.	O
)	O
were	O
correlated	O
with	O
serum	O
concentrations	O
and	O
renal	O
and	O
hepatic	O
function	O
in	O
36	O
patients	O
,	O
30	O
patients	O
had	O
no	O
M.S.	O
change	O
on	O
cimetidine	B-CHEMICAL
and	O
6	O
had	O
moderate	O
to	O
severe	O
changes	O
.	O
These	O
6	O
patients	O
had	O
both	O
renal	O
and	O
liver	O
dysfunction	O
(	O
P	O
less	O
than	O
0.05	O
)	O
,	O
as	O
well	O
as	O
cimetidine	B-CHEMICAL
trough	O
-	O
concentrations	O
of	O
more	O
than	O
1.25	O
microgram	O
/	O
ml	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O
The	O
severity	O
of	O
M.S.	O
changes	O
increased	O
as	O
trough	O
-	O
concentrations	O
rose	O
,	O
5	O
patients	O
had	O
lumbar	O
puncture	O
.	O
The	O
cerebrospinal	O
fluid	O
:	O
serum	O
ratio	O
of	O
cimetidine	B-CHEMICAL
concentrations	O
was	O
0.24:1	O
and	O
indicates	O
that	O
cimetidine	B-CHEMICAL
passes	O
the	O
blood	O
-	O
brain	O
barrier	O
;	O
it	O
also	O
raises	O
the	O
possibility	O
that	O
M.S.	O
changes	O
are	O
due	O
to	O
blockade	O
of	O
histamine	B-CHEMICAL
H2	O
-	O
receptors	O
in	O
the	O
central	O
nervous	O
system	O
.	O
Patients	O
likely	O
to	O
have	O
both	O
raised	O
trough	O
-	O
concentrations	O
and	O
mental	O
confusion	B-DISEASE
are	O
those	O
with	O
both	O
severe	O
renal	O
and	O
hepatic	O
dysfunction	O
.	O
They	O
should	O
be	O
closely	O
observed	O
and	O
should	O
be	O
given	O
reduced	O
doses	O
of	O
cimetidine	B-CHEMICAL
.	O

Different	O
lobular	O
distributions	O
of	O
altered	O
hepatocyte	O
tight	O
junctions	O
in	O
rat	O
models	O
of	O
intrahepatic	O
and	O
extrahepatic	B-DISEASE
cholestasis	I-DISEASE
.	O
Hepatocyte	O
tight	O
junctions	O
(	O
TJs	O
)	O
,	O
the	O
only	O
intercellular	O
barrier	O
between	O
the	O
sinusoidal	O
and	O
the	O
canalicular	O
spaces	O
,	O
play	O
a	O
key	O
role	O
in	O
bile	O
formation	O
.	O
Although	O
hepatocyte	O
TJs	O
are	O
impaired	O
in	O
cholestasis	B-DISEASE
,	O
attempts	O
to	O
localize	O
the	O
precise	O
site	O
of	O
hepatocyte	O
TJ	O
damage	O
by	O
freeze	O
-	O
fracture	O
electron	O
microscopy	O
have	O
produced	O
limited	O
information	O
.	O
Recently	O
,	O
several	O
TJ	O
-	O
associated	O
proteins	O
like	O
ZO-1	O
and	O
7H6	O
have	O
been	O
identified	O
and	O
characterized	O
.	O
Immunolocalization	O
of	O
7H6	O
appears	O
to	O
closely	O
correlate	O
with	O
paracellular	O
permeability	O
.	O
We	O
used	O
rat	O
models	O
of	O
intrahepatic	O
cholestasis	B-DISEASE
by	O
ethinyl	O
estradiol	B-CHEMICAL
(	O
EE	O
)	O
treatment	O
and	O
extrahepatic	B-DISEASE
cholestasis	I-DISEASE
by	O
bile	O
duct	O
ligation	O
(	O
BDL	O
)	O
to	O
precisely	O
determine	O
the	O
site	O
of	O
TJ	O
damage	O
.	O
Alterations	O
in	O
hepatocyte	O
TJs	O
were	O
assessed	O
by	O
double	O
-	O
immunolabeling	O
for	O
7H6	O
and	O
ZO-1	O
using	O
a	O
confocal	O
laser	O
scanning	O
microscope	O
.	O
In	O
control	O
rats	O
,	O
immunostaining	O
for	O
7H6	O
and	O
ZO-1	O
colocalized	O
to	O
outline	O
bile	O
canaliculi	O
in	O
a	O
continuous	O
fashion	O
.	O
In	O
contrast	O
,	O
7H6	O
and	O
ZO-1	O
immunostaining	O
was	O
more	O
discontinuous	O
,	O
outlining	O
the	O
bile	O
canaliculi	O
after	O
BDL	O
.	O
Immunostaining	O
for	O
7H6	O
,	O
not	O
ZO-1	O
,	O
decreased	O
and	O
predominantly	O
appeared	O
as	O
discrete	O
signals	O
in	O
the	O
submembranous	O
cytoplasm	O
of	O
periportal	O
hepatocytes	O
after	O
BDL	O
.	O
After	O
EE	O
treatment	O
,	O
changes	O
in	O
immunostaining	O
for	O
7H6	O
and	O
ZO-1	O
were	O
similar	O
to	O
those	O
seen	O
in	O
periportal	O
hepatocytes	O
after	O
BDL	O
,	O
but	O
distributed	O
more	O
diffusely	O
throughout	O
the	O
lobule	O
.	O
This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
that	O
impairment	O
of	O
hepatocyte	O
TJs	O
occurs	O
heterogenously	O
in	O
the	O
liver	O
lobule	O
after	O
BDL	O
and	O
suggests	O
that	O
BDL	O
and	O
EE	O
treatments	O
produce	O
different	O
lobular	O
distributions	O
of	O
increased	O
paracellular	O
permeability	O
.	O

Long	O
term	O
audiological	O
evaluation	O
of	O
beta	B-DISEASE
-	I-DISEASE
thalassemic	I-DISEASE
patients	O
.	O
OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
incidence	O
and	O
to	O
monitor	O
the	O
progression	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
children	O
and	O
young	O
adults	O
with	O
beta	B-DISEASE
-	I-DISEASE
thalassemia	I-DISEASE
major	O
.	O
METHODS	O
:	O
One	O
hundred	O
and	O
four	O
(	O
104	O
)	O
patients	O
aged	O
6	O
-	O
35	O
years	O
(	O
mean	O
17,2	O
years	O
)	O
participated	O
in	O
the	O
study	O
.	O
All	O
patients	O
were	O
on	O
a	O
regular	O
transfusion	O
-	O
chelation	O
program	O
maintaining	O
a	O
mean	O
hemoglobin	O
level	O
of	O
9.5	O
gr	O
/	O
dl	O
.	O
Subjects	O
were	O
receiving	O
desferrioxamine	B-CHEMICAL
(	O
DFO	O
)	O
chelation	O
treatment	O
with	O
a	O
mean	O
daily	O
dose	O
of	O
50	O
-	O
60	O
mg	O
/	O
kg	O
,	O
5	O
-	O
6	O
days	O
a	O
week	O
during	O
the	O
first	O
six	O
years	O
of	O
the	O
study	O
,	O
which	O
was	O
then	O
reduced	O
to	O
40	O
-	O
50	O
mg	O
/	O
kg	O
for	O
the	O
following	O
eight	O
years	O
.	O
Patients	O
were	O
followed	O
for	O
8	O
-	O
14	O
years	O
.	O
RESULTS	O
:	O
Overall	O
,	O
21	O
out	O
of	O
104	O
patients	O
(	O
20.2	O
%	O
)	O
presented	O
with	O
high	O
frequency	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
SNHL	B-DISEASE
)	O
,	O
either	O
unilateral	O
or	O
bilateral	O
.	O
No	O
ototoxic	O
factor	O
,	O
other	O
than	O
DFO	O
,	O
was	O
present	O
in	O
any	O
of	O
the	O
patients	O
.	O
Patients	O
with	O
SNHL	B-DISEASE
presented	O
with	O
relatively	O
lower	O
serum	O
ferritin	O
levels	O
than	O
those	O
with	O
normal	O
hearing	O
,	O
however	O
,	O
no	O
statistically	O
significant	O
difference	O
was	O
observed	O
.	O
Subjects	O
with	O
SNHL	B-DISEASE
were	O
submitted	O
to	O
DFO	O
reduction	O
or	O
temporary	O
withdrawal	O
.	O
Following	O
intervention	O
,	O
7	O
out	O
of	O
21	O
affected	O
patients	O
recovered	O
,	O
10	O
remained	O
stable	O
and	O
4	O
demonstrated	O
aggravation	O
.	O
CONCLUSION	O
:	O
The	O
findings	O
are	O
indicative	O
of	O
DFO	O
's	O
contributing	O
role	O
in	O
the	O
development	O
of	O
hearing	O
impairment	O
.	O
Regular	O
audiologic	O
evaluation	O
is	O
imperative	O
in	O
all	O
thalassemic	O
patients	O
so	O
that	O
early	O
changes	O
may	O
be	O
recognized	O
and	O
treatment	O
may	O
be	O
judiciously	O
adjusted	O
in	O
order	O
to	O
prevent	O
or	O
reverse	O
hearing	O
impairment	O
.	O

Design	O
and	O
analysis	O
of	O
the	O
HYPREN	O
-	O
trial	O
:	O
safety	O
of	O
enalapril	B-CHEMICAL
and	O
prazosin	B-CHEMICAL
in	O
the	O
initial	O
treatment	O
phase	O
of	O
patients	O
with	O
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
.	O
Since	O
the	O
introduction	O
of	O
angiotensin	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitors	O
into	O
the	O
adjunctive	O
treatment	O
of	O
patients	O
with	O
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
,	O
cases	O
of	O
severe	O
hypotension	B-DISEASE
,	O
especially	O
on	O
the	O
first	O
day	O
of	O
treatment	O
,	O
have	O
occasionally	O
been	O
reported	O
.	O
To	O
assess	O
the	O
safety	O
of	O
the	O
ACE	B-CHEMICAL
inhibitor	I-CHEMICAL
enalapril	B-CHEMICAL
a	O
multicenter	O
,	O
randomized	O
,	O
prazosin	B-CHEMICAL
-	O
controlled	O
trial	O
was	O
designed	O
that	O
compared	O
the	O
incidence	O
and	O
severity	O
of	O
symptomatic	O
hypotension	B-DISEASE
on	O
the	O
first	O
day	O
of	O
treatment	O
.	O
Trial	O
medication	O
was	O
2.5	O
mg	O
enalapril	B-CHEMICAL
or	O
0.5	O
prazosin	B-CHEMICAL
.	O
Subjects	O
were	O
1210	O
inpatients	O
with	O
New	O
York	O
Heart	O
Association	O
(	O
NYHA	O
)	O
functional	O
class	O
II	O
and	O
III	O
.	O
Patients	O
who	O
received	O
enalapril	B-CHEMICAL
experienced	O
clinically	O
and	O
statistically	O
significantly	O
less	O
symptomatic	O
hypotension	B-DISEASE
(	O
5.2	O
%	O
)	O
than	O
the	O
patients	O
who	O
received	O
prazosin	B-CHEMICAL
(	O
12.9	O
%	O
)	O
.	O
All	O
patients	O
recovered	O
.	O
It	O
was	O
concluded	O
that	O
treatment	O
with	O
enalapril	B-CHEMICAL
was	O
well	O
tolerated	O
and	O
it	O
is	O
,	O
therefore	O
,	O
unreasonable	O
to	O
restrict	O
the	O
initiation	O
of	O
treatment	O
with	O
enalapril	B-CHEMICAL
to	O
inpatients	O
.	O

Antagonism	O
between	O
interleukin	O
3	O
and	O
erythropoietin	O
in	O
mice	O
with	O
azidothymidine	O
-	O
induced	O
anemia	B-DISEASE
and	O
in	O
bone	O
marrow	O
endothelial	O
cells	O
.	O
Azidothymidine	O
(	O
AZT)-induced	O
anemia	B-DISEASE
in	O
mice	O
can	O
be	O
reversed	O
by	O
the	O
administration	O
of	O
IGF	O
-	O
IL-3	O
(	O
fusion	O
protein	O
of	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
(	O
IGF	O
II	O
)	O
and	O
interleukin	O
3	O
)	O
.	O
Although	O
interleukin	O
3	O
(	O
IL-3	O
)	O
and	O
erythropoietin	O
(	O
EPO	O
)	O
are	O
known	O
to	O
act	O
synergistically	O
on	O
hematopoietic	O
cell	O
proliferation	O
in	O
vitro	O
,	O
injection	O
of	O
IGF	O
-	O
IL-3	O
and	O
EPO	O
in	O
AZT	B-CHEMICAL
-	O
treated	O
mice	O
resulted	O
in	O
a	O
reduction	O
of	O
red	O
cells	O
and	O
an	O
increase	O
of	O
plasma	O
EPO	O
levels	O
as	O
compared	O
to	O
animals	O
treated	O
with	O
IGF	O
-	O
IL-3	O
or	O
EPO	O
alone	O
.	O
We	O
tested	O
the	O
hypothesis	O
that	O
the	O
antagonistic	O
effect	O
of	O
IL-3	O
and	O
EPO	O
on	O
erythroid	O
cells	O
may	O
be	O
mediated	O
by	O
endothelial	O
cells	O
.	O
Bovine	O
liver	O
erythroid	O
cells	O
were	O
cultured	O
on	O
monolayers	O
of	O
human	O
bone	O
marrow	O
endothelial	O
cells	O
previously	O
treated	O
with	O
EPO	O
and	O
IGF	O
-	O
IL-3	O
.	O
There	O
was	O
a	O
significant	O
reduction	O
of	O
thymidine	B-CHEMICAL
incorporation	O
into	O
both	O
erythroid	O
and	O
endothelial	O
cells	O
in	O
cultures	O
pre	O
-	O
treated	O
with	O
IGF	O
-	O
IL-3	O
and	O
EPO	O
.	O
Endothelial	O
cell	O
culture	O
supernatants	O
separated	O
by	O
ultrafiltration	O
and	O
ultracentrifugation	O
from	O
cells	O
treated	O
with	O
EPO	O
and	O
IL-3	O
significantly	O
reduced	O
thymidine	B-CHEMICAL
incorporation	O
into	O
erythroid	O
cells	O
as	O
compared	O
to	O
identical	O
fractions	O
obtained	O
from	O
the	O
media	O
of	O
cells	O
cultured	O
with	O
EPO	O
alone	O
.	O
These	O
results	O
suggest	O
that	O
endothelial	O
cells	O
treated	O
simultaneously	O
with	O
EPO	O
and	O
IL-3	O
have	O
a	O
negative	O
effect	O
on	O
erythroid	O
cell	O
production	O
.	O

Interactive	O
effects	O
of	O
variations	O
in	O
[	O
Na]o	O
and	O
[	O
Ca]o	O
on	O
rat	O
atrial	O
spontaneous	O
frequency	O
.	O
The	O
effects	O
of	O
varying	O
the	O
extracellular	O
concentrations	O
of	O
Na	O
and	O
Ca	B-CHEMICAL
(	O
[	O
Na]o	O
and	O
[	O
Ca]o	O
)	O
on	O
both	O
,	O
the	O
spontaneous	O
beating	O
and	O
the	O
negative	O
chronotropic	O
action	O
of	O
verapamil	B-CHEMICAL
,	O
were	O
studied	O
in	O
the	O
isolated	O
rat	O
atria	O
.	O
Basal	O
frequency	O
(	O
BF	O
)	O
evaluated	O
by	O
surface	O
electrogram	O
was	O
223	O
+	O
/-	O
4	O
beats	O
/	O
min	O
.	O
in	O
control	O
Krebs	O
-	O
Ringer	O
containing	O
137	O
mM	O
Na	O
and	O
1.35	O
mM	O
Ca	B-CHEMICAL
(	O
N	O
)	O
.	O
It	O
decreased	O
by	O
16	O
+	O
/-	O
3	O
%	O
by	O
lowering	O
[	O
Na]o	O
to	O
78	O
mM	O
(	O
LNa	O
)	O
,	O
23	O
+	O
/-	O
2	O
%	O
by	O
lowering	O
simultaneously	O
[	O
Na]o	O
to	O
78	O
mM	O
and	O
[	O
Ca]o	O
to	O
0.675	O
mM	O
(	O
LNa+LCa	O
)	O
and	O
31	O
+	O
/-	O
5	O
%	O
by	O
lowering	O
[	O
Na]o	O
to	O
78	O
mM	O
plus	O
increasing	O
[	O
Ca]o	O
to	O
3.6	O
mM	O
(	O
LNa+HCa	O
)	O
.	O
At	O
normal	O
[	O
Na]o	O
,	O
decrease	O
(	O
0.675	O
mM	O
)	O
or	O
increase	O
(	O
3.6	O
mM	O
)	O
of	O
[	O
Ca]o	O
did	O
not	O
modify	O
BF	O
;	O
a	O
reduction	O
of	O
ten	O
times	O
(	O
0.135	O
mM	O
of	O
normal	O
[	O
Ca]o	O
was	O
effective	O
to	O
reduce	O
BF	O
by	O
40	O
+	O
/-	O
13	O
%	O
.	O
All	O
negative	O
chronotropic	O
effects	O
were	O
BF	O
-	O
dependent	O
.	O
Dose	O
-	O
dependent	O
bradycardia	B-DISEASE
induced	O
by	O
verapamil	B-CHEMICAL
was	O
potentiated	O
by	O
LNa	O
,	O
LCa	O
,	O
and	O
HCa	O
.	O
Independent	O
but	O
not	O
additive	O
effects	O
of	O
Na	O
and	O
Ca	B-CHEMICAL
are	O
shown	O
by	O
decreases	O
in	O
the	O
values	O
of	O
[	O
verapamil]o	O
needed	O
to	O
reduce	O
BF	O
by	O
30	O
%	O
(	O
IC30	O
)	O
with	O
the	O
following	O
order	O
of	O
inhibitory	O
potency	O
:	O
LNa	O
>	O
LCa	O
>	O
HCa	O
>	O
N	O
,	O
resulting	O
LNa+HCa	O
similar	O
to	O
LNa	O
.	O
The	O
[	O
verapamil]o	O
that	O
arrested	O
atrial	O
beating	O
(	O
AC	O
)	O
was	O
also	O
potentiated	O
with	O
the	O
order	O
LNa	O
=	O
LNa+LCa	O
=	O
LNa+HCa	O
=	O
LCa	O
>	O
HCa	O
=	O
N.	O
The	O
results	O
indicate	O
that	O
rat	O
atrial	O
spontaneous	O
beating	O
is	O
more	O
dependent	O
on	O
[	O
Na]o	O
than	O
on	O
[	O
Ca]o	O
in	O
a	O
range	O
of	O
+	O
/-	O
50	O
%	O
of	O
their	O
normal	O
concentration	O
.	O
Also	O
the	O
enhancement	O
of	O
verapamil	B-CHEMICAL
effects	O
on	O
atrial	O
beating	O
was	O
more	O
pronounced	O
at	O
LNa	O
than	O
at	O
LCa.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Sodium	B-CHEMICAL
status	O
influences	O
chronic	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
nephrotoxicity	B-DISEASE
in	O
rats	O
.	O
The	O
nephrotoxic	B-DISEASE
potential	O
of	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
(	O
5	O
mg	O
/	O
kg	O
per	O
day	O
intraperitoneally	O
for	O
3	O
weeks	O
)	O
has	O
been	O
investigated	O
in	O
salt	B-CHEMICAL
-	O
depleted	O
,	O
normal	O
-	O
salt	B-CHEMICAL
,	O
and	O
salt	B-CHEMICAL
-	O
loaded	O
rats	O
.	O
In	O
salt	B-CHEMICAL
-	O
depleted	O
rats	O
,	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
decreased	O
creatinine	B-CHEMICAL
clearance	O
linearly	O
with	O
time	O
,	O
with	O
an	O
85	O
%	O
reduction	O
by	O
week	O
3	O
.	O
In	O
contrast	O
,	O
in	O
normal	O
-	O
salt	B-CHEMICAL
rats	O
creatinine	B-CHEMICAL
clearance	O
was	O
decreased	O
but	O
to	O
a	O
lesser	O
extent	O
at	O
week	O
2	O
and	O
3	O
,	O
and	O
in	O
salt	B-CHEMICAL
-	O
loaded	O
rats	O
creatinine	B-CHEMICAL
clearance	O
did	O
not	O
change	O
for	O
2	O
weeks	O
and	O
was	O
decreased	O
by	O
43	O
%	O
at	O
week	O
3	O
.	O
All	O
rats	O
in	O
the	O
sodium	B-CHEMICAL
-	O
depleted	O
group	O
had	O
histopathological	O
evidence	O
of	O
patchy	O
tubular	O
cytoplasmic	O
degeneration	O
in	O
tubules	O
that	O
was	O
not	O
observed	O
in	O
any	O
normal	O
-	O
salt	B-CHEMICAL
or	O
salt	B-CHEMICAL
-	O
loaded	O
rat	O
.	O
Concentrations	O
of	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
in	O
plasma	O
were	O
not	O
significantly	O
different	O
among	O
the	O
three	O
groups	O
at	O
any	O
time	O
during	O
the	O
study	O
.	O
However	O
,	O
at	O
the	O
end	O
of	O
3	O
weeks	O
,	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
levels	O
in	O
the	O
kidneys	O
and	O
liver	O
were	O
significantly	O
higher	O
in	O
salt	B-CHEMICAL
-	O
depleted	O
and	O
normal	O
-	O
salt	B-CHEMICAL
rats	O
than	O
those	O
in	O
salt	B-CHEMICAL
-	O
loaded	O
rats	O
,	O
with	O
plasma	O
/	O
kidney	O
ratios	O
of	O
21	O
,	O
14	O
,	O
and	O
8	O
in	O
salt	B-CHEMICAL
-	O
depleted	O
,	O
normal	O
-	O
salt	B-CHEMICAL
,	O
and	O
salt	B-CHEMICAL
-	O
loaded	O
rats	O
,	O
respectively	O
.	O
In	O
conclusion	O
,	O
reductions	O
in	O
creatinine	B-CHEMICAL
clearance	O
and	O
renal	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
accumulation	O
after	O
chronic	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
administration	O
were	O
enhanced	O
by	O
salt	B-CHEMICAL
depletion	O
and	O
attenuated	O
by	O
sodium	B-CHEMICAL
loading	O
in	O
rats	O
.	O

Reversible	O
inferior	O
colliculus	O
lesion	O
in	O
metronidazole	B-CHEMICAL
-	O
induced	O
encephalopathy	B-DISEASE
:	O
magnetic	O
resonance	O
findings	O
on	O
diffusion	O
-	O
weighted	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
imaging	O
.	O
OBJECTIVE	O
:	O
This	O
is	O
to	O
present	O
reversible	O
inferior	O
colliculus	O
lesions	O
in	O
metronidazole	B-CHEMICAL
-	O
induced	O
encephalopathy	B-DISEASE
,	O
to	O
focus	O
on	O
the	O
diffusion	O
-	O
weighted	O
imaging	O
(	O
DWI	O
)	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
(	O
FLAIR	O
)	O
imaging	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
From	O
November	O
2005	O
to	O
September	O
2007	O
,	O
8	O
patients	O
(	O
5	O
men	O
and	O
3	O
women	O
)	O
were	O
diagnosed	O
as	O
having	O
metronidazole	B-CHEMICAL
-	O
induced	O
encephalopathy	B-DISEASE
(	O
age	O
range	O
;	O
43	O
-	O
78	O
years	O
)	O
.	O
They	O
had	O
been	O
taking	O
metronidazole	B-CHEMICAL
(	O
total	O
dosage	O
,	O
45	O
-	O
120	O
g	O
;	O
duration	O
,	O
30	O
days	O
to	O
2	O
months	O
)	O
to	O
treat	O
the	O
infection	B-DISEASE
in	O
various	O
organs	O
.	O
Initial	O
brain	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
were	O
obtained	O
after	O
the	O
hospitalization	O
,	O
including	O
DWI	O
(	O
8/8	O
)	O
,	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
map	O
(	O
4/8	O
)	O
,	O
FLAIR	O
(	O
7/8	O
)	O
,	O
and	O
T2	O
-	O
weighted	O
image	O
(	O
8/8	O
)	O
.	O
Follow	O
-	O
up	O
MRIs	O
were	O
performed	O
on	O
5	O
patients	O
from	O
third	O
to	O
14th	O
days	O
after	O
discontinuation	O
of	O
metronidazole	B-CHEMICAL
administration	O
.	O
Findings	O
of	O
initial	O
and	O
follow	O
-	O
up	O
MRIs	O
were	O
retrospectively	O
evaluated	O
by	O
2	O
neuroradiologists	O
by	O
consensus	O
,	O
to	O
analyze	O
the	O
presence	O
of	O
abnormal	O
signal	O
intensities	O
,	O
their	O
locations	O
,	O
and	O
signal	O
changes	O
on	O
follow	O
-	O
up	O
images	O
.	O
RESULTS	O
:	O
Initial	O
MRIs	O
showed	O
abnormal	O
high	O
signal	O
intensities	O
on	O
DWI	O
and	O
FLAIR	O
(	O
or	O
T2	O
-	O
weighted	O
image	O
)	O
at	O
the	O
dentate	O
nucleus	O
(	O
8/8	O
)	O
,	O
inferior	O
colliculus	O
(	O
6/8	O
)	O
,	O
corpus	O
callosum	O
(	O
2/8	O
)	O
,	O
pons	O
(	O
2/8	O
)	O
,	O
medulla	O
(	O
1/8	O
)	O
,	O
and	O
bilateral	O
cerebral	O
white	O
matter	O
(	O
1/8	O
)	O
.	O
High	O
-	O
signal	O
intensity	O
lesions	O
on	O
DWI	O
tended	O
to	O
show	O
low	O
signal	O
intensity	O
on	O
ADC	O
map	O
(	O
3/4	O
)	O
,	O
but	O
in	O
one	O
patient	O
,	O
high	O
signal	O
intensity	O
was	O
shown	O
at	O
bilateral	O
dentate	O
nuclei	O
on	O
not	O
only	O
DWI	O
but	O
also	O
ADC	O
map	O
.	O
All	O
the	O
lesions	O
in	O
dentate	O
,	O
inferior	O
colliculus	O
,	O
pons	O
,	O
and	O
medullas	O
had	O
been	O
resolved	O
completely	O
on	O
follow	O
-	O
up	O
MRIs	O
in	O
5	O
patients	O
,	O
but	O
in	O
1	O
patient	O
of	O
them	O
,	O
corpus	O
callosal	B-DISEASE
lesion	I-DISEASE
persisted	O
.	O
CONCLUSIONS	O
:	O
Reversible	O
inferior	O
colliculus	O
lesions	O
could	O
be	O
considered	O
as	O
the	O
characteristic	O
for	O
metronidazole	B-CHEMICAL
-	O
induced	O
encephalopathy	B-DISEASE
,	O
next	O
to	O
the	O
dentate	O
nucleus	O
involvement	O
.	O

Comparison	O
of	O
the	O
respiratory	O
effects	O
of	O
i.v	O
.	O
infusions	O
of	O
morphine	B-CHEMICAL
and	O
regional	O
analgesia	B-DISEASE
by	O
extradural	O
block	O
.	O
The	O
incidence	O
of	O
postoperative	O
respiratory	O
apnoea	B-DISEASE
was	O
compared	O
between	O
five	O
patients	O
receiving	O
a	O
continuous	O
i.v	O
.	O
infusion	O
of	O
morphine	B-CHEMICAL
(	O
mean	O
73.6	O
mg	O
)	O
and	O
five	O
patients	O
receiving	O
a	O
continuous	O
extradural	O
infusion	O
of	O
0.25	O
%	O
bupivacaine	O
(	O
mean	O
192	O
mg	O
)	O
in	O
the	O
24	O
-	O
h	O
period	O
following	O
upper	O
abdominal	O
surgery	O
.	O
Monitoring	O
consisted	O
of	O
airflow	O
detection	O
by	O
a	O
carbon	B-CHEMICAL
dioxide	I-CHEMICAL
analyser	O
,	O
chest	O
wall	O
movement	O
detected	O
by	O
pneumatic	O
capsules	O
,	O
and	O
continuous	O
electrocardiograph	O
recorded	O
with	O
a	O
Holter	O
ambulatory	O
monitor	O
.	O
Both	O
obstructive	O
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
central	O
apnoea	B-DISEASE
(	O
P	O
less	O
than	O
0.05	O
)	O
occurred	O
more	O
frequently	O
in	O
patients	O
who	O
had	O
a	O
morphine	B-CHEMICAL
infusion	O
.	O
There	O
was	O
also	O
a	O
higher	O
incidence	O
of	O
tachyarrhythmias	O
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
ventricular	O
ectopic	O
beats	O
(	O
P	O
less	O
than	O
0.05	O
)	O
in	O
the	O
morphine	B-CHEMICAL
infusion	O
group	O
.	O

Magnetic	O
resonance	O
volumetry	O
of	O
the	O
cerebellum	O
in	O
epileptic	B-DISEASE
patients	O
after	O
phenytoin	B-CHEMICAL
overdosages	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
relationship	O
between	O
phenytoin	B-CHEMICAL
medication	O
and	O
cerebellar	B-DISEASE
atrophy	I-DISEASE
in	O
patients	O
who	O
had	O
experienced	O
clinical	O
intoxication	O
.	O
Five	O
females	O
and	O
6	O
males	O
,	O
21	O
-	O
59	O
years	O
of	O
age	O
,	O
were	O
examined	O
with	O
a	O
1.5	O
-	O
T	O
whole	O
-	O
body	O
system	O
using	O
a	O
circular	O
polarized	O
head	O
coil	O
.	O
Conventional	O
spin	O
echo	O
images	O
were	O
acquired	O
in	O
the	O
sagittal	O
and	O
transverse	O
orientation	O
.	O
In	O
addition	O
,	O
we	O
performed	O
a	O
high	O
-	O
resolution	O
3D	O
gradient	O
echo	O
,	O
T1	O
-	O
weighted	O
sequences	O
at	O
a	O
1	O
-	O
mm	O
slice	O
thickness	O
.	O
The	O
images	O
were	O
subsequently	O
processed	O
to	O
obtain	O
volumetric	O
data	O
for	O
the	O
cerebellum	O
.	O
Cerebellar	O
volume	O
for	O
the	O
patient	O
group	O
ranged	O
between	O
67.66	O
and	O
131.08	O
ml	O
(	O
mean	O
108.9	O
ml	O
)	O
.	O
In	O
addition	O
3D	O
gradient	O
echo	O
data	O
sets	O
from	O
10	O
healthy	O
male	O
and	O
10	O
healthy	O
female	O
age	O
-	O
matched	O
volunteers	O
were	O
used	O
to	O
compare	O
cerebellar	O
volumes	O
.	O
Using	O
linear	O
regression	O
we	O
found	O
that	O
no	O
correlation	O
exists	O
between	O
seizure	B-DISEASE
duration	O
,	O
elevation	O
of	O
phenytoin	B-CHEMICAL
serum	O
levels	O
and	O
cerebellar	O
volume	O
.	O
However	O
,	O
multiple	O
regression	O
for	O
the	O
daily	O
dosage	O
,	O
duration	O
of	O
phenytoin	B-CHEMICAL
treatment	O
and	O
cerebellar	O
volume	O
revealed	O
a	O
correlation	O
of	O
these	O
parameters	O
.	O
We	O
conclude	O
that	O
phenytoin	B-CHEMICAL
overdosage	O
does	O
not	O
necessarily	O
result	O
in	O
cerebellar	B-DISEASE
atrophy	I-DISEASE
and	O
it	O
is	O
unlikely	O
that	O
phenytoin	B-CHEMICAL
medication	O
was	O
the	O
only	O
cause	O
of	O
cerebellar	B-DISEASE
atrophy	I-DISEASE
in	O
the	O
remaining	O
patients	O
.	O
Quantitative	O
morphometric	O
studies	O
of	O
the	O
cerebellum	O
provide	O
valuable	O
insights	O
into	O
the	O
pathogenesis	O
of	O
cerebellar	B-DISEASE
disorders	I-DISEASE
.	O

Evaluation	O
of	O
cardiac	O
troponin	O
I	O
and	O
T	O
levels	O
as	O
markers	O
of	O
myocardial	B-DISEASE
damage	I-DISEASE
in	O
doxorubicin	B-CHEMICAL
-	O
induced	O
cardiomyopathy	B-DISEASE
rats	O
,	O
and	O
their	O
relationship	O
with	O
echocardiographic	O
and	O
histological	O
findings	O
.	O
BACKGROUND	O
:	O
Cardiac	O
troponins	O
I	O
(	O
cTnI	O
)	O
and	O
T	O
(	O
cTnT	O
)	O
have	O
been	O
shown	O
to	O
be	O
highly	O
sensitive	O
and	O
specific	O
markers	O
of	O
myocardial	O
cell	O
injury	O
.	O
We	O
investigated	O
the	O
diagnostic	O
value	O
of	O
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	O
of	O
myocardial	B-DISEASE
damage	I-DISEASE
in	O
a	O
rat	O
model	O
of	O
doxorubicin	B-CHEMICAL
(	O
DOX)-induced	O
cardiomyopathy	B-DISEASE
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	B-DISEASE
disorders	I-DISEASE
monitored	O
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model	O
.	O
METHODS	O
:	O
Thirty	O
-	O
five	O
Wistar	O
rats	O
were	O
given	O
1.5	O
mg	O
/	O
kg	O
DOX	O
,	O
i.v	O
.	O
,	O
weekly	O
for	O
up	O
to	O
8	O
weeks	O
for	O
a	O
total	O
cumulative	O
dose	O
of	O
12	O
mg	O
/	O
kg	O
BW	O
.	O
Ten	O
rats	O
received	O
saline	O
as	O
a	O
control	O
group	O
.	O
cTnI	O
was	O
measured	O
with	O
Access(R	O
)	O
(	O
ng	O
/	O
ml	O
)	O
and	O
a	O
research	O
immunoassay	O
(	O
pg	O
/	O
ml	O
)	O
,	O
and	O
compared	O
with	O
cTnT	O
,	O
CK	O
-	O
MB	O
mass	O
and	O
CK	O
.	O
By	O
using	O
transthoracic	O
echocardiography	O
,	O
anterior	O
and	O
posterior	O
wall	O
thickness	O
,	O
LV	O
diameters	O
and	O
LV	O
fractional	O
shortening	O
(	O
FS	O
)	O
were	O
measured	O
in	O
all	O
rats	O
before	O
DOX	O
or	O
saline	O
,	O
and	O
at	O
weeks	O
6	O
and	O
9	O
after	O
treatment	O
in	O
all	O
surviving	O
rats	O
.	O
Histology	O
was	O
performed	O
in	O
DOX	O
-	O
rats	O
at	O
6	O
and	O
9	O
weeks	O
after	O
the	O
last	O
DOX	O
dose	O
and	O
in	O
all	O
controls	O
.	O
RESULTS	O
:	O
Eighteen	O
of	O
the	O
DOX	O
rats	O
died	O
prematurely	O
of	O
general	O
toxicity	B-DISEASE
during	O
the	O
9	O
-	O
week	O
period	O
.	O
End	O
-	O
diastolic	O
(	O
ED	O
)	O
and	O
end	O
-	O
systolic	O
(	O
ES	O
)	O
LV	O
diameters	O
/	O
BW	O
significantly	O
increased	O
,	O
whereas	O
LV	O
FS	O
was	O
decreased	O
after	O
9	O
weeks	O
in	O
the	O
DOX	O
group	O
(	O
p<0.001	O
)	O
.	O
These	O
parameters	O
remained	O
unchanged	O
in	O
controls	O
.	O
Histological	O
evaluation	O
of	O
hearts	O
from	O
all	O
rats	O
given	O
DOX	O
revealed	O
significant	O
slight	O
degrees	O
of	O
perivascular	O
and	O
interstitial	O
fibrosis	B-DISEASE
.	O
In	O
7	O
of	O
the	O
18	O
rats	O
,	O
degeneration	O
and	O
myocyte	O
vacuolisation	O
were	O
found	O
.	O
Only	O
five	O
of	O
the	O
controls	O
exhibited	O
evidence	O
of	O
very	O
slight	O
perivascular	O
fibrosis	B-DISEASE
.	O
A	O
significant	O
rise	O
in	O
cTnT	O
was	O
found	O
in	O
DOX	O
rats	O
after	O
cumulative	O
doses	O
of	O
7.5	O
and	O
12	O
mg	O
/	O
kg	O
in	O
comparison	O
with	O
baseline	O
(	O
p<0.05	O
)	O
.	O
cTnT	O
found	O
in	O
rats	O
after	O
12	O
mg	O
/	O
kg	O
were	O
significantly	O
greater	O
than	O
that	O
found	O
after	O
7.5	O
mg	O
/	O
kg	O
DOX	O
.	O
Maximal	O
cTnI	O
(	O
pg	O
/	O
ml	O
)	O
and	O
cTnT	O
levels	O
were	O
significantly	O
increased	O
in	O
DOX	O
rats	O
compared	O
with	O
controls	O
(	O
p=0.006	O
,	O
0.007	O
)	O
.	O
cTnI	O
(	O
ng	O
/	O
ml	O
)	O
,	O
CK	O
-	O
MB	O
mass	O
and	O
CK	O
remained	O
unchanged	O
in	O
DOX	O
rats	O
compared	O
with	O
controls	O
.	O
All	O
markers	O
remained	O
stable	O
in	O
controls	O
.	O
Analysis	O
of	O
data	O
revealed	O
a	O
significant	O
correlation	O
between	O
maximal	O
cTnT	O
and	O
ED	O
and	O
ES	O
LV	O
diameters	O
/	O
BW	O
(	O
r=0.81	O
and	O
0.65	O
;	O
p<0.0001	O
)	O
.	O
A	O
significant	O
relationship	O
was	O
observed	O
between	O
maximal	O
cTnT	O
and	O
the	O
extent	O
of	O
myocardial	O
morphological	O
changes	O
,	O
and	O
between	O
LV	O
diameters	O
/	O
BW	O
and	O
histological	O
findings	O
.	O
CONCLUSIONS	O
:	O
Among	O
markers	O
of	O
ischemic	B-DISEASE
injury	O
after	O
DOX	O
in	O
rats	O
,	O
cTnT	O
showed	O
the	O
greatest	O
ability	O
to	O
detect	O
myocardial	B-DISEASE
damage	I-DISEASE
assessed	O
by	O
echocardiographic	O
detection	O
and	O
histological	O
changes	O
.	O
Although	O
there	O
was	O
a	O
discrepancy	O
between	O
the	O
amount	O
of	O
cTnI	O
and	O
cTnT	O
after	O
DOX	O
,	O
probably	O
due	O
to	O
heterogeneity	O
in	O
cross	O
-	O
reactivities	O
of	O
mAbs	O
to	O
various	O
cTnI	O
and	O
cTnT	O
forms	O
,	O
it	O
is	O
likely	O
that	O
cTnT	O
in	O
rats	O
after	O
DOX	O
indicates	O
cell	O
damage	O
determined	O
by	O
the	O
magnitude	O
of	O
injury	O
induced	O
and	O
that	O
cTnT	O
should	O
be	O
a	O
useful	O
marker	O
for	O
the	O
prediction	O
of	O
experimentally	O
induced	O
cardiotoxicity	B-DISEASE
and	O
possibly	O
for	O
cardioprotective	O
experiments	O
.	O

Calcineurin	O
-	O
inhibitor	O
induced	O
pain	B-DISEASE
syndrome	B-DISEASE
(	O
CIPS	O
):	O
a	O
severe	O
disabling	O
complication	O
after	O
organ	O
transplantation	O
.	O
Bone	O
pain	B-DISEASE
after	O
transplantation	O
is	O
a	O
frequent	O
complication	O
that	O
can	O
be	O
caused	O
by	O
several	O
diseases	B-DISEASE
.	O
Treatment	O
strategies	O
depend	O
on	O
the	O
correct	O
diagnosis	O
of	O
the	O
pain	B-DISEASE
.	O
Nine	O
patients	O
with	O
severe	O
pain	B-DISEASE
in	O
their	O
feet	O
,	O
which	O
was	O
registered	O
after	O
transplantation	O
,	O
were	O
investigated	O
.	O
Bone	O
scans	O
showed	O
an	O
increased	O
tracer	O
uptake	O
of	O
the	O
foot	O
bones	O
.	O
Magnetic	O
resonance	O
imaging	O
demonstrated	O
bone	O
marrow	O
oedema	O
in	O
the	O
painful	O
bones	O
.	O
Pain	B-DISEASE
was	O
not	O
explained	O
by	O
other	O
diseases	B-DISEASE
causing	O
foot	O
pain	B-DISEASE
,	O
like	O
reflex	B-DISEASE
sympathetic	I-DISEASE
dystrophy	I-DISEASE
,	O
polyneuropathy	B-DISEASE
,	O
Morton	O
's	O
neuralgia	B-DISEASE
,	O
gout	B-DISEASE
,	O
osteoporosis	B-DISEASE
,	O
avascular	B-DISEASE
necrosis	I-DISEASE
,	O
intermittent	B-DISEASE
claudication	I-DISEASE
,	O
orthopaedic	O
foot	B-DISEASE
deformities	I-DISEASE
,	O
stress	B-DISEASE
fractures	B-DISEASE
,	O
and	O
hyperparathyroidism	B-DISEASE
.	O
The	O
reduction	O
of	O
cyclosporine-	O
or	O
tacrolimus	B-CHEMICAL
trough	O
levels	O
and	O
the	O
administration	O
of	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
led	O
to	O
relief	O
of	O
pain	B-DISEASE
.	O
The	O
Calcineurin	O
-	O
inhibitor	O
Induced	O
Pain	B-DISEASE
Syndrome	B-DISEASE
(	O
CIPS	O
)	O
is	O
a	O
rare	O
but	O
severe	O
side	O
effect	O
of	O
cyclosporine	B-CHEMICAL
or	O
tacrolimus	B-CHEMICAL
and	O
is	O
accurately	O
diagnosed	O
by	O
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans	O
.	O
Incorrect	O
diagnosis	O
of	O
the	O
syndrome	B-DISEASE
will	O
lead	O
to	O
a	O
significant	O
reduction	O
of	O
life	O
quality	O
in	O
patients	O
suffering	O
from	O
CIPS	O
.	O

The	O
haemodynamic	O
effects	O
of	O
propofol	B-CHEMICAL
in	O
combination	O
with	O
ephedrine	B-CHEMICAL
in	O
elderly	O
patients	O
(	O
ASA	B-CHEMICAL
groups	O
3	O
and	O
4	O
)	O
.	O
The	O
marked	O
vasodilator	O
and	O
negative	O
inotropic	O
effects	O
of	O
propofol	B-CHEMICAL
are	O
disadvantages	O
in	O
frail	O
elderly	O
patients	O
.	O
We	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
adding	O
different	O
doses	O
of	O
ephedrine	B-CHEMICAL
to	O
propofol	B-CHEMICAL
in	O
order	O
to	O
obtund	O
the	O
hypotensive	B-DISEASE
response	O
.	O
The	O
haemodynamic	O
effects	O
of	O
adding	O
15	O
,	O
20	O
or	O
25	O
mg	O
of	O
ephedrine	B-CHEMICAL
to	O
200	O
mg	O
of	O
propofol	B-CHEMICAL
were	O
compared	O
to	O
control	O
in	O
40	O
ASA	B-CHEMICAL
3/4	O
patients	O
over	O
60	O
years	O
presenting	O
for	O
genito	O
-	O
urinary	O
surgery	O
.	O
The	O
addition	O
of	O
ephedrine	B-CHEMICAL
to	O
propofol	B-CHEMICAL
appears	O
to	O
be	O
an	O
effective	O
method	O
of	O
obtunding	O
the	O
hypotensive	B-DISEASE
response	O
to	O
propofol	B-CHEMICAL
at	O
all	O
doses	O
used	O
in	O
this	O
study	O
.	O
However	O
,	O
marked	O
tachycardia	B-DISEASE
associated	O
with	O
the	O
use	O
of	O
ephedrine	B-CHEMICAL
in	O
combination	O
with	O
propofol	B-CHEMICAL
occurred	O
in	O
the	O
majority	O
of	O
patients	O
,	O
occasionally	O
reaching	O
high	O
levels	O
in	O
individual	O
patients	O
.	O
Due	O
to	O
the	O
risk	O
of	O
this	O
tachycardia	B-DISEASE
inducing	O
myocardial	B-DISEASE
ischemia	I-DISEASE
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	O
of	O
the	O
ephedrine	B-CHEMICAL
/	O
propofol	B-CHEMICAL
/	O
mixtures	O
studied	O
.	O

Neurotoxicity	B-DISEASE
of	O
halogenated	O
hydroxyquinolines	O
:	O
clinical	O
analysis	O
of	O
cases	O
reported	O
outside	O
Japan	O
.	O
An	O
analysis	O
is	O
presented	O
of	O
220	O
cases	O
of	O
possible	O
neurotoxic	B-DISEASE
reactions	O
to	O
halogenated	O
hydroxyquinolines	O
reported	O
from	O
outside	O
Japan	O
.	O
In	O
80	O
cases	O
insufficient	O
information	O
was	O
available	O
for	O
adequate	O
comment	O
and	O
in	O
29	O
a	O
relationship	O
to	O
the	O
administration	O
of	O
clioquinol	O
could	O
be	O
excluded	O
.	O
Of	O
the	O
remainder	O
,	O
a	O
relationship	O
to	O
clioquinol	O
was	O
considered	O
probable	O
in	O
42	O
and	O
possible	O
in	O
69	O
cases	O
.	O
In	O
six	O
of	O
the	O
probable	O
cases	O
the	O
neurological	O
disturbance	O
consisted	O
of	O
an	O
acute	O
reversible	O
encephalopathy	B-DISEASE
usually	O
related	O
to	O
the	O
ingestion	O
of	O
a	O
high	O
dose	O
of	O
clioquinol	O
over	O
a	O
short	O
period	O
.	O
The	O
most	O
common	O
manifestation	O
,	O
observed	O
in	O
15	O
further	O
cases	O
,	O
was	O
isolated	O
optic	B-DISEASE
atrophy	I-DISEASE
.	O
This	O
was	O
most	O
frequently	O
found	O
in	O
children	O
,	O
many	O
of	O
whom	O
had	O
received	O
clioquinol	O
as	O
treatment	O
for	O
acrodermatitis	B-DISEASE
enteropathica	I-DISEASE
.	O
In	O
the	O
remaining	O
cases	O
,	O
a	O
combination	O
of	O
myelopathy	O
,	O
visual	O
disturbance	O
,	O
and	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
was	O
the	O
most	O
common	O
manifestation	O
.	O
Isolated	O
myelopathy	O
or	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
,	O
or	O
these	O
manifestations	O
occurring	O
together	O
,	O
were	O
infrequent	O
.	O
The	O
onset	O
of	O
all	O
manifestations	O
(	O
except	O
toxic	O
encephalopathy	B-DISEASE
)	O
was	O
usually	O
subacute	O
,	O
with	O
subsequent	O
partial	O
recovery	O
.	O
Older	O
subjects	O
tended	O
to	O
display	O
more	O
side	O
effects	O
.	O
The	O
full	O
syndrome	B-DISEASE
of	O
subacute	O
myelo	O
-	O
optic	B-DISEASE
neuropathy	I-DISEASE
was	O
more	O
frequent	O
in	O
women	O
,	O
but	O
they	O
tended	O
to	O
have	O
taken	O
greater	O
quantities	O
of	O
the	O
drug	O
.	O

Epileptic	B-DISEASE
seizures	I-DISEASE
following	O
cortical	O
application	O
of	O
fibrin	O
sealants	O
containing	O
tranexamic	O
acid	O
in	O
rats	O
.	O
BACKGROUND	O
:	O
Fibrin	O
sealants	O
(	O
FS	O
)	O
derived	O
from	O
human	O
plasma	O
are	O
frequently	O
used	O
in	O
neurosurgery	O
.	O
In	O
order	O
to	O
increase	O
clot	O
stability	O
,	O
FS	O
typically	O
contain	O
aprotinin	O
,	O
a	O
natural	O
fibrinolysis	O
inhibitor	O
.	O
Recently	O
,	O
synthetic	O
fibrinolysis	O
inhibitors	O
such	O
as	O
tranexamic	O
acid	O
(	O
tAMCA	B-CHEMICAL
)	O
have	O
been	O
considered	O
as	O
substitutes	O
for	O
aprotinin	O
.	O
However	O
,	O
tAMCA	B-CHEMICAL
has	O
been	O
shown	O
to	O
cause	O
epileptic	B-DISEASE
seizures	I-DISEASE
.	O
We	O
wanted	O
to	O
study	O
whether	O
tAMCA	B-CHEMICAL
retains	O
its	O
convulsive	B-DISEASE
action	O
if	O
incorporated	O
into	O
a	O
FS	O
.	O
METHOD	O
:	O
FS	O
containing	O
aprotinin	O
or	O
different	O
concentrations	O
of	O
tAMCA	B-CHEMICAL
(	O
0.5	O
-	O
47.5	O
mg	O
/	O
ml	O
)	O
were	O
applied	O
to	O
the	O
pial	O
surface	O
of	O
the	O
cortex	O
of	O
anaesthetized	O
rats	O
.	O
The	O
response	O
of	O
the	O
animals	O
was	O
evaluated	O
using	O
electroencephalography	O
and	O
by	O
monitoring	O
the	O
clinical	O
behaviour	O
during	O
and	O
after	O
recovery	O
from	O
anaesthesia	O
.	O
FINDINGS	O
:	O
FS	O
containing	O
tAMCA	B-CHEMICAL
caused	O
paroxysmal	O
brain	O
activity	O
which	O
was	O
associated	O
with	O
distinct	O
convulsive	B-DISEASE
behaviours	O
.	O
The	O
degree	O
of	O
these	O
seizures	B-DISEASE
increased	O
with	O
increasing	O
concentration	O
of	O
tAMCA	B-CHEMICAL
.	O
Thus	O
,	O
FS	O
containing	O
47.5	O
mg	O
/	O
ml	O
tAMCA	B-CHEMICAL
evoked	O
generalized	O
seizures	B-DISEASE
in	O
all	O
tested	O
rats	O
(	O
n=6	O
)	O
while	O
the	O
lowest	O
concentration	O
of	O
tAMCA	B-CHEMICAL
(	O
0.5	O
mg	O
/	O
ml	O
)	O
only	O
evoked	O
brief	O
episodes	O
of	O
jerk	O
-	O
correlated	O
convulsive	B-DISEASE
potentials	O
in	O
1	O
of	O
6	O
rats	O
.	O
In	O
contrast	O
,	O
FS	O
containing	O
aprotinin	O
did	O
not	O
evoke	O
any	O
paroxysmal	O
activity	O
.	O
INTERPRETATION	O
:	O
Tranexamic	O
acid	O
retains	O
its	O
convulsive	B-DISEASE
action	O
within	O
FS	O
.	O
Thus	O
,	O
use	O
of	O
FS	O
containing	O
tAMCA	B-CHEMICAL
for	O
surgery	O
within	O
or	O
close	O
to	O
the	O
CNS	O
may	O
pose	O
a	O
substantial	O
risk	O
to	O
the	O
patient	O
.	O

A	O
diet	O
promoting	O
sugar	O
dependency	O
causes	O
behavioral	B-DISEASE
cross	I-DISEASE
-	I-DISEASE
sensitization	I-DISEASE
to	O
a	O
low	O
dose	O
of	O
amphetamine	O
.	O
Previous	O
research	O
in	O
this	O
laboratory	O
has	O
shown	O
that	O
a	O
diet	O
of	O
intermittent	O
excessive	O
sugar	O
consumption	O
produces	O
a	O
state	O
with	O
neurochemical	O
and	O
behavioral	O
similarities	O
to	O
drug	B-DISEASE
dependency	I-DISEASE
.	O
The	O
present	O
study	O
examined	O
whether	O
female	O
rats	O
on	O
various	O
regimens	O
of	O
sugar	O
access	O
would	O
show	O
behavioral	B-DISEASE
cross	I-DISEASE
-	I-DISEASE
sensitization	I-DISEASE
to	O
a	O
low	O
dose	O
of	O
amphetamine	O
.	O
After	O
a	O
30	O
-	O
min	O
baseline	O
measure	O
of	O
locomotor	O
activity	O
(	O
day	O
0	O
)	O
,	O
animals	O
were	O
maintained	O
on	O
a	O
cyclic	O
diet	O
of	O
12	O
-	O
h	O
deprivation	O
followed	O
by	O
12	O
-	O
h	O
access	O
to	O
10	O
%	O
sucrose	O
solution	O
and	O
chow	O
pellets	O
(	O
12	O
h	O
access	O
starting	O
4	O
h	O
after	O
onset	O
of	O
the	O
dark	O
period	O
)	O
for	O
21	O
days	O
.	O
Locomotor	O
activity	O
was	O
measured	O
again	O
for	O
30	O
min	O
at	O
the	O
beginning	O
of	O
days	O
1	O
and	O
21	O
of	O
sugar	O
access	O
.	O
Beginning	O
on	O
day	O
22	O
,	O
all	O
rats	O
were	O
maintained	O
on	O
ad	O
libitum	O
chow	O
.	O
Nine	O
days	O
later	O
locomotor	O
activity	O
was	O
measured	O
in	O
response	O
to	O
a	O
single	O
low	O
dose	O
of	O
amphetamine	O
(	O
0.5	O
mg	O
/	O
kg	O
)	O
.	O
The	O
animals	O
that	O
had	O
experienced	O
cyclic	O
sucrose	O
and	O
chow	O
were	O
hyperactive	O
in	O
response	O
to	O
amphetamine	O
compared	O
with	O
four	O
control	O
groups	O
(	O
ad	O
libitum	O
10	O
%	O
sucrose	O
and	O
chow	O
followed	O
by	O
amphetamine	O
injection	O
,	O
cyclic	O
chow	O
followed	O
by	O
amphetamine	O
injection	O
,	O
ad	O
libitum	O
chow	O
with	O
amphetamine	O
,	O
or	O
cyclic	O
10	O
%	O
sucrose	O
and	O
chow	O
with	O
a	O
saline	O
injection	O
)	O
.	O
These	O
results	O
suggest	O
that	O
a	O
diet	O
comprised	O
of	O
alternating	O
deprivation	O
and	O
access	O
to	O
a	O
sugar	O
solution	O
and	O
chow	O
produces	O
bingeing	O
on	O
sugar	O
that	O
leads	O
to	O
a	O
long	O
lasting	O
state	O
of	O
increased	O
sensitivity	O
to	O
amphetamine	O
,	O
possibly	O
due	O
to	O
a	O
lasting	O
alteration	O
in	O
the	O
dopamine	B-CHEMICAL
system	O
.	O

D	O
-	O
penicillamine	B-CHEMICAL
-	O
induced	O
angiopathy	B-DISEASE
in	O
rats	O
.	O
The	O
effect	O
of	O
high	O
dose	O
D	O
-	O
penicillamine	B-CHEMICAL
treatment	O
on	O
aortic	O
permeability	O
to	O
albumin	O
and	O
on	O
the	O
ultrastructure	O
of	O
the	O
vessel	O
.	O
Male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
treated	O
with	O
D	O
-	O
penicillamine	B-CHEMICAL
(	O
D	O
-	O
pen	O
)	O
500	O
mg	O
/	O
kg	O
/	O
day	O
for	O
10	O
or	O
42	O
days	O
.	O
Pair	O
fed	O
rats	O
served	O
as	O
controls	O
.	O
Changes	O
in	O
aortic	O
morphology	O
were	O
examined	O
by	O
light-	O
and	O
transmission	O
-	O
electron	O
microscopy	O
(	O
TEM	O
)	O
.	O
In	O
addition	O
,	O
the	O
endothelial	O
permeability	O
and	O
the	O
penetration	O
through	O
the	O
aortic	O
wall	O
of	O
albumin	O
were	O
studied	O
10	O
minutes	O
,	O
24	O
and	O
48	O
hours	O
after	O
i.	O
v.	O
injection	O
of	O
human	O
serum	O
131I	O
-	O
albumin	O
(	O
131I	O
-	O
HSA	O
)	O
.	O
TEM	O
revealed	O
extensive	O
elastolysis	O
in	O
the	O
arterial	O
wall	O
of	O
D	O
-	O
pen	O
-	O
treated	O
rats	O
,	O
consistent	O
with	O
an	O
inhibitory	O
effect	O
on	O
crosslink	O
formation	O
.	O
In	O
experimental	O
animals	O
excess	O
deposition	O
of	O
collagen	O
and	O
glycoaminoglycans	O
was	O
observed	O
in	O
the	O
subendothelial	O
and	O
medial	O
layer	O
of	O
the	O
aortic	O
wall	O
,	O
together	O
with	O
prominent	O
basal	O
membrane	O
substance	O
around	O
aortic	O
smooth	O
muscle	O
cells	O
.	O
The	O
aorta	O
/	O
serum	O
-	O
ratio	O
and	O
the	O
radioactive	O
build	O
-	O
up	O
24	O
and	O
48	O
hours	O
after	O
injection	O
of	O
131I	O
-	O
HSA	O
was	O
reduced	O
in	O
animals	O
treated	O
with	O
D	O
-	O
pen	O
for	O
42	O
days	O
,	O
indicating	O
an	O
impeded	O
transmural	O
transport	O
of	O
tracer	O
which	O
may	O
be	O
caused	O
by	O
a	O
steric	O
exclusion	O
effect	O
of	O
abundant	O
hyaluronate	O
.	O
The	O
endothelial	O
ultrastructure	O
was	O
unaffected	O
by	O
D	O
-	O
pen	O
,	O
and	O
no	O
differences	O
in	O
aortic	O
131I	O
-	O
HSA	O
radioactivity	O
or	O
aorta	O
/	O
serum	O
-	O
ratio	O
were	O
recorded	O
between	O
experimental	O
and	O
control	O
groups	O
10	O
minutes	O
after	O
tracer	O
injection	O
,	O
indicating	O
that	O
the	O
permeability	O
of	O
the	O
endothelial	O
barrier	O
to	O
albumin	O
remained	O
unaffected	O
by	O
D	O
-	O
pen	O
treatment	O
.	O
These	O
observations	O
support	O
the	O
hypothesis	O
that	O
treatment	O
with	O
high	O
doses	O
of	O
D	O
-	O
pen	O
may	O
induce	O
a	O
fibroproliferative	O
response	O
in	O
rat	O
aorta	O
,	O
possibly	O
by	O
an	O
inhibitory	O
effect	O
on	O
the	O
cross	O
-	O
linking	O
of	O
collagen	O
and	O
elastin	O
.	O

Brain	O
natriuretic	O
peptide	O
is	O
a	O
predictor	O
of	O
anthracycline	O
-	O
induced	O
cardiotoxicity	B-DISEASE
.	O
Anthracyclines	O
are	O
effective	O
antineoplastic	B-CHEMICAL
drugs	I-CHEMICAL
,	O
but	O
they	O
frequently	O
cause	O
dose	O
-	O
related	O
cardiotoxicity	B-DISEASE
.	O
The	O
cardiotoxicity	B-DISEASE
of	O
conventional	O
anthracycline	O
therapy	O
highlights	O
a	O
need	O
to	O
search	O
for	O
methods	O
that	O
are	O
highly	O
sensitive	O
and	O
capable	O
of	O
predicting	O
cardiac	B-DISEASE
dysfunction	I-DISEASE
.	O
We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	O
of	O
anthracycline	O
-	O
induced	O
cardiotoxicity	B-DISEASE
in	O
patients	O
with	O
acute	B-DISEASE
leukemia	I-DISEASE
treated	O
with	O
a	O
daunorubicin	B-CHEMICAL
(	O
DNR)-containing	O
regimen	O
.	O
Thirteen	O
patients	O
with	O
acute	B-DISEASE
leukemia	I-DISEASE
were	O
treated	O
with	O
a	O
DNR	O
-	O
containing	O
regimen	O
.	O
Cardiac	O
functions	O
were	O
evaluated	O
with	O
radionuclide	O
angiography	O
before	O
chemotherapies	O
.	O
The	O
plasma	O
levels	O
of	O
atrial	O
natriuretic	O
peptide	O
(	O
ANP	B-CHEMICAL
)	O
and	O
BNP	O
were	O
measured	O
at	O
the	O
time	O
of	O
radionuclide	O
angiography	O
.	O
Three	O
patients	O
developed	O
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O
Five	O
patients	O
were	O
diagnosed	O
as	O
having	O
subclinical	O
heart	B-DISEASE
failure	I-DISEASE
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O
The	O
plasma	O
levels	O
of	O
BNP	O
in	O
all	O
the	O
patients	O
with	O
clinical	O
and	O
subclinical	O
heart	B-DISEASE
failure	I-DISEASE
increased	O
above	O
the	O
normal	O
limit	O
(	O
40	O
pg	O
/	O
ml	O
)	O
before	O
the	O
detection	O
of	O
clinical	O
or	O
subclinical	O
heart	B-DISEASE
failure	I-DISEASE
by	O
radionuclide	O
angiography	O
.	O
On	O
the	O
other	O
hand	O
,	O
BNP	O
did	O
not	O
increase	O
in	O
the	O
patients	O
without	O
heart	B-DISEASE
failure	I-DISEASE
given	O
DNR	O
,	O
even	O
at	O
more	O
than	O
700	O
mg	O
/	O
m(2	O
)	O
.	O
The	O
plasma	O
level	O
of	O
ANP	B-CHEMICAL
did	O
not	O
always	O
increase	O
in	O
all	O
the	O
patients	O
with	O
clinical	O
and	O
subclinical	O
heart	B-DISEASE
failure	I-DISEASE
.	O
These	O
preliminary	O
results	O
suggest	O
that	O
BNP	O
may	O
be	O
useful	O
as	O
an	O
early	O
and	O
sensitive	O
indicator	O
of	O
anthracycline	O
-	O
induced	O
cardiotoxicity	B-DISEASE
.	O

Antibacterial	O
medication	O
use	O
during	O
pregnancy	O
and	O
risk	O
of	O
birth	B-DISEASE
defects	I-DISEASE
:	O
National	O
Birth	B-DISEASE
Defects	I-DISEASE
Prevention	O
Study	O
.	O
OBJECTIVE	O
:	O
To	O
estimate	O
the	O
association	O
between	O
antibacterial	O
medications	O
and	O
selected	O
birth	B-DISEASE
defects	I-DISEASE
.	O
DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
:	O
Population	O
-	O
based	O
,	O
multisite	O
,	O
case	O
-	O
control	O
study	O
of	O
women	O
who	O
had	O
pregnancies	O
affected	O
by	O
1	O
of	O
more	O
than	O
30	O
eligible	O
major	O
birth	B-DISEASE
defects	I-DISEASE
identified	O
via	O
birth	B-DISEASE
defect	I-DISEASE
surveillance	O
programs	O
in	O
10	O
states	O
(	O
n	O
=	O
13	O
155	O
)	O
and	O
control	O
women	O
randomly	O
selected	O
from	O
the	O
same	O
geographical	O
regions	O
(	O
n	O
=	O
4941	O
)	O
.	O
MAIN	O
EXPOSURE	O
:	O
Reported	O
maternal	O
use	O
of	O
antibacterials	O
(	O
1	O
month	O
before	O
pregnancy	O
through	O
the	O
end	O
of	O
the	O
first	O
trimester	O
)	O
.	O
MAIN	O
OUTCOME	O
MEASURE	O
:	O
Odds	O
ratios	O
(	O
ORs	O
)	O
measuring	O
the	O
association	O
between	O
antibacterial	O
use	O
and	O
selected	O
birth	B-DISEASE
defects	I-DISEASE
adjusted	O
for	O
potential	O
confounders	O
.	O
RESULTS	O
:	O
The	O
reported	O
use	O
of	O
antibacterials	O
increased	O
during	O
pregnancy	O
,	O
peaking	O
during	O
the	O
third	O
month	O
.	O
Sulfonamides	O
were	O
associated	O
with	O
anencephaly	B-DISEASE
(	O
adjusted	O
OR	O
[	O
AOR	O
]	O
=	O
3.4	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.3	O
-	O
8.8	O
)	O
,	O
hypoplastic	B-DISEASE
left	I-DISEASE
heart	I-DISEASE
syndrome	I-DISEASE
(	O
AOR	O
=	O
3.2	O
;	O
95	O
%	O
CI	O
,	O
1.3	O
-	O
7.6	O
)	O
,	O
coarctation	B-DISEASE
of	I-DISEASE
the	I-DISEASE
aorta	I-DISEASE
(	O
AOR	O
=	O
2.7	O
;	O
95	O
%	O
CI	O
,	O
1.3	O
-	O
5.6	O
)	O
,	O
choanal	B-DISEASE
atresia	I-DISEASE
(	O
AOR	O
=	O
8.0	O
;	O
95	O
%	O
CI	O
,	O
2.7	O
-	O
23.5	O
)	O
,	O
transverse	O
limb	O
deficiency	O
(	O
AOR	O
=	O
2.5	O
;	O
95	O
%	O
CI	O
,	O
1.0	O
-	O
5.9	O
)	O
,	O
and	O
diaphragmatic	B-DISEASE
hernia	I-DISEASE
(	O
AOR	O
=	O
2.4	O
;	O
95	O
%	O
CI	O
,	O
1.1	O
-	O
5.4	O
)	O
.	O
Nitrofurantoins	O
were	O
associated	O
with	O
anophthalmia	B-DISEASE
or	O
microphthalmos	B-DISEASE
(	O
AOR	O
=	O
3.7	O
;	O
95	O
%	O
CI	O
,	O
1.1	O
-	O
12.2	O
)	O
,	O
hypoplastic	B-DISEASE
left	I-DISEASE
heart	I-DISEASE
syndrome	I-DISEASE
(	O
AOR	O
=	O
4.2	O
;	O
95	O
%	O
CI	O
,	O
1.9	O
-	O
9.1	O
)	O
,	O
atrial	B-DISEASE
septal	I-DISEASE
defects	I-DISEASE
(	O
AOR	O
=	O
1.9	O
;	O
95	O
%	O
CI	O
,	O
1.1	O
-	O
3.4	O
)	O
,	O
and	O
cleft	B-DISEASE
lip	I-DISEASE
with	O
cleft	B-DISEASE
palate	I-DISEASE
(	O
AOR	O
=	O
2.1	O
;	O
95	O
%	O
CI	O
,	O
1.2	O
-	O
3.9	O
)	O
.	O
Other	O
antibacterial	O
agents	O
that	O
showed	O
associations	O
included	O
erythromycins	O
(	O
2	O
defects	O
)	O
,	O
penicillins	O
(	O
1	O
defect	O
)	O
,	O
cephalosporins	B-CHEMICAL
(	O
1	O
defect	O
)	O
,	O
and	O
quinolones	O
(	O
1	O
defect	O
)	O
.	O
CONCLUSIONS	O
:	O
Reassuringly	O
,	O
penicillins	O
,	O
erythromycins	O
,	O
and	O
cephalosporins	B-CHEMICAL
,	O
although	O
used	O
commonly	O
by	O
pregnant	O
women	O
,	O
were	O
not	O
associated	O
with	O
many	O
birth	B-DISEASE
defects	I-DISEASE
.	O
Sulfonamides	O
and	O
nitrofurantoins	O
were	O
associated	O
with	O
several	O
birth	B-DISEASE
defects	I-DISEASE
,	O
indicating	O
a	O
need	O
for	O
additional	O
scrutiny	O
.	O

Incidence	O
of	O
neoplasms	B-DISEASE
in	O
patients	O
with	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
exposed	O
to	O
different	O
treatment	O
regimens	O
.	O
Immunosuppressive	O
drugs	O
have	O
been	O
used	O
during	O
the	O
last	O
30	O
years	O
in	O
treatment	O
of	O
patients	O
with	O
severe	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
.	O
The	O
drugs	O
commonly	O
used	O
are	O
cyclophosphamide	B-CHEMICAL
and	O
chlorambucil	O
(	O
alkylating	B-CHEMICAL
agents	I-CHEMICAL
)	O
,	O
azathioprine	B-CHEMICAL
(	O
purine	O
analogue	O
)	O
,	O
and	O
methotrexate	B-CHEMICAL
(	O
folic	O
acid	O
analogue	O
)	O
.	O
There	O
is	O
evidence	O
that	O
all	O
four	O
immunosuppressive	O
drugs	O
can	O
reduce	O
synovitis	B-DISEASE
,	O
but	O
disease	B-DISEASE
activity	O
almost	O
always	O
recurs	O
after	O
therapy	O
is	O
stopped	O
.	O
Since	O
adverse	O
reactions	O
are	O
frequent	O
,	O
less	O
than	O
50	O
percent	O
of	O
patients	O
are	O
able	O
to	O
continue	O
a	O
particular	O
drug	O
for	O
more	O
than	O
one	O
year	O
.	O
Since	O
it	O
takes	O
three	O
to	O
12	O
months	O
to	O
achieve	O
maximal	O
effects	O
,	O
those	O
patients	O
who	O
are	O
unable	O
to	O
continue	O
the	O
drug	O
receive	O
little	O
benefit	O
from	O
it	O
.	O
Patients	O
treated	O
with	O
alkylating	B-CHEMICAL
agents	I-CHEMICAL
have	O
an	O
increased	O
risk	O
of	O
development	O
of	O
acute	B-DISEASE
nonlymphocytic	I-DISEASE
leukemia	I-DISEASE
,	O
and	O
both	O
alkylating	B-CHEMICAL
agents	I-CHEMICAL
and	O
azathioprine	B-CHEMICAL
are	O
associated	O
with	O
the	O
development	O
of	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	B-DISEASE
.	O
Cyclophosphamide	B-CHEMICAL
therapy	O
increases	O
the	O
risk	O
of	O
carcinoma	B-DISEASE
of	O
the	O
bladder	O
.	O
There	O
have	O
been	O
several	O
long	O
-	O
term	O
studies	O
of	O
patients	O
with	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
treated	O
with	O
azathioprine	B-CHEMICAL
and	O
cyclophosphamide	B-CHEMICAL
and	O
the	O
incidence	O
of	O
most	O
of	O
the	O
common	O
cancers	B-DISEASE
is	O
not	O
increased	O
.	O
Data	O
on	O
the	O
possible	O
increased	O
risk	O
of	O
malignancy	B-DISEASE
in	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
are	O
still	O
being	O
collected	O
,	O
and	O
until	O
further	O
information	O
is	O
available	O
,	O
the	O
use	O
of	O
immunosuppressive	O
drugs	O
,	O
particularly	O
alkylating	B-CHEMICAL
agents	I-CHEMICAL
,	O
in	O
the	O
treatment	O
of	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
should	O
be	O
reserved	O
for	O
patients	O
with	O
severe	O
progressive	O
disease	B-DISEASE
or	O
life	O
-	O
threatening	O
complications	B-DISEASE
.	O

Patterns	O
of	O
hepatic	O
injury	O
induced	O
by	O
methyldopa	B-CHEMICAL
.	O
Twelve	O
patients	O
with	O
liver	B-DISEASE
disease	I-DISEASE
related	O
to	O
methyldopa	B-CHEMICAL
were	O
seen	O
between	O
1967	O
and	O
1977	O
.	O
Illness	O
occurred	O
within	O
1	O
-	O
-9	O
weeks	O
of	O
commencement	O
of	O
therapy	O
in	O
9	O
patients	O
,	O
the	O
remaining	O
3	O
patients	O
having	O
received	O
the	O
drug	O
for	O
13	O
months	O
,	O
15	O
months	O
and	O
7	O
years	O
before	O
experiencing	O
symptoms	O
.	O
Jaundice	B-DISEASE
with	O
tender	O
hepatomegaly	B-DISEASE
,	O
usually	O
preceded	O
by	O
symptoms	O
of	O
malaise	O
,	O
anorexia	B-DISEASE
,	O
nausea	B-DISEASE
and	O
vomiting	B-DISEASE
,	O
and	O
associated	O
with	O
upper	O
abdominal	B-DISEASE
pain	I-DISEASE
,	O
was	O
an	O
invariable	O
finding	O
in	O
all	O
patients	O
.	O
Biochemical	O
liver	O
function	O
tests	O
indicated	O
hepatocellular	O
necrosis	B-DISEASE
and	O
correlated	O
with	O
histopathological	O
evidence	O
of	O
hepatic	O
injury	O
,	O
the	O
spectrum	O
of	O
which	O
ranged	O
from	O
fatty	B-DISEASE
change	I-DISEASE
and	O
focal	O
hepatocellular	O
necrosis	B-DISEASE
to	O
massive	B-DISEASE
hepatic	I-DISEASE
necrosis	I-DISEASE
.	O
Most	O
patients	O
showed	O
moderate	O
to	O
severe	O
acute	B-DISEASE
hepatitis	I-DISEASE
or	O
chronic	B-DISEASE
active	I-DISEASE
hepatitis	I-DISEASE
with	O
associated	O
cholestasis	B-DISEASE
.	O
The	O
drug	O
was	O
withdrawn	O
on	O
presentation	O
to	O
hospital	O
in	O
11	O
patients	O
,	O
with	O
rapid	O
clinical	O
improvement	O
in	O
9	O
.	O
One	O
patient	O
died	O
,	O
having	O
presented	O
in	O
hepatic	O
failure	O
,	O
and	O
another	O
,	O
who	O
had	O
been	O
taking	O
methyldopa	B-CHEMICAL
for	O
7	O
years	O
,	O
showed	O
slower	O
clinical	O
and	O
biochemical	O
resolution	O
over	O
a	O
period	O
of	O
several	O
months	O
.	O
The	O
remaining	O
patient	O
in	O
the	O
series	O
developed	O
fulminant	O
hepatitis	B-DISEASE
when	O
the	O
drug	O
was	O
accidentally	O
recommenced	O
1	O
year	O
after	O
a	O
prior	O
episode	O
of	O
methyldopa	B-CHEMICAL
-	O
induced	O
hepatitis	B-DISEASE
.	O
In	O
this	O
latter	O
patient	O
,	O
and	O
in	O
2	O
others	O
,	O
the	O
causal	O
relationship	O
between	O
methyldopa	B-CHEMICAL
and	O
hepatic	O
dysfunction	O
was	O
proved	O
with	O
the	O
recurrence	B-DISEASE
of	O
hepatitis	B-DISEASE
within	O
2	O
weeks	O
of	O
re	O
-	O
exposure	O
to	O
the	O
drug	O
.	O

A	O
phase	O
I	O
/	O
II	O
study	O
of	O
paclitaxel	B-CHEMICAL
plus	O
cisplatin	B-CHEMICAL
as	O
first	O
-	O
line	O
therapy	O
for	O
head	O
and	O
neck	O
cancers	B-DISEASE
:	O
preliminary	O
results	O
.	O
Improved	O
outcomes	O
among	O
patients	O
with	O
head	O
and	O
neck	O
carcinomas	O
require	O
investigations	O
of	O
new	O
drugs	O
for	O
induction	O
therapy	O
.	O
Preliminary	O
results	O
of	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
study	O
of	O
single	O
-	O
agent	O
paclitaxel	B-CHEMICAL
(	O
Taxol	O
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
reported	O
a	O
37	O
%	O
response	O
rate	O
in	O
patients	O
with	O
head	B-DISEASE
and	I-DISEASE
neck	I-DISEASE
cancer	I-DISEASE
,	O
and	O
the	O
paclitaxel	B-CHEMICAL
/	O
cisplatin	B-CHEMICAL
combination	O
has	O
been	O
used	O
successfully	O
and	O
has	O
significantly	O
improved	O
median	O
response	O
duration	O
in	O
ovarian	B-DISEASE
cancer	I-DISEASE
patients	O
.	O
We	O
initiated	O
a	O
phase	O
I	O
/	O
II	O
trial	O
to	O
determine	O
the	O
response	O
and	O
toxicity	B-DISEASE
of	O
escalating	O
paclitaxel	B-CHEMICAL
doses	O
combined	O
with	O
fixed	O
-	O
dose	O
cisplatin	B-CHEMICAL
with	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
support	O
in	O
patients	O
with	O
untreated	O
locally	O
advanced	O
inoperable	O
head	O
and	O
neck	O
carcinoma	B-DISEASE
.	O
To	O
date	O
,	O
23	O
men	O
with	O
a	O
median	O
age	O
of	O
50	O
years	O
and	O
good	O
performance	O
status	O
have	O
entered	O
the	O
trial	O
.	O
Primary	O
tumor	B-DISEASE
sites	O
were	O
oropharynx	O
,	O
10	O
patients	O
;	O
hypopharynx	O
,	O
four	O
;	O
larynx	O
,	O
two	O
;	O
oral	O
cavity	O
,	O
three	O
;	O
unknown	O
primary	O
,	O
two	O
;	O
and	O
nasal	O
cavity	O
and	O
parotid	O
gland	O
,	O
one	O
each	O
.	O
Of	O
20	O
patients	O
evaluable	O
for	O
toxicity	B-DISEASE
,	O
four	O
had	O
stage	O
III	O
and	O
16	O
had	O
stage	O
IV	O
disease	B-DISEASE
.	O
Treatment	O
,	O
given	O
every	O
21	O
days	O
for	O
a	O
maximum	O
of	O
three	O
cycles	O
,	O
consisted	O
of	O
paclitaxel	B-CHEMICAL
by	O
3	O
-	O
hour	O
infusion	O
followed	O
the	O
next	O
day	O
by	O
a	O
fixed	O
dose	O
of	O
cisplatin	B-CHEMICAL
(	O
75	O
mg	O
/	O
m2	O
)	O
.	O
The	O
dose	O
levels	O
incorporate	O
escalating	O
paclitaxel	B-CHEMICAL
doses	O
,	O
and	O
intrapatient	O
escalations	O
within	O
a	O
given	O
dose	O
level	O
are	O
permitted	O
if	O
toxicity	B-DISEASE
permits	O
.	O
At	O
the	O
time	O
of	O
this	O
writing	O
,	O
dose	O
level	O
4	O
(	O
260	O
,	O
270	O
,	O
and	O
280	O
mg	O
/	O
m2	O
)	O
is	O
being	O
evaluated	O
;	O
three	O
patients	O
from	O
this	O
level	O
are	O
evaluable	O
.	O
With	O
paclitaxel	B-CHEMICAL
doses	O
of	O
200	O
mg	O
/	O
m2	O
and	O
higher	O
,	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
5	O
micrograms	O
/	O
kg	O
/	O
d	O
is	O
given	O
(	O
days	O
4	O
through	O
12	O
)	O
.	O
Of	O
18	O
patients	O
evaluable	O
for	O
response	O
,	O
seven	O
(	O
39	O
%	O
)	O
achieved	O
a	O
complete	O
response	O
and	O
six	O
(	O
33	O
%	O
)	O
achieved	O
a	O
partial	O
response	O
.	O
Three	O
patients	O
had	O
no	O
change	O
and	O
disease	B-DISEASE
progressed	O
in	O
two	O
.	O
The	O
overall	O
response	O
rate	O
is	O
72	O
%	O
.	O
Eleven	O
responding	O
patients	O
had	O
subsequent	O
surgery	O
/	O
radiotherapy	O
or	O
radical	O
radiotherapy	O
.	O
Two	O
pathologic	O
complete	O
responses	O
were	O
observed	O
in	O
patients	O
who	O
had	O
achieved	O
clinical	O
complete	O
responses	O
.	O
Alopecia	B-DISEASE
,	O
paresthesias	O
,	O
and	O
arthralgias	B-DISEASE
/	O
myalgias	O
have	O
occurred	O
frequently	O
,	O
but	O
with	O
one	O
exception	O
(	O
a	O
grade	O
3	O
myalgia	B-DISEASE
)	O
they	O
have	O
been	O
grade	O
1	O
or	O
2	O
.	O
No	O
dose	O
-	O
limiting	O
hematologic	O
toxicity	B-DISEASE
has	O
been	O
seen	O
.	O
Paclitaxel	B-CHEMICAL
/	O
cisplatin	B-CHEMICAL
is	O
an	O
effective	O
first	O
-	O
line	O
regimen	O
for	O
locoregionally	O
advanced	O
head	B-DISEASE
and	I-DISEASE
neck	I-DISEASE
cancer	I-DISEASE
and	O
continued	O
study	O
is	O
warranted	O
.	O
Results	O
thus	O
far	O
suggest	O
no	O
dose	O
-	O
response	O
effect	O
for	O
paclitaxel	B-CHEMICAL
doses	O
above	O
200	O
mg	O
/	O
m2	O
.	O

A	O
phase	O
I	O
study	O
of	O
4'-0	B-CHEMICAL
-	I-CHEMICAL
tetrahydropyranyladriamycin	I-CHEMICAL
.	O
Clinical	O
pharmacology	O
and	O
pharmacokinetics	O
.	O
A	O
Phase	O
I	O
study	O
of	O
intravenous	O
(	O
IV	O
)	O
bolus	O
4'-0	B-CHEMICAL
-	I-CHEMICAL
tetrahydropyranyladriamycin	I-CHEMICAL
(	O
Pirarubicin	B-CHEMICAL
)	O
was	O
done	O
in	O
55	O
patients	O
in	O
good	O
performance	O
status	O
with	O
refractory	O
tumors	B-DISEASE
.	O
Twenty	O
-	O
six	O
had	O
minimal	O
prior	O
therapy	O
(	O
good	O
risk	O
)	O
,	O
23	O
had	O
extensive	O
prior	O
therapy	O
(	O
poor	O
risk	O
)	O
,	O
and	O
six	O
had	O
renal	O
and/or	O
hepatic	O
dysfunction	O
.	O
A	O
total	O
of	O
167	O
courses	O
at	O
doses	O
of	O
15	O
to	O
70	O
mg	O
/	O
m2	O
were	O
evaluable	O
.	O
Maximum	O
tolerated	O
dose	O
in	O
good	O
-	O
risk	O
patients	O
was	O
70	O
mg	O
/	O
m2	O
,	O
and	O
in	O
poor	O
-	O
risk	O
patients	O
,	O
60	O
mg	O
/	O
m2	O
.	O
The	O
dose	O
-	O
limiting	O
toxic	O
effect	O
was	O
transient	O
noncumulative	O
granulocytopenia	O
.	O
Granulocyte	O
nadir	O
was	O
on	O
day	O
14	O
(	O
range	O
,	O
4	O
-	O
22	O
)	O
.	O
Less	O
frequent	O
toxic	O
effects	O
included	O
thrombocytopenia	B-DISEASE
,	O
anemia	B-DISEASE
,	O
nausea	B-DISEASE
,	O
mild	O
alopecia	B-DISEASE
,	O
phlebitis	B-DISEASE
,	O
and	O
mucositis	B-DISEASE
.	O
Myelosuppression	B-DISEASE
was	O
more	O
in	O
patients	O
with	O
hepatic	O
dysfunction	O
.	O
Pharmacokinetic	O
analyses	O
in	O
21	O
patients	O
revealed	O
Pirarubicin	B-CHEMICAL
plasma	O
T	O
1/2	O
alpha	O
(	O
+	O
/-	O
SE	B-DISEASE
)	O
of	O
2.5	O
+	O
/-	O
0.85	O
minutes	O
,	O
T	O
beta	O
1/2	O
of	O
25.6	O
+	O
/-	O
6.5	O
minutes	O
,	O
and	O
T	O
1/2	O
gamma	O
of	O
23.6	O
+	O
/-	O
7.6	O
hours	O
.	O
The	O
area	O
under	O
the	O
curve	O
was	O
537	O
+	O
/-	O
149	O
ng	O
/	O
ml	O
x	O
hours	O
,	O
volume	O
of	O
distribution	O
(	O
Vd	O
)	O
3504	O
+	O
/-	O
644	O
l	O
/	O
m2	O
,	O
and	O
total	O
clearance	O
(	O
ClT	O
)	O
was	O
204	O
+	O
39.3	O
l	O
/	O
hour	O
/	O
m2	O
.	O
Adriamycinol	B-CHEMICAL
,	O
doxorubicin	B-CHEMICAL
,	O
adriamycinone	O
,	O
and	O
tetrahydropyranyladriamycinol	O
were	O
the	O
metabolites	O
detected	O
in	O
plasma	O
and	O
the	O
amount	O
of	O
doxorubicin	B-CHEMICAL
was	O
less	O
than	O
or	O
equal	O
to	O
10	O
%	O
of	O
the	O
total	O
metabolites	O
.	O
Urinary	O
excretion	O
of	O
Pirarubicin	B-CHEMICAL
in	O
the	O
first	O
24	O
hours	O
was	O
less	O
than	O
or	O
equal	O
to	O
10	O
%	O
.	O
Activity	O
was	O
noted	O
in	O
mesothelioma	B-DISEASE
,	O
leiomyosarcoma	B-DISEASE
,	O
and	O
basal	B-DISEASE
cell	I-DISEASE
carcinoma	I-DISEASE
.	O
The	O
recommended	O
starting	O
dose	O
for	O
Phase	O
II	O
trials	O
is	O
60	O
mg	O
/	O
m2	O
IV	O
bolus	O
every	O
3	O
weeks	O
.	O

Differential	O
effects	O
of	O
gamma	O
-	O
hexachlorocyclohexane	O
(	O
lindane	B-CHEMICAL
)	O
on	O
pharmacologically	O
-	O
induced	O
seizures	B-DISEASE
.	O
Gamma	O
-	O
hexachlorocyclohexane	O
(	O
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
)	O
,	O
the	O
active	O
ingredient	O
of	O
the	O
insecticide	O
lindane	B-CHEMICAL
,	O
has	O
been	O
shown	O
to	O
decrease	O
seizure	B-DISEASE
threshold	O
to	O
pentylenetrazol	O
(	O
PTZ	O
)	O
3	O
h	O
after	O
exposure	O
to	O
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
and	O
conversely	O
increase	O
threshold	O
to	O
PTZ	O
-	O
induced	O
seizures	B-DISEASE
24	O
h	O
after	O
exposure	O
to	O
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
(	O
Vohland	O
et	O
al	O
.	O
1981	O
)	O
.	O
In	O
this	O
study	O
,	O
the	O
severity	O
of	O
response	O
to	O
other	O
seizure	B-DISEASE
-	O
inducing	O
agents	O
was	O
tested	O
in	O
mice	O
1	O
and	O
24	O
h	O
after	O
intraperitoneal	O
administration	O
of	O
80	O
mg	O
/	O
kg	O
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
.	O
One	O
hour	O
after	O
the	O
administration	O
of	O
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
,	O
the	O
activity	O
of	O
seizure	B-DISEASE
-	O
inducing	O
agents	O
was	O
increased	O
,	O
regardless	O
of	O
their	O
mechanism	O
,	O
while	O
24	O
h	O
after	O
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
a	O
differential	O
response	O
was	O
observed	O
.	O
Seizure	B-DISEASE
activity	O
due	O
to	O
PTZ	O
and	O
picrotoxin	B-CHEMICAL
(	O
PTX	O
)	O
was	O
significantly	O
decreased	O
;	O
however	O
,	O
seizure	B-DISEASE
activity	O
due	O
to	O
3	B-CHEMICAL
-	I-CHEMICAL
mercaptopropionic	I-CHEMICAL
acid	I-CHEMICAL
(	O
MPA	O
)	O
,	O
bicuculline	O
(	O
BCC	O
)	O
,	O
methyl	O
6,7	O
-	O
dimethoxy-4	O
-	O
ethyl	O
-	O
B	O
-	O
carboline-3	O
-	O
carboxylate	O
(	O
DMCM	O
)	O
,	O
or	O
strychnine	O
(	O
STR	O
)	O
was	O
not	O
different	O
from	O
control	O
.	O
In	O
vitro	O
,	O
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
,	O
pentylenetetrazol	O
and	O
picrotoxin	B-CHEMICAL
were	O
shown	O
to	O
inhibit	O
3H	B-CHEMICAL
-	I-CHEMICAL
TBOB	I-CHEMICAL
binding	O
in	O
mouse	O
whole	O
brain	O
,	O
with	O
IC50	O
values	O
of	O
4.6	O
,	O
404	O
and	O
9.4	O
microM	O
,	O
respectively	O
.	O
MPA	O
,	O
BCC	O
,	O
DMCM	O
,	O
and	O
STR	O
showed	O
no	O
inhibition	O
of	O
3H	B-CHEMICAL
-	I-CHEMICAL
TBOB	I-CHEMICAL
(	O
t	O
-	O
butyl	O
bicyclo	O
-	O
orthobenzoate	O
)	O
binding	O
at	O
concentrations	O
of	O
100	O
micron	O
.	O
The	O
pharmacological	O
challenge	O
data	O
suggest	O
that	O
tolerance	O
may	O
occur	O
to	O
seizure	B-DISEASE
activity	O
induced	O
by	O
PTZ	O
and	O
PTX	O
24	O
h	O
after	O
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
,	O
since	O
the	O
response	O
to	O
only	O
these	O
two	O
seizure	B-DISEASE
-	O
inducing	O
agents	O
is	O
decreased	O
.	O
The	O
in	O
vitro	O
data	O
suggest	O
that	O
the	O
site	O
responsible	O
for	O
the	O
decrease	O
in	O
seizure	B-DISEASE
activity	O
24	O
h	O
after	O
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
may	O
be	O
the	O
GABA	O
-	O
A	O
receptor	O
-	O
linked	O
chloride	O
channel	O
.	O

Severe	O
ocular	O
and	O
orbital	O
toxicity	B-DISEASE
after	O
intracarotid	O
injection	O
of	O
carboplatin	O
for	O
recurrent	O
glioblastomas	O
.	O
BACKGROUND	O
:	O
Glioblastoma	B-DISEASE
is	O
a	O
malignant	O
tumor	B-DISEASE
that	O
occurs	O
in	O
the	O
cerebrum	O
during	O
adulthood	O
.	O
With	O
current	O
treatment	O
regimens	O
including	O
combined	O
surgery	O
,	O
radiation	O
and	O
chemotherapy	O
,	O
the	O
average	O
life	O
expectancy	O
of	O
the	O
patients	O
is	O
limited	O
to	O
approximately	O
1	O
year	O
.	O
Therefore	O
,	O
patients	O
with	O
glioblastoma	B-DISEASE
sometimes	O
have	O
intracarotid	O
injection	O
of	O
carcinostatics	O
added	O
to	O
the	O
treatment	O
regimen	O
.	O
Generally	O
,	O
carboplatin	O
is	O
said	O
to	O
have	O
milder	O
side	O
effects	O
than	O
cisplatin	B-CHEMICAL
,	O
whose	O
ocular	O
and	O
orbital	O
toxicity	B-DISEASE
are	O
well	O
known	O
.	O
However	O
,	O
we	O
experienced	O
a	O
case	O
of	O
severe	O
ocular	O
and	O
orbital	O
toxicity	B-DISEASE
after	O
intracarotid	O
injection	O
of	O
carboplatin	O
,	O
which	O
is	O
infrequently	O
reported	O
.	O
CASE	O
:	O
A	O
58	O
-	O
year	O
-	O
old	O
man	O
received	O
an	O
intracarotid	O
injection	O
of	O
carboplatin	O
for	O
recurrent	O
glioblastomas	O
in	O
his	O
left	O
temporal	O
lobe	O
.	O
He	O
complained	O
of	O
pain	B-DISEASE
and	O
visual	O
disturbance	O
in	O
the	O
ipsilateral	O
eye	O
30	O
h	O
after	O
the	O
injection	O
.	O
Various	O
ocular	O
symptoms	O
and	O
findings	O
caused	O
by	O
carboplatin	O
toxicity	B-DISEASE
were	O
seen	O
.	O
RESULTS	O
:	O
He	O
was	O
treated	O
with	O
intravenous	O
administration	O
of	O
corticosteroids	B-CHEMICAL
and	O
glycerin	O
for	O
6	O
days	O
after	O
the	O
injection	O
.	O
Although	O
the	O
intraocular	O
pressure	O
elevation	O
caused	O
by	O
secondary	O
acute	O
angle	O
-	O
closure	O
glaucoma	B-DISEASE
decreased	O
and	O
ocular	O
pain	B-DISEASE
diminished	O
,	O
inexorable	O
papilledema	B-DISEASE
and	O
exudative	O
retinal	B-DISEASE
detachment	I-DISEASE
continued	O
for	O
3	O
weeks	O
.	O
Finally	O
,	O
6	O
weeks	O
later	O
,	O
diffuse	O
chorioretinal	B-DISEASE
atrophy	I-DISEASE
with	O
optic	B-DISEASE
atrophy	I-DISEASE
occurred	O
and	O
the	O
vision	O
in	O
his	O
left	O
eye	O
was	O
lost	O
.	O
CONCLUSION	O
:	O
When	O
performing	O
intracarotid	O
injection	O
of	O
carboplatin	O
,	O
we	O
must	O
be	O
aware	O
of	O
its	O
potentially	O
blinding	O
ocular	B-DISEASE
toxicity	I-DISEASE
.	O
It	O
is	O
recommended	O
that	O
further	O
studies	O
and	O
investigations	O
are	O
undertaken	O
in	O
the	O
effort	O
to	O
minimize	O
such	O
severe	O
side	O
effects	O
.	O

Phase	O
II	O
study	O
of	O
the	O
amsacrine	O
analogue	O
CI-921	O
(	O
NSC	O
343499	O
)	O
in	O
non	B-DISEASE
-	I-DISEASE
small	I-DISEASE
cell	I-DISEASE
lung	I-DISEASE
cancer	I-DISEASE
.	O
CI-921	O
(	O
NSC	O
343499	O
;	O
9-[[2	B-CHEMICAL
-	I-CHEMICAL
methoxy-4-[(methylsulphonyl)amino]phenyl]amino	I-CHEMICAL
]	I-CHEMICAL
-N,5	I-CHEMICAL
-	I-CHEMICAL
dimethyl-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
acridinecarboxamide	I-CHEMICAL
)	O
is	O
a	O
topoisomerase	O
II	O
poison	O
with	O
high	O
experimental	O
antitumour	O
activity	O
.	O
It	O
was	O
administered	O
by	O
15	O
min	O
infusion	O
to	O
16	O
evaluable	O
patients	O
with	O
non	B-DISEASE
-	I-DISEASE
small	I-DISEASE
cell	I-DISEASE
lung	I-DISEASE
cancer	I-DISEASE
(	O
NSCLC	O
)	O
(	O
7	O
with	O
no	O
prior	O
treatment	O
,	O
9	O
patients	O
in	O
relapse	O
following	O
surgery	O
/	O
radiotherapy	O
)	O
at	O
a	O
dose	O
(	O
648	O
mg	O
/	O
m2	O
divided	O
over	O
3	O
days	O
,	O
repeated	O
every	O
3	O
weeks	O
)	O
determined	O
by	O
phase	O
I	O
trial	O
.	O
Patients	O
had	O
a	O
median	O
performance	O
status	O
of	O
1	O
(	O
WHO	O
)	O
,	O
and	O
median	O
age	O
of	O
61	O
years	O
.	O
The	O
histology	O
comprised	O
squamous	O
carcinoma	B-DISEASE
(	O
11	O
)	O
,	O
adenocarcinoma	B-DISEASE
(	O
1	O
)	O
,	O
mixed	O
histology	O
(	O
2	O
)	O
,	O
bronchio	B-DISEASE
-	I-DISEASE
alveolar	I-DISEASE
carcinoma	I-DISEASE
(	O
1	O
)	O
and	O
large	O
cell	O
undifferentiated	O
carcinoma	B-DISEASE
(	O
1	O
)	O
.	O
Neutropenia	B-DISEASE
grade	O
greater	O
than	O
or	O
equal	O
to	O
3	O
was	O
seen	O
in	O
15	O
patients	O
,	O
infections	B-DISEASE
with	O
recovery	O
in	O
3	O
,	O
and	O
grand	O
mal	O
seizures	B-DISEASE
in	O
1	O
patient	O
.	O
Grade	O
less	O
than	O
or	O
equal	O
to	O
2	O
nausea	B-DISEASE
and	O
vomiting	B-DISEASE
occurred	O
in	O
66	O
%	O
courses	O
and	O
phlebitis	B-DISEASE
in	O
the	O
infusion	O
arm	O
in	O
37	O
%	O
.	O
1	O
patient	O
with	O
squamous	O
cell	O
carcinoma	B-DISEASE
achieved	O
a	O
partial	O
response	O
lasting	O
5	O
months	O
.	O
Further	O
testing	O
in	O
this	O
and	O
other	O
tumour	O
types	O
using	O
multiple	O
daily	O
schedules	O
is	O
warranted	O
.	O

Alpha	O
-	O
lipoic	O
acid	O
prevents	O
mitochondrial	O
damage	O
and	O
neurotoxicity	B-DISEASE
in	O
experimental	O
chemotherapy	O
neuropathy	B-DISEASE
.	O
The	O
study	O
investigates	O
if	O
alpha	O
-	O
lipoic	O
acid	O
is	O
neuroprotective	O
against	O
chemotherapy	O
induced	O
neurotoxicity	B-DISEASE
,	O
if	O
mitochondrial	O
damage	O
plays	O
a	O
critical	O
role	O
in	O
toxic	O
neurodegenerative	O
cascade	O
,	O
and	O
if	O
neuroprotective	O
effects	O
of	O
alpha	O
-	O
lipoic	O
acid	O
depend	O
on	O
mitochondria	O
protection	O
.	O
We	O
used	O
an	O
in	O
vitro	O
model	O
of	O
chemotherapy	O
induced	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
that	O
closely	O
mimic	O
the	O
in	O
vivo	O
condition	O
by	O
exposing	O
primary	O
cultures	O
of	O
dorsal	O
root	O
ganglion	O
(	O
DRG	O
)	O
sensory	O
neurons	O
to	O
paclitaxel	B-CHEMICAL
and	O
cisplatin	B-CHEMICAL
,	O
two	O
widely	O
used	O
and	O
highly	O
effective	O
chemotherapeutic	O
drugs	O
.	O
This	O
approach	O
allowed	O
investigating	O
the	O
efficacy	O
of	O
alpha	O
-	O
lipoic	O
acid	O
in	O
preventing	O
axonal	B-DISEASE
damage	I-DISEASE
and	O
apoptosis	O
and	O
the	O
function	O
and	O
ultrastructural	O
morphology	O
of	O
mitochondria	O
after	O
exposure	O
to	O
toxic	O
agents	O
and	O
alpha	O
-	O
lipoic	O
acid	O
.	O
Our	O
results	O
demonstrate	O
that	O
both	O
cisplatin	B-CHEMICAL
and	O
paclitaxel	B-CHEMICAL
cause	O
early	O
mitochondrial	O
impairment	O
with	O
loss	O
of	O
membrane	O
potential	O
and	O
induction	O
of	O
autophagic	O
vacuoles	O
in	O
neurons	O
.	O
Alpha	O
-	O
lipoic	O
acid	O
exerts	O
neuroprotective	O
effects	O
against	O
chemotherapy	O
induced	O
neurotoxicity	B-DISEASE
in	O
sensory	O
neurons	O
:	O
it	O
rescues	O
the	O
mitochondrial	O
toxicity	B-DISEASE
and	O
induces	O
the	O
expression	O
of	O
frataxin	O
,	O
an	O
essential	O
mitochondrial	O
protein	O
with	O
anti	O
-	O
oxidant	O
and	O
chaperone	O
properties	O
.	O
In	O
conclusion	O
mitochondrial	O
toxicity	B-DISEASE
is	O
an	O
early	O
common	O
event	O
both	O
in	O
paclitaxel	B-CHEMICAL
and	O
cisplatin	B-CHEMICAL
induced	O
neurotoxicity	B-DISEASE
.	O
Alpha	O
-	O
lipoic	O
acid	O
protects	O
sensory	O
neurons	O
through	O
its	O
anti	O
-	O
oxidant	O
and	O
mitochondrial	O
regulatory	O
functions	O
,	O
possibly	O
inducing	O
the	O
expression	O
of	O
frataxin	O
.	O
These	O
findings	O
suggest	O
that	O
alpha	O
-	O
lipoic	O
acid	O
might	O
reduce	O
the	O
risk	O
of	O
developing	O
peripheral	O
nerve	O
toxicity	B-DISEASE
in	O
patients	O
undergoing	O
chemotherapy	O
and	O
encourage	O
further	O
confirmatory	O
clinical	O
trials	O
.	O

Optimising	O
stroke	B-DISEASE
prevention	O
in	O
non	O
-	O
valvular	O
atrial	B-DISEASE
fibrillation	I-DISEASE
.	O
Atrial	B-DISEASE
fibrillation	I-DISEASE
is	O
associated	O
with	O
substantial	O
morbidity	O
and	O
mortality	O
.	O
Pooled	O
data	O
from	O
trials	O
comparing	O
antithrombotic	O
treatment	O
with	O
placebo	O
have	O
shown	O
that	O
warfarin	B-CHEMICAL
reduces	O
the	O
risk	O
of	O
stroke	B-DISEASE
by	O
62	O
%	O
,	O
and	O
that	O
aspirin	O
alone	O
reduces	O
the	O
risk	O
by	O
22	O
%	O
.	O
Overall	O
,	O
in	O
high	O
-	O
risk	O
patients	O
,	O
warfarin	B-CHEMICAL
is	O
superior	O
to	O
aspirin	O
in	O
preventing	O
strokes	B-DISEASE
,	O
with	O
a	O
relative	O
risk	O
reduction	O
of	O
36	O
%	O
.	O
Ximelagatran	O
,	O
an	O
oral	O
direct	B-CHEMICAL
thrombin	I-CHEMICAL
inhibitor	I-CHEMICAL
,	O
was	O
found	O
to	O
be	O
as	O
efficient	O
as	O
vitamin	O
K	O
antagonist	O
drugs	O
in	O
the	O
prevention	O
of	O
embolic	B-DISEASE
events	I-DISEASE
,	O
but	O
has	O
been	O
recently	O
withdrawn	O
because	O
of	O
abnormal	B-DISEASE
liver	I-DISEASE
function	I-DISEASE
tests	O
.	O
The	O
ACTIVE	O
-	O
W	O
(	O
Atrial	B-DISEASE
Fibrillation	I-DISEASE
Clopidogrel	B-CHEMICAL
Trial	O
with	O
Irbesartan	O
for	O
Prevention	O
of	O
Vascular	O
Events	O
)	O
study	O
has	O
demonstrated	O
that	O
warfarin	B-CHEMICAL
is	O
superior	O
to	O
platelet	O
therapy	O
(	O
clopidogrel	B-CHEMICAL
plus	O
aspirin	O
)	O
in	O
the	O
prevention	O
af	O
embolic	B-DISEASE
events	I-DISEASE
.	O
Idraparinux	O
,	O
a	O
Factor	B-CHEMICAL
Xa	I-CHEMICAL
inhibitor	O
,	O
is	O
being	O
evaluated	O
in	O
patients	O
with	O
atrial	B-DISEASE
fibrillation	I-DISEASE
.	O
Angiotensin	O
-	O
converting	O
enzyme	O
inhibitors	O
and	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
receptor	O
-	O
blocking	O
drugs	O
hold	O
promise	O
in	O
atrial	B-DISEASE
fibrillation	I-DISEASE
through	O
cardiac	B-DISEASE
remodelling	I-DISEASE
.	O
Preliminary	O
studies	O
suggest	O
that	O
statins	B-CHEMICAL
could	O
interfere	O
with	O
the	O
risk	O
of	O
recurrence	B-DISEASE
after	O
electrical	O
cardioversion	O
.	O
Finally	O
,	O
percutaneous	O
methods	O
for	O
the	O
exclusion	O
of	O
left	O
atrial	O
appendage	O
are	O
under	O
investigation	O
in	O
high	O
-	O
risk	O
patients	O
.	O

Interaction	O
of	O
cyclosporin	B-CHEMICAL
A	I-CHEMICAL
with	O
antineoplastic	B-CHEMICAL
agents	I-CHEMICAL
.	O
A	O
synergistic	O
effect	O
of	O
etoposide	B-CHEMICAL
and	O
cyclosporin	B-CHEMICAL
A	I-CHEMICAL
was	O
observed	O
in	O
a	O
patient	O
with	O
acute	B-DISEASE
T	I-DISEASE
-	I-DISEASE
lymphocytic	I-DISEASE
leukemia	I-DISEASE
in	O
relapse	O
.	O
The	O
concomitant	O
administration	O
of	O
etoposide	B-CHEMICAL
and	O
cyclosporin	B-CHEMICAL
A	I-CHEMICAL
resulted	O
in	O
eradication	O
of	O
hitherto	O
refractory	O
leukemic	B-DISEASE
infiltration	I-DISEASE
of	O
bone	O
marrow	O
.	O
Severe	O
side	O
effects	O
in	O
terms	O
of	O
mental	O
confusion	B-DISEASE
and	O
progressive	O
hyperbilirubinemia	B-DISEASE
,	O
however	O
,	O
point	O
to	O
an	O
enhancement	O
not	O
only	O
of	O
antineoplastic	O
effects	O
but	O
also	O
of	O
toxicity	B-DISEASE
in	O
normal	O
tissues	O
.	O
This	O
report	O
demonstrates	O
for	O
the	O
first	O
time	O
that	O
the	O
pharmacodynamic	O
properties	O
of	O
cyclosporin	B-CHEMICAL
A	I-CHEMICAL
may	O
not	O
be	O
confined	O
strictly	O
to	O
suppression	O
of	O
normal	O
T	O
-	O
cell	O
functions	O
.	O

The	O
hematologic	O
effects	O
of	O
cefonicid	B-CHEMICAL
and	O
cefazedone	B-CHEMICAL
in	O
the	O
dog	O
:	O
a	O
potential	O
model	O
of	O
cephalosporin	O
hematotoxicity	O
in	O
man	O
.	O
Cephalosporin	O
antibiotics	O
cause	O
a	O
variety	O
of	O
hematologic	O
disturbances	O
in	O
man	O
,	O
the	O
pathogeneses	O
and	O
hematopathology	O
of	O
which	O
remain	O
poorly	O
characterized	O
.	O
There	O
is	O
a	O
need	O
for	O
a	O
well	O
-	O
defined	O
animal	O
model	O
in	O
which	O
these	O
blood	B-DISEASE
dyscrasias	I-DISEASE
can	O
be	O
studied	O
.	O
In	O
four	O
subacute	O
toxicity	B-DISEASE
studies	O
,	O
the	O
intravenous	O
administration	O
of	O
cefonicid	B-CHEMICAL
or	O
cefazedone	B-CHEMICAL
to	O
beagle	O
dogs	O
caused	O
a	O
dose	O
-	O
dependent	O
incidence	O
of	O
anemia	B-DISEASE
,	O
neutropenia	B-DISEASE
,	O
and	O
thrombocytopenia	B-DISEASE
after	O
1	O
-	O
3	O
months	O
of	O
treatment	O
.	O
A	O
nonregenerative	O
anemia	B-DISEASE
was	O
the	O
most	O
compromising	O
of	O
the	O
cytopenias	B-DISEASE
and	O
occurred	O
in	O
approximately	O
50	O
%	O
of	O
dogs	O
receiving	O
400	O
-	O
500	O
mg	O
/	O
kg	O
cefonicid	B-CHEMICAL
or	O
540	O
-	O
840	O
mg	O
/	O
kg	O
cefazedone	B-CHEMICAL
.	O
All	O
three	O
cytopenias	B-DISEASE
were	O
completely	O
reversible	O
following	O
cessation	O
of	O
treatment	O
;	O
the	O
time	O
required	O
for	O
recovery	O
of	O
the	O
erythron	O
(	O
approximately	O
1	O
month	O
)	O
was	O
considerably	O
longer	O
than	O
that	O
of	O
the	O
granulocytes	O
and	O
platelets	O
(	O
hours	O
to	O
a	O
few	O
days	O
)	O
.	O
Upon	O
rechallenge	O
with	O
either	O
cephalosporin	O
,	O
the	O
hematologic	O
syndrome	B-DISEASE
was	O
reproduced	O
in	O
most	O
dogs	O
tested	O
;	O
cefonicid	B-CHEMICAL
(	O
but	O
not	O
cefazedone)-treated	O
dogs	O
showed	O
a	O
substantially	O
reduced	O
induction	O
period	O
(	O
15	O
+	O
/-	O
5	O
days	O
)	O
compared	O
to	O
that	O
of	O
the	O
first	O
exposure	O
to	O
the	O
drug	O
(	O
61	O
+	O
/-	O
24	O
days	O
)	O
.	O
This	O
observation	O
,	O
along	O
with	O
the	O
rapid	O
rate	O
of	O
decline	O
in	O
red	O
cell	O
mass	O
parameters	O
of	O
affected	O
dogs	O
,	O
suggests	O
that	O
a	O
hemolytic	O
component	O
complicated	O
the	O
red	O
cell	O
production	O
problem	O
and	O
that	O
multiple	O
toxicologic	O
mechanisms	O
contributed	O
to	O
the	O
cytopenia	B-DISEASE
.	O
We	O
conclude	O
that	O
the	O
administration	O
of	O
high	O
doses	O
of	O
cefonicid	B-CHEMICAL
or	O
cefazedone	B-CHEMICAL
to	O
dogs	O
can	O
induce	O
hematotoxicity	O
similar	O
to	O
the	O
cephalosporin	O
-	O
induced	O
blood	B-DISEASE
dyscrasias	I-DISEASE
described	O
in	O
man	O
and	O
thus	O
provides	O
a	O
useful	O
model	O
for	O
studying	O
the	O
mechanisms	O
of	O
these	O
disorders	O
.	O

A	O
pyridoxine	B-CHEMICAL
-	O
dependent	O
behavioral	B-DISEASE
disorder	I-DISEASE
unmasked	O
by	O
isoniazid	B-CHEMICAL
.	O
A	O
3	O
-	O
year	O
-	O
old	O
girl	O
had	O
behavioral	B-DISEASE
deterioration	I-DISEASE
,	O
with	O
hyperkinesis	B-DISEASE
,	O
irritability	B-DISEASE
,	O
and	O
sleeping	O
difficulties	O
after	O
the	O
therapeutic	O
administration	O
of	O
isoniazid	B-CHEMICAL
.	O
The	O
administration	O
of	O
pharmacologic	O
doses	O
of	O
pyridoxine	B-CHEMICAL
hydrochloride	I-CHEMICAL
led	O
to	O
a	O
disappearance	O
of	O
symptoms	O
.	O
After	O
discontinuing	O
isoniazid	B-CHEMICAL
therapy	O
a	O
similar	O
pattern	O
of	O
behavior	O
was	O
noted	O
that	O
was	O
controlled	O
by	O
pyridoxine	B-CHEMICAL
.	O
A	O
placebo	O
had	O
no	O
effect	O
,	O
but	O
niacinamide	B-CHEMICAL
was	O
as	O
effective	O
as	O
pyridoxine	B-CHEMICAL
.	O
Periodic	O
withdrawal	O
of	O
pyridoxine	B-CHEMICAL
was	O
associated	O
with	O
return	O
of	O
the	O
hyperkinesis	B-DISEASE
.	O
The	O
level	O
of	O
pyridoxal	O
in	O
the	O
blood	O
was	O
normal	O
during	O
the	O
periods	O
of	O
relapse	O
.	O
Metabolic	O
studies	O
suggested	O
a	O
block	O
in	O
the	O
kynurenine	O
pathway	O
of	O
tryptophan	O
metabolism	O
.	O
The	O
patient	O
has	O
been	O
followed	O
for	O
six	O
years	O
and	O
has	O
required	O
pharmacologic	O
doses	O
of	O
pyridoxine	B-CHEMICAL
to	O
control	O
her	O
behavior	O
.	O

A	O
selective	O
dopamine	B-CHEMICAL
D4	O
receptor	O
antagonist	O
,	O
NRA0160	O
:	O
a	O
preclinical	O
neuropharmacological	O
profile	O
.	O
NRA0160	O
,	O
5	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
2-	I-CHEMICAL
(	I-CHEMICAL
4-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
fluorobenzylidene	I-CHEMICAL
)	I-CHEMICAL
piperidin-1	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
ethyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-(4	I-CHEMICAL
-	I-CHEMICAL
fluorophenyl	I-CHEMICAL
)	I-CHEMICAL
thiazole-2	I-CHEMICAL
-	I-CHEMICAL
carboxamide	I-CHEMICAL
,	O
has	O
a	O
high	O
affinity	O
for	O
human	O
cloned	O
dopamine	B-CHEMICAL
D4.2	O
,	O
D4.4	O
and	O
D4.7	O
receptors	O
,	O
with	O
Ki	O
values	O
of	O
0.5	O
,	O
0.9	O
and	O
2.7	O
nM	O
,	O
respectively	O
.	O
NRA0160	O
is	O
over	O
20,000fold	O
more	O
potent	O
at	O
the	O
dopamine	B-CHEMICAL
D4.2	O
receptor	O
compared	O
with	O
the	O
human	O
cloned	O
dopamine	B-CHEMICAL
D2L	O
receptor	O
.	O
NRA0160	O
has	O
negligible	O
affinity	O
for	O
the	O
human	O
cloned	O
dopamine	B-CHEMICAL
D3	O
receptor	O
(	O
Ki=39	O
nM	O
)	O
,	O
rat	O
serotonin	B-CHEMICAL
(	O
5	O
-	O
HT)2A	O
receptors	O
(	O
Ki=180	O
nM	O
)	O
and	O
rat	O
alpha1	O
adrenoceptor	O
(	O
Ki=237	O
nM	O
)	O
.	O
NRA0160	O
and	O
clozapine	B-CHEMICAL
antagonized	O
locomotor	B-DISEASE
hyperactivity	I-DISEASE
induced	O
by	O
methamphetamine	B-CHEMICAL
(	O
MAP	O
)	O
in	O
mice	O
.	O
NRA0160	O
and	O
clozapine	B-CHEMICAL
antagonized	O
MAP	O
-	O
induced	O
stereotyped	O
behavior	O
in	O
mice	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
inhibition	O
,	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O
NRA0160	O
and	O
clozapine	B-CHEMICAL
significantly	O
induced	O
catalepsy	B-DISEASE
in	O
rats	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
induction	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O
NRA0160	O
and	O
clozapine	B-CHEMICAL
significantly	O
reversed	O
the	O
disruption	O
of	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
in	O
rats	O
produced	O
by	O
apomorphine	O
.	O
NRA0160	O
and	O
clozapine	B-CHEMICAL
significantly	O
shortened	O
the	O
phencyclidine	O
(	O
PCP)-induced	O
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O
These	O
findings	O
suggest	O
that	O
NRA0160	O
may	O
have	O
unique	O
antipsychotic	O
activities	O
without	O
the	O
liability	O
of	O
motor	O
side	O
effects	O
typical	O
of	O
classical	O
antipsychotics	B-CHEMICAL
.	O

Prolonged	O
cholestasis	B-DISEASE
after	O
troleandomycin	O
-	O
induced	O
acute	B-DISEASE
hepatitis	I-DISEASE
.	O
We	O
report	O
the	O
case	O
of	O
a	O
patient	O
in	O
whom	O
troleandomycin	O
-	O
induced	O
hepatitis	B-DISEASE
was	O
followed	O
by	O
prolonged	O
anicteric	O
cholestasis	B-DISEASE
.	O
Jaundice	B-DISEASE
occurred	O
after	O
administration	O
of	O
troleandomycin	O
for	O
7	O
days	O
and	O
was	O
associated	O
with	O
hypereosinophilia	O
.	O
Jaundice	B-DISEASE
disappeared	O
within	O
3	O
months	O
but	O
was	O
followed	O
by	O
prolonged	O
anicteric	O
cholestasis	B-DISEASE
marked	O
by	O
pruritus	B-DISEASE
and	O
high	O
levels	O
of	O
alkaline	B-CHEMICAL
phosphatase	I-CHEMICAL
and	O
gammaglutamyltransferase	O
activities	O
.	O
Finally	O
,	O
pruritus	B-DISEASE
disappeared	O
within	O
19	O
months	O
,	O
and	O
liver	O
tests	O
returned	O
to	O
normal	O
27	O
months	O
after	O
the	O
onset	O
of	O
hepatitis	B-DISEASE
.	O
This	O
observation	O
demonstrates	O
that	O
prolonged	O
cholestasis	B-DISEASE
can	O
follow	O
troleandomycin	O
-	O
induced	O
acute	B-DISEASE
hepatitis	I-DISEASE
.	O

HMG	O
CoA	O
reductase	O
inhibitors	O
.	O
Current	O
clinical	O
experience	O
.	O
Lovastatin	B-CHEMICAL
and	O
simvastatin	B-CHEMICAL
are	O
the	O
2	O
best	O
-	O
known	O
members	O
of	O
the	O
class	O
of	O
hypolipidaemic	O
agents	O
known	O
as	O
HMG	O
CoA	O
reductase	O
inhibitors	O
.	O
Clinical	O
experience	O
with	O
lovastatin	B-CHEMICAL
includes	O
over	O
5000	O
patients	O
,	O
700	O
of	O
whom	O
have	O
been	O
treated	O
for	O
2	O
years	O
or	O
more	O
,	O
and	O
experience	O
with	O
simvastatin	B-CHEMICAL
includes	O
over	O
3500	O
patients	O
,	O
of	O
whom	O
350	O
have	O
been	O
treated	O
for	O
18	O
months	O
or	O
more	O
.	O
Lovastatin	B-CHEMICAL
has	O
been	O
marketed	O
in	O
the	O
United	O
States	O
for	O
over	O
6	O
months	O
.	O
Both	O
agents	O
show	O
substantial	O
clinical	O
efficacy	O
,	O
with	O
reductions	O
in	O
total	O
cholesterol	B-CHEMICAL
of	O
over	O
30	O
%	O
and	O
in	O
LDL	O
-	O
cholesterol	B-CHEMICAL
of	O
40	O
%	O
in	O
clinical	O
studies	O
.	O
Modest	O
increases	O
in	O
HDL	O
-	O
cholesterol	B-CHEMICAL
levels	O
of	O
about	O
10	O
%	O
are	O
also	O
reported	O
.	O
Clinical	O
tolerability	O
of	O
both	O
agents	O
has	O
been	O
good	O
,	O
with	O
fewer	O
than	O
3	O
%	O
of	O
patients	O
withdrawn	O
from	O
treatment	O
because	O
of	O
clinical	O
adverse	O
experiences	O
.	O
Ophthalmological	O
examinations	O
in	O
over	O
1100	O
patients	O
treated	O
with	O
one	O
or	O
the	O
other	O
agent	O
have	O
revealed	O
no	O
evidence	O
of	O
significant	O
short	O
term	O
(	O
up	O
to	O
2	O
years	O
)	O
cataractogenic	O
potential	O
.	O
One	O
to	O
2	O
%	O
of	O
patients	O
have	O
elevations	O
of	O
serum	O
transaminases	O
to	O
greater	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
.	O
These	O
episodes	O
are	O
asymptomatic	O
and	O
reversible	O
when	O
therapy	O
is	O
discontinued	O
.	O
Minor	O
elevations	O
of	O
creatine	B-CHEMICAL
kinase	O
levels	O
are	O
reported	O
in	O
about	O
5	O
%	O
of	O
patients	O
.	O
Myopathy	B-DISEASE
,	O
associated	O
in	O
some	O
cases	O
with	O
myoglobinuria	B-DISEASE
,	O
and	O
in	O
2	O
cases	O
with	O
transient	O
renal	B-DISEASE
failure	I-DISEASE
,	O
has	O
been	O
rarely	O
reported	O
with	O
lovastatin	B-CHEMICAL
,	O
especially	O
in	O
patients	O
concomitantly	O
treated	O
with	O
cyclosporin	O
,	O
gemfibrozil	O
or	O
niacin	O
.	O
Lovastatin	B-CHEMICAL
and	O
simvastatin	B-CHEMICAL
are	O
both	O
effective	O
and	O
well	O
-	O
tolerated	O
agents	O
for	O
lowering	O
elevated	O
levels	O
of	O
serum	O
cholesterol	B-CHEMICAL
.	O
As	O
wider	O
use	O
confirms	O
their	O
safety	O
profile	O
,	O
they	O
will	O
gain	O
increasing	O
importance	O
in	O
the	O
therapeutic	O
approach	O
to	O
hypercholesterolaemia	O
and	O
its	O
consequences	O
.	O

Sulfasalazine	B-CHEMICAL
-	O
induced	O
lupus	B-DISEASE
erythematosus	O
.	O
Pneumonitis	B-DISEASE
,	O
bilateral	O
pleural	B-DISEASE
effusions	I-DISEASE
,	O
echocardiographic	O
evidence	O
of	O
cardiac	B-DISEASE
tamponade	I-DISEASE
,	O
and	O
positive	O
autoantibodies	O
developed	O
in	O
a	O
43	O
-	O
year	O
-	O
old	O
man	O
,	O
who	O
was	O
receiving	O
long	O
-	O
term	O
sulfasalazine	B-CHEMICAL
therapy	O
for	O
chronic	O
ulcerative	B-DISEASE
colitis	I-DISEASE
.	O
After	O
cessation	O
of	O
the	O
sulfasalazine	B-CHEMICAL
and	O
completion	O
of	O
a	O
six	O
-	O
week	O
course	O
of	O
corticosteroids	B-CHEMICAL
,	O
these	O
problems	O
resolved	O
over	O
a	O
period	O
of	O
four	O
to	O
six	O
months	O
.	O
It	O
is	O
suggested	O
that	O
the	O
patient	O
had	O
sulfasalazine	B-CHEMICAL
-	O
induced	O
lupus	B-DISEASE
,	O
which	O
manifested	O
with	O
serositis	B-DISEASE
and	O
pulmonary	O
parenchymal	O
involvement	O
in	O
the	O
absence	O
of	O
joint	O
symptoms	O
.	O
Physicians	O
who	O
use	O
sulfasalazine	B-CHEMICAL
to	O
treat	O
patients	O
with	O
inflammatory	O
bowel	O
disease	B-DISEASE
should	O
be	O
aware	O
of	O
the	O
signs	O
of	O
sulfasalazine	B-CHEMICAL
-	O
induced	O
lupus	B-DISEASE
syndrome	B-DISEASE
.	O

Optimization	O
of	O
levodopa	B-CHEMICAL
therapy	O
.	O
While	O
there	O
is	O
no	O
single	O
correct	O
starting	O
dose	O
for	O
levodopa	B-CHEMICAL
therapy	O
,	O
many	O
individuals	O
can	O
be	O
started	O
on	O
either	O
the	O
25/100	O
or	O
controlled	O
-	O
release	O
formula	O
,	O
following	O
the	O
general	O
rule	O
not	O
to	O
attempt	O
to	O
titrate	O
carbidopa	O
-	O
levodopa	B-CHEMICAL
to	O
the	O
point	O
of	O
"	O
normality	O
,	O
"	O
which	O
can	O
lead	O
to	O
toxicity	B-DISEASE
.	O
The	O
physician	O
should	O
also	O
determine	O
the	O
proper	O
use	O
of	O
any	O
adjunctive	O
medications	O
;	O
such	O
combined	O
therapy	O
has	O
become	O
the	O
standard	O
approach	O
to	O
treatment	O
.	O
Following	O
the	O
initial	O
period	O
of	O
therapy	O
,	O
emerging	O
difficulties	O
require	O
a	O
reassessment	O
of	O
therapeutic	O
approaches	O
,	O
such	O
as	O
dosage	O
adjustment	O
or	O
introduction	O
of	O
a	O
dopamine	B-CHEMICAL
agonist	O
.	O
Other	O
possible	O
adverse	O
effects	O
--	O
such	O
as	O
gastrointestinal	O
disorders	O
,	O
orthostatic	B-DISEASE
hypotension	I-DISEASE
,	O
levodopa	B-CHEMICAL
-	O
induced	O
psychosis	B-DISEASE
,	O
sleep	O
disturbances	O
or	O
parasomnias	B-DISEASE
,	O
or	O
drug	O
interactions	O
--	O
also	O
require	O
carefully	O
monitored	O
individual	O
treatment	O
.	O
Nonpharmacologic	O
concerns	O
can	O
help	O
the	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
patient	O
achieve	O
and	O
maintain	O
optimal	O
functioning	O
,	O
including	O
daily	O
exercise	O
,	O
physical	O
therapy	O
,	O
and	O
involvement	O
with	O
support	O
groups	O
.	O

Alpha	O
and	O
beta	O
coma	B-DISEASE
in	O
drug	O
intoxication	O
uncomplicated	O
by	O
cerebral	B-DISEASE
hypoxia	I-DISEASE
.	O
Four	O
patients	O
who	O
were	O
rendered	O
comatose	B-DISEASE
or	O
stuporous	O
by	O
drug	O
intoxication	O
,	O
but	O
who	O
were	O
not	O
hypoxic	O
,	O
are	O
described	O
.	O
Three	O
patients	O
received	O
high	O
doses	O
of	O
chlormethiazole	O
for	O
alcohol	O
withdrawal	O
symptoms	O
,	O
and	O
one	O
took	O
a	O
suicidal	O
overdose	B-DISEASE
of	O
nitrazepam	O
.	O
The	O
patient	O
with	O
nitrazepam	O
overdose	B-DISEASE
and	O
two	O
of	O
those	O
with	O
chlormethiazole	O
intoxication	O
conformed	O
to	O
the	O
criteria	O
of	O
'	O
alpha	O
coma	B-DISEASE
'	O
,	O
showing	O
non	O
-	O
reactive	O
generalized	O
or	O
frontally	O
predominant	O
alpha	O
activity	O
in	O
the	O
EEG	O
.	O
The	O
fourth	O
patient	O
who	O
was	O
unconscious	O
after	O
chlormethiazole	O
administration	O
exhibite	O
generalized	O
non	O
-	O
reactive	O
activity	O
in	O
the	O
slow	O
beta	O
range	O
.	O
All	O
four	O
recovered	O
completely	O
without	O
neurological	O
sequelae	O
following	O
the	O
withdrawal	O
of	O
the	O
offending	O
agents	O
.	O
The	O
similarities	O
between	O
the	O
effects	O
of	O
structural	O
lesions	O
and	O
pharmacological	O
depression	B-DISEASE
of	O
the	O
brain	O
stem	O
reticular	O
formation	O
are	O
discussed	O
.	O
It	O
is	O
suggested	O
that	O
in	O
both	O
situations	O
disturbed	O
reticulo	O
-	O
thalamic	O
interactions	O
are	O
important	O
in	O
the	O
pathogenesis	O
of	O
alpha	O
coma	B-DISEASE
.	O
It	O
is	O
concluded	O
that	O
when	O
this	O
electroencephalographic	O
and	O
behavioural	O
picture	O
is	O
seen	O
in	O
drug	O
intoxication	O
,	O
in	O
the	O
absence	O
of	O
significant	O
hypoxaemia	O
,	O
a	O
favourable	O
outcome	O
may	O
be	O
anticipated	O
.	O

Omitting	O
fentanyl	B-CHEMICAL
reduces	O
nausea	B-DISEASE
and	O
vomiting	B-DISEASE
,	O
without	O
increasing	O
pain	B-DISEASE
,	O
after	O
sevoflurane	B-CHEMICAL
for	O
day	O
surgery	O
.	O
BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Despite	O
advantages	O
of	O
induction	O
and	O
maintenance	O
of	O
anaesthesia	O
with	O
sevoflurane	B-CHEMICAL
,	O
postoperative	B-DISEASE
nausea	I-DISEASE
and	I-DISEASE
vomiting	I-DISEASE
occurs	O
frequently	O
.	O
Fentanyl	B-CHEMICAL
is	O
a	O
commonly	O
used	O
supplement	O
that	O
may	O
contribute	O
to	O
this	O
,	O
although	O
it	O
may	O
also	O
improve	O
analgesia	B-DISEASE
.	O
METHODS	O
:	O
This	O
double	O
-	O
blind	B-DISEASE
study	O
examined	O
the	O
incidence	O
and	O
severity	O
of	O
postoperative	B-DISEASE
nausea	I-DISEASE
and	I-DISEASE
vomiting	I-DISEASE
and	O
pain	B-DISEASE
in	O
the	O
first	O
24	O
h	O
after	O
sevoflurane	B-CHEMICAL
anaesthesia	O
in	O
216	O
adult	O
day	O
surgery	O
patients	O
.	O
Patients	O
were	O
randomly	O
allocated	O
to	O
either	O
receive	O
or	O
not	O
receive	O
1	O
1	O
fentanyl	B-CHEMICAL
,	O
while	O
a	O
third	O
group	O
received	O
dexamethasone	B-CHEMICAL
in	O
addition	O
to	O
fentanyl	B-CHEMICAL
.	O
RESULTS	O
:	O
Omission	O
of	O
fentanyl	B-CHEMICAL
did	O
not	O
reduce	O
the	O
overall	O
incidence	O
of	O
postoperative	B-DISEASE
nausea	I-DISEASE
and	I-DISEASE
vomiting	I-DISEASE
,	O
but	O
did	O
reduce	O
the	O
incidence	O
of	O
vomiting	B-DISEASE
and/or	O
moderate	O
to	O
severe	O
nausea	B-DISEASE
prior	O
to	O
discharge	O
from	O
20	O
%	O
and	O
17	O
%	O
with	O
fentanyl	B-CHEMICAL
and	O
fentanyl	B-CHEMICAL
-	O
dexamethasone	B-CHEMICAL
,	O
respectively	O
,	O
to	O
5	O
%	O
(	O
P	O
=	O
0.013	O
)	O
.	O
Antiemetic	O
requirements	O
were	O
reduced	O
from	O
24	O
%	O
and	O
31	O
%	O
to	O
7	O
%	O
(	O
P	O
=	O
0.0012	O
)	O
.	O
Dexamethasone	B-CHEMICAL
had	O
no	O
significant	O
effect	O
on	O
the	O
incidence	O
or	O
severity	O
of	O
postoperative	B-DISEASE
nausea	I-DISEASE
and	I-DISEASE
vomiting	I-DISEASE
.	O
Combining	O
the	O
two	O
fentanyl	B-CHEMICAL
groups	O
revealed	O
further	O
significant	O
benefits	O
from	O
the	O
avoidance	O
of	O
opioids	O
,	O
reducing	O
postoperative	B-DISEASE
nausea	I-DISEASE
and	I-DISEASE
vomiting	I-DISEASE
and	O
nausea	B-DISEASE
prior	O
to	O
discharge	O
from	O
35	O
%	O
and	O
33	O
%	O
to	O
22	O
%	O
and	O
19	O
%	O
(	O
P	O
=	O
0.049	O
and	O
P	O
=	O
0.035	O
)	O
,	O
respectively	O
,	O
while	O
nausea	B-DISEASE
in	O
the	O
first	O
24	O
h	O
was	O
decreased	O
from	O
42	O
%	O
to	O
27	O
%	O
(	O
P	O
=	O
0.034	O
)	O
.	O
Pain	B-DISEASE
severity	O
and	O
analgesic	O
requirements	O
were	O
unaffected	O
by	O
the	O
omission	O
of	O
fentanyl	B-CHEMICAL
.	O
Fentanyl	B-CHEMICAL
did	O
reduce	O
minor	O
intraoperative	O
movement	O
but	O
had	O
no	O
sevoflurane	B-CHEMICAL
-	O
sparing	O
effect	O
and	O
increased	O
respiratory	B-DISEASE
depression	I-DISEASE
,	O
hypotension	B-DISEASE
and	O
bradycardia	B-DISEASE
.	O
CONCLUSION	O
:	O
As	O
fentanyl	B-CHEMICAL
exacerbated	O
postoperative	B-DISEASE
nausea	I-DISEASE
and	I-DISEASE
vomiting	I-DISEASE
without	O
an	O
improvement	O
in	O
postoperative	O
pain	B-DISEASE
and	O
also	O
had	O
adverse	O
cardiorespiratory	O
effects	O
,	O
it	O
appears	O
to	O
be	O
an	O
unnecessary	O
and	O
possibly	O
detrimental	O
supplement	O
to	O
sevoflurane	B-CHEMICAL
in	O
day	O
surgery	O
.	O

Renal	B-DISEASE
Fanconi	I-DISEASE
syndrome	I-DISEASE
and	O
myopathy	B-DISEASE
after	O
liver	O
transplantation	O
:	O
drug	O
-	O
related	O
mitochondrial	B-DISEASE
cytopathy	I-DISEASE
?	O
Advances	O
in	O
the	O
field	O
of	O
transplantation	O
provide	O
a	O
better	O
quality	O
of	O
life	O
and	O
allow	O
more	O
favorable	O
conditions	O
for	O
growth	O
and	O
development	O
in	O
children	O
.	O
However	O
,	O
combinations	O
of	O
different	O
therapeutic	O
regimens	O
require	O
consideration	O
of	O
potential	O
adverse	O
reactions	O
.	O
We	O
describe	O
a	O
15	O
-	O
yr	O
-	O
old	O
girl	O
who	O
had	O
orthotopic	O
liver	O
transplantation	O
because	O
of	O
Wilson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
.	O
Tacrolimus	B-CHEMICAL
,	O
MMF	O
,	O
and	O
steroids	B-CHEMICAL
were	O
given	O
as	O
immunosuppressant	O
.	O
Lamivudine	B-CHEMICAL
was	O
added	O
because	O
of	O
de	O
nova	O
hepatitis	B-DISEASE
B	I-DISEASE
infection	B-DISEASE
during	O
her	O
follow	O
-	O
up	O
.	O
Three	O
yr	O
after	O
transplantation	O
she	O
developed	O
renal	B-DISEASE
Fanconi	I-DISEASE
syndrome	I-DISEASE
with	O
severe	O
metabolic	B-DISEASE
acidosis	I-DISEASE
,	O
hypophosphatemia	B-DISEASE
,	O
glycosuria	B-DISEASE
,	O
and	O
aminoaciduria	B-DISEASE
.	O
Although	O
tacrolimus	B-CHEMICAL
was	O
suspected	O
to	O
be	O
the	O
cause	O
of	O
late	O
post	O
-	O
transplant	O
renal	O
acidosis	B-DISEASE
and	O
was	O
replaced	O
by	O
sirolimus	B-CHEMICAL
,	O
acidosis	B-DISEASE
,	O
and	O
electrolyte	O
imbalance	O
got	O
worse	O
.	O
Proximal	O
muscle	B-DISEASE
weakness	I-DISEASE
has	O
developed	O
during	O
her	O
follow	O
-	O
up	O
.	O
Fanconi	B-DISEASE
syndrome	I-DISEASE
,	O
as	O
well	O
as	O
myopathy	B-DISEASE
,	O
is	O
well	O
recognized	O
in	O
patients	O
with	O
mitochondrial	O
disorders	O
and	O
caused	O
by	O
depletion	O
of	O
mtDNA	O
.	O
We	O
suggest	O
that	O
our	O
patient	O
's	O
tubular	O
dysfunction	O
and	O
myopathy	B-DISEASE
may	O
have	O
resulted	O
from	O
mitochondrial	B-DISEASE
dysfunction	I-DISEASE
which	O
is	O
triggered	O
by	O
tacrolimus	B-CHEMICAL
and	O
augmented	O
by	O
lamivudine	B-CHEMICAL
.	O

Antipsychotic	O
-	O
like	O
profile	O
of	O
thioperamide	O
,	O
a	O
selective	O
H3	O
-	O
receptor	O
antagonist	O
in	O
mice	O
.	O
Experimental	O
and	O
clinical	O
evidence	O
points	O
to	O
a	O
role	O
of	O
central	O
histaminergic	O
system	O
in	O
the	O
pathogenesis	O
of	O
schizophrenia	B-DISEASE
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
study	O
the	O
effect	O
of	O
histamine	B-CHEMICAL
H(3)-receptor	O
ligands	O
on	O
neuroleptic	O
-	O
induced	O
catalepsy	B-DISEASE
,	O
apomorphine	O
-	O
induced	O
climbing	O
behavior	O
and	O
amphetamine	O
-	O
induced	O
locomotor	O
activities	O
in	O
mice	O
.	O
Catalepsy	B-DISEASE
was	O
induced	O
by	O
haloperidol	B-CHEMICAL
(	O
2	O
mg	O
/	O
kg	O
p.o	O
.	O
)	O
,	O
while	O
apomorphine	O
(	O
1.5	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
and	O
amphetamine	O
(	O
2	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
were	O
used	O
for	O
studying	O
climbing	O
behavior	O
and	O
locomotor	O
activities	O
,	O
respectively	O
.	O
(	B-CHEMICAL
R)-alpha	I-CHEMICAL
-	I-CHEMICAL
methylhistamine	I-CHEMICAL
(	O
RAMH	O
)	O
(	O
5	O
microg	O
i.c.v	O
.	O
)	O
and	O
thioperamide	O
(	O
THP	O
)	O
(	O
15	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
,	O
per	O
se	B-DISEASE
did	O
not	O
cause	O
catalepsy	B-DISEASE
.	O
Administration	O
of	O
THP	O
(	O
3.75	O
,	O
7.5	O
and	O
15	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
1	O
h	O
prior	O
to	O
haloperidol	B-CHEMICAL
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
catalepsy	B-DISEASE
times	O
(	O
P	O
<	O
0.05	O
)	O
.	O
However	O
,	O
pretreatment	O
with	O
RAMH	O
significantly	O
reversed	O
such	O
an	O
effect	O
of	O
THP	O
(	O
15	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O
RAMH	O
per	O
se	B-DISEASE
showed	O
significant	O
reduction	O
in	O
locomotor	O
time	O
,	O
distance	O
traveled	O
and	O
average	O
speed	O
but	O
THP	O
(	O
15	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
per	O
se	B-DISEASE
had	O
no	O
effect	O
on	O
these	O
parameters	O
.	O
On	O
amphetamine	O
-	O
induced	O
hyperactivity	O
,	O
THP	O
(	O
3.75	O
and	O
7.5	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
reduced	O
locomotor	O
time	O
,	O
distance	O
traveled	O
and	O
average	O
speed	O
(	O
P	O
<	O
0.05	O
)	O
.	O
Pretreatment	O
with	O
RAMH	O
(	O
5	O
microg	O
i.c.v	O
.	O
)	O
could	O
partially	O
reverse	O
such	O
effects	O
of	O
THP	O
(	O
3.75	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O
Climbing	O
behavior	O
induced	O
by	O
apomorphine	O
was	O
reduced	O
in	O
animals	O
treated	O
with	O
THP	O
.	O
Such	O
an	O
effect	O
was	O
,	O
however	O
,	O
reversed	O
in	O
presence	O
of	O
RAMH	O
.	O
THP	O
exhibited	O
an	O
antipsychotic	O
-	O
like	O
profile	O
by	O
potentiating	O
haloperidol	B-CHEMICAL
-	O
induced	O
catalepsy	B-DISEASE
,	O
reducing	O
amphetamine	O
-	O
induced	O
hyperactivity	O
and	O
reducing	O
apomorphine	O
-	O
induced	O
climbing	O
in	O
mice	O
.	O
Such	O
effects	O
of	O
THP	O
were	O
reversed	O
by	O
RAMH	O
indicating	O
the	O
involvement	O
of	O
histamine	B-CHEMICAL
H(3)-receptors	O
.	O
Findings	O
suggest	O
a	O
potential	O
for	O
H(3)-receptor	O
antagonists	O
in	O
improving	O
the	O
refractory	O
cases	O
of	O
schizophrenia	B-DISEASE
.	O

Transient	O
platypnea	B-DISEASE
-	O
orthodeoxia	B-DISEASE
-	O
like	O
syndrome	B-DISEASE
induced	O
by	O
propafenone	O
overdose	B-DISEASE
in	O
a	O
young	O
woman	O
with	O
Ebstein	B-DISEASE
's	I-DISEASE
anomaly	I-DISEASE
.	O
In	O
this	O
report	O
we	O
describe	O
the	O
case	O
of	O
a	O
37	O
-	O
year	O
-	O
old	O
white	O
woman	O
with	O
Ebstein	B-DISEASE
's	I-DISEASE
anomaly	I-DISEASE
,	O
who	O
developed	O
a	O
rare	O
syndrome	B-DISEASE
called	O
platypnea	B-DISEASE
-	O
orthodeoxia	B-DISEASE
,	O
characterized	O
by	O
massive	O
right	O
-	O
to	O
-	O
left	O
interatrial	O
shunting	O
with	O
transient	O
profound	O
hypoxia	B-DISEASE
and	O
cyanosis	B-DISEASE
.	O
This	O
shunt	O
of	O
blood	O
via	O
a	O
patent	O
foramen	O
ovale	O
occurred	O
in	O
the	O
presence	O
of	O
a	O
normal	O
pulmonary	O
artery	O
pressure	O
,	O
and	O
was	O
probably	O
precipitated	O
by	O
a	O
propafenone	O
overdose	B-DISEASE
.	O
This	O
drug	O
caused	O
biventricular	B-DISEASE
dysfunction	I-DISEASE
,	O
due	O
to	O
its	O
negative	O
inotropic	O
effect	O
,	O
and	O
hypotension	B-DISEASE
,	O
due	O
to	O
its	O
peripheral	O
vasodilatory	O
effect	O
.	O
These	O
effects	O
gave	O
rise	O
to	O
an	O
increase	O
in	O
the	O
right	O
atrial	O
pressure	O
and	O
a	O
decrease	O
in	O
the	O
left	O
one	O
with	O
a	O
consequent	O
stretching	O
of	O
the	O
foramen	O
ovale	O
and	O
the	O
creation	O
of	O
massive	O
right	O
-	O
to	O
-	O
left	O
shunting	O
.	O
In	O
our	O
case	O
this	O
interatrial	O
shunt	O
was	O
very	O
accurately	O
detected	O
at	O
bubble	O
contrast	O
echocardiography	O
.	O

A	O
Phase	O
II	O
trial	O
of	O
cisplatin	B-CHEMICAL
plus	O
WR-2721	O
(	O
amifostine	O
)	O
for	O
metastatic	O
breast	B-DISEASE
carcinoma	I-DISEASE
:	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Study	O
(	O
E8188	O
)	O
.	O
BACKGROUND	O
:	O
Cisplatin	B-CHEMICAL
has	O
minimal	O
antitumor	O
activity	O
when	O
used	O
as	O
second-	O
or	O
third	O
-	O
line	O
treatment	O
of	O
metastatic	O
breast	B-DISEASE
carcinoma	I-DISEASE
.	O
Older	O
reports	O
suggest	O
an	O
objective	O
response	O
rate	O
of	O
8	O
%	O
when	O
60	O
-	O
120	O
mg	O
/	O
m2	O
of	O
cisplatin	B-CHEMICAL
is	O
administered	O
every	O
3	O
-	O
4	O
weeks	O
.	O
Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	B-CHEMICAL
,	O
the	O
dose	O
-	O
limiting	O
toxicities	B-DISEASE
associated	O
with	O
cisplatin	B-CHEMICAL
(	O
e.g.	O
,	O
nephrotoxicity	B-DISEASE
,	O
ototoxicity	B-DISEASE
,	O
and	O
neurotoxicity	B-DISEASE
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	B-DISEASE
carcinoma	I-DISEASE
.	O
WR-2721	O
or	O
amifostine	O
initially	O
was	O
developed	O
to	O
protect	O
military	O
personnel	O
in	O
the	O
event	O
of	O
nuclear	O
war	O
.	O
Amifostine	O
subsequently	O
was	O
shown	O
to	O
protect	O
normal	O
tissues	O
from	O
the	O
toxic	O
effects	O
of	O
alkylating	B-CHEMICAL
agents	I-CHEMICAL
and	O
cisplatin	B-CHEMICAL
without	O
decreasing	O
the	O
antitumor	O
effect	O
of	O
the	O
chemotherapy	O
.	O
Early	O
trials	O
of	O
cisplatin	B-CHEMICAL
and	O
amifostine	O
also	O
suggested	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin	B-CHEMICAL
-	O
induced	O
nephrotoxicity	B-DISEASE
,	O
ototoxicity	B-DISEASE
,	O
and	O
neuropathy	B-DISEASE
were	O
reduced	O
.	O
METHODS	O
:	O
A	O
Phase	O
II	O
study	O
of	O
the	O
combination	O
of	O
cisplatin	B-CHEMICAL
plus	O
amifostine	O
was	O
conducted	O
in	O
patients	O
with	O
progressive	O
metastatic	O
breast	B-DISEASE
carcinoma	I-DISEASE
who	O
had	O
received	O
one	O
,	O
but	O
not	O
more	O
than	O
one	O
,	O
chemotherapy	O
regimen	O
for	O
metastatic	O
disease	B-DISEASE
.	O
Patients	O
received	O
amifostine	O
,	O
910	O
mg	O
/	O
m2	O
intravenously	O
over	O
15	O
minutes	O
.	O
After	O
completion	O
of	O
the	O
amifostine	O
infusion	O
,	O
cisplatin	B-CHEMICAL
120	O
mg	O
/	O
m2	O
was	O
administered	O
over	O
30	O
minutes	O
.	O
Intravenous	O
hydration	O
and	O
mannitol	B-CHEMICAL
was	O
administered	O
before	O
and	O
after	O
cisplatin	B-CHEMICAL
.	O
Treatment	O
was	O
administered	O
every	O
3	O
weeks	O
until	O
disease	B-DISEASE
progression	I-DISEASE
.	O
RESULTS	O
:	O
Forty	O
-	O
four	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
of	O
which	O
7	O
(	O
16	O
%	O
)	O
were	O
ineligible	O
.	O
A	O
median	O
of	O
2	O
cycles	O
of	O
therapy	O
was	O
administered	O
to	O
the	O
37	O
eligible	O
patients	O
.	O
Six	O
partial	O
responses	O
were	O
observed	O
for	O
an	O
overall	O
response	O
rate	O
of	O
16	O
%	O
.	O
Most	O
patients	O
(	O
57	O
%	O
)	O
stopped	O
treatment	O
because	O
of	O
disease	B-DISEASE
progression	I-DISEASE
.	O
Neurologic	O
toxicity	B-DISEASE
was	O
reported	O
in	O
52	O
%	O
of	O
patients	O
.	O
Seven	O
different	O
life	O
-	O
threatening	O
toxicities	B-DISEASE
were	O
observed	O
in	O
patients	O
while	O
receiving	O
treatment	O
.	O
CONCLUSIONS	O
:	O
The	O
combination	O
of	O
cisplatin	B-CHEMICAL
and	O
amifostine	O
in	O
this	O
study	O
resulted	O
in	O
an	O
overall	O
response	O
rate	O
of	O
16	O
%	O
.	O
Neither	O
a	O
tumor	B-DISEASE
-	O
protective	O
effect	O
nor	O
reduced	O
toxicity	B-DISEASE
to	O
normal	O
tissues	O
was	O
observed	O
with	O
the	O
addition	O
of	O
amifostine	O
to	O
cisplatin	B-CHEMICAL
in	O
this	O
trial	O
.	O

Warfarin	B-CHEMICAL
-	O
induced	O
iliopsoas	O
hemorrhage	B-DISEASE
with	O
subsequent	O
femoral	B-DISEASE
nerve	I-DISEASE
palsy	I-DISEASE
.	O
We	O
present	O
the	O
case	O
of	O
a	O
28	O
-	O
year	O
-	O
old	O
man	O
on	O
chronic	O
warfarin	B-CHEMICAL
therapy	O
who	O
sustained	O
a	O
minor	O
muscle	O
tear	O
and	O
developed	O
increasing	O
pain	B-DISEASE
and	O
a	O
flexure	O
contracture	B-DISEASE
of	O
the	O
right	O
hip	O
.	O
Surgical	O
exploration	O
revealed	O
an	O
iliopsoas	O
hematoma	B-DISEASE
and	O
femoral	O
nerve	O
entrapment	O
,	O
resulting	O
in	O
a	O
femoral	B-DISEASE
nerve	I-DISEASE
palsy	I-DISEASE
and	O
partial	O
loss	O
of	O
quadriceps	O
functions	O
.	O
Anticoagulant	O
-	O
induced	O
femoral	B-DISEASE
nerve	I-DISEASE
palsy	I-DISEASE
represents	O
the	O
most	O
common	O
form	O
of	O
warfarin	B-CHEMICAL
-	O
induced	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
;	O
it	O
is	O
characterized	O
by	O
severe	O
pain	B-DISEASE
in	O
the	O
inguinal	O
region	O
,	O
varying	O
degrees	O
of	O
motor	O
and	O
sensory	O
impairment	O
,	O
and	O
flexure	O
contracture	B-DISEASE
of	O
the	O
involved	O
extremity	O
.	O

Myasthenia	B-DISEASE
gravis	I-DISEASE
caused	O
by	O
penicillamine	B-CHEMICAL
and	O
chloroquine	B-CHEMICAL
therapy	O
for	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
.	O
We	O
have	O
described	O
a	O
unique	O
patient	O
who	O
had	O
reversible	O
and	O
dose	O
-	O
related	O
myasthenia	B-DISEASE
gravis	I-DISEASE
after	O
penicillamine	B-CHEMICAL
and	O
chloroquine	B-CHEMICAL
therapy	O
for	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
.	O
Although	O
acetylcholine	O
receptor	O
antibodies	O
were	O
not	O
detectable	O
,	O
the	O
time	O
course	O
was	O
consistent	O
with	O
an	O
autoimmune	O
process	O
.	O

Nephrotoxicity	B-DISEASE
of	O
combined	O
cephalothin	B-CHEMICAL
-	O
gentamicin	B-CHEMICAL
regimen	O
.	O
Two	O
patients	O
developed	O
acute	B-DISEASE
tubular	I-DISEASE
necrosis	I-DISEASE
,	O
characterized	O
clinically	O
by	O
acute	O
oliguric	O
renal	B-DISEASE
failure	I-DISEASE
,	O
while	O
they	O
were	O
receiving	O
a	O
combination	O
of	O
cephalothin	B-CHEMICAL
sodium	B-CHEMICAL
and	O
gentamicin	B-CHEMICAL
sulfate	O
therapy	O
.	O
Patients	O
who	O
are	O
given	O
this	O
drug	O
regimen	O
should	O
be	O
observed	O
very	O
carefully	O
for	O
early	O
signs	O
of	O
nephrotoxicity	B-DISEASE
.	O
High	O
doses	O
of	O
this	O
antibiotic	O
combination	O
should	O
be	O
avoided	O
especially	O
in	O
elderly	O
patients	O
.	O
Patients	O
with	O
renal	B-DISEASE
insufficiency	I-DISEASE
should	O
not	O
be	O
given	O
this	O
regimen	O
.	O

Components	O
of	O
lemon	O
essential	O
oil	O
attenuate	O
dementia	B-DISEASE
induced	O
by	O
scopolamine	B-CHEMICAL
.	O
The	O
anti	O
-	O
dementia	B-DISEASE
effects	O
of	O
s	O
-	O
limonene	O
and	O
s	O
-	O
perillyl	B-CHEMICAL
alcohol	I-CHEMICAL
were	O
observed	O
using	O
the	O
passive	O
avoidance	O
test	O
(	O
PA	O
)	O
and	O
the	O
open	O
field	O
habituation	O
test	O
(	O
OFH	O
)	O
.	O
These	O
lemon	O
essential	O
oils	B-CHEMICAL
showed	O
strong	O
ability	O
to	O
improve	O
memory	O
impaired	O
by	O
scopolamine	B-CHEMICAL
;	O
however	O
,	O
s	O
-	O
perillyl	B-CHEMICAL
alcohol	I-CHEMICAL
relieved	O
the	O
deficit	B-DISEASE
of	I-DISEASE
associative	I-DISEASE
memory	I-DISEASE
in	O
PA	O
only	O
,	O
and	O
did	O
not	O
improve	O
non	O
-	O
associative	O
memory	O
significantly	O
in	O
OFH	O
.	O
Analysis	O
of	O
neurotransmitter	O
concentration	O
in	O
some	O
brain	O
regions	O
on	O
the	O
test	O
day	O
showed	O
that	O
dopamine	B-CHEMICAL
concentration	O
of	O
the	O
vehicle	O
/	O
scopolamine	B-CHEMICAL
group	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
vehicle	O
/	O
vehicle	O
group	O
,	O
but	O
this	O
phenomenon	O
was	O
reversed	O
when	O
s	O
-	O
limonene	O
or	O
s	O
-	O
perillyl	B-CHEMICAL
alcohol	I-CHEMICAL
were	O
administered	O
before	O
the	O
injection	O
of	O
scopolamine	B-CHEMICAL
.	O
Simultaneously	O
,	O
we	O
found	O
that	O
these	O
two	O
lemon	O
essential	O
oil	O
components	O
could	O
inhibit	O
acetylcholinesterase	O
activity	O
in	O
vitro	O
using	O
the	O
Ellman	O
method	O
.	O

The	O
selective	O
5	O
-	O
HT6	O
receptor	O
antagonist	O
Ro4368554	O
restores	O
memory	O
performance	O
in	O
cholinergic	O
and	O
serotonergic	O
models	O
of	O
memory	O
deficiency	O
in	O
the	O
rat	O
.	O
Antagonists	O
at	O
serotonin	B-CHEMICAL
type	O
6	O
(	O
5	O
-	O
HT(6	O
)	O
)	O
receptors	O
show	O
activity	O
in	O
models	O
of	O
learning	O
and	O
memory	O
.	O
Although	O
the	O
underlying	O
mechanism(s	O
)	O
are	O
not	O
well	O
understood	O
,	O
these	O
effects	O
may	O
involve	O
an	O
increase	O
in	O
acetylcholine	O
(	O
ACh	B-CHEMICAL
)	O
levels	O
.	O
The	O
present	O
study	O
sought	O
to	O
characterize	O
the	O
cognitive	O
-	O
enhancing	O
effects	O
of	O
the	O
5	O
-	O
HT(6	O
)	O
antagonist	O
Ro4368554	O
(	O
3	B-CHEMICAL
-	I-CHEMICAL
benzenesulfonyl-7-(4	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
piperazin-1	I-CHEMICAL
-	I-CHEMICAL
yl)1H	I-CHEMICAL
-	I-CHEMICAL
indole	I-CHEMICAL
)	O
in	O
a	O
rat	O
object	O
recognition	O
task	O
employing	O
a	O
cholinergic	O
(	O
scopolamine	B-CHEMICAL
pretreatment	O
)	O
and	O
a	O
serotonergic-	O
(	O
tryptophan	O
(	O
TRP	O
)	O
depletion	O
)	O
deficient	O
model	O
,	O
and	O
compared	O
its	O
pattern	O
of	O
action	O
with	O
that	O
of	O
the	O
acetylcholinesterase	O
inhibitor	O
metrifonate	O
.	O
Initial	O
testing	O
in	O
a	O
time	O
-	O
dependent	O
forgetting	O
task	O
employing	O
a	O
24	O
-	O
h	O
delay	O
between	O
training	O
and	O
testing	O
showed	O
that	O
metrifonate	O
improved	O
object	O
recognition	O
(	O
at	O
10	O
and	O
30	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
,	O
whereas	O
Ro4368554	O
was	O
inactive	O
.	O
Both	O
,	O
Ro4368554	O
(	O
3	O
and	O
10	O
mg	O
/	O
kg	O
,	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
)	O
and	O
metrifonate	O
(	O
10	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
,	O
respectively	O
)	O
reversed	O
memory	O
deficits	O
induced	O
by	O
scopolamine	B-CHEMICAL
and	O
TRP	O
depletion	O
(	O
10	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
,	O
and	O
3	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
,	O
respectively	O
)	O
.	O
In	O
conclusion	O
,	O
although	O
Ro4368554	O
did	O
not	O
improve	O
a	O
time	O
-	O
related	O
retention	O
deficit	O
,	O
it	O
reversed	O
a	O
cholinergic	O
and	O
a	O
serotonergic	O
memory	O
deficit	O
,	O
suggesting	O
that	O
both	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
facilitation	O
of	O
object	O
memory	O
by	O
Ro4368554	O
and	O
,	O
possibly	O
,	O
other	O
5	O
-	O
HT(6	O
)	O
receptor	O
antagonists	O
.	O

Lone	O
atrial	B-DISEASE
fibrillation	I-DISEASE
associated	O
with	O
creatine	B-CHEMICAL
monohydrate	O
supplementation	O
.	O
Atrial	B-DISEASE
fibrillation	I-DISEASE
in	O
young	O
patients	O
without	O
structural	O
heart	B-DISEASE
disease	I-DISEASE
is	O
rare	O
.	O
Therefore	O
,	O
when	O
the	O
arrhythmia	B-DISEASE
is	O
present	O
in	O
this	O
population	O
,	O
reversible	O
causes	O
must	O
be	O
identified	O
and	O
resolved	O
.	O
Thyroid	B-DISEASE
disorders	I-DISEASE
,	O
illicit	O
drug	O
or	O
stimulant	O
use	O
,	O
and	O
acute	B-DISEASE
alcohol	I-DISEASE
intoxication	I-DISEASE
are	O
among	O
these	O
causes	O
.	O
We	O
report	O
the	O
case	O
of	O
a	O
30	O
-	O
year	O
-	O
old	O
Caucasian	O
man	O
who	O
came	O
to	O
the	O
emergency	B-DISEASE
department	I-DISEASE
in	O
atrial	B-DISEASE
fibrillation	I-DISEASE
with	O
rapid	O
ventricular	O
response	O
.	O
His	O
medical	O
history	O
was	O
unremarkable	O
,	O
except	O
for	O
minor	O
fractures	B-DISEASE
of	O
the	O
fingers	O
and	O
foot	O
.	O
Thyroid	O
-	O
stimulating	O
hormone	O
,	O
magnesium	B-CHEMICAL
,	O
and	O
potassium	B-CHEMICAL
levels	O
were	O
within	O
normal	O
limits	O
,	O
urine	O
drug	O
screen	O
was	O
negative	O
,	O
and	O
alcohol	O
use	O
was	O
denied	O
.	O
However	O
,	O
when	O
the	O
patient	O
was	O
questioned	O
about	O
use	O
of	O
herbal	O
products	O
and	O
supplements	O
,	O
the	O
use	O
of	O
creatine	B-CHEMICAL
monohydrate	O
was	O
revealed	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
,	O
anticoagulated	O
with	O
unfractionated	O
heparin	B-CHEMICAL
,	O
and	O
given	O
intravenous	O
diltiazem	B-CHEMICAL
for	O
rate	O
control	O
and	O
intravenous	O
amiodarone	B-CHEMICAL
for	O
rate	O
and	O
rhythm	O
control	O
.	O
When	O
discharged	O
less	O
than	O
24	O
hours	O
later	O
,	O
he	O
was	O
receiving	O
metoprolol	B-CHEMICAL
and	O
aspirin	O
,	O
with	O
follow	O
-	O
up	O
plans	O
for	O
echocardiography	O
and	O
nuclear	O
imaging	O
to	O
assess	O
perfusion	O
.	O
Exogenous	O
creatine	B-CHEMICAL
is	O
used	O
by	O
athletes	O
to	O
theoretically	O
improve	O
exercise	O
performance	O
.	O
Vegetarians	O
may	O
also	O
take	O
creatine	B-CHEMICAL
to	O
replace	O
what	O
they	O
are	O
not	O
consuming	O
from	O
meat	O
,	O
fish	O
,	O
and	O
other	O
animal	O
products	O
.	O
Previous	O
anecdotal	O
reports	O
have	O
linked	O
creatine	B-CHEMICAL
to	O
the	O
development	O
of	O
arrhythmia	B-DISEASE
.	O
Clinicians	O
must	O
be	O
diligent	O
when	O
interviewing	O
patients	O
about	O
their	O
drug	O
therapy	O
histories	O
and	O
include	O
questions	O
about	O
their	O
use	O
of	O
herbal	O
products	O
and	O
dietary	O
supplements	O
.	O
In	O
addition	O
,	O
it	O
is	O
important	O
to	O
report	O
adverse	O
effects	O
associated	O
with	O
frequently	O
consumed	O
supplements	O
and	O
herbal	O
products	O
to	O
the	O
Food	O
and	O
Drug	O
Administration	O
and	O
in	O
the	O
literature	O
.	O

Comparison	O
of	O
developmental	O
toxicity	B-DISEASE
of	O
selective	O
and	O
non	O
-	O
selective	O
cyclooxygenase-2	O
inhibitors	O
in	O
CRL:(WI)WUBR	O
Wistar	O
rats	O
--	O
DFU	O
and	O
piroxicam	B-CHEMICAL
study	O
.	O
BACKGROUND	O
:	O
Cyclooxygenase	O
(	O
COX	O
)	O
inhibitors	O
are	O
one	O
of	O
the	O
most	O
often	O
ingested	O
drugs	O
during	O
pregnancy	O
.	O
Unlike	O
general	O
toxicity	B-DISEASE
data	O
,	O
their	O
prenatal	O
toxic	O
effects	O
were	O
not	O
extensively	O
studied	O
before	O
.	O
The	O
aim	O
of	O
the	O
experiment	O
was	O
to	O
evaluate	O
the	O
developmental	O
toxicity	B-DISEASE
of	O
the	O
non	O
-	O
selective	O
(	O
piroxicam	B-CHEMICAL
)	O
and	O
selective	O
(	O
DFU	O
;	O
5,5	B-CHEMICAL
-	I-CHEMICAL
dimethyl-3-(3	I-CHEMICAL
-	I-CHEMICAL
fluorophenyl)-4-(4	I-CHEMICAL
-	I-CHEMICAL
methylsulphonyl	I-CHEMICAL
)	I-CHEMICAL
phenyl-2(5H)-furanon	I-CHEMICAL
)	O
COX-2	O
inhibitors	O
.	O
METHODS	O
:	O
Drugs	O
were	O
separately	O
,	O
orally	O
once	O
daily	O
dosed	O
to	O
pregnant	O
rats	O
from	O
day	O
8	O
to	O
21	O
(	O
GD1	O
=	O
plug	O
day	O
)	O
.	O
Doses	O
were	O
set	O
at	O
0.3	O
,	O
3.0	O
and	O
30.0mg	O
/	O
kg	O
for	O
piroxicam	B-CHEMICAL
and	O
0.2	O
,	O
2.0	O
and	O
20.0mg	O
/	O
kg	O
for	O
DFU	O
.	O
Fetuses	O
were	O
delivered	O
on	O
GD	O
21	O
and	O
routinely	O
examined	O
.	O
Comprehensive	O
clinical	O
and	O
developmental	O
measurements	O
were	O
done	O
.	O
The	O
pooled	O
statistical	O
analysis	O
for	O
ventricular	O
septal	O
(	O
VSD	B-DISEASE
)	O
and	O
midline	O
(	O
MD	O
)	O
defects	O
was	O
performed	O
for	O
rat	O
fetuses	O
exposed	O
to	O
piroxicam	B-CHEMICAL
,	O
selective	O
and	O
non	O
-	O
selective	O
COX-2	O
inhibitor	O
based	O
on	O
present	O
and	O
historic	O
data	O
.	O
RESULTS	O
:	O
Maternal	O
toxicity	B-DISEASE
,	O
intrauterine	O
growth	O
retardation	O
,	O
and	O
increase	O
of	O
external	O
and	O
skeletal	O
variations	O
were	O
found	O
in	O
rats	O
treated	O
with	O
the	O
highest	O
dose	O
of	O
piroxicam	B-CHEMICAL
.	O
Decrease	O
of	O
fetal	O
length	O
was	O
the	O
only	O
signs	O
of	O
the	O
DFU	O
developmental	O
toxicity	B-DISEASE
observed	O
in	O
pups	O
exposed	O
to	O
the	O
highest	O
compound	O
dose	O
.	O
Lack	O
of	O
teratogenicity	O
was	O
found	O
in	O
piroxicam	B-CHEMICAL
and	O
DFU	O
-	O
exposed	O
groups	O
.	O
Prenatal	O
exposure	O
to	O
non	O
-	O
selective	O
COX	O
inhibitors	O
increases	O
the	O
risk	O
of	O
VSD	B-DISEASE
and	O
MD	O
when	O
compared	O
to	O
historic	O
control	O
but	O
not	O
with	O
selective	O
COX-2	O
inhibitors	O
.	O
CONCLUSION	O
:	O
Both	O
selective	O
and	O
non	O
-	O
selective	O
COX-2	O
inhibitors	O
were	O
toxic	O
for	O
rats	O
fetuses	O
when	O
administered	O
in	O
the	O
highest	O
dose	O
.	O
Unlike	O
DFU	O
,	O
piroxicam	B-CHEMICAL
was	O
also	O
highly	O
toxic	O
to	O
the	O
dams	O
.	O
Prenatal	O
exposure	O
to	O
selective	O
COX-2	O
inhibitors	O
does	O
not	O
increase	O
the	O
risk	O
of	O
ventricular	O
septal	O
and	O
midline	O
defects	O
in	O
rat	O
when	O
compared	O
to	O
non	O
-	O
selective	O
drugs	O
and	O
historic	O
control	O
.	O

Protective	O
efficacy	O
of	O
neuroactive	O
steroids	B-CHEMICAL
against	O
cocaine	B-CHEMICAL
kindled	O
-	O
seizures	B-DISEASE
in	O
mice	O
.	O
Neuroactive	O
steroids	B-CHEMICAL
demonstrate	O
pharmacological	O
actions	O
that	O
have	O
relevance	O
for	O
a	O
host	O
of	O
neurological	O
and	O
psychiatric	B-DISEASE
disorders	O
.	O
They	O
offer	O
protection	O
against	O
seizures	B-DISEASE
in	O
a	O
range	O
of	O
models	O
and	O
seem	O
to	O
inhibit	O
certain	O
stages	O
of	O
drug	B-DISEASE
dependence	I-DISEASE
in	O
preclinical	O
assessments	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	B-CHEMICAL
that	O
positively	O
modulate	O
the	O
gamma	B-CHEMICAL
-	I-CHEMICAL
aminobutyric	I-CHEMICAL
acid	I-CHEMICAL
(	O
GABA(A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	B-CHEMICAL
engendered	O
by	O
repeated	O
cocaine	B-CHEMICAL
administration	O
(	O
seizure	B-DISEASE
kindling	O
)	O
.	O
Allopregnanolone	O
(	O
3alpha	B-CHEMICAL
-	I-CHEMICAL
hydroxy-5alpha	I-CHEMICAL
-	I-CHEMICAL
pregnan-20	I-CHEMICAL
-	I-CHEMICAL
one	I-CHEMICAL
)	O
,	O
pregnanolone	B-CHEMICAL
(	O
3alpha	B-CHEMICAL
-	I-CHEMICAL
hydroxy-5beta	I-CHEMICAL
-	I-CHEMICAL
pregnan-20	I-CHEMICAL
-	I-CHEMICAL
one	I-CHEMICAL
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
3alpha	B-CHEMICAL
-	I-CHEMICAL
hydroxy-3beta	I-CHEMICAL
-	I-CHEMICAL
methyl-5alpha	I-CHEMICAL
-	I-CHEMICAL
pregnan-20	I-CHEMICAL
-	I-CHEMICAL
one	I-CHEMICAL
)	O
were	O
tested	O
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	B-CHEMICAL
-	O
kindled	O
seizures	B-DISEASE
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O
Kindled	O
seizures	B-DISEASE
were	O
induced	O
by	O
daily	O
administration	O
of	O
60	O
mg	O
/	O
kg	O
cocaine	B-CHEMICAL
for	O
5	O
days	O
.	O
All	O
of	O
these	O
positive	O
GABA(A	O
)	O
modulators	O
suppressed	O
the	O
expression	O
of	O
kindled	O
seizures	B-DISEASE
,	O
whereas	O
only	O
allopregnanolone	O
and	O
ganaxolone	O
inhibited	O
the	O
development	O
of	O
kindling	O
.	O
Allopregnanolone	O
and	O
pregnanolone	B-CHEMICAL
,	O
but	O
not	O
ganaxolone	O
,	O
also	O
reduced	O
cumulative	O
lethality	O
associated	O
with	O
kindling	O
.	O
These	O
findings	O
demonstrate	O
that	O
some	O
neuroactive	O
steroids	B-CHEMICAL
attenuate	O
convulsant	O
and	O
sensitizing	O
properties	O
of	O
cocaine	B-CHEMICAL
and	O
add	O
to	O
a	O
growing	O
literature	O
on	O
their	O
potential	O
use	O
in	O
the	O
modulation	O
of	O
effects	O
of	O
drugs	O
of	O
abuse	O
.	O

Kidney	O
function	O
and	O
morphology	O
after	O
short	O
-	O
term	O
combination	O
therapy	O
with	O
cyclosporine	B-CHEMICAL
A	O
,	O
tacrolimus	B-CHEMICAL
and	O
sirolimus	B-CHEMICAL
in	O
the	O
rat	O
.	O
BACKGROUND	O
:	O
Sirolimus	B-CHEMICAL
(	O
SRL	O
)	O
may	O
supplement	O
calcineurin	B-CHEMICAL
inhibitors	I-CHEMICAL
in	O
clinical	O
organ	O
transplantation	O
.	O
These	O
are	O
nephrotoxic	B-DISEASE
,	O
but	O
SRL	O
seems	O
to	O
act	O
differently	O
displaying	O
only	O
minor	O
nephrotoxic	B-DISEASE
effects	O
,	O
although	O
this	O
question	O
is	O
still	O
open	O
.	O
In	O
a	O
number	O
of	O
treatment	O
protocols	O
where	O
SRL	O
was	O
combined	O
with	O
a	O
calcineurin	O
inhibitor	O
indications	O
of	O
a	O
synergistic	O
nephrotoxic	B-DISEASE
effect	O
were	O
described	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
further	O
the	O
renal	O
function	O
,	O
including	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
either	O
cyclosporine	B-CHEMICAL
A	O
(	O
CsA	O
)	O
,	O
tacrolimus	B-CHEMICAL
(	O
FK506	O
)	O
or	O
SRL	O
as	O
monotherapies	O
or	O
in	O
different	O
combinations	O
.	O
METHODS	O
:	O
For	O
a	O
period	O
of	O
2	O
weeks	O
,	O
CsA	O
15	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
orally	O
)	O
,	O
FK506	O
3.0	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
orally	O
)	O
or	O
SRL	O
0.4	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
intraperitoneally	O
)	O
was	O
administered	O
once	O
a	O
day	O
as	O
these	O
doses	O
have	O
earlier	O
been	O
found	O
to	O
achieve	O
a	O
significant	O
immunosuppressive	O
effect	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
.	O
In	O
the	O
'	O
conscious	O
catheterized	O
rat	O
'	O
model	O
,	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
was	O
measured	O
as	O
the	O
clearance	O
of	O
Cr(EDTA	O
)	O
.	O
The	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
included	O
a	O
semi	O
-	O
quantitative	O
scoring	O
system	O
analysing	O
the	O
degree	O
of	O
striped	O
fibrosis	B-DISEASE
,	O
subcapsular	O
fibrosis	B-DISEASE
and	O
the	O
number	O
of	O
basophilic	O
tubules	O
,	O
plus	O
an	O
additional	O
stereological	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	B-DISEASE
in	O
the	O
cortex	O
stained	O
with	O
Sirius	O
Red	O
.	O
RESULTS	O
:	O
CsA	O
,	O
FK506	O
and	O
SRL	O
all	O
significantly	O
decreased	O
the	O
GFR	O
.	O
A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	O
was	O
combined	O
with	O
either	O
FK506	O
or	O
SRL	O
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	O
with	O
FK506	O
plus	O
SRL	O
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances	O
.	O
The	O
morphological	O
changes	O
presented	O
a	O
similar	O
pattern	O
.	O
The	O
semi	O
-	O
quantitative	O
scoring	O
was	O
significantly	O
worst	O
in	O
the	O
group	O
treated	O
with	O
CsA	O
plus	O
SRL	O
(	O
P<0.001	O
compared	O
with	O
controls	O
)	O
and	O
the	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	B-DISEASE
also	O
showed	O
the	O
highest	O
proportion	O
in	O
the	O
same	O
group	O
and	O
was	O
significantly	O
different	O
from	O
controls	O
(	O
P<0.02	O
)	O
.	O
The	O
FK506	O
plus	O
SRL	O
combination	O
showed	O
only	O
a	O
marginally	O
higher	O
degree	O
of	O
fibrosis	B-DISEASE
as	O
compared	O
with	O
controls	O
(	O
P=0.05	O
)	O
.	O
CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	O
a	O
synergistic	O
nephrotoxic	B-DISEASE
effect	O
of	O
CsA	O
plus	O
SRL	O
,	O
whereas	O
FK506	O
plus	O
SRL	O
was	O
better	O
tolerated	O
.	O

Effect	O
of	O
fucoidan	O
treatment	O
on	O
collagenase	O
-	O
induced	O
intracerebral	O
hemorrhage	B-DISEASE
in	O
rats	O
.	O
Inflammatory	O
cells	O
are	O
postulated	O
to	O
mediate	O
some	O
of	O
the	O
brain	B-DISEASE
damage	I-DISEASE
following	O
ischemic	B-DISEASE
stroke	I-DISEASE
.	O
Intracerebral	O
hemorrhage	B-DISEASE
is	O
associated	O
with	O
more	O
inflammation	B-DISEASE
than	O
ischemic	B-DISEASE
stroke	I-DISEASE
.	O
We	O
tested	O
the	O
sulfated	O
polysaccharide	O
fucoidan	O
,	O
which	O
has	O
been	O
reported	O
to	O
reduce	O
inflammatory	O
brain	B-DISEASE
damage	I-DISEASE
,	O
in	O
a	O
rat	O
model	O
of	O
intracerebral	O
hemorrhage	B-DISEASE
induced	O
by	O
injection	O
of	O
bacterial	O
collagenase	O
into	O
the	O
caudate	O
nucleus	O
.	O
Rats	O
were	O
treated	O
with	O
seven	O
day	O
intravenous	O
infusion	O
of	O
fucoidan	O
(	O
30	O
micrograms	O
h-1	O
)	O
or	O
vehicle	O
.	O
The	O
hematoma	B-DISEASE
was	O
assessed	O
in	O
vivo	O
by	O
magnetic	O
resonance	O
imaging	O
.	O
Motor	O
behavior	O
,	O
passive	O
avoidance	O
,	O
and	O
skilled	O
forelimb	O
function	O
were	O
tested	O
repeatedly	O
for	O
six	O
weeks	O
.	O
Fucoidan	O
-	O
treated	O
rats	O
exhibited	O
evidence	O
of	O
impaired	O
blood	O
clotting	O
and	O
hemodilution	O
,	O
had	O
larger	O
hematomas	O
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	B-DISEASE
in	O
the	O
vicinity	O
of	O
the	O
hematoma	B-DISEASE
after	O
three	O
days	O
.	O
They	O
showed	O
significantly	O
more	O
rapid	O
improvement	O
of	O
motor	O
function	O
in	O
the	O
first	O
week	O
following	O
hemorrhage	B-DISEASE
and	O
better	O
memory	O
retention	O
in	O
the	O
passive	O
avoidance	O
test	O
.	O
Acute	O
white	O
matter	O
edema	B-DISEASE
and	O
eventual	O
neuronal	O
loss	O
in	O
the	O
striatum	O
adjacent	O
to	O
the	O
hematoma	B-DISEASE
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
.	O
Investigation	O
of	O
more	O
specific	O
anti	O
-	O
inflammatory	O
agents	O
and	O
hemodiluting	O
agents	O
are	O
warranted	O
in	O
intracerebral	O
hemorrhage	B-DISEASE
.	O

Paracetamol	B-CHEMICAL
-	O
associated	O
coma	B-DISEASE
,	O
metabolic	B-DISEASE
acidosis	I-DISEASE
,	O
renal	O
and	O
hepatic	O
failure	O
.	O
A	O
case	O
of	O
metabolic	B-DISEASE
acidosis	I-DISEASE
,	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
and	O
hepatic	O
failure	O
following	O
paracetamol	B-CHEMICAL
ingestion	O
is	O
presented	O
.	O
The	O
diagnostic	O
difficulty	O
at	O
presentation	O
is	O
highlighted	O
.	O
Continuous	O
arteriovenous	O
haemofiltration	O
proved	O
a	O
valuable	O
means	O
of	O
maintaining	O
fluid	O
and	O
electrolyte	O
balance	O
.	O
The	O
patient	O
recovered	O
.	O

Hepatic	O
reactions	O
associated	O
with	O
ketoconazole	B-CHEMICAL
in	O
the	O
United	O
Kingdom	O
.	O
Ketoconazole	B-CHEMICAL
was	O
introduced	O
in	O
the	O
United	O
Kingdom	O
in	O
1981	O
.	O
By	O
November	O
1984	O
the	O
Committee	O
on	O
Safety	O
of	O
Medicines	O
had	O
received	O
82	O
reports	O
of	O
possible	O
hepatotoxicity	O
associated	O
with	O
the	O
drug	O
,	O
including	O
five	O
deaths	B-DISEASE
.	O
An	O
analysis	O
of	O
the	O
75	O
cases	O
that	O
had	O
been	O
adequately	O
followed	O
up	O
suggested	O
that	O
16	O
,	O
including	O
three	O
deaths	B-DISEASE
,	O
were	O
probably	O
related	O
to	O
treatment	O
with	O
the	O
drug	O
.	O
Of	O
the	O
remainder	O
,	O
48	O
were	O
possibly	O
related	O
to	O
treatment	O
,	O
five	O
were	O
unlikely	O
to	O
be	O
so	O
,	O
and	O
six	O
were	O
unclassifiable	O
.	O
The	O
mean	O
age	O
of	O
patients	O
in	O
the	O
16	O
probable	O
cases	O
was	O
57.9	O
,	O
with	O
hepatotoxicity	O
being	O
more	O
common	O
in	O
women	O
.	O
The	O
average	O
duration	O
of	O
treatment	O
before	O
the	O
onset	O
of	O
jaundice	B-DISEASE
was	O
61	O
days	O
.	O
None	O
of	O
these	O
well	O
validated	O
cases	O
occurred	O
within	O
the	O
first	O
10	O
days	O
after	O
treatment	O
.	O
The	O
results	O
of	O
serum	O
liver	O
function	O
tests	O
suggested	O
hepatocellular	O
injury	O
in	O
10	O
(	O
63	O
%	O
)	O
;	O
the	O
rest	O
showed	O
a	O
mixed	O
pattern	O
.	O
In	O
contrast	O
,	O
the	O
results	O
of	O
histological	O
examination	O
of	O
the	O
liver	O
often	O
showed	O
evidence	O
of	O
cholestasis	B-DISEASE
.	O
The	O
characteristics	O
of	O
the	O
48	O
patients	O
in	O
the	O
possible	O
cases	O
were	O
similar	O
.	O
Allergic	B-DISEASE
manifestations	O
such	O
as	O
rash	B-DISEASE
and	O
eosinophilia	B-DISEASE
were	O
rare	O
.	O
Hepatitis	B-DISEASE
was	O
usually	O
reversible	O
when	O
treatment	O
was	O
stopped	O
,	O
with	O
the	O
results	O
of	O
liver	O
function	O
tests	O
returning	O
to	O
normal	O
after	O
an	O
average	O
of	O
3.1	O
months	O
.	O
In	O
two	O
of	O
the	O
three	O
deaths	B-DISEASE
probably	O
associated	O
with	O
ketoconazole	B-CHEMICAL
treatment	O
the	O
drug	O
had	O
been	O
continued	O
after	O
the	O
onset	O
of	O
jaundice	B-DISEASE
and	O
other	O
symptoms	O
of	O
hepatitis	B-DISEASE
.	O
Clinical	O
and	O
biochemical	O
monitoring	O
at	O
regular	O
intervals	O
for	O
evidence	O
of	O
hepatitis	B-DISEASE
is	O
advised	O
during	O
long	O
term	O
treatment	O
with	O
ketoconazole	B-CHEMICAL
to	O
prevent	O
possible	O
serious	O
hepatic	O
injury	O
.	O

Combined	O
effects	O
of	O
prolonged	O
prostaglandin	B-CHEMICAL
E1	I-CHEMICAL
-	O
induced	O
hypotension	B-DISEASE
and	O
haemodilution	O
on	O
human	O
hepatic	O
function	O
.	O
Combined	O
effects	O
of	O
prolonged	O
prostaglandin	B-CHEMICAL
E1	I-CHEMICAL
(	O
PGE1)-induced	O
hypotension	B-DISEASE
and	O
haemodilution	O
on	O
hepatic	O
function	O
were	O
studied	O
in	O
30	O
patients	O
undergoing	O
hip	O
surgery	O
.	O
The	O
patients	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
three	O
groups	O
;	O
those	O
in	O
group	O
A	O
(	O
n	O
=	O
10	O
)	O
were	O
subjected	O
to	O
controlled	O
hypotension	B-DISEASE
alone	O
,	O
those	O
in	O
group	O
B	O
(	O
n	O
=	O
10	O
)	O
to	O
haemodilution	O
alone	O
and	O
those	O
in	O
group	O
C	O
(	O
n	O
=	O
10	O
)	O
to	O
both	O
controlled	O
hypotension	B-DISEASE
and	O
haemodilution	O
.	O
Haemodilution	O
in	O
groups	O
B	O
and	O
C	O
was	O
produced	O
by	O
withdrawing	O
approximately	O
1000	O
mL	O
of	O
blood	O
and	O
replacing	O
it	O
with	O
the	O
same	O
amount	O
of	O
dextran	B-CHEMICAL
solution	O
,	O
and	O
final	O
haematocrit	O
values	O
were	O
21	O
or	O
22	O
%	O
.	O
Controlled	O
hypotension	B-DISEASE
in	O
groups	O
A	O
and	O
C	O
was	O
induced	O
with	O
PGE1	O
to	O
maintain	O
mean	O
arterial	O
blood	O
pressure	O
at	O
55	O
mmHg	O
for	O
180	O
min	O
.	O
Measurements	O
included	O
arterial	O
ketone	O
body	O
ratio	O
(	O
AKBR	O
,	O
aceto	O
-	O
acetate/3	O
-	O
hydroxybutyrate	O
)	O
and	O
clinical	O
hepatic	O
function	O
parameters	O
.	O
AKBR	O
and	O
biological	O
hepatic	O
function	O
tests	O
showed	O
no	O
change	O
throughout	O
the	O
time	O
course	O
in	O
groups	O
A	O
and	O
B.	O
In	O
group	O
C	O
,	O
AKBR	O
showed	O
a	O
significant	O
decrease	O
at	O
120	O
min	O
(	O
-40	O
%	O
)	O
and	O
at	O
180	O
min	O
(	O
-49	O
%	O
)	O
after	O
the	O
start	O
of	O
hypotension	B-DISEASE
and	O
at	O
60	O
min	O
(	O
-32	O
%	O
)	O
after	O
recovery	O
of	O
normotension	O
,	O
and	O
SGOT	O
,	O
SGPT	O
,	O
LDH	O
and	O
total	O
bilirubin	O
showed	O
significant	O
increases	O
after	O
operation	O
.	O
The	O
results	O
suggest	O
that	O
a	O
prolonged	O
combination	O
of	O
more	O
than	O
120	O
min	O
of	O
PGE1	O
-	O
induced	O
hypotension	B-DISEASE
and	O
moderate	O
haemodilution	O
would	O
cause	O
impairment	O
of	O
hepatic	O
function	O
.	O

Levodopa	B-CHEMICAL
-	O
induced	O
dyskinesias	B-DISEASE
in	O
patients	O
with	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
:	O
filling	O
the	O
bench	O
-	O
to	O
-	O
bedside	O
gap	O
.	O
Levodopa	B-CHEMICAL
is	O
the	O
most	O
effective	O
drug	O
for	O
the	O
treatment	O
of	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
.	O
However	O
,	O
the	O
long	O
-	O
term	O
use	O
of	O
this	O
dopamine	B-CHEMICAL
precursor	O
is	O
complicated	O
by	O
highly	O
disabling	O
fluctuations	O
and	O
dyskinesias	B-DISEASE
.	O
Although	O
preclinical	O
and	O
clinical	O
findings	O
suggest	O
pulsatile	O
stimulation	O
of	O
striatal	O
postsynaptic	O
receptors	O
as	O
a	O
key	O
mechanism	O
underlying	O
levodopa	B-CHEMICAL
-	O
induced	O
dyskinesias	B-DISEASE
,	O
their	O
pathogenesis	O
is	O
still	O
unclear	O
.	O
In	O
recent	O
years	O
,	O
evidence	O
from	O
animal	O
models	O
of	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
has	O
provided	O
important	O
information	O
to	O
understand	O
the	O
effect	O
of	O
specific	O
receptor	O
and	O
post	O
-	O
receptor	O
molecular	O
mechanisms	O
underlying	O
the	O
development	O
of	O
dyskinetic	B-DISEASE
movements	I-DISEASE
.	O
Recent	O
preclinical	O
and	O
clinical	O
data	O
from	O
promising	O
lines	O
of	O
research	O
focus	O
on	O
the	O
differential	O
role	O
of	O
presynaptic	O
versus	O
postsynaptic	O
mechanisms	O
,	O
dopamine	B-CHEMICAL
receptor	O
subtypes	O
,	O
ionotropic	O
and	O
metabotropic	O
glutamate	B-CHEMICAL
receptors	O
,	O
and	O
non	O
-	O
dopaminergic	O
neurotransmitter	O
systems	O
in	O
the	O
pathophysiology	O
of	O
levodopa	B-CHEMICAL
-	O
induced	O
dyskinesias	B-DISEASE
.	O

Prevention	O
of	O
seizures	B-DISEASE
and	O
reorganization	O
of	O
hippocampal	O
functions	O
by	O
transplantation	O
of	O
bone	O
marrow	O
cells	O
in	O
the	O
acute	O
phase	O
of	O
experimental	O
epilepsy	B-DISEASE
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
therapeutic	O
potential	O
of	O
bone	O
marrow	O
mononuclear	O
cells	O
(	O
BMCs	O
)	O
in	O
a	O
model	O
of	O
epilepsy	B-DISEASE
induced	O
by	O
pilocarpine	B-CHEMICAL
in	O
rats	O
.	O
BMCs	O
obtained	O
from	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
transgenic	O
mice	O
or	O
rats	O
were	O
transplanted	O
intravenously	O
after	O
induction	O
of	O
status	B-DISEASE
epilepticus	I-DISEASE
(	O
SE	B-DISEASE
)	O
.	O
Spontaneous	B-DISEASE
recurrent	I-DISEASE
seizures	I-DISEASE
(	O
SRS	B-DISEASE
)	O
were	O
monitored	O
using	O
Racine	O
's	O
seizure	B-DISEASE
severity	O
scale	O
.	O
All	O
of	O
the	O
rats	O
in	O
the	O
saline	O
-	O
treated	O
epileptic	B-DISEASE
control	O
group	O
developed	O
SRS	B-DISEASE
,	O
whereas	O
none	O
of	O
the	O
BMC	O
-	O
treated	O
epileptic	B-DISEASE
animals	O
had	O
seizures	B-DISEASE
in	O
the	O
short	O
term	O
(	O
15	O
days	O
after	O
transplantation	O
)	O
,	O
regardless	O
of	O
the	O
BMC	O
source	O
.	O
Over	O
the	O
long	O
-	O
term	O
chronic	O
phase	O
(	O
120	O
days	O
after	O
transplantation	O
)	O
,	O
only	O
25	O
%	O
of	O
BMC	O
-	O
treated	O
epileptic	B-DISEASE
animals	O
had	O
seizures	B-DISEASE
,	O
but	O
with	O
a	O
lower	O
frequency	O
and	O
duration	O
compared	O
to	O
the	O
epileptic	B-DISEASE
control	O
group	O
.	O
The	O
density	O
of	O
hippocampal	O
neurons	O
in	O
the	O
brains	O
of	O
animals	O
treated	O
with	O
BMCs	O
was	O
markedly	O
preserved	O
.	O
At	O
hippocampal	O
Schaeffer	O
collateral	O
-	O
CA1	O
synapses	O
,	O
long	O
-	O
term	O
potentiation	O
was	O
preserved	O
in	O
BMC	O
-	O
transplanted	O
rats	O
compared	O
to	O
epileptic	B-DISEASE
controls	O
.	O
The	O
donor	O
-	O
derived	O
GFP(+	O
)	O
cells	O
were	O
rarely	O
found	O
in	O
the	O
brains	O
of	O
transplanted	O
epileptic	B-DISEASE
rats	O
.	O
In	O
conclusion	O
,	O
treatment	O
with	O
BMCs	O
can	O
prevent	O
the	O
development	O
of	O
chronic	O
seizures	B-DISEASE
,	O
reduce	O
neuronal	O
loss	O
,	O
and	O
influence	O
the	O
reorganization	O
of	O
the	O
hippocampal	O
neuronal	O
network	O
.	O

Cardioprotective	O
effect	O
of	O
salvianolic	B-CHEMICAL
acid	I-CHEMICAL
A	I-CHEMICAL
on	O
isoproterenol	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
in	O
rats	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
cardioprotective	O
potential	O
of	O
salvianolic	B-CHEMICAL
acid	I-CHEMICAL
A	I-CHEMICAL
on	O
isoproterenol	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
in	O
rats	O
.	O
Hemodynamic	O
parameters	O
and	O
lead	O
II	O
electrocardiograph	O
were	O
monitored	O
and	O
recorded	O
continuously	O
.	O
Cardiac	O
marker	O
enzymes	O
and	O
antioxidative	O
parameters	O
in	O
serum	O
and	O
heart	O
tissues	O
were	O
measured	O
.	O
Assay	O
for	O
mitochondrial	O
respiratory	O
function	O
and	O
histopathological	O
examination	O
of	O
heart	O
tissues	O
were	O
performed	O
.	O
Isoproterenol	B-CHEMICAL
-	O
treated	O
rats	O
showed	O
significant	O
increases	O
in	O
the	O
levels	O
of	O
lactate	O
dehydrogenase	O
,	O
aspartate	O
transaminase	O
,	O
creatine	B-CHEMICAL
kinase	O
and	O
malondialdehyde	B-CHEMICAL
and	O
significant	O
decreases	O
in	O
the	O
activities	O
of	O
superoxide	B-CHEMICAL
dismutase	O
,	O
catalase	O
and	O
glutathione	B-CHEMICAL
peroxidase	O
in	O
serum	O
and	O
heart	O
.	O
These	O
rats	O
also	O
showed	O
declines	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
,	O
maximum	O
and	O
minimum	O
rate	O
of	O
developed	O
left	O
ventricular	O
pressure	O
,	O
and	O
elevation	O
of	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
and	O
ST	O
-	O
segment	O
.	O
In	O
addition	O
,	O
mitochondrial	O
respiratory	O
dysfunction	O
characterized	O
by	O
decreased	O
respiratory	O
control	O
ratio	O
and	O
ADP	B-CHEMICAL
/	O
O	O
was	O
observed	O
in	O
isoproterenol	B-CHEMICAL
-	O
treated	O
rats	O
.	O
Administration	O
of	O
salvianolic	B-CHEMICAL
acid	I-CHEMICAL
A	I-CHEMICAL
for	O
a	O
period	O
of	O
8	O
days	O
significantly	O
attenuated	O
isoproterenol	B-CHEMICAL
-	O
induced	O
cardiac	B-DISEASE
dysfunction	I-DISEASE
and	O
myocardial	B-DISEASE
injury	I-DISEASE
and	O
improved	O
mitochondrial	O
respiratory	O
function	O
.	O
The	O
protective	O
role	O
of	O
salvianolic	B-CHEMICAL
acid	I-CHEMICAL
A	I-CHEMICAL
against	O
isoproterenol	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
damage	I-DISEASE
was	O
further	O
confirmed	O
by	O
histopathological	O
examination	O
.	O
The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
salvianolic	B-CHEMICAL
acid	I-CHEMICAL
A	I-CHEMICAL
possessing	O
antioxidant	O
activity	O
has	O
a	O
significant	O
protective	O
effect	O
against	O
isoproterenol	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
.	O

Acute	O
effects	O
of	O
N-(2	O
-	O
propylpentanoyl)urea	O
on	O
hippocampal	O
amino	O
acid	O
neurotransmitters	O
in	O
pilocarpine	B-CHEMICAL
-	O
induced	O
seizure	B-DISEASE
in	O
rats	O
.	O
The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
anticonvulsant	O
activity	O
as	O
well	O
as	O
the	O
effects	O
on	O
the	O
level	O
of	O
hippocampal	O
amino	O
acid	O
neurotransmitters	O
(	O
glutamate	B-CHEMICAL
,	O
aspartate	O
,	O
glycine	B-CHEMICAL
and	O
GABA	O
)	O
of	O
N-(2	O
-	O
propylpentanoyl)urea	O
(	O
VPU	O
)	O
in	O
comparison	O
to	O
its	O
parent	O
compound	O
,	O
valproic	O
acid	O
(	O
VPA	O
)	O
.	O
VPU	O
was	O
more	O
potent	O
than	O
VPA	O
,	O
exhibiting	O
the	O
median	O
effective	O
dose	O
(	O
ED(50	O
)	O
)	O
of	O
49	O
mg	O
/	O
kg	O
in	O
protecting	O
rats	O
against	O
pilocarpine	B-CHEMICAL
-	O
induced	O
seizure	B-DISEASE
whereas	O
the	O
corresponding	O
value	O
for	O
VPA	O
was	O
322	O
mg	O
/	O
kg	O
.	O
In	O
vivo	O
microdialysis	O
demonstrated	O
that	O
an	O
intraperitoneal	O
administration	O
of	O
pilocarpine	B-CHEMICAL
induced	O
a	O
pronounced	O
increment	O
of	O
hippocampal	O
glutamate	B-CHEMICAL
and	O
aspartate	O
whereas	O
no	O
significant	O
change	O
was	O
observed	O
on	O
the	O
level	O
of	O
glycine	B-CHEMICAL
and	O
GABA	O
.	O
Pretreatment	O
with	O
either	O
VPU	O
(	O
50	O
and	O
100	O
mg	O
/	O
kg	O
)	O
or	O
VPA	O
(	O
300	O
and	O
600	O
mg	O
/	O
kg	O
)	O
completely	O
abolished	O
pilocarpine	B-CHEMICAL
-	O
evoked	O
increases	O
in	O
extracellular	O
glutamate	B-CHEMICAL
and	O
aspartate	O
.	O
In	O
addition	O
,	O
a	O
statistically	O
significant	O
reduction	O
was	O
also	O
observed	O
on	O
the	O
level	O
of	O
GABA	O
and	O
glycine	B-CHEMICAL
but	O
less	O
than	O
a	O
drastic	O
reduction	O
of	O
glutamate	B-CHEMICAL
and	O
aspartate	O
level	O
.	O
Based	O
on	O
the	O
finding	O
that	O
VPU	O
and	O
VPA	O
could	O
protect	O
the	O
animals	O
against	O
pilocarpine	B-CHEMICAL
-	O
induced	O
seizure	B-DISEASE
it	O
is	O
suggested	O
that	O
the	O
reduction	O
of	O
inhibitory	O
amino	O
acid	O
neurotransmitters	O
was	O
comparatively	O
minor	O
and	O
offset	O
by	O
a	O
pronounced	O
reduction	O
of	O
glutamate	B-CHEMICAL
and	O
aspartate	O
.	O
Therefore	O
,	O
like	O
VPA	O
,	O
the	O
finding	O
that	O
VPU	O
could	O
drastically	O
reduce	O
pilocarpine	B-CHEMICAL
-	O
induced	O
increases	O
in	O
glutamate	B-CHEMICAL
and	O
aspartate	O
should	O
account	O
,	O
at	O
least	O
partly	O
,	O
for	O
its	O
anticonvulsant	O
activity	O
observed	O
in	O
pilocarpine	B-CHEMICAL
-	O
induced	O
seizure	B-DISEASE
in	O
experimental	O
animals	O
.	O
Some	O
other	O
mechanism	O
than	O
those	O
being	O
reported	O
herein	O
should	O
be	O
further	O
investigated	O
.	O

Acute	B-DISEASE
hepatitis	I-DISEASE
attack	O
after	O
exposure	O
to	O
telithromycin	B-CHEMICAL
.	O
INTRODUCTION	O
:	O
Antibiotic	O
-	O
associated	O
hepatotoxicity	O
is	O
rare	O
.	O
With	O
widespread	O
use	O
of	O
antimicrobial	O
agents	O
,	O
however	O
,	O
hepatic	O
injury	O
occurs	O
frequently	O
,	O
and	O
among	O
adverse	B-DISEASE
drug	I-DISEASE
reactions	I-DISEASE
,	O
idiosyncratic	O
reactions	O
are	O
the	O
most	O
serious	O
.	O
CASE	O
SUMMARY	O
:	O
A	O
25	O
-	O
year	O
-	O
old	O
male	O
patient	O
,	O
with	O
a	O
height	O
of	O
175	O
cm	B-DISEASE
and	O
weight	O
of	O
72	O
kg	O
presented	O
to	O
Marmara	O
University	O
Hospital	O
Emergency	B-DISEASE
Department	I-DISEASE
,	O
Istanbul	O
,	O
Turkey	O
,	O
with	O
5	O
days	O
'	O
history	O
of	O
jaundice	B-DISEASE
,	O
malaise	O
,	O
nausea	B-DISEASE
,	O
and	O
vomiting	B-DISEASE
.	O
He	O
had	O
been	O
prescribed	O
telithromycin	B-CHEMICAL
400	O
mg	O
/	O
d	O
PO	O
to	O
treat	O
an	O
upper	O
respiratory	O
tract	O
infection	B-DISEASE
7	O
days	O
prior	O
.	O
Admission	O
laboratory	O
tests	O
were	O
as	O
follows	O
:	O
alanine	O
aminotransferase	O
,	O
67	O
U	O
/	O
L	O
(	O
reference	O
range	O
,	O
10	O
-	O
37	O
U	O
/	O
L	O
)	O
;	O
aspartate	O
aminotransferase	O
,	O
98	O
U	O
/	O
L	O
(	O
10	O
-	O
40	O
U	O
/	O
L	O
)	O
;	O
alkaline	B-CHEMICAL
phosphatase	I-CHEMICAL
,	O
513	O
U	O
/	O
L	O
(	O
0	O
-	O
270	O
U	O
/	O
L	O
)	O
;	O
gamma	O
-	O
glutamyltransferase	O
,	O
32	O
U	O
/	O
L	O
(	O
7	O
-	O
49	O
U	O
/	O
L	O
)	O
;	O
amylase	O
,	O
46	O
U	O
/	O
L	O
(	O
0	O
-	O
220	O
U	O
/	O
L	O
)	O
;	O
total	O
bilirubin	O
,	O
20.1	O
mg	O
/	O
dL	O
(	O
0.2	O
-	O
1.0	O
mg	O
/	O
dL	O
)	O
;	O
direct	O
bilirubin	O
,	O
14.8	O
mg	O
/	O
dL	O
(	O
0	O
-	O
0.3	O
mg	O
/	O
dL	O
)	O
;	O
and	O
albumin	O
,	O
4.7	O
mg	O
/	O
dL	O
(	O
3.5	O
-	O
5.4	O
mg	O
/	O
dL	O
)	O
.	O
No	O
toxin	O
,	O
alcohol	O
,	O
or	O
other	O
drugs	O
were	O
reported	O
.	O
The	O
patient	O
had	O
suffered	O
a	O
previous	O
episode	O
of	O
"	O
acute	B-DISEASE
hepatitis	I-DISEASE
of	O
unknown	O
origin	O
,	O
"	O
that	O
occurred	O
after	O
telithromycin	B-CHEMICAL
usage	O
.	O
Both	O
incidents	O
occurred	O
within	O
a	O
year	O
.	O
DISCUSSION	O
:	O
Telithromycin	B-CHEMICAL
is	O
the	O
first	O
of	O
the	O
ketolide	O
antibacterials	O
to	O
receive	O
US	O
Food	O
and	O
Drug	O
Administration	O
approval	O
for	O
clinical	O
use	O
.	O
It	O
has	O
been	O
associated	O
with	O
infrequent	O
and	O
usually	O
reversible	O
severe	O
hepatic	O
dysfunction	O
.	O
Based	O
on	O
a	O
score	O
of	O
8	O
on	O
the	O
Naranjo	O
adverse	B-DISEASE
drug	I-DISEASE
reaction	I-DISEASE
probability	O
scale	O
,	O
telithromycin	B-CHEMICAL
was	O
the	O
probable	O
cause	O
of	O
acute	B-DISEASE
hepatitis	I-DISEASE
in	O
this	O
patient	O
,	O
and	O
pathological	O
findings	O
suggested	O
drug	O
-	O
induced	O
toxic	B-DISEASE
hepatitis	I-DISEASE
.	O
Recurrence	B-DISEASE
of	O
hepatitis	B-DISEASE
attack	O
might	O
have	O
been	O
avoided	O
if	O
the	O
initial	O
incident	O
had	O
been	O
communicated	O
to	O
the	O
attending	O
physician	O
who	O
prescribed	O
telithromycin	B-CHEMICAL
the	O
second	O
time	O
.	O
CONCLUSION	O
:	O
Here	O
we	O
report	O
a	O
case	O
of	O
acute	B-DISEASE
hepatitis	I-DISEASE
probably	O
associated	O
with	O
the	O
administration	O
of	O
telithromycin	B-CHEMICAL
.	O

Spironolactone	B-CHEMICAL
-	O
induced	O
renal	B-DISEASE
insufficiency	I-DISEASE
and	O
hyperkalemia	B-DISEASE
in	O
patients	O
with	O
heart	B-DISEASE
failure	I-DISEASE
.	O
BACKGROUND	O
:	O
A	O
previous	O
randomized	O
controlled	O
trial	O
evaluating	O
the	O
use	O
of	O
spironolactone	B-CHEMICAL
in	O
heart	B-DISEASE
failure	I-DISEASE
patients	O
reported	O
a	O
low	O
risk	O
of	O
hyperkalemia	B-DISEASE
(	O
2	O
%	O
)	O
and	O
renal	B-DISEASE
insufficiency	I-DISEASE
(	O
0	O
%	O
)	O
.	O
Because	O
treatments	O
for	O
heart	B-DISEASE
failure	I-DISEASE
have	O
changed	O
since	O
the	O
benefits	O
of	O
spironolactone	B-CHEMICAL
were	O
reported	O
,	O
the	O
prevalence	O
of	O
these	O
complications	B-DISEASE
may	O
differ	O
in	O
current	O
clinical	O
practice	O
.	O
We	O
therefore	O
sought	O
to	O
determine	O
the	O
prevalence	O
and	O
clinical	O
associations	O
of	O
hyperkalemia	B-DISEASE
and	O
renal	B-DISEASE
insufficiency	I-DISEASE
in	O
heart	B-DISEASE
failure	I-DISEASE
patients	O
treated	O
with	O
spironolactone	B-CHEMICAL
.	O
METHODS	O
:	O
We	O
performed	O
a	O
case	O
control	O
study	O
of	O
heart	B-DISEASE
failure	I-DISEASE
patients	O
treated	O
with	O
spironolactone	B-CHEMICAL
in	O
our	O
clinical	O
practice	O
.	O
Cases	O
were	O
patients	O
who	O
developed	O
hyperkalemia	B-DISEASE
(	O
K(+	O
)	O
>	O
5.0	O
mEq	O
/	O
L	O
)	O
or	O
renal	B-DISEASE
insufficiency	I-DISEASE
(	O
Cr	O
>	O
or=2.5	O
mg	O
/	O
dL	O
)	O
,	O
and	O
they	O
were	O
compared	O
to	O
2	O
randomly	O
selected	O
controls	O
per	O
case	O
.	O
Clinical	O
characteristics	O
,	O
medications	O
,	O
and	O
serum	O
chemistries	O
at	O
baseline	O
and	O
follow	O
-	O
up	O
time	O
periods	O
were	O
compared	O
.	O
RESULTS	O
:	O
Sixty	O
-	O
seven	O
of	O
926	O
patients	O
(	O
7.2	O
%	O
)	O
required	O
discontinuation	O
of	O
spironolactone	B-CHEMICAL
due	O
to	O
hyperkalemia	B-DISEASE
(	O
n	O
=	O
33	O
)	O
or	O
renal	B-DISEASE
failure	I-DISEASE
(	O
n	O
=	O
34	O
)	O
.	O
Patients	O
who	O
developed	O
hyperkalemia	B-DISEASE
were	O
older	O
and	O
more	O
likely	O
to	O
have	O
diabetes	B-DISEASE
,	O
had	O
higher	O
baseline	O
serum	O
potassium	B-CHEMICAL
levels	O
and	O
lower	O
baseline	O
potassium	B-CHEMICAL
supplement	O
doses	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
beta	O
-	O
blockers	O
than	O
controls	O
(	O
n	O
=	O
134	O
)	O
.	O
Patients	O
who	O
developed	O
renal	B-DISEASE
insufficiency	I-DISEASE
had	O
lower	O
baseline	O
body	B-DISEASE
weight	I-DISEASE
and	O
higher	O
baseline	O
serum	O
creatinine	B-CHEMICAL
,	O
required	O
higher	O
doses	O
of	O
loop	O
diuretics	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
thiazide	O
diuretics	O
than	O
controls	O
.	O
CONCLUSIONS	O
:	O
Spironolactone	B-CHEMICAL
-	O
induced	O
hyperkalemia	B-DISEASE
and	O
renal	B-DISEASE
insufficiency	I-DISEASE
are	O
more	O
common	O
in	O
our	O
clinical	O
experience	O
than	O
reported	O
previously	O
.	O
This	O
difference	O
is	O
explained	O
by	O
patient	O
comorbidities	O
and	O
more	O
frequent	O
use	O
of	O
beta	O
-	O
blockers	O
.	O

End	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
renal	I-DISEASE
disease	I-DISEASE
(	O
ESRD	B-DISEASE
)	O
after	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
using	O
calcineurin	O
-	O
based	O
immunotherapy	O
:	O
risk	O
of	O
development	O
and	O
treatment	O
.	O
BACKGROUND	O
:	O
The	O
calcineurin	B-CHEMICAL
inhibitors	I-CHEMICAL
cyclosporine	B-CHEMICAL
and	O
tacrolimus	B-CHEMICAL
are	O
both	O
known	O
to	O
be	O
nephrotoxic	B-DISEASE
.	O
Their	O
use	O
in	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
has	O
dramatically	O
improved	O
success	O
rates	O
.	O
Recently	O
,	O
however	O
,	O
we	O
have	O
had	O
an	O
increase	O
of	O
patients	O
who	O
are	O
presenting	O
after	O
OLTX	O
with	O
end	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
renal	I-DISEASE
disease	I-DISEASE
(	O
ESRD	B-DISEASE
)	O
.	O
This	O
retrospective	O
study	O
examines	O
the	O
incidence	O
and	O
treatment	O
of	O
ESRD	B-DISEASE
and	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
(	O
CRF	B-DISEASE
)	O
in	O
OLTX	O
patients	O
.	O
METHODS	O
:	O
Patients	O
receiving	O
an	O
OLTX	O
only	O
from	O
June	O
1985	O
through	O
December	O
of	O
1994	O
who	O
survived	O
6	O
months	O
postoperatively	O
were	O
studied	O
(	O
n=834	O
)	O
.	O
Our	O
prospectively	O
collected	O
database	O
was	O
the	O
source	O
of	O
information	O
.	O
Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	O
,	O
no	O
CRF	B-DISEASE
or	O
ESRD	B-DISEASE
,	O
n=748	O
;	O
CRF	B-DISEASE
,	O
sustained	O
serum	O
creatinine	B-CHEMICAL
>	O
2.5	O
mg	O
/	O
dl	O
,	O
n=41	O
;	O
and	O
ESRD	B-DISEASE
,	O
n=45	O
.	O
Groups	O
were	O
compared	O
for	O
preoperative	O
laboratory	O
variables	O
,	O
diagnosis	O
,	O
postoperative	O
variables	O
,	O
survival	O
,	O
type	O
of	O
ESRD	B-DISEASE
therapy	O
,	O
and	O
survival	O
from	O
onset	O
of	O
ESRD	B-DISEASE
.	O
RESULTS	O
:	O
At	O
13	O
years	O
after	O
OLTX	O
,	O
the	O
incidence	O
of	O
severe	O
renal	B-DISEASE
dysfunction	I-DISEASE
was	O
18.1	O
%	O
(	O
CRF	B-DISEASE
8.6	O
%	O
and	O
ESRD	B-DISEASE
9.5	O
%	O
)	O
.	O
Compared	O
with	O
control	O
patients	O
,	O
CRF	B-DISEASE
and	O
ESRD	B-DISEASE
patients	O
had	O
higher	O
preoperative	O
serum	O
creatinine	B-CHEMICAL
levels	O
,	O
a	O
greater	O
percentage	O
of	O
patients	O
with	O
hepatorenal	B-DISEASE
syndrome	I-DISEASE
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1	O
-	O
year	O
serum	O
creatinine	B-CHEMICAL
.	O
Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	O
creatinine	B-CHEMICAL
compared	O
with	O
average	O
at	O
1	O
year	O
,	O
3	O
months	O
,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
CRF	B-DISEASE
or	O
ESRD	B-DISEASE
with	O
odds	O
ratios	O
of	O
2.6	O
,	O
2.2	O
,	O
and	O
1.6	O
,	O
respectively	O
.	O
Overall	O
survival	O
from	O
the	O
time	O
of	O
OLTX	O
was	O
not	O
significantly	O
different	O
among	O
groups	O
,	O
but	O
by	O
year	O
13	O
,	O
the	O
survival	O
of	O
the	O
patients	O
who	O
had	O
ESRD	B-DISEASE
was	O
only	O
28.2	O
%	O
compared	O
with	O
54.6	O
%	O
in	O
the	O
control	O
group	O
.	O
Patients	O
developing	O
ESRD	B-DISEASE
had	O
a	O
6	O
-	O
year	O
survival	O
after	O
onset	O
of	O
ESRD	B-DISEASE
of	O
27	O
%	O
for	O
the	O
patients	O
receiving	O
hemodialysis	O
versus	O
71.4	O
%	O
for	O
the	O
patients	O
developing	O
ESRD	B-DISEASE
who	O
subsequently	O
received	O
kidney	O
transplants	O
.	O
CONCLUSIONS	O
:	O
Patients	O
who	O
are	O
more	O
than	O
10	O
years	O
post	O
-	O
OLTX	O
have	O
CRF	B-DISEASE
and	O
ESRD	B-DISEASE
at	O
a	O
high	O
rate	O
.	O
The	O
development	O
of	O
ESRD	B-DISEASE
decreases	O
survival	O
,	O
particularly	O
in	O
those	O
patients	O
treated	O
with	O
dialysis	O
only	O
.	O
Patients	O
who	O
develop	O
ESRD	B-DISEASE
have	O
a	O
higher	O
preoperative	O
and	O
1	O
-	O
year	O
serum	O
creatinine	B-CHEMICAL
and	O
are	O
more	O
likely	O
to	O
have	O
hepatorenal	B-DISEASE
syndrome	I-DISEASE
.	O
However	O
,	O
an	O
increase	O
of	O
serum	O
creatinine	B-CHEMICAL
at	O
various	O
times	O
postoperatively	O
is	O
more	O
predictive	O
of	O
the	O
development	O
of	O
CRF	B-DISEASE
or	O
ESRD	B-DISEASE
.	O
New	O
strategies	O
for	O
long	O
-	O
term	O
immunosuppression	O
may	O
be	O
needed	O
to	O
decrease	O
this	O
complication	O
.	O

Effect	O
of	O
intravenous	O
nimodipine	B-CHEMICAL
on	O
blood	O
pressure	O
and	O
outcome	O
after	O
acute	B-DISEASE
stroke	I-DISEASE
.	O
BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intravenous	O
Nimodipine	B-CHEMICAL
West	O
European	O
Stroke	B-DISEASE
Trial	O
(	O
INWEST	O
)	O
found	O
a	O
correlation	O
between	O
nimodipine	B-CHEMICAL
-	O
induced	O
reduction	O
in	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
an	O
unfavorable	O
outcome	O
in	O
acute	B-DISEASE
stroke	I-DISEASE
.	O
We	O
sought	O
to	O
confirm	O
this	O
correlation	O
with	O
and	O
without	O
adjustment	O
for	O
prognostic	O
variables	O
and	O
to	O
investigate	O
outcome	O
in	O
subgroups	O
with	O
increasing	O
levels	O
of	O
BP	O
reduction	O
.	O
METHODS	O
:	O
Patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
ischemic	B-DISEASE
stroke	I-DISEASE
(	O
within	O
24	O
hours	O
)	O
were	O
consecutively	O
allocated	O
to	O
receive	O
placebo	O
(	O
n=100	O
)	O
,	O
1	O
mg	O
/	O
h	O
(	O
low	O
-	O
dose	O
)	O
nimodipine	B-CHEMICAL
(	O
n=101	O
)	O
,	O
or	O
2	O
mg	O
/	O
h	O
(	O
high	O
-	O
dose	O
)	O
nimodipine	B-CHEMICAL
(	O
n=94	O
)	O
.	O
The	O
correlation	O
between	O
average	O
BP	O
change	O
during	O
the	O
first	O
2	O
days	O
and	O
the	O
outcome	O
at	O
day	O
21	O
was	O
analyzed	O
.	O
RESULTS	O
:	O
Two	O
hundred	O
sixty	O
-	O
five	O
patients	O
were	O
included	O
in	O
this	O
analysis	O
(	O
n=92	O
,	O
93	O
,	O
and	O
80	O
for	O
placebo	O
,	O
low	O
dose	O
,	O
and	O
high	O
dose	O
,	O
respectively	O
)	O
.	O
Nimodipine	B-CHEMICAL
treatment	O
resulted	O
in	O
a	O
statistically	O
significant	O
reduction	O
in	O
systolic	O
BP	O
(	O
SBP	O
)	O
and	O
diastolic	O
BP	O
(	O
DBP	O
)	O
from	O
baseline	O
compared	O
with	O
placebo	O
during	O
the	O
first	O
few	O
days	O
.	O
In	O
multivariate	O
analysis	O
,	O
a	O
significant	O
correlation	O
between	O
DBP	O
reduction	O
and	O
worsening	O
of	O
the	O
neurological	O
score	O
was	O
found	O
for	O
the	O
high	O
-	O
dose	O
group	O
(	O
beta=0.49	O
,	O
P=0	O
.	O
048	O
)	O
.	O
Patients	O
with	O
a	O
DBP	O
reduction	O
of	O
>	O
or	O
=	O
20	O
%	O
in	O
the	O
high	O
-	O
dose	O
group	O
had	O
a	O
significantly	O
increased	O
adjusted	O
OR	O
for	O
the	O
compound	O
outcome	O
variable	O
death	B-DISEASE
or	O
dependency	O
(	O
Barthel	O
Index	O
<	O
60	O
)	O
(	O
n	O
/	O
N=25/26	O
,	O
OR	O
10	O
.	O
16	O
,	O
95	O
%	O
CI	O
1.02	O
to	O
101.74	O
)	O
and	O
death	B-DISEASE
alone	O
(	O
n	O
/	O
N=9/26	O
,	O
OR	O
4.336	O
,	O
95	O
%	O
CI	O
1.131	O
16.619	O
)	O
compared	O
with	O
all	O
placebo	O
patients	O
(	O
n	O
/	O
N=62/92	O
and	O
14/92	O
,	O
respectively	O
)	O
.	O
There	O
was	O
no	O
correlation	O
between	O
SBP	O
change	O
and	O
outcome	O
.	O
CONCLUSIONS	O
:	O
DBP	O
,	O
but	O
not	O
SBP	O
,	O
reduction	O
was	O
associated	O
with	O
neurological	O
worsening	O
after	O
the	O
intravenous	O
administration	O
of	O
high	O
-	O
dose	O
nimodipine	B-CHEMICAL
after	O
acute	B-DISEASE
stroke	I-DISEASE
.	O
For	O
low	O
-	O
dose	O
nimodipine	B-CHEMICAL
,	O
the	O
results	O
were	O
not	O
conclusive	O
.	O
These	O
results	O
do	O
not	O
confirm	O
or	O
exclude	O
a	O
neuroprotective	O
property	O
of	O
nimodipine	B-CHEMICAL
.	O

Transient	B-DISEASE
neurologic	I-DISEASE
symptoms	I-DISEASE
after	O
spinal	O
anesthesia	O
:	O
a	O
lower	O
incidence	O
with	O
prilocaine	B-CHEMICAL
and	O
bupivacaine	O
than	O
with	O
lidocaine	B-CHEMICAL
.	O
BACKGROUND	O
:	O
Recent	O
evidence	O
suggests	O
that	O
transient	B-DISEASE
neurologic	I-DISEASE
symptoms	I-DISEASE
(	O
TNSs	B-DISEASE
)	O
frequently	O
follow	O
lidocaine	B-CHEMICAL
spinal	O
anesthesia	O
but	O
are	O
infrequent	O
with	O
bupivacaine	O
.	O
However	O
,	O
identification	O
of	O
a	O
short	O
-	O
acting	O
local	O
anesthetic	O
to	O
substitute	O
for	O
lidocaine	B-CHEMICAL
for	O
brief	O
surgical	O
procedures	O
remains	O
an	O
important	O
goal	O
.	O
Prilocaine	B-CHEMICAL
is	O
an	O
amide	O
local	O
anesthetic	O
with	O
a	O
duration	O
of	O
action	O
similar	O
to	O
that	O
of	O
lidocaine	B-CHEMICAL
.	O
Accordingly	O
,	O
the	O
present	O
,	O
prospective	O
double	O
-	O
blind	B-DISEASE
study	O
compares	O
prilocaine	B-CHEMICAL
with	O
lidocaine	B-CHEMICAL
and	O
bupivacaine	O
with	O
respect	O
to	O
duration	O
of	O
action	O
and	O
relative	O
risk	O
of	O
TNSs	B-DISEASE
.	O
METHODS	O
:	O
Ninety	O
patients	O
classified	O
as	O
American	O
Society	O
of	O
Anesthesiologists	O
physical	O
status	O
I	O
or	O
II	O
who	O
were	O
scheduled	O
for	O
short	O
gynecologic	O
procedures	O
under	O
spinal	O
anesthesia	O
were	O
randomly	O
allocated	O
to	O
receive	O
2.5	O
ml	O
2	O
%	O
lidocaine	B-CHEMICAL
in	O
7.5	O
%	O
glucose	B-CHEMICAL
,	O
2	O
%	O
prilocaine	B-CHEMICAL
in	O
7.5	O
%	O
glucose	B-CHEMICAL
,	O
or	O
0.5	O
%	O
bupivacaine	O
in	O
7.5	O
%	O
glucose	B-CHEMICAL
.	O
All	O
solutions	O
were	O
provided	O
in	O
blinded	O
vials	O
by	O
the	O
hospital	O
pharmacy	O
.	O
Details	O
of	O
spinal	O
puncture	O
,	O
extension	O
and	O
regression	O
of	O
spinal	O
block	O
,	O
and	O
the	O
times	O
to	O
reach	O
discharge	O
criteria	O
were	O
noted	O
.	O
In	O
the	O
evening	O
of	O
postoperative	O
day	O
1	O
,	O
patients	O
were	O
evaluated	O
for	O
TNSs	B-DISEASE
by	O
a	O
physician	O
unaware	O
of	O
the	O
drug	O
administered	O
and	O
the	O
details	O
of	O
the	O
anesthetic	O
procedure	O
.	O
RESULTS	O
:	O
Nine	O
of	O
30	O
patients	O
receiving	O
lidocaine	B-CHEMICAL
experienced	O
TNSs	B-DISEASE
,	O
1	O
of	O
30	O
patients	O
receiving	O
prilocaine	B-CHEMICAL
(	O
P	O
=	O
0.03	O
)	O
had	O
them	O
,	O
and	O
none	O
of	O
30	O
patients	O
receiving	O
bupivacaine	O
had	O
TNSs	B-DISEASE
.	O
Times	O
to	O
ambulate	O
and	O
to	O
void	O
were	O
similar	O
after	O
lidocaine	B-CHEMICAL
and	O
prilocaine	B-CHEMICAL
(	O
150	O
vs.	O
165	O
min	O
and	O
238	O
vs.	O
253	O
min	O
,	O
respectively	O
)	O
but	O
prolonged	O
after	O
bupivacaine	O
(	O
200	O
and	O
299	O
min	O
,	O
respectively	O
;	O
P	O
<	O
0.05	O
)	O
.	O
CONCLUSIONS	O
:	O
Prilocaine	B-CHEMICAL
may	O
be	O
preferable	O
to	O
lidocaine	B-CHEMICAL
for	O
short	O
surgical	O
procedures	O
because	O
it	O
has	O
a	O
similar	O
duration	O
of	O
action	O
but	O
a	O
lower	O
incidence	O
of	O
TNSs	B-DISEASE
.	O

The	O
role	O
of	O
nicotine	B-CHEMICAL
in	O
smoking	B-CHEMICAL
-	O
related	O
cardiovascular	B-DISEASE
disease	I-DISEASE
.	O
Nicotine	B-CHEMICAL
activates	O
the	O
sympathetic	O
nervous	O
system	O
and	O
in	O
this	O
way	O
could	O
contribute	O
to	O
cardiovascular	B-DISEASE
disease	I-DISEASE
.	O
Animal	O
studies	O
and	O
mechanistic	O
studies	O
indicate	O
that	O
nicotine	B-CHEMICAL
could	O
play	O
a	O
role	O
in	O
accelerating	O
atherosclerosis	B-DISEASE
,	O
but	O
evidence	O
among	O
humans	O
is	O
too	O
inadequate	O
to	O
be	O
definitive	O
about	O
such	O
an	O
effect	O
.	O
Almost	O
certainly	O
,	O
nicotine	B-CHEMICAL
via	O
its	O
hemodynamic	O
effects	O
contributes	O
to	O
acute	O
cardiovascular	O
events	O
,	O
although	O
current	O
evidence	O
suggests	O
that	O
the	O
effects	O
of	O
nicotine	B-CHEMICAL
are	O
much	O
less	O
important	O
than	O
are	O
the	O
prothrombotic	O
effects	O
of	O
cigarette	O
smoking	B-CHEMICAL
or	O
the	O
effects	O
of	O
carbon	B-CHEMICAL
monoxide	I-CHEMICAL
.	O
Nicotine	B-CHEMICAL
does	O
not	O
appear	O
to	O
enhance	O
thrombosis	B-DISEASE
among	O
humans	O
.	O
Clinical	O
studies	O
of	O
pipe	O
smokers	O
and	O
people	O
using	O
transdermal	O
nicotine	B-CHEMICAL
support	O
the	O
idea	O
that	O
toxins	O
other	O
than	O
nicotine	B-CHEMICAL
are	O
the	O
most	O
important	O
causes	O
of	O
acute	O
cardiovascular	O
events	O
.	O
Finally	O
,	O
the	O
dose	O
response	O
for	O
cardiovascular	O
events	O
of	O
nicotine	B-CHEMICAL
appears	O
to	O
be	O
flat	O
,	O
suggesting	O
that	O
if	O
nicotine	B-CHEMICAL
is	O
involved	O
,	O
adverse	O
effects	O
might	O
be	O
seen	O
with	O
relatively	O
low	O
-	O
level	O
cigarette	O
exposures	O
.	O

Seizure	B-DISEASE
resulting	O
from	O
a	O
venlafaxine	B-CHEMICAL
overdose	B-DISEASE
.	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
venlafaxine	B-CHEMICAL
overdose	B-DISEASE
.	O
CASE	O
SUMMARY	O
:	O
A	O
40	O
-	O
year	O
-	O
old	O
woman	O
with	O
major	B-DISEASE
depression	I-DISEASE
took	O
an	O
overdose	B-DISEASE
of	O
venlafaxine	B-CHEMICAL
in	O
an	O
apparent	O
suicide	B-DISEASE
attempt	O
.	O
After	O
the	O
ingestion	O
of	O
26	O
venlafaxine	B-CHEMICAL
50	O
-	O
mg	O
tablets	O
,	O
the	O
patient	O
experienced	O
a	O
witnessed	O
generalized	O
seizure	B-DISEASE
.	O
She	O
was	O
admitted	O
to	O
the	O
medical	O
intensive	O
care	O
unit	O
,	O
venlafaxine	B-CHEMICAL
was	O
discontinued	O
,	O
and	O
no	O
further	O
sequelae	O
were	O
seen	O
.	O
DISCUSSION	O
:	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
venlafaxine	B-CHEMICAL
overdose	B-DISEASE
that	O
resulted	O
in	O
a	O
generalized	O
seizure	B-DISEASE
.	O
Based	O
on	O
nonoverdose	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
venlafaxine	B-CHEMICAL
and	O
the	O
potential	O
risks	O
of	O
available	O
interventions	O
,	O
no	O
emergent	O
therapy	O
was	O
instituted	O
.	O
CONCLUSIONS	O
:	O
The	O
venlafaxine	B-CHEMICAL
overdose	B-DISEASE
in	O
our	O
patient	O
resulted	O
in	O
a	O
single	O
episode	O
of	O
generalized	O
seizure	B-DISEASE
but	O
elicited	O
no	O
further	O
sequelae	O
.	O

Effect	O
of	O
nifedipine	B-CHEMICAL
on	O
renal	O
function	O
in	O
liver	O
transplant	O
recipients	O
receiving	O
tacrolimus	B-CHEMICAL
.	O
The	O
effect	O
of	O
nifedipine	B-CHEMICAL
on	O
renal	O
function	O
in	O
liver	O
transplant	O
recipients	O
who	O
were	O
receiving	O
tacrolimus	B-CHEMICAL
was	O
evaluated	O
between	O
January	O
1992	O
and	O
January	O
1996	O
.	O
Two	O
groups	O
of	O
patients	O
receiving	O
tacrolimus	B-CHEMICAL
were	O
compared	O
over	O
a	O
period	O
of	O
1	O
year	O
,	O
one	O
group	O
comprising	O
hypertensive	B-DISEASE
patients	O
who	O
were	O
receiving	O
nifedipine	B-CHEMICAL
,	O
and	O
the	O
other	O
comprising	O
nonhypertensive	O
patients	O
not	O
receiving	O
nifedipine	B-CHEMICAL
.	O
The	O
time	O
from	O
transplant	O
to	O
baseline	O
was	O
similar	O
in	O
all	O
patients	O
.	O
Nifedipine	B-CHEMICAL
significantly	O
improved	O
kidney	O
function	O
as	O
indicated	O
by	O
a	O
significant	O
lowering	O
of	O
serum	O
creatinine	B-CHEMICAL
levels	O
at	O
6	O
and	O
12	O
months	O
.	O
The	O
observed	O
positive	O
impact	O
of	O
nifedipine	B-CHEMICAL
on	O
reducing	O
the	O
nephrotoxicity	B-DISEASE
associated	O
with	O
tacrolimus	B-CHEMICAL
in	O
liver	O
transplant	O
recipients	O
should	O
be	O
an	O
important	O
factor	O
in	O
selecting	O
an	O
agent	O
to	O
treat	O
hypertension	B-DISEASE
in	O
this	O
population	O
.	O

Sinus	B-DISEASE
arrest	I-DISEASE
associated	O
with	O
continuous	O
-	O
infusion	O
cimetidine	B-CHEMICAL
.	O
The	O
administration	O
of	O
intermittent	O
intravenous	O
infusions	O
of	O
cimetidine	B-CHEMICAL
is	O
infrequently	O
associated	O
with	O
the	O
development	O
of	O
bradyarrhythmias	B-DISEASE
.	O
A	O
40	O
-	O
year	O
-	O
old	O
man	O
with	O
leukemia	B-DISEASE
and	O
no	O
history	O
of	O
cardiac	B-DISEASE
disease	I-DISEASE
developed	O
recurrent	O
,	O
brief	O
episodes	O
of	O
apparent	O
sinus	B-DISEASE
arrest	I-DISEASE
while	O
receiving	O
continuous	O
-	O
infusion	O
cimetidine	B-CHEMICAL
50	O
mg	O
/	O
hour	O
.	O
The	O
arrhythmias	B-DISEASE
were	O
temporally	O
related	O
to	O
cimetidine	B-CHEMICAL
administration	O
,	O
disappeared	O
after	O
dechallenge	O
,	O
and	O
did	O
not	O
recur	O
during	O
ranitidine	B-CHEMICAL
treatment	O
.	O
This	O
is	O
the	O
first	O
reported	O
case	O
of	O
sinus	B-DISEASE
arrest	I-DISEASE
associated	O
with	O
continuous	O
-	O
infusion	O
cimetidine	B-CHEMICAL
.	O

Composition	O
of	O
gall	O
bladder	O
stones	O
associated	O
with	O
octreotide	B-CHEMICAL
:	O
response	O
to	O
oral	O
ursodeoxycholic	B-CHEMICAL
acid	I-CHEMICAL
.	O
Octreotide	B-CHEMICAL
,	O
an	O
effective	O
treatment	O
for	O
acromegaly	B-DISEASE
,	O
induces	O
gall	O
bladder	O
stones	O
in	O
13	O
-	O
60	O
%	O
of	O
patients	O
.	O
Because	O
knowledge	O
of	O
stone	O
composition	O
is	O
essential	O
for	O
studies	O
of	O
their	O
pathogenesis	O
,	O
treatment	O
,	O
and	O
prevention	O
,	O
this	O
was	O
investigated	O
by	O
direct	O
and	O
indirect	O
methods	O
in	O
14	O
octreotide	B-CHEMICAL
treated	O
acromegalic	B-DISEASE
patients	O
with	O
gall	O
stones	O
.	O
Chemical	O
analysis	O
of	O
gall	O
stones	O
retrieved	O
at	O
cholecystectomy	O
from	O
two	O
patients	O
,	O
showed	O
that	O
they	O
contained	O
71	O
%	O
and	O
87	O
%	O
cholesterol	B-CHEMICAL
by	O
weight	O
.	O
In	O
the	O
remaining	O
12	O
patients	O
,	O
localised	O
computed	O
tomography	O
of	O
the	O
gall	O
bladder	O
showed	O
that	O
eight	O
had	O
stones	O
with	O
maximum	O
attenuation	O
scores	O
of	O
<	O
100	O
Hounsfield	O
units	O
(	O
values	O
of	O
<	O
100	O
HU	O
predict	O
cholesterol	B-CHEMICAL
rich	O
,	O
dissolvable	O
stones	O
)	O
.	O
Gall	O
bladder	O
bile	O
was	O
obtained	O
by	O
ultrasound	O
guided	O
,	O
fine	O
needle	O
puncture	O
from	O
six	O
patients	O
.	O
All	O
six	O
patients	O
had	O
supersaturated	O
bile	O
(	O
mean	O
(	O
SEM	O
)	O
cholesterol	B-CHEMICAL
saturation	O
index	O
of	O
1.19	O
(	O
0.08	O
)	O
(	O
range	O
1.01	O
-	O
1.53	O
)	O
)	O
and	O
all	O
had	O
abnormally	O
rapid	O
cholesterol	B-CHEMICAL
microcrystal	O
nucleation	O
times	O
(	O
<	O
4	O
days	O
(	O
range	O
1	O
-	O
4	O
)	O
)	O
,	O
whilst	O
in	O
four	O
,	O
the	O
bile	O
contained	O
cholesterol	B-CHEMICAL
microcrystals	O
immediately	O
after	O
sampling	O
.	O
Of	O
the	O
12	O
patients	O
considered	O
for	O
oral	O
ursodeoxycholic	B-CHEMICAL
acid	I-CHEMICAL
(	O
UDCA	O
)	O
treatment	O
,	O
two	O
had	O
a	O
blocked	O
cystic	O
duct	O
and	O
were	O
not	O
started	O
on	O
UDCA	O
while	O
one	O
was	O
lost	O
to	O
follow	O
up	O
.	O
After	O
one	O
year	O
of	O
treatment	O
,	O
five	O
of	O
the	O
remaining	O
nine	O
patients	O
showed	O
either	O
partial	O
(	O
n	O
=	O
3	O
)	O
or	O
complete	O
(	O
n	O
=	O
2	O
)	O
gall	O
stone	O
dissolution	O
,	O
suggesting	O
that	O
their	O
stones	O
were	O
cholesterol	B-CHEMICAL
rich	O
.	O
This	O
corresponds	O
,	O
by	O
actuarial	O
(	O
life	O
table	O
)	O
analysis	O
,	O
to	O
a	O
combined	O
gall	O
stone	O
dissolution	O
rate	O
of	O
58.3	O
(	O
15.9	O
%	O
)	O
.	O
In	O
conclusion	O
,	O
octreotide	B-CHEMICAL
induced	O
gall	O
stones	O
are	O
generally	O
small	O
,	O
multiple	O
,	O
and	O
cholesterol	B-CHEMICAL
rich	O
although	O
,	O
in	O
common	O
with	O
spontaneous	O
gall	O
stone	O
disease	B-DISEASE
,	O
at	O
presentation	O
some	O
patients	O
will	O
have	O
a	O
blocked	O
cystic	O
duct	O
and	O
some	O
gall	O
stones	O
containing	O
calcium	B-CHEMICAL
.	O

Cardiovascular	B-DISEASE
complications	I-DISEASE
associated	O
with	O
terbutaline	B-CHEMICAL
treatment	O
for	O
preterm	O
labor	O
.	O
Severe	O
cardiovascular	B-DISEASE
complications	I-DISEASE
occurred	O
in	O
eight	O
of	O
160	O
patients	O
treated	O
with	O
terbutaline	B-CHEMICAL
for	O
preterm	O
labor	O
.	O
Associated	O
corticosteroid	O
therapy	O
and	O
twin	O
gestations	O
appear	O
to	O
be	O
predisposing	O
factors	O
.	O
Potential	O
mechanisms	O
of	O
the	O
pathophysiology	O
are	O
briefly	O
discussed	O
.	O

Neurologic	O
effects	O
of	O
subarachnoid	O
administration	O
of	O
2	B-CHEMICAL
-	I-CHEMICAL
chloroprocaine	I-CHEMICAL
-	I-CHEMICAL
CE	I-CHEMICAL
,	O
bupivacaine	O
,	O
and	O
low	O
pH	O
normal	O
saline	O
in	O
dogs	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
neurologic	O
consequences	O
of	O
deliberate	O
subarachnoid	O
injection	O
of	O
large	O
volumes	O
of	O
2	B-CHEMICAL
-	I-CHEMICAL
chloroprocaine	I-CHEMICAL
-	I-CHEMICAL
CE	I-CHEMICAL
in	O
experimental	O
animals	O
.	O
The	O
possible	O
role	O
of	O
low	O
pH	O
as	O
well	O
as	O
total	O
volume	O
as	O
potential	O
factors	O
in	O
causing	O
neurotoxicity	B-DISEASE
was	O
evaluated	O
.	O
The	O
65	O
dogs	O
in	O
the	O
study	O
received	O
injections	O
in	O
the	O
subarachnoid	O
space	O
as	O
follows	O
:	O
6	O
to	O
8	O
ml	O
of	O
bupivacaine	O
(	O
N	O
=	O
15	O
)	O
,	O
2	B-CHEMICAL
-	I-CHEMICAL
chloroprocaine	I-CHEMICAL
-	I-CHEMICAL
CE	I-CHEMICAL
(	O
N	O
=	O
20	O
)	O
,	O
low	O
pH	O
normal	O
saline	O
(	O
pH	O
3.0	O
)	O
(	O
N	O
=	O
20	O
)	O
,	O
or	O
normal	O
saline	O
(	O
N	O
=	O
10	O
)	O
.	O
Of	O
the	O
20	O
animals	O
that	O
received	O
subarachnoid	O
injection	O
of	O
2	B-CHEMICAL
-	I-CHEMICAL
chloroprocaine	I-CHEMICAL
-	I-CHEMICAL
CE	I-CHEMICAL
seven	O
(	O
35	O
%	O
)	O
developed	O
hind	O
-	O
limb	O
paralysis	B-DISEASE
.	O
None	O
of	O
the	O
animals	O
that	O
received	O
bupivacaine	O
,	O
normal	O
saline	O
,	O
or	O
normal	O
saline	O
titrated	O
to	O
a	O
pH	O
3.0	O
developed	O
hind	O
-	O
limb	O
paralysis	B-DISEASE
.	O
Of	O
the	O
15	O
spinal	O
cords	O
of	O
the	O
animals	O
that	O
received	O
2	B-CHEMICAL
-	I-CHEMICAL
chloroprocaine	I-CHEMICAL
-	I-CHEMICAL
CE	I-CHEMICAL
,	O
13	O
showed	O
subpial	O
necrosis	B-DISEASE
;	O
the	O
nerve	O
roots	O
and	O
subarachnoid	O
vessels	O
were	O
normal	O
.	O
The	O
spinal	O
cords	O
of	O
the	O
animals	O
that	O
received	O
bupivacaine	O
,	O
low	O
pH	O
normal	O
saline	O
(	O
pH	O
3.0	O
)	O
,	O
or	O
normal	O
saline	O
did	O
not	O
show	O
abnormal	O
findings	O
.	O

Early	O
adjuvant	O
adriamycin	B-CHEMICAL
in	O
superficial	O
bladder	O
carcinoma	B-DISEASE
.	O
A	O
multicenter	O
study	O
was	O
performed	O
in	O
110	O
patients	O
with	O
superficial	O
transitional	O
cell	O
carcinoma	B-DISEASE
of	O
the	O
bladder	O
.	O
Adriamycin	B-CHEMICAL
(	O
50	O
mg/50	O
ml	O
)	O
was	O
administered	O
intravesically	O
within	O
24	O
h	O
after	O
transurethral	O
resection	O
of	O
TA	O
-	O
T1	O
(	O
O	O
-	O
A	O
)	O
bladder	B-DISEASE
tumors	I-DISEASE
.	O
Instillation	O
was	O
repeated	O
twice	O
during	O
the	O
first	O
week	O
,	O
then	O
weekly	O
during	O
the	O
first	O
month	O
and	O
afterwards	O
monthly	O
for	O
1	O
year	O
.	O
The	O
tolerance	O
was	O
evaluated	O
in	O
these	O
110	O
patients	O
,	O
and	O
29	O
patients	O
presented	O
with	O
local	O
side	O
-	O
effects	O
.	O
In	O
24	O
of	O
these	O
patients	O
chemical	O
cystitis	B-DISEASE
was	O
severe	O
enough	O
for	O
them	O
to	O
drop	O
out	O
of	O
the	O
study	O
.	O
No	O
systemic	O
side	O
-	O
effects	O
were	O
observed	O
.	O
Recurrence	B-DISEASE
was	O
studied	O
in	O
82	O
evaluable	O
patients	O
after	O
1	O
year	O
of	O
follow	O
-	O
up	O
and	O
in	O
72	O
patients	O
followed	O
for	O
2	O
-	O
3	O
years	O
(	O
mean	O
32	O
months	O
)	O
.	O
Of	O
the	O
82	O
patients	O
studied	O
after	O
1	O
year	O
,	O
23	O
had	O
primary	O
and	O
59	O
recurrent	O
disease	B-DISEASE
.	O
Of	O
the	O
82	O
evaluable	O
patients	O
,	O
50	O
did	O
not	O
show	O
any	O
recurrence	B-DISEASE
after	O
1	O
year	O
(	O
61	O
%	O
)	O
,	O
while	O
32	O
presented	O
with	O
one	O
or	O
more	O
recurrences	O
(	O
39	O
%	O
)	O
.	O
Of	O
these	O
recurrences	O
,	O
27	O
were	O
T1	O
tumors	B-DISEASE
while	O
five	O
progressed	O
to	O
more	O
highly	O
invasive	O
lesions	O
.	O
In	O
patients	O
that	O
were	O
free	O
of	O
recurrence	B-DISEASE
during	O
the	O
first	O
year	O
,	O
80	O
%	O
remained	O
tumor	B-DISEASE
-	O
free	O
during	O
the	O
2-	O
to	O
3	O
-	O
year	O
follow	O
-	O
up	O
period	O
.	O
Of	O
the	O
patients	O
developing	O
one	O
or	O
more	O
recurrences	O
during	O
the	O
first	O
year	O
,	O
only	O
50	O
%	O
presented	O
with	O
further	O
recurrence	B-DISEASE
once	O
the	O
instillations	O
were	O
stopped	O
.	O
The	O
beneficial	O
effect	O
of	O
Adriamycin	B-CHEMICAL
appears	O
obvious	O
and	O
might	O
be	O
related	O
to	O
the	O
drug	O
itself	O
,	O
the	O
early	O
and	O
repeated	O
instillations	O
after	O
TUR	O
,	O
or	O
both	O
.	O

Hyperkalemia	B-DISEASE
associated	O
with	O
sulindac	B-CHEMICAL
therapy	O
.	O
Hyperkalemia	B-DISEASE
has	O
recently	O
been	O
recognized	O
as	O
a	O
complication	O
of	O
nonsteroidal	O
antiinflammatory	O
agents	O
(	O
NSAID	O
)	O
such	O
as	O
indomethacin	B-CHEMICAL
.	O
Several	O
recent	O
studies	O
have	O
stressed	O
the	O
renal	O
sparing	O
features	O
of	O
sulindac	B-CHEMICAL
,	O
owing	O
to	O
its	O
lack	O
of	O
interference	O
with	O
renal	O
prostacyclin	O
synthesis	O
.	O
We	O
describe	O
4	O
patients	O
in	O
whom	O
hyperkalemia	B-DISEASE
ranging	O
from	O
6.1	O
to	O
6.9	O
mEq	O
/	O
l	O
developed	O
within	O
3	O
to	O
8	O
days	O
of	O
sulindac	B-CHEMICAL
administration	O
.	O
In	O
all	O
of	O
them	O
normal	O
serum	O
potassium	B-CHEMICAL
levels	O
reached	O
within	O
2	O
to	O
4	O
days	O
of	O
stopping	O
sulindac	B-CHEMICAL
.	O
As	O
no	O
other	O
medications	O
known	O
to	O
effect	O
serum	O
potassium	B-CHEMICAL
had	O
been	O
given	O
concomitantly	O
,	O
this	O
course	O
of	O
events	O
is	O
suggestive	O
of	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
between	O
sulindac	B-CHEMICAL
and	O
hyperkalemia	B-DISEASE
.	O
These	O
observations	O
indicate	O
that	O
initial	O
hopes	O
that	O
sulindac	B-CHEMICAL
may	O
not	O
be	O
associated	O
with	O
the	O
adverse	O
renal	O
effects	O
of	O
other	O
NSAID	O
are	O
probably	O
not	O
justified	O
.	O

Ventricular	B-DISEASE
tachyarrhythmias	I-DISEASE
during	O
cesarean	O
section	O
after	O
ritodrine	B-CHEMICAL
therapy	O
:	O
interaction	O
with	O
anesthetics	O
.	O
This	O
case	O
illustrates	O
that	O
patients	O
receiving	O
ritodrine	B-CHEMICAL
for	O
preterm	O
labor	O
may	O
risk	O
interactions	O
between	O
the	O
residual	O
betamimetic	O
effects	O
of	O
ritodrine	B-CHEMICAL
and	O
the	O
effects	O
of	O
anesthetics	O
during	O
cesarean	O
section	O
.	O
Such	O
interactions	O
may	O
result	O
in	O
serious	O
cardiovascular	B-DISEASE
complications	I-DISEASE
even	O
after	O
cessation	O
of	O
an	O
infusion	O
of	O
ritodrine	B-CHEMICAL
.	O
Preoperative	O
assessment	O
should	O
focus	O
on	O
cardiovascular	O
status	O
and	O
serum	O
potassium	B-CHEMICAL
level	O
.	O
Delaying	O
induction	O
of	O
anesthesia	O
should	O
be	O
considered	O
whenever	O
possible	O
.	O
Careful	O
fluid	O
administration	O
and	O
cautious	O
use	O
of	O
titrated	O
doses	O
of	O
ephedrine	B-CHEMICAL
are	O
advised	O
.	O
After	O
delivery	O
of	O
the	O
infant	O
,	O
there	O
should	O
be	O
no	O
contraindication	O
to	O
the	O
use	O
of	O
an	O
alpha	O
-	O
adrenergic	O
vasopressor	O
such	O
as	O
phenylephrine	B-CHEMICAL
to	O
treat	O
hypotensive	B-DISEASE
patients	O
with	O
tachycardia	B-DISEASE
.	O

Immunohistochemical	O
,	O
electron	O
microscopic	O
and	O
morphometric	O
studies	O
of	O
estrogen	B-CHEMICAL
-	O
induced	O
rat	O
prolactinomas	O
after	O
bromocriptine	O
treatment	O
.	O
To	O
clarify	O
the	O
effects	O
of	O
bromocriptine	O
on	O
prolactinoma	B-DISEASE
cells	O
in	O
vivo	O
,	O
immunohistochemical	O
,	O
ultrastructural	O
and	O
morphometrical	O
analyses	O
were	O
applied	O
to	O
estrogen	B-CHEMICAL
-	O
induced	O
rat	O
prolactinoma	B-DISEASE
cells	O
1	O
h	O
and	O
6	O
h	O
after	O
injection	O
of	O
bromocriptine	O
(	O
3	O
mg	O
/	O
kg	O
of	O
body	B-DISEASE
weight	I-DISEASE
)	O
.	O
One	O
h	O
after	O
treatment	O
,	O
serum	O
prolactin	O
levels	O
decreased	O
markedly	O
.	O
Electron	O
microscopy	O
disclosed	O
many	O
secretory	O
granules	O
,	O
slightly	O
distorted	O
rough	O
endoplasmic	O
reticulum	O
,	O
and	O
partially	O
dilated	O
Golgi	O
cisternae	O
in	O
the	O
prolactinoma	B-DISEASE
cells	O
.	O
Morphometric	O
analysis	O
revealed	O
that	O
the	O
volume	O
density	O
of	O
secretory	O
granules	O
increased	O
,	O
while	O
the	O
volume	O
density	O
of	O
cytoplasmic	O
microtubules	O
decreased	O
.	O
These	O
findings	O
suggest	O
that	O
lowered	O
serum	O
prolactin	O
levels	O
in	O
the	O
early	O
phase	O
of	O
bromocriptine	O
treatment	O
may	O
result	O
from	O
an	O
impaired	O
secretion	O
of	O
prolactin	O
due	O
to	O
decreasing	O
numbers	O
of	O
cytoplasmic	O
microtubules	O
.	O
At	O
6	O
h	O
after	O
injection	O
,	O
serum	O
prolactin	O
levels	O
were	O
still	O
considerably	O
lower	O
than	O
in	O
controls	O
.	O
The	O
prolactinoma	B-DISEASE
cells	O
at	O
this	O
time	O
were	O
well	O
granulated	O
,	O
with	O
vesiculated	O
rough	O
endoplasmic	O
reticulum	O
and	O
markedly	O
dilated	O
Golgi	O
cisternae	O
.	O
Electron	O
microscopical	O
immunohistochemistry	O
revealed	O
positive	O
reaction	O
products	O
noted	O
on	O
the	O
secretory	O
granules	O
,	O
Golgi	O
cisternae	O
,	O
and	O
endoplasmic	O
reticulum	O
of	O
the	O
untreated	O
rat	O
prolactinoma	B-DISEASE
cells	O
.	O
However	O
,	O
only	O
secretory	O
granules	O
showed	O
the	O
positive	O
reaction	O
products	O
for	O
prolactin	O
6	O
h	O
after	O
bromocriptine	O
treatment	O
of	O
the	O
adenoma	B-DISEASE
cells	O
.	O
An	O
increase	O
in	O
the	O
volume	O
density	O
of	O
secretory	O
granules	O
and	O
a	O
decrease	O
in	O
the	O
volume	O
densities	O
of	O
rough	O
endoplasmic	O
reticulum	O
and	O
microtubules	O
was	O
determined	O
by	O
morphometric	O
analysis	O
,	O
suggesting	O
that	O
bromocriptine	O
inhibits	O
protein	O
synthesis	O
as	O
well	O
as	O
bringing	O
about	O
a	O
disturbance	O
of	O
the	O
prolactin	O
secretion	O
.	O

On	O
two	O
paradoxical	O
side	O
-	O
effects	O
of	O
prednisolone	B-CHEMICAL
in	O
rats	O
,	O
ribosomal	O
RNA	O
biosyntheses	O
,	O
and	O
a	O
mechanism	O
of	O
action	O
.	O
Liver	O
enlargement	O
and	O
muscle	O
wastage	O
occurred	O
in	O
Wistar	O
rats	O
following	O
the	O
subcutaneous	O
administration	O
of	O
prednisolone	B-CHEMICAL
.	O
In	O
the	O
liver	O
both	O
the	O
content	O
of	O
RNA	O
and	O
the	O
biosynthesis	O
of	O
ribosomal	O
RNA	O
increased	O
while	O
both	O
the	O
RNA	O
content	O
and	O
ribosomal	O
RNA	O
biosynthesis	O
were	O
reduced	O
in	O
the	O
gastrocnemius	O
muscle	O
.	O
It	O
is	O
suggested	O
that	O
the	O
drug	O
acted	O
in	O
a	O
selective	O
and	O
tissue	O
-	O
specific	O
manner	O
to	O
enhance	O
ribosomal	O
RNA	O
synthesis	O
in	O
the	O
liver	O
and	O
depress	O
such	O
synthesis	O
in	O
the	O
muscle	O
.	O
This	O
view	O
supports	O
the	O
contention	O
that	O
the	O
liver	O
and	O
muscle	O
are	O
independent	O
sites	O
of	O
prednisolone	B-CHEMICAL
action	O
.	O

Possible	O
intramuscular	O
midazolam	B-CHEMICAL
-	O
associated	O
cardiorespiratory	B-DISEASE
arrest	I-DISEASE
and	O
death	B-DISEASE
.	O
Midazolam	B-CHEMICAL
hydrochloride	O
is	O
commonly	O
used	O
for	O
dental	O
or	O
endoscopic	O
procedures	O
.	O
Although	O
generally	O
consisted	O
safe	O
when	O
given	O
intramuscularly	O
,	O
intravenous	O
administration	O
is	O
known	O
to	O
cause	O
respiratory	O
and	O
cardiovascular	B-DISEASE
depression	I-DISEASE
.	O
This	O
report	O
describes	O
the	O
first	O
published	O
case	O
of	O
cardiorespiratory	B-DISEASE
arrest	I-DISEASE
and	O
death	B-DISEASE
associated	O
with	O
intramuscular	O
administration	O
of	O
midazolam	B-CHEMICAL
.	O
Information	O
regarding	O
midazolam	B-CHEMICAL
use	O
is	O
reviewed	O
to	O
provide	O
recommendation	O
for	O
safe	O
administration	O
.	O

Serial	O
epilepsy	B-DISEASE
caused	O
by	O
levodopa	B-CHEMICAL
/	O
carbidopa	O
administration	O
in	O
two	O
patients	O
on	O
hemodialysis	O
.	O
Two	O
patients	O
with	O
similar	O
clinical	O
features	O
are	O
presented	O
:	O
both	O
patients	O
had	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
,	O
on	O
hemodialysis	O
for	O
many	O
years	O
but	O
recently	O
begun	O
on	O
a	O
high	O
-	O
flux	O
dialyzer	O
;	O
both	O
had	O
been	O
receiving	O
a	O
carbidopa	O
/	O
levodopa	B-CHEMICAL
preparation	O
;	O
and	O
both	O
had	O
the	O
onset	O
of	O
hallucinosis	O
and	O
recurrent	O
seizures	B-DISEASE
,	O
which	O
were	O
refractory	O
to	O
anticonvulsants	O
.	O
The	O
first	O
patient	O
died	O
without	O
a	O
diagnosis	O
;	O
the	O
second	O
patient	O
had	O
a	O
dramatic	O
recovery	O
following	O
the	O
administration	O
of	O
vitamin	O
B6	O
.	O
Neither	O
patient	O
was	O
considered	O
to	O
have	O
a	O
renal	O
state	O
sufficiently	O
severe	O
enough	O
to	O
explain	O
their	O
presentation	O
.	O

Effect	O
of	O
L	O
-	O
alpha	O
-	O
glyceryl	O
-	O
phosphorylcholine	O
on	O
amnesia	B-DISEASE
caused	O
by	O
scopolamine	B-CHEMICAL
.	O
The	O
present	O
study	O
was	O
carried	O
out	O
to	O
test	O
the	O
effects	O
of	O
L	O
-	O
alpha	O
-	O
glycerylphosphorylcholine	O
(	O
L	O
-	O
alpha	O
-	O
GFC	O
)	O
on	O
memory	B-DISEASE
impairment	I-DISEASE
induced	O
by	O
scopolamine	B-CHEMICAL
in	O
man	O
.	O
Thirty	O
-	O
two	O
healthy	O
young	O
volunteers	O
were	O
randomly	O
allocated	O
to	O
four	O
different	O
groups	O
.	O
They	O
were	O
given	O
a	O
ten	O
day	O
pretreatment	O
with	O
either	O
L	O
-	O
alpha	O
-	O
GFC	O
or	O
placebo	O
,	O
p.o	O
.	O
,	O
and	O
on	O
the	O
eleventh	O
day	O
either	O
scopolamine	B-CHEMICAL
or	O
placebo	O
,	O
i.m	O
.	O
Before	O
and	O
0.5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
6	O
h	O
after	O
injection	O
the	O
subjects	O
were	O
given	O
attention	O
and	O
mnemonic	O
tests	O
.	O
The	O
findings	O
of	O
this	O
study	O
indicate	O
that	O
the	O
drug	O
is	O
able	O
to	O
antagonize	O
impairment	O
of	O
attention	O
and	O
memory	O
induced	O
by	O
scopolamine	B-CHEMICAL
.	O

Seizures	B-DISEASE
induced	O
by	O
the	O
cocaine	B-CHEMICAL
metabolite	O
benzoylecgonine	O
in	O
rats	O
.	O
The	O
half	O
-	O
life	O
(	O
t1/2	O
)	O
of	O
cocaine	B-CHEMICAL
is	O
relatively	O
short	O
,	O
but	O
some	O
of	O
the	O
consequences	O
of	O
its	O
use	O
,	O
such	O
as	O
seizures	B-DISEASE
and	O
strokes	B-DISEASE
,	O
can	O
occur	O
hours	O
after	O
exposure	O
.	O
This	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
metabolite	O
of	O
cocaine	B-CHEMICAL
may	O
be	O
responsible	O
for	O
some	O
of	O
those	O
delayed	O
sequelae	O
.	O
We	O
evaluated	O
the	O
potential	O
of	O
the	O
major	O
metabolite	O
of	O
cocaine	B-CHEMICAL
,	O
benzoylecgonine	O
(	O
BE	O
)	O
,	O
to	O
cause	O
seizures	B-DISEASE
.	O
Two	O
separate	O
equimolar	O
doses	O
(	O
0.2	O
and	O
0.4	O
mumol	O
)	O
of	O
either	O
cocaine	B-CHEMICAL
or	O
BE	O
were	O
injected	O
ventricularly	O
in	O
unanesthetized	O
juvenile	O
rats	O
.	O
Treated	O
rats	O
were	O
then	O
evaluated	O
for	O
incidence	O
,	O
latency	O
,	O
and	O
seizure	B-DISEASE
pattern	O
or	O
for	O
locomotor	O
activity	O
in	O
animals	O
without	O
seizures	B-DISEASE
.	O
BE	O
-	O
Induced	O
seizures	B-DISEASE
occurred	O
more	O
frequently	O
and	O
had	O
significantly	O
longer	O
latencies	O
than	O
those	O
induced	O
by	O
equimolar	O
amounts	O
of	O
cocaine	B-CHEMICAL
.	O
Whereas	O
cocaine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
were	O
best	O
characterized	O
as	O
brief	O
,	O
generalized	O
,	O
and	O
tonic	O
and	O
resulted	O
in	O
death	B-DISEASE
,	O
those	O
induced	O
by	O
BE	O
were	O
prolonged	O
,	O
often	O
multiple	O
and	O
mixed	O
in	O
type	O
,	O
and	O
rarely	O
resulted	O
in	O
death	B-DISEASE
.	O
Electrical	O
recordings	O
from	O
the	O
hippocampus	O
showed	O
a	O
rhythmic	O
progression	O
in	O
EEG	O
frequency	O
and	O
voltage	O
with	O
clinical	O
seizure	B-DISEASE
expression	O
.	O
BE	O
-	O
Injected	O
rats	O
that	O
did	O
not	O
have	O
seizures	B-DISEASE
had	O
significantly	O
more	O
locomotor	O
activity	O
than	O
cocaine	B-CHEMICAL
-	O
injected	O
animals	O
without	O
seizures	B-DISEASE
.	O
The	O
finding	O
that	O
cocaine-	O
and	O
BE	O
-	O
induced	O
seizures	B-DISEASE
differ	O
in	O
several	O
respects	O
suggests	O
more	O
than	O
one	O
mechanism	O
for	O
cocaine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
and	O
emphasizes	O
the	O
importance	O
of	O
a	O
cocaine	B-CHEMICAL
metabolite	O
,	O
BE	O
.	O

Protection	O
against	O
amphetamine	O
-	O
induced	O
neurotoxicity	B-DISEASE
toward	O
striatal	O
dopamine	B-CHEMICAL
neurons	O
in	O
rodents	O
by	O
LY274614	O
,	O
an	O
excitatory	O
amino	O
acid	O
antagonist	O
.	O
LY274614	O
,	O
3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr	B-CHEMICAL
oisoquinoline-3-	I-CHEMICAL
carboxylic	I-CHEMICAL
acid	I-CHEMICAL
,	O
has	O
been	O
described	O
as	O
a	O
potent	O
antagonist	O
of	O
the	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
subtype	O
of	O
glutamate	B-CHEMICAL
receptor	O
.	O
Here	O
its	O
ability	O
to	O
antagonize	O
the	O
prolonged	O
depletion	O
of	O
dopamine	B-CHEMICAL
in	O
the	O
striatum	O
by	O
amphetamine	O
in	O
iprindole	B-CHEMICAL
-	O
treated	O
rats	O
is	O
reported	O
.	O
A	O
single	O
18.4	O
mg	O
/	O
kg	O
(	O
i.p	O
.	O
)	O
dose	O
of	O
(	O
+	O
/-)-amphetamine	O
hemisulfate	O
,	O
given	O
to	O
rats	O
pretreated	O
with	O
iprindole	B-CHEMICAL
,	O
resulted	O
in	O
persistent	O
depletion	O
of	O
dopamine	B-CHEMICAL
in	O
the	O
striatum	O
1	O
week	O
later	O
.	O
This	O
prolonged	O
depletion	O
of	O
dopamine	B-CHEMICAL
in	O
the	O
striatum	O
was	O
antagonized	O
by	O
dizocilpine	O
(	O
MK-801	O
,	O
a	O
non	O
-	O
competitive	O
antagonist	O
of	O
NMDA	O
receptors	O
)	O
or	O
by	O
LY274614	O
(	O
a	O
competitive	O
antagonist	O
of	O
NMDA	O
receptors	O
)	O
.	O
The	O
protective	O
effect	O
of	O
LY274614	O
was	O
dose	O
-	O
dependent	O
,	O
being	O
maximum	O
at	O
10	O
-	O
40	O
mgkg	O
(	O
i.p	O
.	O
)	O
.	O
A	O
10	O
mg	O
/	O
kg	O
dose	O
of	O
LY274614	O
was	O
effective	O
in	O
antagonizing	O
the	O
depletion	O
of	O
dopamine	B-CHEMICAL
in	O
the	O
striatum	O
,	O
when	O
given	O
as	O
long	O
as	B-CHEMICAL
8	I-CHEMICAL
hr	O
prior	O
to	O
amphetamine	O
but	O
not	O
when	O
given	O
24	O
hr	O
prior	O
to	O
amphetamine	O
.	O
Depletion	O
of	O
dopamine	B-CHEMICAL
in	O
the	O
striatum	O
was	O
also	O
antagonized	O
when	O
LY274614	O
was	O
given	O
after	O
the	O
injection	O
of	O
amphetamine	O
;	O
LY274614	O
protected	O
when	O
given	O
up	O
to	O
4	O
hr	O
after	O
but	O
not	O
when	O
given	O
8	O
or	O
24	O
hr	O
after	O
amphetamine	O
.	O
The	O
prolonged	O
depletion	O
of	O
dopamine	B-CHEMICAL
in	O
the	O
striatum	O
in	O
mice	O
,	O
given	O
multiple	O
injections	O
of	O
methamphetamine	B-CHEMICAL
,	O
was	O
also	O
antagonized	O
dose	O
-	O
dependently	O
and	O
completely	O
by	O
LY274614	O
.	O
The	O
data	O
strengthen	O
the	O
evidence	O
that	O
the	O
neurotoxic	B-DISEASE
effect	O
of	O
amphetamine	O
and	O
related	O
compounds	O
toward	O
nigrostriatal	O
dopamine	B-CHEMICAL
neurons	O
involves	O
NMDA	O
receptors	O
and	O
that	O
LY274614	O
is	O
an	O
NMDA	O
receptor	O
antagonist	O
with	O
long	O
-	O
lasting	O
in	O
vivo	O
effects	O
in	O
rats	O
.	O

Neonatal	O
pyridoxine	B-CHEMICAL
responsive	O
convulsions	B-DISEASE
due	O
to	O
isoniazid	B-CHEMICAL
therapy	O
.	O
A	B-CHEMICAL
17	I-CHEMICAL
-	O
day	O
-	O
old	O
infant	O
on	O
isoniazid	B-CHEMICAL
therapy	O
13	O
mg	O
/	O
kg	O
daily	O
from	O
birth	O
because	O
of	O
maternal	O
tuberculosis	B-DISEASE
was	O
admitted	O
after	O
4	O
days	O
of	O
clonic	B-DISEASE
fits	I-DISEASE
.	O
No	O
underlying	O
infective	O
or	O
biochemical	O
cause	O
could	O
be	O
found	O
.	O
The	O
fits	O
ceased	O
within	O
4	O
hours	O
of	O
administering	O
intramuscular	O
pyridoxine	B-CHEMICAL
,	O
suggesting	O
an	O
aetiology	O
of	O
pyridoxine	B-CHEMICAL
deficiency	O
secondary	O
to	O
isoniazid	B-CHEMICAL
medication	O
.	O

Reversal	O
by	O
phenylephrine	B-CHEMICAL
of	O
the	O
beneficial	O
effects	O
of	O
intravenous	O
nitroglycerin	B-CHEMICAL
in	O
patients	O
with	O
acute	B-DISEASE
myocardial	I-DISEASE
infarction	I-DISEASE
.	O
Nitroglycerin	B-CHEMICAL
has	O
been	O
shown	O
to	O
reduce	O
ST	O
-	O
segment	O
elevation	O
during	O
acute	B-DISEASE
myocardial	I-DISEASE
infarction	I-DISEASE
,	O
an	O
effect	O
potentiated	O
in	O
the	O
dog	O
by	O
agents	O
that	O
reverse	O
nitroglycerin	B-CHEMICAL
-	O
induced	O
hypotension	B-DISEASE
.	O
Our	O
study	O
was	O
designed	O
to	O
determine	O
the	O
effects	O
of	O
combined	O
nitroglycerin	B-CHEMICAL
and	O
phenylephrine	B-CHEMICAL
therapy	O
.	O
Ten	O
patients	O
with	O
acute	O
transmural	O
myocardial	O
infarctions	O
received	O
intravenous	O
nitroglycerin	B-CHEMICAL
,	O
sufficient	O
to	O
reduce	O
mean	O
arterial	O
pressure	O
from	O
107	O
+	O
/-	O
6	O
to	O
85	O
+	O
/-	O
6	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0.001	O
)	O
,	O
for	O
60	O
minutes	O
.	O
Left	O
ventricular	O
filling	O
pressure	O
decreased	O
from	O
19	O
+	O
/-	O
2	O
to	O
11	O
+	O
/-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O
SigmaST	O
,	O
the	O
sum	O
of	O
ST	O
-	O
segment	O
elevations	O
in	O
16	O
precordial	O
leads	O
,	O
decreased	O
(	O
P	O
less	O
than	O
0.02	O
)	O
with	O
intravenous	O
nitroglycerin	B-CHEMICAL
.	O
Subsequent	O
addition	O
of	O
phenylephrine	B-CHEMICAL
infusion	O
,	O
sufficient	O
to	O
re	O
-	O
elevate	O
mean	O
arterial	O
pressure	O
to	O
106	O
+	O
/-	O
4	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0.001	O
)	O
for	O
30	O
minutes	O
,	O
increased	O
left	O
ventricular	O
filling	O
pressure	O
to	O
17	O
+	O
/-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
also	O
significantly	O
increased	O
sigmaST	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O
Our	O
results	O
suggest	O
that	O
addition	O
of	O
phenylephrine	B-CHEMICAL
to	O
nitroglycerin	B-CHEMICAL
is	O
not	O
beneficial	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
acute	B-DISEASE
myocardial	I-DISEASE
infarction	I-DISEASE
.	O

Elevation	O
of	O
ADAM10	O
,	O
ADAM17	O
,	O
MMP-2	O
and	O
MMP-9	O
expression	O
with	O
media	O
degeneration	O
features	O
CaCl2	B-CHEMICAL
-	O
induced	O
thoracic	O
aortic	B-DISEASE
aneurysm	I-DISEASE
in	O
a	O
rat	O
model	O
.	O
PURPOSE	O
:	O
This	O
study	O
was	O
designed	O
to	O
establish	O
a	O
rat	O
model	O
of	O
thoracic	O
aortic	B-DISEASE
aneurysm	I-DISEASE
(	O
TAA	B-DISEASE
)	O
by	O
calcium	B-CHEMICAL
chloride	I-CHEMICAL
(	O
CaCl(2))-induced	O
arterial	B-DISEASE
injury	I-DISEASE
and	O
to	O
explore	O
the	O
potential	O
role	O
of	O
a	O
disintegrin	O
and	O
metalloproteinase	O
(	O
ADAM	O
)	O
,	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
and	O
their	O
endogenous	O
inhibitors	O
(	O
TIMPs	O
)	O
in	O
TAA	B-DISEASE
formation	O
.	O
METHODS	O
:	O
Thoracic	O
aorta	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
was	O
exposed	O
to	O
0.5	O
M	O
CaCl(2	B-CHEMICAL
)	I-CHEMICAL
or	O
normal	O
saline	O
(	O
NaCl	O
)	O
.	O
After	O
12weeks	O
,	O
animals	O
were	O
euthanized	O
,	O
and	O
CaCl(2)-treated	O
,	O
CaCl(2)-untreated	O
(	O
n=12	O
)	O
and	O
NaCl	O
-	O
treated	O
aortic	O
segments	O
(	O
n=12	O
)	O
were	O
collected	O
for	O
histological	O
and	O
molecular	O
assessments	O
.	O
MMP	O
-	O
TIMP	O
and	O
ADAM	O
mRNAs	O
were	O
semi	O
-	O
quantitatively	O
analyzed	O
and	O
protein	O
expressions	O
were	O
determined	O
by	O
immunohistochemistry	O
.	O
RESULTS	O
:	O
Despite	O
similar	O
external	O
diameters	O
among	O
CaCl(2)-treated	O
,	O
non	O
-	O
CaCl(2)-treated	O
and	O
NaCl	O
-	O
treated	O
segments	O
,	O
aneurymal	O
alteration	O
(	O
n=6	O
,	O
50	O
%	O
)	O
,	O
media	O
degeneration	O
with	O
regional	O
disruption	O
,	O
fragmentation	O
of	O
elastic	O
fiber	O
,	O
and	O
increased	O
collagen	O
deposition	O
(	O
n=12	O
,	O
100	O
%	O
)	O
were	O
demonstrated	O
in	O
CaCl(2)-treated	O
segments	O
.	O
MMP-2	O
,	O
MMP-9	O
,	O
ADAM-10	O
and	O
ADAM-17	O
mRNA	O
levels	O
were	O
increased	O
in	O
CaCl(2)-treated	O
segments	O
(	O
all	O
p<0.01	O
)	O
,	O
with	O
trends	O
of	O
elevation	O
in	O
CaCl(2)-untreated	O
segments	O
,	O
as	O
compared	O
with	O
NaCl	O
-	O
treated	O
segments	O
.	O
Immunohistochemistry	O
displayed	O
significantly	O
increased	O
expressions	O
of	O
MMP-2	O
,	O
MMP-9	O
,	O
ADAM-10	O
and	O
ADAM-17	O
(	O
all	O
p<0.01	O
)	O
in	O
intima	O
and	O
media	O
for	O
CaCl(2)-treated	O
segments	O
.	O
TIMP	O
mRNA	O
and	O
tissue	O
levels	O
did	O
not	O
differ	O
obviously	O
among	O
the	O
three	O
aortic	O
segments	O
.	O
CONCLUSION	O
:	O
This	O
study	O
establishes	O
a	O
TAA	B-DISEASE
model	O
by	O
periarterial	O
CaCl(2	B-CHEMICAL
)	I-CHEMICAL
exposure	O
in	O
rats	O
,	O
and	O
demonstrates	O
a	O
significant	O
elevation	O
of	O
expression	O
of	O
MMP-2	O
,	O
MMP-9	O
,	O
ADAM10	O
and	O
ADAM17	O
in	O
the	O
pathogenesis	O
of	O
vascular	B-DISEASE
remodeling	I-DISEASE
.	O

When	O
drugs	O
disappear	O
from	O
the	O
patient	O
:	O
elimination	O
of	O
intravenous	O
medication	O
by	O
hemodiafiltration	O
.	O
Twenty	O
-	O
three	O
hours	O
after	O
heart	O
transplantation	O
,	O
life	O
-	O
threatening	O
acute	O
right	O
heart	B-DISEASE
failure	I-DISEASE
was	O
diagnosed	O
in	O
a	O
patient	O
requiring	O
continuous	O
venovenous	O
hemodiafiltration	O
(	O
CVVHDF	O
)	O
.	O
Increasing	O
doses	O
of	O
catecholamines	O
,	O
sedatives	O
,	O
and	O
muscle	O
relaxants	O
administered	O
through	O
a	O
central	O
venous	O
catheter	O
were	O
ineffective	O
.	O
However	O
,	O
a	O
bolus	O
of	O
epinephrine	B-CHEMICAL
injected	O
through	O
an	O
alternative	O
catheter	O
provoked	O
a	O
hypertensive	B-DISEASE
crisis	O
.	O
Thus	O
,	O
interference	O
with	O
the	O
central	O
venous	O
infusion	O
by	O
the	O
dialysis	O
catheter	O
was	O
suspected	O
.	O
The	O
catheters	O
were	O
changed	O
,	O
and	O
hemodynamics	O
stabilized	O
at	O
lower	O
catecholamine	O
doses	O
.	O
When	O
the	O
effects	O
of	O
IV	O
drugs	O
are	O
inadequate	O
in	O
patients	O
receiving	O
CVVHDF	O
,	O
interference	O
with	O
adjacent	O
catheters	O
resulting	O
in	O
elimination	O
of	O
the	O
drug	O
by	O
CVVHDF	O
should	O
be	O
suspected	O
.	O

Long	O
-	O
term	O
glutamate	B-CHEMICAL
supplementation	O
failed	O
to	O
protect	O
against	O
peripheral	O
neurotoxicity	B-DISEASE
of	O
paclitaxel	B-CHEMICAL
.	O
Toxic	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
is	O
still	O
a	O
significant	O
limiting	O
factor	O
for	O
chemotherapy	O
with	O
paclitaxel	B-CHEMICAL
(	O
PAC	O
)	O
,	O
although	O
glutamate	B-CHEMICAL
and	O
its	O
closely	O
related	O
amino	O
acid	O
glutamine	O
were	O
claimed	O
to	O
ameliorate	O
PAC	O
neurotoxicity	B-DISEASE
.	O
This	O
pilot	O
trial	O
aimed	O
to	O
evaluate	O
the	O
role	O
of	O
glutamate	B-CHEMICAL
supplementation	O
for	O
preventing	O
PAC	O
-	O
induced	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
in	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blinded	O
clinical	O
and	O
electro	O
-	O
diagnostic	O
study	O
.	O
Forty	O
-	O
three	O
ovarian	B-DISEASE
cancer	I-DISEASE
patients	O
were	O
available	O
for	O
analysis	O
following	O
six	O
cycles	O
of	O
the	O
same	O
PAC	O
-	O
containing	O
regimen	O
:	O
23	O
had	O
been	O
supplemented	O
by	O
glutamate	B-CHEMICAL
all	O
along	O
the	O
treatment	O
period	O
,	O
at	O
a	O
daily	O
dose	O
of	O
three	O
times	O
500	O
mg	O
(	O
group	O
G	O
)	O
,	O
and	O
20	O
had	O
received	O
a	O
placebo	O
(	O
group	O
P	O
)	O
.	O
Patients	O
were	O
evaluated	O
by	O
neurological	O
examinations	O
,	O
questionnaires	O
and	O
sensory	O
-	O
motor	O
nerve	O
conduction	O
studies	O
.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
frequency	O
of	O
signs	O
or	O
symptoms	O
between	O
the	O
two	O
groups	O
although	O
neurotoxicity	B-DISEASE
symptoms	O
presented	O
mostly	O
with	O
lower	O
scores	O
of	O
severity	O
in	O
group	O
G.	O
However	O
,	O
this	O
difference	O
reached	O
statistical	O
significance	O
only	O
with	O
regard	O
to	O
reported	O
pain	B-DISEASE
sensation	O
(	O
P	O
=	O
0.011	O
)	O
.	O
Also	O
the	O
frequency	O
of	O
abnormal	O
electro	O
-	O
diagnostic	O
findings	O
showed	O
similarity	O
between	O
the	O
two	O
groups	O
(	O
G	O
:	O
7/23	O
=	O
30.4	O
%	O
;	O
P	O
:	O
6/20	O
=	O
30	O
%	O
)	O
.	O
This	O
pilot	O
study	O
leads	O
to	O
the	O
conclusion	O
that	O
glutamate	B-CHEMICAL
supplementation	O
at	O
the	O
chosen	O
regimen	O
fails	O
to	O
protect	O
against	O
peripheral	O
neurotoxicity	B-DISEASE
of	O
PAC	O
.	O

Attentional	O
modulation	O
of	O
perceived	O
pain	B-DISEASE
intensity	O
in	O
capsaicin	B-CHEMICAL
-	O
induced	O
secondary	B-DISEASE
hyperalgesia	I-DISEASE
.	O
Perceived	O
pain	B-DISEASE
intensity	O
is	O
modulated	O
by	O
attention	O
.	O
However	O
,	O
it	O
is	O
not	O
known	O
that	O
how	O
pain	B-DISEASE
intensity	O
ratings	O
are	O
affected	O
by	O
attention	O
in	O
capsaicin	B-CHEMICAL
-	O
induced	O
secondary	B-DISEASE
hyperalgesia	I-DISEASE
.	O
Here	O
we	O
show	O
that	O
perceived	O
pain	B-DISEASE
intensity	O
in	O
secondary	B-DISEASE
hyperalgesia	I-DISEASE
is	O
decreased	O
when	O
attention	O
is	O
distracted	O
away	O
from	O
the	O
painful	O
pinprick	O
stimulus	O
with	O
a	O
visual	O
task	O
.	O
Furthermore	O
,	O
it	O
was	O
found	O
that	O
the	O
magnitude	O
of	O
attentional	O
modulation	O
in	O
secondary	B-DISEASE
hyperalgesia	I-DISEASE
is	O
very	O
similar	O
to	O
that	O
of	O
capsaicin	B-CHEMICAL
-	O
untreated	O
,	O
control	O
condition	O
.	O
Our	O
findings	O
,	O
showing	O
no	O
interaction	O
between	O
capsaicin	B-CHEMICAL
treatment	O
and	O
attentional	O
modulation	O
suggest	O
that	O
capsaicin	B-CHEMICAL
-	O
induced	O
secondary	B-DISEASE
hyperalgesia	I-DISEASE
and	O
attention	O
might	O
affect	O
mechanical	O
pain	B-DISEASE
through	O
independent	O
mechanisms	O
.	O

Testosterone	B-CHEMICAL
-	O
dependent	O
hypertension	B-DISEASE
and	O
upregulation	O
of	O
intrarenal	O
angiotensinogen	O
in	O
Dahl	O
salt	B-CHEMICAL
-	O
sensitive	O
rats	O
.	O
Blood	O
pressure	O
(	O
BP	O
)	O
is	O
more	O
salt	B-CHEMICAL
sensitive	O
in	O
men	O
than	O
in	O
premenopausal	O
women	O
.	O
In	O
Dahl	O
salt	B-CHEMICAL
-	O
sensitive	O
rats	O
(	O
DS	O
)	O
,	O
high	O
-	O
salt	B-CHEMICAL
(	O
HS	O
)	O
diet	O
increases	O
BP	O
more	O
in	O
males	O
than	O
females	O
.	O
In	O
contrast	O
to	O
the	O
systemic	O
renin	O
-	O
angiotensin	O
system	O
,	O
which	O
is	O
suppressed	O
in	O
response	O
to	O
HS	O
in	O
male	O
DS	O
,	O
intrarenal	O
angiotensinogen	O
expression	O
is	O
increased	O
,	O
and	O
intrarenal	O
levels	O
of	O
ANG	O
II	O
are	O
not	O
suppressed	O
.	O
In	O
this	O
study	O
,	O
the	O
hypothesis	O
was	O
tested	O
that	O
there	O
is	O
a	O
sexual	O
dimorphism	O
in	O
HS	O
-	O
induced	O
upregulation	O
of	O
intrarenal	O
angiotensinogen	O
mediated	O
by	O
testosterone	B-CHEMICAL
that	O
also	O
causes	O
increases	O
in	O
BP	O
and	O
renal	B-DISEASE
injury	I-DISEASE
.	O
On	O
a	O
low	O
-	O
salt	B-CHEMICAL
(	O
LS	O
)	O
diet	O
,	O
male	O
DS	O
had	O
higher	O
levels	O
of	O
intrarenal	O
angiotensinogen	O
mRNA	O
than	O
females	O
.	O
HS	O
diet	O
for	O
4	O
wk	O
increased	O
renal	O
cortical	O
angiotensinogen	O
mRNA	O
and	O
protein	O
only	O
in	O
male	O
DS	O
,	O
which	O
was	O
prevented	O
by	O
castration	O
.	O
Ovariectomy	O
of	O
female	O
DS	O
had	O
no	O
effect	O
on	O
intrarenal	O
angiotensinogen	O
expression	O
on	O
either	O
diet	O
.	O
Radiotelemetric	O
BP	O
was	O
similar	O
between	O
males	O
and	O
castrated	O
rats	O
on	O
LS	O
diet	O
.	O
HS	O
diet	O
for	O
4	O
wk	O
caused	O
a	O
progressive	O
increase	O
in	O
BP	O
,	O
protein	O
and	O
albumin	O
excretion	O
,	O
and	O
glomerular	O
sclerosis	B-DISEASE
in	O
male	O
DS	O
rats	O
,	O
which	O
were	O
attenuated	O
by	O
castration	O
.	O
Testosterone	B-CHEMICAL
replacement	O
in	O
castrated	O
DS	O
rats	O
increased	O
BP	O
,	O
renal	B-DISEASE
injury	I-DISEASE
,	O
and	O
upregulation	O
of	O
renal	O
angiotensinogen	O
associated	O
with	O
HS	O
diet	O
.	O
Testosterone	B-CHEMICAL
contributes	O
to	O
the	O
development	O
of	O
hypertension	B-DISEASE
and	O
renal	B-DISEASE
injury	I-DISEASE
in	O
male	O
DS	O
rats	O
on	O
HS	O
diet	O
possibly	O
through	O
upregulation	O
of	O
the	O
intrarenal	O
renin	O
-	O
angiotensin	O
system	O
.	O

Prenatal	O
protein	O
deprivation	O
alters	O
dopamine	B-CHEMICAL
-	O
mediated	O
behaviors	O
and	O
dopaminergic	O
and	O
glutamatergic	O
receptor	O
binding	O
.	O
Epidemiological	O
evidence	O
indicates	O
that	O
prenatal	O
nutritional	O
deprivation	O
may	O
increase	O
the	O
risk	O
of	O
schizophrenia	B-DISEASE
.	O
The	O
goal	O
of	O
these	O
studies	O
was	O
to	O
use	O
an	O
animal	O
model	O
to	O
examine	O
the	O
effects	O
of	O
prenatal	O
protein	O
deprivation	O
on	O
behaviors	O
and	O
receptor	O
binding	O
with	O
relevance	O
to	O
schizophrenia	B-DISEASE
.	O
We	O
report	O
that	O
prenatally	O
protein	O
deprived	O
(	O
PD	O
)	O
female	O
rats	O
showed	O
an	O
increased	O
stereotypic	O
response	O
to	O
apomorphine	O
and	O
an	O
increased	O
locomotor	O
response	O
to	O
amphetamine	O
in	O
adulthood	O
.	O
These	O
differences	O
were	O
not	O
observed	O
during	O
puberty	O
.	O
No	O
changes	O
in	O
haloperidol	B-CHEMICAL
-	O
induced	O
catalepsy	B-DISEASE
or	O
MK-801	O
-	O
induced	O
locomotion	O
were	O
seen	O
following	O
PD	O
.	O
In	O
addition	O
,	O
PD	O
female	O
rats	O
showed	O
increased	O
(	O
3)H	O
-	O
MK-801	O
binding	O
in	O
the	O
striatum	O
and	O
hippocampus	O
,	O
but	O
not	O
in	O
the	O
cortex	O
.	O
PD	O
female	O
rats	O
also	O
showed	O
increased	O
(	O
3)H	O
-	O
haloperidol	B-CHEMICAL
binding	O
and	O
decreased	O
dopamine	B-CHEMICAL
transporter	O
binding	O
in	O
striatum	O
.	O
No	O
statistically	O
significant	O
changes	O
in	O
behavior	O
or	O
receptor	O
binding	O
were	O
found	O
in	O
PD	O
males	O
with	O
the	O
exception	O
of	O
increased	O
(	O
3)H	O
-	O
MK-801	O
binding	O
in	O
cortex	O
.	O
This	O
animal	O
model	O
may	O
be	O
useful	O
to	O
explore	O
the	O
mechanisms	O
by	O
which	O
prenatal	O
nutritional	O
deficiency	O
enhances	O
risk	O
for	O
schizophrenia	B-DISEASE
in	O
humans	O
and	O
may	O
also	O
have	O
implications	O
for	O
developmental	O
processes	O
leading	O
to	O
differential	O
sensitivity	O
to	O
drugs	O
of	O
abuse	O
.	O

mToR	O
inhibitors	O
-	O
induced	O
proteinuria	B-DISEASE
:	O
mechanisms	O
,	O
significance	O
,	O
and	O
management	O
.	O
Massive	O
urinary	O
protein	O
excretion	O
has	O
been	O
observed	O
after	O
conversion	O
from	O
calcineurin	B-CHEMICAL
inhibitors	I-CHEMICAL
to	O
mammalian	O
target	O
of	O
rapamycin	B-CHEMICAL
(	O
mToR	O
)	O
inhibitors	O
,	O
especially	O
sirolimus	B-CHEMICAL
,	O
in	O
renal	O
transplant	O
recipients	O
with	O
chronic	B-DISEASE
allograft	I-DISEASE
nephropathy	I-DISEASE
.	O
Because	O
proteinuria	B-DISEASE
is	O
a	O
major	O
predictive	O
factor	O
of	O
poor	O
transplantation	O
outcome	O
,	O
many	O
studies	O
focused	O
on	O
this	O
adverse	O
event	O
during	O
the	O
past	O
years	O
.	O
Whether	O
proteinuria	B-DISEASE
was	O
due	O
to	O
sirolimus	B-CHEMICAL
or	O
only	O
a	O
consequence	O
of	O
calcineurin	B-CHEMICAL
inhibitors	I-CHEMICAL
withdrawal	O
remained	O
unsolved	O
until	O
high	O
range	O
proteinuria	B-DISEASE
has	O
been	O
observed	O
during	O
sirolimus	B-CHEMICAL
therapy	O
in	O
islet	O
transplantation	O
and	O
in	O
patients	O
who	O
received	O
sirolimus	B-CHEMICAL
de	O
novo	O
.	O
Podocyte	O
injury	O
and	O
focal	O
segmental	B-DISEASE
glomerulosclerosis	I-DISEASE
have	O
been	O
related	O
to	O
mToR	O
inhibition	O
in	O
some	O
patients	O
,	O
but	O
the	O
pathways	O
underlying	O
these	O
lesions	O
remain	O
hypothetic	O
.	O
We	O
discuss	O
herein	O
the	O
possible	O
mechanisms	O
and	O
the	O
significance	O
of	O
mToR	O
blockade	O
-	O
induced	O
proteinuria	B-DISEASE
.	O

Hypothalamic	O
prolactin	O
receptor	O
messenger	O
ribonucleic	O
acid	O
levels	O
,	O
prolactin	O
signaling	O
,	O
and	O
hyperprolactinemic	O
inhibition	O
of	O
pulsatile	O
luteinizing	O
hormone	O
secretion	O
are	O
dependent	O
on	O
estradiol	B-CHEMICAL
.	O
Hyperprolactinemia	B-DISEASE
can	O
reduce	O
fertility	O
and	O
libido	O
.	O
Although	O
central	O
prolactin	O
actions	O
are	O
thought	O
to	O
contribute	O
to	O
this	O
,	O
the	O
mechanisms	O
are	O
poorly	O
understood	O
.	O
We	O
first	O
tested	O
whether	O
chronic	O
hyperprolactinemia	B-DISEASE
inhibited	O
two	O
neuroendocrine	O
parameters	O
necessary	O
for	O
female	O
fertility	O
:	O
pulsatile	O
LH	O
secretion	O
and	O
the	O
estrogen	B-CHEMICAL
-	O
induced	O
LH	O
surge	O
.	O
Chronic	O
hyperprolactinemia	B-DISEASE
induced	O
by	O
the	O
dopamine	B-CHEMICAL
antagonist	O
sulpiride	B-CHEMICAL
caused	O
a	O
40	O
%	O
reduction	O
LH	O
pulse	O
frequency	O
in	O
ovariectomized	O
rats	O
,	O
but	O
only	O
in	O
the	O
presence	O
of	O
chronic	O
low	O
levels	O
of	O
estradiol	B-CHEMICAL
.	O
Sulpiride	B-CHEMICAL
did	O
not	O
affect	O
the	O
magnitude	O
of	O
a	O
steroid	B-CHEMICAL
-	O
induced	O
LH	O
surge	O
or	O
the	O
percentage	O
of	O
GnRH	O
neurons	O
activated	O
during	O
the	O
surge	O
.	O
Estradiol	B-CHEMICAL
is	O
known	O
to	O
influence	O
expression	O
of	O
the	O
long	O
form	O
of	O
prolactin	O
receptors	O
(	O
PRL	O
-	O
R	O
)	O
and	O
components	O
of	O
prolactin	O
's	O
signaling	O
pathway	O
.	O
To	O
test	O
the	O
hypothesis	O
that	O
estrogen	B-CHEMICAL
increases	O
PRL	O
-	O
R	O
expression	O
and	O
sensitivity	O
to	O
prolactin	O
,	O
we	O
next	O
demonstrated	O
that	O
estradiol	B-CHEMICAL
greatly	O
augments	O
prolactin	O
-	O
induced	O
STAT5	O
activation	O
.	O
Lastly	O
,	O
we	O
measured	O
PRL	O
-	O
R	O
and	O
suppressor	O
of	O
cytokine	O
signaling	O
(	O
SOCS-1	O
and	O
-3	O
and	O
CIS	O
,	O
which	O
reflect	O
the	O
level	O
of	O
prolactin	O
signaling	O
)	O
mRNAs	O
in	O
response	O
to	O
sulpiride	B-CHEMICAL
and	O
estradiol	B-CHEMICAL
.	O
Sulpiride	B-CHEMICAL
induced	O
only	O
SOCS-1	O
in	O
the	O
medial	O
preoptic	O
area	O
,	O
where	O
GnRH	O
neurons	O
are	O
regulated	O
,	O
but	O
in	O
the	O
arcuate	O
nucleus	O
and	O
choroid	O
plexus	O
,	O
PRL	O
-	O
R	O
,	O
SOCS-3	O
,	O
and	O
CIS	O
mRNA	O
levels	O
were	O
also	O
induced	O
.	O
Estradiol	B-CHEMICAL
enhanced	O
these	O
effects	O
on	O
SOCS-3	O
and	O
CIS	O
.	O
Interestingly	O
,	O
estradiol	B-CHEMICAL
also	O
induced	O
PRL	O
-	O
R	O
,	O
SOCS-3	O
,	O
and	O
CIS	O
mRNA	O
levels	O
independently	O
.	O
These	O
data	O
show	O
that	O
GnRH	O
pulse	O
frequency	O
is	O
inhibited	O
by	O
chronic	O
hyperprolactinemia	B-DISEASE
in	O
a	O
steroid	B-CHEMICAL
-	O
dependent	O
manner	O
.	O
They	O
also	O
provide	O
evidence	O
for	O
estradiol	B-CHEMICAL
-	O
dependent	O
and	O
brain	O
region	O
-	O
specific	O
regulation	O
of	O
PRL	O
-	O
R	O
expression	O
and	O
signaling	O
responses	O
by	O
prolactin	O
.	O

Estrogen	B-CHEMICAL
prevents	O
cholesteryl	O
ester	O
accumulation	O
in	O
macrophages	O
induced	O
by	O
the	O
HIV	B-DISEASE
protease	O
inhibitor	O
ritonavir	B-CHEMICAL
.	O
Individuals	O
with	O
HIV	B-DISEASE
can	O
now	O
live	O
long	O
lives	O
with	O
drug	O
therapy	O
that	O
often	O
includes	O
protease	O
inhibitors	O
such	O
as	O
ritonavir	B-CHEMICAL
.	O
Many	O
patients	O
,	O
however	O
,	O
develop	O
negative	O
long	O
-	O
term	O
side	O
effects	O
such	O
as	O
premature	O
atherosclerosis	B-DISEASE
.	O
We	O
have	O
previously	O
demonstrated	O
that	O
ritonavir	B-CHEMICAL
treatment	O
increases	O
atherosclerotic	B-DISEASE
lesion	I-DISEASE
formation	O
in	O
male	O
mice	O
to	O
a	O
greater	O
extent	O
than	O
in	O
female	O
mice	O
.	O
Furthermore	O
,	O
peripheral	O
blood	O
monocytes	O
isolated	O
from	O
ritonavir	B-CHEMICAL
-	O
treated	O
females	O
had	O
less	O
cholesteryl	O
ester	O
accumulation	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
female	O
hormones	B-CHEMICAL
influence	O
cholesterol	B-CHEMICAL
metabolism	O
in	O
macrophages	O
in	O
response	O
to	O
the	O
HIV	B-DISEASE
protease	O
inhibitor	O
ritonavir	B-CHEMICAL
.	O
We	O
have	O
utilized	O
the	O
human	O
monocyte	O
cell	O
line	O
,	O
THP-1	O
as	O
a	O
model	O
to	O
address	O
this	O
question	O
.	O
Briefly	O
,	O
cells	O
were	O
differentiated	O
for	O
72	O
h	O
with	O
100	O
nM	O
PMA	O
to	O
obtain	O
a	O
macrophage	O
-	O
like	O
phenotype	O
in	O
the	O
presence	O
or	O
absence	O
of	O
1	O
nM	O
17beta	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
(	O
E2	O
)	O
,	O
100	O
nM	O
progesterone	B-CHEMICAL
or	O
vehicle	O
(	O
0.01	O
%	O
ethanol	B-CHEMICAL
)	O
.	O
Cells	O
were	O
then	O
treated	O
with	O
30	O
ng	O
/	O
ml	O
ritonavir	B-CHEMICAL
or	O
vehicle	O
in	O
the	O
presence	O
of	O
aggregated	O
LDL	O
for	O
24	O
h.	O
Cell	B-CHEMICAL
extracts	I-CHEMICAL
were	O
harvested	O
,	O
and	O
lipid	O
or	O
total	O
RNA	O
was	O
isolated	O
.	O
E2	O
decreased	O
the	O
accumulation	O
of	O
cholesteryl	O
esters	O
in	O
macrophages	O
following	O
ritonavir	B-CHEMICAL
treatment	O
.	O
Ritonavir	B-CHEMICAL
increased	O
the	O
expression	O
of	O
the	O
scavenger	O
receptor	O
,	O
CD36	O
mRNA	O
,	O
responsible	O
for	O
the	O
uptake	O
of	O
LDL	O
.	O
Additionally	O
,	O
ritonavir	B-CHEMICAL
treatment	O
selectively	O
increased	O
the	O
relative	O
levels	O
of	O
PPARgamma	O
mRNA	O
,	O
a	O
transcription	O
factor	O
responsible	O
for	O
the	O
regulation	O
of	O
CD36	O
mRNA	O
expression	O
.	O
Treatment	O
with	O
E2	O
,	O
however	O
,	O
failed	O
to	O
prevent	O
these	O
increases	O
at	O
the	O
mRNA	O
level	O
.	O
E2	O
did	O
,	O
however	O
,	O
significantly	O
suppress	O
CD36	O
protein	O
levels	O
as	O
measured	O
by	O
fluorescent	O
immunocytochemistry	O
.	O
This	O
data	O
suggests	O
that	O
E2	O
modifies	O
the	O
expression	O
of	O
CD36	O
at	O
the	O
level	O
of	O
protein	O
expression	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
resulting	O
in	O
reduced	O
cholesteryl	O
ester	O
accumulation	O
following	O
ritonavir	B-CHEMICAL
treatment	O
.	O

Upregulation	O
of	O
brain	O
expression	O
of	O
P	O
-	O
glycoprotein	O
in	O
MRP2	O
-	O
deficient	O
TR(-	O
)	O
rats	O
resembles	O
seizure	B-DISEASE
-	O
induced	O
up	O
-	O
regulation	O
of	O
this	O
drug	O
efflux	O
transporter	O
in	O
normal	O
rats	O
.	O
PURPOSE	O
:	O
The	O
multidrug	O
resistance	O
protein	O
2	O
(	O
MRP2	O
)	O
is	O
a	O
drug	O
efflux	O
transporter	O
that	O
is	O
expressed	O
predominantly	O
at	O
the	O
apical	O
domain	O
of	O
hepatocytes	O
but	O
seems	O
also	O
to	O
be	O
expressed	O
at	O
the	O
apical	O
membrane	O
of	O
brain	O
capillary	O
endothelial	O
cells	O
that	O
form	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
.	O
MRP2	O
is	O
absent	O
in	O
the	O
transport	O
-	O
deficient	O
(	O
TR(-	O
)	O
)	O
Wistar	O
rat	O
mutant	O
,	O
so	O
that	O
this	O
rat	O
strain	O
was	O
very	O
helpful	O
in	O
defining	O
substrates	O
of	O
MRP2	O
by	O
comparing	O
tissue	O
concentrations	O
or	O
functional	O
activities	O
of	O
compounds	O
in	O
MRP2	O
-	O
deficient	O
rats	O
with	O
those	O
in	O
transport	O
-	O
competent	O
Wistar	O
rats	O
.	O
By	O
using	O
this	O
strategy	O
to	O
study	O
the	O
involvement	O
of	O
MRP2	O
in	O
brain	O
access	O
of	O
antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
,	O
we	O
recently	O
reported	O
that	O
phenytoin	B-CHEMICAL
is	O
a	O
substrate	O
for	O
MRP2	O
in	O
the	O
BBB	O
.	O
However	O
,	O
one	O
drawback	O
of	O
such	O
studies	O
in	O
genetically	O
deficient	O
rats	O
is	O
the	O
fact	O
that	O
compensatory	O
changes	O
with	O
upregulation	O
of	O
other	O
transporters	O
can	O
occur	O
.	O
This	O
prompted	O
us	O
to	O
study	O
the	O
brain	O
expression	O
of	O
P	O
-	O
glycoprotein	O
(	O
Pgp	O
)	O
,	O
a	O
major	O
drug	O
efflux	O
transporter	O
in	O
many	O
tissues	O
,	O
including	O
the	O
BBB	O
,	O
in	O
TR(-	O
)	O
rats	O
compared	O
with	O
nonmutant	O
(	O
wild	O
-	O
type	O
)	O
Wistar	O
rats	O
.	O
METHODS	O
:	O
The	O
expression	O
of	O
MRP2	O
and	O
Pgp	O
in	O
brain	O
and	O
liver	O
sections	O
of	O
TR(-	O
)	O
rats	O
and	O
normal	O
Wistar	O
rats	O
was	O
determined	O
with	O
immunohistochemistry	O
,	O
by	O
using	O
a	O
novel	O
,	O
highly	O
selective	O
monoclonal	O
MRP2	O
antibody	O
and	O
the	O
monoclonal	O
Pgp	O
antibody	O
C219	O
,	O
respectively	O
.	O
RESULTS	O
:	O
Immunofluorescence	O
staining	O
with	O
the	O
MRP2	O
antibody	O
was	O
found	O
to	O
label	O
a	O
high	O
number	O
of	O
microvessels	O
throughout	O
the	O
brain	O
in	O
normal	O
Wistar	O
rats	O
,	O
whereas	O
such	O
labeling	O
was	O
absent	O
in	O
TR(-	O
)	O
rats	O
.	O
TR(-	O
)	O
rats	O
exhibited	O
a	O
significant	O
up	O
-	O
regulation	O
of	O
Pgp	O
in	O
brain	O
capillary	O
endothelial	O
cells	O
compared	O
with	O
wild	O
-	O
type	O
controls	O
.	O
No	O
such	O
obvious	O
upregulation	O
of	O
Pgp	O
was	O
observed	O
in	O
liver	O
sections	O
.	O
A	O
comparable	O
overexpression	O
of	O
Pgp	O
in	O
the	O
BBB	O
was	O
obtained	O
after	O
pilocarpine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
in	O
wild	O
-	O
type	O
Wistar	O
rats	O
.	O
Experiments	O
with	O
systemic	O
administration	O
of	O
the	O
Pgp	O
substrate	O
phenobarbital	B-CHEMICAL
and	O
the	O
selective	O
Pgp	O
inhibitor	O
tariquidar	O
in	O
TR(-	O
)	O
rats	O
substantiated	O
that	O
Pgp	O
is	O
functional	O
and	O
compensates	O
for	O
the	O
lack	O
of	O
MRP2	O
in	O
the	O
BBB	O
.	O
CONCLUSIONS	O
:	O
The	O
data	O
on	O
TR(-	O
)	O
rats	O
indicate	O
that	O
Pgp	O
plays	O
an	O
important	O
role	O
in	O
the	O
compensation	O
of	O
MRP2	O
deficiency	O
in	O
the	O
BBB	O
.	O
Because	O
such	O
a	O
compensatory	O
mechanism	O
most	O
likely	O
occurs	O
to	O
reduce	O
injury	O
to	O
the	O
brain	O
from	O
cytotoxic	O
compounds	O
,	O
the	O
present	O
data	O
substantiate	O
the	O
concept	O
that	O
MRP2	O
performs	O
a	O
protective	O
role	O
in	O
the	O
BBB	O
.	O
Furthermore	O
,	O
our	O
data	O
suggest	O
that	O
TR(-	O
)	O
rats	O
are	O
an	O
interesting	O
tool	O
to	O
study	O
consequences	O
of	O
overexpression	O
of	O
Pgp	O
in	O
the	O
BBB	O
on	O
access	O
of	O
drugs	O
in	O
the	O
brain	O
,	O
without	O
the	O
need	O
of	O
inducing	O
seizures	B-DISEASE
or	O
other	O
Pgp	O
-	O
enhancing	O
events	O
for	O
this	O
purpose	O
.	O

Use	O
of	O
chromosome	O
substitution	O
strains	O
to	O
identify	O
seizure	B-DISEASE
susceptibility	O
loci	O
in	O
mice	O
.	O
Seizure	B-DISEASE
susceptibility	O
varies	O
among	O
inbred	O
mouse	O
strains	O
.	O
Chromosome	O
substitution	O
strains	O
(	O
CSS	O
)	O
,	O
in	O
which	O
a	O
single	O
chromosome	O
from	O
one	O
inbred	O
strain	O
(	O
donor	O
)	O
has	O
been	O
transferred	O
onto	O
a	O
second	O
strain	O
(	O
host	O
)	O
by	O
repeated	O
backcrossing	O
,	O
may	O
be	O
used	O
to	O
identify	O
quantitative	O
trait	O
loci	O
(	O
QTLs	O
)	O
that	O
contribute	O
to	O
seizure	B-DISEASE
susceptibility	O
.	O
QTLs	O
for	O
susceptibility	O
to	O
pilocarpine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
,	O
a	O
model	O
of	O
temporal	B-DISEASE
lobe	I-DISEASE
epilepsy	I-DISEASE
,	O
have	O
not	O
been	O
reported	O
,	O
and	O
CSS	O
have	O
not	O
previously	O
been	O
used	O
to	O
localize	O
seizure	B-DISEASE
susceptibility	O
genes	O
.	O
We	O
report	O
QTLs	O
identified	O
using	O
a	O
B6	O
(	O
host	O
)	O
x	O
A	O
/	O
J	O
(	O
donor	O
)	O
CSS	O
panel	O
to	O
localize	O
genes	O
involved	O
in	O
susceptibility	O
to	O
pilocarpine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
.	O
Three	O
hundred	O
fifty	O
-	O
five	O
adult	O
male	O
CSS	O
mice	O
,	O
58	O
B6	O
,	O
and	O
39	O
A	O
/	O
J	O
were	O
tested	O
for	O
susceptibility	O
to	O
pilocarpine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
.	O
Highest	O
stage	O
reached	O
and	O
latency	O
to	O
each	O
stage	O
were	O
recorded	O
for	O
all	O
mice	O
.	O
B6	O
mice	O
were	O
resistant	O
to	O
seizures	B-DISEASE
and	O
slower	O
to	O
reach	O
stages	O
compared	O
to	O
A	O
/	O
J	O
mice	O
.	O
The	O
CSS	O
for	O
Chromosomes	O
10	O
and	O
18	O
progressed	O
to	O
the	O
most	O
severe	O
stages	O
,	O
diverging	O
dramatically	O
from	O
the	O
B6	O
phenotype	O
.	O
Latencies	O
to	O
stages	O
were	O
also	O
significantly	O
shorter	O
for	O
CSS10	O
and	O
CSS18	O
mice	O
.	O
CSS	O
mapping	O
suggests	O
seizure	B-DISEASE
susceptibility	O
loci	O
on	O
mouse	O
Chromosomes	O
10	O
and	O
18	O
.	O
This	O
approach	O
provides	O
a	O
framework	O
for	O
identifying	O
potentially	O
novel	O
homologous	O
candidate	O
genes	O
for	O
human	O
temporal	B-DISEASE
lobe	I-DISEASE
epilepsy	I-DISEASE
.	O

Investigation	O
of	O
mitochondrial	O
involvement	O
in	O
the	O
experimental	O
model	O
of	O
epilepsy	B-DISEASE
induced	O
by	O
pilocarpine	B-CHEMICAL
.	O
Mitochondrial	O
abnormalities	O
have	O
been	O
associated	O
with	O
several	O
aspects	O
of	O
epileptogenesis	O
,	O
such	O
as	O
energy	O
generation	O
,	O
control	O
of	O
cell	O
death	B-DISEASE
,	O
neurotransmitter	O
synthesis	O
,	O
and	O
free	O
radical	O
(	O
FR	O
)	O
production	O
.	O
Increased	O
production	O
of	O
FRs	O
may	O
cause	O
mtDNA	O
damage	O
leading	O
to	O
decreased	O
activities	O
of	O
oxidative	O
phosphorylation	O
complexes	O
containing	O
mtDNA	O
-	O
encoded	O
subunits	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
increased	O
generation	O
of	O
FR	O
during	O
status	B-DISEASE
epilepticus	I-DISEASE
would	O
be	O
sufficient	O
to	O
provoke	O
abnormalities	O
in	O
mtDNA	O
and	O
in	O
the	O
expression	O
and	O
activity	O
of	O
cytochrome	O
c	O
oxidase	O
(	O
CCO	O
)	O
,	O
complex	O
IV	O
of	O
the	O
respiratory	O
chain	O
,	O
in	O
the	O
chronic	O
phase	O
of	O
the	O
pilocarpine	B-CHEMICAL
model	O
of	O
temporal	B-DISEASE
lobe	I-DISEASE
epilepsy	I-DISEASE
.	O
DNA	O
analysis	O
revealed	O
low	O
amounts	O
of	O
a	O
4.8	O
kb	O
mtDNA	O
deletion	O
but	O
with	O
no	O
differences	O
in	O
frequency	O
or	O
quantity	O
in	O
the	O
control	O
and	O
experimental	O
groups	O
.	O
We	O
did	O
not	O
find	O
abnormalities	O
in	O
the	O
expression	O
and	O
distribution	O
of	O
an	O
mtDNA	O
-	O
encoded	O
subunit	O
of	O
CCO	O
(	O
CCO	O
-	O
I	O
)	O
or	O
a	O
relative	O
decrease	O
in	O
CCO	O
-	O
I	O
when	O
compared	O
with	O
nuclear	O
-	O
encoded	O
subunits	O
(	O
CCO	O
-	O
IV	O
and	O
SDH	O
-	O
fp	O
)	O
.	O
No	O
abnormality	O
in	O
CCO	O
activity	O
was	O
observed	O
through	O
histochemistry	O
.	O
Although	O
evidences	O
of	O
mitochondrial	O
abnormalities	O
were	O
found	O
in	O
previously	O
published	O
studies	O
,	O
our	O
results	O
do	O
not	O
suggest	O
that	O
the	O
FRs	O
,	O
generated	O
during	O
the	O
acute	O
phase	O
,	O
determined	O
important	O
abnormalities	O
in	O
mtDNA	O
,	O
in	O
expression	O
of	O
CCO	O
-	O
I	O
,	O
and	O
in	O
CCO	O
activity	O
.	O

Causes	O
of	O
acute	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
in	O
patients	O
receiving	O
kidney	O
transplantation	O
.	O
OBJECTIVES	O
:	O
Thrombotic	B-DISEASE
microangiopathy	I-DISEASE
is	O
a	O
well	O
-	O
known	O
problem	O
in	O
patients	O
following	O
renal	O
transplantation	O
.	O
In	O
postrenal	O
transplantation	O
,	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
is	O
often	O
a	O
reflection	O
of	O
hemolytic	B-DISEASE
uremic	I-DISEASE
syndrome	I-DISEASE
.	O
We	O
aimed	O
to	O
determine	O
the	O
causes	O
of	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
in	O
a	O
population	O
of	O
renal	O
transplantation	O
recipients	O
and	O
discuss	O
the	O
literature	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
We	O
investigated	O
the	O
causes	O
of	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
during	O
a	O
1	O
-	O
year	O
period	O
,	O
from	O
June	O
2003	O
to	O
June	O
2004	O
,	O
at	O
the	O
King	O
Fahad	O
National	O
Guard	O
Hospital	O
in	O
Riyadh	O
,	O
Saudi	O
Arabia	O
,	O
by	O
reviewing	O
the	O
slides	O
of	O
all	O
transplant	O
biopsies	O
(	O
n=25	O
)	O
performed	O
during	O
this	O
interval	O
.	O
Pre-	O
and	O
posttransplant	O
crossmatching	O
was	O
done	O
when	O
possible	O
.	O
RESULTS	O
:	O
Five	O
cases	O
of	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
were	O
found	O
.	O
Three	O
of	O
these	O
cases	O
were	O
from	O
the	O
25	O
transplantations	O
performed	O
at	O
King	O
Fahad	O
National	O
Guard	O
Hospital	O
,	O
while	O
the	O
other	O
2	O
transplantations	O
had	O
been	O
performed	O
abroad	O
and	O
were	O
referred	O
to	O
us	O
for	O
follow	O
-	O
up	O
.	O
Three	O
cases	O
were	O
related	O
to	O
cyclosporine	B-CHEMICAL
,	O
and	O
1	O
case	O
was	O
secondary	O
to	O
both	O
cyclosporine	B-CHEMICAL
and	O
tacrolimus	B-CHEMICAL
.	O
The	O
fifth	O
case	O
had	O
features	O
of	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
related	O
to	O
an	O
antiphospholipid	B-DISEASE
syndrome	I-DISEASE
in	O
a	O
patient	O
with	O
systemic	O
lupus	B-DISEASE
erythematosus	O
.	O
CONCLUSIONS	O
:	O
In	O
the	O
literature	O
,	O
the	O
most	O
-	O
frequent	O
cause	O
of	O
hemolytic	B-DISEASE
uremic	I-DISEASE
syndrome	I-DISEASE
in	O
patients	O
following	O
renal	O
transplantation	O
is	O
recurrence	B-DISEASE
of	O
the	O
hemolytic	B-DISEASE
uremic	I-DISEASE
syndrome	I-DISEASE
.	O
Other	O
causes	O
include	O
drug	O
-	O
related	O
(	O
cyclosporine	B-CHEMICAL
,	O
tacrolimus	B-CHEMICAL
)	O
toxicity	B-DISEASE
,	O
procoagulant	O
status	O
,	O
and	O
antibody	O
-	O
mediated	O
rejection	O
.	O
We	O
found	O
that	O
the	O
most	O
-	O
frequent	O
cause	O
of	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
was	O
drug	O
related	O
,	O
secondary	O
mainly	O
to	O
cyclosporine	B-CHEMICAL
.	O
In	O
the	O
current	O
study	O
,	O
the	O
frequency	O
of	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
was	O
similar	O
to	O
the	O
percentage	O
reported	O
in	O
the	O
literature	O
(	O
20	O
%	O
)	O
.	O

Severe	O
reversible	O
left	O
ventricular	O
systolic	O
and	O
diastolic	B-DISEASE
dysfunction	I-DISEASE
due	O
to	O
accidental	O
iatrogenic	O
epinephrine	B-CHEMICAL
overdose	B-DISEASE
.	O
Catecholamine	O
-	O
induced	O
cardiomyopathy	B-DISEASE
due	O
to	O
chronic	O
excess	O
of	O
endogenous	O
catecholamines	O
has	O
been	O
recognized	O
for	O
decades	O
as	O
a	O
clinical	O
phenomenon	O
.	O
In	O
contrast	O
,	O
reports	O
of	O
myocardial	O
dysfunction	O
due	O
to	O
acute	O
iatrogenic	O
overdose	B-DISEASE
are	O
rare	O
.	O
A	O
35	O
-	O
year	O
-	O
old	O
woman	O
whose	O
cervix	O
uteri	O
was	O
inadvertently	O
injected	O
with	O
8	O
mg	O
of	O
epinephrine	B-CHEMICAL
developed	O
myocardial	B-DISEASE
stunning	I-DISEASE
that	O
was	O
characterized	O
by	O
severe	O
hemodynamic	O
compromise	O
,	O
profound	O
,	O
albeit	O
transient	O
,	O
left	O
ventricular	O
systolic	O
and	O
diastolic	B-DISEASE
dysfunction	I-DISEASE
,	O
and	O
only	O
modestly	O
elevated	O
biochemical	O
markers	O
of	O
myocardial	O
necrosis	B-DISEASE
.	O
Our	O
case	O
illustrates	O
the	O
serious	O
consequences	O
of	O
medical	O
errors	O
that	O
can	O
be	O
avoided	O
through	O
improved	O
medication	O
labeling	O
and	O
staff	O
supervision	O
.	O

Urinary	B-DISEASE
bladder	I-DISEASE
cancer	I-DISEASE
in	O
Wegener	B-DISEASE
's	I-DISEASE
granulomatosis	I-DISEASE
:	O
risks	O
and	O
relation	O
to	O
cyclophosphamide	B-CHEMICAL
.	O
OBJECTIVE	O
:	O
To	O
assess	O
and	O
characterise	O
the	O
risk	O
of	O
bladder	B-DISEASE
cancer	I-DISEASE
,	O
and	O
its	O
relation	O
to	O
cyclophosphamide	B-CHEMICAL
,	O
in	O
patients	O
with	O
Wegener	B-DISEASE
's	I-DISEASE
granulomatosis	I-DISEASE
.	O
METHODS	O
:	O
In	O
the	O
population	O
based	O
,	O
nationwide	O
Swedish	O
Inpatient	O
Register	O
a	O
cohort	O
of	O
1065	O
patients	O
with	O
Wegener	B-DISEASE
's	I-DISEASE
granulomatosis	I-DISEASE
,	O
1969	O
-	O
95	O
,	O
was	O
identified	O
.	O
Through	O
linkage	O
with	O
the	O
Swedish	O
Cancer	B-DISEASE
Register	O
,	O
all	O
subjects	O
in	O
this	O
cohort	O
diagnosed	O
with	O
bladder	B-DISEASE
cancer	I-DISEASE
were	O
identified	O
.	O
Nested	O
within	O
the	O
cohort	O
,	O
a	O
matched	O
case	O
-	O
control	O
study	O
was	O
performed	O
to	O
estimate	O
the	O
association	O
between	O
cyclophosphamide	B-CHEMICAL
and	O
bladder	B-DISEASE
cancer	I-DISEASE
using	O
odds	O
ratios	O
(	O
ORs	O
)	O
as	O
relative	O
risk	O
.	O
In	O
the	O
cohort	O
the	O
cumulative	O
risk	O
of	O
bladder	B-DISEASE
cancer	I-DISEASE
after	O
Wegener	B-DISEASE
's	I-DISEASE
granulomatosis	I-DISEASE
,	O
and	O
the	O
relative	O
prevalence	O
of	O
a	O
history	O
of	O
bladder	B-DISEASE
cancer	I-DISEASE
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	B-DISEASE
's	I-DISEASE
granulomatosis	I-DISEASE
,	O
were	O
also	O
estimated	O
.	O
RESULTS	O
:	O
The	O
median	O
cumulative	O
doses	O
of	O
cyclophosphamide	B-CHEMICAL
among	O
cases	O
(	O
n	O
=	O
11	O
)	O
and	O
controls	O
(	O
n	O
=	O
25	O
)	O
were	O
113	O
g	O
and	O
25	O
g	O
,	O
respectively	O
.	O
The	O
risk	O
of	O
bladder	B-DISEASE
cancer	I-DISEASE
doubled	O
for	O
every	O
10	O
g	O
increment	O
in	O
cyclophosphamide	B-CHEMICAL
(	O
OR	O
=	O
2.0	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.8	O
to	O
4.9	O
)	O
.	O
Treatment	O
duration	O
longer	O
than	O
1	O
year	O
was	O
associated	O
with	O
an	O
eightfold	O
increased	O
risk	O
(	O
OR	O
=	O
7.7	O
,	O
95	O
%	O
CI	O
0.9	O
to	O
69	O
)	O
.	O
The	O
absolute	O
risk	O
for	O
bladder	B-DISEASE
cancer	I-DISEASE
in	O
the	O
cohort	O
reached	O
10	O
%	O
16	O
years	O
after	O
diagnosis	O
of	O
Wegener	B-DISEASE
's	I-DISEASE
granulomatosis	I-DISEASE
,	O
and	O
a	O
history	O
of	O
bladder	B-DISEASE
cancer	I-DISEASE
was	O
(	O
non	O
-	O
significantly	O
)	O
twice	O
as	O
common	O
as	O
expected	O
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	B-DISEASE
's	I-DISEASE
granulomatosis	I-DISEASE
.	O
CONCLUSION	O
:	O
The	O
results	O
indicate	O
a	O
dose	O
-	O
response	O
relationship	O
between	O
cyclophosphamide	B-CHEMICAL
and	O
the	O
risk	O
of	O
bladder	B-DISEASE
cancer	I-DISEASE
,	O
high	O
cumulative	O
risks	O
in	O
the	O
entire	O
cohort	O
,	O
and	O
also	O
the	O
possibility	O
of	O
risk	O
factors	O
operating	O
even	O
before	O
Wegener	B-DISEASE
's	I-DISEASE
granulomatosis	I-DISEASE
.	O

L	O
-	O
arginine	O
transport	O
in	O
humans	O
with	O
cortisol	B-CHEMICAL
-	O
induced	O
hypertension	B-DISEASE
.	O
A	O
deficient	O
L	O
-	O
arginine	O
-	O
nitric	O
oxide	O
system	O
is	O
implicated	O
in	O
cortisol	B-CHEMICAL
-	O
induced	O
hypertension	B-DISEASE
.	O
We	O
investigate	O
whether	O
abnormalities	O
in	O
L	O
-	O
arginine	O
uptake	O
contribute	O
to	O
this	O
deficiency	O
.	O
Eight	O
healthy	O
men	O
were	O
recruited	O
.	O
Hydrocortisone	B-CHEMICAL
acetate	I-CHEMICAL
(	O
50	O
mg	O
)	O
was	O
given	O
orally	O
every	O
6	O
hours	O
for	O
24	O
hours	O
after	O
a	O
5	O
-	O
day	O
fixed	O
-	O
salt	B-CHEMICAL
diet	O
(	O
150	O
mmol	O
/	O
d	O
)	O
.	O
Crossover	O
studies	O
were	O
performed	O
2	O
weeks	O
apart	O
.	O
Thirty	O
milliliters	O
of	O
blood	O
was	O
obtained	O
for	O
isolation	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
after	O
each	O
treatment	O
period	O
.	O
L	O
-	O
arginine	O
uptake	O
was	O
assessed	O
in	O
mononuclear	O
cells	O
incubated	O
with	O
L	O
-	O
arginine	O
(	O
1	O
to	O
300	O
micromol	O
/	O
L	O
)	O
,	O
incorporating	O
100	O
nmol	O
/	O
L	O
[	O
3H]-l	O
-	O
arginine	O
for	O
a	O
period	O
of	O
5	O
minutes	O
at	O
37	O
degrees	O
C.	O
Forearm	O
[	O
3H]-L	O
-	O
arginine	O
extraction	O
was	O
calculated	O
after	O
infusion	O
of	O
[	O
3H]-L	O
-	O
arginine	O
into	O
the	O
brachial	O
artery	O
at	O
a	O
rate	O
of	O
100	O
nCi	O
/	O
min	O
for	O
80	O
minutes	O
.	O
Deep	O
forearm	O
venous	O
samples	O
were	O
collected	O
for	O
determination	O
of	O
L	O
-	O
arginine	O
extraction	O
.	O
Plasma	O
cortisol	B-CHEMICAL
concentrations	O
were	O
significantly	O
raised	O
during	O
the	O
active	O
phase	O
(	O
323+/-43	O
to	O
1082+/-245	O
mmol	O
/	O
L	O
,	O
P<0.05	O
)	O
.	O
Systolic	O
blood	O
pressure	O
was	O
elevated	O
by	O
an	O
average	O
of	O
7	O
mm	O
Hg	O
.	O
Neither	O
L	O
-	O
arginine	O
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
26.3+/-3.6	O
vs	O
29.0+/-2.1	O
pmol/10	O
000	O
cells	O
per	O
5	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	O
-	O
arginine	O
concentration	O
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
arginine	O
extraction	O
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
1	O
868	O
904+/-434	O
962	O
vs	O
2	O
013	O
910+/-770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	B-CHEMICAL
treatment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O
term	O
cortisol	B-CHEMICAL
treatment	O
.	O
We	O
conclude	O
that	O
cortisol	B-CHEMICAL
-	O
induced	O
increases	O
in	O
blood	O
pressure	O
are	O
not	O
associated	O
with	O
abnormalities	O
in	O
the	O
l	O
-	O
arginine	O
transport	O
system	O
.	O

MR	O
imaging	O
with	O
quantitative	O
diffusion	O
mapping	O
of	O
tacrolimus	B-CHEMICAL
-	O
induced	O
neurotoxicity	B-DISEASE
in	O
organ	O
transplant	O
patients	O
.	O
Our	O
objective	O
was	O
to	O
investigate	O
brain	O
MR	O
imaging	O
findings	O
and	O
the	O
utility	O
of	O
diffusion	O
-	O
weighted	O
(	O
DW	O
)	O
imaging	O
in	O
organ	O
transplant	O
patients	O
who	O
developed	O
neurologic	O
symptoms	O
during	O
tacrolimus	B-CHEMICAL
therapy	O
.	O
Brain	O
MR	O
studies	O
,	O
including	O
DW	O
imaging	O
,	O
were	O
prospectively	O
performed	O
in	O
14	O
organ	O
transplant	O
patients	O
receiving	O
tacrolimus	B-CHEMICAL
who	O
developed	O
neurologic	O
complications	B-DISEASE
.	O
In	O
each	O
patient	O
who	O
had	O
abnormalities	O
on	O
the	O
initial	O
MR	O
study	O
,	O
a	O
follow	O
-	O
up	O
MR	O
study	O
was	O
performed	O
1	O
month	O
later	O
.	O
Apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
values	O
on	O
the	O
initial	O
MR	O
study	O
were	O
correlated	O
with	O
reversibility	O
of	O
the	O
lesions	O
.	O
Of	O
the	O
14	O
patients	O
,	O
5	O
(	O
35.7	O
%	O
)	O
had	O
white	O
matter	O
abnormalities	O
,	O
1	O
(	O
7.1	O
%	O
)	O
had	O
putaminal	B-DISEASE
hemorrhage	I-DISEASE
,	O
and	O
8	O
(	O
57.1	O
%	O
)	O
had	O
normal	O
findings	O
on	O
initial	O
MR	O
images	O
.	O
Among	O
the	O
5	O
patients	O
with	O
white	O
matter	O
abnormalities	O
,	O
4	O
patients	O
(	O
80.0	O
%	O
)	O
showed	O
higher	O
than	O
normal	O
ADC	O
values	O
on	O
initial	O
MR	O
images	O
,	O
and	O
all	O
showed	O
complete	O
resolution	O
on	O
follow	O
-	O
up	O
images	O
.	O
The	O
remaining	O
1	O
patient	O
(	O
20.0	O
%	O
)	O
showed	O
lower	O
than	O
normal	O
ADC	O
value	O
and	O
showed	O
incomplete	O
resolution	O
with	O
cortical	B-DISEASE
laminar	I-DISEASE
necrosis	I-DISEASE
.	O
Diffusion	O
-	O
weighted	O
imaging	O
may	O
be	O
useful	O
in	O
predicting	O
the	O
outcomes	O
of	O
the	O
lesions	O
of	O
tacrolimus	B-CHEMICAL
-	O
induced	O
neurotoxicity	B-DISEASE
.	O

Octreotide	B-CHEMICAL
-	O
induced	O
hypoxemia	B-DISEASE
and	O
pulmonary	B-DISEASE
hypertension	I-DISEASE
in	O
premature	O
neonates	O
.	O
The	O
authors	O
report	O
2	O
cases	O
of	O
premature	O
neonates	O
who	O
had	O
enterocutaneous	O
fistula	B-DISEASE
complicating	O
necrotizing	O
enterocolitis	B-DISEASE
.	O
Pulmonary	B-DISEASE
hypertension	I-DISEASE
developed	O
after	O
administration	O
of	O
a	O
somatostatin	B-CHEMICAL
analogue	O
,	O
octreotide	B-CHEMICAL
,	O
to	O
enhance	O
resolution	O
of	O
the	O
fistula	B-DISEASE
.	O
The	O
authors	O
discuss	O
the	O
mechanism	O
of	O
the	O
occurrence	O
of	O
this	O
complication	O
and	O
recommend	O
caution	O
of	O
its	O
use	O
in	O
high	O
-	O
risk	O
premature	O
neonates	O
.	O

Sequential	O
observations	O
of	O
exencephaly	B-DISEASE
and	O
subsequent	O
morphological	O
changes	O
by	O
mouse	O
exo	O
utero	O
development	O
system	O
:	O
analysis	O
of	O
the	O
mechanism	O
of	O
transformation	O
from	O
exencephaly	B-DISEASE
to	O
anencephaly	B-DISEASE
.	O
Anencephaly	B-DISEASE
has	O
been	O
suggested	O
to	O
develop	O
from	O
exencephaly	B-DISEASE
;	O
however	O
,	O
there	O
is	O
little	O
direct	O
experimental	O
evidence	O
to	O
support	O
this	O
,	O
and	O
the	O
mechanism	O
of	O
transformation	O
remains	O
unclear	O
.	O
We	O
examined	O
this	O
theory	O
using	O
the	O
exo	O
utero	O
development	O
system	O
that	O
allows	O
direct	O
and	O
sequential	O
observations	O
of	O
mid-	O
to	O
late	O
-	O
gestation	O
mouse	O
embryos	O
.	O
We	O
observed	O
the	O
exencephaly	B-DISEASE
induced	O
by	O
5	B-CHEMICAL
-	I-CHEMICAL
azacytidine	I-CHEMICAL
at	O
embryonic	O
day	O
13.5	O
(	O
E13.5	O
)	O
,	O
let	O
the	O
embryos	O
develop	O
exo	O
utero	O
until	O
E18.5	O
,	O
and	O
re	O
-	O
observed	O
the	O
same	O
embryos	O
at	O
E18.5	O
.	O
We	O
confirmed	O
several	O
cases	O
of	O
transformation	O
from	O
exencephaly	B-DISEASE
to	O
anencephaly	B-DISEASE
.	O
However	O
,	O
in	O
many	O
cases	O
,	O
the	O
exencephalic	B-DISEASE
brain	O
tissue	O
was	O
preserved	O
with	O
more	O
or	O
less	O
reduction	O
during	O
this	O
period	O
.	O
To	O
analyze	O
the	O
transformation	O
patterns	O
,	O
we	O
classified	O
the	O
exencephaly	B-DISEASE
by	O
size	O
and	O
shape	O
of	O
the	O
exencephalic	B-DISEASE
tissue	O
into	O
several	O
types	O
at	O
E13.5	O
and	O
E18.5	O
.	O
It	O
was	O
found	O
that	O
the	O
transformation	O
of	O
exencephalic	B-DISEASE
tissue	O
was	O
not	O
simply	O
size	O
-	O
dependent	O
,	O
and	O
all	O
cases	O
of	O
anencephaly	B-DISEASE
at	O
E18.5	O
resulted	O
from	O
embryos	O
with	O
a	O
large	O
amount	O
of	O
exencephalic	B-DISEASE
tissue	O
at	O
E13.5	O
.	O
Microscopic	O
observation	O
showed	O
the	O
configuration	O
of	O
exencephaly	B-DISEASE
at	O
E13.5	O
,	O
frequent	O
hemorrhaging	O
and	O
detachment	O
of	O
the	O
neural	O
plate	O
from	O
surface	O
ectoderm	O
in	O
the	O
exencephalic	B-DISEASE
head	O
at	O
E15.5	O
,	O
and	O
multiple	O
modes	O
of	O
reduction	O
in	O
the	O
exencephalic	B-DISEASE
tissue	O
at	O
E18.5	O
.	O
From	O
observations	O
of	O
the	O
vasculature	O
,	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
were	O
identified	O
in	O
the	O
exencephalic	B-DISEASE
head	O
.	O
These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	B-DISEASE
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	O
circulatory	B-DISEASE
failure	I-DISEASE
and/or	O
hemorrhaging	O
in	O
various	O
parts	O
of	O
the	O
exencephalic	B-DISEASE
head	O
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	B-DISEASE
to	O
anencephaly	B-DISEASE
.	O

Acute	O
cocaine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
:	O
differential	O
sensitivity	O
of	O
six	O
inbred	O
mouse	O
strains	O
.	O
Mature	O
male	O
and	O
female	O
mice	O
from	O
six	O
inbred	O
stains	O
were	O
tested	O
for	O
susceptibility	O
to	O
behavioral	O
seizures	B-DISEASE
induced	O
by	O
a	O
single	O
injection	O
of	O
cocaine	B-CHEMICAL
.	O
Cocaine	B-CHEMICAL
was	O
injected	O
ip	O
over	O
a	O
range	O
of	O
doses	O
(	O
50	O
-	O
100	O
mg	O
/	O
kg	O
)	O
and	O
behavior	O
was	O
monitored	O
for	O
20	O
minutes	O
.	O
Seizure	B-DISEASE
end	O
points	O
included	O
latency	O
to	O
forelimb	O
or	O
hindlimb	O
clonus	O
,	O
latency	O
to	O
clonic	O
running	O
seizure	B-DISEASE
and	O
latency	O
to	O
jumping	O
bouncing	O
seizure	B-DISEASE
.	O
A	O
range	O
of	O
strain	O
specific	O
sensitivities	O
was	O
documented	O
with	O
A	O
/	O
J	O
and	O
SJL	O
mice	O
being	O
most	O
sensitive	O
and	O
C57BL/6J	O
most	O
resistant	O
.	O
DBA/2J	O
,	O
BALB	O
/	O
cByJ	O
and	O
NZW	O
/	O
LacJ	O
strains	O
exhibited	O
intermediate	O
sensitivity	O
.	O
EEG	O
recordings	O
were	O
made	O
in	O
SJL	O
,	O
A	O
/	O
J	O
and	O
C57BL/6J	O
mice	O
revealing	O
a	O
close	O
correspondence	O
between	O
electrical	O
activity	O
and	O
behavior	O
.	O
Additionally	O
,	O
levels	O
of	O
cocaine	B-CHEMICAL
determined	O
in	O
hippocampus	O
and	O
cortex	O
were	O
not	O
different	O
between	O
sensitive	O
and	O
resistant	O
strains	O
.	O
Additional	O
studies	O
of	O
these	O
murine	O
strains	O
may	O
be	O
useful	O
for	O
investigating	O
genetic	O
influences	O
on	O
cocaine	B-CHEMICAL
-	O
induced	O
seizures	B-DISEASE
.	O

Microangiopathic	O
hemolytic	O
anemia	B-DISEASE
complicating	O
FK506	O
(	O
tacrolimus	B-CHEMICAL
)	O
therapy	O
.	O
We	O
describe	O
3	O
episodes	O
of	O
microangiopathic	O
hemolytic	O
anemia	B-DISEASE
(	O
MAHA	O
)	O
in	O
2	O
solid	O
organ	O
recipients	O
under	O
FK506	O
(	O
tacrolimus	B-CHEMICAL
)	O
therapy	O
.	O
In	O
both	O
cases	O
,	O
discontinuation	O
of	O
FK506	O
and	O
treatment	O
with	O
plasma	O
exchange	O
,	O
fresh	O
frozen	O
plasma	O
replacement	O
,	O
corticosteroids	B-CHEMICAL
,	O
aspirin	O
,	O
and	O
dipyridamole	B-CHEMICAL
led	O
to	O
resolution	O
of	O
MAHA	O
.	O
In	O
one	O
patient	O
,	O
reintroduction	O
of	O
FK506	O
led	O
to	O
rapid	O
recurrence	B-DISEASE
of	O
MAHA	O
.	O
FK506	O
-	O
associated	O
MAHA	O
is	O
probably	O
rare	O
but	O
physicians	O
must	O
be	O
aware	O
of	O
this	O
severe	O
complication	O
.	O
In	O
our	O
experience	O
and	O
according	O
to	O
the	O
literature	O
,	O
FK506	O
does	O
not	O
seem	O
to	O
cross	O
-	O
react	O
with	O
cyclosporin	B-CHEMICAL
A	I-CHEMICAL
(	O
CyA	O
)	O
,	O
an	O
immuno	O
-	O
suppressive	O
drug	O
already	O
known	O
to	O
induce	O
MAHA	O
.	O

Variant	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
in	O
desipramine	B-CHEMICAL
toxicity	B-DISEASE
.	O
We	O
report	O
a	O
case	O
of	O
variant	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
induced	O
by	O
desipramine	B-CHEMICAL
toxicity	B-DISEASE
.	O
Unusual	O
features	O
of	O
the	O
arrhythmia	B-DISEASE
are	O
repetitive	O
group	O
beating	O
,	O
progressive	O
shortening	O
of	O
the	O
R	O
-	O
R	O
interval	O
,	O
progressive	O
widening	O
of	O
the	O
QRS	O
complex	O
with	O
eventual	O
failure	O
of	O
intraventricular	O
conduction	O
,	O
and	O
changes	O
in	O
direction	O
of	O
the	O
QRS	O
axis	O
.	O
Recognition	O
of	O
variant	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
is	O
important	O
because	O
therapy	O
differs	O
from	O
that	O
of	O
classic	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
.	O

Desipramine	B-CHEMICAL
-	O
induced	O
delirium	B-DISEASE
at	O
"	O
subtherapeutic	O
"	O
concentrations	O
:	O
a	O
case	O
report	O
.	O
An	O
elderly	O
patient	O
treated	O
with	O
low	O
dose	O
Desipramine	B-CHEMICAL
developed	O
a	O
delirium	B-DISEASE
while	O
her	O
plasma	O
level	O
was	O
in	O
the	O
"	O
subtherapeutic	O
"	O
range	O
.	O
Delirium	B-DISEASE
,	O
which	O
may	O
be	O
induced	O
by	O
tricyclic	O
drug	O
therapy	O
in	O
the	O
elderly	O
,	O
can	O
be	O
caused	O
by	O
tricyclics	O
with	O
low	O
anticholinergic	O
potency	O
.	O
Therapeutic	O
ranges	O
for	O
antidepressants	O
that	O
have	O
been	O
derived	O
from	O
general	O
adult	O
population	O
studies	O
may	O
not	O
be	O
appropriate	O
for	O
the	O
elderly	O
.	O
Further	O
studies	O
of	O
specifically	O
elderly	O
patients	O
are	O
now	O
required	O
to	O
establish	O
safer	O
and	O
more	O
appropriate	O
guidelines	O
for	O
drug	O
therapy	O
.	O

Mouse	O
strain	O
-	O
dependent	O
effect	O
of	O
amantadine	O
on	O
motility	O
and	O
brain	O
biogenic	B-CHEMICAL
amines	I-CHEMICAL
.	O
The	O
effect	O
of	O
amantadine	O
hydrochloride	O
,	O
injected	O
i.p	O
.	O
in	O
6	O
increments	O
of	O
100	O
mg	O
/	O
kg	O
each	O
over	O
30	O
hr	O
,	O
on	O
mouse	O
motility	O
and	O
whole	O
brain	O
content	O
of	O
selected	O
biogenic	B-CHEMICAL
amines	I-CHEMICAL
and	O
major	O
metabolites	O
was	O
studied	O
in	O
4	O
strains	O
of	O
mice	O
.	O
These	O
were	O
the	O
albino	O
Sprague	O
-	O
Dawley	O
ICR	O
and	O
BALB	O
/	O
C	O
,	O
the	O
black	O
C57BL/6	O
and	O
the	O
brown	O
CDF	O
-	O
I	O
mouse	O
strains	O
.	O
Amantadine	O
treatment	O
produced	O
a	O
biphasic	O
effect	O
on	O
mouse	O
motility	O
.	O
The	O
initial	O
dose	O
of	O
amantadine	O
depressed	B-DISEASE
locomotor	O
activity	O
in	O
all	O
mouse	O
strains	O
studied	O
with	O
the	O
BALB	O
/	O
C	O
mice	O
being	O
the	O
most	O
sensitive	O
.	O
Subsequent	O
amantadine	O
treatments	O
produced	O
enhancement	O
of	O
motility	O
from	O
corresponding	O
control	O
in	O
all	O
mouse	O
strains	O
with	O
the	O
BALB	O
/	O
C	O
mice	O
being	O
the	O
least	O
sensitive	O
.	O
The	O
locomotor	O
activity	O
was	O
decreased	O
from	O
corresponding	O
controls	O
in	O
all	O
strains	O
studied	O
,	O
except	O
for	O
the	O
ICR	O
mice	O
,	O
during	O
an	O
overnight	O
drug	O
-	O
free	O
period	O
following	O
the	O
fourth	O
amantadine	O
treatment	O
.	O
Readministration	O
of	O
amantadine	O
,	O
after	O
a	O
drug	O
-	O
free	O
overnight	O
period	O
,	O
increased	O
motility	O
from	O
respective	O
saline	O
control	O
in	O
all	O
strains	O
with	O
exception	O
of	O
the	O
BALB	O
/	O
C	O
mice	O
where	O
suppression	O
of	O
motility	O
occurred	O
.	O
Treatment	O
with	O
amantadine	O
did	O
not	O
alter	O
whole	O
brain	O
dopamine	B-CHEMICAL
levels	O
but	O
decreased	O
the	O
amounts	O
of	O
3,4	B-CHEMICAL
-	I-CHEMICAL
dihydroxyphenylacetic	I-CHEMICAL
acid	I-CHEMICAL
in	O
the	O
BALB	O
/	O
C	O
mice	O
compared	O
to	O
saline	O
control	O
.	O
Conversely	O
,	O
brain	O
normetanephrine	O
concentration	O
was	O
increased	O
from	O
saline	O
control	O
by	O
amantadine	O
in	O
the	O
BALB	O
/	O
C	O
mice	O
.	O
The	O
results	O
suggest	O
a	O
strain	O
-	O
dependent	O
effect	O
of	O
amantadine	O
on	O
motility	O
and	O
indicate	O
a	O
differential	O
response	O
to	O
the	O
acute	O
and	O
multiple	O
dose	O
regimens	O
used	O
.	O
The	O
BALB	O
/	O
C	O
mouse	O
was	O
the	O
most	O
sensitive	O
strain	O
and	O
could	O
serve	O
as	O
the	O
strain	O
of	O
choice	O
for	O
evaluating	O
the	O
side	O
effects	O
of	O
amantadine	O
.	O
The	O
biochemical	O
results	O
of	O
brain	O
biogenic	B-CHEMICAL
amines	I-CHEMICAL
of	O
BALB	O
/	O
C	O
mouse	O
strain	O
suggest	O
a	O
probable	O
decrease	O
of	O
catecholamine	O
turnover	O
rate	O
and/or	O
metabolism	O
by	O
monoamine	O
oxidase	O
and	O
a	O
resulting	O
increase	O
in	O
O	O
-	O
methylation	O
of	O
norepinephrine	B-CHEMICAL
which	O
may	O
account	O
for	O
a	O
behavioral	B-DISEASE
depression	I-DISEASE
caused	O
by	O
amantadine	O
in	O
the	O
BALB	O
/	O
C	O
mice	O
.	O

No	O
enhancement	O
by	O
phenobarbital	B-CHEMICAL
of	O
the	O
hepatocarcinogenicity	O
of	O
a	O
choline	B-CHEMICAL
-	O
devoid	O
diet	O
in	O
the	O
rat	O
.	O
An	O
experiment	O
was	O
performed	O
to	O
test	O
whether	O
inclusion	O
of	O
phenobarbital	B-CHEMICAL
in	O
a	O
choline	B-CHEMICAL
-	O
devoid	O
diet	O
would	O
increase	O
the	O
hepatocarcinogenicity	O
of	O
the	O
diet	O
.	O
Groups	O
of	O
5	O
-	O
week	O
old	O
male	O
Fischer-344	O
rats	O
were	O
fed	O
for	O
7	O
-	O
25	O
months	O
semipurified	O
choline	B-CHEMICAL
-	O
devoid	O
or	O
choline	B-CHEMICAL
-	O
supplemented	O
diets	O
,	O
containing	O
or	O
not	O
0.06	O
%	O
phenobarbital	B-CHEMICAL
.	O
No	O
hepatic	O
preneoplastic	O
nodules	O
or	O
hepatocellular	O
carcinomas	O
developed	O
in	O
rats	O
fed	O
the	O
plain	O
choline	B-CHEMICAL
-	O
supplemented	O
diet	O
,	O
while	O
one	O
preneoplastic	O
nodule	O
and	O
one	O
hepatocellular	O
carcinoma	B-DISEASE
developed	O
in	O
two	O
rats	O
fed	O
the	O
same	O
diet	O
containing	O
phenobarbital	B-CHEMICAL
.	O
The	O
incidence	O
of	O
preneoplastic	O
nodules	O
and	O
of	O
hepatocellular	O
carcinomas	O
was	O
10	O
%	O
and	O
37	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
fed	O
the	O
plain	O
choline	B-CHEMICAL
-	O
devoid	O
diet	O
,	O
and	O
17	O
%	O
and	O
30	O
%	O
,	O
in	O
rats	O
fed	O
the	O
phenobarbital	B-CHEMICAL
-	O
containing	O
choline	B-CHEMICAL
-	O
devoid	O
diet	O
.	O
The	O
results	O
evinced	O
no	O
enhancement	O
of	O
the	O
hepatocarcinogenicity	O
of	O
the	O
choline	B-CHEMICAL
-	O
devoid	O
diet	O
by	O
phenobarbital	B-CHEMICAL
.	O
Sporadic	O
neoplastic	O
lesions	O
were	O
observed	O
in	O
organs	O
other	O
than	O
the	O
liver	O
of	O
some	O
of	O
the	O
animals	O
,	O
irrespective	O
of	O
the	O
diet	O
fed	O
.	O

Effect	O
of	O
direct	O
intracoronary	O
administration	O
of	O
methylergonovine	O
in	O
patients	O
with	O
and	O
without	O
variant	B-DISEASE
angina	I-DISEASE
.	O
The	O
effects	O
of	O
intracoronary	O
administration	O
of	O
methylergonovine	O
were	O
studied	O
in	O
21	O
patients	O
with	O
variant	B-DISEASE
angina	I-DISEASE
and	O
22	O
patients	O
with	O
atypical	O
chest	B-DISEASE
pain	I-DISEASE
and	O
in	O
others	O
without	O
angina	B-DISEASE
pectoris	I-DISEASE
(	O
control	O
group	O
)	O
.	O
Methylergonovine	O
was	O
administered	O
continuously	O
at	O
a	O
rate	O
of	O
10	O
micrograms	O
/	O
min	O
up	O
to	O
50	O
micrograms	O
.	O
In	O
all	O
patients	O
with	O
variant	B-DISEASE
angina	I-DISEASE
,	O
coronary	B-DISEASE
spasm	I-DISEASE
was	O
provoked	O
at	O
a	O
mean	O
dose	O
of	O
28	O
+	O
/-	O
13	O
micrograms	O
(	O
mean	O
+	O
/-	O
SD	B-DISEASE
)	O
.	O
In	O
the	O
control	O
group	O
neither	O
ischemic	B-DISEASE
ST	O
change	O
nor	O
localized	O
spasm	B-DISEASE
occurred	O
.	O
The	O
basal	O
tone	O
of	O
the	O
right	O
coronary	O
artery	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
left	O
coronary	O
artery	O
.	O
The	O
percentage	O
of	O
vasoconstriction	O
of	O
the	O
right	O
coronary	O
artery	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
left	O
coronary	O
artery	O
.	O
These	O
results	O
suggest	O
that	O
spasm	B-DISEASE
provocation	O
tests	O
,	O
which	O
use	O
an	O
intracoronary	O
injection	O
of	O
a	O
relatively	O
low	O
dose	O
of	O
methylergonovine	O
,	O
have	O
a	O
high	O
sensitivity	O
in	O
variant	B-DISEASE
angina	I-DISEASE
and	O
the	O
vasoreactivity	O
of	O
the	O
right	O
coronary	O
artery	O
may	O
be	O
greater	O
than	O
that	O
of	O
the	O
other	O
coronary	O
arteries	O
.	O

Dobutamine	B-CHEMICAL
stress	B-DISEASE
echocardiography	O
:	O
a	O
sensitive	O
indicator	O
of	O
diminished	O
myocardial	O
function	O
in	O
asymptomatic	O
doxorubicin	B-CHEMICAL
-	O
treated	O
long	O
-	O
term	O
survivors	O
of	O
childhood	O
cancer	B-DISEASE
.	O
Doxorubicin	B-CHEMICAL
is	O
an	O
effective	O
anticancer	O
chemotherapeutic	O
agent	O
known	O
to	O
cause	O
acute	O
and	O
chronic	O
cardiomyopathy	B-DISEASE
.	O
To	O
develop	O
a	O
more	O
sensitive	O
echocardiographic	O
screening	O
test	O
for	O
cardiac	B-DISEASE
damage	I-DISEASE
due	O
to	O
doxorubicin	B-CHEMICAL
,	O
a	O
cohort	O
study	O
was	O
performed	O
using	O
dobutamine	B-CHEMICAL
infusion	O
to	O
differentiate	O
asymptomatic	O
long	O
-	O
term	O
survivors	O
of	O
childhood	O
cancer	B-DISEASE
treated	O
with	O
doxorubicin	B-CHEMICAL
from	O
healthy	O
control	O
subjects	O
.	O
Echocardiographic	O
data	O
from	O
the	O
experimental	O
group	O
of	O
21	O
patients	O
(	O
mean	O
age	O
16	O
+	O
/-	O
5	O
years	O
)	O
treated	O
from	O
1.6	O
to	O
14.3	O
years	O
(	O
median	O
5.3	O
)	O
before	O
this	O
study	O
with	O
27	O
to	O
532	O
mg	O
/	O
m2	O
of	O
doxorubicin	B-CHEMICAL
(	O
mean	O
196	O
)	O
were	O
compared	O
with	O
echocardiographic	O
data	O
from	O
12	O
normal	O
age	O
-	O
matched	O
control	O
subjects	O
.	O
Graded	O
dobutamine	B-CHEMICAL
infusions	O
of	O
0.5	O
,	O
2.5	O
,	O
5	O
and	O
10	O
micrograms	O
/	O
kg	O
per	O
min	O
were	O
administered	O
.	O
Echocardiographic	O
Doppler	O
studies	O
were	O
performed	O
before	O
infusion	O
and	O
after	O
15	O
min	O
of	O
infusion	O
at	O
each	O
rate	O
.	O
Dobutamine	B-CHEMICAL
infusion	O
at	O
10	O
micrograms	O
/	O
kg	O
per	O
min	O
was	O
discontinued	O
after	O
six	O
studies	O
secondary	O
to	O
a	O
50	O
%	O
incidence	O
rate	O
of	O
adverse	O
symptoms	O
.	O
The	O
most	O
important	O
findings	O
were	O
that	O
compared	O
with	O
values	O
in	O
control	O
subjects	O
,	O
end	O
-	O
systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
and	O
percent	O
of	O
left	O
ventricular	O
posterior	O
wall	O
thickening	O
in	O
doxorubicin	B-CHEMICAL
-	O
treated	O
patients	O
were	O
decreased	O
at	O
baseline	O
study	O
and	O
these	O
findings	O
were	O
more	O
clearly	O
delineated	O
with	O
dobutamine	B-CHEMICAL
stimulation	O
.	O
End	O
-	O
systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
at	O
baseline	O
for	O
the	O
doxorubicin	B-CHEMICAL
-	O
treated	O
group	O
was	O
11	O
+	O
/-	O
1.9	O
mm	O
versus	O
13.1	O
+	O
/-	O
1.5	O
mm	O
for	O
control	O
subjects	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O
End	O
-	O
systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
at	O
the	O
5	O
-	O
micrograms	O
/	O
kg	O
per	O
min	O
dobutamine	B-CHEMICAL
infusion	O
for	O
the	O
doxorubicin	B-CHEMICAL
-	O
treated	O
group	O
was	O
14.1	O
+	O
/-	O
2.4	O
mm	O
versus	O
19.3	O
+	O
/-	O
2.6	O
mm	O
for	O
control	O
subjects	O
(	O
p	O
less	O
than	O
0.01).(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Effects	O
of	O
aminophylline	O
on	O
the	O
threshold	O
for	O
initiating	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
during	O
respiratory	B-DISEASE
failure	I-DISEASE
.	O
Cardiac	B-DISEASE
arrhythmias	I-DISEASE
have	O
frequently	O
been	O
reported	O
in	O
association	O
with	O
respiratory	B-DISEASE
failure	I-DISEASE
.	O
The	O
possible	O
additive	O
role	O
of	O
pharmacologic	O
agents	O
in	O
precipitating	O
cardiac	B-DISEASE
disturbances	I-DISEASE
in	O
patients	O
with	O
respiratory	B-DISEASE
failure	I-DISEASE
has	O
only	O
recently	O
been	O
emphasized	O
.	O
The	O
effects	O
of	O
aminophylline	O
on	O
the	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
threshold	O
during	O
normal	O
acid	O
-	O
base	O
conditions	O
and	O
during	O
respiratory	B-DISEASE
failure	I-DISEASE
were	O
studied	O
in	O
anesthetized	O
open	O
chest	O
dogs	O
.	O
The	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
threshold	O
was	O
measured	O
by	O
passing	O
a	O
gated	O
train	O
of	O
12	O
constant	O
current	O
pulses	O
through	O
the	O
ventricular	O
myocardium	O
during	O
the	O
vulnerable	O
period	O
of	O
the	O
cardiac	O
cycle	O
.	O
During	O
the	O
infusion	O
of	O
aminophylline	O
,	O
the	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
threshold	O
was	O
reduced	O
by	O
30	O
to	O
40	O
percent	O
of	O
the	O
control	O
when	O
pH	O
and	O
partial	O
pressures	O
of	O
oxygen	B-CHEMICAL
(	O
PO2	O
)	O
and	O
carbon	B-CHEMICAL
dioxide	I-CHEMICAL
(	O
CO2	B-CHEMICAL
)	O
were	O
kept	O
within	O
normal	O
limits	O
.	O
When	O
respiratory	B-DISEASE
failure	I-DISEASE
was	O
produced	O
by	O
hypoventilation	B-DISEASE
(	O
pH	O
7.05	O
to	O
7.25	O
;	O
PC02	O
70	O
to	O
100	O
mm	O
Hg	O
:	O
P02	O
20	O
to	O
40	O
mm	O
Hg	O
)	O
,	O
infusion	O
of	O
aminophylline	O
resulted	O
in	O
an	O
even	O
greater	O
decrease	O
in	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
threshold	O
to	O
60	O
percent	O
of	O
the	O
control	O
level	O
.	O
These	O
experiments	O
suggest	O
that	O
although	O
many	O
factors	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
ventricular	B-DISEASE
arrhythmias	I-DISEASE
in	O
respiratory	B-DISEASE
failure	I-DISEASE
,	O
pharmacologic	O
agents	O
,	O
particularly	O
aminophylline	O
,	O
may	O
play	O
a	O
significant	O
role	O
.	O

Case	O
report	O
:	O
acute	O
unintentional	O
carbachol	O
intoxication	O
.	O
INTRODUCTION	O
:	O
Intoxications	O
with	O
carbachol	O
,	O
a	O
muscarinic	O
cholinergic	O
receptor	O
agonist	O
are	O
rare	O
.	O
We	O
report	O
an	O
interesting	O
case	O
investigating	O
a	O
(	O
near	O
)	O
fatal	O
poisoning	B-DISEASE
.	O
METHODS	O
:	O
The	O
son	O
of	O
an	O
84	O
-	O
year	O
-	O
old	O
male	O
discovered	O
a	O
newspaper	O
report	O
stating	O
clinical	O
success	O
with	O
plant	O
extracts	O
in	O
Alzheimer	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
.	O
The	O
mode	O
of	O
action	O
was	O
said	O
to	O
be	O
comparable	O
to	O
that	O
of	O
the	O
synthetic	O
compound	O
'	O
carbamylcholin	O
'	O
;	O
that	O
is	O
,	O
carbachol	O
.	O
He	O
bought	O
25	O
g	O
of	O
carbachol	O
as	O
pure	O
substance	O
in	O
a	O
pharmacy	O
,	O
and	O
the	O
father	O
was	O
administered	O
400	O
to	O
500	O
mg	O
.	O
Carbachol	O
concentrations	O
in	O
serum	O
and	O
urine	O
on	O
day	O
1	O
and	O
2	O
of	O
hospital	O
admission	O
were	O
analysed	O
by	O
HPLC	O
-	O
mass	O
spectrometry	O
.	O
RESULTS	O
:	O
Minutes	O
after	O
oral	O
administration	O
,	O
the	O
patient	O
developed	O
nausea	B-DISEASE
,	O
sweating	O
and	O
hypotension	B-DISEASE
,	O
and	O
finally	O
collapsed	O
.	O
Bradycardia	B-DISEASE
,	O
cholinergic	O
symptoms	O
and	O
asystole	B-DISEASE
occurred	O
.	O
Initial	O
cardiopulmonary	O
resuscitation	O
and	O
immediate	O
treatment	O
with	O
adrenaline	B-CHEMICAL
(	O
epinephrine	B-CHEMICAL
)	O
,	O
atropine	O
and	O
furosemide	B-CHEMICAL
was	O
successful	O
.	O
On	O
hospital	O
admission	O
,	O
blood	O
pressure	O
of	O
the	O
intubated	O
,	O
bradyarrhythmic	O
patient	O
was	O
100/65	O
mmHg	O
.	O
Further	O
signs	O
were	O
hyperhidrosis	B-DISEASE
,	O
hypersalivation	O
,	O
bronchorrhoea	B-DISEASE
,	O
and	O
severe	O
miosis	B-DISEASE
;	O
the	O
electrocardiographic	O
finding	O
was	O
atrio	B-DISEASE
-	I-DISEASE
ventricular	I-DISEASE
dissociation	I-DISEASE
.	O
High	O
doses	O
of	O
atropine	O
(	O
up	O
to	O
50	O
mg	O
per	O
24	O
hours	O
)	O
,	O
adrenaline	B-CHEMICAL
and	O
dopamine	B-CHEMICAL
were	O
necessary	O
.	O
The	O
patient	O
was	O
extubated	O
1	O
week	O
later	O
.	O
However	O
,	O
increased	O
dyspnoea	B-DISEASE
and	O
bronchospasm	B-DISEASE
necessitated	O
reintubation	O
.	O
Respiratory	B-DISEASE
insufficiency	I-DISEASE
was	O
further	O
worsened	O
by	O
Proteus	B-DISEASE
mirabilis	I-DISEASE
infection	I-DISEASE
and	O
severe	O
bronchoconstriction	O
.	O
One	O
week	O
later	O
,	O
the	O
patient	O
was	O
again	O
extubated	O
and	O
3	O
days	O
later	O
was	O
transferred	O
to	O
a	O
peripheral	O
ward	O
.	O
On	O
the	O
next	O
day	O
he	O
died	O
,	O
probably	O
as	O
a	O
result	O
of	O
heart	B-DISEASE
failure	I-DISEASE
.	O
Serum	O
samples	O
from	O
the	O
first	O
and	O
second	O
days	O
contained	O
3.6	O
and	O
1.9	O
mg	O
/	O
l	O
carbachol	O
,	O
respectively	O
.	O
The	O
corresponding	O
urine	O
concentrations	O
amounted	O
to	O
374	O
and	O
554	O
mg	O
/	O
l.	O
CONCLUSION	O
:	O
This	O
case	O
started	O
with	O
a	O
media	O
report	O
in	O
a	O
popular	O
newspaper	O
,	O
initiated	O
by	O
published	O
,	O
peer	O
-	O
reviewed	O
research	O
on	O
herbals	O
,	O
and	O
involved	O
human	O
failure	O
in	O
a	O
case	O
history	O
,	O
medical	O
examination	O
and	O
clinical	O
treatment	O
.	O
For	O
the	O
first	O
time	O
,	O
an	O
analytical	O
method	O
for	O
the	O
determination	O
of	O
carbachol	O
in	O
plasma	O
and	O
urine	O
has	O
been	O
developed	O
.	O
The	O
analysed	O
carbachol	O
concentration	O
exceeded	O
the	O
supposed	O
serum	O
level	O
resulting	O
from	O
a	O
therapeutic	O
dose	O
by	O
a	O
factor	O
of	O
130	O
to	O
260	O
.	O
Especially	O
in	O
old	O
patients	O
,	O
intensivists	O
should	O
consider	O
intoxications	O
(	O
with	O
cholinergics	B-CHEMICAL
)	O
as	O
a	O
cause	O
of	O
acute	B-DISEASE
cardiovascular	I-DISEASE
failure	I-DISEASE
.	O

Crossover	O
comparison	O
of	O
efficacy	O
and	O
preference	O
for	O
rizatriptan	B-CHEMICAL
10	O
mg	O
versus	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
in	O
migraine	B-DISEASE
.	O
Rizatriptan	B-CHEMICAL
is	O
a	O
selective	O
5	O
-	O
HT(1B/1D	O
)	O
receptor	O
agonist	O
with	O
rapid	O
oral	O
absorption	O
and	O
early	O
onset	O
of	O
action	O
in	O
the	O
acute	O
treatment	O
of	O
migraine	B-DISEASE
.	O
This	O
randomized	O
double-	O
blind	B-DISEASE
crossover	O
outpatient	O
study	O
assessed	O
the	O
preference	O
for	O
1	O
rizatriptan	B-CHEMICAL
10	O
mg	O
tablet	O
to	O
2	O
ergotamine	B-CHEMICAL
1	O
mg	O
/	O
caffeine	B-CHEMICAL
100	O
mg	O
tablets	O
in	O
439	O
patients	O
treating	O
a	O
single	O
migraine	B-DISEASE
attack	O
with	O
each	O
therapy	O
.	O
Of	O
patients	O
expressing	O
a	O
preference	O
(	O
89.1	O
%	O
)	O
,	O
more	O
than	O
twice	O
as	O
many	O
preferred	O
rizatriptan	B-CHEMICAL
to	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
(	O
69.9	O
vs.	O
30.1	O
%	O
,	O
p	O
<	O
or	O
=	O
0.001	O
)	O
.	O
Faster	O
relief	O
of	O
headache	B-DISEASE
was	O
the	O
most	O
important	O
reason	O
for	O
preference	O
,	O
cited	O
by	O
67.3	O
%	O
of	O
patients	O
preferring	O
rizatriptan	B-CHEMICAL
and	O
54.2	O
%	O
of	O
patients	O
who	O
preferred	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
.	O
The	O
co	B-CHEMICAL
-	O
primary	O
endpoint	O
of	O
being	O
pain	B-DISEASE
free	O
at	O
2	O
h	O
was	O
also	O
in	O
favor	O
of	O
rizatriptan	B-CHEMICAL
.	O
Forty	O
-	O
nine	O
percent	O
of	O
patients	O
were	O
pain	B-DISEASE
free	O
2	O
h	O
after	O
rizatriptan	B-CHEMICAL
,	O
compared	O
with	O
24.3	O
%	O
treated	O
with	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
,	O
rizatriptan	B-CHEMICAL
being	O
superior	O
within	O
1	O
h	O
of	O
treatment	O
.	O
Headache	B-DISEASE
relief	O
at	O
2	O
h	O
was	O
75.9	O
%	O
for	O
rizatriptan	B-CHEMICAL
and	O
47.3	O
%	O
for	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
,	O
with	O
rizatriptan	B-CHEMICAL
being	O
superior	O
to	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
within	O
30	O
min	O
of	O
dosing	O
.	O
Almost	O
36	O
%	O
of	O
patients	O
taking	O
rizatriptan	B-CHEMICAL
were	O
pain	B-DISEASE
free	O
at	O
2	O
h	O
and	O
had	O
no	O
recurrence	B-DISEASE
or	O
need	O
for	O
additional	O
medication	O
within	O
24	O
h	O
,	O
compared	O
to	O
20	O
%	O
of	O
patients	O
on	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
.	O
Rizatriptan	B-CHEMICAL
was	O
also	O
superior	O
to	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
in	O
the	O
proportions	O
of	O
patients	O
with	O
no	O
nausea	B-DISEASE
,	O
vomiting	B-DISEASE
,	O
phonophobia	O
or	O
photophobia	B-DISEASE
and	O
for	O
patients	O
with	O
normal	O
function	O
2	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
.	O
More	O
patients	O
were	O
(	O
completely	O
,	O
very	O
or	O
somewhat	O
)	O
satisfied	O
2	O
h	O
after	O
treatment	O
with	O
rizatriptan	B-CHEMICAL
(	O
69.8	O
%	O
)	O
than	O
at	O
2	O
h	O
after	O
treatment	O
with	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
(	O
38.6	O
%	O
,	O
p	O
<	O
or	O
=	O
0.001	O
)	O
.	O
Recurrence	B-DISEASE
rates	O
were	O
31.4	O
%	O
with	O
rizatriptan	B-CHEMICAL
and	O
15.3	O
%	O
with	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
.	O
Both	O
active	O
treatments	O
were	O
well	O
tolerated	O
.	O
The	O
most	O
common	O
adverse	O
events	O
(	O
incidence	O
>	O
or	O
=	O
5	O
%	O
in	O
one	O
group	O
)	O
after	O
rizatriptan	B-CHEMICAL
and	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
,	O
respectively	O
,	O
were	O
dizziness	B-DISEASE
(	O
6.7	O
and	O
5.3	O
%	O
)	O
,	O
nausea	B-DISEASE
(	O
4.2	O
and	O
8.5	O
%	O
)	O
and	O
somnolence	B-DISEASE
(	O
5.5	O
and	O
2.3	O
%	O
)	O
.	O

Thrombotic	B-DISEASE
microangiopathy	I-DISEASE
and	O
renal	B-DISEASE
failure	I-DISEASE
associated	O
with	O
antineoplastic	O
chemotherapy	O
.	O
Five	O
patients	O
with	O
carcinoma	B-DISEASE
developed	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
(	O
characterized	O
by	O
renal	B-DISEASE
insufficiency	I-DISEASE
,	O
microangiopathic	O
hemolytic	O
anemia	B-DISEASE
,	O
and	O
usually	O
thrombocytopenia	B-DISEASE
)	O
after	O
treatment	O
with	O
cisplatin	B-CHEMICAL
,	O
bleomycin	O
,	O
and	O
a	O
vinca	O
alkaloid	O
.	O
One	O
patient	O
had	O
thrombotic	B-DISEASE
thrombocytopenic	O
purpura	B-DISEASE
,	O
three	O
the	O
hemolytic	B-DISEASE
-	I-DISEASE
uremic	I-DISEASE
syndrome	I-DISEASE
,	O
and	O
one	O
an	O
apparent	O
forme	O
fruste	O
of	O
one	O
of	O
these	O
disorders	O
.	O
Histologic	O
examination	O
of	O
the	O
renal	O
tissue	O
showed	O
evidence	O
of	O
intravascular	O
coagulation	O
,	O
primarily	O
affecting	O
the	O
small	O
arteries	O
,	O
arterioles	O
,	O
and	O
glomeruli	O
.	O
Because	O
each	O
patient	O
was	O
tumor	B-DISEASE
-	O
free	O
or	O
had	O
only	O
a	O
small	O
tumor	B-DISEASE
at	O
the	O
onset	O
of	O
this	O
syndrome	B-DISEASE
,	O
the	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
may	O
have	O
been	O
induced	O
by	O
chemotherapy	O
.	O
Diagnosis	O
of	O
this	O
potentially	O
fatal	O
complication	O
may	O
be	O
delayed	O
or	O
missed	O
if	O
renal	O
tissue	O
or	O
the	O
peripheral	O
blood	O
smear	O
is	O
not	O
examined	O
,	O
because	O
renal	B-DISEASE
failure	I-DISEASE
may	O
be	O
ascribed	O
to	O
cisplatin	B-CHEMICAL
nephrotoxicity	B-DISEASE
and	O
the	O
anemia	B-DISEASE
and	O
thrombocytopenia	B-DISEASE
to	O
drug	O
-	O
induced	O
bone	B-DISEASE
marrow	I-DISEASE
suppression	I-DISEASE
.	O

Salvage	O
therapy	O
with	O
nelarabine	B-CHEMICAL
,	O
etoposide	B-CHEMICAL
,	O
and	O
cyclophosphamide	B-CHEMICAL
in	O
relapsed	O
/	O
refractory	O
paediatric	O
T	O
-	O
cell	O
lymphoblastic	O
leukaemia	O
and	O
lymphoma	B-DISEASE
.	O
A	O
combination	O
of	O
5	O
d	O
of	O
nelarabine	B-CHEMICAL
(	O
AraG	B-CHEMICAL
)	O
with	O
5	O
d	O
of	O
etoposide	B-CHEMICAL
(	O
VP	O
)	O
and	O
cyclophosphamide	B-CHEMICAL
(	O
CPM	O
)	O
and	O
prophylactic	O
intrathecal	O
chemotherapy	O
was	O
used	O
as	O
salvage	O
therapy	O
in	O
seven	O
children	O
with	O
refractory	O
or	O
relapsed	O
T	O
-	O
cell	O
leukaemia	O
or	O
lymphoma	B-DISEASE
.	O
The	O
most	O
common	O
side	O
effects	O
attributable	O
to	O
the	O
AraG	B-CHEMICAL
included	O
Grade	O
2	O
and	O
3	O
sensory	O
and	O
motor	O
neuropathy	B-DISEASE
and	O
musculoskeletal	B-DISEASE
pain	I-DISEASE
.	O
Haematological	O
toxicity	B-DISEASE
was	O
greater	O
for	O
the	O
combination	O
than	O
AraG	B-CHEMICAL
alone	O
,	O
although	O
median	O
time	O
to	O
neutrophil	O
and	O
platelet	O
recovery	O
was	O
consistent	O
with	O
other	O
salvage	O
therapies	O
.	O
All	O
patients	O
had	O
some	O
response	O
to	O
the	O
combined	O
therapy	O
and	O
five	O
of	O
the	O
seven	O
went	O
into	O
complete	O
remission	O
after	O
one	O
or	O
two	O
courses	O
of	O
AraG	B-CHEMICAL
/	O
VP	O
/	O
CPM	O
.	O
Our	O
experience	O
supports	O
the	O
safety	O
of	O
giving	O
AraG	B-CHEMICAL
as	O
salvage	O
therapy	O
in	O
synchrony	O
with	O
etoposide	B-CHEMICAL
and	O
cyclophosphamide	B-CHEMICAL
,	O
although	O
neurological	O
toxicity	B-DISEASE
must	O
be	O
closely	O
monitored	O
.	O

The	O
3	O
-	O
week	O
sulphasalazine	B-CHEMICAL
syndrome	B-DISEASE
strikes	O
again	O
.	O
A	O
34	O
-	O
year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	O
of	O
dermatitis	B-DISEASE
,	O
fever	B-DISEASE
,	O
lymphadenopathy	B-DISEASE
and	O
hepatitis	B-DISEASE
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	B-CHEMICAL
for	O
sero	O
-	O
negative	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
.	O
Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	B-DISEASE
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	B-DISEASE
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	B-DISEASE
drug	I-DISEASE
reaction	I-DISEASE
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	B-DISEASE
-	I-DISEASE
induced	I-DISEASE
hepatitis	I-DISEASE
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	B-DISEASE
)	O
,	O
and	O
accompanied	O
by	O
multi	O
-	O
organ	O
failure	O
and	O
sepsis	B-DISEASE
,	O
supervened	O
.	O
She	O
subsequently	O
died	O
some	O
5	O
weeks	O
after	O
the	O
commencement	O
of	O
her	O
drug	O
therapy	O
.	O
Post	O
-	O
mortem	O
examination	O
showed	O
evidence	O
of	O
massive	O
hepatocellular	O
necrosis	B-DISEASE
,	O
acute	O
hypersensitivity	B-DISEASE
myocarditis	B-DISEASE
,	O
focal	O
acute	O
tubulo	O
-	O
interstitial	B-DISEASE
nephritis	I-DISEASE
and	O
extensive	O
bone	B-DISEASE
marrow	I-DISEASE
necrosis	I-DISEASE
,	O
with	O
no	O
evidence	O
of	O
malignancy	B-DISEASE
.	O
It	O
is	O
thought	O
that	O
the	O
clinico	O
-	O
pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
"	O
3	O
-	O
week	O
sulphasalazine	B-CHEMICAL
syndrome	B-DISEASE
"	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	O
,	O
immunoallergic	O
reaction	O
to	O
sulphasalazine	B-CHEMICAL
.	O

Bupropion	O
(	O
Zyban	O
)	O
toxicity	B-DISEASE
.	O
Bupropion	O
is	O
a	O
monocyclic	O
antidepressant	O
structurally	O
related	O
to	O
amphetamine	O
.	O
Zyban	O
,	O
a	O
sustained	O
-	O
release	O
formulation	O
of	O
bupropion	O
hydrochloride	O
,	O
was	O
recently	O
released	O
in	O
Ireland	O
,	O
as	O
a	O
smoking	B-CHEMICAL
cessation	O
aid	O
.	O
In	O
the	O
initial	O
6	O
months	O
since	O
it	O
's	O
introduction	O
,	O
12	O
overdose	B-DISEASE
cases	O
have	O
been	O
reported	O
to	O
The	O
National	O
Poisons	O
Information	O
Centre	O
.	O
8	O
patients	O
developed	O
symptoms	O
of	O
toxicity	B-DISEASE
.	O
Common	O
features	O
included	O
tachycardia	B-DISEASE
,	O
drowsiness	B-DISEASE
,	O
hallucinations	B-DISEASE
and	O
convulsions	B-DISEASE
.	O
Two	O
patients	O
developed	O
severe	O
cardiac	B-DISEASE
arrhythmias	I-DISEASE
,	O
including	O
one	O
patient	O
who	O
was	O
resuscitated	O
following	O
a	O
cardiac	B-DISEASE
arrest	I-DISEASE
.	O
All	O
patients	O
recovered	O
without	O
sequelae	O
.	O
We	O
report	O
a	O
case	O
of	O
a	O
31	O
year	O
old	O
female	O
who	O
required	O
admission	O
to	O
the	O
Intensive	O
Care	O
Unit	O
for	O
ventilation	O
and	O
full	O
supportive	O
therapy	O
,	O
following	O
ingestion	O
of	O
13.5	O
g	O
bupropion	O
.	O
Recurrent	O
seizures	B-DISEASE
were	O
treated	O
with	O
diazepam	B-CHEMICAL
and	O
broad	O
complex	O
tachycardia	B-DISEASE
was	O
successfully	O
treated	O
with	O
adenosine	O
.	O
Zyban	O
caused	O
significant	O
neurological	O
and	O
cardiovascular	B-DISEASE
toxicity	I-DISEASE
in	O
overdose	B-DISEASE
.	O
The	O
potential	O
toxic	O
effects	O
should	O
be	O
considered	O
when	O
prescribing	O
it	O
as	O
a	O
smoking	B-CHEMICAL
cessation	O
aid	O
.	O

Survey	O
of	O
complications	B-DISEASE
of	O
indocyanine	O
green	O
angiography	O
in	O
Japan	O
.	O
PURPOSE	O
:	O
We	O
evaluated	O
the	O
safety	O
of	O
indocyanine	O
green	O
for	O
use	O
in	O
fundus	O
angiography	O
.	O
METHODS	O
:	O
We	O
sent	O
a	O
questionnaire	O
concerning	O
complications	B-DISEASE
of	O
indocyanine	O
green	O
to	O
32	O
institutions	O
in	O
Japan	O
,	O
which	O
were	O
selected	O
on	O
the	O
basis	O
of	O
the	O
client	O
list	O
from	O
the	O
Topcon	O
Company	O
,	O
which	O
manufactures	O
the	O
indocyanine	O
green	O
fundus	O
camera	O
.	O
RESULTS	O
:	O
Ophthalmologists	O
at	O
15	O
institutions	O
responded	O
,	O
reporting	O
a	O
total	O
of	O
3,774	O
indocyanine	O
green	O
angiograms	O
performed	O
on	O
2,820	O
patients	O
between	O
June	O
1984	O
and	O
September	O
1992	O
.	O
Before	O
angiography	O
,	O
intradermal	O
or	O
intravenous	O
indocyanine	O
green	O
testing	O
,	O
or	O
both	O
was	O
performed	O
at	O
13	O
of	O
15	O
institutions	O
.	O
For	O
three	O
patients	O
,	O
the	O
decision	O
was	O
made	O
not	O
to	O
proceed	O
with	O
angiography	O
after	O
positive	O
preangiographic	O
testing	O
.	O
The	O
dosage	O
of	O
indocyanine	O
green	O
used	O
for	O
angiography	O
varied	O
from	O
25	O
to	O
75	O
mg	O
,	O
depending	O
upon	O
the	O
institution	O
.	O
There	O
were	O
13	O
cases	O
of	O
adverse	O
reactions	O
(	O
0.34	O
%	O
)	O
,	O
ten	O
of	O
which	O
were	O
mild	O
reactions	O
such	O
as	O
nausea	B-DISEASE
,	O
exanthema	B-DISEASE
,	O
urtication	O
,	O
itchiness	O
,	O
and	O
urgency	O
to	O
defecate	O
,	O
and	O
did	O
not	O
require	O
treatment	O
.	O
Also	O
recorded	O
were	O
one	O
case	O
of	O
pain	B-DISEASE
of	O
the	O
vein	O
,	O
which	O
required	O
treatment	O
,	O
and	O
two	O
cases	O
of	O
hypotension	B-DISEASE
.	O
The	O
two	O
hypotensive	B-DISEASE
patients	O
required	O
treatment	O
for	O
shock	B-DISEASE
.	O
CONCLUSIONS	O
:	O
A	O
comparison	O
of	O
frequency	O
of	O
adverse	O
reactions	O
to	O
indocyanine	O
green	O
with	O
the	O
previously	O
reported	O
frequency	O
of	O
such	O
reactions	O
to	O
fluorescein	B-CHEMICAL
sodium	B-CHEMICAL
indicated	O
that	O
indocyanine	O
green	O
is	O
a	O
safe	O
as	O
fluorescein	B-CHEMICAL
for	O
use	O
in	O
angiography	O
.	O

Bradykinin	B-CHEMICAL
receptors	O
antagonists	O
and	O
nitric	O
oxide	O
synthase	O
inhibitors	O
in	O
vincristine	B-CHEMICAL
and	O
streptozotocin	B-CHEMICAL
induced	O
hyperalgesia	B-DISEASE
in	O
chemotherapy	O
and	O
diabetic	B-DISEASE
neuropathy	I-DISEASE
rat	O
model	O
.	O
PURPOSE	O
:	O
The	O
influence	O
of	O
an	O
irreversible	O
inhibitor	O
of	O
constitutive	O
NO	O
synthase	O
(	O
L	O
-	O
NOArg	O
;	O
1.0	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
a	O
relatively	O
selective	O
inhibitor	O
of	O
inducible	O
NO	O
synthase	O
(	O
L	O
-	O
NIL	O
;	O
1.0	O
mg	O
/	O
kg	O
ip	O
)	O
and	O
a	O
relatively	O
specific	O
inhibitor	O
of	O
neuronal	O
NO	O
synthase	O
(	O
7	O
-	O
NI	O
;	O
0.1	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
on	O
antihyperalgesic	O
action	O
of	O
selective	O
antagonists	O
of	O
B2	O
and	O
B1	O
receptors	O
:	O
D	O
-	O
Arg-[Hyp3,Thi5,D	O
-	O
Tic7,Oic8	O
]	O
bradykinin	B-CHEMICAL
(	O
HOE	O
140	O
;	O
70	O
nmol	O
/	O
kg	O
ip	O
)	O
or	O
des	O
Arg10	O
HOE	O
140	O
(	O
70	O
nmol	O
/	O
kg	O
ip	O
)	O
respectively	O
,	O
in	O
model	O
of	O
diabetic	B-DISEASE
(	O
streptozotocin	B-CHEMICAL
-	O
induced	O
)	O
and	O
toxic	O
(	O
vincristine	B-CHEMICAL
-	O
induced	O
)	O
neuropathy	B-DISEASE
was	O
investigated	O
.	O
METHODS	O
:	O
The	O
changes	O
in	O
pain	B-DISEASE
thresholds	O
were	O
determined	O
using	O
mechanical	O
stimuli	O
--	O
the	O
modification	O
of	O
the	O
classic	O
paw	O
withdrawal	O
test	O
described	O
by	O
Randall	O
-	O
Selitto	O
.	O
RESULTS	O
:	O
The	O
results	O
of	O
this	O
paper	O
confirm	O
that	O
inhibition	O
of	O
bradykinin	B-CHEMICAL
receptors	O
and	O
inducible	O
NO	O
synthase	O
but	O
not	O
neuronal	O
NO	O
synthase	O
activity	O
reduces	O
diabetic	B-DISEASE
hyperalgesia	I-DISEASE
.	O
Pretreatment	O
with	O
L	O
-	O
NOArg	O
and	O
L	O
-	O
NIL	O
but	O
not	O
7	O
-	O
NI	O
,	O
significantly	O
increases	O
antihyperalgesic	O
activity	O
both	O
HOE	O
140	O
and	O
des	O
Arg10	O
HOE	O
140	O
.	O
It	O
was	O
also	O
shown	O
that	O
both	O
products	O
of	O
inducible	O
NO	O
synthase	O
and	O
neuronal	O
NO	O
synthase	O
activation	O
as	O
well	O
as	O
bradykinin	B-CHEMICAL
are	O
involved	O
in	O
hyperalgesia	B-DISEASE
produced	O
by	O
vincristine	B-CHEMICAL
.	O
Moreover	O
,	O
L	O
-	O
NOArg	O
and	O
7	O
-	O
NI	O
but	O
not	O
L	O
-	O
NIL	O
intensify	O
antihyperalgesic	O
activity	O
of	O
HOE	O
140	O
or	O
des	O
-	O
Arg10HOE	O
140	O
in	O
toxic	O
neuropathy	B-DISEASE
.	O
CONCLUSIONS	O
:	O
Results	O
of	O
these	O
studies	O
suggest	O
that	O
B1	O
and	O
B2	O
receptors	O
are	O
engaged	O
in	O
transmission	O
of	O
nociceptive	O
stimuli	O
in	O
both	O
diabetic	B-DISEASE
and	O
toxic	O
neuropathy	B-DISEASE
.	O
In	O
streptozotocin	B-CHEMICAL
-	O
induced	O
hyperalgesia	B-DISEASE
,	O
inducible	O
NO	O
synthase	O
participates	O
in	O
pronociceptive	O
activity	O
of	O
bradykinin	B-CHEMICAL
,	O
whereas	O
in	O
vincristine	B-CHEMICAL
-	O
induced	O
hyperalgesia	B-DISEASE
bradykinin	B-CHEMICAL
seemed	O
to	O
activate	O
neuronal	O
NO	O
synthase	O
pathway	O
.	O
Therefore	O
,	O
concomitant	O
administration	O
of	O
small	O
doses	O
of	O
bradykinin	B-CHEMICAL
receptor	I-CHEMICAL
antagonists	I-CHEMICAL
and	O
NO	O
synthase	O
inhibitors	O
can	O
be	O
effective	O
in	O
alleviation	O
of	O
neuropathic	B-DISEASE
pain	I-DISEASE
,	O
even	O
in	O
hospital	O
care	O
.	O

Cardiac	B-DISEASE
toxicity	I-DISEASE
observed	O
in	O
association	O
with	O
high	O
-	O
dose	O
cyclophosphamide	B-CHEMICAL
-	O
based	O
chemotherapy	O
for	O
metastatic	O
breast	B-DISEASE
cancer	I-DISEASE
.	O
INTRODUCTION	O
:	O
Cyclophosphamide	B-CHEMICAL
is	O
an	O
alkylating	O
agent	O
given	O
frequently	O
as	O
a	O
component	O
of	O
many	O
conditioning	O
regimens	O
.	O
In	O
high	O
doses	O
,	O
its	O
nonhematological	O
dose	O
-	O
limiting	O
toxicity	B-DISEASE
is	O
cardiomyopathy	B-DISEASE
.	O
STUDY	O
DESIGN	O
:	O
We	O
combined	O
paclitaxel	B-CHEMICAL
,	O
melphalan	B-CHEMICAL
and	O
high	O
-	O
dose	O
cyclophosphamide	B-CHEMICAL
,	O
thiotepa	O
,	O
and	O
carboplatin	O
in	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
for	O
patients	O
with	O
metastatic	O
breast	B-DISEASE
cancer	I-DISEASE
.	O
Analysis	O
was	O
performed	O
on	O
61	O
women	O
with	O
chemotherapy	O
-	O
responsive	O
metastatic	O
breast	B-DISEASE
cancer	I-DISEASE
receiving	O
96	O
-	O
h	O
infusional	O
cyclophosphamide	B-CHEMICAL
as	O
part	O
of	O
a	O
triple	O
sequential	O
high	O
-	O
dose	O
regimen	O
to	O
assess	O
association	O
between	O
presence	O
of	O
peritransplant	O
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
(	O
CHF	B-DISEASE
)	O
and	O
the	O
following	O
pretreatment	O
characteristics	O
:	O
presence	O
of	O
electrocardiogram	O
(	O
EKG	O
)	O
abnormalities	O
,	O
age	O
,	O
hypertension	B-DISEASE
,	O
prior	O
cardiac	O
history	O
,	O
smoking	B-CHEMICAL
,	O
diabetes	B-DISEASE
mellitus	I-DISEASE
,	O
prior	O
use	O
of	O
anthracyclines	O
,	O
and	O
left	O
-	O
sided	O
chest	O
irradiation	O
.	O
RESULTS	O
:	O
Six	O
of	O
61	O
women	O
(	O
10	O
%	O
)	O
developed	O
clinically	O
reversible	O
grade	O
3	O
CHF	B-DISEASE
following	O
infusional	O
cyclophosphamide	B-CHEMICAL
with	O
a	O
median	O
percent	O
decline	O
in	O
ejection	O
fraction	O
of	O
31	O
%	O
.	O
Incidence	O
of	O
transient	O
cyclophosphamide	B-CHEMICAL
-	O
related	O
cardiac	B-DISEASE
toxicity	I-DISEASE
(	O
10	O
%	O
)	O
is	O
comparable	O
to	O
previous	O
recorded	O
literature	O
.	O
Older	O
age	O
was	O
significantly	O
correlated	O
with	O
the	O
CHF	B-DISEASE
development	O
;	O
with	O
median	O
ages	O
for	O
the	O
entire	O
group	O
and	O
for	O
patients	O
developing	O
CHF	B-DISEASE
of	O
45	O
and	O
59	O
,	O
respectively	O
.	O
No	O
association	O
was	O
found	O
with	O
other	O
pretreatment	O
characteristics	O
.	O
CONCLUSIONS	O
:	O
As	O
a	O
result	O
of	O
these	O
findings	O
,	O
oncologists	O
should	O
carefully	O
monitor	O
fluid	O
balance	O
in	O
older	O
patients	O
.	O
Routine	O
EKG	O
monitoring	O
during	O
infusional	O
cyclophosphamide	B-CHEMICAL
did	O
not	O
predict	O
CHF	B-DISEASE
development	O
.	O

Inappropriate	O
use	O
of	O
carbamazepine	B-CHEMICAL
and	O
vigabatrin	B-CHEMICAL
in	O
typical	O
absence	B-DISEASE
seizures	I-DISEASE
.	O
Carbamazepine	B-CHEMICAL
and	O
vigabatrin	B-CHEMICAL
are	O
contraindicated	O
in	O
typical	O
absence	B-DISEASE
seizures	I-DISEASE
.	O
Of	O
18	O
consecutive	O
referrals	O
of	O
children	O
with	O
resistant	O
typical	O
absences	O
only	O
,	O
eight	O
were	O
erroneously	O
treated	O
with	O
carbamazepine	B-CHEMICAL
either	O
as	O
monotherapy	O
or	O
as	O
an	O
add	O
-	O
on	O
.	O
Vigabatrin	B-CHEMICAL
was	O
also	O
used	O
in	O
the	O
treatment	O
of	O
two	O
children	O
.	O
Frequency	O
of	O
absences	O
increased	O
in	O
four	O
children	O
treated	O
with	O
carbamazepine	B-CHEMICAL
and	O
two	O
of	O
these	O
developed	O
myoclonic	B-DISEASE
jerks	I-DISEASE
,	O
which	O
resolved	O
on	O
withdrawal	O
of	O
carbamazepine	B-CHEMICAL
.	O
Absences	O
were	O
aggravated	O
in	O
both	O
cases	O
where	O
vigabatrin	B-CHEMICAL
was	O
added	O
on	O
to	O
concurrent	O
treatment	O
.	O
Optimal	O
control	O
of	O
the	O
absences	O
was	O
achieved	O
with	O
sodium	B-CHEMICAL
valproate	O
,	O
lamotrigine	O
,	O
or	O
ethosuximide	O
alone	O
or	O
in	O
combination	O
.	O

Hemolytic	O
anemia	B-DISEASE
associated	O
with	O
the	O
use	O
of	O
omeprazole	B-CHEMICAL
.	O
Omeprazole	B-CHEMICAL
is	O
the	O
first	O
drug	O
designed	O
to	O
block	O
the	O
final	O
step	O
in	O
the	O
acid	O
secretory	O
process	O
within	O
the	O
parietal	O
cell	O
.	O
It	O
has	O
been	O
shown	O
to	O
be	O
extremely	O
effective	O
in	O
the	O
treatment	O
of	O
peptic	B-DISEASE
ulcer	I-DISEASE
disease	B-DISEASE
,	O
reflux	O
esophagitis	B-DISEASE
,	O
and	O
the	O
Zollinger	B-DISEASE
-	I-DISEASE
Ellison	I-DISEASE
syndrome	I-DISEASE
.	O
Although	O
clinical	O
experience	O
with	O
omeprazole	B-CHEMICAL
is	O
still	O
limited	O
,	O
many	O
controlled	O
studies	O
have	O
established	O
the	O
short	O
-	O
term	O
safety	O
of	O
this	O
drug	O
.	O
We	O
report	O
the	O
first	O
case	O
of	O
a	O
serious	O
short	O
-	O
term	O
adverse	O
reaction	O
with	O
the	O
use	O
of	O
omeprazole	B-CHEMICAL
:	O
hemolytic	O
anemia	B-DISEASE
.	O
The	O
patient	O
developed	O
weakness	B-DISEASE
,	O
lethargy	B-DISEASE
,	O
and	O
shortness	B-DISEASE
of	I-DISEASE
breath	I-DISEASE
2	O
days	O
after	O
starting	O
therapy	O
with	O
omeprazole	B-CHEMICAL
.	O
Two	O
weeks	O
after	O
the	O
initiation	O
of	O
therapy	O
,	O
her	O
hematocrit	O
had	O
decreased	O
from	O
44.1	O
%	O
to	O
20.4	O
%	O
,	O
and	O
she	O
had	O
a	O
positive	O
direct	O
Coombs	O
antiglobulin	O
test	O
and	O
an	O
elevated	O
indirect	O
bilirubin	O
.	O
After	O
she	O
discontinued	O
the	O
omeprazole	B-CHEMICAL
,	O
her	O
hemoglobin	O
and	O
hematocrit	O
gradually	O
returned	O
to	O
normal	O
.	O
The	O
mechanism	O
by	O
which	O
omeprazole	B-CHEMICAL
caused	O
the	O
patient	O
's	O
hemolytic	O
anemia	B-DISEASE
is	O
uncertain	O
,	O
but	O
physicians	O
should	O
be	O
alerted	O
to	O
this	O
possible	O
adverse	O
effect	O
.	O

The	O
use	O
and	O
toxicity	B-DISEASE
of	O
didanosine	B-CHEMICAL
(	O
ddI	O
)	O
in	O
HIV	B-DISEASE
antibody	O
-	O
positive	O
individuals	O
intolerant	O
to	O
zidovudine	B-CHEMICAL
(	O
AZT	B-CHEMICAL
)	O
One	O
hundred	O
and	O
fifty	O
-	O
one	O
patients	O
intolerant	O
to	O
zidovudine	B-CHEMICAL
(	O
AZT	B-CHEMICAL
)	O
received	O
didanosine	B-CHEMICAL
(	O
ddI	O
)	O
to	O
a	O
maximum	O
dose	O
of	O
12.5	O
mg	O
/	O
kg	O
/	O
day	O
.	O
Patient	O
response	O
was	O
assessed	O
using	O
changes	O
in	O
CD4	O
+	O
lymphocyte	O
subset	O
count	O
,	O
HIV	B-DISEASE
p24	O
antigen	O
,	O
weight	O
,	O
and	O
quality	O
of	O
life	O
.	O
Seventy	O
patients	O
developed	O
major	O
opportunistic	B-DISEASE
infections	I-DISEASE
whilst	O
on	O
therapy	O
;	O
this	O
was	O
the	O
first	O
AIDS	B-DISEASE
diagnosis	O
in	O
17	O
.	O
Only	O
minor	O
changes	O
in	O
CD4	O
+	O
lymphocyte	O
subset	O
count	O
were	O
observed	O
in	O
AIDS	B-DISEASE
patients	O
,	O
although	O
a	O
more	O
significant	O
rise	O
occurred	O
in	O
those	O
with	O
earlier	O
stages	O
of	O
disease	B-DISEASE
.	O
Of	O
those	O
positive	O
for	O
p24	O
antigen	O
at	O
the	O
commencement	O
of	O
the	O
study	O
67	O
%	O
showed	O
a	O
positive	O
response	O
,	O
and	O
this	O
was	O
most	O
likely	O
in	O
those	O
with	O
CD4	O
+	O
lymphocyte	O
subset	O
counts	O
above	O
100	O
mm3	O
.	O
A	O
positive	O
weight	O
response	O
was	O
seen	O
in	O
16	O
%	O
of	O
patients	O
.	O
Most	O
patients	O
showed	O
improvement	O
in	O
individual	O
parameters	O
and	O
global	O
score	O
of	O
quality	O
of	O
life	O
.	O
Adverse	O
reactions	O
possibly	O
attributable	O
to	O
didanosine	B-CHEMICAL
were	O
common	O
.	O
The	O
most	O
common	O
side	O
-	O
effect	O
was	O
diarrhoea	B-DISEASE
,	O
which	O
resulted	O
in	O
cessation	O
of	O
therapy	O
in	O
19	O
individuals	O
.	O
Peripheral	B-DISEASE
neuropathy	I-DISEASE
occurred	O
in	O
12	O
patients	O
and	O
pancreatitis	B-DISEASE
in	O
six	O
.	O
Thirteen	O
patients	O
developed	O
a	O
raised	O
serum	O
amylase	O
without	O
abdominal	B-DISEASE
pain	I-DISEASE
.	O
Seven	O
patients	O
developed	O
glucose	B-CHEMICAL
tolerance	O
curves	O
characteristic	O
of	O
diabetes	B-DISEASE
but	O
these	O
were	O
mild	O
,	O
did	O
not	O
require	O
treatment	O
and	O
returned	O
to	O
normal	O
on	O
ceasing	O
didanosine	B-CHEMICAL
.	O

Can	O
angiogenesis	O
be	O
a	O
target	O
of	O
treatment	O
for	O
ribavirin	B-CHEMICAL
associated	O
hemolytic	O
anemia	B-DISEASE
?	O
BACKGROUND	O
/	O
AIMS	O
:	O
Recently	O
ribavirin	B-CHEMICAL
has	O
been	O
found	O
to	O
inhibit	O
angiogenesis	O
and	O
a	O
number	O
of	O
angiogenesis	B-CHEMICAL
inhibitors	I-CHEMICAL
such	O
as	O
sunitinib	O
and	O
sorafenib	B-CHEMICAL
have	O
been	O
found	O
to	O
cause	O
acute	O
hemolysis	B-DISEASE
.	O
We	O
aimed	O
to	O
investigate	O
whether	O
there	O
is	O
a	O
relation	O
between	O
hemoglobin	O
,	O
haptoglobin	O
and	O
angiogenesis	O
soluble	O
markers	O
which	O
are	O
modifiable	O
and	O
can	O
help	O
in	O
developing	O
strategies	O
against	O
anemia	B-DISEASE
.	O
METHODS	O
:	O
Fourteen	O
patients	O
chronically	B-DISEASE
infected	I-DISEASE
with	I-DISEASE
hepatitis	I-DISEASE
C	I-DISEASE
virus	I-DISEASE
were	O
treated	O
by	O
pegylated	O
interferon	O
alpha	O
2a	O
and	O
ribavirin	B-CHEMICAL
.	O
Serum	O
hemoglobin	O
,	O
haptoglobin	O
and	O
angiogenesis	O
markers	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
angiopoetin-2	O
were	O
investigated	O
before	O
and	O
after	O
therapy	O
.	O
RESULTS	O
:	O
We	O
observed	O
a	O
significant	O
decrease	O
in	O
haptoglobin	O
levels	O
at	O
the	O
end	O
of	O
the	O
treatment	O
period	O
.	O
Hemoglobin	O
levels	O
also	O
decreased	O
but	O
insignificantly	O
by	O
treatment	O
.	O
In	O
contrast	O
with	O
the	O
literature	O
,	O
serum	O
levels	O
of	O
angiogenesis	O
factors	O
did	O
not	O
change	O
significantly	O
by	O
pegylated	O
interferon	O
and	O
ribavirin	B-CHEMICAL
therapy	O
.	O
We	O
found	O
no	O
correlation	O
of	O
angiogenesis	O
soluble	O
markers	O
with	O
either	O
hemoglobin	O
or	O
haptoglobin	O
.	O
CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
study	O
in	O
the	O
literature	O
investigating	O
a	O
link	O
between	O
angiogenesis	O
soluble	O
markers	O
and	O
ribavirin	B-CHEMICAL
induced	O
anemia	B-DISEASE
in	O
patients	O
with	O
hepatitis	B-DISEASE
C	I-DISEASE
and	O
we	O
could	O
not	O
find	O
any	O
relation	O
.	O
Future	O
research	O
with	O
larger	O
number	O
of	O
patients	O
is	O
needed	O
to	O
find	O
out	O
modifiable	O
factors	O
that	O
will	O
improve	O
the	O
safety	O
of	O
ribavirin	B-CHEMICAL
therapy	O
.	O

Cocaine	B-CHEMICAL
causes	O
memory	O
and	O
learning	O
impairments	O
in	O
rats	O
:	O
involvement	O
of	O
nuclear	O
factor	O
kappa	O
B	O
and	O
oxidative	O
stress	B-DISEASE
,	O
and	O
prevention	O
by	O
topiramate	O
.	O
Different	O
mechanisms	O
have	O
been	O
suggested	O
for	O
cocaine	B-CHEMICAL
toxicity	B-DISEASE
including	O
an	O
increase	O
in	O
oxidative	O
stress	B-DISEASE
but	O
the	O
association	O
between	O
oxidative	O
status	O
in	O
the	O
brain	O
and	O
cocaine	B-CHEMICAL
induced	O
-	O
behaviour	O
is	O
poorly	O
understood	O
.	O
Nuclear	O
factor	O
kappa	O
B	O
(	O
NFkappaB	O
)	O
is	O
a	O
sensor	O
of	O
oxidative	O
stress	B-DISEASE
and	O
participates	O
in	O
memory	O
formation	O
that	O
could	O
be	O
involved	O
in	O
drug	B-DISEASE
toxicity	I-DISEASE
and	O
addiction	O
mechanisms	O
.	O
Therefore	O
NFkappaB	O
activity	O
,	O
oxidative	O
stress	B-DISEASE
,	O
neuronal	O
nitric	O
oxide	O
synthase	O
(	O
nNOS	O
)	O
activity	O
,	O
spatial	O
learning	O
and	O
memory	O
as	O
well	O
as	O
the	O
effect	O
of	O
topiramate	O
,	O
a	O
previously	O
proposed	O
therapy	O
for	O
cocaine	B-DISEASE
addiction	I-DISEASE
,	O
were	O
evaluated	O
in	O
an	O
experimental	O
model	O
of	O
cocaine	B-CHEMICAL
administration	O
in	O
rats	O
.	O
NFkappaB	O
activity	O
was	O
decreased	O
in	O
the	O
frontal	O
cortex	O
of	O
cocaine	B-CHEMICAL
treated	O
rats	O
,	O
as	O
well	O
as	O
GSH	O
concentration	O
and	O
glutathione	B-CHEMICAL
peroxidase	O
activity	O
in	O
the	O
hippocampus	O
,	O
whereas	O
nNOS	O
activity	O
in	O
the	O
hippocampus	O
was	O
increased	O
.	O
Memory	O
retrieval	O
of	O
experiences	O
acquired	O
prior	O
to	O
cocaine	B-CHEMICAL
administration	O
was	O
impaired	O
and	O
negatively	O
correlated	O
with	O
NFkappaB	O
activity	O
in	O
the	O
frontal	O
cortex	O
.	O
In	O
contrast	O
,	O
learning	O
of	O
new	O
tasks	O
was	O
enhanced	O
and	O
correlated	O
with	O
the	O
increase	O
of	O
nNOS	O
activity	O
and	O
the	O
decrease	O
of	O
glutathione	B-CHEMICAL
peroxidase	O
.	O
These	O
results	O
provide	O
evidence	O
for	O
a	O
possible	O
mechanistic	O
role	O
of	O
oxidative	O
and	O
nitrosative	O
stress	B-DISEASE
and	O
NFkappaB	O
in	O
the	O
alterations	O
induced	O
by	O
cocaine	B-CHEMICAL
.	O
Topiramate	O
prevented	O
all	O
the	O
alterations	O
observed	O
,	O
showing	O
novel	O
neuroprotective	O
properties	O
.	O

Antinociceptive	O
and	O
antiamnesic	O
properties	O
of	O
the	O
presynaptic	O
cholinergic	O
amplifier	O
PG-9	O
.	O
The	O
antinociceptive	O
effect	O
of	O
3	B-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
tropyl	I-CHEMICAL
2-(p	I-CHEMICAL
-	I-CHEMICAL
bromophenyl)propionate	I-CHEMICAL
[	O
(	O
+	O
/-)-PG-9	O
]	O
(	O
10	O
-	O
40	O
mg	O
kg-1	O
s.c	O
.	O
;	O
30	O
-	O
60	O
mg	O
kg-1	O
p.o	O
.	O
;	O
10	O
-	O
30	O
mg	O
kg-1	O
i.v	O
.	O
;	O
10	O
-	O
30	O
micrograms	O
/	O
mouse	O
i.c.v	O
.	O
)	O
was	O
examined	O
in	O
mice	O
,	O
rats	O
and	O
guinea	O
pigs	O
by	O
use	O
of	O
the	O
hot	O
-	O
plate	O
,	O
abdominal	O
-	O
constriction	O
,	O
tail	O
-	O
flick	O
and	O
paw	O
-	O
pressure	O
tests	O
.	O
(	O
+	O
/-)-PG-9	O
antinociception	O
peaked	O
15	O
min	O
after	O
injection	O
and	O
then	O
slowly	O
diminished	O
.	O
The	O
antinociception	O
produced	O
by	O
(	O
+	O
/-)-PG-9	O
was	O
prevented	O
by	O
the	O
unselective	O
muscarinic	O
antagonist	O
atropine	O
,	O
the	O
M1	O
-	O
selective	O
antagonists	O
pirenzepine	O
and	O
dicyclomine	B-CHEMICAL
and	O
the	O
acetylcholine	O
depletor	O
hemicholinium-3	O
,	O
but	O
not	O
by	O
the	O
opioid	O
antagonist	O
naloxone	B-CHEMICAL
,	O
the	O
gamma	O
-	O
aminobutyric	O
acidB	O
antagonist	O
3	B-CHEMICAL
-	I-CHEMICAL
aminopropyl	I-CHEMICAL
-	I-CHEMICAL
diethoxy	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
phosphinic	I-CHEMICAL
acid	I-CHEMICAL
,	O
the	O
H3	O
agonist	O
R-(alpha)-methylhistamine	O
,	O
the	O
D2	O
antagonist	O
quinpirole	O
,	O
the	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine4	I-CHEMICAL
antagonist	O
2	B-CHEMICAL
-	I-CHEMICAL
methoxy-4	I-CHEMICAL
-	I-CHEMICAL
amino-5	I-CHEMICAL
-	I-CHEMICAL
chlorobenzoic	I-CHEMICAL
acid	I-CHEMICAL
2-(diethylamino)ethyl	I-CHEMICAL
ester	I-CHEMICAL
hydrochloride	O
,	O
the	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamin1A	I-CHEMICAL
antagonist	O
1-(2	B-CHEMICAL
-	I-CHEMICAL
methoxyphenyl)-4-[4-(2	I-CHEMICAL
-	I-CHEMICAL
phthalimido)butyl]piperazine	I-CHEMICAL
hydrobromide	O
and	O
the	O
polyamines	O
depletor	O
reserpine	B-CHEMICAL
.	O
Based	O
on	O
these	O
data	O
,	O
it	O
can	O
be	O
postulated	O
that	O
(	O
+	O
/-)-PG-9	O
exerted	O
an	O
antinociceptive	O
effect	O
mediated	O
by	O
a	O
central	O
potentiation	O
of	O
cholinergic	O
transmission	O
.	O
(	O
+	O
/-)-PG-9	O
(	O
10	O
-	O
40	O
mg	O
kg-1	O
i.p	O
.	O
)	O
was	O
able	O
to	O
prevent	O
amnesia	B-DISEASE
induced	O
by	O
scopolamine	B-CHEMICAL
(	O
1	O
mg	O
kg-1	O
i.p	O
.	O
)	O
and	O
dicyclomine	B-CHEMICAL
(	O
2	O
mg	O
kg-1	O
i.p	O
.	O
)	O
in	O
the	O
mouse	O
passive	O
-	O
avoidance	O
test	O
.	O
Affinity	O
profiles	O
of	O
(	O
+	O
/-)-PG-9	O
for	O
muscarinic	O
receptor	O
subtypes	O
,	O
determined	O
by	O
functional	O
studies	O
(	O
rabbit	O
vas	O
deferens	O
for	O
M1	O
,	O
guinea	O
pig	O
atrium	O
for	O
M2	O
,	O
guinea	O
pig	O
ileum	O
for	O
M3	O
and	O
immature	O
guinea	O
pig	O
uterus	O
for	O
putative	O
M4	O
)	O
,	O
have	O
shown	O
an	O
M4	O
/	O
M1	O
selectivity	O
ratio	O
of	O
10.2	O
that	O
might	O
be	O
responsible	O
for	O
the	O
antinociception	O
and	O
the	O
anti	O
-	O
amnesic	B-DISEASE
effect	O
induced	O
by	O
(	O
+	O
/-)-PG-9	O
through	O
an	O
increase	O
in	O
acetylcholine	O
extracellular	O
levels	O
.	O
In	O
the	O
antinociceptive	O
and	O
antiamnesic	O
dose	O
range	O
,	O
(	O
+	O
/-)-PG-9	O
did	O
not	O
impair	O
mouse	O
performance	O
evaluated	O
by	O
the	O
rota	O
-	O
rod	O
test	O
and	O
Animex	O
apparatus	O
.	O

Hyperbaric	O
oxygen	B-CHEMICAL
therapy	O
for	O
control	O
of	O
intractable	O
cyclophosphamide	B-CHEMICAL
-	O
induced	O
hemorrhagic	O
cystitis	B-DISEASE
.	O
We	O
report	O
a	O
case	O
of	O
intractable	O
hemorrhagic	O
cystitis	B-DISEASE
due	O
to	O
cyclophosphamide	B-CHEMICAL
therapy	O
for	O
Wegener	B-DISEASE
's	I-DISEASE
granulomatosis	I-DISEASE
.	O
Conservative	O
treatment	O
,	O
including	O
bladder	O
irrigation	O
with	O
physiological	O
saline	O
and	O
instillation	O
of	O
prostaglandin	O
F2	O
alpha	O
,	O
failed	O
to	O
totally	O
control	O
hemorrhage	B-DISEASE
.	O
We	O
then	O
used	O
hyperbaric	O
oxygen	B-CHEMICAL
at	O
an	O
absolute	O
pressure	O
of	O
2	O
atm	O
,	O
5	O
days	O
a	O
week	O
for	O
8	O
consecutive	O
weeks	O
.	O
The	O
bleeding	B-DISEASE
ceased	O
completely	O
by	O
the	O
end	O
of	O
treatment	O
and	O
the	O
patient	O
remained	O
free	O
of	O
hematuria	B-DISEASE
thereafter	O
.	O
No	O
side	O
effect	O
was	O
noted	O
during	O
the	O
course	O
of	O
therapy	O
.	O
In	O
future	O
,	O
this	O
form	O
of	O
therapy	O
can	O
offer	O
a	O
safe	O
alternative	O
in	O
the	O
treatment	O
of	O
cyclophosphamide	B-CHEMICAL
-	O
induced	O
hemorrhagic	O
cystitis	B-DISEASE
.	O

Further	O
studies	O
on	O
effects	O
of	O
irrigation	O
solutions	O
on	O
rat	O
bladders	O
.	O
Further	O
studies	O
on	O
the	O
effects	O
of	O
certain	O
irrigating	O
fluids	O
on	O
the	O
rat	O
bladder	O
for	O
18	O
hours	O
are	O
reported	O
.	O
The	O
results	O
have	O
shown	O
that	O
the	O
degradation	O
product	O
p	O
-	O
choloroaniline	O
is	O
not	O
a	O
significant	O
factor	O
in	O
chlorhexidine	B-CHEMICAL
-	O
digluconate	O
associated	O
erosive	O
cystitis	B-DISEASE
.	O
A	O
high	O
percentage	O
of	O
kanamycin	B-CHEMICAL
-	O
colistin	O
and	O
povidone	O
-	O
iodine	O
irrigations	O
were	O
associated	O
with	O
erosive	O
cystitis	B-DISEASE
and	O
suggested	O
a	O
possible	O
complication	O
with	O
human	O
usage	O
.	O
Picloxydine	B-CHEMICAL
irrigations	O
appeared	O
to	O
have	O
a	O
lower	O
incidence	O
of	O
erosive	O
cystitis	B-DISEASE
but	O
further	O
studies	O
would	O
have	O
to	O
be	O
performed	O
before	O
it	O
could	O
be	O
recommended	O
for	O
use	O
in	O
urological	O
procedures	O
.	O

Clinical	O
experiences	O
in	O
an	O
open	O
and	O
a	O
double	O
-	O
blind	B-DISEASE
trial	O
.	O
A	O
total	O
of	O
sixty	O
patients	O
were	O
trated	O
with	O
bromperidol	O
first	O
in	O
open	O
conditions	O
(	O
20	O
patients	O
)	O
,	O
then	O
on	O
a	O
double	O
blind	B-DISEASE
basis	O
(	O
40	O
patients	O
)	O
with	O
haloperidol	B-CHEMICAL
as	O
the	O
reference	O
substance	O
.	O
The	O
open	O
study	O
lasted	O
for	O
four	O
weeks	O
;	O
the	O
drug	O
was	O
administrated	O
in	O
the	O
form	O
of	O
1	O
mg	O
tablets	O
.	O
The	O
daily	O
dose	O
(	O
initial	O
dose	O
:	O
1	O
mg	O
;	O
mean	O
dose	O
at	O
the	O
end	O
of	O
the	O
trial	O
:	O
4.47	O
mg	O
)	O
was	O
always	O
administered	O
in	O
one	O
single	O
dose	O
.	O
Nineteen	O
patients	O
finished	O
the	O
trial	O
,	O
and	O
in	O
18	O
cases	O
the	O
therapeutic	O
result	O
was	O
considered	O
very	O
good	O
to	O
good	O
.	O
These	O
results	O
were	O
confirmed	O
by	O
statistical	O
analysis	O
.	O
Nine	O
patients	O
exhibited	O
mild	O
to	O
moderate	O
extrapyramidal	B-DISEASE
concomitant	I-DISEASE
symptoms	I-DISEASE
;	O
no	O
other	O
side	O
effects	O
were	O
observed	O
.	O
The	O
results	O
of	O
detailed	O
laboratory	O
tests	O
and	O
evaluations	O
of	O
various	O
quantitative	O
and	O
qualitative	O
tolerability	O
parameters	O
were	O
not	O
indicative	O
of	O
toxic	O
effects	O
.	O
In	O
the	O
double	O
blind	B-DISEASE
study	O
with	O
haloperidol	B-CHEMICAL
,	O
both	O
substances	O
were	O
found	O
to	O
be	O
highly	O
effective	O
in	O
the	O
treatment	O
of	O
psychotic	O
syndromes	O
belonging	O
predominantly	O
to	O
the	O
schizophrenia	B-DISEASE
group	O
.	O
Certain	O
clues	O
,	O
including	O
the	O
onset	O
of	O
action	O
,	O
seem	O
to	O
be	O
indicative	O
of	O
the	O
superiority	O
of	O
bromperidol	O
.	O
No	O
differences	O
were	O
observed	O
with	O
respect	O
to	O
side	O
effects	O
and	O
general	O
tolerability	O
.	O

Curcumin	B-CHEMICAL
ameliorates	O
cognitive	B-DISEASE
dysfunction	I-DISEASE
and	O
oxidative	O
damage	O
in	O
phenobarbitone	B-CHEMICAL
and	O
carbamazepine	B-CHEMICAL
administered	O
rats	O
.	O
The	O
antiepileptic	O
drugs	O
,	O
phenobarbitone	B-CHEMICAL
and	O
carbamazepine	B-CHEMICAL
are	O
well	O
known	O
to	O
cause	O
cognitive	O
impairment	O
on	O
chronic	O
use	O
.	O
The	O
increase	O
in	O
free	O
radical	O
generation	O
has	O
been	O
implicated	O
as	O
one	O
of	O
the	O
important	O
mechanisms	O
of	O
cognitive	O
impairment	O
by	O
antiepileptic	O
drugs	O
.	O
Curcumin	B-CHEMICAL
has	O
shown	O
antioxidant	O
,	O
anti	O
-	O
inflammatory	O
and	O
neuro	O
-	O
protective	O
properties	O
.	O
Therefore	O
,	O
the	O
present	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
effect	O
of	O
chronic	O
curcumin	B-CHEMICAL
administration	O
on	O
phenobarbitone-	O
and	O
carbamazepine	B-CHEMICAL
-	O
induced	O
cognitive	O
impairment	O
and	O
oxidative	O
stress	B-DISEASE
in	O
rats	O
.	O
Pharmacokinetic	O
interactions	O
of	O
curcumin	B-CHEMICAL
with	O
phenobarbitone	B-CHEMICAL
and	O
carbamazepine	B-CHEMICAL
were	O
also	O
studied	O
.	O
Vehicle	O
/	O
drugs	O
were	O
administered	O
daily	O
for	O
21days	O
to	O
male	O
Wistar	O
rats	O
.	O
Passive	O
avoidance	O
paradigm	O
and	O
elevated	O
plus	O
maze	O
test	O
were	O
used	O
to	O
assess	O
cognitive	O
function	O
.	O
At	O
the	O
end	O
of	O
study	O
period	O
,	O
serum	O
phenobarbitone	B-CHEMICAL
and	O
carbamazepine	B-CHEMICAL
,	O
whole	O
brain	O
malondialdehyde	B-CHEMICAL
and	O
reduced	O
glutathione	B-CHEMICAL
levels	O
were	O
estimated	O
.	O
The	O
administration	O
of	O
phenobarbitone	B-CHEMICAL
and	O
carbamazepine	B-CHEMICAL
for	O
21days	O
caused	O
a	O
significant	O
impairment	O
of	O
learning	O
and	O
memory	O
as	O
well	O
as	O
an	O
increased	O
oxidative	O
stress	B-DISEASE
.	O
Concomitant	O
curcumin	B-CHEMICAL
administration	O
prevented	O
the	O
cognitive	O
impairment	O
and	O
decreased	O
the	O
increased	O
oxidative	O
stress	B-DISEASE
induced	O
by	O
these	O
antiepileptic	O
drugs	O
.	O
Curcumin	B-CHEMICAL
co	B-CHEMICAL
-	O
administration	O
did	O
not	O
cause	O
any	O
significant	O
alteration	O
in	O
the	O
serum	O
concentrations	O
of	O
both	O
phenobarbitone	B-CHEMICAL
as	O
well	O
as	O
carbamazepine	B-CHEMICAL
.	O
These	O
results	O
show	O
that	O
curcumin	B-CHEMICAL
has	O
beneficial	O
effect	O
in	O
mitigating	O
the	O
deterioration	B-DISEASE
of	I-DISEASE
cognitive	I-DISEASE
functions	I-DISEASE
and	O
oxidative	O
damage	O
in	O
rats	O
treated	O
with	O
phenobarbitone	B-CHEMICAL
and	O
carbamazepine	B-CHEMICAL
without	O
significantly	O
altering	O
their	O
serum	O
concentrations	O
.	O
The	O
findings	O
suggest	O
that	O
curcumin	B-CHEMICAL
can	O
be	O
considered	O
as	O
a	O
potential	O
safe	O
and	O
effective	O
adjuvant	O
to	O
phenobarbitone	B-CHEMICAL
and	O
carbamazepine	B-CHEMICAL
therapy	O
in	O
preventing	O
cognitive	O
impairment	O
associated	O
with	O
these	O
drugs	O
.	O

Pyrrolidine	O
dithiocarbamate	O
protects	O
the	O
piriform	O
cortex	O
in	O
the	O
pilocarpine	B-CHEMICAL
status	B-DISEASE
epilepticus	I-DISEASE
model	O
.	O
Pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
has	O
a	O
dual	O
mechanism	O
of	O
action	O
as	O
an	O
antioxidant	O
and	O
an	O
inhibitor	O
of	O
the	O
transcription	O
factor	O
kappa	O
-	O
beta	O
.	O
Both	O
,	O
production	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
as	O
well	O
as	O
activation	O
of	O
NF	O
-	O
kappaB	O
have	O
been	O
implicated	O
in	O
severe	O
neuronal	B-DISEASE
damage	I-DISEASE
in	O
different	O
sub	O
-	O
regions	O
of	O
the	O
hippocampus	O
as	O
well	O
as	O
in	O
the	O
surrounding	O
cortices	O
.	O
The	O
effect	O
of	O
PDTC	O
on	O
status	B-DISEASE
epilepticus	I-DISEASE
-	O
associated	O
cell	O
loss	O
in	O
the	O
hippocampus	O
and	O
piriform	O
cortex	O
was	O
evaluated	O
in	O
the	O
rat	O
fractionated	O
pilocarpine	B-CHEMICAL
model	O
.	O
Treatment	O
with	O
150	O
mg	O
/	O
kg	O
PDTC	O
before	O
and	O
following	O
status	B-DISEASE
epilepticus	I-DISEASE
significantly	O
increased	O
the	O
mortality	O
rate	O
to	O
100	O
%	O
.	O
Administration	O
of	O
50	O
mg	O
/	O
kg	O
PDTC	O
(	O
low	O
-	O
dose	O
)	O
did	O
not	O
exert	O
major	O
effects	O
on	O
the	O
development	O
of	O
a	O
status	B-DISEASE
epilepticus	I-DISEASE
or	O
the	O
mortality	O
rate	O
.	O
In	O
vehicle	O
-	O
treated	O
rats	O
,	O
status	B-DISEASE
epilepticus	I-DISEASE
caused	O
pronounced	O
neuronal	B-DISEASE
damage	I-DISEASE
in	O
the	O
piriform	O
cortex	O
comprising	O
both	O
pyramidal	O
cells	O
and	O
interneurons	O
.	O
Low	O
-	O
dose	O
PDTC	O
treatment	O
almost	O
completely	O
protected	O
from	O
lesions	O
in	O
the	O
piriform	O
cortex	O
.	O
A	O
significant	O
decrease	O
in	O
neuronal	O
density	O
of	O
the	O
hippocampal	O
hilar	O
formation	O
was	O
identified	O
in	O
vehicle-	O
and	O
PDTC	O
-	O
treated	O
rats	O
following	O
status	B-DISEASE
epilepticus	I-DISEASE
.	O
In	O
conclusion	O
,	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
and	O
antioxidant	O
PDTC	O
protected	O
the	O
piriform	O
cortex	O
,	O
whereas	O
it	O
did	O
not	O
affect	O
hilar	O
neuronal	O
loss	O
.	O
These	O
data	O
might	O
indicate	O
that	O
the	O
generation	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
and	O
activation	O
of	O
NF	O
-	O
kappaB	O
plays	O
a	O
more	O
central	O
role	O
in	O
seizure	B-DISEASE
-	O
associated	O
neuronal	B-DISEASE
damage	I-DISEASE
in	O
the	O
temporal	O
cortex	O
as	O
compared	O
to	O
the	O
hippocampal	O
hilus	O
.	O
However	O
,	O
future	O
investigations	O
are	O
necessary	O
to	O
exactly	O
analyze	O
the	O
biochemical	O
mechanisms	O
by	O
which	O
PDTC	O
exerted	O
its	O
beneficial	O
effects	O
in	O
the	O
piriform	O
cortex	O
.	O

Safety	O
profile	O
of	O
a	O
nicotine	B-CHEMICAL
lozenge	O
compared	O
with	O
that	O
of	O
nicotine	B-CHEMICAL
gum	O
in	O
adult	O
smokers	O
with	O
underlying	O
medical	O
conditions	O
:	O
a	O
12	O
-	O
week	O
,	O
randomized	O
,	O
open	O
-	O
label	O
study	O
.	O
BACKGROUND	O
:	O
Nicotine	B-CHEMICAL
polacrilex	O
lozenges	O
deliver	O
25	O
%	O
to	O
27	O
%	O
more	O
nicotine	B-CHEMICAL
compared	O
with	O
equivalent	O
doses	O
of	O
nicotine	B-CHEMICAL
polacrilex	O
gum	O
.	O
The	O
increased	O
nicotine	B-CHEMICAL
exposure	O
from	O
the	O
lozenge	O
has	O
raised	O
questions	O
about	O
the	O
relative	O
safety	O
of	O
the	O
lozenge	O
and	O
gum	O
.	O
OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
safety	O
profiles	O
of	O
the	O
4	O
-	O
mg	O
nicotine	B-CHEMICAL
lozenge	O
and	O
4	O
-	O
mg	O
nicotine	B-CHEMICAL
gum	O
in	O
smokers	O
with	O
selected	O
label	O
-	O
restricted	O
diseases	B-DISEASE
.	O
METHODS	O
:	O
This	O
was	O
a	O
multicenter	O
,	O
randomized	O
,	O
open	O
-	O
label	O
study	O
in	O
adult	O
smokers	O
with	O
heart	B-DISEASE
disease	I-DISEASE
,	O
hypertension	B-DISEASE
not	O
controlled	O
by	O
medication	O
,	O
and/or	O
diabetes	B-DISEASE
mellitus	I-DISEASE
.	O
Patients	O
were	O
randomized	O
in	O
a	O
1:1	O
ratio	O
to	O
receive	O
the	O
4	O
-	O
mg	O
nicotine	B-CHEMICAL
lozenge	O
or	O
4	O
-	O
mg	O
nicotine	B-CHEMICAL
gum	O
.	O
Safety	O
assessments	O
were	O
made	O
at	O
baseline	O
and	O
at	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
12	O
weeks	O
after	O
the	O
start	O
of	O
product	O
use	O
.	O
RESULTS	O
:	O
Nine	O
hundred	O
one	O
patients	O
were	O
randomized	O
to	O
treatment	O
,	O
447	O
who	O
received	O
the	O
lozenge	O
and	O
454	O
who	O
received	O
the	O
gum	O
(	O
safety	O
population	O
)	O
.	O
The	O
majority	O
were	O
women	O
(	O
52.7	O
%	O
)	O
.	O
Patients	O
'	O
mean	O
age	O
was	O
53.9	O
years	O
,	O
their	O
mean	O
weight	O
was	O
193.9	O
pounds	O
,	O
and	O
they	O
smoked	O
a	O
mean	O
of	O
25.2	O
cigarettes	O
per	O
day	O
at	O
baseline	O
.	O
Five	O
hundred	O
fifty	O
-	O
three	O
patients	O
,	O
264	O
taking	O
the	O
lozenge	O
and	O
289	O
taking	O
the	O
gum	O
,	O
used	O
the	O
study	O
product	O
for	O
>	O
or	O
=	O
4	O
days	O
per	O
week	O
during	O
the	O
first	O
2	O
weeks	O
(	O
evaluable	O
population	O
)	O
.	O
The	O
nicotine	B-CHEMICAL
lozenge	O
and	O
nicotine	B-CHEMICAL
gum	O
were	O
equally	O
well	O
tolerated	O
,	O
despite	O
increased	O
nicotine	B-CHEMICAL
exposure	O
from	O
the	O
lozenge	O
.	O
The	O
incidence	O
of	O
adverse	O
events	O
in	O
the	O
2	O
groups	O
was	O
similar	O
during	O
the	O
first	O
2	O
weeks	O
of	O
product	O
use	O
(	O
evaluation	O
population	O
:	O
55.3	O
%	O
lozenge	O
,	O
54.7	O
%	O
gum	O
)	O
,	O
as	O
well	O
as	O
during	O
the	O
entire	O
study	O
(	O
safety	O
population	O
:	O
63.8	O
%	O
and	O
58.6	O
%	O
,	O
respectively	O
)	O
.	O
Stratification	O
of	O
patients	O
by	O
sex	O
,	O
age	O
,	O
extent	O
of	O
concurrent	O
smoking	B-CHEMICAL
,	O
extent	O
of	O
product	O
use	O
,	O
and	O
severity	O
of	O
adverse	O
events	O
revealed	O
no	O
clinically	O
significant	O
differences	O
between	O
the	O
lozenge	O
and	O
gum	O
.	O
The	O
most	O
common	O
adverse	O
events	O
were	O
nausea	B-DISEASE
(	O
17.2	O
%	O
and	O
16.1	O
%	O
;	O
95	O
%	O
CI	O
,	O
-3.7	O
to	O
6.0	O
)	O
,	O
hiccups	B-DISEASE
(	O
10.7	O
%	O
and	O
6.6	O
%	O
;	O
95	O
%	O
CI	O
,	O
0.5	O
to	O
7.8	O
)	O
,	O
and	O
headache	B-DISEASE
(	O
8.7	O
%	O
and	O
9.9	O
%	O
;	O
95	O
%	O
Cl	O
,	O
-5.0	O
to	O
2.6	O
)	O
.	O
Serious	O
adverse	O
events	O
were	O
reported	O
in	O
11	O
and	O
13	O
patients	O
in	O
the	O
respective	O
groups	O
.	O
Fewer	O
than	O
6	O
%	O
of	O
patients	O
in	O
either	O
group	O
were	O
considered	O
by	O
the	O
investigator	O
to	O
have	O
a	O
worsening	O
of	O
their	O
overall	O
disease	B-DISEASE
condition	O
during	O
the	O
study	O
.	O
The	O
majority	O
of	O
patients	O
(	O
>	O
60	O
%	O
)	O
experienced	O
no	O
change	O
in	O
their	O
disease	B-DISEASE
status	O
from	O
baseline	O
.	O
CONCLUSION	O
:	O
The	O
4	O
-	O
mg	O
nicotine	B-CHEMICAL
lozenge	O
and	O
4	O
-	O
mg	O
nicotine	B-CHEMICAL
gum	O
had	O
comparable	O
safety	O
profiles	O
in	O
these	O
patients	O
with	O
label	O
-	O
restricted	O
medical	O
conditions	O
.	O

Development	O
of	O
levodopa	B-CHEMICAL
-	O
induced	O
dyskinesias	B-DISEASE
in	O
parkinsonian	B-DISEASE
monkeys	O
may	O
depend	O
upon	O
rate	O
of	O
symptom	O
onset	O
and/or	O
duration	O
of	O
symptoms	O
.	O
Levodopa	B-CHEMICAL
-	O
induced	O
dyskinesias	B-DISEASE
(	O
LIDs	O
)	O
present	O
a	O
major	O
problem	O
for	O
the	O
long	O
-	O
term	O
management	O
of	O
Parkinson	B-DISEASE
's	I-DISEASE
disease	I-DISEASE
(	O
PD	O
)	O
patients	O
.	O
Due	O
to	O
the	O
interdependence	O
of	O
risk	O
factors	O
in	O
clinical	O
populations	O
,	O
it	O
is	O
difficult	O
to	O
independently	O
examine	O
factors	O
that	O
may	O
influence	O
the	O
development	O
of	O
LIDs	O
.	O
Using	O
macaque	O
monkeys	O
with	O
different	O
types	O
of	O
MPTP	O
-	O
induced	O
parkinsonism	B-DISEASE
,	O
the	O
current	O
study	O
evaluated	O
the	O
degree	O
to	O
which	O
rate	O
of	O
symptom	O
progression	O
,	O
symptom	O
severity	O
,	O
and	O
response	O
to	O
and	O
duration	O
of	O
levodopa	B-CHEMICAL
therapy	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
LIDs	O
.	O
Monkeys	O
with	O
acute	O
(	O
short	O
-	O
term	O
)	O
MPTP	O
exposure	O
,	O
rapid	O
symptom	O
onset	O
and	O
short	O
symptom	O
duration	O
prior	O
to	O
initiation	O
of	O
levodopa	B-CHEMICAL
therapy	O
developed	O
dyskinesia	B-DISEASE
between	O
11	O
and	O
24	O
days	O
of	O
daily	O
levodopa	B-CHEMICAL
administration	O
.	O
In	O
contrast	O
,	O
monkeys	O
with	O
long	O
-	O
term	O
MPTP	O
exposure	O
,	O
slow	O
symptom	O
progression	O
and/or	O
long	O
symptom	O
duration	O
prior	O
to	O
initiation	O
of	O
levodopa	B-CHEMICAL
therapy	O
were	O
more	O
resistant	O
to	O
developing	O
LIDs	O
(	O
e.g.	O
,	O
dyskinesia	B-DISEASE
developed	O
no	O
sooner	O
than	O
146	O
days	O
of	O
chronic	O
levodopa	B-CHEMICAL
administration	O
)	O
.	O
All	O
animals	O
were	O
similarly	O
symptomatic	O
at	O
the	O
start	O
of	O
levodopa	B-CHEMICAL
treatment	O
and	O
had	O
similar	O
therapeutic	O
responses	O
to	O
the	O
drug	O
.	O
These	O
data	O
suggest	O
distinct	O
differences	O
in	O
the	O
propensity	O
to	O
develop	O
LIDs	O
in	O
monkeys	O
with	O
different	O
rates	O
of	O
symptom	O
progression	O
or	O
symptom	O
durations	O
prior	O
to	O
levodopa	B-CHEMICAL
and	O
demonstrate	O
the	O
value	O
of	O
these	O
models	O
for	O
further	O
studying	O
the	O
pathophysiology	O
of	O
LIDs	O
.	O

Propylthiouracil	B-CHEMICAL
-	O
induced	O
perinuclear	O
-	O
staining	O
antineutrophil	O
cytoplasmic	O
autoantibody	O
-	O
positive	O
vasculitis	B-DISEASE
in	O
conjunction	O
with	O
pericarditis	B-DISEASE
.	O
OBJECTIVE	O
:	O
To	O
describe	O
a	O
case	O
of	O
propylthiouracil	B-CHEMICAL
-	O
induced	O
vasculitis	B-DISEASE
manifesting	O
with	O
pericarditis	B-DISEASE
.	O
METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	B-DISEASE
treated	O
with	O
propylthiouracil	B-CHEMICAL
in	O
whom	O
a	O
syndrome	B-DISEASE
of	O
pericarditis	B-DISEASE
,	O
fever	B-DISEASE
,	O
and	O
glomerulonephritis	B-DISEASE
developed	O
.	O
Serologic	O
testing	O
and	O
immunologic	O
studies	O
were	O
done	O
,	O
and	O
a	O
pericardial	O
biopsy	O
was	O
performed	O
.	O
RESULTS	O
:	O
A	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	O
Graves	O
'	O
disease	B-DISEASE
had	O
a	O
febrile	B-DISEASE
illness	I-DISEASE
and	O
evidence	O
of	O
pericarditis	B-DISEASE
,	O
which	O
was	O
confirmed	O
by	O
biopsy	O
.	O
Serologic	O
evaluation	O
revealed	O
the	O
presence	O
of	O
perinuclear	O
-	O
staining	O
antineutrophil	O
cytoplasmic	O
autoantibodies	O
(	O
pANCA	O
)	O
against	O
myeloperoxidase	O
(	O
MPO	O
)	O
.	O
Propylthiouracil	B-CHEMICAL
therapy	O
was	O
withdrawn	O
,	O
and	O
she	O
was	O
treated	O
with	O
a	O
1	O
-	O
month	O
course	O
of	O
prednisone	B-CHEMICAL
,	O
which	O
alleviated	O
her	O
symptoms	O
.	O
A	O
literature	O
review	O
revealed	O
no	O
prior	O
reports	O
of	O
pericarditis	B-DISEASE
in	O
anti	O
-	O
MPO	O
pANCA	O
-	O
positive	O
vasculitis	B-DISEASE
associated	O
with	O
propylthio-	O
uracil	B-CHEMICAL
therapy	O
.	O
CONCLUSION	O
:	O
Pericarditis	B-DISEASE
may	O
be	O
the	O
initial	O
manifestation	O
of	O
drug	O
-	O
induced	O
vasculitis	B-DISEASE
attributable	O
to	O
propylthio-	O
uracil	B-CHEMICAL
therapy	O
.	O

Two	O
mouse	O
lines	O
selected	O
for	O
differential	O
sensitivities	O
to	O
beta	O
-	O
carboline	O
-	O
induced	O
seizures	B-DISEASE
are	O
also	O
differentially	O
sensitive	O
to	O
various	O
pharmacological	O
effects	O
of	O
other	O
GABA(A	O
)	O
receptor	O
ligands	O
.	O
Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	B-DISEASE
induced	O
by	O
a	O
single	O
i.p	O
.	O
injection	O
of	O
methyl	O
beta	O
-	O
carboline-3	O
-	O
carboxylate	O
(	O
beta	O
-	O
CCM	O
)	O
,	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA(A	O
)	O
receptor	O
benzodiazepine	O
site	O
.	O
Our	O
aim	O
was	O
to	O
characterize	O
both	O
lines	O
'	O
sensitivities	O
to	O
various	O
physiological	O
effects	O
of	O
other	O
ligands	O
of	O
the	O
GABA(A	O
)	O
receptor	O
.	O
We	O
measured	O
diazepam	B-CHEMICAL
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	B-CHEMICAL
-	O
induced	O
sedation	O
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin-	O
and	O
pentylenetetrazol	O
-	O
induced	O
seizures	B-DISEASE
after	O
i.p	O
.	O
injections	O
.	O
Results	O
presented	O
here	O
show	O
that	O
the	O
differential	O
sensitivities	O
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta	O
-	O
CCM	O
can	O
be	O
extended	O
to	O
diazepam	B-CHEMICAL
,	O
picrotoxin	B-CHEMICAL
,	O
and	O
pentylenetetrazol	O
,	O
suggesting	O
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA(A	O
)	O
receptor	O
.	O

Analgesic	O
effect	O
of	O
intravenous	O
ketamine	B-CHEMICAL
in	O
cancer	B-DISEASE
patients	O
on	O
morphine	B-CHEMICAL
therapy	O
:	O
a	O
randomized	O
,	O
controlled	O
,	O
double	O
-	O
blind	B-DISEASE
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O
Pain	B-DISEASE
not	O
responsive	O
to	O
morphine	B-CHEMICAL
is	O
often	O
problematic	O
.	O
Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
antagonists	O
,	O
such	O
as	O
ketamine	B-CHEMICAL
,	O
may	O
be	O
effective	O
in	O
improving	O
opioid	O
analgesia	B-DISEASE
in	O
difficult	O
pain	B-DISEASE
syndromes	O
,	O
such	O
as	O
neuropathic	B-DISEASE
pain	I-DISEASE
.	O
A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	B-CHEMICAL
(	O
0.25	O
mg	O
/	O
kg	O
or	O
0.50	O
mg	O
/	O
kg	O
)	O
was	O
given	O
to	O
10	O
cancer	B-DISEASE
patients	O
whose	O
pain	B-DISEASE
was	O
unrelieved	O
by	O
morphine	B-CHEMICAL
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	B-DISEASE
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O
Pain	B-DISEASE
intensity	O
on	O
a	O
0	O
to	O
10	O
numerical	O
scale	O
;	O
nausea	B-DISEASE
and	O
vomiting	B-DISEASE
,	O
drowsiness	B-DISEASE
,	O
confusion	B-DISEASE
,	O
and	O
dry	B-DISEASE
mouth	I-DISEASE
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	O
of	O
drugs	O
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	O
(	O
T30	O
)	O
,	O
60	O
minutes	O
(	O
T60	O
)	O
,	O
120	O
minutes	O
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	O
(	O
T180	O
)	O
.	O
Ketamine	B-CHEMICAL
,	O
but	O
not	O
saline	O
solution	O
,	O
significantly	O
reduced	O
the	O
pain	B-DISEASE
intensity	O
in	O
almost	O
all	O
the	O
patients	O
at	O
both	O
doses	O
.	O
This	O
effect	O
was	O
more	O
relevant	O
in	O
patients	O
treated	O
with	O
higher	O
doses	O
.	O
Hallucinations	B-DISEASE
occurred	O
in	O
4	O
patients	O
,	O
and	O
an	O
unpleasant	O
sensation	O
(	O
"	O
empty	O
head	O
"	O
)	O
was	O
also	O
reported	O
by	O
2	O
patients	O
.	O
These	O
episodes	O
reversed	O
after	O
the	O
administration	O
of	O
diazepam	B-CHEMICAL
1	O
mg	O
intravenously	O
.	O
Significant	O
increases	O
in	O
drowsiness	B-DISEASE
were	O
reported	O
in	O
patients	O
treated	O
with	O
ketamine	B-CHEMICAL
in	O
both	O
groups	O
and	O
were	O
more	O
marked	O
with	O
ketamine	B-CHEMICAL
0.50	O
mg	O
/	O
kg	O
.	O
A	O
significant	O
difference	O
in	O
MMSE	O
was	O
observed	O
at	O
T30	O
in	O
patients	O
who	O
received	O
0.50	O
mg	O
/	O
kg	O
of	O
ketamine	B-CHEMICAL
.	O
Ketamine	B-CHEMICAL
can	O
improve	O
morphine	B-CHEMICAL
analgesia	B-DISEASE
in	O
difficult	O
pain	B-DISEASE
syndromes	O
,	O
such	O
as	O
neuropathic	B-DISEASE
pain	I-DISEASE
.	O
However	O
,	O
the	O
occurrence	O
of	O
central	O
adverse	O
effects	O
should	O
be	O
taken	O
into	O
account	O
,	O
especially	O
when	O
using	O
higher	O
doses	O
.	O
This	O
observation	O
should	O
be	O
tested	O
in	O
studies	O
of	O
prolonged	O
ketamine	B-CHEMICAL
administration	O
.	O

Endocrine	O
screening	O
in	O
1,022	O
men	O
with	O
erectile	B-DISEASE
dysfunction	I-DISEASE
:	O
clinical	O
significance	O
and	O
cost	O
-	O
effective	O
strategy	O
.	O
PURPOSE	O
:	O
We	O
reviewed	O
the	O
results	O
of	O
serum	O
testosterone	B-CHEMICAL
and	O
prolactin	O
determination	O
in	O
1,022	O
patients	O
referred	O
because	O
of	O
erectile	B-DISEASE
dysfunction	I-DISEASE
and	O
compared	O
the	O
data	O
with	O
history	O
,	O
results	O
of	O
physical	O
examination	O
,	O
other	O
etiological	O
investigations	O
and	O
effects	O
of	O
endocrine	O
therapy	O
to	O
refine	O
the	O
rules	O
of	O
cost	O
-	O
effective	O
endocrine	O
screening	O
and	O
to	O
pinpoint	O
actual	O
responsibility	O
for	O
hormonal	O
abnormalities	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Testosterone	B-CHEMICAL
and	O
prolactin	O
were	O
determined	O
by	O
radioimmunoassay	O
.	O
Every	O
patient	O
was	O
screened	O
for	O
testosterone	B-CHEMICAL
and	O
451	O
were	O
screened	O
for	O
prolactin	O
on	O
the	O
basis	O
of	O
low	B-DISEASE
sexual	I-DISEASE
desire	I-DISEASE
,	O
gynecomastia	B-DISEASE
or	O
testosterone	B-CHEMICAL
less	O
than	O
4	O
ng./ml	O
.	O
Determination	O
was	O
repeated	O
in	O
case	O
of	O
abnormal	O
first	O
results	O
.	O
Prolactin	O
results	O
were	O
compared	O
with	O
those	O
of	O
a	O
previous	O
personal	O
cohort	O
of	O
1,340	O
patients	O
with	O
erectile	B-DISEASE
dysfunction	I-DISEASE
and	O
systematic	O
prolactin	O
determination	O
.	O
Main	O
clinical	O
criteria	O
tested	O
regarding	O
efficiency	O
in	O
hormone	O
determination	O
were	O
low	B-DISEASE
sexual	I-DISEASE
desire	I-DISEASE
,	O
small	O
testes	O
and	O
gynecomastia	B-DISEASE
.	O
Endocrine	O
therapy	O
consisted	O
of	O
testosterone	B-CHEMICAL
heptylate	O
or	O
human	O
chorionic	O
gonadotropin	O
for	O
hypogonadism	B-DISEASE
and	O
bromocriptine	O
for	O
hyperprolactinemia	B-DISEASE
.	O
RESULTS	O
:	O
Testosterone	B-CHEMICAL
was	O
less	O
than	O
3	O
ng./ml	O
.	O
in	O
107	O
patients	O
but	O
normal	O
in	O
40	O
%	O
at	O
repeat	O
determination	O
.	O
The	O
prevalence	O
of	O
repeatedly	O
low	O
testosterone	B-CHEMICAL
increased	O
with	O
age	O
(	O
4	O
%	O
before	O
age	O
50	O
years	O
and	O
9	O
%	O
50	O
years	O
or	O
older	O
)	O
.	O
Two	O
pituitary	B-DISEASE
tumors	I-DISEASE
were	O
discovered	O
after	O
testosterone	B-CHEMICAL
determination	O
.	O
Most	O
of	O
the	O
other	O
low	O
testosterone	B-CHEMICAL
levels	O
seemed	O
to	O
result	O
from	O
nonorganic	O
hypothalamic	O
dysfunction	O
because	O
of	O
normal	O
serum	O
luteinizing	O
hormone	O
and	O
prolactin	O
and	O
to	O
have	O
only	O
a	O
small	O
role	O
in	O
erectile	B-DISEASE
dysfunction	I-DISEASE
(	O
definite	O
improvement	O
in	O
only	O
16	O
of	O
44	O
[	O
36	O
%	O
]	O
after	O
androgen	O
therapy	O
,	O
normal	O
morning	O
or	O
nocturnal	O
erections	O
in	O
30	O
%	O
and	O
definite	O
vasculogenic	O
contributions	O
in	O
42	O
%	O
)	O
.	O
Determining	O
testosterone	B-CHEMICAL
only	O
in	O
cases	O
of	O
low	B-DISEASE
sexual	I-DISEASE
desire	I-DISEASE
or	O
abnormal	O
physical	O
examination	O
would	O
have	O
missed	O
40	O
%	O
of	O
the	O
cases	O
with	O
low	O
testosterone	B-CHEMICAL
,	O
including	O
37	O
%	O
of	O
those	O
subsequently	O
improved	O
by	O
androgen	O
therapy	O
.	O
Prolactin	O
exceeded	O
20	O
ng./ml	O
.	O
in	O
5	O
men	O
and	O
was	O
normal	O
in	O
2	O
at	O
repeat	O
determination	O
.	O
Only	O
1	O
prolactinoma	B-DISEASE
was	O
discovered	O
.	O
These	O
data	O
are	O
lower	O
than	O
those	O
we	O
found	O
during	O
the	O
last	O
2	O
decades	O
(	O
overall	O
prolactin	O
greater	O
than	O
20	O
ng./ml	O
.	O
in	O
1.86	O
%	O
of	O
1,821	O
patients	O
,	O
prolactinomas	O
in	O
7	O
,	O
0.38	O
%	O
)	O
.	O
Bromocriptine	O
was	O
definitely	O
effective	O
in	O
cases	O
with	O
prolactin	O
greater	O
than	O
35	O
ng./ml	O
.	O
(	O
8	O
of	O
12	O
compared	O
to	O
only	O
9	O
of	O
22	O
cases	O
with	O
prolactin	O
between	O
20	O
and	O
35	O
ng./ml	O
.	O
)	O
.	O
Testosterone	B-CHEMICAL
was	O
low	O
in	O
less	O
than	O
50	O
%	O
of	O
cases	O
with	O
prolactin	O
greater	O
than	O
35	O
ng./ml	O
.	O
CONCLUSIONS	O
:	O
Low	O
prevalences	O
and	O
effects	O
of	O
low	O
testosterone	B-CHEMICAL
and	O
high	O
prolactin	O
in	O
erectile	B-DISEASE
dysfunction	I-DISEASE
can	O
not	O
justify	O
their	O
routine	O
determination	O
.	O
However	O
,	O
cost	O
-	O
effective	O
screening	O
strategies	O
recommended	O
so	O
far	O
missed	O
40	O
to	O
50	O
%	O
of	O
cases	O
improved	O
with	O
endocrine	O
therapy	O
and	O
the	O
pituitary	B-DISEASE
tumors	I-DISEASE
.	O
We	O
now	O
advocate	O
that	O
before	O
age	O
50	O
years	O
testosterone	B-CHEMICAL
be	O
determined	O
only	O
in	O
cases	O
of	O
low	B-DISEASE
sexual	I-DISEASE
desire	I-DISEASE
and	O
abnormal	O
physical	O
examination	O
but	O
that	O
it	O
be	O
measured	O
in	O
all	O
men	O
older	O
than	O
50	O
years	O
.	O
Prolactin	O
should	O
be	O
determined	O
only	O
in	O
cases	O
of	O
low	B-DISEASE
sexual	I-DISEASE
desire	I-DISEASE
,	O
gynecomastia	B-DISEASE
and/or	O
testosterone	B-CHEMICAL
less	O
than	O
4	O
ng./ml	O
.	O

Thiopentone	B-CHEMICAL
pretreatment	O
for	O
propofol	B-CHEMICAL
injection	O
pain	B-DISEASE
in	O
ambulatory	O
patients	O
.	O
This	O
study	O
investigated	O
propofol	B-CHEMICAL
injection	O
pain	B-DISEASE
in	O
patients	O
undergoing	O
ambulatory	O
anaesthesia	O
.	O
In	O
a	O
randomized	O
,	O
double	O
-	O
blind	B-DISEASE
trial	O
,	O
90	O
women	O
were	O
allocated	O
to	O
receive	O
one	O
of	O
three	O
treatments	O
prior	O
to	O
induction	O
of	O
anaesthesia	O
with	O
propofol	B-CHEMICAL
.	O
Patients	O
in	O
Group	O
C	O
received	O
2	O
ml	O
normal	O
saline	O
,	O
Group	O
L	O
,	O
2	O
ml	O
,	O
lidocaine	B-CHEMICAL
2	O
%	O
(	O
40	O
mg	O
)	O
and	O
Group	O
T	O
,	O
2	O
ml	O
thiopentone	B-CHEMICAL
2.5	O
%	O
(	O
50	O
mg	O
)	O
.	O
Venous	O
discomfort	O
was	O
assessed	O
with	O
a	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
5	O
-	O
15	O
sec	O
after	O
commencing	O
propofol	B-CHEMICAL
administration	O
using	O
an	O
infusion	O
pump	O
(	O
rate	O
1000	O
micrograms.kg-1.min-1	O
)	O
.	O
Loss	O
of	O
consciousness	O
occurred	O
in	O
60	O
-	O
90	O
sec	O
.	O
Visual	O
analogue	O
scores	O
(	O
mean	O
+	O
/-	O
SD	B-DISEASE
)	O
during	O
induction	O
were	O
lower	O
in	O
Groups	O
L	O
(	O
3.3	O
+	O
/-	O
2.5	O
)	O
and	O
T	O
(	O
4.1	O
+	O
/-	O
2.7	O
)	O
than	O
in	O
Group	O
C	O
(	O
5.6	O
+	O
/-	O
2.3	O
)	O
;	O
P	O
=	O
0.0031	O
.	O
The	O
incidence	O
of	O
venous	O
discomfort	O
was	O
lower	O
in	O
Group	O
L	O
(	O
76.6	O
%	O
;	O
P	O
<	O
0.05	O
)	O
than	O
in	O
Group	O
C	O
(	O
100	O
%	O
)	O
but	O
not	O
different	O
from	O
Group	O
T	O
(	O
90	O
%	O
)	O
.	O
The	O
VAS	O
scores	O
for	O
recall	O
of	O
pain	B-DISEASE
in	O
the	O
recovery	O
room	O
were	O
correlated	O
with	O
the	O
VAS	O
scores	O
during	O
induction	O
(	O
r	O
=	O
0.7045	O
;	O
P	O
<	O
0.0001	O
)	O
.	O
Recovery	O
room	O
discharge	O
times	O
were	O
similar	O
:	O
C	O
(	O
75.9	O
+	O
/-	O
19.4	O
min	O
)	O
;	O
L	O
73.6	O
+	O
/-	O
21.6	O
min	O
)	O
;	O
T	O
(	O
77.1	O
+	O
/-	O
18.9	O
min	O
)	O
.	O
Assessing	O
their	O
overall	O
satisfaction	O
,	O
89.7	O
%	O
would	O
choose	O
propofol	B-CHEMICAL
anaesthesia	O
again	O
.	O
We	O
conclude	O
that	O
lidocaine	B-CHEMICAL
reduces	O
the	O
incidence	O
and	O
severity	O
of	O
propofol	B-CHEMICAL
injection	O
pain	B-DISEASE
in	O
ambulatory	O
patients	O
whereas	O
thiopentone	B-CHEMICAL
only	O
reduces	O
its	O
severity	O
.	O

Comparison	O
of	O
i.v	O
.	O
glycopyrrolate	B-CHEMICAL
and	O
atropine	O
in	O
the	O
prevention	O
of	O
bradycardia	B-DISEASE
and	O
arrhythmias	B-DISEASE
following	O
repeated	O
doses	O
of	O
suxamethonium	B-CHEMICAL
in	O
children	O
.	O
The	O
effectiveness	O
of	O
administration	O
of	O
glycopyrrolate	B-CHEMICAL
5	O
and	O
10	O
micrograms	O
kg-1	O
and	O
atropine	O
10	O
and	O
20	O
micrograms	O
kg-1	O
i.v	O
.	O
immediately	O
before	O
the	O
induction	O
of	O
anaesthesia	O
,	O
to	O
prevent	O
arrhythmia	B-DISEASE
and	O
bradycardia	B-DISEASE
following	O
repeated	O
doses	O
of	O
suxamethonium	B-CHEMICAL
in	O
children	O
,	O
was	O
studied	O
.	O
A	O
control	O
group	O
was	O
included	O
for	O
comparison	O
with	O
the	O
lower	O
dose	O
range	O
of	O
glycopyrrolate	B-CHEMICAL
and	O
atropine	O
.	O
A	O
frequency	O
of	O
bradycardia	B-DISEASE
of	O
50	O
%	O
was	O
noted	O
in	O
the	O
control	O
group	O
,	O
but	O
this	O
was	O
not	O
significantly	O
different	O
from	O
the	O
frequency	O
with	O
the	O
active	O
drugs	O
.	O
Bradycardia	B-DISEASE
(	O
defined	O
as	O
a	O
decrease	O
in	O
heart	O
rate	O
to	O
less	O
than	O
50	O
beat	O
min-1	O
)	O
was	O
prevented	O
when	O
the	O
larger	O
dose	O
of	O
either	O
active	O
drug	O
was	O
used	O
.	O
It	O
is	O
recommended	O
that	O
either	O
glycopyrrolate	B-CHEMICAL
10	O
micrograms	O
kg-1	O
or	O
atropine	O
20	O
micrograms	O
kg-1	O
i.v	O
.	O
should	O
immediately	O
precede	O
induction	O
of	O
anaesthesia	O
,	O
in	O
children	O
,	O
if	O
the	O
repeated	O
administration	O
of	O
suxamethonium	B-CHEMICAL
is	O
anticipated	O
.	O

Reduction	O
in	O
caffeine	B-CHEMICAL
toxicity	B-DISEASE
by	O
acetaminophen	B-CHEMICAL
.	O
A	O
patient	O
who	O
allegedly	O
consumed	O
100	O
tablets	O
of	O
an	O
over	O
-	O
the	O
-	O
counter	O
analgesic	O
containing	O
sodium	B-CHEMICAL
acetylsalicylate	O
,	O
caffeine	B-CHEMICAL
,	O
and	O
acetaminophen	B-CHEMICAL
displayed	O
no	O
significant	O
CNS	O
stimulation	O
despite	O
the	O
presence	O
of	O
175	O
micrograms	O
of	O
caffeine	B-CHEMICAL
per	O
mL	O
of	O
serum	O
.	O
Because	O
salicylates	O
have	O
been	O
reported	O
to	O
augment	O
the	O
stimulatory	O
effects	O
of	O
caffeine	B-CHEMICAL
on	O
the	O
CNS	O
,	O
attention	O
was	O
focused	O
on	O
the	O
possibility	O
that	O
the	O
presence	O
of	O
acetaminophen	B-CHEMICAL
(	O
52	O
micrograms	O
/	O
mL	O
)	O
reduced	O
the	O
CNS	O
toxicity	B-DISEASE
of	O
caffeine	B-CHEMICAL
.	O
Studies	O
in	O
DBA/2J	O
mice	O
showed	O
that	O
:	O
1	O
)	O
pretreatment	O
with	O
acetaminophen	B-CHEMICAL
(	O
100	O
mg	O
/	O
kg	O
)	O
increased	O
the	O
interval	O
between	O
the	O
administration	O
of	O
caffeine	B-CHEMICAL
(	O
300	O
to	O
450	O
mg	O
/	O
kg	O
IP	O
)	O
and	O
the	O
onset	O
of	O
fatal	O
convulsions	B-DISEASE
by	O
a	O
factor	O
of	O
about	O
two	O
;	O
and	O
2	O
)	O
pretreatment	O
with	O
acetaminophen	B-CHEMICAL
(	O
75	O
mg	O
/	O
kg	O
)	O
reduced	O
the	O
incidence	O
of	O
audiogenic	O
seizures	B-DISEASE
produced	O
in	O
the	O
presence	O
of	O
caffeine	B-CHEMICAL
(	O
12.5	O
to	O
75	O
mg	O
/	O
kg	O
IP	O
)	O
.	O
The	O
frequency	O
of	O
sound	O
-	O
induced	O
seizures	B-DISEASE
after	O
12.5	O
or	O
25	O
mg	O
/	O
kg	O
caffeine	B-CHEMICAL
was	O
reduced	O
from	O
50	O
to	O
5	O
%	O
by	O
acetaminophen	B-CHEMICAL
.	O
In	O
the	O
absence	O
of	O
caffeine	B-CHEMICAL
,	O
acetaminophen	B-CHEMICAL
(	O
up	O
to	O
300	O
mg	O
/	O
kg	O
)	O
did	O
not	O
modify	O
the	O
seizures	B-DISEASE
induced	O
by	O
maximal	O
electroshock	O
and	O
did	O
not	O
alter	O
the	O
convulsant	O
dose	O
of	O
pentylenetetrezol	O
in	O
mice	O
(	O
tests	O
performed	O
by	O
the	O
Anticonvulsant	O
Screening	O
Project	O
of	O
NINCDS	O
)	O
.	O
Acetaminophen	B-CHEMICAL
(	O
up	O
to	O
150	O
micrograms	O
/	O
mL	O
)	O
did	O
not	O
retard	O
the	O
incorporation	O
of	O
radioactive	O
adenosine	O
into	O
ATP	B-CHEMICAL
in	O
slices	O
of	O
rat	O
cerebral	O
cortex	O
.	O
Thus	O
the	O
mechanism	O
by	O
which	O
acetaminophen	B-CHEMICAL
antagonizes	O
the	O
actions	O
of	O
caffeine	B-CHEMICAL
in	O
the	O
CNS	O
remains	O
unknown	O
.	O

Flestolol	B-CHEMICAL
:	O
an	O
ultra	O
-	O
short	O
-	O
acting	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
.	O
Flestolol	B-CHEMICAL
(	O
ACC-9089	O
)	O
is	O
a	O
nonselective	O
,	O
competitive	O
,	O
ultra	O
-	O
short	O
-	O
acting	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
,	O
without	O
any	O
intrinsic	O
sympathomimetic	O
activity	O
.	O
Flestolol	B-CHEMICAL
is	O
metabolized	O
by	O
plasma	O
esterases	O
and	O
has	O
an	O
elimination	O
half	O
-	O
life	O
of	O
approximately	O
6.5	O
minutes	O
.	O
This	O
agent	O
was	O
well	O
tolerated	O
in	O
healthy	O
volunteers	O
at	O
doses	O
up	O
to	O
100	O
micrograms	O
/	O
kg	O
/	O
min	O
.	O
In	O
long	O
-	O
term	O
infusion	O
studies	O
,	O
flestolol	B-CHEMICAL
was	O
well	O
tolerated	O
at	O
the	O
effective	O
beta	O
-	O
blocking	O
dose	O
(	O
5	O
micrograms	O
/	O
kg	O
/	O
min	O
)	O
for	O
up	O
to	O
seven	O
days	O
.	O
Flestolol	B-CHEMICAL
blood	O
concentrations	O
increased	O
linearly	O
with	O
increasing	O
dose	O
and	O
good	O
correlation	O
exists	O
between	O
blood	O
concentrations	O
of	O
flestolol	B-CHEMICAL
and	O
beta	O
-	O
adrenergic	O
blockade	O
.	O
Flestolol	B-CHEMICAL
produced	O
a	O
dose	O
-	O
dependent	O
attenuation	O
of	O
isoproterenol	B-CHEMICAL
-	O
induced	O
tachycardia	B-DISEASE
.	O
Electrophysiologic	O
and	O
hemodynamic	O
effects	O
of	O
flestolol	B-CHEMICAL
are	O
similar	O
to	O
those	O
of	O
other	O
beta	O
blockers	O
.	O
In	O
contrast	O
with	O
other	O
beta	O
blockers	O
,	O
flestolol	B-CHEMICAL
-	O
induced	O
effects	O
reverse	O
rapidly	O
(	O
within	O
30	O
minutes	O
)	O
following	O
discontinuation	O
because	O
of	O
its	O
short	O
half	O
-	O
life	O
.	O
Flestolol	B-CHEMICAL
effectively	O
reduced	O
heart	O
rate	O
in	O
patients	O
with	O
supraventricular	O
tachyarrhythmia	O
.	O
In	O
patients	O
with	O
unstable	O
angina	B-DISEASE
,	O
flestolol	B-CHEMICAL
infusion	O
was	O
found	O
to	O
be	O
safe	O
and	O
effective	O
in	O
controlling	O
chest	B-DISEASE
pain	I-DISEASE
.	O
It	O
is	O
concluded	O
that	O
flestolol	B-CHEMICAL
is	O
a	O
potent	O
,	O
well	O
-	O
tolerated	O
,	O
ultra	O
-	O
short	O
-	O
acting	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
.	O
Use	O
of	O
flestolol	B-CHEMICAL
in	O
the	O
critical	O
care	O
setting	O
is	O
currently	O
undergoing	O
investigation	O
.	O

Adverse	O
effect	O
of	O
the	O
calcium	B-CHEMICAL
channel	O
blocker	O
nitrendipine	B-CHEMICAL
on	O
nephrosclerosis	B-DISEASE
in	O
rats	O
with	O
renovascular	O
hypertension	B-DISEASE
.	O
The	O
effect	O
of	O
a	O
6	O
-	O
week	O
treatment	O
with	O
the	O
calcium	B-CHEMICAL
channel	O
blocker	O
nitrendipine	B-CHEMICAL
or	O
the	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
enalapril	B-CHEMICAL
on	O
blood	O
pressure	O
,	O
albuminuria	B-DISEASE
,	O
renal	O
hemodynamics	O
,	O
and	O
morphology	O
of	O
the	O
nonclipped	O
kidney	O
was	O
studied	O
in	O
rats	O
with	O
two	O
-	O
kidney	O
,	O
one	O
clip	O
renovascular	O
hypertension	B-DISEASE
.	O
Six	O
weeks	O
after	O
clipping	O
of	O
one	O
renal	O
artery	O
,	O
hypertensive	B-DISEASE
rats	O
(	O
178	O
+	O
/-	O
4	O
mm	O
Hg	O
)	O
were	O
randomly	O
assigned	O
to	O
three	O
groups	O
:	O
untreated	O
hypertensive	B-DISEASE
controls	O
(	O
n	O
=	O
8)	O
,	O
enalapril	B-CHEMICAL
-	O
treated	O
(	O
n	O
=	O
8)	O
,	O
or	O
nitrendipine	B-CHEMICAL
-	O
treated	O
(	O
n	O
=	O
10	O
)	O
.	O
Sham	O
-	O
operated	O
rats	O
served	O
as	O
normotensive	O
controls	O
(	O
128	O
+	O
/-	O
3	O
mm	O
Hg	O
,	O
n	O
=	O
8)	O
.	O
After	O
6	O
weeks	O
of	O
treatment	O
,	O
renal	O
hemodynamics	O
(	O
glomerular	O
filtration	O
rate	O
and	O
renal	O
plasma	O
flow	O
)	O
were	O
measured	O
in	O
the	O
anesthetized	O
rats	O
.	O
Renal	O
tissue	O
was	O
obtained	O
for	O
determination	O
of	O
glomerular	O
size	O
and	O
sclerosis	B-DISEASE
.	O
Enalapril	B-CHEMICAL
but	O
not	O
nitrendipine	B-CHEMICAL
reduced	O
blood	O
pressure	O
significantly	O
.	O
After	O
6	O
weeks	O
of	O
therapy	O
,	O
glomerular	O
filtration	O
rate	O
was	O
not	O
different	O
among	O
the	O
studied	O
groups	O
.	O
Renal	O
plasma	O
flow	O
increased	O
,	O
but	O
albumin	O
excretion	O
and	O
glomerulosclerosis	O
did	O
not	O
change	O
after	O
enalapril	B-CHEMICAL
treatment	O
.	O
In	O
contrast	O
,	O
in	O
the	O
nitrendipine	B-CHEMICAL
-	O
treated	O
group	O
albuminuria	B-DISEASE
increased	O
from	O
12.8	O
+	O
/-	O
2	O
progressively	O
to	O
163	O
+	O
/-	O
55	O
compared	O
with	O
19.2	O
+	O
/-	O
9	O
mg/24	O
hr	O
in	O
the	O
hypertensive	B-DISEASE
controls	O
.	O
Furthermore	O
,	O
glomerulosclerosis	O
index	O
was	O
significantly	O
increased	O
in	O
the	O
nitrendipine	B-CHEMICAL
-	O
treated	O
group	O
compared	O
with	O
the	O
hypertensive	B-DISEASE
controls	O
(	O
0.38	O
+	O
/-	O
0.1	O
versus	O
0.13	O
+	O
/-	O
0.04	O
)	O
.	O
In	O
addition	O
,	O
glomerular	O
size	O
was	O
higher	O
in	O
the	O
nitrendipine	B-CHEMICAL
-	O
treated	O
group	O
(	O
14.9	O
+	O
/-	O
0.17	O
10(-3	O
)	O
mm2	O
)	O
but	O
lower	O
in	O
the	O
enalapril	B-CHEMICAL
-	O
treated	O
group	O
(	O
11.5	O
+	O
/-	O
0.15	O
10(-3	O
)	O
mm2	O
)	O
compared	O
with	O
the	O
hypertensive	B-DISEASE
controls	O
(	O
12.1	O
+	O
/-	O
0.17	O
10(-3	O
)	O
mm2).(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Treatment	O
of	O
tinnitus	B-DISEASE
by	O
intratympanic	O
instillation	O
of	O
lignocaine	B-CHEMICAL
(	O
lidocaine	B-CHEMICAL
)	O
2	O
per	O
cent	O
through	O
ventilation	O
tubes	O
.	O
Idiopathic	O
subjective	O
tinnitus	B-DISEASE
(	O
IST	O
)	O
is	O
one	O
of	O
the	O
most	O
obscure	O
otological	O
pathologies	O
.	O
This	O
paper	O
presents	O
the	O
results	O
of	O
treating	O
IST	O
by	O
intratympanic	O
instillation	O
of	O
lignocaine	B-CHEMICAL
(	O
lidocaine	B-CHEMICAL
)	O
2	O
per	O
cent	O
through	O
a	O
grommet	O
,	O
for	O
five	O
weekly	O
courses	O
.	O
Fifty	O
-	O
two	O
patients	O
suffering	O
from	O
intractable	O
tinnitus	B-DISEASE
entered	O
this	O
therapeutic	O
trial	O
,	O
but	O
only	O
nine	O
finished	O
all	O
five	O
courses	O
.	O
In	O
one	O
patient	O
,	O
the	O
tinnitus	B-DISEASE
was	O
almost	O
completely	O
abolished	O
,	O
but	O
in	O
all	O
the	O
nine	O
patients	O
the	O
decompensated	O
tinnitus	B-DISEASE
changed	O
to	O
a	O
compensated	O
one	O
.	O
We	O
suggest	O
this	O
mode	O
of	O
treatment	O
for	O
patients	O
that	O
were	O
previously	O
treated	O
by	O
drugs	O
,	O
acupuncture	O
and	O
biofeedback	O
,	O
with	O
disappointing	O
results	O
.	O
Patients	O
should	O
be	O
warned	O
about	O
the	O
side	O
effects	O
of	O
vertigo	B-DISEASE
and	O
vomiting	B-DISEASE
,	O
which	O
subsides	O
gradually	O
with	O
every	O
new	O
instillation	O
,	O
and	O
that	O
the	O
tinnitus	B-DISEASE
may	O
not	O
disappear	O
but	O
will	O
be	O
alleviated	O
,	O
enabling	O
them	O
to	O
cope	O
more	O
easily	O
with	O
the	O
disease	B-DISEASE
and	O
lead	O
a	O
more	O
normal	O
life	O
.	O

Perhexiline	B-CHEMICAL
maleate	I-CHEMICAL
and	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
.	O
Peripheral	B-DISEASE
neuropathy	I-DISEASE
has	O
been	O
noted	O
as	O
a	O
complication	O
of	O
therapy	O
with	O
perhexiline	B-CHEMICAL
maleate	I-CHEMICAL
,	O
a	O
drug	O
widely	O
used	O
in	O
France	O
(	O
and	O
in	O
clinical	O
trials	O
in	O
the	O
United	O
States	O
)	O
for	O
the	O
prophylactic	O
treatment	O
of	O
angina	B-DISEASE
pectoris	I-DISEASE
.	O
In	O
24	O
patients	O
with	O
this	O
complication	O
,	O
the	O
marked	O
slowing	O
of	O
motor	O
nerve	O
conduction	O
velocity	O
and	O
the	O
electromyographic	O
changes	O
imply	O
mainly	O
a	O
demyelinating	B-DISEASE
disorder	I-DISEASE
.	O
Improvement	O
was	O
noted	O
with	O
cessation	O
of	O
therapy	O
.	O
In	O
a	O
few	O
cases	O
the	O
presence	O
of	O
active	O
denervation	O
signified	O
a	O
poor	O
prognosis	O
,	O
with	O
only	O
slight	O
improvement	O
.	O
The	O
underlying	O
mechanism	O
causing	O
the	O
neuropathy	B-DISEASE
is	O
not	O
yet	O
fully	O
known	O
,	O
although	O
some	O
evidence	O
indicates	O
that	O
it	O
may	O
be	O
a	O
lipid	O
storage	O
process	O
.	O

Effect	O
of	O
humoral	O
modulators	O
of	O
morphine	B-CHEMICAL
-	O
induced	O
increase	O
in	O
locomotor	O
activity	O
of	O
mice	O
.	O
The	O
effect	O
of	O
humoral	O
modulators	O
on	O
the	O
morphine	B-CHEMICAL
-	O
induced	O
increase	O
in	O
locomotor	O
activity	O
of	O
mice	O
was	O
studied	O
.	O
The	O
subcutaneous	O
administration	O
of	O
10	O
mg	O
/	O
kg	O
of	O
morphine	B-CHEMICAL
-	O
HC1	O
produced	O
a	O
marked	O
increase	O
in	O
locomotor	O
activity	O
in	O
mice	O
.	O
The	O
morphine	B-CHEMICAL
-	O
induced	O
hyperactivity	O
was	O
potentiated	O
by	O
scopolamine	B-CHEMICAL
and	O
attenuated	O
by	O
physostigmine	O
.	O
In	O
contrast	O
,	O
both	O
methscopolamine	O
and	O
neostigmine	O
,	O
which	O
do	O
not	O
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
had	O
no	O
effect	O
on	O
the	O
hyperactivity	O
produced	O
by	O
morphine	B-CHEMICAL
.	O
Pretreatment	O
of	O
mice	O
with	O
alpha	O
-	O
methyltyrosine	O
(	O
20	O
mg	O
/	O
kg	O
i.p	O
.	O
,	O
one	O
hour	O
)	O
,	O
an	O
inhibitor	O
of	O
tyrosine	B-CHEMICAL
hydroxylase	O
,	O
significantly	O
decreased	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	B-CHEMICAL
.	O
On	O
the	O
other	O
hand	O
,	O
pretreatment	O
with	O
p	O
-	O
chlorophenylalamine	O
(	O
3	O
X	O
320	O
mg	O
/	O
kg	O
i.p	O
.	O
,	O
24	O
hr	O
)	O
,	O
a	O
serotonin	B-CHEMICAL
depletor	O
,	O
caused	O
no	O
significant	O
change	O
in	O
the	O
hyperactivity	O
.	O
The	O
study	O
suggests	O
that	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	B-CHEMICAL
are	O
mediated	O
by	O
the	O
release	O
of	O
catecholamines	O
from	O
adrenergic	O
neurons	O
in	O
the	O
brain	O
.	O
And	O
the	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
morphine	B-CHEMICAL
acts	O
by	O
retarding	O
the	O
release	O
of	O
acetylcholine	O
at	O
some	O
central	O
cholinergic	O
synapses	O
.	O
It	O
is	O
also	O
suggested	O
from	O
collected	O
evidence	O
that	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	B-CHEMICAL
in	O
mice	O
are	O
mediated	O
by	O
mechanisms	O
different	O
from	O
those	O
which	O
mediate	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	B-CHEMICAL
in	O
rats	O
.	O

Mechanisms	O
of	O
FK	O
506	O
-	O
induced	O
hypertension	B-DISEASE
in	O
the	O
rat	O
.	O
-Tacrolimus	O
(	O
FK	O
506	O
)	O
is	O
a	O
powerful	O
,	O
widely	O
used	O
immunosuppressant	O
.	O
The	O
clinical	O
utility	O
of	O
FK	O
506	O
is	O
complicated	O
by	O
substantial	O
hypertension	B-DISEASE
and	O
nephrotoxicity	B-DISEASE
.	O
To	O
clarify	O
the	O
mechanisms	O
of	O
FK	O
506	O
-	O
induced	O
hypertension	B-DISEASE
,	O
we	O
studied	O
the	O
chronic	O
effects	O
of	O
FK	O
506	O
on	O
the	O
synthesis	O
of	O
endothelin-1	O
(	O
ET-1	O
)	O
,	O
the	O
expression	O
of	O
mRNA	O
of	O
ET-1	O
and	O
endothelin	O
-	O
converting	O
enzyme-1	O
(	O
ECE-1	O
)	O
,	O
the	O
endothelial	O
nitric	O
oxide	O
synthase	O
(	O
eNOS	O
)	O
activity	O
,	O
and	O
the	O
expression	O
of	O
mRNA	O
of	O
eNOS	O
and	O
C	O
-	O
type	O
natriuretic	O
peptide	O
(	O
CNP	O
)	O
in	O
rat	O
blood	O
vessels	O
.	O
In	O
addition	O
,	O
the	O
effect	O
of	O
the	O
specific	O
endothelin	O
type	O
A	O
receptor	O
antagonist	O
FR	O
139317	O
on	O
FK	O
506	O
-	O
induced	O
hypertension	B-DISEASE
in	O
rats	O
was	O
studied	O
.	O
FK	O
506	O
,	O
5	O
mg	O
.	O
kg-1	O
.	O
d-1	O
given	O
for	O
4	O
weeks	O
,	O
elevated	O
blood	O
pressure	O
from	O
102+/-13	O
to	O
152+/-15	O
mm	O
Hg	O
and	O
increased	O
the	O
synthesis	O
of	O
ET-1	O
and	O
the	O
levels	O
of	O
ET-1	O
mRNA	O
in	O
the	O
mesenteric	O
artery	O
(	O
240	O
%	O
and	O
230	O
%	O
,	O
respectively	O
)	O
.	O
Little	O
change	O
was	O
observed	O
in	O
the	O
expression	O
of	O
ECE-1	O
mRNA	O
and	O
CNP	O
mRNA	O
.	O
FK	O
506	O
decreased	O
eNOS	O
activity	O
and	O
the	O
levels	O
of	O
eNOS	O
mRNA	O
in	O
the	O
aorta	O
(	O
48	O
%	O
and	O
55	O
%	O
,	O
respectively	O
)	O
.	O
The	O
administration	O
of	O
FR	O
139317	O
(	O
10	O
mg	O
.	O
kg-1	O
.	O
d-1	O
)	O
prevented	O
FK	O
506	O
-	O
induced	O
hypertension	B-DISEASE
in	O
rats	O
.	O
These	O
results	O
indicate	O
that	O
FK	O
506	O
may	O
increase	O
blood	O
pressure	O
not	O
only	O
by	O
increasing	O
ET-1	O
production	O
but	O
also	O
by	O
decreasing	O
NO	O
synthesis	O
in	O
the	O
vasculature	O
.	O

Suxamethonium	B-CHEMICAL
induced	O
prolonged	O
apnea	B-DISEASE
in	O
a	O
patient	O
receiving	O
electroconvulsive	O
therapy	O
.	O
Suxamethonium	B-CHEMICAL
causes	O
prolonged	O
apnea	B-DISEASE
in	O
patients	O
in	O
whom	O
pseudocholinesterase	O
enzyme	O
gets	O
deactivated	O
by	O
organophosphorus	O
(	O
OP	O
)	O
poisons	O
.	O
Here	O
,	O
we	O
present	O
a	O
similar	O
incident	O
in	O
a	O
severely	O
depressed	B-DISEASE
patient	O
who	O
received	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
.	O
Prolonged	O
apnea	B-DISEASE
in	O
our	O
case	O
ensued	O
because	O
the	O
information	O
about	O
suicidal	O
attempt	O
by	O
OP	O
compound	O
was	O
concealed	O
from	O
the	O
treating	O
team	O
.	O

The	O
effects	O
of	O
the	O
adjunctive	O
bupropion	O
on	O
male	O
sexual	B-DISEASE
dysfunction	I-DISEASE
induced	O
by	O
a	O
selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitor	O
:	O
a	O
double	O
-	O
blind	B-DISEASE
placebo	O
-	O
controlled	O
and	O
randomized	O
study	O
.	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
adjunctive	O
bupropion	O
sustained	O
-	O
release	O
(	O
SR	O
)	O
on	O
male	O
sexual	B-DISEASE
dysfunction	I-DISEASE
(	O
SD	B-DISEASE
)	O
induced	O
by	O
a	O
selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitor	O
(	O
SSRI	O
)	O
,	O
as	O
SD	B-DISEASE
is	O
a	O
common	O
side	O
-	O
effect	O
of	O
SSRIs	O
and	O
the	O
most	O
effective	O
treatments	O
have	O
yet	O
to	O
be	O
determined	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
The	O
randomized	O
sample	O
consisted	O
of	O
234	O
euthymic	O
men	O
who	O
were	O
receiving	O
some	O
type	O
of	O
SSRI	O
.	O
The	O
men	O
were	O
randomly	O
assigned	O
to	O
bupropion	O
SR	O
(	O
150	O
mg	O
twice	O
daily	O
,	O
117	O
)	O
or	O
placebo	O
(	O
twice	O
daily	O
,	O
117	O
)	O
for	O
12	O
weeks	O
.	O
Efficacy	O
was	O
evaluated	O
using	O
the	O
Clinical	O
Global	O
Impression	O
-	O
Sexual	O
Function	O
(	O
CGI	O
-	O
SF	O
;	O
the	O
primary	O
outcome	O
measure	O
)	O
,	O
the	O
International	O
Index	O
of	O
Erectile	O
Function	O
(	O
IIEF	O
)	O
,	O
Arizona	O
Sexual	O
Experience	O
Scale	O
(	O
ASEX	O
)	O
,	O
and	O
Erectile	B-DISEASE
Dysfunction	I-DISEASE
Inventory	O
of	O
Treatment	O
Satisfaction	O
(	O
EDITS	O
)	O
(	O
secondary	O
outcome	O
measures	O
)	O
.	O
Participants	O
were	O
followed	O
biweekly	O
during	O
study	O
period	O
.	O
RESULTS	O
:	O
After	O
12	O
weeks	O
of	O
treatment	O
,	O
the	O
mean	O
(	O
sd	B-DISEASE
)	O
scores	O
for	O
CGI	O
-	O
SF	O
were	O
significantly	O
lower	O
,	O
i.e.	O
better	O
,	O
in	O
patients	O
on	O
bupropion	O
SR	O
,	O
at	O
2.4	O
(	O
1.2	O
)	O
,	O
than	O
in	O
the	O
placebo	O
group	O
,	O
at	O
3.9	O
(	O
1.1	O
)	O
(	O
P=	O
0.01	O
)	O
.	O
Men	O
who	O
received	O
bupropion	O
had	O
a	O
significant	O
increase	O
in	O
the	O
total	O
IIEF	O
score	O
(	O
54.4	O
%	O
vs	O
1.2	O
%	O
;	O
P=	O
0.003	O
)	O
,	O
and	O
in	O
the	O
five	O
different	O
domains	O
of	O
the	O
IIEF	O
.	O
Total	O
ASEX	O
scores	O
were	O
significantly	O
lower	O
,	O
i.e.	O
better	O
,	O
among	O
men	O
who	O
received	O
bupropion	O
than	O
placebo	O
,	O
at	O
15.5	O
(	O
4.3	O
)	O
vs	O
21.5	O
(	O
4.7	O
)	O
(	O
P=	O
0.002	O
)	O
.	O
The	O
EDITS	O
scores	O
were	O
67.4	O
(	O
10.2	O
)	O
for	O
the	O
bupropion	O
and	O
36.3	O
(	O
11.7	O
)	O
for	O
the	O
placebo	O
group	O
(	O
P=	O
0.001	O
)	O
.	O
The	O
ASEX	O
score	O
and	O
CGI	O
-	O
SF	O
score	O
were	O
correlated	O
(	O
P=	O
0.003	O
)	O
.	O
In	O
linear	O
regression	O
analyses	O
the	O
CGI	O
-	O
SF	O
score	O
was	O
not	O
affected	O
significantly	O
by	O
the	O
duration	O
of	O
SD	B-DISEASE
,	O
type	O
of	O
SSRI	O
used	O
and	O
age	O
.	O
CONCLUSIONS	O
:	O
Bupropion	O
is	O
an	O
effective	O
treatment	O
for	O
male	O
SD	B-DISEASE
induced	O
by	O
SSRIs	O
.	O
These	O
results	O
provide	O
empirical	O
support	O
for	O
conducting	O
a	O
further	O
study	O
of	O
bupropion	O
.	O

Lamivudine	B-CHEMICAL
for	O
the	O
prevention	O
of	O
hepatitis	B-DISEASE
B	I-DISEASE
virus	O
reactivation	O
in	O
hepatitis	B-DISEASE
-	O
B	O
surface	O
antigen	O
(	O
HBSAG	O
)	O
seropositive	O
cancer	B-DISEASE
patients	O
undergoing	O
cytotoxic	O
chemotherapy	O
.	O
Hepatitis	B-DISEASE
B	I-DISEASE
virus	O
(	O
HBV	O
)	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
chronic	B-DISEASE
liver	I-DISEASE
disease	I-DISEASE
worldwide	O
.	O
Cancer	B-DISEASE
patients	O
who	O
are	O
chronic	O
carriers	O
of	O
HBV	O
have	O
a	O
higher	O
hepatic	O
complication	O
rate	O
while	O
receiving	O
cytotoxic	O
chemotherapy	O
(	O
CT	O
)	O
and	O
this	O
has	O
mainly	O
been	O
attributed	O
to	O
HBV	O
reactivation	O
.	O
In	O
this	O
study	O
,	O
cancer	B-DISEASE
patients	O
who	O
have	O
solid	O
and	O
hematological	O
malignancies	B-DISEASE
with	O
chronic	O
HBV	O
infection	B-DISEASE
received	O
the	O
antiviral	O
agent	O
lamivudine	B-CHEMICAL
prior	O
and	O
during	O
CT	O
compared	O
with	O
historical	O
control	O
group	O
who	O
did	O
not	O
receive	O
lamivudine	B-CHEMICAL
.	O
The	O
objectives	O
were	O
to	O
assess	O
the	O
efficacy	O
of	O
lamivudine	B-CHEMICAL
in	O
reducing	O
the	O
incidence	O
of	O
HBV	O
reactivation	O
,	O
and	O
diminishing	O
morbidity	O
and	O
mortality	O
during	O
CT	O
.	O
Two	O
groups	O
were	O
compared	O
in	O
this	O
study	O
.	O
The	O
prophylactic	O
lamivudin	O
group	O
consisted	O
of	O
37	O
patients	O
who	O
received	O
prophylactic	O
lamivudine	B-CHEMICAL
treatment	O
.	O
The	O
historical	O
controls	O
consisted	O
of	O
50	O
consecutive	O
patients	O
who	O
underwent	O
CT	O
without	O
prophylactic	O
lamivudine	B-CHEMICAL
.	O
They	O
were	O
followed	O
up	O
during	O
and	O
for	O
8	O
weeks	O
after	O
CT	O
.	O
The	O
outcomes	O
were	O
compared	O
for	O
both	O
groups	O
.	O
Of	O
our	O
control	O
group	O
(	O
n=	O
50	O
)	O
,	O
21	O
patients	O
(	O
42	O
%	O
)	O
were	O
established	O
hepatitis	B-DISEASE
.	O
Twelve	O
(	O
24	O
%	O
)	O
of	O
them	O
were	O
evaluated	O
as	O
severe	O
hepatitis	B-DISEASE
.	O
In	O
the	O
prophylactic	O
lamivudine	B-CHEMICAL
group	O
severe	O
hepatitis	B-DISEASE
were	O
observed	O
only	O
in	O
1	O
patient	O
(	O
2.7	O
%	O
)	O
of	O
37	O
patients	O
(	O
p	O
<	O
0.006	O
)	O
.	O
Comparison	O
of	O
the	O
mean	O
ALT	O
values	O
revealed	O
significantly	O
higher	O
mean	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
values	O
in	O
the	O
control	O
group	O
than	O
the	O
prophylactic	O
lamivudine	B-CHEMICAL
group	O
;	O
154:64	O
(	O
p	O
<	O
0.32	O
)	O
.	O
Our	O
study	O
suggests	O
that	O
prophylactic	O
lamivudine	B-CHEMICAL
significantly	O
decreases	O
the	O
incidence	O
of	O
HBV	O
reactivation	O
and	O
overall	O
morbidity	O
in	O
cancer	B-DISEASE
patients	O
during	O
and	O
after	O
immunosuppressive	O
therapy	O
.	O
Further	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
most	O
appropriate	O
nucleoside	O
or	O
nucleotide	O
analogue	O
for	O
antiviral	O
prophylaxis	O
during	O
CT	O
and	O
the	O
optimal	O
duration	O
of	O
administration	O
after	O
completion	O
of	O
CT	O
.	O

Ginsenoside	B-CHEMICAL
Rg1	I-CHEMICAL
restores	O
the	O
impairment	O
of	O
learning	O
induced	O
by	O
chronic	O
morphine	B-CHEMICAL
administration	O
in	O
rats	O
.	O
Rg1	O
,	O
as	O
a	O
ginsenoside	O
extracted	O
from	O
Panax	O
ginseng	O
,	O
could	O
ameliorate	O
spatial	O
learning	O
impairment	O
.	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
Rg1	O
might	O
be	O
a	O
useful	O
agent	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
the	O
adverse	O
effects	O
of	O
morphine	B-CHEMICAL
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
Rg1	O
on	O
learning	O
impairment	O
by	O
chronic	O
morphine	B-CHEMICAL
administration	O
and	O
the	O
mechanism	O
responsible	O
for	O
this	O
effect	O
.	O
Male	O
rats	O
were	O
subcutaneously	O
injected	O
with	O
morphine	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
)	O
twice	O
a	O
day	O
at	O
12	O
hour	O
intervals	O
for	O
10	O
days	O
,	O
and	O
Rg1	O
(	O
30	O
mg	O
/	O
kg	O
)	O
was	O
intraperitoneally	O
injected	O
2	O
hours	O
after	O
the	O
second	O
injection	O
of	O
morphine	B-CHEMICAL
once	O
a	O
day	O
for	O
10	O
days	O
.	O
Spatial	O
learning	O
capacity	O
was	O
assessed	O
in	O
the	O
Morris	O
water	O
maze	O
.	O
The	O
results	O
showed	O
that	O
rats	O
treated	O
with	O
Morphine	B-CHEMICAL
/	O
Rg1	O
decreased	O
escape	O
latency	O
and	O
increased	O
the	O
time	O
spent	O
in	O
platform	O
quadrant	O
and	O
entering	O
frequency	O
.	O
By	O
implantation	O
of	O
electrodes	O
and	O
electrophysiological	O
recording	O
in	O
vivo	O
,	O
the	O
results	O
showed	O
that	O
Rg1	O
restored	O
the	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
impaired	O
by	O
morphine	B-CHEMICAL
in	O
both	O
freely	O
moving	O
and	O
anaesthetised	O
rats	O
.	O
The	O
electrophysiological	O
recording	O
in	O
vitro	O
showed	O
that	O
Rg1	O
restored	O
the	O
LTP	O
in	O
slices	O
from	O
the	O
rats	O
treated	O
with	O
morphine	B-CHEMICAL
,	O
but	O
not	O
changed	O
LTP	O
in	O
the	O
slices	O
from	O
normal	O
saline-	O
or	O
morphine	B-CHEMICAL
/	O
Rg1	O
-	O
treated	O
rats	O
;	O
this	O
restoration	O
could	O
be	O
inhibited	O
by	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptor	O
antagonist	O
MK801	O
.	O
We	O
conclude	O
that	O
Rg1	O
may	O
significantly	O
improve	O
the	O
spatial	O
learning	O
capacity	O
impaired	O
by	O
chonic	O
morphine	B-CHEMICAL
administration	O
and	O
restore	O
the	O
morphine	B-CHEMICAL
-	O
inhibited	O
LTP	O
.	O
This	O
effect	O
is	O
NMDA	O
receptor	O
dependent	O
.	O

A	O
study	O
on	O
the	O
effect	O
of	O
the	O
duration	O
of	O
subcutaneous	O
heparin	B-CHEMICAL
injection	O
on	O
bruising	B-DISEASE
and	O
pain	B-DISEASE
.	O
AIM	O
:	O
This	O
study	O
was	O
carried	O
out	O
to	O
determine	O
the	O
effect	O
of	O
injection	O
duration	O
on	O
bruising	B-DISEASE
and	O
pain	B-DISEASE
following	O
the	O
administration	O
of	O
the	O
subcutaneous	O
injection	O
of	O
heparin	B-CHEMICAL
.	O
BACKGROUND	O
:	O
Although	O
different	O
methods	O
to	O
prevent	O
bruising	B-DISEASE
and	O
pain	B-DISEASE
following	O
the	O
subcutaneous	O
injection	O
of	O
heparin	B-CHEMICAL
have	O
been	O
widely	O
studied	O
and	O
described	O
,	O
the	O
effect	O
of	O
injection	O
duration	O
on	O
the	O
occurrence	O
of	O
bruising	B-DISEASE
and	O
pain	B-DISEASE
is	O
little	O
documented	O
.	O
DESIGN	O
:	O
This	O
study	O
was	O
designed	O
as	O
within	O
-	O
subject	O
,	O
quasi	O
-	O
experimental	O
research	O
.	O
METHOD	O
:	O
The	O
sample	O
for	O
the	O
study	O
consisted	O
of	O
50	O
patients	O
to	O
whom	O
subcutaneous	O
heparin	B-CHEMICAL
was	O
administered	O
.	O
Heparin	B-CHEMICAL
was	O
injected	O
over	O
10	O
seconds	O
on	O
the	O
right	O
abdominal	O
site	O
and	O
30	O
seconds	O
on	O
the	O
left	O
abdominal	O
site	O
.	O
Injections	O
areas	O
were	O
assessed	O
for	O
the	O
presence	O
of	O
bruising	B-DISEASE
at	O
48	O
and	O
72	O
hours	O
after	O
each	O
injection	O
.	O
Dimensions	O
of	O
the	O
bruising	B-DISEASE
on	O
the	O
heparin	B-CHEMICAL
applied	O
areas	O
were	O
measured	O
using	O
transparent	O
millimetric	O
measuring	O
paper	O
.	O
The	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
was	O
used	O
to	O
measure	O
pain	B-DISEASE
intensity	O
and	O
a	O
stop	O
-	O
watch	O
was	O
used	O
to	O
time	O
the	O
pain	B-DISEASE
period	O
.	O
Data	O
were	O
analysed	O
using	O
chi	O
-	O
square	O
test	O
,	O
Mann	O
-	O
Whitney	O
U	O
,	O
Wilcoxon	O
signed	O
ranks	O
tests	O
and	O
correlation	O
.	O
RESULTS	O
:	O
The	O
percentage	O
of	O
bruising	B-DISEASE
occurrence	O
was	O
64	O
%	O
with	O
the	O
injection	O
of	O
10	O
seconds	O
duration	O
and	O
42	O
%	O
in	O
the	O
30	O
-	O
second	O
injection	O
.	O
It	O
was	O
determined	O
that	O
the	O
size	O
of	O
the	O
bruising	B-DISEASE
was	O
smaller	O
in	O
the	O
30	O
-	O
second	O
injection	O
.	O
Pain	B-DISEASE
intensity	O
and	O
pain	B-DISEASE
period	O
were	O
statistically	O
significantly	O
lower	O
for	O
the	O
30	O
-	O
second	O
injection	O
than	O
for	O
the	O
10	O
-	O
second	O
injection	O
.	O
CONCLUSIONS	O
:	O
It	O
was	O
determined	O
that	O
injection	O
duration	O
had	O
an	O
effect	O
on	O
bruising	B-DISEASE
and	O
pain	B-DISEASE
following	O
the	O
subcutaneous	O
administration	O
of	O
heparin	B-CHEMICAL
.	O
This	O
study	O
should	O
be	O
repeated	O
on	O
a	O
larger	O
sample	O
.	O
RELEVANCE	O
TO	O
CLINICAL	O
PRACTICE	O
:	O
When	O
administering	O
subcutaneous	O
heparin	B-CHEMICAL
injections	O
,	O
it	O
is	O
important	O
to	O
extend	O
the	O
duration	O
of	O
the	O
injection	O
.	O

Acute	O
reserpine	B-CHEMICAL
and	O
subchronic	O
haloperidol	B-CHEMICAL
treatments	O
change	O
synaptosomal	O
brain	O
glutamate	B-CHEMICAL
uptake	O
and	O
elicit	O
orofacial	O
dyskinesia	B-DISEASE
in	O
rats	O
.	O
Reserpine-	O
and	O
haloperidol	B-CHEMICAL
-	O
induced	O
orofacial	O
dyskinesia	B-DISEASE
are	O
putative	O
animal	O
models	O
of	O
tardive	B-DISEASE
dyskinesia	I-DISEASE
(	O
TD	B-DISEASE
)	O
whose	O
pathophysiology	O
has	O
been	O
related	O
to	O
free	O
radical	O
generation	O
and	O
oxidative	O
stress	B-DISEASE
.	O
In	O
the	O
present	O
study	O
,	O
the	O
authors	O
induced	O
orofacial	O
dyskinesia	B-DISEASE
by	O
acute	O
reserpine	B-CHEMICAL
and	O
subchronic	O
haloperidol	B-CHEMICAL
administration	O
to	O
rats	O
.	O
Reserpine	B-CHEMICAL
injection	O
(	O
one	O
dose	O
of	O
1	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
every	O
other	O
day	O
for	O
3	O
days	O
caused	O
a	O
significant	O
increase	O
in	O
vacuous	O
chewing	O
,	O
tongue	O
protrusion	O
and	O
duration	O
of	O
facial	O
twitching	O
,	O
compared	O
to	O
the	O
control	O
.	O
Haloperidol	B-CHEMICAL
administration	O
(	O
one	O
dose	O
of	O
12	O
mg	O
/	O
kg	O
once	O
a	O
week	O
s.c	O
.	O
)	O
for	O
4	O
weeks	O
caused	O
an	O
increase	O
in	O
vacuous	O
chewing	O
,	O
tongue	O
protrusion	O
and	O
duration	O
of	O
facial	O
twitching	O
observed	O
in	O
four	O
weekly	O
evaluations	O
.	O
After	O
the	O
treatments	O
and	O
behavioral	O
observation	O
,	O
glutamate	B-CHEMICAL
uptake	O
by	O
segments	O
of	O
the	O
brain	O
was	O
analyzed	O
.	O
A	O
decreased	O
glutamate	B-CHEMICAL
uptake	O
was	O
observed	O
in	O
the	O
subcortical	O
parts	O
of	O
animals	O
treated	O
with	O
reserpine	B-CHEMICAL
and	O
haloperidol	B-CHEMICAL
,	O
compared	O
to	O
the	O
control	O
.	O
Importantly	O
,	O
a	O
decrease	O
in	O
glutamate	B-CHEMICAL
uptake	O
correlates	O
negatively	O
with	O
an	O
increase	O
in	O
the	O
incidence	O
of	O
orofacial	O
diskinesia	O
.	O
These	O
results	O
indicate	O
that	O
early	O
changes	O
in	O
glutamate	B-CHEMICAL
transport	O
may	O
be	O
related	O
to	O
the	O
development	O
of	O
vacuous	O
chewing	O
movements	O
in	O
rats	O
.	O

Acute	O
psychosis	B-DISEASE
due	O
to	O
treatment	O
with	O
phenytoin	B-CHEMICAL
in	O
a	O
nonepileptic	O
patient	O
.	O
The	O
development	O
of	O
psychosis	B-DISEASE
related	O
to	O
antiepileptic	O
drug	O
treatment	O
is	O
usually	O
attributed	O
to	O
the	O
interaction	O
between	O
the	O
epileptic	B-DISEASE
brain	O
substratum	O
and	O
the	O
antiepileptic	O
drugs	O
.	O
The	O
case	O
of	O
a	O
nonepileptic	O
patient	O
who	O
developed	O
psychosis	B-DISEASE
following	O
phenytoin	B-CHEMICAL
treatment	O
for	O
trigeminal	B-DISEASE
neuralgia	I-DISEASE
is	O
described	O
.	O
This	O
case	O
suggests	O
that	O
the	O
psychotic	B-DISEASE
symptoms	I-DISEASE
that	O
occur	O
following	O
phenytoin	B-CHEMICAL
treatment	O
in	O
some	O
epileptic	B-DISEASE
patients	O
may	O
be	O
the	O
direct	O
result	O
of	O
medication	O
,	O
unrelated	O
to	O
seizures	B-DISEASE
.	O

The	O
effect	O
of	O
treatment	O
with	O
gum	B-CHEMICAL
Arabic	I-CHEMICAL
on	O
gentamicin	B-CHEMICAL
nephrotoxicity	B-DISEASE
in	O
rats	O
:	O
a	O
preliminary	O
study	O
.	O
In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	O
of	O
rats	O
with	O
gum	B-CHEMICAL
Arabic	I-CHEMICAL
on	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
induced	O
by	O
gentamicin	B-CHEMICAL
(	O
GM	O
)	O
nephrotoxicity	B-DISEASE
.	O
Rats	O
were	O
treated	O
with	O
the	O
vehicle	O
(	O
2	O
mL	O
/	O
kg	O
of	O
distilled	O
water	O
and	O
5	O
%	O
w	O
/	O
v	O
cellulose	O
,	O
10	O
days	O
)	O
,	O
gum	B-CHEMICAL
Arabic	I-CHEMICAL
(	O
2	O
mL	O
/	O
kg	O
of	O
a	O
10	O
%	O
w	O
/	O
v	O
aqueous	O
suspension	O
of	O
gum	B-CHEMICAL
Arabic	I-CHEMICAL
powder	O
,	O
orally	O
for	O
10	O
days	O
)	O
,	O
or	O
gum	B-CHEMICAL
Arabic	I-CHEMICAL
concomitantly	O
with	O
GM	O
(	O
80mg	O
/	O
kg	O
/	O
day	O
intramuscularly	O
,	O
during	O
the	O
last	O
six	O
days	O
of	O
the	O
treatment	O
period	O
)	O
.	O
Nephrotoxicity	B-DISEASE
was	O
assessed	O
by	O
measuring	O
the	O
concentrations	O
of	O
creatinine	B-CHEMICAL
and	O
urea	B-CHEMICAL
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	B-CHEMICAL
(	O
GSH	O
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O
The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	B-CHEMICAL
Arabic	I-CHEMICAL
and	O
GM	O
significantly	O
increased	O
creatinine	B-CHEMICAL
and	O
urea	B-CHEMICAL
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	O
proximal	O
tubular	B-DISEASE
necrosis	I-DISEASE
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	B-CHEMICAL
Arabic	I-CHEMICAL
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O
It	O
could	O
be	O
inferred	O
that	O
gum	B-CHEMICAL
Arabic	I-CHEMICAL
treatment	O
has	O
induced	O
a	O
modest	O
amelioration	O
of	O
some	O
of	O
the	O
histological	O
and	O
biochemical	O
indices	O
of	O
GM	O
nephrotoxicity	B-DISEASE
.	O
Further	O
work	O
is	O
warranted	O
on	O
the	O
effect	O
of	O
the	O
treatments	O
on	O
renal	O
functional	O
aspects	O
in	O
models	O
of	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
,	O
and	O
on	O
the	O
mechanism(s	O
)	O
involved	O
.	O

Visual	B-DISEASE
hallucinations	I-DISEASE
associated	O
with	O
zonisamide	B-CHEMICAL
.	O
Zonisamide	B-CHEMICAL
is	O
a	O
broad	O
-	O
spectrum	O
antiepileptic	O
drug	O
used	O
to	O
treat	O
various	O
types	O
of	O
seizures	B-DISEASE
.	O
Although	O
visual	B-DISEASE
hallucinations	I-DISEASE
have	O
not	O
been	O
reported	O
as	O
an	O
adverse	O
effect	O
of	O
this	O
agent	O
,	O
we	O
describe	O
three	O
patients	O
who	O
experienced	O
complex	O
visual	B-DISEASE
hallucinations	I-DISEASE
and	O
altered	O
mental	O
status	O
after	O
zonisamide	B-CHEMICAL
treatment	O
was	O
begun	O
or	O
its	O
dosage	O
increased	O
.	O
All	O
three	O
had	O
been	O
diagnosed	O
earlier	O
with	O
epilepsy	B-DISEASE
,	O
and	O
their	O
electroencephalogram	O
(	O
EEG	O
)	O
findings	O
were	O
abnormal	O
.	O
During	O
monitoring	O
,	O
visual	B-DISEASE
hallucinations	I-DISEASE
did	O
not	O
correlate	O
with	O
EEG	O
readings	O
,	O
nor	O
did	O
video	O
recording	O
capture	O
any	O
of	O
the	O
described	O
events	O
.	O
None	O
of	O
the	O
patients	O
had	O
experienced	O
visual	B-DISEASE
hallucinations	I-DISEASE
before	O
this	O
event	O
.	O
The	O
only	O
recent	O
change	O
in	O
their	O
treatment	O
was	O
the	O
introduction	O
or	O
increased	O
dosage	O
of	O
zonisamide	B-CHEMICAL
.	O
With	O
either	O
discontinuation	O
or	O
decreased	O
dosage	O
of	O
the	O
drug	O
the	O
symptoms	O
disappeared	O
and	O
did	O
not	O
recur	O
.	O
Further	O
observations	O
and	O
reports	O
will	O
help	O
clarify	O
this	O
adverse	O
effect	O
.	O
Until	O
then	O
,	O
clinicians	O
need	O
to	O
be	O
aware	O
of	O
this	O
possible	O
complication	O
associated	O
with	O
zonisamide	B-CHEMICAL
.	O

GLEPP1	O
receptor	O
tyrosine	B-CHEMICAL
phosphatase	O
(	O
Ptpro	O
)	O
in	O
rat	O
PAN	O
nephrosis	B-DISEASE
.	O
A	O
marker	O
of	O
acute	O
podocyte	O
injury	O
.	O
Glomerular	O
epithelial	O
protein	O
1	O
(	O
GLEPP1	O
)	O
is	O
a	O
podocyte	O
receptor	O
membrane	O
protein	O
tyrosine	B-CHEMICAL
phosphatase	O
located	O
on	O
the	O
apical	O
cell	O
membrane	O
of	O
visceral	O
glomerular	O
epithelial	O
cell	O
and	O
foot	O
processes	O
.	O
This	O
receptor	O
plays	O
a	O
role	O
in	O
regulating	O
the	O
structure	O
and	O
function	O
of	O
podocyte	O
foot	O
process	O
.	O
To	O
better	O
understand	O
the	O
utility	O
of	O
GLEPP1	O
as	O
a	O
marker	O
of	O
glomerular	O
injury	O
,	O
the	O
amount	O
and	O
distribution	O
of	O
GLEPP1	O
protein	O
and	O
mRNA	O
were	O
examined	O
by	O
immunohistochemistry	O
,	O
Western	O
blot	O
and	O
RNase	O
protection	O
assay	O
in	O
a	O
model	O
of	O
podocyte	O
injury	O
in	O
the	O
rat	O
.	O
Puromycin	O
aminonucleoside	O
nephrosis	B-DISEASE
was	O
induced	O
by	O
single	O
intraperitoneal	O
injection	O
of	O
puromycin	O
aminonucleoside	O
(	O
PAN	O
,	O
20	O
mg/100	O
g	O
BW	O
)	O
.	O
Tissues	O
were	O
analyzed	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
days	O
after	O
PAN	O
injection	O
so	O
as	O
to	O
include	O
both	O
the	O
acute	O
phase	O
of	O
proteinuria	B-DISEASE
associated	O
with	O
foot	O
process	O
effacement	O
(	O
days	O
5	O
-	O
11	O
)	O
and	O
the	O
chronic	O
phase	O
of	O
proteinuria	B-DISEASE
associated	O
with	O
glomerulosclerosis	O
(	O
days	O
45	O
-	O
126	O
)	O
.	O
At	O
day	O
5	O
,	O
GLEPP1	O
protein	O
and	O
mRNA	O
were	O
reduced	O
from	O
the	O
normal	O
range	O
(	O
265.2	O
+	O
/-	O
79.6	O
x	O
10(6	O
)	O
moles	O
/	O
glomerulus	O
and	O
100	O
%	O
)	O
to	O
15	O
%	O
of	O
normal	O
(	O
41.8	O
+	O
/-	O
4.8	O
x	O
10(6	O
)	O
moles	O
/	O
glomerulus	O
,	O
p	O
<	O
0.005	O
)	O
.	O
This	O
occurred	O
in	O
association	O
with	O
an	O
increase	O
in	O
urinary	O
protein	O
content	O
from	O
1.8	O
+	O
/-	O
1	O
to	O
99.0	O
+	O
/-	O
61	O
mg	O
/	O
day	O
(	O
p	O
<	O
0.001	O
)	O
.	O
In	O
contrast	O
,	O
podocalyxin	O
did	O
not	O
change	O
significantly	O
at	O
this	O
time	O
.	O
By	O
day	O
11	O
,	O
GLEPP1	O
protein	O
and	O
mRNA	O
had	O
begun	O
to	O
return	O
towards	O
baseline	O
.	O
By	O
day	O
45	O
-	O
126	O
,	O
at	O
a	O
time	O
when	O
glomerular	O
scarring	O
was	O
present	O
,	O
GLEPP1	O
was	O
absent	O
from	O
glomerulosclerotic	O
areas	O
although	O
the	O
total	O
glomerular	O
content	O
of	O
GLEPP1	O
was	O
not	O
different	O
from	O
normal	O
.	O
We	O
conclude	O
that	O
GLEPP1	O
expression	O
,	O
unlike	O
podocalyxin	O
,	O
reflects	O
podocyte	O
injury	O
induced	O
by	O
PAN	O
.	O
GLEPP1	O
expression	O
may	O
be	O
a	O
useful	O
marker	O
of	O
podocyte	O
injury	O
.	O

Ticlopidine	B-CHEMICAL
-	O
induced	O
aplastic	B-DISEASE
anemia	I-DISEASE
:	O
report	O
of	O
three	O
Chinese	O
patients	O
and	O
review	O
of	O
the	O
literature	O
.	O
In	O
this	O
study	O
,	O
three	O
Chinese	O
patients	O
with	O
ticlopidine	B-CHEMICAL
-	O
induced	O
aplastic	B-DISEASE
anemia	I-DISEASE
were	O
reported	O
and	O
another	O
13	O
patients	O
in	O
the	O
English	O
literature	O
were	O
reviewed	O
.	O
We	O
attempted	O
to	O
find	O
underlying	O
similarities	O
,	O
evaluate	O
the	O
risk	O
factors	O
,	O
and	O
identify	O
appropriate	O
treatment	O
for	O
this	O
complication	O
.	O
All	O
but	O
one	O
of	O
the	O
patients	O
were	O
over	O
60	O
years	O
old	O
,	O
and	O
the	O
6	O
who	O
died	O
were	O
all	O
older	O
than	O
65	O
.	O
Therefore	O
,	O
old	O
age	O
may	O
be	O
a	O
risk	O
factor	O
for	O
developing	O
this	O
complication	O
.	O
Agranulocytosis	B-DISEASE
occurred	O
3	O
-	O
20	O
weeks	O
after	O
initiation	O
of	O
ticlopidine	B-CHEMICAL
,	O
so	O
frequent	O
examination	O
of	O
white	O
cell	O
count	O
during	O
treatment	O
is	O
recommended	O
.	O
There	O
seemed	O
to	O
be	O
no	O
direct	O
correlation	O
between	O
the	O
dose	O
or	O
duration	O
used	O
and	O
the	O
severity	O
of	O
bone	B-DISEASE
marrow	I-DISEASE
suppression	I-DISEASE
.	O
Treatment	O
for	O
ticlopidine	B-CHEMICAL
-	O
induced	O
aplastic	B-DISEASE
anemia	I-DISEASE
with	O
colony	O
-	O
stimulating	O
factors	O
seemed	O
to	O
have	O
little	O
effect	O
.	O
The	O
fact	O
that	O
5	O
of	O
the	O
6	O
patients	O
who	O
received	O
concurrent	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
died	O
,	O
should	O
alert	O
clinicians	O
to	O
be	O
more	O
cautious	O
when	O
using	O
these	O
two	O
drugs	O
simultaneously	O
.	O

Facilitation	O
of	O
memory	O
retrieval	O
by	O
pre	O
-	O
test	O
morphine	B-CHEMICAL
and	O
its	O
state	O
dependency	O
in	O
the	O
step	O
-	O
through	O
type	O
passive	O
avoidance	O
learning	O
test	O
in	O
mice	O
.	O
Amnesia	B-DISEASE
produced	O
by	O
scopolamine	B-CHEMICAL
and	O
cycloheximide	B-CHEMICAL
were	O
reversed	O
by	O
morphine	B-CHEMICAL
given	O
30	O
min	O
before	O
the	O
test	O
trial	O
(	O
pre	O
-	O
test	O
)	O
,	O
and	O
pre	O
-	O
test	O
morphine	B-CHEMICAL
also	O
facilitated	O
the	O
memory	O
retrieval	O
in	O
the	O
animals	O
administered	O
naloxone	B-CHEMICAL
during	O
the	O
training	O
trial	O
.	O
Similarly	O
,	O
pre	O
-	O
test	O
scopolamine	B-CHEMICAL
partially	O
reversed	O
the	O
scopolamine	B-CHEMICAL
-	O
induced	O
amnesia	B-DISEASE
,	O
but	O
not	O
significantly	O
;	O
and	O
pre	O
-	O
test	O
cycloheximide	B-CHEMICAL
failed	O
to	O
reverse	O
the	O
cycloheximide	B-CHEMICAL
-	O
induced	O
amnesia	B-DISEASE
.	O
These	O
results	O
suggest	O
that	O
the	O
facilitation	O
of	O
memory	O
retrieval	O
by	O
pre	O
-	O
test	O
morphine	B-CHEMICAL
might	O
be	O
the	O
direct	O
action	O
of	O
morphine	B-CHEMICAL
rather	O
than	O
a	O
state	O
dependent	O
effect	O
.	O

Test	O
conditions	O
influence	O
the	O
response	O
to	O
a	O
drug	O
challenge	O
in	O
rodents	O
.	O
These	O
studies	O
were	O
conducted	O
to	O
examine	O
the	O
differential	O
response	O
to	O
a	O
drug	O
challenge	O
under	O
varied	O
experimental	O
test	O
conditions	O
routinely	O
employed	O
to	O
study	O
drug	O
-	O
induced	O
behavioral	O
and	O
neurophysiological	O
responses	O
in	O
rodents	O
.	O
Apomorphine	O
,	O
a	O
nonselective	O
dopamine	B-CHEMICAL
agonist	O
,	O
was	O
selected	O
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	O
to	O
induce	O
hypothermia	B-DISEASE
,	O
and	O
to	O
produce	O
distinct	O
changes	O
to	O
dopamine	B-CHEMICAL
turnover	O
in	O
the	O
rodent	O
brain	O
.	O
From	O
such	O
experiments	O
there	O
is	O
evidence	O
that	O
characterization	O
and	O
detection	O
of	O
apomorphine	O
-	O
induced	O
activity	O
in	O
rodents	O
critically	O
depends	O
upon	O
the	O
test	O
conditions	O
employed	O
.	O
In	O
rats	O
,	O
detection	O
of	O
apomorphine	O
-	O
induced	O
hyperactivity	O
was	O
facilitated	O
by	O
a	O
period	O
of	O
acclimatization	O
to	O
the	O
test	O
conditions	O
.	O
Moreover	O
,	O
test	O
conditions	O
can	O
impact	O
upon	O
other	O
physiological	O
responses	O
to	O
apomorphine	O
such	O
as	O
drug	O
-	O
induced	O
hypothermia	B-DISEASE
.	O
In	O
mice	O
,	O
apomorphine	O
produced	O
qualitatively	O
different	O
responses	O
under	O
novel	O
conditions	O
when	O
compared	O
to	O
those	O
behaviors	O
elicited	O
in	O
the	O
home	O
test	O
cage	O
.	O
Drug	O
-	O
induced	O
gross	O
activity	O
counts	O
were	O
increased	O
in	O
the	O
novel	O
exploratory	O
box	O
only	O
,	O
while	O
measures	O
of	O
stereotypic	O
behavior	O
were	O
similar	O
in	O
both	O
.	O
By	O
contrast	O
,	O
apomorphine	O
-	O
induced	O
locomotion	O
was	O
more	O
prominent	O
in	O
the	O
novel	O
exploratory	O
box	O
.	O
Dopamine	B-CHEMICAL
turnover	O
ratios	O
(	O
DOPAC	B-CHEMICAL
:	O
DA	O
and	O
HVA	O
:	O
DA	O
)	O
were	O
found	O
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	O
to	O
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O
However	O
,	O
apomorphine	O
-	O
induced	O
reductions	O
in	O
striatal	O
dopamine	B-CHEMICAL
turnover	O
were	O
detected	O
in	O
both	O
novel	O
and	O
home	O
cage	O
environments	O
.	O
The	O
implications	O
of	O
these	O
findings	O
are	O
discussed	O
with	O
particular	O
emphasis	O
upon	O
conducting	O
psychopharmacological	O
challenge	O
tests	O
in	O
rodents	O
.	O

